"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A,US 1650703 A,107-120-197-160-856,1927-11-29,1927,US 6289725 A,1925-10-16,US 6289725 A,1925-10-16,Match packet,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/107-120-197-160-856,Granted Patent,no,0,2,1,1,0,A24F27/12;;A24F27/12,A24F27/12,,0,0,,,,EXPIRED
2,US,A,US 1814749 A,188-955-575-513-908,1931-07-14,1931,US 39412329 A,1929-09-20,US 39412329 A,1929-09-20,Toilet accessory,,LUPE INC,WILLIAM FRIEDMAN,,https://lens.org/188-955-575-513-908,Granted Patent,no,0,0,1,1,0,A45D33/008;;A45D33/008,A45D33/00,,0,0,,,,EXPIRED
3,CA,A,CA 269133 A,073-988-218-028-091,1927-03-15,1927,CA 269133D A,,CA 269133T A,,TOILET PACKET,,FRIEDMAN WILLIAM,FRIEDMAN WILLIAM,,https://lens.org/073-988-218-028-091,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
4,US,A,US 1895187 A,073-668-321-317-868,1933-01-24,1933,US 54682531 A,1931-06-25,US 54682531 A,1931-06-25,Toilet accessory,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/073-668-321-317-868,Granted Patent,no,0,4,1,1,0,A45D33/04;;A45D33/04,A45D33/04,,0,0,,,,EXPIRED
5,US,A,US 2568915 A,190-393-298-602-24X,1951-09-25,1951,US 8829149 A,1949-04-19,US 8829149 A,1949-04-19,Disposable syringe,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/190-393-298-602-24X,Granted Patent,no,3,17,1,1,0,A61M3/0262;;Y10S206/811;;A61M3/0262;;Y10S206/811,A61M3/02,,0,0,,,,EXPIRED
6,US,A,US 1743813 A,013-673-438-372-094,1930-01-14,1930,US 22247127 A,1927-09-28,US 22247127 A,1927-09-28,Toilet accessory,,LUPE INC,WILLIAM FRIEDMAN,,https://lens.org/013-673-438-372-094,Granted Patent,no,0,0,1,1,0,A45D33/008;;A45D33/008,A45D33/00,,0,0,,,,EXPIRED
7,US,A,US 1577406 A,071-329-025-974-901,1926-03-16,1926,US 6693325 A,1925-11-05,US 6693325 A,1925-11-05,Toilet packet,,JOHN W ARNOLD;;DAN H ARNOLD;;ADELAIDE F ARNOLD;;MILDRED C ARNOLD,WILLIAM FRIEDMAN,,https://lens.org/071-329-025-974-901,Granted Patent,no,0,6,1,1,0,A45D40/24;;A45D40/24,A45D40/24,,0,0,,,,EXPIRED
8,US,A,US 2836925 A,011-826-120-393-065,1958-06-03,1958,US 59556956 A,1956-06-27,US 59556956 A;;US 25792451 A,1951-11-23,Unitary take-up escutcheon,,REED CROMEX CORP,WILLIAM FRIEDMAN,,https://lens.org/011-826-120-393-065,Granted Patent,no,3,1,1,2,0,A47B91/00;;A47B91/00;;E03C1/32;;E03C1/32,A47B91/00;;E03C1/32,,0,0,,,,EXPIRED
9,US,A,US 1887299 A,027-745-359-828-047,1932-11-08,1932,US 54828631 A,1931-07-02,US 54828631 A,1931-07-02,Toilet accessory,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/027-745-359-828-047,Granted Patent,no,0,7,1,1,0,A45D40/023;;A45D40/023,A45D40/02,,0,0,,,,EXPIRED
10,US,A,US 2760245 A,105-948-702-011-489,1956-08-28,1956,US 25792451 A,1951-11-23,US 25792451 A,1951-11-23,Unitary take-up escutcheon mold,,REED CROMEX CORP,WILLIAM FRIEDMAN,,https://lens.org/105-948-702-011-489,Granted Patent,no,9,0,1,2,0,B22C9/06;;B22C9/06,B22C9/06,,0,0,,,,EXPIRED
11,US,A,US 1949201 A,105-473-443-267-183,1934-02-27,1934,US 63217832 A,1932-09-08,US 63217832 A,1932-09-08,Fountain pen,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/105-473-443-267-183,Granted Patent,no,0,4,1,1,0,B43K5/17;;B43K5/17,B43K5/17,,0,0,,,,EXPIRED
12,US,A,US 1733189 A,116-820-914-683-531,1929-10-29,1929,US 9873126 A,1926-03-31,US 9873126 A,1926-03-31,Syringe,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/116-820-914-683-531,Granted Patent,no,0,12,1,1,0,A61M3/0279;;A61M3/0279,A61M3/02,,0,0,,,,EXPIRED
13,CA,A,CA 266222 A,119-857-952-068-992,1926-11-30,1926,CA 266222D A,,CA 266222T A,,BRUSH AND COMB,,FRIEDMAN WILLIAM,FRIEDMAN WILLIAM,,https://lens.org/119-857-952-068-992,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
14,US,A,US 1626674 A,136-386-904-353-439,1927-05-03,1927,US 63069523 A,1923-04-09,US 63069523 A,1923-04-09,Combined window stop and weather strip,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/136-386-904-353-439,Granted Patent,no,0,0,1,1,0,E06B7/232;;E06B7/232,E06B7/232,,0,0,,,,EXPIRED
15,US,A,US 1641263 A,026-284-024-977-555,1927-09-06,1927,US 7133225 A,1925-11-25,US 7133225 A,1925-11-25,Combination packet,,JOHN W ARNOLD;;DAN H ARNOLD;;ADELAIDE F ARNOLD;;MILDRED C ARNOLD,WILLIAM FRIEDMAN,,https://lens.org/026-284-024-977-555,Granted Patent,no,0,6,1,1,0,A45D40/24;;A45D40/24,A45D40/24,,0,0,,,,EXPIRED
16,US,A,US 1903357 A,137-728-871-947-25X,1933-04-04,1933,US 23378427 A,1927-11-17,US 23378427 A,1927-11-17,Container,,LUPE INC,WILLIAM FRIEDMAN,,https://lens.org/137-728-871-947-25X,Granted Patent,no,0,8,1,1,0,A45D33/06;;A45D33/06,A45D33/06,,0,0,,,,EXPIRED
17,CA,A,CA 309599 A,004-812-009-169-785,1931-03-24,1931,CA 309599D A,,CA 309599T A,,TOILET ACCESSORY,,FRIEDMAN WILLIAM,FRIEDMAN WILLIAM,,https://lens.org/004-812-009-169-785,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
18,US,A,US 1858218 A,085-563-561-388-07X,1932-05-10,1932,US 40427429 A,1929-11-02,US 40427429 A,1929-11-02,Toilet accessory,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/085-563-561-388-07X,Granted Patent,no,0,2,1,1,0,A45D33/06;;A45D33/06,A45D33/06,,0,0,,,,EXPIRED
19,US,A,US 1672519 A,155-914-045-706-798,1928-06-05,1928,US 2605525 A,1925-04-27,US 2605525 A,1925-04-27,Match packet,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/155-914-045-706-798,Granted Patent,no,0,1,1,1,0,A24F27/12;;A24F27/12,A24F27/12,,0,0,,,,EXPIRED
20,US,A,US 1630566 A,055-316-186-525-688,1927-05-31,1927,US 12498426 A,1926-07-26,US 12498426 A,1926-07-26,Toilet accessory,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/055-316-186-525-688,Granted Patent,no,0,5,2,2,0,A45D40/18;;A45D40/18,A45D40/18,,0,0,,,,EXPIRED
21,FR,A,FR 637896 A,108-327-988-772-386,1928-05-10,1928,FR 637896D A,1927-07-19,US 637896T A,1926-07-26,Accessoire de toilette,,,FRIEDMAN WILLIAM,,https://lens.org/108-327-988-772-386,Granted Patent,no,0,0,1,1,0,A45D40/08,A45D40/08,,0,0,,,,EXPIRED
22,US,A,US 1887298 A,191-516-305-452-176,1932-11-08,1932,US 49396830 A,1930-11-07,US 49396830 A,1930-11-07,Toilet accessory,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/191-516-305-452-176,Granted Patent,no,0,9,1,1,0,A45D34/02;;B65D39/0047;;B65D39/0047;;A45D34/02,A45D34/02;;B65D39/00,,0,0,,,,EXPIRED
23,US,A,US 1652402 A,030-981-647-970-286,1927-12-13,1927,US 8781126 A,1926-02-12,US 8781126 A,1926-02-12,Toilet article,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/030-981-647-970-286,Granted Patent,no,0,7,1,1,0,A45D40/24;;Y10S206/823;;A45D40/24;;Y10S206/823,A45D40/24,,0,0,,,,EXPIRED
24,US,A,US 1977183 A,073-695-249-643-266,1934-10-16,1934,US 64242332 A,1932-11-12,US 64242332 A,1932-11-12,Brush,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/073-695-249-643-266,Granted Patent,no,0,2,1,1,0,A46B11/0058;;A46B11/0058,A46B11/00,,0,0,,,,EXPIRED
25,US,A,US 1681110 A,042-692-289-473-435,1928-08-14,1928,US 21244927 A,1927-08-12,US 21244927 A,1927-08-12,Cooling vending container for drinks,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/042-692-289-473-435,Granted Patent,no,0,18,1,1,0,B65D81/18;;B65D85/305;;F25D3/08;;F25D2303/081;;F25D2331/803;;F25D2331/809;;B65D81/18;;F25D2331/809;;B65D85/305;;F25D2331/803;;F25D3/08;;F25D2303/081,B65D81/18;;B65D85/30;;F25D3/08,,0,0,,,,EXPIRED
26,US,A,US 1626927 A,051-394-114-481-207,1927-05-03,1927,US 8781226 A,1926-02-12,US 8781226 A,1926-02-12,Toilet article,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/051-394-114-481-207,Granted Patent,no,0,1,1,1,0,A45D40/24;;A45D40/24,A45D40/24,,0,0,,,,EXPIRED
27,US,A,US 1719428 A,162-033-923-173-686,1929-07-02,1929,US 19324927 A,1927-05-21,US 19324927 A,1927-05-21,Syringe,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/162-033-923-173-686,Granted Patent,no,0,61,1,1,0,A61M3/0291;;A61M3/0291,A61M3/02,,0,0,,,,EXPIRED
28,US,A,US 1814748 A,009-656-157-480-348,1931-07-14,1931,US 38305529 A,1929-08-02,US 38305529 A;;GB 3501529 A;;US 27531028 A,1928-05-05,Toilet accessory,,LUPE INC,WILLIAM FRIEDMAN,,https://lens.org/009-656-157-480-348,Granted Patent,no,0,4,3,5,0,A45D33/06;;A45D33/06,A45D33/06,,0,0,,,,EXPIRED
29,US,A,US 1634712 A,077-219-852-889-461,1927-07-05,1927,US 2447925 A,1925-04-20,US 2447925 A,1925-04-20,Combination match packet and pad,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/077-219-852-889-461,Granted Patent,no,0,4,1,1,0,A24F27/12;;A24F27/12,A24F27/12,,0,0,,,,EXPIRED
30,US,A,US 1580030 A,114-571-173-490-216,1926-04-06,1926,US 755425 A,1925-02-07,US 755425 A,1925-02-07,Combination toilet article,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/114-571-173-490-216,Granted Patent,no,0,1,1,1,0,A46B15/00;;A46B15/00,A46B15/00,,0,0,,,,EXPIRED
31,US,A,US 1854373 A,164-446-953-132-330,1932-04-19,1932,US 27531028 A,1928-05-05,US 27531028 A,1928-05-05,Container,,LUPE INC,WILLIAM FRIEDMAN,,https://lens.org/164-446-953-132-330,Granted Patent,no,0,3,1,5,0,A45D33/06;;A45D33/06,A45D33/06,,0,0,,,,EXPIRED
32,US,A,US 2677861 A,051-888-911-940-12X,1954-05-11,1954,US 29641452 A,1952-06-30,US 29641452 A,1952-06-30,Weather stripping for windows having vertically slidable sashes,,LEO H WEISS;;DAVE COHEN;;DAVID LIFSHUTZ,WILLIAM FRIEDMAN,,https://lens.org/051-888-911-940-12X,Granted Patent,no,4,2,1,1,0,E06B7/18;;E06B7/18,E06B7/18,,0,0,,,,EXPIRED
33,US,A,US 1852455 A,023-247-366-686-799,1932-04-05,1932,US 48856930 A,1930-10-14,US 48856930 A,1930-10-14,Toilet accessory,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/023-247-366-686-799,Granted Patent,no,0,56,1,1,0,A45D33/00;;A45D33/00,A45D33/00,,0,0,,,,EXPIRED
34,US,A,US 1814747 A,118-563-519-679-071,1931-07-14,1931,US 38112129 A,1929-07-26,US 38112129 A,1929-07-26,Toilet accessory,,LUPE INC,WILLIAM FRIEDMAN,,https://lens.org/118-563-519-679-071,Granted Patent,no,0,4,1,1,0,A45D33/06;;A45D33/06,A45D33/06,,0,0,,,,EXPIRED
35,US,A,US 1794602 A,054-755-170-817-000,1931-03-03,1931,US 38231229 A,1929-07-31,US 38231229 A,1929-07-31,Toilet accessory,,LUPE INC,WILLIAM FRIEDMAN,,https://lens.org/054-755-170-817-000,Granted Patent,no,0,5,1,1,0,A45D33/06;;A45D33/06,A45D33/06,,0,0,,,,EXPIRED
36,US,A,US 1739634 A,118-359-856-832-091,1929-12-17,1929,US 19649127 A,1927-06-04,US 19649127 A,1927-06-04,Bag,,WILLIAM FRIEDMAN,WILLIAM FRIEDMAN,,https://lens.org/118-359-856-832-091,Granted Patent,no,0,1,1,1,0,A45C3/06;;A45C3/06,A45C3/06,,0,0,,,,EXPIRED
37,US,A,US 2712652 A,125-322-963-092-951,1955-07-12,1955,US 30194952 A,1952-07-31,US 30194952 A,1952-07-31,Universal lavatory leg adapter,,REED CROMEX CORP,WILLIAM FRIEDMAN,,https://lens.org/125-322-963-092-951,Granted Patent,no,4,0,1,1,0,E03C1/328;;E03C1/328,E03C1/328,,0,0,,,,EXPIRED
38,JP,A,JP H1162840 A,015-762-560-915-432,1999-03-05,1999,JP 16900098 A,1998-06-16,US 88054297 A,1997-06-23,AIR PUMP,"PROBLEM TO BE SOLVED: To provide a lightweight and simple vacuum pump for a vehicular toilet. SOLUTION: An air pump is provided with a reciprocating diaphragm air pump 14 to which power is to be supplied by an electric motor for rotating an eccentric, and first and second disc valves 34, 35 faced to each other. The disc valves 34, 35 are provided with elastic disc valve components formed by blanking a flat plate. The components are connected to a bored recessed surface of a dividing wall 38 of a pump housing box 31.",ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,,https://lens.org/015-762-560-915-432,Patent Application,no,0,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,PENDING
39,EP,A3,EP 0887478 A3,050-596-065-420-019,1999-10-20,1999,EP 98102838 A,1998-02-18,US 88054297 A,1997-06-23,Vacuum toilet system,"A vacuum toilet assembly including a vacuum toilet (11) and a vacuum tank (12) (e.g. a combined holding and vacuum tank) uses a simple air pump (14) to remove air from the tank (12) to create a partial vacuum. The air pump (14) is capable of achieving about ten inches mercury of vacuum in an empty 9.5 gallon vacuum tank in roughly one minute, and can pump at least about one liter of liquid per minute. A combined sound muffler and odor filter (19) and/or rat-tail check valve and noise reducer, is/are connected to the outlet (17) from the air pump (14). The pump (14) comprises a powered reciprocating diaphragm pump having a reciprocating diaphragm (24) powered by an electric motor (28) and oppositely directed first and second disk valves (34, 35). The disk valves have elastomeric disk valve elements die-cut from flat sheets which co-operate with perforated concave surfaces in a dividing wall (38) in the pump housing (14).",ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,ELECTROLUX GMBH (2003-01-02);;DOMETIC GMBH (2003-01-22),https://lens.org/050-596-065-420-019,Search Report,yes,6,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 9, no. 22 (M - 354)<1745> 30 January 1985 (1985-01-30)",EXPIRED
40,US,A,US 1694874 A,112-638-008-426-609,1928-12-11,1928,US 57398122 A,1922-07-10,US 57398122 A,1922-07-10,Method of electrical signaling,,FRIEDMAN WILLIAM F,FRIEDMAN WILLIAM F,,https://lens.org/112-638-008-426-609,Granted Patent,no,0,2,1,1,0,H04L5/06;;H04L5/06,H04L5/06,,0,0,,,,EXPIRED
41,AU,A,AU 1998/069819 A,115-300-334-356-15X,1998-12-24,1998,AU 1998/069819 A,1998-05-29,US 88054297 A,1997-06-23,Vacuum toilet system,,DOMETIC GMBH,FRIEDMAN WILLIAM J,DOMETIC GMBH (2003-06-26),https://lens.org/115-300-334-356-15X,Patent Application,no,0,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,EXPIRED
42,DK,C,DK 31833 C,163-100-412-304-932,1923-06-11,1923,DK 31833D A,1922-05-26,US 31833X A,1922-01-14,Skedesprøjte.,,FRIEDMAN ISAAC WILLIAM,FRIEDMAN ISAAC WILLIAM,,https://lens.org/163-100-412-304-932,Granted Patent,no,0,0,1,1,0,,,30,0,0,,,,EXPIRED
43,WO,A1,WO 1993/017666 A1,128-509-618-444-599,1993-09-16,1993,US 9301491 W,1993-02-19,US 84410792 A,1992-03-02,"METHOD OF TREATMENT FOR NASAL AND SINUS DYSFUNCTION, AND HORSERADISH PREPARATION THEREFOR","A method of treatment for nasal and sinus dysfunction is disclosed comprising topically applying a horseradish, sinigrin or allyl isothiocyanate preparation to affected mucosa. Preparations for the treatment of nasal and sinus dysfunction are also disclosed, including preparations of horseradish, sinigrin and allyl isothiocyanate.",FRIEDMAN WILLIAM H,FRIEDMAN WILLIAM H,,https://lens.org/128-509-618-444-599,Patent Application,yes,1,0,11,12,0,A61K9/0043;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/31;;A61P27/16;;A61P37/08;;A61K36/31;;A61K31/7028;;A61K31/26;;A61K9/0043;;A61K9/12;;A61K9/008;;A61P11/02;;A61K31/70;;A61K9/0043;;A61K31/26;;A61K36/31;;A61K33/14,A61K9/00;;A61K9/08;;A61K9/107;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/18;;A61K36/31;;A61P27/16;;A61P37/08,,0,0,,,,PATENTED
44,EP,B1,EP 0887478 B1,197-841-323-269-452,2003-05-07,2003,EP 98102838 A,1998-02-18,US 88054297 A,1997-06-23,Vacuum toilet system,,DOMETIC GMBH,FRIEDMAN WILLIAM J,ELECTROLUX GMBH (2003-01-02);;DOMETIC GMBH (2003-01-22),https://lens.org/197-841-323-269-452,Granted Patent,yes,6,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 9, no. 22 (M-354) [1745], 30 January 1985 (1985-01-30) & JP 59 168257 A (YOSHIHISA NOMURA), 21 September 1984 (1984-09-21)",EXPIRED
45,DE,D1,DE 69814238 D1,017-100-051-907-960,2003-06-12,2003,DE 69814238 T,1998-02-18,US 88054297 A,1997-06-23,Vakuumtoilettensystem,,DOMETIC GMBH,FRIEDMAN WILLIAM J,,https://lens.org/017-100-051-907-960,Granted Patent,no,0,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,EXPIRED
46,US,A,US 6082979 A,082-713-617-091-120,2000-07-04,2000,US 88054297 A,1997-06-23,US 88054297 A,1997-06-23,Air pump for vacuum toilet systems,"A vacuum toilet assembly including a vacuum toilet and a vacuum tank (e.g. a combined holding and vacuum tank) uses a simple air pump to remove air from the tank to create a partial vacuum. The air pump is capable of achieving about ten inches mercury of vacuum in an empty 9.5 gallon vacuum tank in roughly one minute, and can pump at least about one liter of liquid per minute. A combined sound muffler and odor filter and/or rat-tail check valve and noise reducer, is/are connected to the outlet from the air pump. The pump comprises a powered reciprocating diaphragm pump having a reciprocating diaphragm powered by an electric motor rotating an eccentric at about 2300 rpm, and oppositely directed first and second disk valves. The disk valves have elastomeric disk valve elements die-cut from flat sheets which cooperate with perforated concave surfaces in a dividing wall in the pump housing. The reciprocating diaphragm has a total stroke length of about 0.3-0.33 inches.",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J,DOMETIC CORPORATION (2008-12-30);;DOMETIC SANITATION CORPORATION (2005-04-07),https://lens.org/082-713-617-091-120,Granted Patent,yes,31,24,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,417/566;;4/431;;417/413.1,2,0,,,"Modern Plastics, McGraw Hill, pp. 23 30, 84 85, Oct. 1991.;;Webster s New Collegiate Dictionary, p. 12, Dec. 1979.",EXPIRED
47,US,A,US 1522775 A,111-003-325-982-187,1925-01-13,1925,US 55257822 A,1922-04-14,US 55257822 A,1922-04-14,Secret-signaling apparatus for automatically enciphering and deciphering messages,,FRIEDMAN WILLIAM F,FRIEDMAN WILLIAM F,,https://lens.org/111-003-325-982-187,Granted Patent,no,0,10,1,1,0,H04L9/38;;H04L9/38,H04L9/38,,0,0,,,,EXPIRED
48,US,A,US 2011335 A,179-134-982-665-859,1935-08-13,1935,US 74993934 A,1934-10-25,US 74993934 A,1934-10-25,Arc welding apparatus,,DAVID CLAYMAN;;EUGENE UNGAR,FRIEDMAN WILLIAM H,,https://lens.org/179-134-982-665-859,Granted Patent,no,0,2,1,1,0,B23K9/073;;B23K9/073,B23K9/073,,0,0,,,,EXPIRED
49,US,A,US 6097812 A,001-485-448-097-440,2000-08-01,2000,US 68209633 A,1933-07-25,US 68209633 A,1933-07-25,Cryptographic system,"The crytographic system automatically and continuously changes the cipher equivalents representing plaintext characters so as to prevent any periodicity in the relationship. The system has a series of juxtaposed, rotatable, connection changing mechanisms to provide a large number of alternative paths for the passage of an electric current corresponding to a message character. Further, the system has parts for the irregular and permutative displacements of the members of a set of circuit changing mechanisms to thwart cryptanalysis.",US NATIONAL SECURITY AGENCY,FRIEDMAN WILLIAM F,,https://lens.org/001-485-448-097-440,Granted Patent,yes,4,12,1,1,0,H04L9/38;;H04L9/38;;H04L9/16;;H04L9/16,H04L9/38,380/26;;380/287;;380/52;;380/56;;380/57;;380/59;;341/50;;341/90;;341/91,0,0,,,,EXPIRED
50,US,A,US 1608590 A,034-279-241-956-690,1926-11-30,1926,US 7977426 A,1926-01-07,US 7977426 A,1926-01-07,Alphabetical chart,,FRIEDMAN WILLIAM F,FRIEDMAN WILLIAM F,,https://lens.org/034-279-241-956-690,Granted Patent,no,0,1,1,1,0,B42D15/00;;B42D15/00,B42D15/00,,0,0,,,,EXPIRED
51,DE,T2,DE 69807787 T2,125-523-249-471-322,2003-02-06,2003,DE 69807787 T,1998-02-18,US 88054297 A,1997-06-23,Luftpumpe,,ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,"DOMETIC GMBH, 57074 SIEGEN, DE (2003-03-13)",https://lens.org/125-523-249-471-322,Granted Patent,no,0,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,EXPIRED
52,DE,D1,DE 69325265 D1,017-753-495-235-868,1999-07-15,1999,DE 69325265 T,1993-02-19,US 84410792 A;;US 9301491 W,1992-03-02,VERFAHREN ZUR BEHANDLUNG VON NASEN- UND NEBENHÖHLENFUNKTIONSSTÖRUNG UND MEERRETTICHZUBEREITUNG HIERFÜR,"A method of treatment for nasal and sinus dysfunction is disclosed comprising topically applying a horseradish, sinigrin or allyl isothiocyanate preparation to affected mucosa. Preparations for the treatment of nasal and sinus dysfunction are also disclosed, including preparations of horseradish, sinigrin and allyl isothiocyanate.",FRIEDMAN WILLIAM H,FRIEDMAN WILLIAM H,,https://lens.org/017-753-495-235-868,Granted Patent,no,0,0,11,12,0,A61K9/0043;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/31;;A61P27/16;;A61P37/08;;A61K36/31;;A61K31/7028;;A61K31/26;;A61K9/0043;;A61K9/12;;A61K9/008;;A61P11/02;;A61K31/70;;A61K9/0043;;A61K31/26;;A61K36/31;;A61K33/14,A61K9/08;;A61K9/00;;A61K9/107;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/18;;A61K36/31;;A61P27/16;;A61P37/08,,0,0,,,,EXPIRED
53,AU,B2,AU 752110 B2,121-594-058-833-493,2002-09-05,2002,AU 1998/069819 A,1998-05-29,US 88054297 A,1997-06-23,Vacuum toilet system,,ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,DOMETIC GMBH (2003-06-26),https://lens.org/121-594-058-833-493,Granted Patent,no,3,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,EXPIRED
54,US,A,US 1699105 A,173-137-533-749-032,1929-01-15,1929,US 24132527 A,1927-12-20,US 24132527 A,1927-12-20,Banner-display fixture,,FRIEDMAN WILLIAM E,FRIEDMAN WILLIAM E,,https://lens.org/173-137-533-749-032,Granted Patent,no,0,1,1,1,0,A47H23/04;;A47H23/04,A47H23/04,,0,0,,,,EXPIRED
55,US,A,US 5385734 A,009-419-907-048-943,1995-01-31,1995,US 6899893 A,1993-05-27,US 6899893 A;;US 84410792 A,1992-03-02,Horseradish preparation for the treatment of nasal and sinus dysfunction,"A method of treatment for nasal and sinus dysfunction is disclosed comprising topically applying a horseradish, sinigrin or allyl isothiocyanate preparation to affected mucosa. Preparations for the treatment of nasal and sinus dysfunction are also disclosed, including preparations of horseradish, sinigrin and allyl isothiocyanate.",HORSERADISH SPRAY INC,FRIEDMAN WILLIAM H,HORSERADISH SPRAY INC (1993-10-21),https://lens.org/009-419-907-048-943,Granted Patent,yes,2,70,11,12,0,A61K9/0043;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/31;;A61P27/16;;A61P37/08;;A61K36/31;;A61K31/7028;;A61K31/26;;A61K9/0043;;A61K9/12;;A61K9/008;;A61P11/02;;A61K31/70;;A61K9/0043;;A61K31/26;;A61K36/31;;A61K33/14,A61K9/00;;A61K9/107;;A61K31/26;;A61K9/08;;A61K31/70;;A61K33/14;;A61K36/18;;A61K36/31;;A61P27/16;;A61P37/08,424/434;;424/195.1;;424/489;;514/951,1,0,,,"Fan Yung et al, Dispersion Characteristics of Vegetable Juices , Izvestiya Vysshikh Uchebnykh Zavedenii, Pishcheyaya Tekhnologiya 1980, No. 2, 138 139, Abstract only.",EXPIRED
56,DE,T1,DE 887552 T1,078-879-322-642-015,2000-03-02,2000,DE 98102837 T,1998-02-18,US 88054297 A,1997-06-23,Luftpumpe,,ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,,https://lens.org/078-879-322-642-015,Granted Patent,no,0,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,EXPIRED
57,EP,A4,EP 0630232 A4,099-636-149-888-390,1995-07-12,1995,EP 93906980 A,1993-02-19,US 9301491 W;;US 84410792 A,1992-03-02,"METHOD OF TREATMENT FOR NASAL AND SINUS DYSFUNCTION, AND HORSERADISH PREPARATION THEREFOR.","A method of treatment for nasal and sinus dysfunction is disclosed comprising topically applying a horseradish, sinigrin or allyl isothiocyanate preparation to affected mucosa. Preparations for the treatment of nasal and sinus dysfunction are also disclosed, including preparations of horseradish, sinigrin and allyl isothiocyanate.",FRIEDMAN WILLIAM H,FRIEDMAN WILLIAM H,,https://lens.org/099-636-149-888-390,Search Report,no,1,0,11,12,0,A61K9/0043;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/31;;A61P27/16;;A61P37/08;;A61K36/31;;A61K31/7028;;A61K31/26;;A61K9/0043;;A61K9/12;;A61K9/008;;A61P11/02;;A61K31/70;;A61K9/0043;;A61K31/26;;A61K36/31;;A61K33/14,A61K9/08;;A61K9/00;;A61K9/107;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/18;;A61K36/31;;A61P27/16;;A61P37/08,,0,0,,,,EXPIRED
58,EP,A2,EP 0887552 A2,037-562-600-672-941,1998-12-30,1998,EP 98102837 A,1998-02-18,US 88054297 A,1997-06-23,Air pump,"A reciprocating diaphragm air pump (14) powered by an electric motor (28) rotating an eccentric and oppositely directed first and second disk valves (34, 35). The disk valves have elastomeric disk valve elements die-cut from flat sheets which co-operate with perforated concave surfaces in a dividing wall (38) in the pump housing (31).",ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,DOMETIC GMBH (2003-04-01),https://lens.org/037-562-600-672-941,Patent Application,yes,0,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,EXPIRED
59,AU,A,AU 1993/037749 A,047-238-931-163-664,1993-10-05,1993,AU 1993/037749 A,1993-02-19,US 9301491 W;;US 84410792 A,1992-03-02,"METHOD OF TREATMENT FOR NASAL AND SINUS DYSFUNCTION, AND HORSERADISH PREPARATION THEREFOR",,WILLIAM H FRIEDMAN,FRIEDMAN WILLIAM H,,https://lens.org/047-238-931-163-664,Patent Application,no,0,0,1,12,0,,A61K9/14,,0,0,,,,PENDING
60,US,A,US 1653163 A,104-907-964-955-861,1927-12-20,1927,US 52093021 A,1921-12-08,US 52093021 A,1921-12-08,Syringe,,WILLIAM FRIEDMAN ISAAC,WILLIAM FRIEDMAN ISAAC,,https://lens.org/104-907-964-955-861,Granted Patent,no,0,1,1,1,0,A61M3/0279;;A61M3/0279,A61M3/02,,0,0,,,,EXPIRED
61,US,A,US 2518458 A,109-032-158-226-456,1950-08-15,1950,US 55117244 A,1944-08-25,US 55117244 A,1944-08-25,Authenticating device,,FRIEDMAN WILLIAM F,FRIEDMAN WILLIAM F,,https://lens.org/109-032-158-226-456,Granted Patent,no,6,5,1,1,0,G09C1/12;;G09C1/12,G09C1/12;;H04L9/38,,0,0,,,,EXPIRED
62,US,A,US 2395863 A,156-664-259-829-248,1946-03-05,1946,US 30021239 A,1939-10-19,US 30021239 A,1939-10-19,Cryptographic device,,FRIEDMAN WILLIAM F,FRIEDMAN WILLIAM F,,https://lens.org/156-664-259-829-248,Granted Patent,no,0,3,1,1,0,G09C1/04;;G09C1/04,G09C1/04,,0,0,,,,EXPIRED
63,EP,A1,EP 0630232 A1,149-879-495-478-878,1994-12-28,1994,EP 93906980 A,1993-02-19,US 9301491 W;;US 84410792 A,1992-03-02,"METHOD OF TREATMENT FOR NASAL AND SINUS DYSFUNCTION, AND HORSERADISH PREPARATION THEREFOR.","A method of treatment for nasal and sinus dysfunction is disclosed comprising topically applying a horseradish, sinigrin or allyl isothiocyanate preparation to affected mucosa. Preparations for the treatment of nasal and sinus dysfunction are also disclosed, including preparations of horseradish, sinigrin and allyl isothiocyanate.",FRIEDMAN WILLIAM H,FRIEDMAN WILLIAM H,,https://lens.org/149-879-495-478-878,Patent Application,yes,0,0,11,12,0,A61K9/0043;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/31;;A61P27/16;;A61P37/08;;A61K36/31;;A61K31/7028;;A61K31/26;;A61K9/0043;;A61K9/12;;A61K9/008;;A61P11/02;;A61K31/70;;A61K9/0043;;A61K31/26;;A61K36/31;;A61K33/14,A61K9/08;;A61K9/00;;A61K9/107;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/18;;A61K36/31;;A61P27/16;;A61P37/08,,0,0,,,,EXPIRED
64,DE,T2,DE 69814238 T2,168-034-147-526-794,2004-01-08,2004,DE 69814238 T,1998-02-18,US 88054297 A,1997-06-23,Vakuumtoilettensystem,,DOMETIC GMBH,FRIEDMAN WILLIAM J,,https://lens.org/168-034-147-526-794,Granted Patent,no,0,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,EXPIRED
65,AU,B2,AU 752014 B2,193-578-705-827-893,2002-09-05,2002,AU 1998/069820 A,1998-05-29,US 88054297 A,1997-06-23,Air pump,,ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,,https://lens.org/193-578-705-827-893,Granted Patent,no,3,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,EXPIRED
66,US,A,US 2552548 A,034-036-906-051-188,1951-05-15,1951,US 47819343 A,1943-03-06,US 47819343 A,1943-03-06,Facsimile enciphering system,,FRIEDMAN WILLIAM F,FRIEDMAN WILLIAM F,,https://lens.org/034-036-906-051-188,Granted Patent,no,7,3,1,1,0,H04N1/448;;H04N1/448,H04N1/44,,0,0,,,,EXPIRED
67,AU,A,AU 1997/024855 A,082-637-150-637-668,1998-12-17,1998,AU 1997/024855 A,1997-06-12,AU 1997/024855 A,1997-06-12,"Method of treatment for nasal and sinus dysfunction, and horseradish preparation therefor",,HORSERADISH SPRAY INC,FRIEDMAN WILLIAM H,,https://lens.org/082-637-150-637-668,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
68,US,A,US 2139676 A,123-640-520-862-639,1938-12-13,1938,US 15738337 A,1937-08-04,US 15738337 A,1937-08-04,Cryptographic apparatus,,FRIEDMAN WILLIAM F,FRIEDMAN WILLIAM F,,https://lens.org/123-640-520-862-639,Granted Patent,no,0,14,1,1,0,G09C3/08;;G09C3/08,G09C1/12,,0,0,,,,EXPIRED
69,CA,A1,CA 2131458 A1,151-622-835-419-54X,1993-09-16,1993,CA 2131458 A,1993-02-19,US 84410792 A,1992-03-02,"METHOD OF TREATMENT FOR NASAL AND SINUS DYSFUNCTION, AND HORSERADISH PREPARATION THEREFOR","2131458 9317666 PCTABS00025 A method of treatment for nasal and sinus dysfunction is disclosed comprising topically applying a horseradish, sinigrin or allyl isothiocyanate preparation to affected mucosa. Preparations for the treatment of nasal and sinus dysfunction are also disclosed, including preparations of horseradish, sinigrin and allyl isothiocyanate.",FRIEDMAN WILLIAM H,FRIEDMAN WILLIAM H,,https://lens.org/151-622-835-419-54X,Patent Application,no,0,0,11,12,0,A61K9/0043;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/31;;A61P27/16;;A61P37/08;;A61K36/31;;A61K31/7028;;A61K31/26;;A61K9/0043;;A61K9/12;;A61K9/008;;A61P11/02;;A61K31/70;;A61K9/0043;;A61K31/26;;A61K36/31;;A61K33/14,A61K9/08;;A61K9/00;;A61K9/107;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/18;;A61K36/31;;A61P27/16;;A61P37/08,,0,0,,,,DISCONTINUED
70,US,A,US 6130946 A,138-404-653-188-81X,2000-10-10,2000,US 10724436 A,1936-10-23,US 10724436 A,1936-10-23,Cryptographs,"The cryptographic system automatically and continuously changes the cipher equivalents representing plaintext characters so as to prevent any periodicity in the relationship. The system has a series of juxtaposed, rotatable, connection changing mechanisms to provide a large number of alternative paths for the passage of an electric current corresponding to a message character. Further, the system has parts for the irregular and permutative displacements of the members of a set of circuit changing mechanisms to thwart cryptanalysis. The juxtaposed cipher commutators are controlled by cam wheels of different diameters.",US NATIONAL SECURITY AGENCY,FRIEDMAN WILLIAM F,,https://lens.org/138-404-653-188-81X,Granted Patent,yes,4,7,1,1,0,G09C1/10;;G09C1/10,H04L9/10;;H04L9/38,380/26;;380/287;;380/52;;380/56;;380/57;;380/59;;341/50;;341/90;;341/91,0,0,,,,EXPIRED
71,EP,A3,EP 0887552 A3,098-577-188-741-267,1999-10-20,1999,EP 98102837 A,1998-02-18,US 88054297 A,1997-06-23,Air pump,"A reciprocating diaphragm air pump (14) powered by an electric motor (28) rotating an eccentric and oppositely directed first and second disk valves (34, 35). The disk valves have elastomeric disk valve elements die-cut from flat sheets which co-operate with perforated concave surfaces in a dividing wall (38) in the pump housing (31).",ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,DOMETIC GMBH (2003-04-01),https://lens.org/098-577-188-741-267,Search Report,yes,3,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 9, no. 22 (M - 354)<1745> 30 January 1985 (1985-01-30)",EXPIRED
72,US,A,US 1204558 A,165-162-542-433-392,1916-11-14,1916,US 1913/0793783 A,1913-10-06,US 1913/0793783 A,1913-10-06,RECORDING INSTRUMENT.,,FRIEDMAN WILLIAM L,FRIEDMAN WILLIAM L,,https://lens.org/165-162-542-433-392,Granted Patent,no,0,2,1,1,0,G01D15/14;;G01D15/14,,,0,0,,,,EXPIRED
73,US,A,US 1530660 A,033-043-447-837-34X,1925-03-24,1925,US 57764922 A,1922-07-26,US 57764922 A,1922-07-26,Printing-telegraph system,,FRIEDMAN WILLIAM F,FRIEDMAN WILLIAM F,,https://lens.org/033-043-447-837-34X,Granted Patent,no,0,1,1,1,0,H04L27/26;;H04L27/26,H04L27/26,,0,0,,,,EXPIRED
74,US,A,US 2140424 A,052-204-883-949-720,1938-12-13,1938,US 14690637 A,1937-06-07,US 14690637 A,1937-06-07,Cryptographic device,,FRIEDMAN WILLIAM F,FRIEDMAN WILLIAM F,,https://lens.org/052-204-883-949-720,Granted Patent,no,0,2,1,1,0,G09C1/04;;G09C1/04,G09C1/08,,0,0,,,,EXPIRED
75,JP,A,JP H1170059 A,107-802-040-644-586,1999-03-16,1999,JP 16900398 A,1998-06-16,US 88054297 A,1997-06-23,VACUUM TOILET SYSTEM,"PROBLEM TO BE SOLVED: To provide a light-weight and simple toilet system for automobiles. SOLUTION: A vacuum toilet assembly 10 includes a vacuum toilet 11 and a vacuum tank 12, and a single cylinder air pump 14 is used to remove air from the tank 12 and create a partial vacuum. A composite silencer/filter 19 and/or a narrow and round check valve or a noise suppresser are connected to a discharge port 17 from the air pump 14. The pump 14 is a power reciprocating diaphragm pump, and it is provided with a reciprocating diaphragm 24 which is powered from an electric motor 28 and a first and a second disc valves facing to each other. These disc valves have elastic disc valve components made by punching a flat plate. The components are associated with an apertured dent surface of the division wall of the pump 14 housing.",ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,,https://lens.org/107-802-040-644-586,Patent Application,no,0,1,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,PENDING
76,AU,A,AU 1998/069820 A,180-796-640-219-558,1998-12-24,1998,AU 1998/069820 A,1998-05-29,US 88054297 A,1997-06-23,Air pump,,ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,,https://lens.org/180-796-640-219-558,Patent Application,no,0,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,EXPIRED
77,CH,A,CH 100323 A,182-751-783-254-83X,1923-07-16,1923,CH 100323D A,1922-05-30,US 100323X A,1922-01-14,Vaginal-Irrigator.,,ISAAC WILLIAM FRIEDMAN,WILLIAM FRIEDMAN ISAAC,,https://lens.org/182-751-783-254-83X,Granted Patent,no,0,0,1,1,0,,,116K,0,0,,,,EXPIRED
78,EP,B1,EP 0887552 B1,057-056-675-283-047,2002-09-11,2002,EP 98102837 A,1998-02-18,US 88054297 A,1997-06-23,Air pump,,ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,DOMETIC GMBH (2003-04-01),https://lens.org/057-056-675-283-047,Granted Patent,yes,3,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 9, no. 22 (M-354) [1745], 30 January 1985 (1985-01-30) & JP 59 168257 A (YOSHIHISA NOMURA), 21 September 1984 (1984-09-21)",EXPIRED
79,US,A,US 1358685 A,184-944-126-401-215,1920-11-09,1920,US 12688916 A,1916-10-21,US 12688916 A,1916-10-21,Means for viewing pictures in relief,,FRIEDMAN WILLIAM L,FRIEDMAN WILLIAM L,,https://lens.org/184-944-126-401-215,Granted Patent,no,0,6,1,1,0,G03B21/606;;G03B21/606,G03B21/60,,0,0,,,,EXPIRED
80,US,A,US 1105898 A,038-972-137-061-249,1914-08-04,1914,US 1912/0730070 A,1912-11-07,US 1912/0730070 A,1912-11-07,RECORDING-THERMOMETER.,,FRIEDMAN WILLIAM L,FRIEDMAN WILLIAM L,,https://lens.org/038-972-137-061-249,Granted Patent,no,0,0,1,1,0,G01K1/022;;G01K1/022,,,0,0,,,,EXPIRED
81,US,A,US 2877565 A,047-878-891-460-511,1959-03-17,1959,US 54908644 A,1944-08-11,US 54908644 A,1944-08-11,Electrical cryptograph,,FRIEDMAN WILLIAM F,FRIEDMAN WILLIAM F,,https://lens.org/047-878-891-460-511,Granted Patent,no,6,2,1,1,0,G09C1/10;;G09C1/10,H04L9/38,,0,0,,,,EXPIRED
82,EP,A2,EP 0887478 A2,111-775-106-890-362,1998-12-30,1998,EP 98102838 A,1998-02-18,US 88054297 A,1997-06-23,Vacuum toilet system,"A vacuum toilet assembly including a vacuum toilet (11) and a vacuum tank (12) (e.g. a combined holding and vacuum tank) uses a simple air pump (14) to remove air from the tank (12) to create a partial vacuum. The air pump (14) is capable of achieving about ten inches mercury of vacuum in an empty 9.5 gallon vacuum tank in roughly one minute, and can pump at least about one liter of liquid per minute. A combined sound muffler and odor filter (19) and/or rat-tail check valve and noise reducer, is/are connected to the outlet (17) from the air pump (14). The pump (14) comprises a powered reciprocating diaphragm pump having a reciprocating diaphragm (24) powered by an electric motor (28) and oppositely directed first and second disk valves (34, 35). The disk valves have elastomeric disk valve elements die-cut from flat sheets which co-operate with perforated concave surfaces in a dividing wall (38) in the pump housing (14).",ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,ELECTROLUX GMBH (2003-01-02);;DOMETIC GMBH (2003-01-22),https://lens.org/111-775-106-890-362,Patent Application,yes,0,3,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,EXPIRED
83,US,A,US 1020754 A,009-192-972-874-228,1912-03-19,1912,US 1911/0604491 A,1911-01-24,US 1911/0604491 A,1911-01-24,DETACHABLE HAT-PIN HEAD.,,FRIEDMAN WILLIAM LLOYD,FRIEDMAN WILLIAM LLOYD,,https://lens.org/009-192-972-874-228,Granted Patent,no,0,0,1,1,0,A44B1/28;;A44B1/28;;Y10T24/4627;;Y10T24/4627,,,0,0,,,,EXPIRED
84,EP,B1,EP 0630232 B1,128-236-885-972-934,1999-06-09,1999,EP 93906980 A,1993-02-19,US 9301491 W;;US 84410792 A,1992-03-02,"METHOD OF TREATMENT FOR NASAL AND SINUS DYSFUNCTION, AND HORSERADISH PREPARATION THEREFOR","A method of treatment for nasal and sinus dysfunction is disclosed comprising topically applying a horseradish, sinigrin or allyl isothiocyanate preparation to affected mucosa. Preparations for the treatment of nasal and sinus dysfunction are also disclosed, including preparations of horseradish, sinigrin and allyl isothiocyanate.",FRIEDMAN WILLIAM H,FRIEDMAN WILLIAM H,,https://lens.org/128-236-885-972-934,Granted Patent,yes,2,0,11,12,0,A61K9/0043;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/31;;A61P27/16;;A61P37/08;;A61K36/31;;A61K31/7028;;A61K31/26;;A61K9/0043;;A61K9/12;;A61K9/008;;A61P11/02;;A61K31/70;;A61K9/0043;;A61K31/26;;A61K36/31;;A61K33/14,A61K9/08;;A61K9/00;;A61K9/107;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/18;;A61K36/31;;A61P27/16;;A61P37/08,,0,0,,,,EXPIRED
85,AT,T1,AT E180967 T1,003-121-973-681-982,1999-06-15,1999,AT 93906980 T,1993-02-19,US 84410792 A,1992-03-02,VERFAHREN ZUR BEHANDLUNG VON NASEN- UND NEBENHÖHLENFUNKTIONSSTÖRUNG UND MEERRETTICHZUBEREITUNG HIERFÜR,"A method of treatment for nasal and sinus dysfunction is disclosed comprising topically applying a horseradish, sinigrin or allyl isothiocyanate preparation to affected mucosa. Preparations for the treatment of nasal and sinus dysfunction are also disclosed, including preparations of horseradish, sinigrin and allyl isothiocyanate.",FRIEDMAN WILLIAM H,FRIEDMAN WILLIAM H,,https://lens.org/003-121-973-681-982,Granted Patent,no,0,0,11,12,0,A61K9/0043;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/31;;A61P27/16;;A61P37/08;;A61K36/31;;A61K31/7028;;A61K31/26;;A61K9/0043;;A61K9/12;;A61K9/008;;A61P11/02;;A61K31/70;;A61K9/0043;;A61K31/26;;A61K36/31;;A61K33/14,A61K9/08;;A61K9/00;;A61K9/107;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/18;;A61K36/31;;A61P27/16;;A61P37/08,,0,0,,,,DISCONTINUED
86,US,A,US 5248504 A,055-864-990-144-867,1993-09-28,1993,US 84410792 A,1992-03-02,US 84410792 A,1992-03-02,METHOD OF TREATMENT FOR NASAL AND SINUS DYSFUNCTION,"A method of treatment for nasal and sinus dysfunction is disclosed comprising topically applying a horseradish, sinigrin or allyl isothiocyanate preparation to affected mucosa. Preparations for the treatment of nasal and sinus dysfunction are also disclosed, including preparations of horseradish, sinigrin and allyl isothiocyanate.",FRIEDMAN WILLIAM H,FRIEDMAN WILLIAM H,HORSERADISH SPRAY INC (1993-10-21),https://lens.org/055-864-990-144-867,Granted Patent,yes,14,26,11,12,0,A61K9/0043;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/31;;A61P27/16;;A61P37/08;;A61K36/31;;A61K31/7028;;A61K31/26;;A61K9/0043;;A61K9/12;;A61K9/008;;A61P11/02;;A61K31/70;;A61K9/0043;;A61K31/26;;A61K36/31;;A61K33/14,A61K9/00;;A61K9/107;;A61K9/08;;A61K31/26;;A61K31/70;;A61K33/14;;A61K36/18;;A61K36/31;;A61P27/16;;A61P37/08,424/434;;424/489;;514/951,4,0,,,"Aldrich Chemical Company, Inc., Catalog Nos. A3 320 5 and 5 330 5.;;Gosselin, et al., Clinical Toxicology of Commercial Products, Williams and Wilkins, Ref. 1359, 5th Edition, 1985.;;Physician s Desk Reference (1992), pp. 751, 1036, 2064, 2419.;;The Merck Index, 11th Edition (1989), Ref. No. 293 (p. 50), Ref. No. 4668 (p. 750), Ref. No. 6224 (p. 995), Ref. No. 6919 (p. 1102), Ref. No. 8495 (p. 1352), Ref. No. 9993 (p. 1591).",EXPIRED
87,DE,T1,DE 887478 T1,057-552-808-697-343,2000-03-02,2000,DE 98102838 T,1998-02-18,US 88054297 A,1997-06-23,Vakuumtoilettensystem,,ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,,https://lens.org/057-552-808-697-343,Granted Patent,no,0,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,EXPIRED
88,DE,D1,DE 69807787 D1,115-788-530-895-857,2002-10-17,2002,DE 69807787 T,1998-02-18,US 88054297 A,1997-06-23,Luftpumpe,,ELECTROLUX SIEGEN GMBH,FRIEDMAN WILLIAM J,"DOMETIC GMBH, 57074 SIEGEN, DE (2003-03-13)",https://lens.org/115-788-530-895-857,Granted Patent,no,0,0,19,19,0,E03F1/006;;E03F1/006,A47K11/00;;B60R15/04;;B63B29/14;;E03F1/00;;F04B45/04,,0,0,,,,EXPIRED
89,US,A,US 2080416 A,195-772-759-595-25X,1937-05-18,1937,US 2850035 A,1935-06-26,US 2850035 A,1935-06-26,Message authenticating system,,FRIEDMAN WILLIAM F,FRIEDMAN WILLIAM F,,https://lens.org/195-772-759-595-25X,Granted Patent,no,0,1,1,1,0,H04L12/02;;H04L12/02,H04L12/02,,0,0,,,,EXPIRED
90,US,A,US 1263947 A,119-130-344-472-759,1918-04-23,1918,US 19678017 A,1917-10-16,US 19678017 A,1917-10-16,COMPOSITE CUSHIONING NON-INFLATABLE TIRE.,,SHOMER WILLIAM;;FRIEDMAN HARRY,SHOMER WILLIAM;;FRIEDMAN HARRY,,https://lens.org/119-130-344-472-759,Granted Patent,no,0,5,1,1,0,Y10T152/10378;;B60C7/101;;Y10T152/10378;;B60C7/101,,,0,0,,,,EXPIRED
91,DE,T2,DE 3853295 T2,038-358-563-756-764,1995-08-10,1995,DE 3853295 T,1988-12-02,US 12827387 A;;US 8804303 W,1987-12-03,VORRICHTUNG FÜR STEREOTAKTISCHE RADIOCHIRURGIE.,,UNIV FLORIDA,BOVA FRANK;;FRIEDMAN WILLIAM,,https://lens.org/038-358-563-756-764,Granted Patent,no,0,0,9,9,0,A61B2017/00707;;A61B2017/00712;;A61N5/10;;A61N5/103;;A61N5/1031;;A61N5/1049;;A61B2090/363;;A61B2090/101;;A61N5/1049;;A61N5/1031;;A61N5/10;;A61N5/103;;A61B2017/00712;;A61B2017/00707;;A61B2090/363;;A61B2090/101,A61B17/00;;A61B19/00;;A61N5/10,,0,0,,,,EXPIRED
92,BG,B1,BG 64742 B1,027-792-767-323-058,2006-02-28,2006,BG 10391699 A,1999-11-23,US 5149997 P,1997-07-01,SERTRALINE-CONTAINING BATCHED FORMS WITH DELAYED RELEASE,The batched forms reduce Tmax and any side effects. By them the place is determined and the time of the delayed release of the medicamentous form along the course of the gastrointestinal tract is controlled. The identification of the controlled release of the batched forms is made by in vitro testing.,PFIZER PROD INC,CURATOLO WILLIAM;;FRIEDMAN HYLAR,,https://lens.org/027-792-767-323-058,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K31/00;;A61K/;;A61K9/00;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
93,US,A,US 2072327 A,164-528-024-351-909,1937-03-02,1937,US 64902432 A,1932-12-27,US 64902432 A,1932-12-27,Dispensing device,,LINDNER,WILLIAM FRIEDMAN;;BENJAMIN LINDNER,,https://lens.org/164-528-024-351-909,Granted Patent,no,0,10,1,1,0,B65D83/0005;;B65D83/0005,B65D83/00,,0,0,,,,EXPIRED
94,US,A,US 2378072 A,116-707-837-120-094,1945-06-12,1945,US 43983842 A,1942-04-21,US 43983842 A,1942-04-21,Tip holder and feeder for sewing machines,,WILLIAM FARKAS;;ISIDOR FRIEDMAN,WILLIAM FARKAS;;ISIDOR FRIEDMAN,,https://lens.org/116-707-837-120-094,Granted Patent,no,0,0,1,1,0,D05B3/22;;D05B3/22;;D05B33/006;;D05B33/006;;D05D2303/12;;D05D2303/12;;D10B2503/10;;D10B2503/10,D05B3/22;;D05B33/00,,0,0,,,,EXPIRED
95,DE,D1,DE 3853295 D1,067-888-492-656-423,1995-04-13,1995,DE 3853295 T,1988-12-02,US 12827387 A;;US 8804303 W,1987-12-03,VORRICHTUNG FÜR STEREOTAKTISCHE RADIOCHIRURGIE.,,UNIV FLORIDA,BOVA FRANK;;FRIEDMAN WILLIAM,,https://lens.org/067-888-492-656-423,Granted Patent,no,0,0,9,9,0,A61B2017/00707;;A61B2017/00712;;A61N5/10;;A61N5/103;;A61N5/1031;;A61N5/1049;;A61B2090/363;;A61B2090/101;;A61N5/1049;;A61N5/1031;;A61N5/10;;A61N5/103;;A61B2017/00712;;A61B2017/00707;;A61B2090/363;;A61B2090/101,A61B17/00;;A61B19/00;;A61N5/10,,0,0,,,,EXPIRED
96,US,A,US 4410104 A,124-238-765-086-843,1983-10-18,1983,US 28433081 A,1981-07-17,US 28433081 A,1981-07-17,Vending machine,"A vending apparatus well suited for vending such articles as newspapers, magazines or the like which vary in size, in which the articles to be vended are supplied to one side of an access opening in the vending apparatus enclosure. Access opening gating normally in a closed position prevents removal of an article unless, after paying a prescribed fee, the customer operates a gating actuator to cause the gating to be shifted to an open position in which an article can be removed through the access opening. Removal of the article causes the release of the gating permitting it to be returned to its normally closed position. The size of the access opening is readily adjustable, preferably by tubular members movable to more or less obstruct the access opening, and including elongated blocking members one of which extends through each of the tubular adjusting members to close the access opening.",CARSWELL WILLIAM;;FRIEDMAN EVELYN,CARSWELL WILLIAM;;FRIEDMAN EVELYN,,https://lens.org/124-238-765-086-843,Granted Patent,yes,7,3,1,2,0,G07F11/045;;G07F11/045,G07F11/04,221/241;;221/279;;221/281;;194/2;;194/57,0,0,,,,EXPIRED
97,US,A,US 3633578 A,055-635-442-049-798,1972-01-11,1972,US 3633578D A,1970-06-24,US 4953370 A,1970-06-24,METHOD OF MAINTAINING THE INTEGRITY OF BLOOD,"There is provided improved physiologically acceptable articles made from various fluorocarbon polymers and a process for maintaining the normal integrity of the blood of warm-blooded animals with said articles. The physiologically acceptable articles include specific medial devices such as catheters, etc., useful in contact with blood or tissue in warm-blooded animals.",AMERICAN CYANAMID CO,ROTH ROY WILLIAM;;FRIEDMAN EDWARD,,https://lens.org/055-635-442-049-798,Granted Patent,no,7,7,1,1,0,A61L17/04;;A61L27/16;;A61L29/041;;A61L33/064;;A61L29/041;;A61L27/16;;A61L17/04;;A61L33/064,A61L17/04;;A61L27/16;;A61L29/04;;A61L33/06,128214   R;;3/1;;128/334;;128/348;;260 296  F,0,0,,,,EXPIRED
98,US,A1,US 2013/0117847 A1,096-719-097-439-538,2013-05-09,2013,US 201213669235 A,2012-11-05,US 201213669235 A;;US 201161556817 P;;US 201261699823 P,2011-11-07,Streaming Method and System for Processing Network Metadata,"A method and system for processing network metadata is described. Network metadata may be processed by dynamically instantiated executable software modules which make policy-based decisions about the character of the network metadata and about presentation of the network metadata to consumers of the information carried by the network metadata. The network metadata may be type classified and each subclass within a type may be mapped to a definition by a unique fingerprint value. The fingerprint value may be used for matching the network metadata subclasses against relevant policies and transformation rules. For template-based network metadata such as NetFlow v9, an embodiment of the invention can constantly monitor network traffic for unknown templates, capture template definitions, and informs administrators about templates for which custom policies and conversion rules do not exist. Conversion modules can efficiently convert selected types and/or subclasses of network metadata into alternative metadata formats.",FRIEDMAN WILLIAM G;;VELEDNITSKY ALEXANDER,FRIEDMAN WILLIAM G;;VELEDNITSKY ALEXANDER,NETFLOW LOGIC CORPORATION (2014-12-06),https://lens.org/096-719-097-439-538,Patent Application,yes,11,244,14,36,0,H04L63/102;;H04L63/1425;;H04L63/102;;H04L61/4511;;H04L63/1425;;H04L43/16;;H04L47/20;;H04L63/1416;;H04L63/20,G06F15/16;;G06F21/00;;H04L47/20,726/22;;709/201,0,0,,,,ACTIVE
99,US,A,US 4971186 A,141-373-240-404-229,1990-11-20,1990,US 33791089 A,1989-04-14,US 33791089 A;;US 16260288 A,1988-03-01,Price mechanism for coin operated vending machine,A coin operated vending machine is disclosed having a mechanism for setting at least three prices at which an article is to be vended. Price selection is remotely effected by an externally accessible lock.,EB METAL IND INC,FRIEDMAN EVELYN;;CARSWELL WILLIAM R,,https://lens.org/141-373-240-404-229,Granted Patent,yes,10,0,1,3,0,G07F5/08;;G07F5/08,G07F5/08,194/226;;194/227,0,0,,,,EXPIRED
100,WO,A3,WO 2006/089112 A3,018-800-946-198-580,2007-02-15,2007,US 2006/0005633 W,2006-02-17,US 65372405 P,2005-02-17,SYSTEMS AND METHODS FOR PLANNING MEDICAL PROCEDURES AND DESIGNING MEDICAL DEVICES BASED ON ANATOMICAL SCAN DEFORMATIONS,"A method of formulating a patient-specific plan for a diagnostic or therapeutic procedure performed upon a patient is provided. The method includes obtaining a standard plan based upon a scan of an anatomy of a standard anatomic specimen, the scan defining a standard scan. The method also includes scanning the patient to obtain a patient-specific scan of an anatomy of the patient. Additionally, the method includes morphing the standard scan to the anatomy of the patient by mapping the standard scan to the patient-specific scan. The method further includes determining the patient-specific plan by modifying the standard plan based upon the mapping.",UNIV FLORIDA;;BOVA FRANK;;FRIEDMAN WILLIAM A,BOVA FRANK;;FRIEDMAN WILLIAM A,,https://lens.org/018-800-946-198-580,Search Report,yes,4,0,4,4,0,G16H50/50;;G16H50/20;;G16Z99/00;;G16H50/20;;G16H50/50;;G16Z99/00,G06Q10/00;;G16Z99/00,,0,0,,,,PENDING
101,US,A1,US 2017/0013001 A1,099-562-268-484-55X,2017-01-12,2017,US 201615206267 A,2016-07-09,US 201615206267 A;;US 201213669235 A;;US 201161556817 P;;US 201261699823 P,2011-11-07,Streaming Method and System for Processing Network Metadata,"A method and system for processing network metadata is described. Network metadata may be processed by dynamically instantiated executable software modules which make policy-based decisions about the character of the network metadata and about presentation of the network metadata to consumers of the information carried by the network metadata. The network metadata may be type classified and each subclass within a type may be mapped to a definition by a unique fingerprint value. The fingerprint value may be used for matching the network metadata subclasses against relevant policies and transformation rules. For template-based network metadata such as NetFlow v 9 , an embodiment of the invention can constantly monitor network traffic for unknown templates, capture template definitions, and informs administrators about templates for which custom policies and conversion rules do not exist. Conversion modules can efficiently convert selected types and/or subclasses of network metadata into alternative metadata formats.",NETFLOW LOGIC CORP,FRIEDMAN WILLIAM G;;VELEDNITSKY ALEXANDER,NETFLOW LOGIC CORPORATION (2016-08-10),https://lens.org/099-562-268-484-55X,Patent Application,yes,18,10,14,36,0,H04L63/102;;H04L63/1425;;H04L63/102;;H04L61/4511;;H04L63/1425;;H04L43/16;;H04L47/20;;H04L63/1416;;H04L63/20,H04L47/20,,0,0,,,,ACTIVE
102,US,B2,US 10079843 B2,027-086-339-443-08X,2018-09-18,2018,US 201615206267 A,2016-07-09,US 201615206267 A;;US 201213669235 A;;US 201161556817 P;;US 201261699823 P,2011-11-07,Streaming method and system for processing network metadata,"A method and system for processing network metadata is described. Network metadata may be processed by dynamically instantiated executable software modules which make policy-based decisions about the character of the network metadata and about presentation of the network metadata to consumers of the information carried by the network metadata. The network metadata may be type classified and each subclass within a type may be mapped to a definition by a unique fingerprint value. The fingerprint value may be used for matching the network metadata subclasses against relevant policies and transformation rules. For template-based network metadata such as NetFlow v9, an embodiment of the invention can constantly monitor network traffic for unknown templates, capture template definitions, and informs administrators about templates for which custom policies and conversion rules do not exist. Conversion modules can efficiently convert selected types and/or subclasses of network metadata into alternative metadata formats.",NETFLOW LOGIC CORP,FRIEDMAN WILLIAM G;;VELEDNITSKY ALEXANDER,NETFLOW LOGIC CORPORATION (2016-08-10),https://lens.org/027-086-339-443-08X,Granted Patent,yes,25,5,14,36,0,H04L63/102;;H04L63/1425;;H04L63/102;;H04L61/4511;;H04L63/1425;;H04L43/16;;H04L47/20;;H04L63/1416;;H04L63/20,G06F15/16;;H04L47/20,,3,0,,,"USPTO, ISA/US, International Search Report and Written Opinion in PCT Application No. PCT/US2014/010932, dated Jun. 3, 2014, 9 pages.;;Open Network Foundation, “Software-Defined Networking: The New Norm for Networks”, (online) published Apr. 13, 2012 (retrieved on May 20, 2014) URL:https://www.opennetworking.org/images/stories/download/sdn-resources/white-papers/wp-sdn-newborn.pdf, 12 pages.;;Korean Intellectual Property Office, ISA/KR, “International Search Report and Written Opinion” in PCT Application No. PCT/US2012/063749, dated Feb 25, 2013, 12 pages.",ACTIVE
103,US,A,US 4445625 A,150-397-320-752-269,1984-05-01,1984,US 41438182 A,1982-09-02,US 41438182 A;;US 28433081 A,1981-07-17,Vending machine having access blocking members,"A vending apparatus well suited for vending such articles as newspapers, magazines or the like which vary in size, in which the articles to be vended are supplied to one side of an access opening in the vending apparatus enclosure. Access opening gating structure normally in a closed position prevent removal of an article unless, after paying a prescribed fee, the customer operates a gating actuator to cause the gating structure to be shifted to an open position in which an article can be removed through the access opening. Removal of the article causes the release of the gating structure permitting it to be returned to its normally closed position. In a preferred embodiment, the gating means includes at least two mutually independently movable blocking members which normally close the access opening.",FRIEDMAN EVELYN;;CARSWELL WILLIAM R,FRIEDMAN EVELYN;;CARSWELL WILLIAM R,,https://lens.org/150-397-320-752-269,Granted Patent,yes,1,1,1,2,0,G07F11/045;;G07F11/045,G07F11/04,221/241;;221/279,0,0,,,,EXPIRED
104,US,A,US 4349257 A,171-840-516-439-536,1982-09-14,1982,US 23112481 A,1981-02-03,US 23112481 A,1981-02-03,Camera having a selected pattern of pre-exposure for final exposure correction,An in-camera supplemental exposure correction system for achieving an evenly exposed final photographic image in a situation wherein the photographic scene is non-uniformly illuminated by an artificial light source by pre-exposing the film to supplemental illumination having a non-uniform pattern which is the inverse of the artificial scene illumination.,POLAROID CORP,FRIEDMAN MELVIN;;HOLMES WILLIAM A,POLAROID CORPORATION A CORP. OF DE (1981-01-30),https://lens.org/171-840-516-439-536,Granted Patent,yes,4,7,1,1,0,G03B15/02;;G03B15/02,G03B15/02,354/126,1,0,,,"IBM Technical Disclosure Bulletin, ""Illumination Compensation for COS.sup.4 -Lens Attenuation,"" by G. W. Hobgood, Jr., vol. 14, No. 11, Apr. 1972, p. 3324.",EXPIRED
105,WO,A2,WO 2006/089112 A2,175-547-321-672-816,2006-08-24,2006,US 2006/0005633 W,2006-02-17,US 65372405 P,2005-02-17,SYSTEMS AND METHODS FOR PLANNING MEDICAL PROCEDURES AND DESIGNING MEDICAL DEVICES BASED ON ANATOMICAL SCAN DEFORMATIONS,"A method of formulating a patient-specific plan for a diagnostic or therapeutic procedure performed upon a patient is provided. The method includes obtaining a standard plan based upon a scan of an anatomy of a standard anatomic specimen, the scan defining a standard scan. The method also includes scanning the patient to obtain a patient-specific scan of an anatomy of the patient. Additionally, the method includes morphing the standard scan to the anatomy of the patient by mapping the standard scan to the patient-specific scan. The method further includes determining the patient-specific plan by modifying the standard plan based upon the mapping.",UNIV FLORIDA;;BOVA FRANK;;FRIEDMAN WILLIAM A,BOVA FRANK;;FRIEDMAN WILLIAM A,,https://lens.org/175-547-321-672-816,Patent Application,yes,0,0,4,4,0,G16H50/50;;G16H50/20;;G16Z99/00;;G16H50/20;;G16H50/50;;G16Z99/00,A01N25/08;;G16Z99/00,,0,0,,,,PENDING
106,WO,A1,WO 2013/070631 A1,190-778-914-059-20X,2013-05-16,2013,US 2012/0063749 W,2012-11-06,US 201161556817 P;;US 201213669235 A;;US 201261699823 P,2011-11-07,A STREAMING METHOD AND SYSTEM FOR PROCESSING NETWORK METADATA,"A method and system for processing network metadata is described. Network metadata may be processed by dynamically instantiated executable software modules which make policy- based decisions about the character of the network metadata and about presentation of the network metadata to consumers of the information carried by the network metadata. The network metadata may be type classified and each subclass within a type may be mapped to a definition by a unique fingerprint value. The fingerprint value may be used for matching the network metadata subclasses against relevant policies and transformation rules. For template- based network metadata such as NetFlow v9, an embodiment of the invention can constantly monitor network traffic for unknown templates, capture template definitions, and informs administrators about templates for which custom policies and conversion rules do not exist. Conversion modules can efficiently convert selected types and/or subclasses of network metadata into alternative metadata formats.",NETFLOW LOGIC CORP,FRIEDMAN WILLIAM G;;VELEDNITSKY ALEXANDER,,https://lens.org/190-778-914-059-20X,Patent Application,yes,6,6,14,36,0,H04L63/102;;H04L63/1425;;H04L63/102;;H04L61/4511;;H04L63/1425;;H04L43/16;;H04L47/20;;H04L63/1416;;H04L63/20,H04L47/20,,0,0,,,,PENDING
107,US,A,US 4981027 A,170-893-407-979-974,1991-01-01,1991,US 33790689 A,1989-04-14,US 33790689 A;;US 16260288 A,1988-03-01,Three position lock mechanism for a vending machine,A coin operated vending machine is disclosed having a mechanism for setting at least three prices at which an article is to be vended. Price selection is remotely effected by an externally accessible lock.,EB METAL IND INC,FRIEDMAN EVELYN;;CARSWELL WILLIAM R,,https://lens.org/170-893-407-979-974,Granted Patent,yes,21,12,1,3,0,G07F5/08;;Y10T70/7588;;Y10T70/7565;;Y10T70/765;;Y10T70/7599;;Y10T70/7588;;Y10T70/7565;;Y10T70/765;;Y10T70/7599;;G07F5/08,G07F5/08,70/358;;70/369;;70/490;;70/492;;194/226,0,0,,,,EXPIRED
108,US,S,US D0509313 S,076-034-247-478-501,2005-09-06,2005,US 21043004 F,2004-07-29,US 21043004 F,2004-07-29,Light fixture,,ACUITY BRANDS INC,FRIEDMAN FRANK;;GENDRON WILLIAM T,ACUITY BRANDS INC (2004-11-11);;ABL IP HOLDING LLC (2007-09-26),https://lens.org/076-034-247-478-501,Design Right,no,0,1,3,3,0,,,2605;;D26/71;;D26/87;;D26/92,0,0,,,,EXPIRED
109,EP,A1,EP 2777226 A1,093-177-335-895-561,2014-09-17,2014,EP 12847345 A,2012-11-06,US 201161556817 P;;US 201261699823 P;;US 201213669235 A;;US 2012/0063749 W,2011-11-07,A STREAMING METHOD AND SYSTEM FOR PROCESSING NETWORK METADATA,,NETFLOW LOGIC CORP,FRIEDMAN WILLIAM G;;VELEDNITSKY ALEXANDER,,https://lens.org/093-177-335-895-561,Patent Application,yes,0,2,14,36,0,H04L63/102;;H04L63/1425;;H04L63/102;;H04L61/4511;;H04L63/1425;;H04L43/16;;H04L47/20;;H04L63/1416;;H04L63/20,H04L47/20,,0,0,,,,ACTIVE
110,US,A,US 4844229 A,110-080-781-427-841,1989-07-04,1989,US 16260288 A,1988-03-01,US 16260288 A,1988-03-01,Price mechanism for coin operated vending machine,A coin operated vending machine is disclosed having a mechanism for setting at least three prices at which an article is to be vended. Price selection is remotely effected by an externally accessible lock. A totalizer sums the inserted coins and in response to the insertion of the required amount permits the opening of the vending door. An important feature resides in the provision of a lock by which any one of the prices can be selected.,EB METAL IND INC,FRIEDMAN EVELYN;;CARSWELL WILLIAM R,EB METAL INDUSTRIES INC (1988-02-29),https://lens.org/110-080-781-427-841,Granted Patent,yes,9,4,1,3,0,G07F5/08;;G07F5/08,G07F5/08,194/226;;194/227,0,0,,,,EXPIRED
111,US,S,US D0501945 S,036-682-542-089-757,2005-02-15,2005,US 19499703 F,2003-12-03,US 19499703 F,2003-12-03,Light fixture,,ACUITY BRANDS INC,FRIEDMAN FRANK;;GENDRON WILLIAM T,ACUITY BRANDS INC (2004-02-10);;ABL IP HOLDING LLC (2007-09-26),https://lens.org/036-682-542-089-757,Design Right,yes,11,0,3,3,0,,,D26/71;;D26/87;;D26/92,3,0,,,"U.S. Appl. No. 29/194,225, filed Nov. 19, 2003.;;U.S. Appl. No. 29/194,854, filed Dec. 1, 2003.;;U.S. Patent Design Application for a Light Fixture forwarded to the U.S. Patent and Trademark Office on Jul. 29, 2004 (U.S. Appl. No. 29/210,430).",EXPIRED
112,US,S,US D0501944 S,048-604-140-714-638,2005-02-15,2005,US 19422503 F,2003-11-19,US 19422503 F,2003-11-19,Light fixture,,ACUITY BRANDS INC,FRIEDMAN FRANK;;GENDRON WILLIAM T,ACUITY BRANDS INC (2004-02-10);;ABL IP HOLDING LLC (2007-09-26),https://lens.org/048-604-140-714-638,Design Right,yes,11,4,3,3,0,,,D26/71;;D26/87;;D26/92,3,0,,,"U.S. Patent Design Application for a Light Fixture forwarded to the U.S. Patent and Trademark Office on Jul. 29, 2004 (U.S. Appl. No. 29/210,430).;;U.S. Appl. No. 29/194,854, filed Dec. 1, 2003.;;U.S. Appl. No. 29/194,997, filed Dec. 3, 2003.",EXPIRED
113,KR,A,KR 20140106547 A,066-800-465-472-770,2014-09-03,2014,KR 20147015404 A,2012-11-06,US 201213669235 A;;US 201161556817 P;;US 201261699823 P;;US 2012/0063749 W,2011-11-07,A STREAMING METHOD AND SYSTEM FOR PROCESSING NETWORK METADATA,,NETFLOW LOGIC CORP,FRIEDMAN WILLIAM G;;VELEDNITSKY ALEXANDER,,https://lens.org/066-800-465-472-770,Patent Application,no,0,1,14,36,0,H04L63/102;;H04L63/1425;;H04L63/102;;H04L61/4511;;H04L63/1425;;H04L43/16;;H04L47/20;;H04L63/1416;;H04L63/20,H04L47/20,,0,0,,,,DISCONTINUED
114,US,S,US D0502279 S,134-269-622-390-930,2005-02-22,2005,US 19485403 F,2003-12-01,US 19485403 F,2003-12-01,Light fixture,,ACUITY BRANDS INC,FRIEDMAN FRANK;;GENDRON WILLIAM T,ACUITY BRANDS INC (2004-02-10);;ABL IP HOLDING LLC (2007-09-26),https://lens.org/134-269-622-390-930,Design Right,yes,11,0,3,3,0,,,D26/71;;D26/87;;D26/92,3,0,,,"U.S. patent application Ser. No. 29/194,225, filed Nov. 19, 2003 (ATTY DKT 7260-108).;;U.S. patent application Ser. No. 29/194,997, filed Dec. 3, 2003 (ATTYDKT 7260-110).;;U.S. Patent Design Application for a Light Fixture forwarded to the U.S. Patent and Trademark Office on Jul. 29, 2004 (ATTY DKY. 7620-111) (Ser. No. 29/210430).",EXPIRED
115,US,A,US 4592461 A,130-245-091-352-406,1986-06-03,1986,US 48984883 A,1983-04-29,US 48984883 A,1983-04-29,Vending machine with coin sorter and totalizer,"A vending machine for newspapers and the like having a coin operated mechanism with: (a) a coin sorter; (b) a coin chute assembly having a plurality of vertical chutes through which coins of different denominations, from the coin sorter, fall; (c) a trip wire, one end of which extends through the coin chutes and can move downwardly in the chutes with downward movement of coins; (d) a totalizer, connected to the other end of the trip wire, for counting the value of coins which fall through the coin chutes; and (e) a vending controller connected to the totalizer. The coin operated mechanism has an improved totalizer with: a lever, connected at one end to the other end of the trip wire and rotatably connected between its ends to the mechanism; a dog, rotatably connected to the lever between the other end of the lever and the rotatable connection of the lever to the mechanism; the dog being adapted to revolve with the other end of the lever about the rotatable connection of the lever to the mechanism; one end of the dog extending toward the rotatable connection of the lever to the mechanism and being adapted to revolve about the rotatable connection of the dog to the lever, so as to move vertically relative to the lever; and a ratchet wheel, parallel to the lever and the dog and located on the same side of the lever as the dog; the ratchet wheel being adapted to rotate about the rotatable connection of the lever to the mechanism; the one end of the dog being adapted to urge a gear tooth on the circumference of the ratchet wheel to revolve about the rotatable connection of the lever to the mechanism with revolution of the dog about the rotatable connection of the lever to the mechanism when the one end of the lever moves downwardly with the one end of the trip wire.",FRIEDMAN EVELYN,FRIEDMAN EVELYN;;CARSWELL WILLIAM R,FRIEDMAN EVELYN (1983-04-28),https://lens.org/130-245-091-352-406,Granted Patent,yes,3,6,1,2,0,G07F5/08;;G07F11/045;;G07F5/08;;G07F11/045,G07F5/08;;G07F11/04,194/227;;X133  3D,0,0,,,,EXPIRED
116,CA,A1,CA 2854883 A1,039-710-619-593-05X,2013-05-16,2013,CA 2854883 A,2012-11-06,US 201161556817 P;;US 201261699823 P;;US 201213669235 A;;US 2012/0063749 W,2011-11-07,A STREAMING METHOD AND SYSTEM FOR PROCESSING NETWORK METADATA,"A method and system for processing network metadata is described. Network metadata may be processed by dynamically instantiated executable software modules which make policy- based decisions about the character of the network metadata and about presentation of the network metadata to consumers of the information carried by the network metadata. The network metadata may be type classified and each subclass within a type may be mapped to a definition by a unique fingerprint value. The fingerprint value may be used for matching the network metadata subclasses against relevant policies and transformation rules. For template- based network metadata such as NetFlow v9, an embodiment of the invention can constantly monitor network traffic for unknown templates, capture template definitions, and informs administrators about templates for which custom policies and conversion rules do not exist. Conversion modules can efficiently convert selected types and/or subclasses of network metadata into alternative metadata formats.",NETFLOW LOGIC CORP,FRIEDMAN WILLIAM G;;VELEDNITSKY ALEXANDER,,https://lens.org/039-710-619-593-05X,Patent Application,no,0,1,14,36,0,H04L63/102;;H04L63/1425;;H04L63/102;;H04L61/4511;;H04L63/1425;;H04L43/16;;H04L47/20;;H04L63/1416;;H04L63/20,H04L47/20,,0,0,,,,DISCONTINUED
117,US,A,US 2365494 A,139-722-353-818-736,1944-12-19,1944,US 51662644 A,1944-01-01,US 51662644 A,1944-01-01,Computer for aircraft load distribution,,YORK RES CORP,SCHLIEBEN ERNEST W;;WILLIAM FRIEDMAN,,https://lens.org/139-722-353-818-736,Granted Patent,no,0,3,1,1,0,G06G1/14;;G06G1/14,G06G1/14,,0,0,,,,EXPIRED
118,EP,A4,EP 2777226 A4,026-739-577-484-898,2015-10-14,2015,EP 12847345 A,2012-11-06,US 201161556817 P;;US 201261699823 P;;US 201213669235 A;;US 2012/0063749 W,2011-11-07,A STREAMING METHOD AND SYSTEM FOR PROCESSING NETWORK METADATA,,NETFLOW LOGIC CORP,FRIEDMAN WILLIAM G;;VELEDNITSKY ALEXANDER,,https://lens.org/026-739-577-484-898,Search Report,no,2,0,14,36,0,H04L63/102;;H04L63/1425;;H04L63/102;;H04L61/4511;;H04L63/1425;;H04L43/16;;H04L47/20;;H04L63/1416;;H04L63/20,H04L47/20,,1,0,,,See also references of WO 2013070631A1,ACTIVE
119,US,B2,US 9392010 B2,195-897-886-958-577,2016-07-12,2016,US 201213669235 A,2012-11-05,US 201213669235 A;;US 201161556817 P;;US 201261699823 P,2011-11-07,Streaming method and system for processing network metadata,"A method and system for processing network metadata is described. Network metadata may be processed by dynamically instantiated executable software modules which make policy-based decisions about the character of the network metadata and about presentation of the network metadata to consumers of the information carried by the network metadata. The network metadata may be type classified and each subclass within a type may be mapped to a definition by a unique fingerprint value. The fingerprint value may be used for matching the network metadata subclasses against relevant policies and transformation rules. For template-based network metadata such as NetFlow v9, an embodiment of the invention can constantly monitor network traffic for unknown templates, capture template definitions, and informs administrators about templates for which custom policies and conversion rules do not exist. Conversion modules can efficiently convert selected types and/or subclasses of network metadata into alternative metadata formats.",FRIEDMAN WILLIAM G;;VELEDNITSKY ALEXANDER;;NETFLOW LOGIC CORP,FRIEDMAN WILLIAM G;;VELEDNITSKY ALEXANDER,NETFLOW LOGIC CORPORATION (2014-12-06),https://lens.org/195-897-886-958-577,Granted Patent,yes,20,27,14,36,0,H04L63/102;;H04L63/1425;;H04L63/102;;H04L61/4511;;H04L63/1425;;H04L43/16;;H04L47/20;;H04L63/1416;;H04L63/20,H04L47/20;;G06F15/16,,3,0,,,"USPTO, ISA/US, ""International Search Report and Written Opinion"" in PCT Application No. PCT/US2014/010932, Jun. 3, 2014, 9 pages.;;Open Network Foundation, ""Software-Defined Networking: The New Norm for Networks"", (online) published Apr. 13, 2012 (retrieved on May 20, 2014) URL:https://www.opennetworking.org/images/stories/downloads/sdn-resources/white-papers/wp-sdn-newnorm.pfd, 12 pages.;;Korean Intellectual Property Office, ISA/KR, ""International Search Report and Written Opinion"" in PCT Application No. PCT/US2012/063749, Feb. 25, 2013, 12 pages.",ACTIVE
120,CN,A,CN 104115463 A,142-525-083-877-36X,2014-10-22,2014,CN 201280066276 A,2012-11-06,US 2012/0063749 W;;US 201161556817 P;;US 201261699823 P;;US 201213669235 A,2011-11-07,A streaming method and system for processing network metadata,"A method and system for processing network metadata is described. Network metadata may be processed by dynamically instantiated executable software modules which make policy- based decisions about the character of the network metadata and about presentation of the network metadata to consumers of the information carried by the network metadata. The network metadata may be type classified and each subclass within a type may be mapped to a definition by a unique fingerprint value. The fingerprint value may be used for matching the network metadata subclasses against relevant policies and transformation rules. For template- based network metadata such as NetFlow v9, an embodiment of the invention can constantly monitor network traffic for unknown templates, capture template definitions, and informs administrators about templates for which custom policies and conversion rules do not exist. Conversion modules can efficiently convert selected types and/or subclasses of network metadata into alternative metadata formats.",NETFLOW LOGIC CORP,FRIEDMAN WILLIAM G;;VELEDNITSKY ALEXANDER,,https://lens.org/142-525-083-877-36X,Patent Application,no,7,17,14,36,0,H04L63/102;;H04L63/1425;;H04L63/102;;H04L61/4511;;H04L63/1425;;H04L43/16;;H04L47/20;;H04L63/1416;;H04L63/20,H04L47/20,,0,0,,,,ACTIVE
121,EP,B1,EP 2777226 B1,141-885-552-491-199,2019-08-28,2019,EP 12847345 A,2012-11-06,US 201161556817 P;;US 201261699823 P;;US 201213669235 A;;US 2012/0063749 W,2011-11-07,A STREAMING METHOD AND SYSTEM FOR PROCESSING NETWORK METADATA,,NETFLOW LOGIC CORP,FRIEDMAN WILLIAM G;;VELEDNITSKY ALEXANDER,,https://lens.org/141-885-552-491-199,Granted Patent,yes,7,3,14,36,0,H04L63/102;;H04L63/1425;;H04L63/102;;H04L61/4511;;H04L63/1425;;H04L43/16;;H04L47/20;;H04L63/1416;;H04L63/20,H04L47/20,,0,0,,,,ACTIVE
122,US,A,US 5488383 A,194-384-038-118-356,1996-01-30,1996,US 18174794 A,1994-01-21,US 18174794 A,1994-01-21,Method for accurizing mesh fabric reflector panels of a deployable reflector,"A method for sewing a plurality of gore-shaped metalized mesh fabric panels to each other to form a parabolic dish-shaped reflector surface for subsequent attachment to the radially extendable rib members of a deployable parabolic reflector. The method includes using a template having ""cut"" and ""sew"" lines indicated thereon for cutting out a desired number of gore-shaped panels from a bolt of metalized mesh fabric and sewing the panels together along adjacent side edges thereof to form the dish-shaped reflector surface. The dish-shaped reflector surface is then attached to the reflector by sewing the mesh fabric panels to stitch holes provided in each rib member. The reflector surface is accurized by using a wedge-shaped tool which is placed on a slack reflector panel adjacent a gore seam. A cord is then laced thereover along its length, after which the tool is removed, and the two ends of the cord are pulled tight thereby forming a tuck seam in the reflector panel which takes up slack in the reflector surface. A novel metalized mesh fabric construction is also disclosed and includes silver coated nylon strands and denier dacron strands interwoven in a ""Marquisette"" or ""Leno"" style weave. The weave has openings sized sufficiently large to minimizing the effects of wind load yet sufficiently small to provide good reflective performance of radio frequencies up to and including X-Band frequencies.",LOCKHEED MISSILES SPACE,FRIEDMAN ARNOLD;;RIBBLE WILLIAM;;WADE WILLIAM D,LOCKHEED MISSILES & SPACE CO. INC (1994-03-01);;LOCKHEED MARTIN CORPORATION (1996-01-25);;LOCKHEED CORPORATION (1996-01-25),https://lens.org/194-384-038-118-356,Granted Patent,yes,11,44,1,1,0,H01Q15/147;;H01Q15/168;;Y10T29/49016;;Y10T29/49016;;H01Q15/168;;H01Q15/147,H01Q15/14;;H01Q15/16,343/912;;343/897;;343/915;;112/475.08;;29/600,0,0,,,,EXPIRED
123,DE,T1,DE 861981 T1,081-962-243-627-12X,1999-05-06,1999,DE 97116475 T,1997-09-22,US 80671797 A,1997-02-27,Vibrationsdämpfer für Pumpsysteme Entleeren von Schiffsbehältern,,SEALAND TECHNOLOGY INC,SCHEIBE MARK;;SIGLER JAMES;;FRIEDMAN WILLIAM,,https://lens.org/081-962-243-627-12X,Granted Patent,no,0,0,7,7,0,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/0025;;Y10T137/3118;;Y10T137/3118;;B63B29/16;;B63B13/00;;F04B11/0025;;E03D5/00,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/00,,0,0,,,,EXPIRED
124,US,A1,US 2008/0167547 A1,100-079-333-895-325,2008-07-10,2008,US 88463106 A,2006-02-17,US 88463106 A;;US 65372405 P;;US 2006/0005633 W,2005-02-17,Systems and Methods For Planning Medical Procedures and Designing Medical Devices Based on Anatomical Scan Deformations,"A method of formulating a patient-specific plan for a diagnostic or therapeutic procedure performed upon a patient is provided. The method includes obtaining a standard plan based upon a scan of an anatomy of a standard anatomic specimen, the scan defining a standard scan. The method also includes scanning the patient to obtain a patient-specific scan of an anatomy of the patient. Additionally, the method includes morphing the standard scan to the anatomy of the patient by mapping the standard scan to the patient-specific scan. The method further includes determining the patient-specific plan by modifying the standard plan based upon the mapping.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC (2006-07-20),https://lens.org/100-079-333-895-325,Patent Application,yes,6,21,4,4,0,G16H50/50;;G16H50/20;;G16Z99/00;;G16H50/20;;G16H50/50;;G16Z99/00,A61B6/00;;G16Z99/00;;A61B5/05,600/407,0,0,,,,ACTIVE
125,US,A,US 4471376 A,127-172-008-382-995,1984-09-11,1984,US 22493181 A,1981-01-14,US 22493181 A,1981-01-14,Amorphous devices and interconnect system and method of fabrication,"An amorphous semiconductor device on a silicon substrate having a first level contact and interconnect of aluminum and coextensive layer of molybdenum and a second level contact and interconnect of molybdenum and coextensive layer of aluminum. Contacts to the amorphous device are by the two molybdenum layers and the contact of the second level contacts to the substrate is through the first level contacts. The method of fabrication includes forming a first aluminum layer on and through contact openings in a first insulating layer and a first layer of molybdenum on the aluminum, coetching these layers to form first level contacts and interconnects forming a second layer of insulating material, forming a layer of amorphous semiconductor material through an opening in the second insulating layer; forming a second layer of molybdenum over the substrate and through contact openings in the second insulating layer and a second layer of aluminum on the second layer of molybdenum, and coetching the second layers of molybdenum and aluminum to form second level contacts and interconnects.",HARRIS CORP,MORCOM WILLIAM R;;FRIEDMAN GLENN M,HARRIS CORPORATION A CORP. OF DE (1980-08-05);;INTERSIL CORPORATION (1999-08-13),https://lens.org/127-172-008-382-995,Granted Patent,yes,5,57,1,1,0,H01L29/04;;H01L29/04;;H01L23/53223;;H01L23/53223;;H01L2924/0002;;H01L2924/0002,H01L23/532;;H01L29/04,H1K KHAA          HAA,1,0,,,"IBM Technical Disclosure Bulletin, vol. 15, No. 2, Jul. 1972, pp. 577 579.",EXPIRED
126,ID,A,ID 23187 A,124-551-541-272-998,2000-03-23,2000,ID 989916 A,1998-06-16,US 5149997 P,1997-07-01,BENTUK BENTUK DOSIS SERTRALINA LEPAS TUNDA,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/124-551-541-272-998,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/14;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,PENDING
127,US,A1,US 2007/0100224 A1,163-842-332-814-599,2007-05-03,2007,US 54575206 A,2006-10-10,US 54575206 A;;US 72608305 P,2005-10-11,Preplanning of guided medical procedures,"A method of preplaining for guided medical procedures includes obtaining a first 3D diagnostic dataset for a region of interest of a subject. This first dataset can be a non-stereotactic dataset and provide sufficient contrast to identify target tissue in the region of interest. A treatment preplan is developed to treat the target tissue using the first dataset exclusive of stereotactic data. The treatment preplan includes placement locations for a plurality of initial radiation beams and their respective dose intensities. A second, stereotactic 3D dataset can be obtained for the region of interest. A registered dataset can then be created by registering the first dataset to the second dataset. The treatment preplan can be modified using data associated with the registering step to generate a stereotactic treatment plan including a plurality of radiation treatment beams with respective placement positions based on the registered dataset to treat the target tissue.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC (2009-12-08),https://lens.org/163-842-332-814-599,Patent Application,yes,9,7,3,3,0,A61N5/103;;A61N5/103;;A61B34/10;;A61B34/10;;A61B2090/101;;A61B2090/101;;A61B2090/364;;A61B2090/364,A61B5/05,600/407,0,0,,,,ACTIVE
128,WO,A1,WO 2007/118189 A1,194-167-179-245-083,2007-10-18,2007,US 2007/0066132 W,2007-04-06,US 40001506 A,2006-04-07,FRAMELESS STEREOTACTIC GUIDANCE OF MEDICAL PROCEDURES,"Devices, methods and systems for frameless guidance of image-based medical procedures such as stereotactic radiotherapy and surgery. Devices including custom fitting subject-specific articles include contoured surfaces that provide spatial reference to the location of target regions within the subject. The devices are attached exclusive of fasteners anchored to the tissue of the subject and reside on the front of a head of the subject when attached. The devices and articles can be fabricated using computer-directed fabrication technology.",UNIV FLORIDA;;BOVA FRANK J;;FRIEDMAN WILLIAM A,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/194-167-179-245-083,Patent Application,yes,4,1,4,4,0,A61B90/10;;A61B90/10;;A61B34/20;;A61B34/20;;A61B90/11;;A61B90/11;;A61B2017/3405;;A61B2017/3405;;A61B2034/105;;A61B2034/105;;A61B2034/107;;A61B2034/107;;A61B2034/108;;A61B2034/108;;A61B2034/2051;;A61B2034/2051;;A61B2034/2055;;A61B2034/2055;;A61B2034/2072;;A61B2034/2072;;A61B2034/256;;A61B2034/256;;A61B2090/3983;;A61B2090/3983;;B33Y80/00;;B33Y80/00,A61B19/00,,0,0,,,,PENDING
129,US,A1,US 2014/0370475 A1,032-302-193-178-053,2014-12-18,2014,US 201414300561 A,2014-06-10,US 201414300561 A;;US 201361834033 P,2013-06-12,SIMULATION SYSTEM AND METHODS FOR SURGICAL TRAINING,A three-dimensional radiological image of a living being is acquired and an anatomical feature of interest therein is identified. A three-dimensional print of the feature is created; the print has haptic characteristics that are similar to those of the anatomical feature of interest. The print is incorporated into a model upon which a medical student can simulate a surgical operation. A simulator is provided; the simulator simulates the operation of a c-arm fluoroscope. This enables the medical student to simulate surgery while operating a fluoroscope.,UNIV FLORIDA;;UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM ALAN,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (2014-06-09),https://lens.org/032-302-193-178-053,Patent Application,yes,3,9,2,2,0,G09B23/285;;G09B23/285;;G09B23/281;;G09B23/34;;G09B23/00;;G09B23/303;;G09B23/30;;G09B23/28,G09B23/28,434/267,2,1,080-365-278-688-764,10.4253/wjge.v3.i7.140;;pmc3159502;;21860683,"Boix, Jaume. Lorenzo-Zuniga, Vincente. World Journal of Gastrointestinal Endoscopy. 'Radiation dose to patients during endoscopic retrograde cholangiopancreatography.' Published online July 16 2011 at <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159502>. Accessed July 06 2016. Pages 1-8.;;Wu, Y. Ted. 3D Doctor. 'From CT Image to 3D Model'. Published online August 2001. Accessed July 11 2016 from <http://www.ablesw.com/3d-doctor-surgmod.html>. Pages 1-3.",ACTIVE
130,US,A1,US 2006/0181285 A1,043-322-009-599-892,2006-08-17,2006,US 31290205 A,2005-12-19,US 31290205 A;;US 93010401 A;;US 24188800 P,2000-10-20,Method for differentiating between burdened and cracked ultrasonically tuned blades,"A method for differentiating between ultrasonically tuned blades which are broken or cracked, and blades which are gunked by evaluating measured impedance differences when a system is first excited with a low displacement signal and then with a high displacement signal. The method is performed irrespective of the age of the hand piece/blade, the temperature or specific type of hand piece or blade, and is not affected by self healing effects of slightly cracked blades. Moreover, the method facilitates the quantifiable determination of the amount of gunk on the blade. Absolute impedance measurements of the transducer or blade are unnecessary. Instead, only relative impedance measurements are required, which greatly simplifies the measuring criteria. This provides a way to measure the amount of gunk accumulation, and thereby a way to calculate/estimate the amount of heat generated at the sheath, as well as a way to calculate/estimate the amounts of degradation to the load curve of the ultrasonic system.",FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,,https://lens.org/043-322-009-599-892,Patent Application,yes,8,10,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,G01R27/00;;A61B17/00;;A61B17/32;;A61B18/00;;A61F9/007;;B06B1/06;;G01R27/04,324/600;;324/633,0,0,,,,DISCONTINUED
131,DE,T2,DE 69714005 T2,064-945-845-202-46X,2003-01-30,2003,DE 69714005 T,1997-08-28,US 80580397 A,1997-02-25,Schlauch mit niedriger Permeabilität für Geruch,"Flexible PVC hose (25) can be used with toilet systems (10, 12, etc.) in vehicles, such as boats (18), recreational vehicles, etc, or at pumpout stations. The hose includes about 40-55% by weight PVC resin, and at least 10% by weight of an EVA high molecular weight plasticizer. The hose also typically includes a low molecular weight plasticizer, stabilizer, lubricant, filler (such as 5-20% by weight dense filler like calcium carbonate), and pigment. The hose typically will not fail (that is will not transmit odor) for the life of the toilet system, or mechanical life of the hose. <IMAGE>",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;KLINE SALLY A,,https://lens.org/064-945-845-202-46X,Granted Patent,no,0,0,7,7,0,B60R15/04;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;B60R15/04,B60R15/04,,0,0,,,,EXPIRED
132,ES,T3,ES 2202858 T3,090-530-991-229-159,2004-04-01,2004,ES 98923022 T,1998-06-16,US 5149997 P,1997-07-01,FORMAS DE DOSIFICACION DE SERTRALINA DE LIBERACION RETARDADA.,"Una forma de dosificación oral de liberación espacialmente retardada adecuada para la administración oral a un mamífero, que comprende sertralina o una sal farmacéuticamente aceptable de la misma y un vehículo farmacéuticamente aceptable, no liberando dicha forma de dosificación, después de la ingestión por dicho mamífero, más del 10% de la sertralina incorporada en la misma en el estómago de dicho mamífero, y efectuando la liberación inmediata de la sertralina restante incorporada en la misma después de pasar al intestino delgado de dicho mamífero.",PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/090-530-991-229-159,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/22;;A61K9/14;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
133,CA,A,CA 1118140 A,126-302-469-756-722,1982-02-09,1982,CA 341694 A,1979-12-12,US 252679 A,1979-01-11,STABILIZED OLEFIN POLYMERS,"078205-M STABILIZED OLEFIN POLYMERS : Hydrolytically stable triaryl phosphites. The tris-(o-alkylphenyl)phosphites are more stable to hydrolysis then the tris-(p-alkylphenyl)phosphites and this makes them more useful as heat-stabilizing additives in olefin polymer compositions, especially in polypropylene compositions. The alkyl groups are the higher molecular weight alkyl groups, viz., those having 8-12 carbon atoms.",BORG WARNER CHEMICALS INC,HORN WILLIAM E JR;;FRIEDMAN LESTER,,https://lens.org/126-302-469-756-722,Granted Patent,no,0,0,8,8,0,C08K5/526,C08L23/00;;C08K5/52;;C08K5/526;;C08L7/00;;C08L21/00;;C08L101/00,400-97,0,0,,,,EXPIRED
134,WO,A1,WO 1996/041059 A1,004-566-176-384-414,1996-12-19,1996,US 9610505 W,1996-06-07,US 48484395 A,1995-06-07,VACUUM TANK CONSTRUCTION FOR A VACUUM TOILET ASSEMBLY,"A particular vacuum tank (13) construction is provided for a vacuum toilet assembly which mounts a vacuum pump (14), has great versatility and accessibility, and ensures optimized washing effect of water and waste into the vacuum tank (13). A tank inlet (18) is located at the opposite end of the tank from a sump (36) formed in the tank bottom (27), and an inlet fitting at the inlet is rotatable at least about 180° about a vertical axis. Connected to a tank outlet is a dip tube assembly (38) including a substantially rigid dip tube (39) which has an oval shaped end termination (46) opening which is above, but spaced from, the sump and positioned so that objects of a size that would harm the vacuum pump (14) connected to the tank outlet (19) cannot enter the dip tube (39). The tank is of plastic having a nominal wall thickness of about 5/16th inch, and no flat surface area is greater than about 80 square inches. The inlet (18) is connected to a vacuum toilet, and the vacuum pump outlet (21) is connected to a waste (holding) tank. The vacuum pump is mounted on a first top surface (28) of the vacuum tank and is readily connected or disconnected to and from the dip tube (39) by a spin nut (40). The tank includes a hollow vertical portion (31) having an inner sidewall in which the tank outlet opening (19) is formed, and to which a vacuum swtich (66) is connected.",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;SIGLER JAMES A,,https://lens.org/004-566-176-384-414,Patent Application,yes,1,4,6,6,0,E03D5/00;;E03D5/00;;E03F1/006;;E03F1/006,E03D5/00;;E03F1/00,,0,0,,,,PATENTED
135,EP,A4,EP 0472646 A4,012-226-204-594-005,1992-08-12,1992,EP 90908832 A,1990-05-11,US 35381689 A,1989-05-18,DOSIMETRIC TECHNIQUE FOR STEREOTACTIC RADIOSURGERY,,THE UNIVERSITY OF FLORIDA,"BOVA, FRANK, J.;;FRIEDMAN, WILLIAM, A.",,https://lens.org/012-226-204-594-005,Search Report,no,6,0,6,6,0,A61B2017/00707;;A61B2017/00712;;A61N5/10;;A61N5/103;;A61N5/1031;;A61N5/1048;;A61N5/1049;;A61B6/506;;A61B2090/363;;A61B2090/101;;A61N5/1049;;A61N5/1048;;A61N5/1031;;A61B2017/00712;;A61B2017/00707;;A61N5/103;;A61N5/10;;A61B6/506;;A61B2090/363;;A61B2090/101,A61B17/00;;A61B19/00;;A61N5/10,,0,0,,,,DISCONTINUED
136,US,A,US 4023230 A,018-608-665-823-546,1977-05-17,1977,US 61045075 A,1975-09-04,US 61045075 A,1975-09-04,Retractable bristle brush,"A retractable bristle brush comprising a housing having a bottom side, a top side, spaced side walls and spaced end walls, a plurality of openings extending inwardly from the bottom side, a plurality of bristles aligned with said openings, means mounted for movement between retracted and extended positions of adjustment relative to the housing, the inner ends of said bristles being connected to said means for movement of said bristles through said openings to retracted position within the housing responsive to movement of said means to retracted position and for movement to extend perpendicularly outwardly from the bottom side of the housing responsive to movement of said means to extended position.",FRIEDMAN JACK S,FRIEDMAN JACK S;;KENNEY WILLIAM J,,https://lens.org/018-608-665-823-546,Granted Patent,yes,3,20,1,1,0,A46B7/023;;A46B7/023;;A46B17/04;;A46B17/04;;A46B2200/104;;A46B2200/104,A46B7/02;;A46B17/04,15/185,0,0,,,,EXPIRED
137,JP,A,JP 2003000610 A,021-754-697-956-451,2003-01-07,2003,JP 2001360102 A,2001-10-22,US 24188800 P;;US 93010401 A,2000-10-20,METHOD FOR RECOGNIZING BURDENED AND CRACKED ULTRASONICALLY SYNCHRONIZED BLADE,"PROBLEM TO BE SOLVED: To provide a means for recognizing a burdened and cracked ultrasonically synchronized blade. SOLUTION: A means for recognizing respective blades which are ultrasonically synchronized with the defective or cracked and sticky conditions depending on the difference of impedance measured when the system is excited by lower displacement of signals followed by higher displacement of signals, whereas this means can be applied irrespective of the use time of a handpiece or the blade, temperature of the handpiece or the blade and is not affected by self-cure effects of the slightly cracked blade. Further, this means makes it easier to quantitatively determine sticky substances on the blade. It is not required, however, to measure an absolute impedance of a transducer or a blade. Instead, it is required to measure a relative impedance since the measurement criteria can be largely simplified.",ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,,https://lens.org/021-754-697-956-451,Patent Application,no,0,21,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/00;;A61B17/32;;A61B18/00;;A61F9/007;;B06B1/06,,0,0,,,,EXPIRED
138,US,A,US 5189687 A,045-097-138-129-867,1993-02-23,1993,US 70981291 A,1991-06-04,US 70981291 A;;US 8804303 W;;US 35381689 A;;US 12827387 A,1987-12-03,Apparatus for stereotactic radiosurgery,"Stereostactic radiosurgery apparatus for eliminating misalignments due to mechanical inaccuracies and sag of a linear accelerator radiation-emitting head which is swung through an arc comprises a guiding and support structure with a first bearing system for accurately rotating a collimator through a precise arc in a vertical plane with respect to a predetermined center point in the plane corresponding to a treatment location, a second gimbal bearing system for coupling the collimator to the head so that the rotating head can drive the collimator through its arc while mechanically uncoupling the head from the collimator by eliminating torques and forces on the collimator which would be exerted by mechanical inaccuracies or sag of the head, and a third bearing system for rotatably supporting a stereotactic floorstand for rotation about a vertical axis which intersects the center point. Since the movement of the collimator and the rotation of the floorstand are precisely controlled with respect to the center point, the apparatus ensures that radiation from the head will be accurately focused at the center point for all rotational positions of the head and floorstand. Mechanical linking arrangements are shown for allowing the floorstand to rotate automatically upon rotation of a patient treatment table. Although the linking arrangements are used to drive the rotation of the floorstand, the linkage arrangements prevent the introduction of positional inaccuracies in the floorstand rotation.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (1992-06-11),https://lens.org/045-097-138-129-867,Granted Patent,yes,28,209,9,9,0,A61B2017/00707;;A61B2017/00712;;A61N5/10;;A61N5/103;;A61N5/1031;;A61N5/1049;;A61B2090/363;;A61B2090/101;;A61N5/1049;;A61N5/1031;;A61N5/10;;A61N5/103;;A61B2017/00712;;A61B2017/00707;;A61B2090/363;;A61B2090/101,A61B17/00;;A61B19/00;;A61N5/10,378/65;;378/4;;378/15;;378/68;;378/195;;378/208;;378/20,1,1,024-671-005-704-890,10.1016/0360-3016(88)90446-4;;3276655,"A System for Stereotactic Radiosurgery With a Linear Accelerator, Wendell Lutz, PH.D. et al., vol. 14, No. 2, Feb. 1988, pp. 373 381.",EXPIRED
139,US,B1,US 7024237 B1,045-493-010-625-065,2006-04-04,2006,US 43003499 A,1999-10-29,US 43003499 A,1999-10-29,Mask system and method for stereotactic radiotherapy and image guided procedures,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a face mask. The face mask has at least three fiducial markers on it. By detecting the position of the markers, the position of features within the patient can be determined with great precision. The features can be the location of head or neck cancer or other target to which radiation or other medical procedure is to be applied. Since the face mask has been molded to uniquely fit to the patient's face, it may be removed after an initial imaging of the patient. The face mask may then be re-attached one or more times to the teeth. The face mask is molded to conform to the patient's face by using thermoplastic material.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,FLORIDA UNIVERSITY OF (2000-02-08);;UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC (2003-10-02),https://lens.org/045-493-010-625-065,Granted Patent,yes,4,46,1,1,0,A61B5/1127;;A61N5/1049;;A61N2005/1059;;A61B2090/101;;A61N5/1049;;A61B5/1127;;A61N2005/1059;;A61B2090/101,A61B5/00,600/429;;606/130,0,0,,,,EXPIRED
140,US,A,US 5939160 A,076-318-504-487-455,1999-08-17,1999,US 80580397 A,1997-02-25,US 80580397 A,1997-02-25,Low odor permeable hose,"Flexible PVC hose can be used with toilet systems in vehicles, such as boats, recreational vehicles, etc, or at pumpout stations. The hose includes about 40-55% by weight PVC resin, and at least 10% by weight of an EVA high molecular weight plasticizer. The hose also typically includes a low molecular weight plasticizer, stabilizer, lubricant, filler (such as 5-20% by weight dense filler like calcium carbonate), and pigment. The hose typically will not fail (that is will not transmit odor) for the life of the toilet system, or mechanical life of the hose.",SEALAND TECHNOLOGY INC,KLINE SALLY A;;FRIEDMAN WILLIAM J,DOMETIC CORPORATION (2008-12-30);;DOMETIC SANITATION CORPORATION (2005-04-07),https://lens.org/076-318-504-487-455,Granted Patent,yes,14,3,7,7,0,B60R15/04;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;B60R15/04,B60R15/04,428/36.9;;428/36.6;;428/36.91;;524/567;;524/569;;138/118,0,0,,,,EXPIRED
141,US,A1,US 2012/0047542 A1,183-683-088-713-656,2012-02-23,2012,US 80675010 A,2010-08-20,US 80675010 A,2010-08-20,System and method for rule based dynamic server side streaming manifest files,"There is provided a system and method for rule-based dynamic server-side streaming manifest files. There is provided a method comprising receiving a request to provide a first video content for playback, evaluating a plurality of rules for the first video content, generating a dynamic manifest file referencing the first video content, and providing the dynamic manifest file in response to the request, thereby enabling an application to playback the first video content for output on a display by interpreting the dynamic manifest file. The rules may implement various features such as dynamic advertisement insertion, load balancing, client customization, user and device targeting, enhanced security mechanisms, global announcements, and others. As streaming protocols are widely supported by default on many client platforms, the dynamic manifest files can be utilized in a user friendly and transparent manner compared to client-side solutions requiring cumbersome client software installations.",LEWIS JASON;;WATTS WILLIAM;;FRIEDMAN PETER;;DISNEY ENTPR INC,LEWIS JASON;;WATTS WILLIAM;;FRIEDMAN PETER,DISNEY ENTERPRISES INC (2010-08-19),https://lens.org/183-683-088-713-656,Patent Application,yes,9,361,2,2,0,H04N21/44016;;H04N21/812;;H04N21/8456;;H04N21/8456;;H04N21/44016;;H04N21/812,H04N7/173,725/97,0,0,,,,ACTIVE
142,WO,A1,WO 1990/014129 A1,177-796-068-628-829,1990-11-29,1990,US 9002578 W,1990-05-11,US 35381689 A,1989-05-18,DOSIMETRIC TECHNIQUE FOR STEREOTACTIC RADIOSURGERY,"Stereotactic radiosurgery is facilitated by a technique for computing the doses at various points within the patient's body. In particular, the doses are computed at a relatively high density of points within a fine dose grid (572) and at a relatively low density of points within a coarse dose grid (580). In that fashion, the user can quickly obtain necessary information about the radiation dose distribution before implementation of a proposed treatment plan. An advantageous technique of locating the intersection between the radiation beam and the contour or other surface of the patient is also provided. The method is especially well suited for use with a particular structure which allows one to utilize relatively narrow beam widths as a result of great mechanical accuracy.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/177-796-068-628-829,Patent Application,yes,4,36,6,6,0,A61B2017/00707;;A61B2017/00712;;A61N5/10;;A61N5/103;;A61N5/1031;;A61N5/1048;;A61N5/1049;;A61B6/506;;A61B2090/363;;A61B2090/101;;A61N5/1049;;A61N5/1048;;A61N5/1031;;A61B2017/00712;;A61B2017/00707;;A61N5/103;;A61N5/10;;A61B6/506;;A61B2090/363;;A61B2090/101,A61B17/00;;A61B19/00;;A61N5/10,,0,0,,,,PENDING
143,US,A,US 3359352 A,188-070-427-336-841,1967-12-19,1967,US 58001866 A,1966-09-16,US 58001866 A;;US 46497965 A,1965-06-18,Process for producing decorative surface covering,,CONGOLEUM NAIRN INC,POWELL WILLIAM H;;FRIEDMAN LAWRENCE J,CONGOLEUM CORPORATION (FORMERLY NAMED FIBIC CORPORATION) A CORP. OF DE (1980-01-29);;N & R FUNDING CORP. A CORP. OF DE (1984-06-01);;CONGOLEUM CORPORATION (1984-06-04),https://lens.org/188-070-427-336-841,Granted Patent,no,0,32,1,7,0,B44C1/26;;B44C3/02;;B44C3/08;;C08J9/06;;C08J9/24;;D06N3/0093;;D06N3/06;;D06N7/0013;;D06N7/0057;;Y10S264/82;;Y10T428/24802;;Y10T428/166;;Y10T428/24802;;Y10T428/166;;B44C1/26;;B44C3/08;;D06N3/0093;;D06N7/0013;;D06N7/0057;;D06N3/06;;C08J9/06;;C08J9/24;;B44C3/02;;Y10S264/82,B44C1/26;;B44C3/02;;B44C3/08;;C08J9/06;;C08J9/24;;D06N3/00;;D06N3/06;;D06N7/00;;D06N7/04,,0,0,,,,EXPIRED
144,EP,B1,EP 1199045 B1,063-515-791-522-102,2008-06-11,2008,EP 01308879 A,2001-10-19,US 24188800 P;;US 93010401 A,2000-10-20,Method for differentiating between burdened and cracked ultrasonically tuned blades,,ETHICON ENDO SURGERY,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,ETHICON ENDO-SURGERY (2008-06-18),https://lens.org/063-515-791-522-102,Granted Patent,yes,5,78,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/32;;A61B17/00;;A61B18/00;;A61F9/007;;B06B1/06,,0,0,,,,EXPIRED
145,YU,A,YU 27195 A,069-103-200-773-792,1999-03-04,1999,YU 27195 A,1995-04-28,US 23506994 A,1994-04-29,ORAL DOSAGE FOR ADMINISTERING AZITHROMYCIN,"Opisani su oralni dozni oblici azitromicina kao što su tablete sa dodatnim dezintegralom, prah za oralnu suspenziju sa anhidrovanim puferom ili jedinično dozno pakovanje sa sredstvom za dispergovanje. Svaki od oblika ima jednu ili obe od sledećih osobina: (i) rastvorljivost azitromicina od najmanje oko 90 % tokom oko 30 minuta kada se količina doznog oblika ekvivalentna 200 mg azitromicina testira prema USP testu <711>u USP-2 aparaturi za rastvaranje pod najmanje sledećim striktno povezanim uslovima: 900 ml natrijumfosfatni pufer, pH od 6,0, pri 37В°C, sa lopaticama koje se okreću pri 100 sec-1; i/ili (ii) vrednost (AUCfed)/(AUCfst) od najmanje 0,80 sa donjom 90-postotnom granicom pouzdanosti od najmanje 0,75. Prethodno uzeta hrana ne pokazuje negativne efekte na bilo koji od ovih oblika.",PFIZER,WILLIAM CURATOLO;;GEORGE FOULDS;;HYLAR FRIEDMAN,,https://lens.org/069-103-200-773-792,Patent Application,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
146,EP,A2,EP 1279369 A2,112-952-185-842-748,2003-01-29,2003,EP 02022455 A,1995-05-24,EP 95920588 A;;US 38802495 A;;US 63808896 A,1995-02-14,Repeat fixation for frameless stereotactic procedure,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate (26) has at least three fiducial markers (38) on it. The fiducial markers (38) may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers (38), the position of features within the patient (14) (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient (14). The bite plate (26) may then re-attached one or more times to the teeth and the location of the features will be in a known position relative to the sensed markers.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,"UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (2003-07-23)",https://lens.org/112-952-185-842-748,Patent Application,yes,4,0,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B19/00;;A61B5/055;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,DISCONTINUED
147,BR,A,BR 9809895 A,139-200-964-375-50X,2000-08-01,2000,BR 9809895 A,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,Formas de dosagem da sertralina de liberação retardada,"Patente de Invenção: <B>""FORMAS DE DOSAGEM DA SERTRALINA DE LIBERAçãO RETARDADA""<D>. As formas de dosagem de liberação retardada da sertralina que reduzem o T~ max~ os efeitos colaterais. As formas de dosagem são, em geral, de retardamento espacial por serem sensíveis ao seu posicionamento ao longo do trato gastrointestinal, ou de retardamento temporal por conseguirem um retardamento em um período deteminado, independemente da sua posição ao longo do trato gastrointestinal. São apresentados também testes in vitro para identificarem estas formas de dosagem.",PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/139-200-964-375-50X,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,DISCONTINUED
148,PE,A1,PE 84399 A1,141-628-194-854-385,1999-09-11,1999,PE 00057798 A,1998-06-26,US 5149997 P,1997-07-01,FORMAS DE DOSIFICACION DE SERTRALINA DE LIBERACION RETARDADA,"CARACTERIZADA PORQUE COMPRENDE UN NUCLEO DE LIBERACION INMEDIATA DE SERTRALINA RECUBIERTO CON UN POLIMERO IMPERMEABLE AL pH DEL ESTOMAGO, PERO PERMEABLE AL pH DEL INTESTINO DELGADO; EL POLIMERO SE SELECCIONA DE ACETATO DE FTALATO DE CELULOSA, POLI(ACETATO-FTALATO DE VINILO), FTALATO DE HIDROXIPROPILHIPROMELOSA, ENTRE OTROS; EL NUCLEO PUEDE SER MULTIPARTICULADO, UN COMPRIMIDO, UNA CAPSULA, O UNA CAPSULA DE GELATINA; EL NUCLEO ES SENSIBLE AL pH Y A LAS ENZIMAS. TAMBIEN SE REFIERE A OTRA FORMA DE DOSIFICACION QUE COMPRENDE UN NUCLEO, UNA MEMBRANA QUE RODEA AL NUCLEO, QUE PUEDE SER DE UN MATERIAL HIDROFOBO MICROPOROSO Y UN LIQUIDO HIDROFOBO ATRAPADO EN LOS POROS DE DICHA MEMBRANA, SIENDO DICHO LIQUIDO IMPERMEABLE AL AGUA Y A LA SERTRALINA, PERO CAMBIA POR DEGRADACION ENZIMATICA, RESULTANDO LA MEMBRANA PERMEABLE AL AGUA Y A LA SERTRALINA EN EL INTESTINO DELGADO. EL NUCLEO TAMBIEN PUEDE COMPRENDER UN AGENTE OSMOTICO. EL RECUBRIMIENTO ES SOLUBLE EN AGUA O DISGREGABLE EN AGUA. LA FORMA DE DOSIFICACION PERMITE LA LIBERACION DE NO MAS DE 10% DE SERTRALINA EN EL ESTOMAGO; PUDIENDO SER UTIL PARA TRATAR UNA ENFERMEDAD PSIQUIATRICA, EYACULACION PRECOZ, DEPENDENCIA QUIMICA, TRASTORNO DISFORICO PREMESTRUAL U OBESIDAD",PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/141-628-194-854-385,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K/;;A61K9/32;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
149,US,B2,US 8528597 B2,151-997-958-942-198,2013-09-10,2013,US 26876808 A,2008-11-11,US 26876808 A;;US 39667106 A,2006-04-03,Actuator and valve assembly,"An actuator for selectively moving a part relative to another part includes a shape memory wire, which contracts when heated. One portion of the shape memory wire is fixed to a first body, and another portion of the shape memory wire is coupled to a second body, which is movable relative to the first body. When heated the shape memory wire contracts and moves the second body in a direction of travel from a first position relative to the first body toward a second position. The actuator further includes a magnetic field for generating a magnetic force on the second body. The magnetic force acts on and moves the second body in the direction of travel to the second position after the shape memory wire initially contracts, and further decouples the second body from the shape memory wire when applying the magnetic force to the second body to thereby unload the load on the shape memory wire when the second body is moved to the second position.",FRIEDMAN MARK WILLIAM;;KNEPPLE ROBERT BRIAN;;HUMPHREY PROD CO,FRIEDMAN MARK WILLIAM;;KNEPPLE ROBERT BRIAN,,https://lens.org/151-997-958-942-198,Granted Patent,yes,16,8,6,6,0,F16K11/044;;F16K11/044;;F16K31/025;;F16K31/025;;Y10T137/86879;;Y10T137/86879,F16K11/07,137/625.48;;251/65,0,0,,,,ACTIVE
150,EP,A3,EP 0861981 A3,158-907-325-811-166,1999-02-17,1999,EP 97116475 A,1997-09-22,US 80671797 A,1997-02-27,Pulsation damper for marine tank pumpout systems,"A marine tank (such as a toilet system holding tank, or bilge tank) pump out system includes a positive displacement pump (11) connectable at the inlet (13) to a marine tank to be pumped out and connectable at the outlet (14) to a discharge tank or area. A pulsation dampener is connected between the pump outlet and the discharge tank or area, preferably directly to the pump so that a pump check valve is within the pulsation dampener (20). The pulsation dampener has an open chamber (26) extending upwardly from the pump outlet (14) into which pumped fluent material may flow, and has no moving parts (such as a diaphragm). Typically two different outlets (23,24) from the dampener are provided for versatility and connecting up to discharge tanks or areas, one of the outlets filled with a plug (29). The dampener may comprise either a substantially L-shaped or C-shaped (when viewed from the dampener inlet) casing, which nests with the pump motor.",SEALAND TECHNOLOGY INC,SCHEIBE MARK;;SIGLER JAMES;;FRIEDMAN WILLIAM,,https://lens.org/158-907-325-811-166,Search Report,yes,7,0,7,7,0,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/0025;;Y10T137/3118;;Y10T137/3118;;B63B29/16;;B63B13/00;;F04B11/0025;;E03D5/00,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/00,,0,0,,,,EXPIRED
151,EP,B1,EP 1007024 B1,169-375-142-182-701,2003-07-23,2003,EP 98923022 A,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,PFIZER PRODUCTS INC. (2007-10-30),https://lens.org/169-375-142-182-701,Granted Patent,yes,4,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/22;;A61K9/14;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
152,TR,T2,TR 199903295 T2,192-120-638-974-568,2000-08-21,2000,TR 9903295 T,1998-06-16,US 5149997 P,1997-07-01,Sertralinin ertelemeli salgilanan dozaj biçimleri.,"Bu bulus, sertralinin Tmax'i ve yan etkileri azaltan ertelemeli salgilanan dozaj biçimleri ile ilgilidir. Genelde dozaj biçimleri gastroentestinal sistem boyuncaki durumlarina duyarli bir sekilde alansal olarak ertelenir ya da gastroentestinal sistem boyuncaki durumlarindan bagimsiz bir biçimde daha önceden belirlenmis bir zaman araligi için geçici olarak ertelenir. Bu tür dozaj biçimlerini tanimlamak için in vitro testler sunulmustur.",PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/192-120-638-974-568,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,PENDING
153,AU,A,AU 2001/081509 A,000-872-157-360-37X,2002-05-02,2002,AU 2001/081509 A,2001-10-19,US 24188800 P;;US 93010401 A,2000-10-20,Method for differentiating between burdened and cracked ultrasonically tuned blades,,ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,,https://lens.org/000-872-157-360-37X,Patent Application,no,0,0,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/00;;A61B17/32;;A61B18/00;;A61F9/007;;B06B1/06,,0,0,,,,EXPIRED
154,US,A,US 1503250 A,029-774-779-761-112,1924-07-29,1924,US 40193520 A,1920-08-07,US 40193520 A,1920-08-07,Apparatus for and method of rapid transmission of telegraphic messages,,PAUL E SABINE,SABINE PAUL E;;FRIEDMAN WILLIAM F,,https://lens.org/029-774-779-761-112,Granted Patent,no,0,0,1,1,0,H04L25/44;;H04L25/44,,,0,0,,,,EXPIRED
155,AU,A,AU 1998/075451 A,018-177-185-936-427,1999-01-25,1999,AU 1998/075451 A,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,Delayed-release dosage forms of sertraline,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/018-177-185-936-427,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
156,CN,C,CN 1151783 C,016-176-945-873-872,2004-06-02,2004,CN 98806429 A,1998-06-16,US 5149997 P,1997-07-01,Delayed-release dosage forms of sertraline,本发明涉及能够减小T#-[max]并减少副作用的舍曲林缓释剂型。简而言之，该剂型可以根据对它们在胃肠道中不同位置的敏感程度产生空间延迟；或根据在一段预定时间内的延迟产生时间延迟，而不依赖它们在胃肠道中的位置。本发明还提供了鉴定这些剂型的体外试验。,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/016-176-945-873-872,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
157,US,A1,US 2002/0049551 A1,091-863-295-942-286,2002-04-25,2002,US 93010401 A,2001-08-14,US 93010401 A;;US 24188800 P,2000-10-20,Method for differentiating between burdened and cracked ultrasonically tuned blades,"
   A method for differentiating between ultrasonically tuned blades which are broken or cracked, and blades which are gunked by evaluating measured impedance differences when a system is first excited with a low displacement signal and then with a high displacement signal. The method is performed irrespective of the age of the hand piece/blade, the temperature or specific type of hand piece or blade, and is not affected by self healing effects of slightly cracked blades. Moreover, the method facilitates the quantifiable determination of the amount of gunk on the blade. Absolute impedance measurements of the transducer or blade are unnecessary. Instead, only relative impedance measurements are required, which greatly simplifies the measuring criteria. This provides a way to measure the amount of gunk accumulation, and thereby a way to calculate/estimate the amount of heat generated at the sheath, as well as a way to calculate/estimate the amounts of degradation to the load curve of the ultrasonic system. 
",ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN LESLIE;;DONOFRIO WILLIAM T,ETHICON ENDO-SURGERY INC (2001-08-08),https://lens.org/091-863-295-942-286,Patent Application,yes,9,460,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/00;;A61B17/32;;A61B18/00;;A61F9/007;;B06B1/06,702/65,0,0,,,,DISCONTINUED
158,US,A,US 5588430 A,122-847-467-194-425,1996-12-31,1996,US 38802495 A,1995-02-14,US 38802495 A;;US 63808896 A,1995-02-14,Repeat fixation for frameless stereotactic procedure,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate. The bite plate has at least three fiducial markers on it. The fiducial markers may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers, the position of features within the patient (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient. The bite plate may then be re-attached one or more times to the teeth and the location of the features will be in a known position relative to the sensed markers. The patient's position can then be adjusted in order to bring the features to a desired location, such as bringing an intracranial target to the isocenter of a planned application of radiation. Importantly, the bite plate is mechanically independent of any structures used for positioning (that is moving) the patient such that no error introducing forces or torques are applied to the bite plate by adjusting patient position.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC (1995-10-10),https://lens.org/122-847-467-194-425,Granted Patent,yes,13,271,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B5/055;;A61B6/03;;A61B19/00;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,128/653.1;;606/130;;433/68;;433/75;;433/27;;433/213;;378/204;;378/205;;378/207;;378/208,1,1,006-808-376-654-791,1633444;;10.1016/s1042-3680(18)30686-7,"Linear Accelerator Radiosurgery at the University of Florida; William A. Friedman, MD, Frank J. Bova, and Roberto Spiegelmann, MD; Reprinted from Neurosurgery Clinics of North America, vol. 3, No. 1, Jan. 1992 pp. 141 166.",EXPIRED
159,DE,B,DE 1298023 B,145-228-389-790-521,1969-06-19,1969,DE C0039381 A,1966-06-16,US 46497965 A,1965-06-18,Verfahren zur Herstellung eines nichtporoesen dekorativen Oberflaechenueberzugs mit eingelegtem Dekorationsmuster,,CONGOLEUM NAIRN INC,HENRY POWELL WILLIAM;;JAY FRIEDMAN LAWRENCE,,https://lens.org/145-228-389-790-521,Patent Application,no,0,1,4,7,0,B44C1/26;;B44C3/02;;B44C3/08;;C08J9/06;;C08J9/24;;D06N3/0093;;D06N3/06;;D06N7/0013;;D06N7/0057,B44C1/26;;B44C3/02;;B44C3/08;;C08J9/06;;C08J9/24;;D06N3/00;;D06N3/06;;D06N7/00,,1,0,,,None,DISCONTINUED
160,CA,A,CA 500676 A,184-499-592-762-074,1954-03-16,1954,CA 500676D A,,CA 500676T A,,REFINING OF ORGANIC COMPOUNDS,,CITIES SERVICE OIL CO,HUGHES WILLIAM B;;FRIEDMAN LOUIS D,,https://lens.org/184-499-592-762-074,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
161,DE,D1,DE 60134373 D1,178-951-648-837-946,2008-07-24,2008,DE 60134373 T,2001-10-19,US 24188800 P;;US 93010401 A,2000-10-20,Verfahren zum Unterscheiden zwischen verschmutzten und gebrochenen Ultraschall betriebenen Klingen,,ETHICON ENDO SURGERY,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,,https://lens.org/178-951-648-837-946,Granted Patent,no,0,0,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/32;;A61B17/00;;A61B18/00;;A61F9/007;;B06B1/06,,0,0,,,,EXPIRED
162,UY,A1,UY 25068 A1,186-872-770-439-479,2000-12-29,2000,UY 25068 A,1998-06-29,US 5149997 P,1997-07-01,FORMAS DE DOSIFICACIÓN DE SERTRALINA DE LIBERACIÓN RETARDADA,"Formas de dosificación de sertralina de liberación retardada que reducen el T Max y reducen los efectos secundarios. Las formas están, por lo general, especialmente retardadas por ser sensibles a su posición a lo largo del tracto gastrointestinal, o temporalmente retardadas por estar retardadas durante un período predeterminado, independiente de su posición a lo largo del tracto gastrointestinal. Se presentan ensayos in vivo para identificar dichas formas de dosificación. La sertralina es un inhibidor selectivo de la reabsorción de serotonina, que es útil como agente antidepresivo.",PFIZER PROD INC,LEWIS FRIEDMAN HYLAR;;JOHN CURATOLO WILLIAM,,https://lens.org/186-872-770-439-479,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,DISCONTINUED
163,US,A,US 4060854 A,189-138-001-450-019,1977-12-06,1977,US 76219877 A,1977-01-24,US 66160376 A,1976-02-26,Belt and buckle assembly,"A belt and buckle assembly in which first and second ends of a belt are adapted to be interconnected and the belt has means for receiving and releasably retaining a buckle member; and a plurality of buckle members, each having means for attachment to the belt, such that one of a plurality of available buckles may be selectively attached to the belt and subsequently removed and replaced by a second of the buckles.",BUXTON INC,FRIEDMAN HARVEY WILLIAM;;COREY DONALD WYMAN,BUXTON INC (1982-08-26);;DHP LIMITED PARTNERSHIP A DE. LIMITED PARTNERSHIP (1989-12-12),https://lens.org/189-138-001-450-019,Granted Patent,yes,2,3,1,1,0,A41F9/002;;A44B11/22;;A41F9/002;;A44B11/22,A41F9/00;;A44B11/22,2/338,0,0,,,,EXPIRED
164,US,A1,US 2008/0015620 A1,003-722-098-443-903,2008-01-17,2008,US 77660607 A,2007-07-12,US 77660607 A;;US 31290205 A;;US 93010401 A;;US 24188800 P,2000-10-20,METHOD FOR DIFFERENTIATING BETWEEN BURDENED AND CRACKED ULTRASONICALLY TUNED BLADES,"A method for differentiating between ultrasonically tuned blades which are broken or cracked, and blades which are gunked by evaluating measured impedance differences. The method is performed irrespective of the age of the hand piece/blade, the temperature or specific type of hand piece or blade, and is not affected by self healing effects of slightly cracked blades. Moreover, the method facilitates the quantifiable determination of the amount of gunk on the blade. Absolute impedance measurements of the transducer or blade are unnecessary. Instead, only relative impedance measurements are required, which greatly simplifies the measuring criteria. This provides a way to measure the amount of gunk accumulation, and thereby a way to calculate/estimate the amount of heat generated at the sheath, as well as a way to calculate/estimate the amounts of degradation to the load curve of the ultrasonic system.",FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,,https://lens.org/003-722-098-443-903,Patent Application,yes,32,9,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/00;;A61B17/32;;A61B18/00;;A61F9/007;;B06B1/06;;G01N29/00,606/169;;73/584,0,0,,,,DISCONTINUED
165,CA,A1,CA 2220949 A1,046-658-153-101-68X,1996-08-22,1996,CA 2220949 A,1995-05-24,US 38802495 A;;US 9506425 W;;US 63808896 A,1995-02-14,REPEAT FIXATION FOR FRAMELESS STEREOTACTIC PROCEDURE,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate (26) has at least three fiducial markers (38) on it. The fiducial markers (38) may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers (38), the position of features within the patient (14) (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient (14). The bite plate (26) may then be re-attached one or more times to the teeth and the location of the features will be in a known position relative to the sensed markers.",UNIV FLORIDA,FRIEDMAN WILLIAM A;;BOVA FRANK J,,https://lens.org/046-658-153-101-68X,Patent Application,no,0,0,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B19/00;;A61B5/055;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,EXPIRED
166,WO,B1,WO 2007/118189 B1,090-444-453-507-712,2007-12-21,2007,US 2007/0066132 W,2007-04-06,US 40001506 A,2006-04-07,FRAMELESS STEREOTACTIC GUIDANCE OF MEDICAL PROCEDURES,"Devices, methods and systems for frameless guidance of image-based medical procedures such as stereotactic radiotherapy and surgery. Devices including custom fitting subject-specific articles include contoured surfaces that provide spatial reference to the location of target regions within the subject. The devices are attached exclusive of fasteners anchored to the tissue of the subject and reside on the front of a head of the subject when attached. The devices and articles can be fabricated using computer-directed fabrication technology.",UNIV FLORIDA;;BOVA FRANK J;;FRIEDMAN WILLIAM A,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/090-444-453-507-712,Patent Application,no,0,0,4,4,0,A61B90/10;;A61B90/10;;A61B34/20;;A61B34/20;;A61B90/11;;A61B90/11;;A61B2017/3405;;A61B2017/3405;;A61B2034/105;;A61B2034/105;;A61B2034/107;;A61B2034/107;;A61B2034/108;;A61B2034/108;;A61B2034/2051;;A61B2034/2051;;A61B2034/2055;;A61B2034/2055;;A61B2034/2072;;A61B2034/2072;;A61B2034/256;;A61B2034/256;;A61B2090/3983;;A61B2090/3983;;B33Y80/00;;B33Y80/00,A61B19/00,,0,0,,,,PENDING
167,EC,A,EC SP982565 A,151-923-868-487-994,1999-01-26,1999,EC SP982565 A,1998-06-29,EC SP982565 A,1998-06-29,FORMAS DE DOSIFICACION DE SERTRALINA DE LIBERACION RETARDADA,"Formas de dosificación de sertralina de liberación retardada que reducen el Tmax y reducen los efectos secundarios. Las formas están, por lo general, especialmente retardadas por ser sensibles a su posición a lo largo del tracto gastrointestinal, o temporalmente retardadas por estar retardadas durante un periodo predeterminado, independiente de su posición a lo largo del tracto gastrointestinal. Se presentan ensayos en vivo para identificar dichas formas de dosificación.",,CURATOLO WILLIAM JHON;;FRIEDMAN HYLAR L,,https://lens.org/151-923-868-487-994,Patent Application,no,0,0,1,1,0,,A61K9/28;;A61K31/13;;C07C211/58,,0,0,,,,PENDING
168,EP,A1,EP 1007024 A1,136-151-828-725-774,2000-06-14,2000,EP 98923022 A,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,PFIZER PRODUCTS INC. (2007-10-30),https://lens.org/136-151-828-725-774,Patent Application,yes,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/22;;A61K9/14;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
169,EP,A4,EP 0809465 A4,169-126-827-595-675,1998-08-05,1998,EP 95920588 A,1995-05-24,US 9506425 W;;US 38802495 A;;US 63808896 A,1995-02-14,REPEAT FIXATION FOR FRAMELESS STEREOTACTIC PROCEDURE,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate (26) has at least three fiducial markers (38) on it. The fiducial markers (38) may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers (38), the position of features within the patient (14) (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient (14). The bite plate (26) may then re-attached one or more times to the teeth and the location of the features will be in a known position relative to the sensed markers. <IMAGE>",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,"UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPO (2003-09-01)",https://lens.org/169-126-827-595-675,Search Report,no,3,0,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B19/00;;A61B5/055;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,EXPIRED
170,JP,A,JP 2002301089 A,185-863-319-788-85X,2002-10-15,2002,JP 2002019106 A,2002-01-28,US 63808896 A,1996-04-26,MARKER SYSTEM AND THREE-DIMENSIONAL STEREOTAXIC TREATMENT COMBINED THEREWITH,"PROBLEM TO BE SOLVED: To provide a repeated fixing method for medical treatment using an non-invading locator, in particularl a bite plate. SOLUTION: The bite plate 26 has at least three position markers, and the position markers may be formed of an LED, an angiographic radiotransparent marker, a computed tomographic(CT) image forming marker, or a nuclear magnetic resonance image(MRI) forming marker. The position of the marker is detected, whereby the position of a characteristic part (cerebral cancer) within a patient can be detected with extremely high precision. Since the bite plate 26 independently registers the tooth of each patient, it can be removed after the first imaging of the patient. Thereafter, the bite plate 26 is mounted on the tooth again. In a modified example, a head holder such as a head ring 18 equipped with LED, a head mask system 276, or the like is used.",UNIV OF FLORIDA RES FOUNDATION,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/185-863-319-788-85X,Patent Application,no,5,5,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B5/055;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28;;A61B19/00,,0,0,,,,EXPIRED
171,DE,A1,DE 3000745 A1,014-684-555-875-424,1980-07-17,1980,DE 3000745 A,1980-01-10,US 252679 A,1979-01-11,WAERMESTABILISIERTE FORMMASSEN AUF DER BASIS VON OLEFIN-POLYMERISATEN,,BORG WARNER,HORN JUN WILLIAM E;;FRIEDMAN LESTER,"GE SPECIALTY CHEMICALS, INC. (N.D.GES.D.STAATES DE (1993-01-21);;BORG-WARNER CHEMICALS, INC.(N.D.GES.DES STAATES DE (1982-07-29)",https://lens.org/014-684-555-875-424,Patent Application,no,8,0,8,8,0,C08K5/526,C08L23/00;;C08K5/52;;C08K5/526;;C08L7/00;;C08L21/00;;C08L101/00,,0,0,,,,EXPIRED
172,CA,A1,CA 2290969 A1,020-993-600-482-328,1999-01-14,1999,CA 2290969 A,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE,"Delayed-release dosage forms of sertraline which reduce Tmax and reduce side effects. The dosage forms are, in general, spatially delayed by being sensitive to their position along the gastrointestinal tract, or temporally delayed by being delayed for a preset period, independent of their position along the gastrointestinal tract. In vitro tests for identifying such dosage forms are presented.",PFIZER PROD INC,FRIEDMAN HYLAR LEWIS;;CURATOLO WILLIAM JOHN,,https://lens.org/020-993-600-482-328,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
173,MA,A1,MA 24585 A1,051-889-683-358-457,1998-12-31,1998,MA 25144 A,1998-06-30,US 5149997 P,1997-07-01,FORMES POSOLOGIQUES DE SERTRALINE A LIBERATION RETARDEE,,PFIZER PROD INC,WILLIAM J CURATOLO;;HYLAR L FRIEDMAN,,https://lens.org/051-889-683-358-457,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/14;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
174,US,B2,US 7697969 B2,063-235-401-596-258,2010-04-13,2010,US 54575206 A,2006-10-10,US 54575206 A;;US 72608305 P,2005-10-11,Preplanning of guided medical procedures,"A method of preplanning for guided medical procedures includes obtaining a first 3D diagnostic dataset for a region of interest of a subject. This first dataset can be a non-stereotactic dataset and provide sufficient contrast to identify target tissue in the region of interest. A treatment preplan is developed to treat the target tissue using the first dataset exclusive of stereotactic data. The treatment preplan includes placement locations for a plurality of initial radiation beams and their respective dose intensities. A second, stereotactic 3D dataset can be obtained for the region of interest. A registered dataset can then be created by registering the first dataset to the second dataset. The treatment preplan can be modified using data associated with the registering step to generate a stereotactic treatment plan including a plurality of radiation treatment beams with respective placement positions based on the registered dataset to treat the target tissue.",UNIV FLORIDA,BOVA FRANK JOSEPH;;FRIEDMAN WILLIAM ALAN,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC (2009-12-08),https://lens.org/063-235-401-596-258,Granted Patent,yes,9,0,3,3,0,A61N5/103;;A61N5/103;;A61B34/10;;A61B34/10;;A61B2090/101;;A61B2090/101;;A61B2090/364;;A61B2090/364,A61B5/05;;A61N5/10;;G06K9/00,600/407;;600/414;;600/426;;600/427;;382/128;;382/294;;378/65,0,0,,,,ACTIVE
175,EP,A1,EP 0472646 A1,067-660-070-256-082,1992-03-04,1992,EP 90908832 A,1990-05-11,US 35381689 A,1989-05-18,DOSIMETRIC TECHNIQUE FOR STEREOTACTIC RADIOSURGERY.,"La radiochirurgie stéréotactique est facilitée par une technique de calcul des doses en divers points du corps d'un patient. En particulier, les doses sont calculées à une densité de points relativement élevée dans une grille de doses fines (572) et à une densité de points relativement faible dans une grille de doses grossières (580). De cette manière, l'utilisateur peut obtenir rapidement les informations nécessaires concernant la distribution de la dose de rayonnement avant de mettre en oeuvre un plan de traitement proposé. Une technique avantageuse de localisation de l'intersection entre le rayon de radiation et le contour ou autre surface du patient est également divulgué. Le procédé est particulièrement bien adapté à une structure particulière qui permet d'utiliser des largeurs de rayons relativement étroites résultant d'une grande précision mécanique.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/067-660-070-256-082,Patent Application,yes,0,0,6,6,0,A61B2017/00707;;A61B2017/00712;;A61N5/10;;A61N5/103;;A61N5/1031;;A61N5/1048;;A61N5/1049;;A61B6/506;;A61B2090/363;;A61B2090/101;;A61N5/1049;;A61N5/1048;;A61N5/1031;;A61B2017/00712;;A61B2017/00707;;A61N5/103;;A61N5/10;;A61B6/506;;A61B2090/363;;A61B2090/101,A61B17/00;;A61B19/00;;A61N5/10,,0,0,,,,DISCONTINUED
176,NO,L,NO 996519 L,122-107-578-443-021,2000-02-29,2000,NO 996519 A,1999-12-28,IB 9800937 W;;US 5149997 P,1997-07-01,Doseringsformer av sertralin med forsinket frigjøring,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/122-107-578-443-021,Abstract,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/14;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,DISCONTINUED
177,US,A,US 4328801 A,118-675-350-918-562,1982-05-11,1982,US 20465780 A,1980-11-06,US 20465780 A;;US 20241280 A,1980-10-30,Automated intravenous fluid regulating and administering apparatus,"Automated dispensing apparatus is disclosed for administering intravenous fluid to a patient under gravity pressure at a controlled volumetric rate, such that deviations from a desired fluid volumetric rate are automatically corrected. The area and maximum width of each fluid drop are measured with two intersecting light beams. The light beams are either collimated or converging. Use of converging light beams is particularly advantageous when fogging or imperfections are present in the walls of a transparent tube through which the intravenous fluid flows. Apparatus, responsive to the light beams, generates signals representative of drop area and width, and these two parameters are combined to obtain a signal proportional to drop volume. The measured drop volume signal is compared with a rate control signal to automatically correct the fluid flow rate.",MARX ALVIN J,MARX ALVIN J;;FRIEDMAN WILLIAM D,ALDERSON LABORATORIES INC. A CORP OF DE (1984-03-26);;MARX ALVIN J (1980-11-03),https://lens.org/118-675-350-918-562,Granted Patent,yes,7,115,1,2,0,A61M5/1689;;A61M5/1689,A61M5/168,128214E,0,0,,,,EXPIRED
178,DK,T3,DK 1007024 T3,134-649-387-400-688,2003-11-17,2003,DK 98923022 T,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,Doseringsformer af sertralin med forsinket frigivelse,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/134-649-387-400-688,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/14;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
179,US,A1,US 2006/0212044 A1,186-288-912-671-925,2006-09-21,2006,US 40001506 A,2006-04-07,US 40001506 A;;US 67741903 A,2003-10-02,Frameless stereotactic guidance of medical procedures,"Devices, methods and systems for frameless guidance of image-based medical procedures such as stereotactic radiotherapy and surgery. Devices including custom fitting subject-specific articles include contoured surfaces that provide spatial reference to the location of target regions within the subject. The devices are attached exclusive of fasteners anchored to the tissue of the subject and reside on the front of a head of the subject when attached. The devices and articles can be fabricated using computer-directed fabrication technology.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC (2006-04-25),https://lens.org/186-288-912-671-925,Patent Application,yes,50,58,4,4,0,A61B90/10;;A61B90/10;;A61B34/20;;A61B34/20;;A61B90/11;;A61B90/11;;A61B2017/3405;;A61B2017/3405;;A61B2034/105;;A61B2034/105;;A61B2034/107;;A61B2034/107;;A61B2034/108;;A61B2034/108;;A61B2034/2051;;A61B2034/2051;;A61B2034/2055;;A61B2034/2055;;A61B2034/2072;;A61B2034/2072;;A61B2034/256;;A61B2034/256;;A61B2090/3983;;A61B2090/3983;;B33Y80/00;;B33Y80/00,A61B19/00,606/130,0,0,,,,EXPIRED
180,CA,A1,CA 2252645 A1,194-493-825-660-999,1997-11-06,1997,CA 2252645 A,1997-04-14,US 63808896 A;;US 9705498 W,1996-04-26,MARKER SYSTEM AND RELATED STEREOTACTIC PROCEDURE,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate has at least three fiducial markers on it. The fiducial markers may be LEDs (162), radiopaque markers for angiography, or computerized tomography (CT) imaging, or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers, the position of features within the patient (such as a brain tumor) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient. The bite plate (26) may then be reattached one or more times to the teeth. An alternate embodiment uses a head ring (18) or head holder such as a head mask system (276) with the LEDs thereon.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/194-493-825-660-999,Patent Application,no,0,0,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B19/00;;A61B5/055;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,EXPIRED
181,EP,A2,EP 0861981 A2,196-764-719-690-670,1998-09-02,1998,EP 97116475 A,1997-09-22,US 80671797 A,1997-02-27,Pulsation damper for marine tank pumpout systems,"A marine tank (such as a toilet system holding tank, or bilge tank) pump out system includes a positive displacement pump (11) connectable at the inlet (13) to a marine tank to be pumped out and connectable at the outlet (14) to a discharge tank or area. A pulsation dampener is connected between the pump outlet and the discharge tank or area, preferably directly to the pump so that a pump check valve is within the pulsation dampener (20). The pulsation dampener has an open chamber (26) extending upwardly from the pump outlet (14) into which pumped fluent material may flow, and has no moving parts (such as a diaphragm). Typically two different outlets (23,24) from the dampener are provided for versatility and connecting up to discharge tanks or areas, one of the outlets filled with a plug (29). The dampener may comprise either a substantially L-shaped or C-shaped (when viewed from the dampener inlet) casing, which nests with the pump motor.",SEALAND TECHNOLOGY INC,SCHEIBE MARK;;SIGLER JAMES;;FRIEDMAN WILLIAM,,https://lens.org/196-764-719-690-670,Patent Application,yes,0,0,7,7,0,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/0025;;Y10T137/3118;;Y10T137/3118;;B63B29/16;;B63B13/00;;F04B11/0025;;E03D5/00,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/00,,0,0,,,,EXPIRED
182,EP,B1,EP 0395711 B1,046-507-454-577-173,1995-03-08,1995,EP 89900991 A,1988-12-02,US 8804303 W;;US 12827387 A,1987-12-03,APPARATUS FOR STEREOTACTIC RADIOSURGERY.,,UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/046-507-454-577-173,Granted Patent,yes,6,8,9,9,0,A61B2017/00707;;A61B2017/00712;;A61N5/10;;A61N5/103;;A61N5/1031;;A61N5/1049;;A61B2090/363;;A61B2090/101;;A61N5/1049;;A61N5/1031;;A61N5/10;;A61N5/103;;A61B2017/00712;;A61B2017/00707;;A61B2090/363;;A61B2090/101,A61B17/00;;A61B19/00;;A61N5/10,,0,0,,,,EXPIRED
183,US,A,US 2224646 A,111-234-836-023-103,1940-12-10,1940,US 13846837 A,1937-04-22,US 13846837 A,1937-04-22,"Electric control system for tabulating cards, documents, and the like",,FRIEDMAN WILLIAM F;;WHITMAN VERNON E,FRIEDMAN WILLIAM F;;WHITMAN VERNON E,,https://lens.org/111-234-836-023-103,Granted Patent,no,0,47,1,1,0,B07C5/3412;;B07C5/3412,,,0,0,,,,EXPIRED
184,PA,A1,PA 8454201 A1,143-414-588-450-569,2000-09-29,2000,PA 8454201 A,1998-06-25,US 5149997 P,1997-07-01,FORMAS DE DOSIFICACION DE SERTRALINA DE LIBERACION RETARDADA,"FORMAS DE DOSIFICACION DE SERTRALINA DE LIBERACION RETARDADA QUE REDUCEN EL TMAX Y REDUCEN LOS EFECTOS SECUNDARIOS. LAS FORMAS ESTAN, POR LO GENERAL, ESPECIALMENTE RETARDADAS POR SER SENSIBLES A SU POSICION A LO LARGO DEL TRACTO GASTROINTESTINAL, O TEMPORALMENTE RETARDADAS POR ESTAR RETARDADAS DURANTE UN PERIODO PREDETERMINADO, INDEPENDIENTE DE SU POSICION A LO LARGO DEL TRACTO GASTROINTESTINAL. SE PRESENTAN ENSAYOS IN VIVO PARA IDENTIFICAR DICHAS FORMAS DE DOSIFICACION.",PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/143-414-588-450-569,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/14;;A61K9/32;;A61K9/48;;A61K9/50;;A61K9/52;;A61K9/58;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,PENDING
185,CZ,A3,CZ 464399 A3,161-188-335-763-399,2000-05-17,2000,CZ 464399 A,1998-06-16,CZ 464399 A,1998-06-16,Setraline dosing form with controlled release,,PFIZER PROD INC,CURATOLO JOHN WILLIAM;;FRIEDMAN HYLAR LEWIS,,https://lens.org/161-188-335-763-399,Patent Application,no,0,0,1,1,0,,A61K9/28;;A61K31/135;;A61P3/04;;A61P15/00;;A61P25/18;;A61P25/24;;A61P25/30,,0,0,,,,PENDING
186,CA,A,CA 793202 A,187-357-174-480-280,1968-08-27,1968,CA 793202D A,,CA 793202T A,,PROCESS FOR PRODUCING DECORATIVE SURFACE COVERING,,CONGOLEUM NAIRN INC,POWELL WILLIAM H;;FRIEDMAN LAWRENCE J,,https://lens.org/187-357-174-480-280,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
187,EP,A3,EP 1279369 A3,195-174-029-070-216,2004-01-28,2004,EP 02022455 A,1995-05-24,EP 95920588 A;;US 38802495 A;;US 63808896 A,1995-02-14,Repeat fixation for frameless stereotactic procedure,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate (26) has at least three fiducial markers (38) on it. The fiducial markers (38) may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers (38), the position of features within the patient (14) (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient (14). The bite plate (26) may then re-attached one or more times to the teeth and the location of the features will be in a known position relative to the sensed markers.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,"UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (2003-07-23)",https://lens.org/195-174-029-070-216,Search Report,yes,3,0,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B19/00;;A61B5/055;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,DISCONTINUED
188,WO,A3,WO 2007/130208 A3,000-865-846-168-716,2008-10-16,2008,US 2007/0005994 W,2007-03-08,US 39667106 A,2006-04-03,ACTUATOR AND VALVE ASSEMBLY,"An actuator for selectively moving a part relative to another part includes a shape memory wire, which contracts upon heating, and a magnetic field. One end of the wire is fixed to a first body. The other end of the wire is coupled to a second body, which is movable relative to the first body. When heated, the wire contracts and moves the second body in a direction of travel from a first position relative to the first body toward a second position. A magnetic field generates a magnetic force on the second body, which acts on and moves the second body in the direction of travel to the second position after the wire initially contracts to thereby reduce the load on the wire when the second body is moved to the second position. The actuator may be used, for example, to move the valve stem in a valve.",HUMPHREY PRODUCTS;;FRIEDMAN MARK WILLIAM;;KNEPPLE ROBERT BRIAN,FRIEDMAN MARK WILLIAM;;KNEPPLE ROBERT BRIAN,,https://lens.org/000-865-846-168-716,Search Report,yes,2,0,6,6,0,F16K11/044;;F16K11/044;;F16K31/025;;F16K31/025;;Y10T137/86879;;Y10T137/86879,F03G7/06,,0,0,,,,PENDING
189,GB,A,GB 675535 A,043-854-735-090-65X,1952-07-09,1952,GB 63850 A,1950-01-10,GB 63850 A,1950-01-10,Removal of carbonyl impurities from organic compounds,"Aldehydic or ketonic impurities are removed from hydrocarbons and their oxygenated derivatives by adding an aldehyde or ketone thereto to bring the molar ratio of aldehyde to ketone present to about 1-9 : 1, condensing in the presence of a basic condensing agent to give an aldehyde-ketone condensation product which is less volatile than the compound to be purified and separating the latter. Alcohols, particularly lower alkanols made by hydrocarbon oxidation or the Synthol process, hydrocarbons, ethers, esters and acetals may be treated. Formaldehyde, benzaldehyde, furfuraldehyde, and acetaldehyde may be added to condense with ketones present, while acetone, methyl ethyl ketone, acetophenone, and benzophenone may be used for aldehydic impurities. The carbonyl compound may be added as a dilute or concentrated solution or as a polymer. The condensing agent may be an alkali or alkaline earth metal carbonate, bicarbonate, oxide or hydroxide or an organo-metallic base. With formaldehyde the pH should be below 14, and below 12 if alkali metal hydroxides are used. With higher aldehydes, a pH above 14 is suitable. The condensing agent is preferably added in small increments to maintain a pH between 9 and 14+. The condensation product obtained by treating with formaldehyde is a syrup from which a crystalline material may be separated of high hydroxyl content. It may be modified by reaction with additional aldehyde or ketone. In examples: (1) anhydrous or hydrated methanol containing methyl ethyl ketone is treated with paraformaldehyde and potassium carbonate or calcium hydroxide at various temperatures from 50 DEG C. upwards; (2) methanol containing methyl ethyl, diethyl and di-isopropyl ketones is treated with formaldehyde and calcium or sodium hydroxide or potassium carbonate; (3) a fraction of the aqueous products of the Synthol process containing ethanol, propanol, butanol and higher alcohols contaminated with ketones and aldehydes is similarly reacted with paraformaldehyde; (4) crude methanol produced by oxidation of hydrocarbon gases is purified by formaldehyde or acetaldehyde or the hydroxyfraction is purified with benzaldehyde, furfuraldehyde or acetaldehyde or the hydroxymethylated product obtained by condensation of carbonyl impurities with formaldehyde. This product may be used for purification in a first stage followed by formaldehyde in a second; (6) n-heptane is purified from ketones by heating with paraformaldehyde in methanol, sodium methylate in methanol being the condensing agent, and butyl acetate is treated with paraformaldehyde and calcium hydroxide.",CITIES SERVICE OIL CO,FRIEDMAN LOUIS DAVID;;HUGHES WILLIAM BENTON,,https://lens.org/043-854-735-090-65X,Granted Patent,no,0,0,1,1,0,C07C29/74,C07C29/74,C2C CCE;;C2C CUU;;C2C CYK;;C2C C20Y;;C2C C20Y;;C2C C20Y;;C2C C208;;C2C C209;;C2C C229;;C2C C299;;C2C C30Y;;C2C C30Y;;C2C C30Y;;C2C C351;;C2C C355;;C2C C36Y;;C2C C360;;C2C C361;;C2C C366;;C2C C368;;C2C C37X;;C2C C386;;C2C C40Y;;C2C C408;;C2C C408;;C2C C409;;C2C C43X;;C2C C43X;;C2C C46X;;C2C C50Y;;C2C C509;;C2C C566;;C2C C567;;C2C C568;;C2C C569;;C2C C623;;C2C C625;;C2C C628;;C2C C65Y;;C2C C655;;C2C C66Y,0,0,,,,EXPIRED
190,US,A,US 2544308 A,062-357-001-833-583,1951-03-06,1951,US 68142046 A,1946-07-03,US 68142046 A,1946-07-03,Refining of organic compounds,,CITIES SERVICE OIL CO,FRIEDMAN LOUIS D;;HUGHES WILLIAM B,,https://lens.org/062-357-001-833-583,Granted Patent,no,8,2,1,1,0,C07C7/14875;;C07C29/88;;C07C67/60;;C07C7/14875;;C07C29/88;;C07C67/60,,,0,0,,,,EXPIRED
191,NO,D0,NO 996519 D0,078-146-685-045-326,1999-12-28,1999,NO 996519 A,1999-12-28,IB 9800937 W;;US 5149997 P,1997-07-01,Doseringsformer av sertralin med forsinket frigjoering,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/078-146-685-045-326,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,DISCONTINUED
192,AP,A,AP 1199 A,124-160-207-181-742,2003-08-28,2003,AP 9801278 A,1998-06-25,US 5149997 P,1997-07-01,Delayed-release dosage forms of sertraline.,"Delayed release dosage forms of sertraline which reduce tmax and reduce side effects. The dosage forms are, in general spatially delayed by being sensitive to their position along the gastrointenstinal tract, or temporally delayed by being delayed for a preset period, independent of their position along the gastrointenstinal tract. In vitro tests for identifying such dosage forms are presented.",PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR L,,https://lens.org/124-160-207-181-742,Granted Patent,no,2,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
193,EP,A1,EP 0809465 A1,129-003-179-355-479,1997-12-03,1997,EP 95920588 A,1995-05-24,US 9506425 W;;US 38802495 A;;US 63808896 A,1995-02-14,REPEAT FIXATION FOR FRAMELESS STEREOTACTIC PROCEDURE,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate (26) has at least three fiducial markers (38) on it. The fiducial markers (38) may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers (38), the position of features within the patient (14) (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient (14). The bite plate (26) may then re-attached one or more times to the teeth and the location of the features will be in a known position relative to the sensed markers. <IMAGE>",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,"UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPO (2003-09-01)",https://lens.org/129-003-179-355-479,Patent Application,yes,0,0,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B19/00;;A61B5/055;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,EXPIRED
194,AT,T1,AT E245415 T1,131-129-449-767-71X,2003-08-15,2003,AT 98923022 T,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,VERABREICHUNGSFORM FÜR SERTRALIN MIT VERZÖGERTER WIRKSTOFFFREIGABE,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/131-129-449-767-71X,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,DISCONTINUED
195,US,B2,US 7651506 B2,029-697-969-149-091,2010-01-26,2010,US 40001506 A,2006-04-07,US 40001506 A;;US 67741903 A,2003-10-02,Frameless stereotactic guidance of medical procedures,"Devices, methods and systems for frameless guidance of image-based medical procedures such as stereotactic radiotherapy and surgery. Devices including custom fitting subject-specific articles include contoured surfaces that provide spatial reference to the location of target regions within the subject. The devices are attached exclusive of fasteners anchored to the tissue of the subject and reside on the front of a head of the subject when attached. The devices and articles can be fabricated using computer-directed fabrication technology.",UNIV FLORIDA,BOVA FRANK JOSEPH;;FRIEDMAN WILLIAM ALLEN,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC (2006-04-25),https://lens.org/029-697-969-149-091,Granted Patent,yes,15,31,4,4,0,A61B90/10;;A61B90/10;;A61B34/20;;A61B34/20;;A61B90/11;;A61B90/11;;A61B2017/3405;;A61B2017/3405;;A61B2034/105;;A61B2034/105;;A61B2034/107;;A61B2034/107;;A61B2034/108;;A61B2034/108;;A61B2034/2051;;A61B2034/2051;;A61B2034/2055;;A61B2034/2055;;A61B2034/2072;;A61B2034/2072;;A61B2034/256;;A61B2034/256;;A61B2090/3983;;A61B2090/3983;;B33Y80/00;;B33Y80/00,A61B19/00,606/130;;606/167;;606/172;;600/407;;600/425;;600/427,2,1,019-629-442-287-917,10.1097/00007632-200102150-00012;;11224883,"Birnbaum et al. ""Computer-Assisted Orthopedic Surgery With Individual Templates and Comparison to Conventional Operation Method"" SPINE, 2001, 26(4):365-370.;;Yoo et al. ""Template Guided Intervention: Interactive Visualization and Design for Medical Fused Deposition Models"" Proceedings of the Workshop on Interactive Medical Image Visualization and Image Analysis, Oct. 2001, pp. 45-48.",EXPIRED
196,US,A,US 2724571 A,034-763-765-487-148,1955-11-22,1955,US 33425253 A,1953-01-30,US 33425253 A,1953-01-30,Adjustable article support,,NAT IDEAL COMPANY,FRIEDMAN ABRAHAM S;;COMPTON WILLIAM C,,https://lens.org/034-763-765-487-148,Granted Patent,no,7,6,1,1,0,A01K39/014;;A47B9/18;;A47B9/18;;A01K39/014,A01K39/014;;A47B9/18,,0,0,,,,EXPIRED
197,DE,A1,DE 3000744 A1,069-779-188-857-28X,1980-07-17,1980,DE 3000744 A,1980-01-10,US 252579 A,1979-01-11,WAERMESTABILISIERTE FORMMASSEN AUF DER BASIS VON PFROPFCOPOLYMERISATEN,,BORG WARNER,HORN JUN WILLIAM E;;FRIEDMAN LESTER,,https://lens.org/069-779-188-857-28X,Patent Application,no,0,0,9,9,0,C08K5/526,C08L51/00;;C08K5/52;;C08K5/526;;C08L51/04;;C08L55/00;;C08L55/02,,0,0,,,,EXPIRED
198,TN,A1,TN SN98122 A1,072-026-635-635-796,2005-03-15,2005,TN SN98122 A,1998-06-30,US 5149997 P,1997-07-01,FORMES POSOLOGIQUES DE SERTRALINE A LIBERATION RETARDEE,"L'INVENTION CONCERNE DES FORMES POSOLOGIQUES DE SERTRALINE A LIBERATION RETARDEE. CES FORMES POSOLOGIQUES PRESENTENT UN RETARD SPATIAL EN FONCTION DE LEUR POSITION LE LONG DU TRACTUS GASTRO INTESTINAL OU UN RETARD TEMPOREL, CE QUI PERMET DE REDUIRE LES EFFETS SECONDAIRES. APPLICATION : UTILISATION DANS LE TRAITEMENT DE DIVERSES MALADIES.",PFIZER PROD INC,WILLIAM JOHN CURATOLO;;HYLAR LEWIS FRIEDMAN,,https://lens.org/072-026-635-635-796,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,PENDING
199,AT,T1,AT E220615 T1,084-495-844-853-48X,2002-08-15,2002,AT 97114907 T,1997-08-28,US 80580397 A,1997-02-25,SCHLAUCH MIT NIEDRIGER PERMEABILITÄT FÜR GERUCH,"Flexible PVC hose (25) can be used with toilet systems (10, 12, etc.) in vehicles, such as boats (18), recreational vehicles, etc, or at pumpout stations. The hose includes about 40-55% by weight PVC resin, and at least 10% by weight of an EVA high molecular weight plasticizer. The hose also typically includes a low molecular weight plasticizer, stabilizer, lubricant, filler (such as 5-20% by weight dense filler like calcium carbonate), and pigment. The hose typically will not fail (that is will not transmit odor) for the life of the toilet system, or mechanical life of the hose. <IMAGE>",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;KLINE SALLY A,,https://lens.org/084-495-844-853-48X,Granted Patent,no,0,0,7,7,0,B60R15/04;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;B60R15/04,B60R15/04,,0,0,,,,DISCONTINUED
200,IS,A,IS 5267 A,102-462-960-396-183,1999-11-23,1999,IS 5267 A,1999-11-23,IB 9800937 W;;US 5149997 P,1997-07-01,Skammtaform af sertralíni sem losna seint,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/102-462-960-396-183,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/14;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,PENDING
201,US,A,US 2028772 A,119-533-350-283-002,1936-01-28,1936,US 58834432 A,1932-01-23,US 58834432 A,1932-01-23,Cryptographic system,,FRIEDMAN WILLIAM F;;GRAHAM GEORGE A,FRIEDMAN WILLIAM F;;GRAHAM GEORGE A,,https://lens.org/119-533-350-283-002,Granted Patent,no,0,5,1,1,0,G09C1/14;;G09C1/14,G09C1/14,,0,0,,,,EXPIRED
202,US,A,US 1698836 A,119-971-691-211-007,1929-01-15,1929,US 7641625 A,1925-12-19,US 7641625 A,1925-12-19,Mold,,BARTLEY WILLIAM A;;FRIEDMAN ELLIS O,BARTLEY WILLIAM A;;FRIEDMAN ELLIS O,,https://lens.org/119-971-691-211-007,Granted Patent,no,0,12,1,1,0,B22C9/065;;B22C9/065;;B22C9/06;;B22C9/06;;B22C9/08;;B22C9/08,B22C9/06;;B22C9/08,,0,0,,,,EXPIRED
203,AU,B2,AU 781746 B2,015-728-594-614-882,2005-06-09,2005,AU 2001/081509 A,2001-10-19,US 24188800 P;;US 93010401 A,2000-10-20,Method for differentiating between burdened and cracked ultrasonically tuned blades,,ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,,https://lens.org/015-728-594-614-882,Granted Patent,no,3,0,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/00;;A61B17/32;;A61B18/00;;A61F9/007;;B06B1/06,,0,0,,,,EXPIRED
204,US,A,US 5621924 A,011-120-007-287-522,1997-04-22,1997,US 48484395 A,1995-06-07,US 48484395 A,1995-06-07,Vacuum tank construction for a vacuum toilet assembly,"A particular vacuum tank construction is provided for a vacuum toilet assembly which mounts a vacuum pump, has great versatility and accessibility, and ensures optimized washing effect of water and waste into the vacuum tank. A tank inlet is located at the opposite end of the tank from a sump formed in the tank bottom, and an inlet fitting at the inlet is rotatable at least about 180.degree. about a vertical axis. Connected to a tank outlet is a dip tube assembly including a substantially rigid dip tube which has an oval shaped end termination opening which is above, but spaced from, the sump and positioned so that objects of a size that would harm the vacuum pump connected to the tank outlet cannot enter the dip tube. The tank is of plastic having a nominal wall thickness of about 5/16th inch, and no flat surface area is greater than about 80 square inches. The inlet is connected to a vacuum toilet, and the vacuum pump outlet is connected to a waste (holding) tank. The vacuum pump is mounted on a first top surface of a vacuum pump and is readily connected or disconnected to and from the dip tube by a spin nut. The tank includes a hollow vertical portion having an inner sidewall in which the tank outlet opening is formed, and to which a vacuum switch is connected.",SEALAND TTECHNOLOGY INC,FRIEDMAN WILLIAM J;;SIGLER JAMES A,DOMETIC CORPORATION (2008-12-30);;DOMETIC SANITATION CORPORATION (2005-04-07),https://lens.org/011-120-007-287-522,Granted Patent,yes,5,29,6,6,0,E03D5/00;;E03D5/00;;E03F1/006;;E03F1/006,E03D5/00;;E03F1/00,4/431;;4/433;;4/321;;4/434;;4/323,0,0,,,,EXPIRED
205,WO,A1,WO 1997/040766 A1,033-262-284-655-698,1997-11-06,1997,US 9705498 W,1997-04-14,US 63808896 A,1996-04-26,MARKER SYSTEM AND RELATED STEREOTACTIC PROCEDURE,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate has at least three fiducial markers on it. The fiducial markers may be LEDs (162), radiopaque markers for angiography, or computerized tomography (CT) imaging, or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers, the position of features within the patient (such as a brain tumor) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient. The bite plate (26) may then be reattached one or more times to the teeth. An alternate embodiment uses a head ring (18) or head holder such as a head mask system (276) with the LEDs thereon.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/033-262-284-655-698,Patent Application,yes,11,34,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B5/055;;A61B19/00;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,PENDING
206,EP,B1,EP 1588671 B1,063-838-610-408-105,2009-08-26,2009,EP 05076515 A,2001-10-19,EP 01308879 A;;US 24188800 P;;US 93010401 A,2000-10-20,Method for determining a damping level of a handpiece/blade in an ultrasonic system,,ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,,https://lens.org/063-838-610-408-105,Granted Patent,yes,2,0,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/32;;A61B17/00;;A61B18/00;;A61F9/007;;B06B1/06,,0,0,,,,EXPIRED
207,CA,C,CA 2252645 C,078-106-366-021-785,2008-02-26,2008,CA 2252645 A,1997-04-14,US 63808896 A;;US 9705498 W,1996-04-26,MARKER SYSTEM AND RELATED STEREOTACTIC PROCEDURE,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate has at least three fiducial markers on it. The fiducial markers may be LEDs (162), radiopaque markers for angiography, or computerized tomography (CT) imaging, or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers, the position of features within the patient (such as a brain tumor) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient. The bite plate (26) may then be reattached one or more times to the teeth. An alternate embodiment uses a head ring (18) or head holder such as a head mask system (276) with the LEDs thereon.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/078-106-366-021-785,Granted Patent,no,0,0,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B19/00;;A61B5/055;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,EXPIRED
208,HK,A1,HK 1027982 A1,103-023-448-234-304,2001-02-02,2001,HK 00107492 A,2000-11-23,IB 9800937 W;;US 5149997 P,1997-07-01,DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/103-023-448-234-304,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/14;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
209,EP,A1,EP 0830483 A1,108-726-652-908-217,1998-03-25,1998,EP 96921668 A,1996-06-07,US 9610505 W;;US 48484395 A,1995-06-07,VACUUM TANK CONSTRUCTION FOR A VACUUM TOILET ASSEMBLY,,SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;SIGLER JAMES A,,https://lens.org/108-726-652-908-217,Patent Application,yes,0,0,6,6,0,E03D5/00;;E03D5/00;;E03F1/006;;E03F1/006,E03D5/00;;E03F1/00,,1,0,,,See references of WO 9641059A1,EXPIRED
210,DE,D1,DE 69714005 D1,123-069-318-964-72X,2002-08-22,2002,DE 69714005 T,1997-08-28,US 80580397 A,1997-02-25,Schlauch mit niedriger Permeabilität für Geruch,"Flexible PVC hose (25) can be used with toilet systems (10, 12, etc.) in vehicles, such as boats (18), recreational vehicles, etc, or at pumpout stations. The hose includes about 40-55% by weight PVC resin, and at least 10% by weight of an EVA high molecular weight plasticizer. The hose also typically includes a low molecular weight plasticizer, stabilizer, lubricant, filler (such as 5-20% by weight dense filler like calcium carbonate), and pigment. The hose typically will not fail (that is will not transmit odor) for the life of the toilet system, or mechanical life of the hose. <IMAGE>",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;KLINE SALLY A,,https://lens.org/123-069-318-964-72X,Granted Patent,no,0,0,7,7,0,B60R15/04;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;B60R15/04,B60R15/04,,0,0,,,,EXPIRED
211,WO,A2,WO 1989/005171 A2,130-320-721-336-601,1989-06-15,1989,US 8804303 W,1988-12-02,US 12827387 A,1987-12-03,APPARATUS FOR STEREOTACTIC RADIOSURGERY,"Stereotactic radiosurgery apparatus for eliminating misalignments due to mechanical inaccuracies and sag of a linear accelerator radiation-emitting head which is swung through an arc comprises a guiding and support structure (54) with a first bearing system for accurately rotating a collimator (32) through a precise arc in a vertical plane (30) with respect to a predetermined center point (34) in the plane corresponding to a treatment location, a second gimbal bearing system (70) for coupling the collimator (32) to the head (16) so that the rotating head can drive the collimator (32) through its arc while mechanically uncoupling the head from the collimator by eliminating torques and forces on the collimator which would be exerted by mechanical inaccuracies or sag of the head, and a third bearing system (86) for rotatably supporting a stereotactic floorstand (28) for rotation about a vertical axis (30) which intersects the center point. Since the movement of the collimator (32) and the rotation of the floorstand are precisely controlled with respect to the center point, the apparatus ensures that radiation from the head will be accurately focused at the center point (34) for all rotational positions of the head and floorstand. Mechanical linking arrangements are shown for allowing the floorstand to rotate automatically upon rotation of a patient treatment table (20). Although the linking arrangements are used to drive the rotation of the floorstand, the linkage arrangements prevent the introduction of positional inaccuracies in the floorstand rotation.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/130-320-721-336-601,Patent Application,yes,0,4,9,9,0,A61B2017/00707;;A61B2017/00712;;A61N5/10;;A61N5/103;;A61N5/1031;;A61N5/1049;;A61B2090/363;;A61B2090/101;;A61N5/1049;;A61N5/1031;;A61N5/10;;A61N5/103;;A61B2017/00712;;A61B2017/00707;;A61B2090/363;;A61B2090/101,A61B17/00;;A61B19/00;;A61N5/10,,0,0,,,,PATENTED
212,US,A,US 5954647 A,179-407-644-842-067,1999-09-21,1999,US 63808896 A,1996-04-26,US 63808896 A;;US 38802495 A,1995-02-14,Marker system and related stereotactic procedure,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate. The bite plate has at least three fiducial markers on it. The fiducial markers may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers, the position of features within the patient (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient. The bite plate may then be re-attached one or more times to the teeth. An alternate embodiment uses a head ring or head holder such as a head mask system with the LEDs thereon. The head ring is useful for single fraction treatments. A comparison is made between the relative patient position and the position of a medical device and a desired relative positioning. One or more error signals are the result of the comparison and are used for display purposes such that a person may manually null or minimize the errors or as feedback control signals for automatic error correction.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC (1997-03-18);;FLORIDA UNIVRSITY OF (1996-06-14),https://lens.org/179-407-644-842-067,Granted Patent,yes,34,205,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B5/055;;A61B19/00;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,600/407;;606/130;;378/205;;433/213;;433/75,1,1,006-808-376-654-791,1633444;;10.1016/s1042-3680(18)30686-7,"Friedman et al, Linear Accelerator Radiosurgery at the University of Florida, reprinted from Neurosurgery Clinics of North America, vol. 3, No. 1, pp. 141 166 (Jan. 1992).",EXPIRED
213,US,A,US 5483932 A,196-861-369-544-140,1996-01-16,1996,US 23064294 A,1994-04-21,US 23064294 A,1994-04-21,Hollow balance shaft,"A balance shaft for an automobile engine is disclosed. The balance shaft has a hollow tubular body and a pair of end plug members permanently secured thereto, as by welding. Notches or bob weights either in line or 180.degree. out of phase are provided in the two end plug members. The balance shaft is rotated at twice the crankshaft speed in order to balance second order forces.",SIMPSON IND INC,FRIEDMAN RONALD S;;SISCO WILLIAM C,METALDYNE MACHINING AND ASSEMBLY COMPANY INC (2001-03-22);;METALDYNE LLC (2009-10-16),https://lens.org/196-861-369-544-140,Granted Patent,yes,7,16,1,1,0,F02B75/22;;F02B75/22;;F16F15/268;;F16F15/268;;Y10T74/2183;;Y10T74/2183,F02B75/22;;F16F15/26,123/192.2;;74/603,0,0,,,,EXPIRED
214,WO,A2,WO 2007/130208 A2,002-371-193-017-066,2007-11-15,2007,US 2007/0005994 W,2007-03-08,US 39667106 A,2006-04-03,ACTUATOR AND VALVE ASSEMBLY,"An actuator for selectively moving a part relative to another part includes a shape memory wire, which contracts upon heating, and a magnetic field. One end of the wire is fixed to a first body. The other end of the wire is coupled to a second body, which is movable relative to the first body. When heated, the wire contracts and moves the second body in a direction of travel from a first position relative to the first body toward a second position. A magnetic field generates a magnetic force on the second body, which acts on and moves the second body in the direction of travel to the second position after the wire initially contracts to thereby reduce the load on the wire when the second body is moved to the second position. The actuator may be used, for example, to move the valve stem in a valve.",HUMPHREY PRODUCTS;;FRIEDMAN MARK WILLIAM;;KNEPPLE ROBERT BRIAN,FRIEDMAN MARK WILLIAM;;KNEPPLE ROBERT BRIAN,,https://lens.org/002-371-193-017-066,Patent Application,yes,0,0,6,6,0,F16K11/044;;F16K11/044;;F16K31/025;;F16K31/025;;Y10T137/86879;;Y10T137/86879,F16K31/08,,0,0,,,,PENDING
215,US,A1,US 2007/0228309 A1,045-924-136-948-339,2007-10-04,2007,US 39667106 A,2006-04-03,US 39667106 A,2006-04-03,Actuator and valve assembly,"An actuator for selectively moving a part relative to another part includes a shape memory wire, which contracts upon heating, and a magnetic field. One end of the shape memory wire is fixed to a first body. The other end of the shape memory wire is coupled to a second body, which is movable relative to the first body. When heated, the shape memory wire contracts and moves the second body in a direction of travel from a first position relative to the first body toward a second position. A magnetic field generates a magnetic force on the second body, which acts on and moves the second body in the direction of travel to the second position after the shape memory wire initially contracts to thereby reduce the load on the shape memory wire when the second body is moved to the second position. The actuator may be used, for example, to move the valve stem in a valve.",FRIEDMAN MARK WILLIAM;;KNEPPLE ROBERT BRIAN,FRIEDMAN MARK WILLIAM;;KNEPPLE ROBERT BRIAN,HUMPHREY PRODUCTS COMPANY (2006-04-03),https://lens.org/045-924-136-948-339,Patent Application,yes,15,15,6,6,0,F16K11/044;;F16K11/044;;F16K31/025;;F16K31/025;;Y10T137/86879;;Y10T137/86879,F16K31/08,251/65,0,0,,,,ACTIVE
216,US,B2,US 7448411 B2,067-256-754-723-193,2008-11-11,2008,US 39667106 A,2006-04-03,US 39667106 A,2006-04-03,Actuator and valve assembly,"An actuator for selectively moving a part relative to another part includes a shape memory wire, which contracts upon heating, and a magnetic field. One end of the shape memory wire is fixed to a first body. The other end of the shape memory wire is coupled to a second body, which is movable relative to the first body. When heated, the shape memory wire contracts and moves the second body in a direction of travel from a first position relative to the first body toward a second position. A magnetic field generates a magnetic force on the second body, which acts on and moves the second body in the direction of travel to the second position after the shape memory wire initially contracts to thereby reduce the load on the shape memory wire when the second body is moved to the second position. The actuator may be used, for example, to move the valve stem in a valve.",HUMPHREY PROD CO,FRIEDMAN MARK WILLIAM;;KNEPPLE ROBERT BRIAN,HUMPHREY PRODUCTS COMPANY (2006-04-03),https://lens.org/067-256-754-723-193,Granted Patent,yes,15,21,6,6,0,F16K11/044;;F16K11/044;;F16K31/025;;F16K31/025;;Y10T137/86879;;Y10T137/86879,F16K31/08;;F16K11/07,137/625.48;;251/65;;355/1;;60/528,0,0,,,,ACTIVE
217,SI,T1,SI 1007024 T1,058-497-631-959-076,2003-12-31,2003,SI 9830494 T,1998-06-16,EP 98923022 A;;IB 9800937 W;;US 5149997 P,1997-07-01,DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/058-497-631-959-076,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/22;;A61K9/14;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
218,DZ,A1,DZ 2547 A1,067-488-123-594-578,2003-02-08,2003,DZ 980157 A,1998-06-30,US 5149997 P,1997-07-01,Formes posologiques de sertraline à libération prolongée.,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLER LEWIS,,https://lens.org/067-488-123-594-578,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/14;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
219,EP,B1,EP 0809465 B1,076-570-045-181-960,2003-04-16,2003,EP 95920588 A,1995-05-24,US 9506425 W;;US 38802495 A;;US 63808896 A,1995-02-14,REPEAT FIXATION FOR FRAMELESS STEREOTACTIC PROCEDURE,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate (26) has at least three fiducial markers (38) on it. The fiducial markers (38) may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers (38), the position of features within the patient (14) (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient (14). The bite plate (26) may then re-attached one or more times to the teeth and the location of the features will be in a known position relative to the sensed markers. <IMAGE>",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,"UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPO (2003-09-01)",https://lens.org/076-570-045-181-960,Granted Patent,yes,7,1,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B19/00;;A61B5/055;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,EXPIRED
220,EP,A1,EP 0395711 A1,097-175-778-674-852,1990-11-07,1990,EP 89900991 A,1988-12-02,US 8804303 W;;US 12827387 A,1987-12-03,APPARATUS FOR STEREOTACTIC RADIOSURGERY.,"Appareil de radiochirurgie stéréotactique permettant d'éliminer les désalignements dus à des imprécisions et à des déflexions mécaniques d'une tête d'accélérateur linéaire émettant un rayonnement que l'on fait osciller à travers un arc, comprenant une structure de guidage et de support (54) comportant un premier système de support destiné à faire tourner avec précision un collimateur (32) à travers un arc précis dans un plan vertical (30) par rapport à un point central prédéterminé (34) dans le plan correspondant à un emplacement de traitement. La structure comporte un second système de support à balancier (70) permettant d'accoupler le collimateur (32) à la tête (16) de sorte que la tête tournante peut entraîner le collimateur (32) à travers son arc tout en désaccouplant mécaniquement la tête du collimateur par élimination des couples de torsion et des forces qui s'exerceraient sur le collimateur à cause des imprécisions ou des déflexions mécaniques de la tête. La structure comporte un troisième système de support (86) permettant de supporter de manière rotative un pied stéréotactique (28) en vue d'une rotation autour d'un axe vertical (30) entrecroisant le point central. Comme le mouvement du collimateur (32) et la rotation du pied sont commandés avec précision par rapport au point central, l'appareil garantit que le rayonnement émanant de la tête est focalisé avec précision au point central (34) pour toutes les positions de rotation de la tête et du pied. Des agencements de liaisons mécaniques sont présentés, permettant au pied de tourner automatiquement lors de la rotation d'une table (20) de traitement de patient. Bien que les agencements de liaisons soient utilisés pour entraîner la rotation du pied, ils permettent d'éviter des imprécisions de position dans sa rotation.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/097-175-778-674-852,Patent Application,yes,0,0,9,9,0,A61B2017/00707;;A61B2017/00712;;A61N5/10;;A61N5/103;;A61N5/1031;;A61N5/1049;;A61B2090/363;;A61B2090/101;;A61N5/1049;;A61N5/1031;;A61N5/10;;A61N5/103;;A61B2017/00712;;A61B2017/00707;;A61B2090/363;;A61B2090/101,A61B17/00;;A61B19/00;;A61N5/10,,0,0,,,,EXPIRED
221,CN,A,CN 1261273 A,140-891-785-757-01X,2000-07-26,2000,CN 98806429 A,1998-06-16,US 5149997 P,1997-07-01,Delayed-release dosage forms of sertraline,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/140-891-785-757-01X,Patent Application,no,0,2,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
222,WO,A3,WO 1989/005171 A3,141-796-547-963-53X,1989-08-24,1989,US 8804303 W,1988-12-02,US 12827387 A,1987-12-03,APPARATUS FOR STEREOTACTIC RADIOSURGERY,,UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/141-796-547-963-53X,Search Report,no,6,0,9,9,0,A61B2017/00707;;A61B2017/00712;;A61N5/10;;A61N5/103;;A61N5/1031;;A61N5/1049;;A61B2090/363;;A61B2090/101;;A61N5/1049;;A61N5/1031;;A61N5/10;;A61N5/103;;A61B2017/00712;;A61B2017/00707;;A61B2090/363;;A61B2090/101,A61B17/00;;A61B19/00;;A61N5/10,,0,0,,,,PATENTED
223,GB,A,GB 190400791 A,150-210-696-873-365,1904-04-14,1904,GB 190400791D A,1904-01-12,GB 190400791T A,1904-01-12,Improvements in Heat Regulating Apparatus,"791. Nash, N. E., and Friedman, W. B. Jan. 12. Thermostats.-Relates to apparatus of the kind in which an expanding piece opens or closes a vent in a passage by whih compressed air is led to a motor, which actuates a valve controlling the supply of steam or hot water to radiators. The compressed-air inlet B and outlet C, in the shell A, are connected by channels a, b, to a chamber D, which is in connection with the outer air by a port L and an outlet N. The channel a leads to a channel I, provided with a regulating-valve, and passing into a Bourdon spring bent over and fastened to a piece 0, to the end of which a valve stem is adjustably fitted. This stem passes through the wall of the chamber D and carries a rubber valve which, when the spring is not distended, closes the inlet of the channel a into the chamber D. The nickel and porcelain expanding piece P, the nickel of which is cut away to expose the porcelain to the atmosphere on both sides, is screwed to the bottom of the shell, and, at the other end, is provided with a hollow regulating-screw containing apiece of raw hide or like substance which normally fills and stops a nozzle n, opening from the interior of the Bourdon spring. The apparatus is adjusted to maintain any desired temperature. When the room is below this temperature, the nozzle n is opened, the spring relaxed, and the rubber valve closes communication between the compressed-air inlet and the valve-motor outlet ; the valve thus remains open and steam or hot water passes into the radiator. When the desired temperature is reached, the piece P contracts so that the nozzle n is closed and the Bourdon spring distended, and compressed air passes to the valve motor and closes the valve.",NASH NATHAN EDWARD;;FRIEDMAN WILLIAM ELLIS,NASH NATHAN EDWARD;;FRIEDMAN WILLIAM ELLIS,,https://lens.org/150-210-696-873-365,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
224,DE,D1,DE 69710175 D1,140-559-773-810-691,2002-03-14,2002,DE 69710175 T,1997-09-22,US 80671797 A,1997-02-27,Vibrationsdämpfer für Pumpsysteme zum Entleeren von Schiffsbehältern,,SEALAND TECHNOLOGY INC,SCHEIBE MARK;;SIGLER JAMES;;FRIEDMAN WILLIAM,,https://lens.org/140-559-773-810-691,Granted Patent,no,0,0,7,7,0,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/0025;;Y10T137/3118;;Y10T137/3118;;B63B29/16;;B63B13/00;;F04B11/0025;;E03D5/00,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/00,,0,0,,,,EXPIRED
225,EP,B1,EP 0860329 B1,167-622-393-823-668,2002-07-17,2002,EP 97114907 A,1997-08-28,US 80580397 A,1997-02-25,Low odor permeable hose,"Flexible PVC hose (25) can be used with toilet systems (10, 12, etc.) in vehicles, such as boats (18), recreational vehicles, etc, or at pumpout stations. The hose includes about 40-55% by weight PVC resin, and at least 10% by weight of an EVA high molecular weight plasticizer. The hose also typically includes a low molecular weight plasticizer, stabilizer, lubricant, filler (such as 5-20% by weight dense filler like calcium carbonate), and pigment. The hose typically will not fail (that is will not transmit odor) for the life of the toilet system, or mechanical life of the hose. <IMAGE>",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;KLINE SALLY A,,https://lens.org/167-622-393-823-668,Granted Patent,yes,3,0,7,7,0,B60R15/04;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;B60R15/04,B60R15/04,,0,0,,,,EXPIRED
226,FR,A,FR 345090 A,173-700-456-858-314,1904-11-21,1904,FR 345090D A,1904-01-12,FR 345090T A,1904-01-12,Perfectionnements aux appareils régulateurs de température,,NATHAN EDWARD NASH;;WILLIAM ELLIS FRIEDMAN,NASH NATHAN EDWARD;;FRIEDMAN WILLIAM ELLIS,,https://lens.org/173-700-456-858-314,Granted Patent,no,0,0,1,1,0,G05D23/1854,G05D23/185,"XV, 3",0,0,,,,EXPIRED
227,EP,B1,EP 0830483 B1,175-158-443-672-962,2004-07-28,2004,EP 96921668 A,1996-06-07,US 9610505 W;;US 48484395 A,1995-06-07,VACUUM TANK CONSTRUCTION FOR A VACUUM TOILET ASSEMBLY,,SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;SIGLER JAMES A,,https://lens.org/175-158-443-672-962,Granted Patent,yes,1,0,6,6,0,E03D5/00;;E03D5/00;;E03F1/006;;E03F1/006,E03D5/00;;E03F1/00,,0,0,,,,EXPIRED
228,US,A,US 1516180 A,180-234-657-971-637,1924-11-18,1924,US 56586822 A,1922-06-05,US 56586822 A,1922-06-05,Secret signaling system employing apparatus for automatically enciphering and deciphering messages,,FRIEDMAN WILLIAM F;;EVANS LOUIS M,FRIEDMAN WILLIAM F;;EVANS LOUIS M,,https://lens.org/180-234-657-971-637,Granted Patent,no,0,2,1,1,0,H04L9/38;;H04L9/14;;H04L9/38;;H04L9/14,H04L9/38,,0,0,,,,EXPIRED
229,WO,A1,WO 1999/001122 A1,196-258-814-794-61X,1999-01-14,1999,IB 9800937 W,1998-06-16,US 5149997 P,1997-07-01,DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE,"Delayed-release dosage forms of sertraline which reduce Tmax and reduce side effects. The dosage forms are, in general, spatially delayed by being sensitive to their position along the gastrointestinal tract, or temporally delayed by being delayed for a preset period, independent of their position along the gastrointestinal tract. In vitro tests for identifying such dosage forms are presented.",PFIZER PROD INC;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/196-258-814-794-61X,Patent Application,yes,4,10,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/14;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,PATENTED
230,US,B2,US 8099152 B2,018-170-748-757-800,2012-01-17,2012,US 88463106 A,2006-02-17,US 88463106 A;;US 65372405 P;;US 2006/0005633 W,2005-02-17,Systems and methods for planning medical procedures and designing medical devices based on anatomical scan deformations,"A method of formulating a patient-specific plan for a diagnostic or therapeutic procedure performed upon a patient is provided. The method includes obtaining a standard plan based upon a scan of an anatomy of a standard anatomic specimen, the scan defining a standard scan. The method also includes scanning the patient to obtain a patient-specific scan of an anatomy of the patient. Additionally, the method includes morphing the standard scan to the anatomy of the patient by mapping the standard scan to the patient-specific scan. The method further includes determining the patient-specific plan by modifying the standard plan based upon the mapping.",BOVA FRANK J;;FRIEDMAN WILLIAM A;;UNIVERISTY OF FLORIDA RES FOUNDATION INC,BOVA FRANK J;;FRIEDMAN WILLIAM A,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC (2006-07-20),https://lens.org/018-170-748-757-800,Granted Patent,yes,6,2,4,4,0,G16H50/50;;G16H50/20;;G16Z99/00;;G16H50/20;;G16H50/50;;G16Z99/00,A61B5/05;;G16Z99/00,600/424;;600/407;;600/425,1,0,,,"International Search Report and Written Opinion, dated Nov. 7, 2006.",ACTIVE
231,US,A,US 5027818 A,046-468-810-952-007,1991-07-02,1991,US 35381689 A,1989-05-18,US 35381689 A;;US 12827387 A,1987-12-03,Dosimetric technique for stereotactic radiosurgery same,"Stereotactic radiosurgery is facilitated by a technique for computing the doses at various points within the patient's body. In particular, the doses are computed at a relatively high density of points within a fine dose grid and at a relatively low density of points within a coarse dose grid. In that fashion, the user can quickly obtain necessary information about the radiation dose distribution before implementation of a proposed treatment plan. An advantageous technique of locating the intersection between the radiation beam and the contour or other surface of the patient is also provided. The method is especially well suited for use with a particular structure which allows one to utilize relatively narrow beam widths as a result of great mechanical accuracy.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,FLORIDA UNIVERSITY OF (1991-02-21);;UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED A NOT FOR PROFIT CORP. OF FLORIDA (1991-06-05),https://lens.org/046-468-810-952-007,Granted Patent,yes,17,380,6,6,0,A61B2017/00707;;A61B2017/00712;;A61N5/10;;A61N5/103;;A61N5/1031;;A61N5/1048;;A61N5/1049;;A61B6/506;;A61B2090/363;;A61B2090/101;;A61N5/1049;;A61N5/1048;;A61N5/1031;;A61B2017/00712;;A61B2017/00707;;A61N5/103;;A61N5/10;;A61B6/506;;A61B2090/363;;A61B2090/101,A61B17/00;;A61B19/00;;A61N5/10,12865300 R;;364/413.14;;364/413.15;;364/413.16;;364/413.22;;378/65;;606/130,2,0,,,"The Physics of Radiology, Harold Elford Johns & John Robert Cunningham, Fourth Edition, pp. 385 388.;;The Physics of Radiation Therapy, Faiz M. Khan, Ph.D., pp. 249 254.",EXPIRED
232,HK,A1,HK 1003614 A1,051-336-771-149-575,1998-11-06,1998,HK 98102948 A,1998-04-08,US 9506425 W;;US 38802495 A;;US 63808896 A,1995-02-14,REPEAT FIXATION FOR FRAMELESS STEREOTACTIC PROCEDURE,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate (26) has at least three fiducial markers (38) on it. The fiducial markers (38) may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers (38), the position of features within the patient (14) (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient (14). The bite plate (26) may then re-attached one or more times to the teeth and the location of the features will be in a known position relative to the sensed markers. <IMAGE>",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/051-336-771-149-575,Patent Application,no,0,0,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B5/055;;A61B6/03;;A61B19/00;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,EXPIRED
233,SK,A3,SK 173299 A3,069-840-810-059-262,2000-11-07,2000,SK 173299 A,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE,,PFIZER PROD INC,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L,,https://lens.org/069-840-810-059-262,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/14;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,PENDING
234,WO,A1,WO 2007/044692 A1,063-095-733-297-578,2007-04-19,2007,US 2006/0039448 W,2006-10-10,US 72608305 P,2005-10-11,PREPLANNING OF GUIDED MEDICAL PROCEDURES,"A method of preplanning for guided medical procedures includes obtaining a first 3D diagnostic dataset for a region of interest of a subject. This first dataset can be a non- stereotactic dataset and provide sufficient contrast to identify target tissue in the region of interest. A treatment preplan is developed to treat the target tissue using the first dataset exclusive of stereotactic data. The treatment preplan includes placement locations for a plurality of initial radiation beams and their respective dose intensities. A second, stereotactic 3D dataset can be obtained for the region of interest. A registered dataset can then be created by registering the first dataset to the second dataset. The treatment preplan can be modified using data associated with the registering step to generate a stereotactic treatment plan including a plurality of radiation treatment beams with respective placement positions based on the registered dataset to treat the target tissue.",UNIV FLORIDA;;BOVA FRANK JOSEPH;;FRIEDMAN WILLIAM ALAN,BOVA FRANK JOSEPH;;FRIEDMAN WILLIAM ALAN,,https://lens.org/063-095-733-297-578,Patent Application,yes,6,0,3,3,0,A61N5/103;;A61N5/103;;A61B34/10;;A61B34/10;;A61B2090/101;;A61B2090/101;;A61B2090/364;;A61B2090/364,A61N5/10;;A61B19/00,,0,0,,,,PENDING
235,ZA,B,ZA 985710 B,110-721-876-637-427,2000-01-10,2000,ZA 985710 A,1998-06-30,US 5149997 P,1997-07-01,Delayed-release dosage forms of sertraline.,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/110-721-876-637-427,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/14;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
236,TW,B,TW 575437 B,136-969-287-593-051,2004-02-11,2004,TW 87110269 A,1998-06-25,US 5149997 P,1997-07-01,Delayed-release dosage forms of sertraline,"Delayed-release dosage forms of sertraline which reduce Tmax and reduce side effects. The dosage forms are, in general, spatially delayed by being sensitive to their position along the gastrointestinal tract, or temporally delayed by being delayed for a preset period, independent of their position along the gastrointestinal tract. In vitro tests for identifying such dosage forms are presented.",PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/136-969-287-593-051,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/14;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
237,US,B2,US 8677428 B2,185-816-303-114-39X,2014-03-18,2014,US 80675010 A,2010-08-20,US 80675010 A,2010-08-20,System and method for rule based dynamic server side streaming manifest files,"There is provided a system and method for rule-based dynamic server-side streaming manifest files. There is provided a method comprising receiving a request to provide a first video content for playback, evaluating a plurality of rules for the first video content, generating a dynamic manifest file referencing the first video content, and providing the dynamic manifest file in response to the request, thereby enabling an application to playback the first video content for output on a display by interpreting the dynamic manifest file. The rules may implement various features such as dynamic advertisement insertion, load balancing, client customization, user and device targeting, enhanced security mechanisms, global announcements, and others. As streaming protocols are widely supported by default on many client platforms, the dynamic manifest files can be utilized in a user friendly and transparent manner compared to client-side solutions requiring cumbersome client software installations.",LEWIS JASON;;WATTS WILLIAM;;FRIEDMAN PETER;;DISNEY ENTPR INC,LEWIS JASON;;WATTS WILLIAM;;FRIEDMAN PETER,DISNEY ENTERPRISES INC (2010-08-19),https://lens.org/185-816-303-114-39X,Granted Patent,yes,9,75,2,2,0,H04N21/44016;;H04N21/812;;H04N21/8456;;H04N21/8456;;H04N21/44016;;H04N21/812,H04N7/173,725/91;;725/36;;725/97,0,0,,,,ACTIVE
238,EP,A1,EP 1199045 A1,009-995-961-303-891,2002-04-24,2002,EP 01308879 A,2001-10-19,US 24188800 P;;US 93010401 A,2000-10-20,Method for differentiating between burdened and cracked ultrasonically tuned blades,"A method for differentiating between ultrasonically tuned blades which are broken or cracked, and blades which are gunked by evaluating measured impedance differences when a system is first excited with a low displacement signal and then with a high displacement signal. The method is performed irrespective of the age of the hand piece/blade, the temperature or specific type of hand piece or blade, and is not affected by self healing effects of slightly cracked blades. Moreover, the method facilitates the quantifiable determination of the amount of gunk on the blade. Absolute impedance measurements of the transducer or blade are unnecessary. Instead, only relative impedance measurements are required, which greatly simplifies the measuring criteria. This provides a way to measure the amount of gunk accumulation, and thereby a way to calculate/estimate the amount of heat generated at the sheath, as well as a way to calculate/estimate the amounts of degradation to the load curve of the ultrasonic system.",ETHICON ENDO SURGERY,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,ETHICON ENDO-SURGERY (2008-06-18),https://lens.org/009-995-961-303-891,Patent Application,yes,5,39,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/00;;A61B17/32;;A61B18/00;;A61F9/007;;B06B1/06,,0,0,,,,EXPIRED
239,PL,A1,PL 337799 A1,029-389-481-025-808,2000-09-11,2000,PL 33779998 A,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,SERTRALIN DOSAGE FORMS OF RETARDED RELEASE,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/029-389-481-025-808,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/22;;A61K9/14;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,PENDING
240,DE,D1,DE 60139721 D1,073-984-227-362-704,2009-10-08,2009,DE 60139721 T,2001-10-19,US 24188800 P;;US 93010401 A,2000-10-20,Verfahren zur Bestimmung der Dämpfung eines Handstücks in einem Ultraschallschneidegerät,,ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,,https://lens.org/073-984-227-362-704,Granted Patent,no,0,0,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/32;;A61B17/00;;A61B18/00;;A61F9/007;;B06B1/06,,0,0,,,,EXPIRED
241,CA,A1,CA 2359142 A1,122-070-128-162-381,2002-04-20,2002,CA 2359142 A,2001-10-17,US 24188800 P;;US 93010401 A,2000-10-20,METHOD FOR DIFFERENTIATING BETWEEN BURDENED AND CRACKED ULTRASONICALLY TUNED BLADES,"A method for differentiating between ultrasonically tuned blades which are broken or cracked, and blades which are gunked by evaluating measured impedance differences when a system is first excited with a low displacement signal and then with a high displacement signal. The method is performed irrespective of the age of the hand piece/blade, the temperature or specific type of hand piece or blade, and is not affected by self healing effects of slightly cracked blades. Moreover, the method facilitates the quantifiable determination of the amoun t of gunk on the blade. Absolute impedance measurements of the transducer or blade are unnecessary. Instead, only relative impedance measurements are required, which greatly simplifies the measuring criteria. This provides a way to measure the amount of gunk accumulation, and thereby a way to calculate/estimate the amount of heat generated at the sheath, as well as a way to calculate/estimate the amounts of degradation to the load curve of the ultrasonic system.",ETHICON ENDO SURGERY INC,DONOFRIO WILLIAM T;;FRIEDMAN ALLAN L,,https://lens.org/122-070-128-162-381,Patent Application,no,0,0,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/00;;A61B17/32;;A61B18/00;;A61F9/007;;B06B1/06,,0,0,,,,EXPIRED
242,US,A,US 2166137 A,141-851-626-404-401,1939-07-18,1939,US 3686835 A,1935-08-19,US 3686835 A,1935-08-19,Electrical switching mechanism,,FRIEDMAN WILLIAM F;;ROWLETT FRANK B,FRIEDMAN WILLIAM F;;ROWLETT FRANK B,,https://lens.org/141-851-626-404-401,Granted Patent,no,0,5,1,1,0,G07C15/00;;G07C15/00,G07C15/00,,0,0,,,,EXPIRED
243,BG,A,BG 103916 A,154-725-216-191-540,2000-07-31,2000,BG 10391699 A,1999-11-23,US 5149997 P,1997-07-01,SERTRALINE-CONTAINING BATCHED FORMS WITH DELAYED RELEASE,The batched forms reduce Tmax and any side effects. By them the place is determined and the time of the delayed release of the medicamentous form along the course of the gastrointestinal tract is controlled. The identification of the controlled release of the batched forms is made by in vitro testing. 53 claims,PFIZER PROD INC,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L,,https://lens.org/154-725-216-191-540,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
244,US,B1,US 6216284 B1,144-580-696-089-23X,2001-04-17,2001,US 14527998 A,1998-09-02,US 14527998 A;;US 80580397 A,1997-02-25,Low odor permeable hose,"Flexible PVC hose can be used with toilet systems in vehicles, such as boats, recreational vehicles, etc, or at pumpout stations. The hose includes about 40-55% by weight PVC resin, and at least 10% by weight of an EVA high molecular weight plasticizer. The hose also typically includes a low molecular weight plasticizer, stabilizer, lubricant, filler (such as 5-20% by weight dense filler like calcium carbonate), and pigment. The hose typically will not fail (that is will not transmit odor) for the life of the toilet system, or mechanical life of the hose.",SEALAND TECHNOLOGY INC,KLINE SALLY A;;FRIEDMAN WILLIAM J,DOMETIC CORPORATION (2008-12-30);;DOMETIC SANITATION CORPORATION (2005-04-07),https://lens.org/144-580-696-089-23X,Granted Patent,yes,16,3,7,7,0,B60R15/04;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;B60R15/04,B60R15/04,4/431;;73/40.7;;138/118;;428/36.6;;428/36.8;;428/36.9;;428/36.91;;524/567;;524/569,0,0,,,,EXPIRED
245,OA,A,OA 11247 A,173-860-064-142-440,2002-11-19,2002,OA 9900307 A,1999-12-23,US 5149997 P,1997-07-01,Delayed-release dosage forms of sertraline,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/173-860-064-142-440,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/14;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
246,CA,A,CA 586609 A,191-714-234-550-285,1959-11-10,1959,CA 586609D A,,CA 586609T A,,REMOVING CARBONYL IMPURITIES FROM ORGANIC MATERIALS,,CITIES SERVICE OIL CO,FRIEDMAN LOUIS D;;HUGHES WILLIAM B,,https://lens.org/191-714-234-550-285,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
247,NZ,A,NZ 501249 A,193-209-026-292-096,2001-06-29,2001,NZ 50124998 A,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,Delayed-release (pH or enzymatically triggered) dosage forms of sertraline,"Sertraline is a selective serotonin reuptake inhibitor (SSRI), which is useful as an antidepressant and anorectic agent, and in the treatment of obsessive-compulsive disorder, post-traumatic stress disorder, anxiety-related disorders and panic. Delayed-release dosage forms of sertraline, which reduce Tmax and side effects, are described. The dosage forms are, in general, spatially delayed by being sensitive to their position along the gastrointestinal tract, or temporally delayed by being delayed for a preset period, independent of their position along the gastrointestinal tract. In vitro tests for identifying such dosage forms are presented.",PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/193-209-026-292-096,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/14;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,PENDING
248,CA,C,CA 2220949 C,192-217-534-271-236,2002-11-12,2002,CA 2220949 A,1995-05-24,US 38802495 A;;US 9506425 W;;US 63808896 A,1995-02-14,REPEAT FIXATION FOR FRAMELESS STEREOTACTIC PROCEDURE,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate (26) has at least three fiducial markers (38) on it. The fiducial markers (38) may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging o r magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers (38), the position of features within the patien t (14) (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be remov ed after an initial imaging of the patient (14). The bite plate (26) may then b e re-attached one or more times to the teeth and the location of the features will be in a known position relative to the sensed markers.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/192-217-534-271-236,Granted Patent,no,0,0,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B19/00;;A61B5/055;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,EXPIRED
249,AT,T1,AT E237279 T1,007-857-961-173-312,2003-05-15,2003,AT 95920588 T,1995-05-24,US 38802495 A;;US 9506425 W;;US 63808896 A,1995-02-14,MEHRFACH-FIXIERUNG BEI EINEM RAHMENLOSEN STEREOTAXIEVERFAHREN,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate (26) has at least three fiducial markers (38) on it. The fiducial markers (38) may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers (38), the position of features within the patient (14) (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient (14). The bite plate (26) may then re-attached one or more times to the teeth and the location of the features will be in a known position relative to the sensed markers. <IMAGE>",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/007-857-961-173-312,Granted Patent,no,0,0,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B19/00;;A61B5/055;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,DISCONTINUED
250,CA,A,CA 1149092 A,007-621-802-317-584,1983-06-28,1983,CA 342141 A,1979-12-18,US 252579 A,1979-01-11,PHOSPHITE HEAT STABILIZED GRAFT DIENE COPOLYMERS,": Hydrolytically stable triaryl phosphites. The tris-(o-alkylphenyl)phosphites are more stable to hydrolgsis than the tris-(p-alkylphenyl)phosphites and this makes them more useful as heat-stabliizing additives in certain graft copolymer compositions, especially in ABS resin compositions. The alkyl groups are those having 3-12 carbon atoms.",BORG WARNER,HORN WILLIAM E JR;;FRIEDMAN LESTER,,https://lens.org/007-621-802-317-584,Granted Patent,no,0,0,9,9,0,C08K5/526,C08L51/00;;C08K5/52;;C08K5/526;;C08L51/04;;C08L55/00;;C08L55/02,400-53.058,0,0,,,,EXPIRED
251,EP,A4,EP 0904027 A4,053-282-735-423-970,2000-02-02,2000,EP 97917827 A,1997-04-14,US 9705498 W;;US 63808896 A,1996-04-26,MARKER SYSTEM AND RELATED STEREOTACTIC PROCEDURE,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate (26) has at least three fiducial markers (38) on it. The fiducial markers (38) may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers (38), the position of features within the patient (14) (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient (14). The bite plate (26) may then re-attached one or more times to the teeth and the location of the features will be in a known position relative to the sensed markers. <IMAGE>",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/053-282-735-423-970,Search Report,no,4,0,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B19/00;;A61B5/055;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,DISCONTINUED
252,US,A1,US 2009/0065721 A1,070-048-976-948-744,2009-03-12,2009,US 26876808 A,2008-11-11,US 26876808 A;;US 39667106 A,2006-04-03,ACTUATOR AND VALVE ASSEMBLY,"An actuator for selectively moving a part relative to another part includes a shape memory wire, which contracts when heated. One portion of the shape memory wire is fixed to a first body, and another portion of the shape memory wire is coupled to a second body, which is movable relative to the first body. When heated the shape memory wire contracts and moves the second body in a direction of travel from a first position relative to the first body toward a second position. The actuator further includes a magnetic field for generating a magnetic force on the second body. The magnetic force acts on and moves the second body in the direction of travel to the second position after the shape memory wire initially contracts, and further decouples the second body from the shape memory wire when applying the magnetic force to the second body to thereby unload the load on the shape memory wire when the second body is moved to the second position.",HUMPHREY PROD CO,FRIEDMAN MARK WILLIAM;;KNEPPLE ROBERT BRIAN,,https://lens.org/070-048-976-948-744,Patent Application,yes,16,4,6,6,0,F16K11/044;;F16K11/044;;F16K31/025;;F16K31/025;;Y10T137/86879;;Y10T137/86879,F16K31/66;;F16K31/02,251/129.06;;251/294;;251/11;;251/65,0,0,,,,ACTIVE
253,EP,A1,EP 0860329 A1,110-399-051-307-48X,1998-08-26,1998,EP 97114907 A,1997-08-28,US 80580397 A,1997-02-25,Low odor permeable hose,"Flexible PVC hose (25) can be used with toilet systems (10, 12, etc.) in vehicles, such as boats (18), recreational vehicles, etc, or at pumpout stations. The hose includes about 40-55% by weight PVC resin, and at least 10% by weight of an EVA high molecular weight plasticizer. The hose also typically includes a low molecular weight plasticizer, stabilizer, lubricant, filler (such as 5-20% by weight dense filler like calcium carbonate), and pigment. The hose typically will not fail (that is will not transmit odor) for the life of the toilet system, or mechanical life of the hose.",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;KLINE SALLY A,,https://lens.org/110-399-051-307-48X,Patent Application,yes,3,0,7,7,0,B60R15/04;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;Y10T428/1379;;Y10T428/139;;Y10T428/1393;;Y10T428/1386;;B60R15/04,B60R15/04,,0,0,,,,EXPIRED
254,US,B2,US 10854111 B2,159-670-765-361-019,2020-12-01,2020,US 201414300561 A,2014-06-10,US 201414300561 A;;US 201361834033 P,2013-06-12,Simulation system and methods for surgical training,A three-dimensional radiological image of a living being is acquired and an anatomical feature of interest therein is identified. A three-dimensional print of the feature is created; the print has haptic characteristics that are similar to those of the anatomical feature of interest. The print is incorporated into a model upon which a medical student can simulate a surgical operation. A simulator is provided; the simulator simulates the operation of a c-arm fluoroscope. This enables the medical student to simulate surgery while operating a fluoroscope.,UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM ALAN,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (2014-06-09),https://lens.org/159-670-765-361-019,Granted Patent,yes,10,2,2,2,0,G09B23/285;;G09B23/285;;G09B23/281;;G09B23/34;;G09B23/00;;G09B23/303;;G09B23/30;;G09B23/28,G09B23/00;;G09B23/28;;G09B23/30;;G09B23/34,,3,2,080-365-278-688-764;;026-883-751-897-388,10.4253/wjge.v3.i7.140;;pmc3159502;;21860683;;23117306;;10.1097/sih.0b013e3182662c69,"Boix, Jaume. Lorenzo-Zuniga, Vincente. World Journal of Gastrointestinal Endoscopy. ‘Radiation dose to patients during endoscopic retrograde cholangiopancreatography.’ Published online Jul. 16, 2011 at <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159502>. Accessed Jul. 6, 2016. pp. 1-8.;;Wu, Y. Ted. 3D Doctor. ‘From CT Image to 3D Model’. Published online Aug. 2001. Accessed Jul. 11, 2016 from <http://www.ablesw.com/3d-doctor-surgmod.html>. pp. 1-3.;;Yudkowsky, Rachel, Practice on an Augmented Reality/Haptic Simulator and Library of Virtual Brains Improves Residents' Ability to Perform a Ventriculostomy, Simulation in Healthcare: The Journal of the Society for Simulation in Healthcare, Feb. 2013—vol. 8—Issue 1—pp. 25-31.",ACTIVE
255,CA,C,CA 2359142 C,180-692-756-567-195,2010-09-28,2010,CA 2359142 A,2001-10-17,US 24188800 P;;US 93010401 A,2000-10-20,METHOD FOR DIFFERENTIATING BETWEEN BURDENED AND CRACKED ULTRASONICALLY TUNED BLADES,"A method for differentiating between ultrasonically tuned blades which are broken or cracked, and blades which are gunked by evaluating measured impedance differences when a system is first excited with a low displacement signal and then with a high displacement signal. The method is performed irrespective of the age of the hand piece/blade, the temperature or specific type of hand piece or blade, and is not affected by self healing effects of slightly cracked blades. Moreover, the method facilitates the quantifiable determination of the amount of gunk on the blade. Absolute impedance measurements of the transducer or blade are unnecessary. Instead, only relative impedance measurements are required, which greatly simplifies the measuring criteria. This provides a way to measure the amount of gunk accumulation, and thereby a way to calculate/estimate the amount of heat generated at the sheath, as well as a way to calculate/estimate the amounts of degradation to the load curve of the ultrasonic system.",ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,,https://lens.org/180-692-756-567-195,Granted Patent,no,0,0,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/32;;A61B17/00;;A61B18/00;;A61F9/007;;B06B1/06;;G01H15/00,,0,0,,,,EXPIRED
256,EP,A1,EP 1588671 A1,194-404-178-390-015,2005-10-26,2005,EP 05076515 A,2001-10-19,EP 01308879 A;;US 24188800 P;;US 93010401 A,2000-10-20,Method for determining a damping level of a handpiece/blade in an ultrasonic system,A method for determining a damping level of a handpiece/blade in an ultrasonic system is provided.,ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,,https://lens.org/194-404-178-390-015,Patent Application,yes,6,3,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/00;;A61B17/32;;A61B18/00;;A61F9/007;;B06B1/06,,0,0,,,,EXPIRED
257,EA,B1,EA 001906 B1,196-702-959-625-081,2001-10-22,2001,EA 199900965 A,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE,"1. A spatially delayed-release oral dosage form suitable for oral administration to a mammal, comprising sertraline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, which dosage form, following ingestion by said mammal, releases not more than 10% of the sertraline contained therein into said mammal's stomach, and which effects immediate release of the remaining sertraline contained therein after having passed into said mammal's small intestine. 2. A dosage form as defined in Claim 1, which is pH-triggered. 3. A dosage form as defined in Claim 2, comprising an immediate-release core coated with a material comprising a polymer that is substantially impermeable to sertraline at the pH of the stomach, but which is permeable to sertraline at the pH of the small intestine. 4. A dosage form as defined in Claim 3, wherein said polymer is selected from cellulose acetatephthalate, polyvinylacetatephthalate, hydroxypropylmethylcellulose phthalate, cellulose acetatetrimellitate, anionic acrylic copolymers of methacrylic acid and methylmethacrylate, and copolymers comprising acrylic acid and at least one acrylic acid ester. 5. A dosage form as defined in Claim 3, wherein said core is multiparticulate. 6. A dosage form as defined in Claim 3, wherein said core is a tablet. 7. A dosage form as defined in Claim 3, wherein said core is a capsule. 8. A dosage form as defined in Claim 7, in the form of a gelatin capsule coated with a polymer that is substantially impermeable to sertraline of the pH of the stomach, but that is permeable to sertraline at the pH of the small intestine. 9. A dosage form as defined in Claim 1, which is enzyme-triggered. 10. A dosage form as defined in Claim 9, comprising: an immediate-release core comprising sertraline and a pharmaceutically acceptable carrier, a membrane surrounding said core, wherein said membrane is fabricated from a microporous hydrophobic material; and a hydrophobic liquid entrained within the pores of said membrane, said hydrophobic liquid being substantially impermeable to water and sertraline, but capable of changing, through enzymatic degradation, so that said membrane becomes substantially permeable to water and sertraline when said dosage form moves into the small intestine. 11. A dosage form as defined in Claim 9, wherein said core is a tablet. 12. A dosage forth as defined in Claim 9, wherein said core is a multiparticulate. 13. A dosage form as defined in Claim 1, wherein said mammal is a human. 14. A pH-triggered delayed release dosage form suitable for oral adminstration to a mammal, comprising (1) an immediate-release core comprising sertraline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, and (2) a pH-sensitive coating surrounding said core, which dosage form, when dissolution tested in vitro, releases not more than 10% of its incorporated sertraline in 2 hours in 750 ml of 0.1 n HCl, and which, following said 2 hours, effects immediate release of its remaining sertraline in a liter of 0.05 M sodium phosphate buffer, pH 6.8, containing 1% polysorbate 80. 15. A dosage forth as defined in Claim 14, comprising an immediate-release core coated with a polymer that is substantially impermeable to sertraline in said hydrochloric acid but which is permeable to sertraline in said buffer. 16. A dosage form as defined in Claim 15, wherein said polymer is selected from cellulose acetatephthalate, polyvinylacetatephthalate, hydroxypropylmethylcellulose phthalate, cellulose acetatetrimellitate, anionic acrylic copolymers of methacrylic acid and methylmethacrylate, and copolymers comprising acrylic acid and at least one acrylic acid ester. 17. A dosage form as defined in Claim 15, wherein said core is multiparticulate. 18. A dosage form as defined in Claim 15, wherein said core is a tablet. 19. A dosage form as defined in Claim 15, wherein said core is a capsule. 20. A dosage forth as defined in Claim 19, in the form of a gelatin capsule coated with a polymer that is substantially impermeable to sertraline in said acid, but that is permeable to sertraline in said buffer. 21. An enzyme-triggered delayed release dosage form suitable for oral administration to a mammal, comprising (1) an immediate-release core comprising sertraline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, and (2) an enzymatically degradable coating surrounding said core, which dosage form, when dissolution tested in vitro, releases not more than 10% of its incorporated sertraline in 2 hours in 750 ml of 0.1 n HCl, and which, following said 2 hours, effects immediate release of its remaining sertraline in a liter of 0.05 M sodium-phosphate buffer, pH 6.8, containing 1% polysorbate 80, in the presence of an enzyme suitable for enzymatically degrading said coating. 22. A dosage form as defined in Claim 21, wherein said core is a tablet. 23. A dosage form as defined in Claim 21, wherein said core is multiparticulate. 24. A dosage form as defined in Claim 22, comprising: a core comprising sertraline and a pharmaceutically acceptable carrier, a membrane surrounding said core, wherein said membrane is fabricated from a microporous hydrophobic material; a hydrophobic liquid entrained within the pores of said membrane, said hydrophobic liquid being substantially impermeable to water and sertraline, but capable of changing, through enzymatic degradation, so that said membrane becomes permeable to water and sertraline in said buffer. 25. A dosage form as defined in Claim 24, wherein said core further comprises at least one osmagent. 26. A dosage form as defined in Claim 21, wherein said mammal is a human. 27. A temporally delayed dosage form suitable for oral adminstration to a mammal, comprising (1) an immediate release core comprising sertraline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and (2) a coating surrounding said core, which dosage form, following ingestion by said mammal, releases substantially no sertraline during a first period of about 10 minutes, releases not more than 10% of the sertraline contained therein during a second period lasting up to 2 hours following said first period, and then effects immediate release of the remaining sertraline contained therein. 28. A dosage form as defined in Claim 27, wherein said core is a tablet. 29. A dosage form as defined in Claim 27, wherein said core is multiparticulate. 30. A dosage form as defined in Claim 28, wherein said tablet is coated with a water-soluble or water-disintegrable coating. 31. A dosage form as defined in Claim 29, wherein said multiparticulate is coated with a water-soluble or water-disintegrable coating. 32. A dosage form as defined in Claim 27, in the form of a gelatin capsule coated with a water-soluble or water-disintegrable coating. 33. A dosage form as defined in Claim 27, wherein said mammal is a human. 34. A temporally delayed dosage form suitable for administration to a mammal, comprising (1) an immediate-release core comprising sertraline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and (2) a coating surrounding said core, which dosage form, when dissolution tested in vitro in a USP-2 apparatus containing 900 ml of acetic acid/acetate buffer, pH 4.0, together with NaCl which is added to said acetate buffer up to concentration of 0.075 M in NaCl, releases substantially no sertraline during a first period of about 10 minutes, releases not more than 10% of the sertraline contained therein during a second period lasting up to 2 hours following said first period, and which then effects immediate release of the remaining sertraline contained therein following said second period. 35. A dosage form as defined in Claim 34, wherein said core is a tablet. 36. A dosage form as defined in Claim 34, wherein said core is multiparticulate. 37. A dosage form as defined in Claim 35, wherein said tablet is coated with a water soluble or water-disintegrable coating. 38. A dosage form as defined in Claim 36, wherein said multiparticulate is coated with a water-soluble or water-disintegrable coating. 39. A dosage form as defined in Claim 34, in the form of a gelatin capsule coated with a water soluble or water-disintegrable coating. 40. A dosage form as defined in Claim 34, wherein said mammal is a human. 41. A delayed-release dosage form suitable for oral administration to a mammal, comprising sertraline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, said dosage form exhibiting, in vivo, a sertraline plasma Tmax which is shorter than Tmax determined after ingestion of an equal amount of sertraline in an immediate release dosage form. 42. A dosage form as defined in Claim 41, wherein Tmax determined with said delayed release dosage form is at least 0.5 hour shorter than Tmax determined with said immediate release dosage form. 43. A dosage form as defined in Claim 41, wherein Tmax determined with said delayed release dosage form is at least 1 hour shorter than Tmax determined with said immediate release dosage form. 44. A dosage form as defined in Claim 41, wherein said mammal is a human. 45. A dosage form as defined in Claim 41, which is spatially delayed. 46. A dosage form as defined in Claim 41, which is temporally delayed. 47. A dosage form as defined in Claim 41, wherein said shortened Tmax is determined as the average Tmax from dosing at least 12 normal healthy human subjects in a cross-over study in which said immediate release dosage form is an immediate release tablet. 48. A method for treating a psychiatric illness, premature ejaculation, chemical dependency, premenstrual dysphoric disorder, or obesity, comprising administering to a mammal in need of such treatment, including a human patient, a therapeutically effective amount of sertraline in a delayed-release oral dosage form as defined in Claim",PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/196-702-959-625-081,Granted Patent,no,0,1,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/14;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
258,DE,T2,DE 69710175 T2,195-177-017-872-75X,2002-09-26,2002,DE 69710175 T,1997-09-22,US 80671797 A,1997-02-27,Vibrationsdämpfer für Pumpsysteme zum Entleeren von Schiffsbehältern,,SEALAND TECHNOLOGY INC,SCHEIBE MARK;;SIGLER JAMES;;FRIEDMAN WILLIAM,,https://lens.org/195-177-017-872-75X,Granted Patent,no,0,1,7,7,0,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/0025;;Y10T137/3118;;Y10T137/3118;;B63B29/16;;B63B13/00;;F04B11/0025;;E03D5/00,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/00,,0,0,,,,EXPIRED
259,US,A,US 2465367 A,005-011-173-518-947,1949-03-29,1949,US 47886843 A,1943-03-12,US 47886843 A,1943-03-12,System for enciphering facsimiles,,FRIEDMAN WILLIAM F;;MAUBORGNE JOSEPH O,FRIEDMAN WILLIAM F;;MAUBORGNE JOSEPH O,,https://lens.org/005-011-173-518-947,Granted Patent,no,7,3,1,1,0,H04N1/448;;H04N1/448,H04N1/44,,0,0,,,,EXPIRED
260,GT,A,GT 199800091 A,016-245-962-652-883,1999-12-21,1999,GT 199800091 A,1998-06-29,US 5149997 P,1997-07-01,FORMAS DE DOSIFICACION DE SERTRALINA DE LIBERACION RETARDADA.,ESTA INVENCION SE REFIERE A UNA FORMA DE DOSIFICACION DE LIBERACION RETARDADA DE SERTRALINA QUE TIENE UN TIEMPO MAS CORTO HASTA ALCANZAR LOS NIVELES MAXIMOS EN PLASMA DESPUES DE LA DOSIFICACION ORAL. TAMBIEN SE REFIERE A FORMAS DE DOSIFICACION QUE TIENEN UN PERFIL DE EFECTOS SECUNDARIOS MEJORADO Y A UN PROCEDIMIENTO DE TRATAMIENTO DE ENFERMEDADES PSIQUIATRICAS O DE OTRO TIPO.,,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/016-245-962-652-883,Amended Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/14;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K31/428;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30;;C07C43/235;;C07D277/68,,0,0,,,,PENDING
261,WO,A1,WO 1996/025098 A1,045-782-152-071-505,1996-08-22,1996,US 9506425 W,1995-05-24,US 38802495 A;;US 63808896 A,1995-02-14,REPEAT FIXATION FOR FRAMELESS STEREOTACTIC PROCEDURE,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate (26) has at least three fiducial markers (38) on it. The fiducial markers (38) may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers (38), the position of features within the patient (14) (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient (14). The bite plate (26) may then be re-attached one or more times to the teeth and the location of the features will be in a known position relative to the sensed markers.",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/045-782-152-071-505,Patent Application,yes,7,3,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B5/055;;A61B19/00;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,PATENTED
262,CA,C,CA 2290969 C,045-976-947-985-680,2004-02-17,2004,CA 2290969 A,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE,"Delayed-release dosage forms of sertraline which reduce Tmax and reduce side effects. The dosage forms are, in general, spatially delayed by being sensitive to their position along the gastrointestinal trac t, or temporally delayed by being delayed for a preset period, independent of their position along the gastrointestinal tract. In vitro tes ts for identifying such dosage forms are presented.",PFIZER PROD INC,FRIEDMAN HYLAR LEWIS;;CURATOLO WILLIAM JOHN,,https://lens.org/045-976-947-985-680,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
263,EP,A1,EP 0904027 A1,050-146-007-482-846,1999-03-31,1999,EP 97917827 A,1997-04-14,US 9705498 W;;US 63808896 A,1996-04-26,MARKER SYSTEM AND RELATED STEREOTACTIC PROCEDURE,"Repeat fixation for medical procedures is accomplished using a non-invasive locator, specifically a bite plate (26). The bite plate (26) has at least three fiducial markers (38) on it. The fiducial markers (38) may be LEDs, radiopaque markers for angiography or computerized tomography (CT) imaging or magnetic resonance markers for magnetic resonance (MR) imaging. By detecting the position of the markers (38), the position of features within the patient (14) (such as a brain tumor or other intracranial target to which radiation is to be applied) can be determined with great precision. Since the bite plate (26) has been molded to uniquely fit to the patient's teeth, it may be removed after an initial imaging of the patient (14). The bite plate (26) may then re-attached one or more times to the teeth and the location of the features will be in a known position relative to the sensed markers. <IMAGE>",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,,https://lens.org/050-146-007-482-846,Patent Application,yes,0,0,23,23,0,A61B6/035;;A61B6/08;;A61N5/1049;;A61N5/1069;;A61N2005/1059;;A61B2090/3983;;A61B90/16;;A61B2034/2055;;A61B2034/2072;;A61B2090/363;;A61B2090/3945;;A61B34/20;;A61B2090/101;;A61B90/14;;A61B6/08;;A61B6/035;;A61N2005/1059;;A61N5/1069;;A61N5/1049;;A61B2090/363;;A61B2090/3945;;A61B2034/2055;;A61B90/16;;A61B2090/3983;;A61B34/20;;A61B2034/2072;;A61B2090/101;;A61B90/14,A61B19/00;;A61B5/055;;A61B6/03;;A61B6/04;;A61B6/08;;A61N5/10;;G01R33/28,,0,0,,,,DISCONTINUED
264,US,A1,US 2005/0075649 A1,101-422-981-569-570,2005-04-07,2005,US 67741903 A,2003-10-02,US 67741903 A,2003-10-02,Frameless stereotactic guidance of medical procedures,"Devices, methods and systems for frameless guidance of image-based medical procedures such as stereotactic radiotherapy and surgery. Devices including custom fitting subject-specific articles include contoured surfaces that provide spatial reference to the location of target regions within the subject. The devices and articles can be fabricated using computer-directed fabrication technology.",BOVA FRANK JOSEPH;;FRIEDMAN WILLIAM ALAN,BOVA FRANK JOSEPH;;FRIEDMAN WILLIAM ALAN,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC (2004-07-19);;UNIVERSITY OF FLORIDA (2003-10-01),https://lens.org/101-422-981-569-570,Patent Application,yes,4,49,3,3,0,A61B2017/3405;;A61B2090/3983;;A61B90/10;;A61B2034/2055;;A61B2034/2072;;A61B34/20;;A61B90/11;;A61B2034/107;;A61B2034/108;;A61B90/10;;A61B2017/3405;;A61B2034/2055;;A61B2090/3983;;A61B2034/108;;A61B90/11;;A61B2034/2072;;A61B34/20;;A61B2034/107,A61B19/00,60613,0,0,,,,DISCONTINUED
265,HR,B1,HR P980376 B1,088-137-867-070-686,2002-12-31,2002,HR P980376 A,1998-07-01,US 5149997 P,1997-07-01,DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/088-137-867-070-686,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/14;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
266,US,B1,US 6546279 B1,088-480-375-146-267,2003-04-08,2003,US 97520001 A,2001-10-12,US 97520001 A;;US 0132070 W,2001-10-12,Computer controlled guidance of a biopsy needle,"
    A computer controlled system for guiding the needle device, such as a biopsy needle, by reference to a single mode medical imaging system employing any one of computed tomography imaging (CTI) equipment, magnetic resonance imaging equipment (MRI), fluoroscopic imaging equipment, or 3D ultrasound system, or alternatively, by reference to a multi-modal imaging system, which includes any combination of the aforementioned systems. The 3D ultrasound system includes a combination of an ultrasound probe and both passive and active infrared tracking systems so that the combined system enables a real time image display of the entire region of interest without probe movement. 
",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A,FLORIDA UNIVERSITY OF (2001-12-19),https://lens.org/088-480-375-146-267,Granted Patent,yes,32,375,2,2,0,A61B8/4416;;A61B8/4416;;A61B8/0833;;A61B8/0833;;A61B8/0841;;A61B8/0841;;A61B8/4245;;A61B8/4245;;A61B17/3403;;A61B17/3403;;A61B34/20;;A61B34/20;;A61B90/17;;A61B90/17;;A61B90/36;;A61B90/36;;A61B2017/3413;;A61B2017/3413;;A61B2034/107;;A61B2034/107;;A61B2034/2055;;A61B2034/2055;;A61B2034/2072;;A61B2034/2072;;A61B2090/365;;A61B2090/365;;A61B2090/378;;A61B2090/378,A61B8/08;;A61B17/34;;A61B19/00,600/429;;600/410;;600/411;;600/417;;600/424;;600/428;;600/434;;600/437;;600/439;;606/130,1,1,044-791-405-485-465,2303369;;10.1016/0360-3016(90)90111-v,"Barth, Norman H. ""An Inverse Problem in Radiation Therapy."" Int. J. Radiation Oncology, Biol., Phys. V. 18, No. 2. Feb. 1990. pp. 425-431.",EXPIRED
267,EP,B1,EP 0861981 B1,117-047-733-624-242,2002-01-30,2002,EP 97116475 A,1997-09-22,US 80671797 A,1997-02-27,Pulsation damper for marine tank pumpout systems,,SEALAND TECHNOLOGY INC,SCHEIBE MARK;;SIGLER JAMES;;FRIEDMAN WILLIAM,,https://lens.org/117-047-733-624-242,Granted Patent,yes,7,0,7,7,0,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/0025;;Y10T137/3118;;Y10T137/3118;;B63B29/16;;B63B13/00;;F04B11/0025;;E03D5/00,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/00,,0,0,,,,EXPIRED
268,AU,B2,AU 727152 B2,134-264-840-092-429,2000-12-07,2000,AU 1998/075451 A,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,Delayed-release dosage forms of sertraline,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/134-264-840-092-429,Granted Patent,no,3,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K9/14;;A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
269,HU,A2,HU P0301787 A2,139-345-265-212-362,2003-11-28,2003,HU P0301787 A,1998-06-16,IB 9800937 W;;US 5149997 P,1997-07-01,DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE,"A jelen találmány olyan késleltetet kibocsátású sertralindózisformákról gondoskodik, amelyek a Tmax értéket és amellékhatásokat csökkentik. A dózisformák általában agasztrointesztinális rendszerben helyzetükre érzékeny térbelilegkésleltetett formák, vagy egy előre beállított periódus alapjánidőlegesen késleltetett formák, utóbbi esetben a gasztrointesztinálisrendszerben elfoglalt helyzetüktől függetlenek. Az ilyen dózisformákazonosítására szolgáló in vitro teszteket is bemutatják. Ó",PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/139-345-265-212-362,Patent Application,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,PENDING
270,PT,E,PT 1007024 E,166-513-830-561-469,2003-11-28,2003,PT 98923022 T,1998-06-16,US 5149997 P,1997-07-01,FORMAS DE DOSAGEM DA SERTRALINA DE LIBERTACAO RETARDADA,,PFIZER PROD INC,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS,,https://lens.org/166-513-830-561-469,Granted Patent,no,0,0,59,59,0,A61K9/2013;;A61K9/2846;;A61K9/2886;;A61K9/5026;;A61K31/135;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61K31/135,A61K/;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/14;;A61K9/32;;A61K9/50;;A61K9/52;;A61K31/135;;A61K31/136;;A61K47/32;;A61K47/38;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,EXPIRED
271,ES,T3,ES 2306692 T3,180-842-195-991-439,2008-11-16,2008,ES 01308879 T,2001-10-19,US 24188800 P;;US 93010401 A,2000-10-20,PROCEDIMIENTO PARA DIFERENCIAR ENTRE CUCHILLAS CARGADAS Y MEDALLAS SINTONIZADAS ULTRASONICAMENTE.,"Un procedimiento para distinguir entre cuchillas sintonizadas de forma ultrasónica con materiales de desecho y melladas en un sistema quirúrgico ultrasónico, que comprende las etapas de: la aplicación de una señal de accionamiento que tiene un nivel de corriente de accionamiento y un nivel de tensión de accionamiento hasta una pieza manual/cuchilla que utiliza un generador ultrasónico a través de una gama de frecuencias predeterminada, en el que dicha señal de accionamiento se aplica a un primer nivel de excitación y a un segundo nivel de excitación mayor que dicho primer nivel de excitación; la medición para cada uno de dichos niveles de excitación de a) la magnitud de impedancia mínima a través de dicha gama de frecuencias o b) la diferencia de fase máxima entre la corriente de accionamiento y la tensión de accionamiento a través de dicha gama de frecuencias; la representación de un primer mensaje en una pantalla de cristal líquido, si la magnitud de impedancia mínima a dicho primer nivel de excitación es menor que la magnitud de impedancia mínima a dicho segundo nivel de excitación, o la diferencia de fase máxima obtenida a dicho primer nivel de excitación es mayor que la diferencia de fase máxima obtenida a dicho segundo nivel de excitación; y si no, mostrar un segundo mensaje en la pantalla de cristal líquido.",ETHICON ENDO SURGERY,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,,https://lens.org/180-842-195-991-439,Granted Patent,no,0,0,16,16,0,A61B17/320068;;A61B2017/00022;;A61B2017/00026;;A61B2017/00106;;A61B2017/00725;;G01N29/09;;G01N29/4427;;G01N2291/018;;G01N2291/02881;;G01N2291/101;;G01N2291/2698;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B2017/320075;;A61B2017/320071;;A61B2017/320069;;A61B17/320068;;G01N29/4427;;A61B2017/00106;;G01N2291/101;;G01N2291/2698;;A61B2017/00022;;G01N2291/018;;G01N2291/02881;;A61B2017/00026;;G01N29/09;;A61B2017/00725,A61B17/32;;A61B17/00;;A61B18/00;;A61F9/007;;B06B1/06,,0,0,,,,EXPIRED
272,AR,A1,AR 073530 A1,046-973-084-388-620,2010-11-10,2010,AR P090103822 A,2009-10-02,US 10224208 P,2008-10-02,INHIBIDORES DE JANUS QUINASAS PARA EL TRATAMIENTO DE OJO SECO Y OTRAS ENFERMEDADES RELACIONADAS CON LOS OJOS. INSERTO OFTALMICO,"Reivindicacion 1: Un método para el tratamiento de un desorden de ojo seco en un paciente en necesidad del mismo, caracterizado porque comprende administrar a dicho paciente una cantidad terapéuticamente efectiva de un agente seleccionado entre (a) compuestos de formula (1) donde A1 y A2 se seleccionan independientemente entre C y N; T, U, y V se seleccionan independientemente entre O, S, N, CR5, y NR6; donde el anillo de 5 miembros formado por A1, A2, U, T, y V es aromático; X es N o CR4; Y es alquileno C1-8, alquenileno C2-8, alquinileno C2-8, (CR11R12)p-(cicloalquilen C3-10)-(CR11R12)q, (CR11R12)p-(arilen)-(CR11R12)q, (CR11R12)-(heterocicloalquilen C1-10)-(CR11R12)q, (CR11R12)p-(heteroarilen)-(CR11R12)q, (CR11R12)pO(CR11R12)q, (CR11R12)pS(CR11R12)q, (CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, (CR11R12)OC(O)(CR11R12)q, (CR11R12)pOC(O)NRc(CR11R12)q, (CR11R12)pNRc(CR11R12)q, (CR11R12)pNRcC(O)NRd(CR11R12)q, (CR11R12)pS(O)(CR11R12)q, (CR11R12)pS(O)NRc(CR11R12)q, (CR11R12)pS(O)2(CR11R12)q, o (CR11R12)pS(O)2NRc(CR11R12)q, donde dicho alquileno C1-8, alquenileno C2-8, alquinileno C2-8, cicloalquileno, arileno, heterocicloalquileno, o heteroarileno, se sustituye opcionalmente con 1, 2, o 3 sustituyentes seleccionados independientemente entre -D1-D2-D3-D4; Z es H, halo, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, haloalquilo C1-4, halosulfanilo, hidroxialquilo C1-4, cianoalquilo C1-4, =C-Ri, =N-Ri, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(=NRi)NRcRd, NRcC(=NRi)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=NOH)Rb, C(=NO(alquil C1-6)Rb, y S(O)2NRcRd, donde dicho alquilo C1-8, alquenilo C2-8, o alquinilo C2-8, se sustituye opcionalmente con 1, 2, 3, 4, 5, o 6 sustituyentes seleccionados independientemente entre halo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, halosulfanilo, hidroxialquilo C1-4, cianoalquilo C1-4, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(o)oRa, C(=NRi)NRcRd, NRcC(=NRi)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=NOH)Rb, C(=NO(alquil C1-6))Rb, y S(O)2NRcRd; donde cuando Z es H, n es 1; o la porcion -(Y)n-Z se toma junto con i) A2 al cual la porcion se encuentra unido, ii) R5 o R6 de tanto T como V, y iii) el átomo de C o N al cual el R5 o R6 de tanto T como V se encuentra unido para formar un anillo arilo, cicloalquilo, heteroarilo, o heterocicloalquilo de 4 a 20 miembros fusionado al anillo de 5 miembros formado por A1, A2, U, T, y V, donde dicho anillo arilo, cicloalquilo, heteroarilo, o heterocicloalquilo de 4 a 20 miembros se sustituye opcionalmente con 1, 2, 3, 4, o 5 sustituyentes seleccionados independientemente entre -(W)m-Q; W es alquilenilo C1-8, alquenilenilo C2-8, alquinilenilo C2-8, O, S, C(O), C(O)NRc', C(O)O, OC(O), OC(O)NRc', NRc', NRc'C(O)NRd', S(O), S(O)NRc', S(O)2, o S(O)2NRc'; Q es H, halo, CN, NO2, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, haloalquilo C1-8, halosulfanilo, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo, donde dicho alquilo C1-8, alquenilo C2-8, alquinilo C2-8, haloalquilo C1-8, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo se sustituyen opcionalmente con 1, 2, 3 o 4 sustituyentes seleccionados independientemente entre halo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, halosulfanilo, hidroxialquilo C1-4, cianoalquilo C1-4, Cy2, CN, NO2, ORa', SRa', C(O)Rb', C(O)NRc'Rd', c(o)oRa', OC(O)Rb', OC(O)NRc'Rd', NRc'Rd', NRc'C(O)Rb', NRc'C(O)NRc'Rd', NRc'C(O)ORa', S(O)Rb', S(O)NRc'Rd', S(O)2Rb', NRc'S(O)2Rb', y S(O)2NRc'Rd'; Cy1 y Cy2 se seleccionan independientemente entre arilo, heteroarilo, cicloalquilo, y heterocicloalquilo, cada uno opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados independientemente entre halo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, halosulfanilo, hidroxialquilo C1-4, cianoalquilo C1-4, CN, NO2, ORa'', SRa'', C(O)Rb'', C(O)NRc''Rd'', c(o)oRa'', OC(O)Rb'', OC(O)NRc''Rd'', NRc''Rd'', NRc''C(O)Rb'', NRc''C(O)NRc''Rd'', NRc''C(O)ORa'', S(O)Rb'', S(O)NRc''Rd'', S(O)2Rb'', NRc''S(O)2Rb, y S(O)2NRc''Rd''; R1, R2, R3, y R4 se seleccionan independientemente entre H, halo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, halosulfanilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7, OC(O)R8, OC(O)NR9R10, NR9R10,NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, y S(O)2NR9R10; R5 es H, halo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, halosulfanilo, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7, OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, o S(O)2NR9R10; R6 es H, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, OR7, C(O)R8, C(O)NR9R10, C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, o S(O)2NR9R10; R7 es H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo; R8 es H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo; R9 y R10 se seleccionan independientemente entre H, alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilcarbonilo C1-6, arilcarbonilo, alquilsulfonilo C1-6, arilsulfonilo, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo; o R9 y R10 junto con el átomo de N al cual se encuentran unidos forman un grupo heterocicloalquilo de 4, 5, 6 o 7 miembros; R11 y R12 se seleccionan independientemente entre H y -E1-E2-E3-E4; D1 y E1 se encuentran independientemente ausentes o se seleccionan independientemente entre alquileno C1-6, alquenileno C2-6, alquinileno C2-6, arileno, cicloalquileno, heteroarileno, y heterocicloalquileno, donde cada uno de alquileno C1-6, alquenileno C2-6, alquinileno C2-6, arileno, cicloalquileno, heteroarileno, y heterocicloalquileno se sustituye opcionalmente con 1, 2 o 3 sustituyentes seleccionados independientemente entre halo, CN, NO2, N3, SCN, OH, alquilo C1-6, haloalquilo C1-6, alcoxialquilo C2-8, alcoxi C1-6, haloalcoxi C1-6, amino, alquilamino C1-6, y dialquilamino C2-8; D2 y E2 se encuentran independientemente ausentes o se seleccionan independientemente entre alquileno C1-6, alquenileno C2-6, alquinileno C2-6, (alquilen C1-6)r-O-(alquilen C1-6)s, (alquilen C1-6)r-S-(alquilen C1-6)s, (alquilen C1-6)r-NRe-(alquilen C1-6)s, (alquilen C1-6)r-CO-(alquilen C1-6)s, (alquilen C1-6)r-C(O)O-(alquilen C1-6)s, (alquilen C1-6)r-CONRe-(alquilen C1-6)s, (alquilen C1-6)r-SO-(alquilen C1-6)s, (alquilen)r-SO2-(alquilen C1-6)s, (alquilen C1-6)r-SONRe-(alquilen C1-6)s, y (alquilen)r-NReCONRf-(alquilen C1-6)s, donde cada uno de alquileno C1-6, alquenileno C2-6, y alquinileno C2-6 se sustituyen opcionalmente con 1, 2 o 3 sustituyentes seleccionados independientemente entre halo, CN, NO2, N3, SCN, OH, alquilo C1-6, haloalquilo C1-6, alcoxialquilo C2-8, alcoxi C1-6, haloalcoxi C1-6, amino, alquilamino C1-6, y dialquilamino C2-8; D3 y E3 se encuentran independientemente ausentes o se seleccionan independientemente entre alquileno C1-6, alquenileno C2-6, alquinileno C2-6, arileno, cicloalquileno, heteroarileno, y heterocicloalquileno, donde cada uno de alquileno C1-6, alquenileno C2-6, alquinileno C2-6, arileno, cicloalquileno, heteroarileno, y heterocicloalquileno se sustituye opcionalmente con 1, 2 o 3 sus sustituyentes seleccionados independientemente entre halo, CN, NO2, N3, SCN, OH, alquilo C1-6, haloalquilo C1-6, alcoxialquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, amino, alquilamino C1-6, y dialquilamino C2-8; D4 y E4 se seleccionan independientemente entre H, halo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, halosulfanilo, hidroxialquilo C1-4, cianoalquilo C1-4, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(o)oRa, C(=NRi)NRcRd, NRcC(=NRi)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=NOH)Rb, C(=NO(alquil C1-6))Rb, y S(O)2NRcRd; donde dicho alquilo C1-8, alquenilo C1-8, o alquinilo C1-6, se sustituye opcionalmente con 1, 2, 3, 4, 5,o 6 sustituyentes seleccionados independientemente entre halo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, halosulfanilo, hidroxialquilo C1-4, cianoalquilo C1-4, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(o)oRa, C(=NRi)NRcRd, NRcC(=NRi)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(=NOH)Rb, C(=NO(alquil C1-6))Rb, y S(O)2NRcRd; Ra es H, Cy1, -(alquil C1-6)-Cy1, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, donde dicho alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, o alquinilo C2-6 se sustituye opcionalmente con 1, 2, o 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, alquilo C1-6, haloalquilo C1-6, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Rb es H, Cy1, -(alquil C1-6)-Cy1, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, donde dicho alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, o alquinilo C2-6 se sustituye opcionalmente con 1, 2, o 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, alquilo, halo, alquilo C1-6, haloalquilo C1-6, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Ra' y Ra'' se seleccionan independientemente entre H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo",INCYTE CORP,FRIEDMAN JORDAN S;;FRIEDMAN PAUL A;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/046-973-084-388-620,Patent Application,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,,,0,0,,,,DISCONTINUED
273,AR,A2,AR 112822 A2,105-423-996-255-275,2019-12-18,2019,AR P180102672 A,2018-09-19,US 10224208 P,2008-10-02,MÉTODO CON INHIBIDORES DE JANUS QUINASAS PARA EL TRATAMIENTO DE OJO SECO Y OTRAS ENFERMEDADES RELACIONADAS CON LOS OJOS,"Reivindicación 1: Un método para el tratamiento de un desorden de ojo seco en un paciente en necesidad del mismo, caracterizado porque comprende administrar a dicho paciente una cantidad terapéuticamente efectiva de un agente seleccionado entre: (a) compuestos de fórmula (1), donde: A¹ y A² se seleccionan independientemente entre C y N; T, U, y V se seleccionan independientemente entre O, S, N, CR⁵, y NR⁶; donde el anillo de 5 miembros formado por A¹, A², U, T, y V es aromático; X es N o CR⁴; Y es C₁₋₈ alquileno, C₂₋₈ alquenileno, C₂₋₈ alquinileno, (CR¹¹R¹²)ₚ-(C₃₋₁₀ cicloalquilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚ-(arilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚ-(C₁₋₁₀ heterocicloalquilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚ-(heteroarilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚO(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(CR¹¹R¹²)q, (CR¹¹R¹²)ₚC(O)(CR¹¹R¹²)q, (CR¹¹R¹²)ₚC(O)NRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚC(O)O(CR¹¹R¹²)q, (CR¹¹R¹²)ₚOC(O)(CR¹¹R¹²)q, (CR¹¹R¹²)ₚOC(O)NRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚNRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚNRᶜC(O)NRᵈ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(O)(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(O)NRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(O)₂(CR¹¹R¹²)q, o (CR¹¹R¹²)ₚS(O)₂NRᶜ(CR¹¹R¹²)q, donde dicho C₁₋₈ alquileno, C₂₋₈ alquenileno, C₂₋₈ alquinileno, cicloalquileno, arileno, heterocicloalquileno, o heteroarileno, se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre -D¹-D²-D³-D⁴; Z es H, halo, C₁₋₈ alquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, =C-Rⁱ, =N-Rⁱ, Cy¹, CN, NO₂, ORᵃ, SRᵃ, C(O)Rᵇ, C(O)NRᶜRᵈ, C(O)ORᵃ, OC(O)Rᵇ, OC(O)NRᶜRᵈ, NRᶜRᵈ, NRᶜC(O)Rᵇ, NRᶜC(O)NRᶜRᵈ, NRᶜC(O)ORᵃ, C(=NRⁱ)NRᶜRᵈ, NRᶜC(=NRⁱ)NRᶜRᵈ, S(O)Rᵇ, S(O)NRᶜRᵈ, S(O)₂Rᵇ, NRᶜS(O)₂Rᵇ, C(=NOH)Rᵇ, C(=NO(C₁₋₆ alquil))Rᵇ, y S(O)₂NRᶜRᵈ, donde dicho C₁₋₈ alquilo, C₂₋₈ alquenilo, o C₂₋₈ alquinilo, se sustituye opcionalmente con 1, 2, 3, 4, 5, ó 6 sustituyentes seleccionados independientemente entre halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, Cy¹, CN, NO₂, ORᵃ, SRᵃ, C(O)Rᵇ, C(O)NRᶜRᵈ, C(O)ORᵃ, OC(O)Rᵇ, OC(O)NRᶜRᵈ, NRᶜRᵈ, NRᶜC(O)Rᵇ, NRᶜC(O)NRᶜRᵈ, NRᶜC(O)ORᵃ, C(=NRⁱ)NRᶜRᵈ, NRᶜC(=NRⁱ)NRᶜRᵈ, S(O)Rᵇ, S(O)NRᶜRᵈ, S(O)₂Rᵇ, NRᶜS(O)₂Rᵇ, C(=NOH)Rᵇ, C(=NO(C₁₋₆ alquil))Rᵇ, y S(O)₂NRᶜRᵈ; donde cuando Z es H, n es 1; o la porción -(Y)ₙ-Z se toma junto con i) A² al cual la porción se encuentra unido, ii) R⁵ o R⁶ de tanto T como V, y iii) el átomo de C o N al cual el R⁵ o R⁶ de tanto T como V se encuentra unido para formar un anillo arilo, cicloalquilo, heteroarilo, o heterocicloalquilo de 4 a 20 miembros fusionado al anillo de 5 miembros formado por A¹, A², U, T, y V, donde dicho anillo arilo, cicloalquilo, heteroarilo, o heterocicloalquilo de 4 a 20 miembros se sustituye opcionalmente con 1, 2, 3, 4, ó 5 sustituyentes seleccionados independientemente entre -(W)ₘ-Q; W es C₁₋₈ alquilenilo, C₂₋₈ alquenilenilo, C₂₋₈ alquinilenilo, O, S, C(O), C(O)NRᶜ’, C(O)O, OC(O), OC(O)NRᶜ’, NRᶜ’, NRᶜ’C(O)NRᵈ’, S(O), S(O)NRᶜ’, S(O)₂, o S(O)₂NRᶜ’; Q es H, halo, CN, NO₂, C₁₋₈ alquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo, C₁₋₈ haloalquilo, halosulfanilo, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo, donde dicho C₁₋₈ alquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo, C₁₋₈ haloalquilo, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo se sustituye opcionalmente con 1, 2, 3 ó 4 sustituyentes seleccionados independientemente entre halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, Cy², CN, NO₂, ORᵃ’, SRᵃ’, C(O)Rᵇ’, C(O)NRᶜ’Rᵈ’, C(O)ORᵃ’, OC(O)Rᵇ’, OC(O)NRᶜ’Rᵈ’, NRᶜ’Rᵈ’, NRᶜ’C(O)Rᵇ’, NRᶜ’C(O)NRᶜ’Rᵈ’, NRᶜ’C(O)ORᵃ’, S(O)Rᵇ’, S(O)NRᶜ’Rᵈ’, S(O)₂Rᵇ’, NRᶜ’S(O)₂Rᵇ’, y S(O)₂NRᶜ’Rᵈ’; Cy¹ y Cy² se seleccionan independientemente entre arilo, heteroarilo, cicloalquilo, y heterocicloalquilo, cada uno opcionalmente sustituido con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente entre halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, CN, NO₂, ORᵃ’’, SRᵃ’’, C(O)Rᵇ’’, C(O)NRᶜ’’Rᵈ’’, C(O)ORᵃ’’, OC(O)Rᵇ’’, OC(O)NRᶜ’’Rᵈ’’, NRᶜ’’Rᵈ’’, NRᶜ’’C(O)Rᵇ’’, NRᶜ’’C(O)ORᵃ’’, NRᶜ’’S(O)Rᵇ’’, NRᶜ’’S(O)₂Rᵇ’’, S(O)Rᵇ’’, S(O)NRᶜ’’Rᵈ’’, S(O)₂Rᵇ’’, y S(O)₂NRᶜ’’Rᵈ’’; R¹, R², R³, y R⁴ se seleccionan independientemente entre H, halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO₂, OR⁷, SR⁷, C(O)R⁸, C(O)NR⁹R¹⁰, C(O)OR⁷, OC(O)R⁸, OC(O)NR⁹R¹⁰, NR⁹R¹⁰, NR⁹C(O)R⁸, NRᶜC(O)OR⁷, S(O)R⁸, S(O)NR⁹R¹⁰, S(O)₂R⁸, NR⁹S(O)₂R⁸, y S(O)₂NR⁹R¹⁰; R⁵ es H, halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, CN, NO₂, OR⁷, SR⁷, C(O)R⁸, C(O)NR⁹R¹⁰, C(O)OR⁷, OC(O)R⁸, OC(O)NR⁹R¹⁰, NR⁹R¹⁰, NR⁹C(O)R⁸, NR⁹C(O)OR⁷, S(O)R⁸, S(O)NR⁹R¹⁰, S(O)₂R⁸, NR⁹S(O)₂R⁸, o S(O)₂NR⁹R¹⁰; R⁶ es H, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, OR⁷, C(O)R⁸, C(O)NR⁹R¹⁰, C(O)OR⁷, S(O)R⁸, S(O)NR⁹R¹⁰, S(O)₂R⁸, o S(O)₂NR⁹R¹⁰; R⁷ es H, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo; R⁸ es H, C₁₋₆, alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo; R⁹ y R¹⁰ se seleccionan independientemente entre H, C₁₋₁₀ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆, alquilcarbonilo, arilcarbonilo, C₁₋₆ alquilsulfonilo, arilsulfonilo, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo; o R⁹ y R¹⁰ junto con el átomo de N al cual se encuentran unidos forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros; R¹¹ y R¹² se seleccionan independientemente entre H y -E¹-E²-E³-E⁴; D¹ y E¹ se encuentran independientemente ausentes o se seleccionan independientemente entre C₁₋₆ alquileno, C₂₋₆ alquenileno, C₂₋₈ alquinileno, arileno, cicloalquileno, heteroarileno, y heterocicloalquileno, donde cada uno de C₁₋₆ alquileno, C₂₋₆, alquenileno, C₂₋₆ alquinileno, arileno, cicloalquileno, heteroarileno, y heterocicloalquileno se sustituye opcionalmente con 1, 2 ó 3 sustituyentes seleccionados independientemente entre halo, CN, NO₂, N₃, SCN, OH, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₈ alcoxialquilo, C₁₋₆ alcoxi, C₁₋₆ haloalcoxi, amino, C₁₋₆ alquilamino, y C₂₋₈ dialquilamino; D² y E² se encuentran independientemente ausentes o se seleccionan independientemente entre C₁₋₆ alquileno, C₂₋₆ alquenileno, C₂₋₆ alquinileno, (C₁₋₆ alquilen)ʳ-O-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-S-(C₁₋₆ alquilen)ₛ, (C₁₋₈ alquilen)ʳ-NRᵉ-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-CO-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-COO-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-CONRᵉ-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-SO-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-SO₂-(C₁₋₆ alquilen)ₛ, (C₁₋₆ alquilen)ʳ-SONRᵉ-(C₁₋₆ alquilen)ₛ, y (C₁₋₆ alquilen)ʳ-NRᵉCONRᶠ-(C₁₋₆ alquilen)ₛ, donde cada uno de C₁₋₆ alquileno, C₂₋₆ alquenileno, y C₂₋₆ alquinileno se sustituye opcionalmente con 1, 2 ó 3 sustituyentes seleccionados independientemente entre halo, CN, NO₂, N₃, SCN, OH, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₈ alcoxialquilo, C₁₋₆ alcoxi, C₁₋₆ haloalcoxi, amino, C₁₋₆ alquilamino, y C₂₋₈ dialquilamino; D³ y E³ se encuentran independientemente ausentes o se seleccionan independientemente entre C₁₋₆ alquileno, C₂₋₆ alquenileno, C₂₋₆ alquinileno, arileno, cicloalquileno, heteroarileno, y heterocicloalquileno, donde cada uno de C₁₋₆ alquileno, C₂₋₆ alquenileno, C₂₋₆ alquinileno, arileno, cicloalquileno, heteroarileno, y heterocicloalquileno se sustituye opcionalmente con 1, 2 ó 3 sustituyentes seleccionados independientemente entre halo, CN, NO₂, N₃, SCN, OH, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₈ alcoxialquilo, C₁₋₈ alcoxi, C₁₋₆ haloalcoxi, amino, C₁₋₆ alquilamino, y C₂₋₈ dialquilamino; D⁴ y E⁴ se seleccionan independientemente entre H, halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, Cy¹, CN, NO₂, ORᵃ, SRᵃ, C(O)Rᵇ, C(O)NRᶜRᵈ, C(O)ORᵃ, OC(O)Rᵇ, OC(O)NRᶜRᵈ, NRᶜRᵈ, NRᶜC(O)Rᵇ, NRᶜC(O)NRᶜRᵈ, NRᶜC(O)ORᵃ, C(=NRⁱ)NRᶜRᵈ, NRᶜC(=NRⁱ)NRᶜRᵈ, S(O)Rᵇ, S(O)NRᶜRᵈ, S(O)₂Rᵇ, NRᶜS(O)₂Rᵇ, C(=NOH)Rᵇ, C(=NO(C₁₋₆ alquil))Rᵇ, y S(O)₂NRᶜRᵈ, donde dicho C₁₋₈ alquilo, C₂₋₆ alquenilo, o C₂₋₈ alquinilo, se sustituye opcionalmente con 1, 2, 3, 4, 5 ó 6 sustituyentes seleccionados independientemente entre halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, Cy¹, CN, NO₂, ORᵃ, SRᵃ, C(O)Rᵇ, C(O)NRᶜRᵈ, C(O)ORᵃ, OC(O)Rᵇ, OC(O)NRᶜRᵈ, NRᶜRᵈ, NRᶜC(O)Rᵇ, NRᶜC(O)NRᶜRᵈ, NRᶜC(O)ORᵃ, C(=NRⁱ)NRᶜRᵈ, NRᶜC(=NRⁱ)NRᶜRᵈ, S(O)Rᵇ, S(O)NRᶜRᵈ, S(O)₂Rᵇ, NRᶜS(O)₂Rᵇ, C(=NOH)Rᵇ, C(=NO(C₁₋₆ alquil))Rᵇ, y S(O)₂NRᶜRᵈ; Rᵃ es H, Cy¹, -(C₁₋₆ alquil)-Cy¹, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, donde dicho C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, o C₂₋₆ alquinilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Rᵇ es H, Cy¹, -(C₁₋₆ alquil)-Cy¹, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, donde dicho C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, o C₂₋₆ alquinilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Rᵃ’ y Rᵃ’’ se seleccionan independientemente entre H, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Rᵇ’ y Rᵇ’’ se seleccionan independientemente entre H, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Rᶜ y Rᵈ se seleccionan independientemente entre H, Cy¹, -(C₁₋₆ alquil)-Cy¹, C₁₋₁₀ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, donde dicho C₁₋₁₀ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, o C₂₋₆ alquinilo, se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre Cy¹, -(C₁₋₆ alquil)-Cy¹, OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, y halosulfanilo; o Rᶜ y Rᵈ junto con el átomo de N al cual se encuentran unidos forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros opcionalmente sustituido con 1, 2, ó 3 sustituyentes seleccionados independientemente entre Cy¹, -(C₁₋₆ alquil)-Cy¹, OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, y halosulfanilo; Rᶜ’ y Rᵈ’ se seleccionan independientemente entre H, C₁₋₁₀ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho C₁₋₁₀ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; o Rᶜ’ y Rᵈ’ junto con el átomo de N al cual se encuentran unidos forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros opcionalmente sustituido con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Rᶜ’’ y Rᵈ’’ se seleccionan independientemente entre H, C₁₋₁₀ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho C₁₋₁₀ alquilo, C₁₋₈ haloalquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, halosulfanilo, C₁₋₆ haloalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; o Rᶜ’’ y Rᵈ’’ junto con el átomo de N al cual se encuentran unidos forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros opcionalmente sustituido con 1, 2, ó 3 sustituyentes seleccionados independientemente entre OH, CN, amino, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalquilo, halosulfanilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo y heterocicloalquilo; Rⁱ es H, CN, NO₂, o C₁₋₆ alquilo; Rᵉ y Rᶠ se seleccionan independientemente entre H y C₁₋₆ alquilo; Rⁱ es H, CN, o NO₂; m es 0 ó 1; n es 0 ó 1; p es 0, 1, 2, 3, 4, 5 ó 6; q es 0, 1, 2, 3, 4, 5 ó 6; r es 0 ó 1; y s es 0 ó 1; donde cuando X es N, n es 1, y la porción formada por A¹, A², U, T, V, y -(Y)ₙ-Z tiene la fórmula (4); luego Y es diferente de (CR¹¹R¹²)ₚC(O)NRᶜ(CR¹¹R¹²)q; (b) compuestos de fórmula (2), donde: Lᵃ es SO₂ o CO; R¹ᵃ es C₁₋₆ alquilo, C₃₋₇ cicloalquilo, fenilo, heteroarilo de 5 ó 6 miembros, indolilo, NR²ᵃR³ᵃ, o OR⁴ᵃ, donde dicho alquilo, cicloalquilo, fenilo, o heteroarilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre F, CN, y C₁₋₄ alquilo; R²ᵃ y R³ᵃ se seleccionan independientemente entre H, C₁₋₄ alquilo, y fenilo; y R⁴ᵃ es C₁₋₆ alquilo, fenilo, o bencilo; (c) compuestos de fórmula (3), donde: R⁵ᵃ y R⁶ᵃ se seleccionan independientemente entre H, F, CN, OH, C₁₋₄ alquilo, benciloxi, C₂₋₆ dialquilaminosulfonilo, y heteroarilo de 5 miembros, donde dicho alquilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados entre F, OH, CN, y C₁₋₄ alcoxi, y donde dicho heteroarilo de 5 miembros se sustituye opcionalmente con C₁₋₄ alquilo; y sales aceptables farmacéuticamente del mismo; siempre que el compuesto de fórmula (1) no se seleccione entre 4-[5-(2-isopropil-5-metilciclohexiloximetil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(4-tert-butilfenoximetil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-ciclopentiletil-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(2,6-difluorofenil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(1-tert-butil-3-metil-1H-pirazol-5-il)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(benciloximetil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(3-fluorofenil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(fenoximetil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(4-metoxibencil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(feniltiometil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(3-metilbutil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-bencil-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(2,2-dimetilpropil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-metil-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(formil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(furan-2-il)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(1-metil-1H-pirrol-2-il)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-(sec-butil)-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; 4-[5-ciclopropil-1,2-4-oxadiazol-3-il]-1H-pirrolo[2,3-b]piridina; y sales aceptables farmacéuticamente de cualquiera de los precedentes. Reivindicación 18: Un método de acuerdo con la reivindicación 17, caracterizado porque dicho agente terapéutico adicional es acetónido de fluocinolona, rimexolona, ciclosporina, riaminolona, dexametasona, fluocinolona, cortisona, prednisolona, flumetolona, civamida, testosterona, ecabet de sodio, ácido 15-(s)-hidroxieicosatetraenoico, (2S,3S,4R,5R)-3,4-dihidroxi-5-[6-[(3-iodofenil)metilamino]purin-9-il]-N-metil-oxolan-2-carboxamida, gefarnato, cevilemina, doxiclina, minociclina, oxitetraciclina, voclosporina, rivoglitazona, lacritin rebamipida, pilocarpina, tacrolimus, pimecrolimus, loteprednol etabonato, rituximab, diquafosol tetrasódico, dehidroepiandrosterona, anakinra, efalizumab, micofenolato de sodio, etanercept, hidroxicloroquina o talidomida. Reivindicación 51: Un equipo para el tratamiento de desórdenes de ojo seco, que comprende una composición oftálmica o farmacéutica e instrucciones; caracterizado porque dicha composición comprende una cantidad terapéuticamente efectiva de un agente seleccionado entre: (a) compuestos de fórmula (1), donde: A¹ y A² se seleccionan independientemente entre C y N; T, U, y V se seleccionan independientemente entre O, S, N, CR⁵, y NR⁶; donde el anillo de 5 miembros formado por A¹, A², U, T, y V es aromático; X es N o CR⁴; Y es C₁₋₈ alquileno, C₂₋₈ alquenileno, C₂₋₈ alquinileno, (CR¹¹R¹²)ₚ-(C₃₋₁₀ cicloalquilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚ-(arilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚ-(C₁₋₁₀ heterocicloalquilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚ-(heteroarilen)-(CR¹¹R¹²)q, (CR¹¹R¹²)ₚO(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(CR¹¹R¹²)q, (CR¹¹R¹²)ₚC(O)(CR¹¹R¹²)q, (CR¹¹R¹²)ₚC(O)NRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚC(O)O(CR¹¹R¹²)q, (CR¹¹R¹²)ₚOC(O)(CR¹¹R¹²)q, (CR¹¹R¹²)ₚOC(O)NRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚNRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚNRᶜC(O)NRᵈ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(O)(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(O)NRᶜ(CR¹¹R¹²)q, (CR¹¹R¹²)ₚS(O)₂(CR¹¹R¹²)q, o (CR¹¹R¹²)ₚS(O)₂NRᶜ(CR¹¹R¹²)q, donde dicho C₁₋₈ alquileno, C₂₋₈ alquenileno, C₂₋₈ alquinileno, cicloalquileno, arileno, heterocicloalquileno, o heteroarileno, se sustituye opcionalmente con 1, 2, ó 3 sustituyentes seleccionados independientemente entre -D¹-D²-D³-D⁴; Z es H, halo, C₁₋₈ alquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, =C-Rⁱ, =N-Rⁱ, Cy¹, CN, NO₂, ORᵃ, SRᵃ, C(O)Rᵇ, C(O)NRᶜRᵈ, C(O)ORᵃ, OC(O)Rᵇ, OC(O)NRᶜRᵈ, NRᶜRᵈ, NRᶜC(O)Rᵇ, NRᶜC(O)NRᶜRᵈ, NRᶜC(O)ORᵃ, C(=NRⁱ)NRᶜRᵈ, NRᶜC(=NRⁱ)NRᶜRᵈ, S(O)Rᵇ, S(O)NRᶜRᵈ, S(O)₂Rᵇ, NRᶜS(O)₂Rᵇ, C(=NOH)Rᵇ, C(=NO(C₁₋₆ alquil))Rᵇ, y S(O)₂NRᶜRᵈ, donde dicho C₁₋₈ alquilo, C₂₋₈ alquenilo, o C₂₋₈ alquinilo, se sustituye opcionalmente con 1, 2, 3, 4, 5, ó 6 sustituyentes seleccionados independientemente entre halo, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, halosulfanilo, C₁₋₄ hidroxialquilo, C₁₋₄ cianoalquilo, Cy¹, CN, NO₂, ORᵃ,",INCYTE HOLDINGS CORP,WILLIAMS WILLIAM V;;LUCHI MONICA E;;FRIEDMAN JORDAN S;;FRIEDMAN PAUL A,,https://lens.org/105-423-996-255-275,Amended Application,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/519;;A61P27/02,,0,0,,,,PENDING
274,ZA,B,ZA 882658 B,077-779-630-363-419,1989-03-29,1989,ZA 882658 A,1988-04-15,US 4001387 A,1987-04-17,METHOD FOR DETECTING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS,,UNIV NEW YORK,CAO YUNZHEN;;YUNZHEN CAO;;BORKOWSKY WILLIAM;;WILLIAM BORKOWSKY;;FRIEDMAN-KIEN ALVIN E;;ALVIN E FRIEDMAN-KIEN,,https://lens.org/077-779-630-363-419,Granted Patent,no,0,0,15,22,0,G01N33/56988;;Y10S435/81;;Y10S435/974;;Y10S436/811;;Y10S436/808;;C12Q1/70;;G01N33/56988;;Y10S436/808;;Y10S436/811;;Y10S435/81;;Y10S435/974,G01N33/569,,0,0,,,,EXPIRED
275,US,B2,US 7810147 B2,087-891-247-407-354,2010-10-05,2010,US 60783606 A,2006-12-01,US 60783606 A;;US 74113605 P,2005-12-01,Detecting and preventing replay in authentication systems,"A system for detecting and preventing replay attacks includes a plurality of interconnected authentication servers, and one or more tokens for generating a one-time passcode and providing the one-time passcode to one of the authentication servers for authentication. The system includes an adjudicator function associated with each authentication server. The adjudicator evaluates a high water mark value associated with a token seeking authentication, allows authentication to proceed for the token if the high water mark evaluation indicates that the one-time passcode was not used in a previous authentication, and prevents authentication if the high water mark evaluation indicates that the one-time passcode was used in a previous authentication. The token is associated with a home authentication server that maintains a current high water mark of the token. The home authentication server validates the current high water mark on behalf of the adjudicator function evaluating the token for authentication.",EMC CORP,DUANE WILLIAM;;FRIEDMAN LAWRENCE N;;VOLANIS ALEXANDER,RSA SECURITY HOLDING INC (2009-12-22);;RSA SECURITY INC (2007-06-25);;RSA SECURITY LLC (2020-09-01);;EMC CORPORATION (2009-12-31);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/087-891-247-407-354,Granted Patent,yes,27,11,2,2,0,H04L63/0838;;H04L63/0838;;H04L63/1441;;H04L63/1441,G06F7/04;;G06F15/16,726/9;;726/5;;726/6;;726/29;;713/169;;713/182;;709/225,0,0,,,,ACTIVE
276,CA,C,CA 2359152 C,086-217-875-190-44X,2009-09-29,2009,CA 2359152 A,2001-10-17,US 24189500 P;;US 86694801 A,2000-10-20,METHOD FOR DRIVING AN ULTRASONIC SYSTEM TO IMPROVE ACQUISITION OF BLADE RESONANCE FREQUENCY AT STARTUP,"The ability of an ultrasonic system to sweep and lock onto a resonance frequency of a blade subjected to a heavy load at startup is improved by applying a high drive voltage or a high drive current while systematically increasing the level of the applied signa l. Increasing the drive signal to the hand piece results in an improved and more pronounced ""impedan ce spectrum."" That is, under load, the increased drive signal causes the maximum phase margin t o become higher and the minimum/maximum impedance magnitude to become more pronounced. Increasin g the excitation drive signal to the hand piece/blade at startup significantly alleviates the limiting factors associated with ultrasonic generators, which results in an increase of the maximum load capability at startup.",ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN;;WIENER EITAN;;DONOFRIO WILLIAM T,,https://lens.org/086-217-875-190-44X,Granted Patent,no,0,0,12,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/00725;;A61B2017/00725;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/32;;A61B17/00,,0,0,,,,EXPIRED
277,EP,A1,EP 2513394 A1,149-626-617-908-675,2012-10-24,2012,EP 10838255 A,2010-12-16,US 64095909 A;;US 2010/0060806 W,2009-12-17,COLLAPSIBLE SHADE DEVICE,,SWIMWAYS CORP,FRIEDMAN ROBERT;;RANDALL WADE;;MORALES WILLIAM MICHAEL,"AMERICAN QUALITY HOUSING LLC (2016-01-20);;FRIEDMAN, STEVE (2017-08-30)",https://lens.org/149-626-617-908-675,Patent Application,yes,0,0,8,8,0,E04H15/06;;E04H15/06;;E04H15/003;;E04H15/003;;E04H15/38;;E04H15/38,E04H15/38;;E04H15/00;;E04H15/06,,0,0,,,,DISCONTINUED
278,US,A1,US 2011/0146737 A1,113-340-011-244-114,2011-06-23,2011,US 64095909 A,2009-12-17,US 64095909 A,2009-12-17,Collapsible Shade Device,"A shade device for protecting a user from harmful sunrays is provided. The shade device may be held in the erected position with nubs such that to erect the shade device, frame support members are pushed to the erected position. To collapse the shade device, the frame support members are pushed past nubs. Accordingly, the shade device incorporates a simple push release mechanism to erect and collapse the shade device such that no assembly or disassembly of the shade device is required for tear down or set up.",FRIEDMAN ROBERT;;RANDALL WADE;;MORALES WILLIAM MICHAEL,FRIEDMAN ROBERT;;RANDALL WADE;;MORALES WILLIAM MICHAEL,AMERICAN QUALITY HOUSING (2015-11-02);;SWIMWAYS CORPORATION (2011-05-06);;FRIEDMAN STEVE (2017-05-30);;ISLAND SHADE SHACKS INC (2009-12-17),https://lens.org/113-340-011-244-114,Patent Application,yes,27,13,8,8,0,E04H15/06;;E04H15/06;;E04H15/003;;E04H15/003;;E04H15/38;;E04H15/38,E04H15/48;;E04H15/06,135/88.13;;135/153,0,0,,,,DISCONTINUED
279,US,A,US 5122446 A,051-718-254-713-477,1992-06-16,1992,US 20487188 A,1988-06-10,US 20487188 A;;US 4001387 A,1987-04-17,Method for detecting antibodies to human immunodeficiency virus,Disclosed herein is a method of screening mammals for antibodies to viral agents by collecting a urine sample from a mammal to be tested and assaying the sample for antibodies directed against the specific viral agent.,UNIV NEW YORK,FRIEDMAN-KIEN ALVIN;;YUNZHEN CAO;;BORKOWSKY WILLIAM,NEW YORK UNIVERSITY (1988-08-02),https://lens.org/051-718-254-713-477,Granted Patent,yes,6,14,1,22,0,G01N33/56988;;Y10S435/974;;Y10S435/975;;Y10S436/811;;Y10S436/808;;G01N33/56988;;Y10S436/808;;Y10S435/974;;Y10S435/975;;Y10S436/811,G01N33/569,435/5;;435/7.92;;435/7.93;;435/7.94;;435/7.95;;435/974;;435/975;;436/501;;436/513;;436/808;;436/811,10,8,006-503-978-452-444;;038-136-789-266-123;;083-398-664-576-170;;040-933-581-544-853;;089-481-404-757-00X;;041-548-844-808-490;;067-695-380-079-624;;045-423-362-199-692,10.1172/jci104538;;14464245;;pmc290983;;10.1182/blood.v67.3.831.831;;3484980;;6723069;;10.1016/0009-8981(84)90199-2;;10.1016/s0140-6736(88)91696-0;;10.1089/aid.1989.5.311;;2543432;;10.1016/0042-6822(61)90327-0;;13761075;;6363697;;4475786,"Journal of Clinical Investigation, vol. 41, No. 4, 1962, pp. 805 815, M. Lerner et al., Neutralizing Antibody to Polioviruses in Normal Human Urine .;;Chemical Abstracts, vol. 77, Sep. 22, 1977, Abstract No. 86578.;;Blood, vol. 67, No. 3, 1986, pp. 831 834, New York, D. W. Archibald et al., Antibodies to Human T Lymphotropic Virus Type III (HTLV III) in Saliva of Acquired Immunodeficiency Syndrome (AIDS) Patients and in Persons at Risk for AIDS .;;Clinica Chimica Acta, vol. 139, 1984, pp. 113 117, T. R. Trinick et al., Measurement of Urinary Immunoglobulins G, A and M by an Enzyme Linked Immunosorbent Assay (ELISA) .;;Lancet, Apr. 9, 1988, pp. 831, 832, Cao et al., IGG Antibodies to HIV 1 in Urine of HIV 1 Seropositive Individuals .;;AIDS Research and Human Retroviruses, vol. 5, No. 3, 1989, pp. 311 320, New York, Y. Cao et al., Antibodies to Human Immunodeficiency Virus Type 1 in the Urine Specimens of HIV 1 Seropositive Individuals .;;Lerner et al., Neutralizing Antibody to Poliovirus in Normal Human Urine , Virology, (1961), 14:383 5.;;Meryhew, N. L. et al., J. Rheumat., 10:913 919, 1983.;;Takayanagi et al., Clinicopathological Significance of the Analysis of Urinary Antibody Activatives, Rinsho Byroi, The Japanese Journal of Clinical Pathology, vol. 22 (Suppl.), Oct., 1974, p. 184, (English Translation).;;Bulletino Dell Istituto Sieriterapico Milanese, vol. 51, No. 1, 1972, pp. 90 102, D. DeDonate et al., Sugli Anticorpi Antivirali Delle Urine , ( Chemical Abstracts , vol. 77, Sep. 22, 1977, Abstract No. 86578).",EXPIRED
280,CA,A1,CA 2359152 A1,008-908-892-145-273,2002-04-20,2002,CA 2359152 A,2001-10-17,US 24189500 P;;US 86694801 A,2000-10-20,METHOD FOR DRIVING AN ULTRASONIC SYSTEM TO IMPROVE ACQUISITION OF BLADE RESONANCE FREQUENCY AT STARTUP,"The ability of an ultrasonic system to sweep and lock onto a resonance frequency of a blade subjected to a heavy load at startup is improved by applying a high drive voltage or a high drive current while systematically increasing the level of the applied signa l. Increasing the drive signal to the hand piece results in an improved and more pronounced ""impedan ce spectrum."" That is, under load, the increased drive signal causes the maximum phase margin t o become higher and the minimum/maximum impedance magnitude to become more pronounced. Increasin g the excitation drive signal to the hand piece/blade at startup significantly alleviates the limiting factors associated with ultrasonic generators, which results in an increase of the maximum load capability at startup.",ETHICON ENDO SURGERY INC,DONOFRIO WILLIAM T;;WIENER EITAN;;FRIEDMAN ALLAN,,https://lens.org/008-908-892-145-273,Patent Application,no,0,0,12,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/00725;;A61B2017/00725;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,,0,0,,,,EXPIRED
281,AU,B2,AU 2010/330912 B2,153-314-821-153-777,2016-12-08,2016,AU 2010/330912 A,2010-12-16,US 64095909 A;;US 2010/0060806 W,2009-12-17,Collapsible shade device,"A shade device for protecting a user from harmful sunrays is provided. The shade device may be held in the erected position with nubs such that to erect the shade device, frame support members are pushed to the erected position. To collapse the shade device, the frame support members are pushed past nubs. Accordingly, the shade device incorporates a simple push release mechanism to erect and collapse the shade device such that no assembly or disassembly of the shade device is required for tear down or set up.",FRIEDMAN STEVE,FRIEDMAN ROBERT;;RANDALL WADE;;MORALES WILLIAM MICHAEL,"AMERICAN QUALITY HOUSING LLC (2016-03-24);;FRIEDMAN, STEVE (2017-07-13)",https://lens.org/153-314-821-153-777,Granted Patent,no,4,0,8,8,0,E04H15/003;;E04H15/06;;E04H15/38;;E04H15/06;;E04H15/003;;E04H15/38,E04H15/38,,0,0,,,,ACTIVE
282,EP,A4,EP 2513394 A4,098-101-345-510-793,2016-09-07,2016,EP 10838255 A,2010-12-16,US 64095909 A;;US 2010/0060806 W,2009-12-17,COLLAPSIBLE SHADE DEVICE,,AMERICAN QUALITY HOUSING LLC,FRIEDMAN ROBERT;;RANDALL WADE;;MORALES WILLIAM MICHAEL,"AMERICAN QUALITY HOUSING LLC (2016-01-20);;FRIEDMAN, STEVE (2017-08-30)",https://lens.org/098-101-345-510-793,Search Report,no,3,0,8,8,0,E04H15/003;;E04H15/06;;E04H15/38;;E04H15/06;;E04H15/003;;E04H15/38,E04H15/38;;E04H15/00;;E04H15/06,,1,0,,,See also references of WO 2011075583A1,DISCONTINUED
283,WO,A1,WO 2011/075583 A1,061-657-003-911-790,2011-06-23,2011,US 2010/0060806 W,2010-12-16,US 64095909 A,2009-12-17,COLLAPSIBLE SHADE DEVICE,"A shade device for protecting a user from harmful sunrays is provided. The shade device may be held in the erected position with nubs such that to erect the shade device, frame support members are pushed to the erected position. To collapse the shade device, the frame support members are pushed past nubs. Accordingly, the shade device incorporates a simple push release mechanism to erect and collapse the shade device such that no assembly or disassembly of the shade device is required for tear down or set up.",SWIMWAYS CORP;;FRIEDMAN ROBERT;;RANDALL WADE;;MORALES WILLIAM MICHAEL,FRIEDMAN ROBERT;;RANDALL WADE;;MORALES WILLIAM MICHAEL,,https://lens.org/061-657-003-911-790,Patent Application,yes,7,0,8,8,0,E04H15/06;;E04H15/06;;E04H15/003;;E04H15/003;;E04H15/38;;E04H15/38,E04H15/38,,1,0,,,See also references of EP 2513394A4,PENDING
284,US,A1,US 2005/0022703 A1,067-746-958-852-431,2005-02-03,2005,US 62709503 A,2003-07-24,US 62709503 A;;US 39853402 P;;US 39853502 P,2002-07-24,Support for modular containers with outwardly-extending access panels,"A module support for forming a unitary display preferably from containers having outwardly extending access panels. The invention provides, in particular, a common module support for creating an array from two or more container modules. The invention may be advantageously utilized as a stand alone display for floor, shelf, and/or counter placement. The module support may also be hung on a wall or column using hanging means, e.g., double-sided adhesives, hook and loop fastening means, and hook and/or aperture means.",WINTERMUTE WILLIAM R.;;FRIEDMAN ROBERT;;BUCALO CARMINE,WINTERMUTE WILLIAM R;;FRIEDMAN ROBERT;;BUCALO CARMINE,MARS INCORPORATED (2004-09-08),https://lens.org/067-746-958-852-431,Patent Application,yes,27,7,2,9,0,A47F5/116;;A47F5/116;;A47B43/02;;A47B43/02;;A47F3/063;;A47F3/063,A47B43/02;;A47F3/06;;A47F5/11,108/165,0,0,,,,EXPIRED
285,AU,A1,AU 2010/330912 A1,169-435-159-480-678,2012-07-05,2012,AU 2010/330912 A,2010-12-16,US 64095909 A;;US 2010/0060806 W,2009-12-17,Collapsible shade device,"A shade device for protecting a user from harmful sunrays is provided. The shade device may be held in the erected position with nubs such that to erect the shade device, frame support members are pushed to the erected position. To collapse the shade device, the frame support members are pushed past nubs. Accordingly, the shade device incorporates a simple push release mechanism to erect and collapse the shade device such that no assembly or disassembly of the shade device is required for tear down or set up.",SWIMWAYS CORP,FRIEDMAN ROBERT;;RANDALL WADE;;MORALES WILLIAM MICHAEL,"AMERICAN QUALITY HOUSING LLC (2016-03-24);;FRIEDMAN, STEVE (2017-07-13)",https://lens.org/169-435-159-480-678,Patent Application,no,0,0,8,8,0,E04H15/06;;E04H15/06;;E04H15/003;;E04H15/003;;E04H15/38;;E04H15/38,E04H15/38,,0,0,,,,ACTIVE
286,US,A1,US 2007/0256123 A1,160-566-401-858-652,2007-11-01,2007,US 60783606 A,2006-12-01,US 60783606 A;;US 74113605 P,2005-12-01,Detecting and preventing replay in authentication systems,"A system for detecting and preventing replay attacks includes a plurality of interconnected authentication servers, and one or more tokens for generating a one-time passcode and providing the one-time passcode to one of the authentication servers for authentication. The system includes an adjudicator function associated with each authentication server. The adjudicator evaluates a high water mark value associated with a token seeking authentication, allows authentication to proceed for the token if the high water mark evaluation indicates that the one-time passcode was not used in a previous authentication, and prevents authentication if the high water mark evaluation indicates that the one-time passcode was used in a previous authentication. The token is associated with a home authentication server that maintains a current high water mark of the token. The home authentication server validates the current high water mark on behalf of the adjudicator function evaluating the token for authentication.",RSA SECURITY INC,DUANE WILLIAM;;FRIEDMAN LAWRENCE N;;VOLANIS ALEXANDER,RSA SECURITY HOLDING INC (2009-12-22);;RSA SECURITY INC (2007-06-25);;RSA SECURITY LLC (2020-09-01);;EMC CORPORATION (2009-12-31);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/160-566-401-858-652,Patent Application,yes,26,88,2,2,0,H04L63/0838;;H04L63/0838;;H04L63/1441;;H04L63/1441,H04L9/32,726/6,0,0,,,,ACTIVE
287,US,B1,US 6234197 B1,002-450-071-447-258,2001-05-22,2001,US 71790496 A,1996-09-23,US 71790496 A,1996-09-23,Holding tank vacuum relief,"A plastic sewage holding tank in a boat, associated with a toilet, includes a vent check valve for providing vacuum relief. By mounting the vent check valve in the top of the tank, when the tank is being emptied by rapid pumpout implosion or other damage to the tank is prevented. The vent check valve may include a valve body with an interior surface mounting a quad sealing ring, with a valve element guided for reciprocal movement between a sealing position where an axially elongated substantially cylindrical peripheral surface of the valve element engages the quad ring, to an open position where the valve element is moved against spring bias away from the valve body. A spider, with a collar for guiding a shaft portion of the valve element, may mount a coil spring to provide a biasing action.",SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;SIGLER JAMES A;;FRIEDMAN WILLIAM J,SEALAND AND TECHNOLOGY INC (1996-09-17);;KEE ACTION SPORTS LLC (2010-02-05);;DOMETIC CORPORATION (2008-12-30);;DOMETIC SANITATION CORPORATION (2005-04-07),https://lens.org/002-450-071-447-258,Granted Patent,yes,15,18,7,7,0,B63B29/14;;E03D5/00;;E03F1/006;;Y10T137/7897;;Y10T137/7897;;B63B29/14;;E03D5/00;;E03F1/006,B63B29/14;;E03D5/00;;E03F1/00,137/526;;4/321;;4/323,0,0,,,,EXPIRED
288,DE,D1,DE 69721722 D1,020-303-915-176-543,2003-06-12,2003,DE 69721722 T,1997-02-26,EP 97103102 A,1997-02-26,Kombinierter Vakuum- und Lagerbehälter,"A vacuum sewage handling assembly particularly for boats and recreational vehicles or caravans has a minimum of components because the conventional vacuum and holding tanks have been combined into a single substantially unreinforced, non-cylindrical, all plastic tank (25). The tank (25) has a contoured, convoluted, discontinuous surface (e. g. formed by grooves, channels, and other discontinuities 37, 44, 137, 87) so that it has no continuous flat surface area of more than about 200 square centimeters The combined vacuum and holding tank may mount a vacuum pump (53, 153), and optionally mounts a sewage discharge pump (59). The tank preferably has a generally parallelepiped configuration, and an interior volume of between about 45-65 liters, has a maximum vacuum level of about 26 cm of mercury, and is connected to other conventional portions (10, 11) of a vehicle toilet system, including outlets (19, 22) penetrating the exterior (18) of the vehicle. <IMAGE>",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;SIGLER JAMES A;;MCKIERNAN EDWARD,,https://lens.org/020-303-915-176-543,Granted Patent,no,0,0,5,5,0,E03D5/00;;E03F1/006,E03D5/00;;E03F1/00,,0,0,,,,EXPIRED
289,EP,A2,EP 0831182 A2,049-330-603-580-623,1998-03-25,1998,EP 97112116 A,1997-07-16,US 71790496 A,1996-09-23,Holding tank vacuum relief,"A plastic sewage holding tank (117) in a boat, associated with a toilet, includes a vent check valve (140) for providing vacuum relief. By mounting the vent check valve in the top (118) of the tank, when the tank is being emptied by rapid pumpout implosion or other damage to the tank is prevented. The vent check valve may include a valve body (141) with an interior surface (143) mounting a quad sealing ring (75), with a valve element (153) guided for reciprocal movement between a sealing position where an axially elongated substantially cylindrical peripheral surface (146) of the valve element engages the quad ring (75), to an open position where the valve element is moved against spring bias away from the valve body. A spider (80), with a collar (81) for guiding a shaft portion (149) of the valve element (153), may mount a coil spring (159) to provide a biasing action.",SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;SIGLER JAMES A;;FRIEDMAN WILLIAM J,,https://lens.org/049-330-603-580-623,Patent Application,yes,0,2,7,7,0,B63B29/14;;E03D5/00;;E03F1/006;;Y10T137/7897;;Y10T137/7897;;B63B29/14;;E03D5/00;;E03F1/006,B63B29/14;;E03D5/00;;E03F1/00,,0,0,,,,EXPIRED
290,JP,A,JP 2002282270 A,003-228-394-160-189,2002-10-02,2002,JP 2001323806 A,2001-10-22,US 24189500 P,2000-10-20,METHOD FOR DRIVING ULTRASONIC SYSTEM TO IMPROVE RETENTION OF BLADE RESONANCE FREQUENCY IN STARTING,"PROBLEM TO BE SOLVED: To provide a method for driving an ultrasonic system to improve retention of resonance of a hand-piece/blade in starting. SOLUTION: The resonance frequency of the blade to which heavy load is applied in starting is swept, and the capability of the ultrasonic wave system for locking to sweeping is improved by feeding high driving voltage or high driving current while the level of a feed signal is systematically heightened. The driving signal to the hand-piece is increased to obtain improved and clarified impedance spectrum. That is, in loading, the increased driving signal is further heightened in the maximum phase margin to further clarify the magnitude of the minimum/maximum impedance. In starting, an excitation driving signal to the hand-piece/blade is increased to thereby remarkably relax a limit factor of an ultrasonic generator, so that the maximum load in starting can be increased.",ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T;;WIENER EITAN,,https://lens.org/003-228-394-160-189,Patent Application,no,0,1,2,15,0,,A61B17/3211;;A61B17/32;;A61B18/00;;B06B1/06,,0,0,,,,EXPIRED
291,US,A,US 6065493 A,119-973-049-887-738,2000-05-23,2000,US 8328098 A,1998-05-22,US 8328098 A,1998-05-22,Vacuum relief valve for sewage holding tank,"A plastic sewage holding tank in a boat, associated with a toilet, includes a vent check valve assembly for providing vacuum relief. By mounting the vent check valve in the top of the tank, when the tank is being emptied by rapid pumpout implosion or other damage to the tank is prevented. The vent check valve assembly may include a valve body surface operatively connected to the tank and having a plurality of openings formed in it, and a flexible material diaphragm covering the openings adjacent the inside of the tank, and uncovering openings to allow air flow through the openings substantially only when a vacuum condition exists inside the tank. A plastic disk biases the diaphragm into its opening-covering position, but a partial vacuum of at least about 2-5 inches of water allows air to flow through the openings past the diaphragm.",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;MCKIERNAN EDWARD;;SIGLER JAMES A,DOMETIC CORPORATION (2008-12-30);;DOMETIC SANITATION CORPORATION (2005-04-07),https://lens.org/119-973-049-887-738,Granted Patent,yes,6,10,6,6,0,B63B29/16;;F16K24/06;;Y10T137/789;;Y10T137/7897;;Y10T137/784;;Y10T137/7504;;Y10T137/7897;;Y10T137/7504;;F16K24/06;;B63B29/16;;F16K15/148;;F16K15/1402,B63B29/16;;F16K24/06,137/512.15;;137/454.2;;137/526;;137/854;;4/321;;4/323,0,0,,,,EXPIRED
292,EP,A3,EP 1199048 A3,165-273-814-210-267,2002-08-21,2002,EP 01308910 A,2001-10-19,US 24189500 P;;US 86694801 A,2000-10-20,Method for driving an ultrasonic system to improve acquisition of blade resonance frequency at startup,"The ability of an ultrasonic system to sweep and lock onto a resonance frequency of a blade subjected to a heavy load at startup is improved by applying a high drive voltage or a high drive current while systematically increasing the level of the applied signal. Increasing the drive signal to the hand piece results in an improved and more pronounced ""impedance spectrum."" That is, under load, the increased drive signal causes the maximum phase margin to become higher and the minimum/maximum impedance magnitude to become more pronounced. Increasing the excitation drive signal to the hand piece/blade at startup significantly alleviates the limiting factors associated with ultrasonic generators, which results in an increase of the maximum load capability at startup.",ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T;;WIENER EITAN,,https://lens.org/165-273-814-210-267,Search Report,yes,2,0,12,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/00725;;A61B2017/00725;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,,0,0,,,,EXPIRED
293,EP,B1,EP 1199048 B1,103-182-417-633-503,2009-02-04,2009,EP 01308910 A,2001-10-19,US 24189500 P;;US 86694801 A,2000-10-20,Method for driving an ultrasonic system to improve acquisition of blade resonance frequency at startup,,ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T;;WIENER EITAN,,https://lens.org/103-182-417-633-503,Granted Patent,yes,2,1,12,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/00725;;A61B2017/00725;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/32;;A61B17/00,,0,0,,,,EXPIRED
294,DE,D1,DE 69724720 D1,151-163-161-850-13X,2003-10-16,2003,DE 69724720 T,1997-07-16,US 71790496 A,1996-09-23,Behälter mit Vakuumentlastung,"A plastic sewage holding tank (117) in a boat, associated with a toilet, includes a vent check valve (140) for providing vacuum relief. By mounting the vent check valve in the top (118) of the tank, when the tank is being emptied by rapid pumpout implosion or other damage to the tank is prevented. The vent check valve may include a valve body (141) with an interior surface (143) mounting a quad sealing ring (75), with a valve element (153) guided for reciprocal movement between a sealing position where an axially elongated substantially cylindrical peripheral surface (146) of the valve element engages the quad ring (75), to an open position where the valve element is moved against spring bias away from the valve body. A spider (80), with a collar (81) for guiding a shaft portion (149) of the valve element (153), may mount a coil spring (159) to provide a biasing action. <IMAGE>",SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;SIGLER JAMES A;;FRIEDMAN WILLIAM J,,https://lens.org/151-163-161-850-13X,Granted Patent,no,0,0,7,7,0,B63B29/14;;E03D5/00;;E03F1/006;;Y10T137/7897;;Y10T137/7897;;B63B29/14;;E03D5/00;;E03F1/006,B63B29/14;;E03D5/00;;E03F1/00,,0,0,,,,EXPIRED
295,US,B2,US 7089872 B2,163-761-929-905-747,2006-08-15,2006,US 62709503 A,2003-07-24,US 62709503 A;;US 39853402 P;;US 39853502 P,2002-07-24,Support for modular containers with outwardly-extending access panels,"A module support for forming a unitary display preferably from containers having outwardly extending access panels. In particular, a common module support for creating an array from two or more container modules is provided. The module support may be advantageously utilized as a stand alone display for floor, shelf, and/or counter placement. The module support may also be hung on a wall or column using hanging elements, e.g., double-sided adhesives, hook and loop fastening elements, and hook and/or aperture elements.",MARS INC,WINTERMUTE II WILLIAM R;;FRIEDMAN ROBERT;;BUCALO CARMINE,MARS INCORPORATED (2004-09-08),https://lens.org/163-761-929-905-747,Granted Patent,yes,31,17,2,9,0,A47F5/116;;A47F5/116;;A47B43/02;;A47B43/02;;A47F3/063;;A47F3/063,A47B43/02;;A47F3/06;;A47F5/11,108/165;;211/135;;312/259,0,0,,,,ACTIVE
296,OA,A,OA 09026 A,048-951-382-369-722,1991-03-31,1991,OA 59493 A,1988-12-16,US 4001387 A,1987-04-17,Method for detecting antibodies to human immunodeficiency virus.,,UNIV NEW YORK,FRIEDMAN-KIEN ALVIN E;;YUNZHEN CAO;;WILLIAM BORKOWSKY,,https://lens.org/048-951-382-369-722,Granted Patent,no,0,0,15,22,0,G01N33/56988;;Y10S435/81;;Y10S435/974;;Y10S436/811;;Y10S436/808;;C12Q1/70;;G01N33/56988;;Y10S436/808;;Y10S436/811;;Y10S435/81;;Y10S435/974,G01N33/569,,0,0,,,,EXPIRED
297,CA,A1,CA 2198178 A1,148-672-009-096-483,1998-08-21,1998,CA 2198178 A,1997-02-21,CA 2198178 A,1997-02-21,PLASTIC COMBINED VACUUM AND HOLDING TANK,"A vacuum sewage handling assembly particularly for boats and recreational vehicles or caravans has a minimum of components because the conventional vacuum and holding tanks have been combined into a single substantially unreinforced, non-cylindrical, all plastic tank. The tank has a contoured, convoluted, discontinuous surface (e.g. formed by grooves, channels, and other discontinuities) so that it has no continuous flat surface area of more than about 200 square centimeters The combined vacuum and holding tank may mount a vacuum pump, and optionally mounts a sewage discharge pump. The tank preferably has a generally parallelepiped configuration, and an interior volume of between about 45-65 liters, has a maximum vacuum level of about 26 cm of mercury, and is connected to other conventional portions of a vehicle toilet system, including outlets penetrating the exterior of the vehicle.",SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;FRIEDMAN WILLIAM J;;SIGLER JAMES A,,https://lens.org/148-672-009-096-483,Patent Application,no,0,2,1,1,0,E03F1/006;;E03F11/00,E03F1/00;;E03F11/00,,0,0,,,,DISCONTINUED
298,US,A,US 3374167 A,163-312-284-996-640,1968-03-19,1968,US 53098966 A,1966-03-01,US 53098966 A,1966-03-01,Preparation of motor fuels having an octane number above 100,,AIR PROD & CHEM,CRAIG ROBERT G;;LEE FRIEDMAN;;SCHWARTZ WILLIAM A,,https://lens.org/163-312-284-996-640,Granted Patent,no,1,3,5,5,0,C10G35/085;;C10G59/02;;C10L1/06;;C10G35/085;;C10L1/06;;C10G59/02,C10G35/085;;C10G59/02;;C10L1/06,208/65,0,0,,,,EXPIRED
299,US,A,US 5931642 A,180-286-645-142-107,1999-08-03,1999,US 83926797 A,1997-04-17,US 83926797 A;;US 55102995 A,1995-10-31,Plastic combined vacuum and holding tank,"A vacuum sewage handling assembly particularly for boats and recreational vehicles or caravans has a minimum of components because the conventional vacuum and holding tanks have been combined into a single substantially unreinforced, non-cylindrical, all plastic tank. The tank has a contoured, convoluted, discontinuous surface (e.g. formed by grooves, channels, and other discontinuities) so that it has no continuous flat surface area of more than about 80 square inches. The combined vacuum and holding tank may mount a vacuum pump, and optionally mounts a sewage discharge pump. The tank preferably has a generally parallelepiped configuration, and an interior volume of between about 45-65 liters, has a maximum vacuum level of about 26 cm of mercury, and is connected to other conventional portions of a vehicle toilet system, including outlets penetrating the exterior of the vehicle. The tank may have wheels and a handle.",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;SIGLER JAMES A;;MCKIERNAN EDWARD,DOMETIC CORPORATION (2008-12-30);;DOMETIC SANITATION CORPORATION (2005-04-07),https://lens.org/180-286-645-142-107,Granted Patent,yes,18,27,1,2,0,B63B29/16;;E03D5/00;;E03F1/006;;B63B29/16;;E03F1/006;;E03D5/00,B63B29/16;;B63J4/00;;E03D5/00;;E03F1/00,417/36;;417/53;;4/431,0,0,,,,EXPIRED
300,FI,A,FI 885868 A,190-442-434-308-001,1988-12-19,1988,FI 885868 A,1988-12-19,US 4001387 A;;US 8801304 W,1987-04-17,FOERFARANDE FOER UPPTAECKANDE AV ANTIKROPPAR FOER IMMUNITETSBRISTVIRUS.,,UNIV NEW YORK,FRIEDMAN-KIEN ALVIN E;;CAO YUNZHEN;;BORKOWSKY WILLIAM,,https://lens.org/190-442-434-308-001,Patent Application,no,0,0,15,22,0,G01N33/56988;;Y10S435/81;;Y10S435/974;;Y10S436/811;;Y10S436/808;;C12Q1/70;;G01N33/56988;;Y10S436/808;;Y10S436/811;;Y10S435/81;;Y10S435/974,G01N33/569,,0,0,,,,DISCONTINUED
301,NO,D0,NO 885617 D0,024-491-038-385-04X,1988-12-16,1988,NO 885617 A,1988-12-16,US 4001387 A;;US 8801304 W,1987-04-17,FREMGANGSMAATE VED PAAVISNING AV MENNESKELIG IMMUNSVIKTVIRUS,,UNIV NEW YORK,FRIEDMAN-KIEN ALVIN E;;CAO YUNZHEN;;BORKOWSKY WILLIAM,,https://lens.org/024-491-038-385-04X,Patent Application,no,0,0,6,22,0,,C12Q/;;C12Q1/70;;G01N/;;G01N33/00;;G01N33/53;;G01N33/569,,0,0,,,,DISCONTINUED
302,DE,D1,DE 69919443 D1,112-852-409-020-033,2004-09-23,2004,DE 69919443 T,1999-05-25,US 8328098 A,1998-05-22,Vakuumentlastungsventil für einen Abwasserauffangbehälter,,SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;FRIEDMAN WILLIAM J;;SIGLER JAMES A,,https://lens.org/112-852-409-020-033,Granted Patent,no,0,0,6,6,0,B63B29/16;;F16K24/06;;Y10T137/789;;Y10T137/7897;;Y10T137/784;;Y10T137/7504;;Y10T137/7897;;Y10T137/7504;;F16K24/06;;B63B29/16;;F16K15/148;;F16K15/1402,B63B29/16;;F16K24/06,,0,0,,,,EXPIRED
303,EP,B1,EP 0831182 B1,188-915-414-248-174,2003-09-10,2003,EP 97112116 A,1997-07-16,US 71790496 A,1996-09-23,Holding tank vacuum relief,"A plastic sewage holding tank (117) in a boat, associated with a toilet, includes a vent check valve (140) for providing vacuum relief. By mounting the vent check valve in the top (118) of the tank, when the tank is being emptied by rapid pumpout implosion or other damage to the tank is prevented. The vent check valve may include a valve body (141) with an interior surface (143) mounting a quad sealing ring (75), with a valve element (153) guided for reciprocal movement between a sealing position where an axially elongated substantially cylindrical peripheral surface (146) of the valve element engages the quad ring (75), to an open position where the valve element is moved against spring bias away from the valve body. A spider (80), with a collar (81) for guiding a shaft portion (149) of the valve element (153), may mount a coil spring (159) to provide a biasing action. <IMAGE>",SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;SIGLER JAMES A;;FRIEDMAN WILLIAM J,,https://lens.org/188-915-414-248-174,Granted Patent,yes,2,0,7,7,0,B63B29/14;;E03D5/00;;E03F1/006;;Y10T137/7897;;Y10T137/7897;;B63B29/14;;E03D5/00;;E03F1/006,B63B29/14;;E03D5/00;;E03F1/00,,0,0,,,,EXPIRED
304,US,A,US 5806454 A,007-250-281-349-90X,1998-09-15,1998,US 70172696 A,1996-08-22,US 70172696 A,1996-08-22,Discharge hose adapter for boat holding tank,"A discharge hose adapter adapts a standard marine thru hull fitting to a standard sanitation hose enabling discharge of a boat holding tank into a dump station. The adapter preferably includes a first component and a second component. The first end of the first component is frictionally engageable with the standard marine thru hull fitting, a first end of the second component is engageable with the second end of the first component, and a second end of the second component is engageable with the sanitation hose. The first component is preferably PVC injection molded plastic, and the second component is preferably compression molded rubber derived from vinyl monomers.",SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;SIGLER JAMES A;;FRIEDMAN WILLIAM J,SEALAND TECHNOLOGY INC (1996-08-13);;DOMETIC CORPORATION (2008-12-30),https://lens.org/007-250-281-349-90X,Granted Patent,yes,13,5,1,1,0,B63B29/16;;Y10S285/915;;B63B29/16;;Y10S285/915,B63B29/16,114/270;;4/321;;285/119;;285/139.1;;285/915,0,0,,,,EXPIRED
305,US,B1,US 9119539 B1,100-720-572-946-231,2015-09-01,2015,US 201213432732 A,2012-03-28,US 201213432732 A;;US 201113336573 A,2011-12-23,Performing an authentication operation during user access to a computerized resource,"A method, electronic apparatus and computer program product for performing authentication operation is disclosed. An authentication request is received from user of computerized resource. The request comprises user identifier identifying user. The authenticity of user is verified based on user identifier. An access session is established in which user can access resource in response to successfully verifying user. An electronic input signal is received from electronic input device during session. The device is configured to take a biometric measurement from the user. Biometric data is derived from signal. A comparison is performed between biometric data and expected biometric data. An authentication result is generated based on comparison between biometric data and expected biometric data, wherein result can be used for further authentication of user during session.",DOTAN YEDIDYA;;FRIEDMAN LAWRENCE N;;DUANE WILLIAM M;;EMC CORP,DOTAN YEDIDYA;;FRIEDMAN LAWRENCE N;;DUANE WILLIAM M,EMC CORPORATION (2012-03-26);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/100-720-572-946-231,Granted Patent,yes,6,50,1,2,0,A61B5/02438;;G06F21/32;;G06F21/32;;H04L63/0861;;H04L63/0861;;H04L67/04;;H04L67/04;;H04L67/14;;H04L67/14;;H04W12/065;;H04W12/065;;H04W12/068;;H04W12/068,G08B21/00;;A61B5/024,,0,0,,,,ACTIVE
306,EP,A3,EP 0831182 A3,155-601-880-160-074,1998-09-30,1998,EP 97112116 A,1997-07-16,US 71790496 A,1996-09-23,Holding tank vacuum relief,"A plastic sewage holding tank (117) in a boat, associated with a toilet, includes a vent check valve (140) for providing vacuum relief. By mounting the vent check valve in the top (118) of the tank, when the tank is being emptied by rapid pumpout implosion or other damage to the tank is prevented. The vent check valve may include a valve body (141) with an interior surface (143) mounting a quad sealing ring (75), with a valve element (153) guided for reciprocal movement between a sealing position where an axially elongated substantially cylindrical peripheral surface (146) of the valve element engages the quad ring (75), to an open position where the valve element is moved against spring bias away from the valve body. A spider (80), with a collar (81) for guiding a shaft portion (149) of the valve element (153), may mount a coil spring (159) to provide a biasing action.",SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;SIGLER JAMES A;;FRIEDMAN WILLIAM J,,https://lens.org/155-601-880-160-074,Search Report,yes,3,0,7,7,0,B63B29/14;;E03D5/00;;E03F1/006;;Y10T137/7897;;Y10T137/7897;;B63B29/14;;E03D5/00;;E03F1/006,B63B29/14;;E03D5/00;;E03F1/00,,0,0,,,,EXPIRED
307,DK,A,DK 697188 A,134-948-145-161-67X,1989-02-16,1989,DK 697188 A,1988-12-15,US 4001387 A;;US 8801304 W,1987-04-17,FREMGANGSMAADE TIL DETEKTERING AF ANTISTOF MOD HIV (HUMAN IMMUNODEFICIENCY VIRUS),,UNIV NEW YORK,FRIEDMAN-KIEN ALVIN E;;CAO YUNZHEN;;BORKOWSKY WILLIAM,,https://lens.org/134-948-145-161-67X,Patent Application,no,0,0,6,22,0,,C12Q/;;C12Q1/70;;G01N/;;G01N33/00;;G01N33/53;;G01N33/569,,0,0,,,,DISCONTINUED
308,AU,B2,AU 729527 B2,030-152-570-600-472,2001-02-01,2001,AU 1997/014895 A,1997-02-25,AU 1997/014895 A,1997-02-25,Plastic combined vacuum and holding tank,,SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;SIGLER JAMES A;;MCKIERNAN EDWARD,,https://lens.org/030-152-570-600-472,Granted Patent,no,3,0,2,2,0,Y02A50/30,A47K11/02,,0,0,,,,EXPIRED
309,CA,C,CA 2359400 C,094-776-655-349-755,2010-10-12,2010,CA 2359400 A,2001-10-17,US 24225100 P;;US 95300601 A,2000-10-20,METHOD FOR DETECTING TRANSVERSE VIBRATIONS IN AN ULTRASONIC HAND PIECE,"A method for detecting transverse mode vibrations in an ultrasonic hand piece/blade is achieved by monitoring the power delivered to the hand piece/blade to determine whether it increases as expected when power levels applied to the hand piece/blade are changed. While the blade is being held in midair, the power delivered to the hand piece/blade and for the impedance of the hand piece/blade is measured at a first power level. Using the value obtained at the first power level, the expected power at a second power level is calculated and used to set a pass/fail threshold level for an actual measured power. Alternatively, the threshold is set for the impedance is set. Next, the actual power delivered to the hand piece/blade and/or the impedance of the hand piece/blade is measured at a level 5 power setting. A determination is made whether the hand piece/blade exhibits transverse mode behavior based on whether the actual measured power exceeds the established pass/fail threshold level. If this is the case, operation of the generator is inhibited, a ""Transverse Mode Vibrations Present in Hand Piece/Blade"" error code is stored in the generator, and a ""Bad Hand Piece"" message is displayed on a liquid crystal display on the generator. In addition, a method for detecting transverse mode vibration in an ultrasonic hand piece/blade is achieved by monitoring power delivered to the hand piece/blade to determine if the an extraordinary power increase occurs as the drive frequency is shifted downward and/or upward from a primary intended resonance operating frequency.",ETHICON ENDO SURGERY INC,WIENER EITAN;;DONOFRIO WILLIAM T;;FRIEDMAN ALLAN L,,https://lens.org/094-776-655-349-755,Granted Patent,no,0,0,13,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/0003;;A61B2017/0003;;A61B2017/00119;;A61B2017/00119;;A61B2017/00137;;A61B2017/00137;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/32;;A61B17/00;;G01H15/00;;G01M7/02,,0,0,,,,EXPIRED
310,DE,T2,DE 69724720 T2,176-796-058-780-791,2004-07-01,2004,DE 69724720 T,1997-07-16,US 71790496 A,1996-09-23,Behälter mit Vakuumentlastung,"A plastic sewage holding tank (117) in a boat, associated with a toilet, includes a vent check valve (140) for providing vacuum relief. By mounting the vent check valve in the top (118) of the tank, when the tank is being emptied by rapid pumpout implosion or other damage to the tank is prevented. The vent check valve may include a valve body (141) with an interior surface (143) mounting a quad sealing ring (75), with a valve element (153) guided for reciprocal movement between a sealing position where an axially elongated substantially cylindrical peripheral surface (146) of the valve element engages the quad ring (75), to an open position where the valve element is moved against spring bias away from the valve body. A spider (80), with a collar (81) for guiding a shaft portion (149) of the valve element (153), may mount a coil spring (159) to provide a biasing action. <IMAGE>",SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;SIGLER JAMES A;;FRIEDMAN WILLIAM J,,https://lens.org/176-796-058-780-791,Granted Patent,no,0,0,7,7,0,B63B29/14;;E03D5/00;;E03F1/006;;Y10T137/7897;;Y10T137/7897;;B63B29/14;;E03D5/00;;E03F1/006,B63B29/14;;E03D5/00;;E03F1/00,,0,0,,,,EXPIRED
311,EP,A2,EP 0302997 A2,197-337-334-662-820,1989-02-15,1989,EP 88106076 A,1988-04-15,US 4001387 A,1987-04-17,Method for detecting antibodies to human immunodeficiency virus.,"Disclosed herein is a method of screening mammals for antibodies to viral agents by collecting a urine sample from a mammal to be tested and assaying the sample for antibodies directed against the specific viral agent.  ",UNIV NEW YORK,FRIEDMAN-KIEN ALVIN E;;CAO YUNZHEN;;BROKOWSKY WILLIAM,,https://lens.org/197-337-334-662-820,Patent Application,yes,0,2,15,22,0,G01N33/56988;;Y10S435/81;;Y10S435/974;;Y10S436/811;;Y10S436/808;;C12Q1/70;;G01N33/56988;;Y10S436/808;;Y10S436/811;;Y10S435/81;;Y10S435/974,G01N33/569,,0,0,,,,DISCONTINUED
312,DE,T2,DE 69919443 T2,105-848-704-058-127,2005-09-15,2005,DE 69919443 T,1999-05-25,US 8328098 A,1998-05-22,Vakuumentlastungsventil für einen Abwasserauffangbehälter,,SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;FRIEDMAN WILLIAM J;;SIGLER JAMES A,,https://lens.org/105-848-704-058-127,Granted Patent,no,0,0,6,6,0,B63B29/16;;F16K24/06;;Y10T137/789;;Y10T137/7897;;Y10T137/784;;Y10T137/7504;;Y10T137/7897;;Y10T137/7504;;F16K24/06;;B63B29/16;;F16K15/148;;F16K15/1402,B63B29/16;;F16K24/06,,0,0,,,,EXPIRED
313,FI,A0,FI 885868 A0,047-124-503-306-248,1988-12-19,1988,FI 885868 A,1988-12-19,US 4001387 A;;US 8801304 W,1987-04-17,FOERFARANDE FOER UPPTAECKANDE AV ANTIKROPPAR FOER IMMUNITETSBRISTVIRUS.,,UNIV NEW YORK,FRIEDMAN-KIEN ALVIN E;;CAO YUNZHEN;;BORKOWSKY WILLIAM,,https://lens.org/047-124-503-306-248,Patent Application,no,0,0,15,22,0,G01N33/56988;;Y10S435/81;;Y10S435/974;;Y10S436/811;;Y10S436/808;;C12Q1/70;;G01N33/56988;;Y10S436/808;;Y10S436/811;;Y10S435/81;;Y10S435/974,G01N33/569,,0,0,,,,DISCONTINUED
314,US,A,US 5681148 A,052-575-889-410-69X,1997-10-28,1997,US 55102995 A,1995-10-31,US 55102995 A,1995-10-31,Vacuum/holding tank,"A sewage handling assembly particularly for boats and recreational vehicles with a minimum of components. The waste discharge of a toilet is connected to an inlet for a combined vacuum and holding tank which mounts a vacuum pump, and optionally mounts a sewage discharge pump. A sewage discharge conduit, which may be connected to the optional sewage discharge pump, is connected to a first outlet from the tank, in turn connected to a dip tube terminating in an open end just above the tank bottom. A second outlet from the tank is connected to the vacuum pump (in turn connected to a gas conduit with an end termination penetrating an exterior partition of the boat or RV), and an upwardly extending gas tube inside the tank, having an opening near the interior top of the tank, is connected to the second outlet. The tank is controlled so that a gas volume of about 2 and 1/2-4 gallons is always maintained in the tank, with a vacuum level of between about 8-10 inches of mercury. Once the volume of sewage in the tank reaches a predetermined level--so that sewage might be inadvertently withdrawn by the vacuum pump--the vacuum pump is controlled so that it will not operate until the tank is emptied (or the sewage level otherwise reduced).",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;SIGLER JAMES A;;MCKIERNAN EDWARD,DOMETIC SANITATION CORPORATION (1995-12-27),https://lens.org/052-575-889-410-69X,Granted Patent,yes,12,24,1,2,0,B63B29/16;;E03D5/00;;E03F1/006;;B63B29/16;;E03F1/006;;E03D5/00,B63B29/16;;B63J4/00;;E03D5/00;;E03F1/00,417/36;;417/53;;4/431,0,0,,,,EXPIRED
315,EP,B1,EP 0861947 B1,066-801-204-363-941,2003-05-07,2003,EP 97103102 A,1997-02-26,EP 97103102 A,1997-02-26,Combined vacuum and holding tank,"A vacuum sewage handling assembly particularly for boats and recreational vehicles or caravans has a minimum of components because the conventional vacuum and holding tanks have been combined into a single substantially unreinforced, non-cylindrical, all plastic tank (25). The tank (25) has a contoured, convoluted, discontinuous surface (e. g. formed by grooves, channels, and other discontinuities 37, 44, 137, 87) so that it has no continuous flat surface area of more than about 200 square centimeters The combined vacuum and holding tank may mount a vacuum pump (53, 153), and optionally mounts a sewage discharge pump (59). The tank preferably has a generally parallelepiped configuration, and an interior volume of between about 45-65 liters, has a maximum vacuum level of about 26 cm of mercury, and is connected to other conventional portions (10, 11) of a vehicle toilet system, including outlets (19, 22) penetrating the exterior (18) of the vehicle. <IMAGE>",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;SIGLER JAMES A;;MCKIERNAN EDWARD,,https://lens.org/066-801-204-363-941,Granted Patent,yes,5,0,5,5,0,E03D5/00;;E03F1/006,E03D5/00;;E03F1/00,,0,0,,,,EXPIRED
316,EP,A2,EP 1199048 A2,076-237-269-636-70X,2002-04-24,2002,EP 01308910 A,2001-10-19,US 24189500 P;;US 86694801 A,2000-10-20,Method for driving an ultrasonic system to improve acquisition of blade resonance frequency at startup,"The ability of an ultrasonic system to sweep and lock onto a resonance frequency of a blade subjected to a heavy load at startup is improved by applying a high drive voltage or a high drive current while systematically increasing the level of the applied signal. Increasing the drive signal to the hand piece results in an improved and more pronounced ""impedance spectrum."" That is, under load, the increased drive signal causes the maximum phase margin to become higher and the minimum/maximum impedance magnitude to become more pronounced. Increasing the excitation drive signal to the hand piece/blade at startup significantly alleviates the limiting factors associated with ultrasonic generators, which results in an increase of the maximum load capability at startup.",ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T;;WIENER EITAN,,https://lens.org/076-237-269-636-70X,Patent Application,yes,0,2,12,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/00725;;A61B2017/00725;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,,0,0,,,,EXPIRED
317,AU,B2,AU 780332 B2,095-515-587-157-68X,2005-03-17,2005,AU 2001/079485 A,2001-10-17,US 24189500 P;;US 86694801 A,2000-10-20,Method for driving an ultrasonic system to improve acquisition of blade resonance frequency at startup,,ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T;;WIENER EITAN,,https://lens.org/095-515-587-157-68X,Granted Patent,no,3,0,12,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/00725;;A61B2017/00725;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,,0,0,,,,EXPIRED
318,CN,A,CN 113366610 A,129-843-117-909-327,2021-09-07,2021,CN 202080012279 A,2020-02-24,US 201962810176 P;;US 202016791488 A;;US 2020/0019399 W,2019-02-25,SYSTEM AND METHOD FOR PUMPING LASER SUSTAINED PLASMA WITH INTERLACED PULSED ILLUMINATION SOURCES,"A system for pumping laser sustained plasma is disclosed. The system includes a plurality of pump modules configured to generate respective pulses of pump illumination for the laser sustained plasma, wherein at least one pump module is configured to generate a train of pump pulses that is interlaced in time with another train of pump pulses generated by at least one other pump module of the plurality of pump modules. The system further includes a plurality of non-collinear illumination paths configured to direct the respective pulses of pump illumination from the plurality of pump modules into a collection volume of the laser sustained plasma.",KLA TENCOR CORP,BEZEL ILYA;;DERSTINE MATTHEW;;SCHUMAKER WILLIAM;;FRIEDMAN MARK,,https://lens.org/129-843-117-909-327,Patent Application,no,4,0,7,7,0,H05G2/008;;H01J65/04;;H01J61/025;;H01J61/302;;H01J65/042;;H01S3/0943;;H01S3/1312;;F21V9/06;;H01S3/13013;;H01S3/1024;;H01S3/09;;H01S5/04;;H01S3/1001,H01J61/02;;H01J61/30;;H01J65/04,,0,0,,,,ACTIVE
319,AT,T1,AT E239835 T1,169-212-874-669-500,2003-05-15,2003,AT 97103102 T,1997-02-26,EP 97103102 A,1997-02-26,KOMBINIERTER VAKUUM- UND LAGERBEHÄLTER,"A vacuum sewage handling assembly particularly for boats and recreational vehicles or caravans has a minimum of components because the conventional vacuum and holding tanks have been combined into a single substantially unreinforced, non-cylindrical, all plastic tank (25). The tank (25) has a contoured, convoluted, discontinuous surface (e. g. formed by grooves, channels, and other discontinuities 37, 44, 137, 87) so that it has no continuous flat surface area of more than about 200 square centimeters The combined vacuum and holding tank may mount a vacuum pump (53, 153), and optionally mounts a sewage discharge pump (59). The tank preferably has a generally parallelepiped configuration, and an interior volume of between about 45-65 liters, has a maximum vacuum level of about 26 cm of mercury, and is connected to other conventional portions (10, 11) of a vehicle toilet system, including outlets (19, 22) penetrating the exterior (18) of the vehicle. <IMAGE>",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;SIGLER JAMES A;;MCKIERNAN EDWARD,,https://lens.org/169-212-874-669-500,Granted Patent,no,0,0,5,5,0,E03D5/00;;E03F1/006,E03D5/00;;E03F1/00,,0,0,,,,DISCONTINUED
320,CA,A,CA 813875 A,165-368-161-365-529,1969-05-27,1969,CA 813875D A,,CA 813875T A,,PREPARATION OF MOTOR FUELS HAVING AN OCTANE NUMBER ABOVE 100,,AIR PROD & CHEM,FRIEDMAN LEE;;SCHWARTZ WILLIAM A;;CRAIG ROBERT G,,https://lens.org/165-368-161-365-529,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
321,US,A,US 2487797 A,000-439-485-569-853,1949-11-15,1949,US 71523546 A,1946-12-10,US 71523546 A,1946-12-10,Detection of water in fuels,,HERBERT FRIEDMAN;;ZISMAN WILLIAM A;;SULLIVAN MILES V,HERBERT FRIEDMAN;;ZISMAN WILLIAM A;;SULLIVAN MILES V,,https://lens.org/000-439-485-569-853,Granted Patent,no,5,17,1,1,0,F16L2101/30;;F16L2101/30;;G01N23/12;;G01N23/12;;G01N23/083;;G01N23/083,,,0,0,,,,EXPIRED
322,WO,A1,WO 1988/008039 A1,028-698-544-720-326,1988-10-20,1988,US 8801304 W,1988-04-15,US 4001387 A,1987-04-17,METHOD FOR DETECTING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS,Disclosed herein is a method of screening mammals for antibodies to viral agents by collecting a urine sample from a mammal to be tested and assaying the sample for antibodies directed against the specific viral agent.,UNIV NEW YORK,FRIEDMAN-KIEN ALVIN E;;CAO YUNZHEN;;BORKOWSKY WILLIAM,,https://lens.org/028-698-544-720-326,Patent Application,yes,2,1,15,22,0,G01N33/56988;;Y10S435/81;;Y10S435/974;;Y10S436/811;;Y10S436/808;;C12Q1/70;;G01N33/56988;;Y10S436/808;;Y10S436/811;;Y10S435/81;;Y10S435/974,G01N33/569,G1B BAD           BAD;;G1B B103          BAD;;G1B B301          BAD;;G1B B306          BAD;;U1S S1296,0,0,,,,PENDING
323,AU,A,AU 2001/079485 A,044-442-459-398-089,2002-05-02,2002,AU 2001/079485 A,2001-10-17,US 24189500 P;;US 86694801 A,2000-10-20,Method for driving an ultrasonic system to improve acquisition of blade resonance frequency at startup,,ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;WIENER EITAN;;DONOFRIO WILLIAM T,,https://lens.org/044-442-459-398-089,Patent Application,no,0,0,12,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/00725;;A61B2017/00725;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,,0,0,,,,EXPIRED
324,JP,A,JP H10248749 A,134-190-669-663-076,1998-09-22,1998,JP 4822297 A,1997-03-03,JP 4822297 A,1997-03-03,TANK MADE OF PLASTIC,"PROBLEM TO BE SOLVED: To reduce a cost, to save a space, to increase tank strength and to manufacture even a large-sized tank by providing a wavy noncontinuous surface on the tank and eliminating the presence of a continuous plane exceeding a specified area. SOLUTION: This tank 25 is provided with first and second end walls 26 and 27 and first and second side walls 28 and 29, a peak part surface 30 is provided near the side wall 28 and a peak part pump attaching surface 31 and a projection part 32 are provided on the surface 30. The peak part surface 33 is provided on the opposite side of the tank 25 from the surfaces 30 and 32 and the different pump attaching peak part surface 34 is provided between them. On the surface of the tank 25, many irregular surface parts called grooves or channels are provided. The irregular shape parts are provided so as to eliminate the presence of the continuous plane exceeding the area of about 200cm<2> on the tank 25.",SEALAND TECHNOL INC,WILLIAM J FRIEDMAN;;JAMES A SIGRER;;EDWARD MAKUKIIRUNAN,,https://lens.org/134-190-669-663-076,Patent Application,no,0,1,1,1,0,,A47K11/00;;B60R15/04,,0,0,,,,DISCONTINUED
325,US,A,US 5248060 A,146-102-893-531-900,1993-09-28,1993,US 83814292 A,1992-02-18,US 83814292 A,1992-02-18,Theft deterrent device for newspaper dispensing machines,A theft deterrent device restricts the number of newspapers or other periodicals that can be retrieved from a newspaper vending machine at one time. The device includes a cover gate forming a generally T-shaped opening with a vertical passageway and a horizontal slot opening. The cover gate mounts over an access opening of the vending machine behind a hinged door that closes against the vending machine. The cover gate restricts the number of periodicals that can be withdrawn at one time from a storage cabinet portion of the machine after the hinged door is opened and lowered by a customer. The deterrent device is easily installed on existing newspaper vending machines by way of an engagement member that securely engages a fixed part of the vending machine in the region of the access opening. A lock mechanism on the cover gate serves to lock the cover gate to the dispensing machine and firmly hold the gate in place over the access opening.,EB METAL IND INC,FRIEDMAN EVELYN;;CARSWELL WILLIAM;;SHAMES HOWARD;;BORHO MARTIN,EB METAL INDUSTRIES INC. A CORP. OF NEW YORK (1992-02-14),https://lens.org/146-102-893-531-900,Granted Patent,yes,11,18,1,1,0,G07F11/045;;G07F11/045,G07F11/04,221/28;;221/154;;221/155;;221/241;;221/304;;194/350;;49/142,1,0,,,"Sho Rack Coin Operated Newspaper Racks, One By One , Kaspar Wire Works, Inc., Mar. 1991, p. 1.",EXPIRED
326,EP,A1,EP 0861947 A1,146-542-369-412-891,1998-09-02,1998,EP 97103102 A,1997-02-26,EP 97103102 A,1997-02-26,Plastic combined vacuum and holding tank,"A vacuum sewage handling assembly particularly for boats and recreational vehicles or caravans has a minimum of components because the conventional vacuum and holding tanks have been combined into a single substantially unreinforced, non-cylindrical, all plastic tank (25). The tank (25) has a contoured, convoluted, discontinuous surface (e. g. formed by grooves, channels, and other discontinuities 37, 44, 137, 87) so that it has no continuous flat surface area of more than about 200 square centimeters The combined vacuum and holding tank may mount a vacuum pump (53, 153), and optionally mounts a sewage discharge pump (59). The tank preferably has a generally parallelepiped configuration, and an interior volume of between about 45-65 liters, has a maximum vacuum level of about 26 cm of mercury, and is connected to other conventional portions (10, 11) of a vehicle toilet system, including outlets (19, 22) penetrating the exterior (18) of the vehicle.",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;SIGLER JAMES A;;MCKIERNAN EDWARD,,https://lens.org/146-542-369-412-891,Patent Application,yes,13,3,5,5,0,E03D5/00;;E03F1/006,E03D5/00;;E03F1/00,,0,0,,,,EXPIRED
327,KR,B1,KR 960001503 B1,153-242-521-699-356,1996-01-31,1996,KR 880701685 A,1988-12-16,US 4001387 A;;US 8801304 W,1987-04-17,METHOD FOR RDETECTING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS,,UNIV NEW YORK,FRIEDMAN-KIEN ALVIN E;;CAO YUNZHEN;;BORKOWSKY WILLIAM,,https://lens.org/153-242-521-699-356,Granted Patent,no,0,0,15,22,0,G01N33/56988;;Y10S435/81;;Y10S435/974;;Y10S436/811;;Y10S436/808;;C12Q1/70;;G01N33/56988;;Y10S436/808;;Y10S436/811;;Y10S435/81;;Y10S435/974,G01N33/569,,0,0,,,,EXPIRED
328,AT,T1,AT E249557 T1,117-981-066-620-75X,2003-09-15,2003,AT 97112116 T,1997-07-16,US 71790496 A,1996-09-23,BEHÄLTER MIT VAKUUMENTLASTUNG,"A plastic sewage holding tank (117) in a boat, associated with a toilet, includes a vent check valve (140) for providing vacuum relief. By mounting the vent check valve in the top (118) of the tank, when the tank is being emptied by rapid pumpout implosion or other damage to the tank is prevented. The vent check valve may include a valve body (141) with an interior surface (143) mounting a quad sealing ring (75), with a valve element (153) guided for reciprocal movement between a sealing position where an axially elongated substantially cylindrical peripheral surface (146) of the valve element engages the quad ring (75), to an open position where the valve element is moved against spring bias away from the valve body. A spider (80), with a collar (81) for guiding a shaft portion (149) of the valve element (153), may mount a coil spring (159) to provide a biasing action. <IMAGE>",SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;SIGLER JAMES A;;FRIEDMAN WILLIAM J,,https://lens.org/117-981-066-620-75X,Granted Patent,no,0,0,7,7,0,B63B29/14;;E03D5/00;;E03F1/006;;Y10T137/7897;;Y10T137/7897;;B63B29/14;;E03D5/00;;E03F1/006,B63B29/14;;E03D5/00;;E03F1/00,,0,0,,,,DISCONTINUED
329,AU,A,AU 1988/017182 A,144-349-155-800-082,1988-11-04,1988,AU 1988/017182 A,1988-04-15,US 4001387 A,1987-04-17,METHOD FOR DETECTING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS,,UNIV NEW YORK,FRIEDMAN-KIEN ALVIN E;;BORKOWSKY WILLIAM;;CAO YUNZHEN,,https://lens.org/144-349-155-800-082,Patent Application,no,0,0,15,22,0,G01N33/56988;;Y10S435/81;;Y10S435/974;;Y10S436/811;;Y10S436/808;;C12Q1/70;;G01N33/56988;;Y10S436/808;;Y10S436/811;;Y10S435/81;;Y10S435/974,G01N33/569,,0,0,,,,EXPIRED
330,DK,D0,DK 697188 D0,037-235-583-106-463,1988-12-15,1988,DK 697188 A,1988-12-15,US 4001387 A;;US 8801304 W,1987-04-17,FREMGANGSMAADE TIL DETEKTERING AF ANTISTOF MOD HIV (HUMAN IMMUNODEFICIENCY VIRUS),,UNIV NEW YORK,FRIEDMAN-KIEN ALVIN E;;CAO YUNZHEN;;BORKOWSKY WILLIAM,,https://lens.org/037-235-583-106-463,Patent Application,no,0,0,6,22,0,,C12Q/;;C12Q1/70;;G01N/;;G01N33/00;;G01N33/53;;G01N33/569,,0,0,,,,DISCONTINUED
331,EP,A2,EP 0959281 A2,139-862-235-812-397,1999-11-24,1999,EP 99710003 A,1999-05-25,US 8328098 A,1998-05-22,Vacuum relief valve for sewage holding tank,"A plastic sewage holding tank (17) in a boat (10), associated with a toilet (14), includes a vent check valve assembly (40) for providing vacuum relief. By mounting the vent check valve (40) in the top of the tank (17), when the tank is being emptied by rapid pumpout implosion or other damage to the tank is prevented. The vent check valve assembly (40) may include a valve body surface (45) operatively connected to the tank (17) and having a plurality of openings (46,47) formed in it, and a flexible material diaphragm (60) covering the openings (46,47) adjacent the inside of the tank (17), and uncovering openings (46,47) to allow air flow through the openings (46,47) substantially only when a vacuum condition exists inside the tank (17). A plastic disk (61) biases the diaphragm (60) into its opening-covering position, but a partial vacuum of at least about 2-5 inches of water allows air to flow through the openings past the diaphragm (60).",SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;FRIEDMAN WILLIAM J;;SIGLER JAMES A,,https://lens.org/139-862-235-812-397,Patent Application,yes,0,2,6,6,0,B63B29/16;;F16K24/06;;Y10T137/789;;Y10T137/7897;;Y10T137/784;;Y10T137/7504;;Y10T137/7897;;Y10T137/7504;;F16K24/06;;B63B29/16;;F16K15/148;;F16K15/1402,B63B29/16;;F16K24/06,,0,0,,,,EXPIRED
332,DE,T2,DE 69721722 T2,148-242-022-783-376,2004-03-11,2004,DE 69721722 T,1997-02-26,EP 97103102 A,1997-02-26,Kombinierter Vakuum- und Lagerbehälter,"A vacuum sewage handling assembly particularly for boats and recreational vehicles or caravans has a minimum of components because the conventional vacuum and holding tanks have been combined into a single substantially unreinforced, non-cylindrical, all plastic tank (25). The tank (25) has a contoured, convoluted, discontinuous surface (e. g. formed by grooves, channels, and other discontinuities 37, 44, 137, 87) so that it has no continuous flat surface area of more than about 200 square centimeters The combined vacuum and holding tank may mount a vacuum pump (53, 153), and optionally mounts a sewage discharge pump (59). The tank preferably has a generally parallelepiped configuration, and an interior volume of between about 45-65 liters, has a maximum vacuum level of about 26 cm of mercury, and is connected to other conventional portions (10, 11) of a vehicle toilet system, including outlets (19, 22) penetrating the exterior (18) of the vehicle. <IMAGE>",SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;SIGLER JAMES A;;MCKIERNAN EDWARD,,https://lens.org/148-242-022-783-376,Granted Patent,no,0,4,5,5,0,E03D5/00;;E03F1/006,E03D5/00;;E03F1/00,,0,0,,,,EXPIRED
333,NO,L,NO 885617 L,152-824-673-478-564,1988-12-16,1988,NO 885617 A,1988-12-16,US 4001387 A;;US 8801304 W,1987-04-17,FREMGANGSMAATE VED PAAVISNING AV MENNESKELIG IMMUNSVIKTVIRUS,,UNIV NEW YORK,FRIEDMAN-KIEN ALVIN E;;CAO YUNZHEN;;BORKOWSKY WILLIAM,,https://lens.org/152-824-673-478-564,Abstract,no,0,0,6,22,0,,C12Q/;;C12Q1/70;;G01N/;;G01N33/00;;G01N33/53;;G01N33/569,,0,0,,,,DISCONTINUED
334,CA,A1,CA 2359400 A1,167-670-196-401-649,2002-04-20,2002,CA 2359400 A,2001-10-17,US 24225100 P;;US 95300601 A,2000-10-20,METHOD FOR DETECTING TRANSVERSE VIBRATIONS IN AN ULTRASONIC HAND PIECE,"A method for detecting transverse mode vibrations in an ultrasonic hand piece/blade is achieved by monitoring the power delivered to the hand piece/blade to determine whether it increases as expected when power levels applied to the hand piece/blade are changed. While the blade is being held in midair, the power delivered to the hand piece/blade a nd /or the impedance of the hand piece/blade is measured at a first power level. Using the value obtained at the first power level, the expected power at a second power level is calculated and us ed to set a pass/fail threshold level for an actual measured power. Alternatively, the threshold i s set for the impedance is set. Next, the actual power delivered to the hand piece/blade and/or the impedance of the hand piece/blade is measured at a level 5 power setting. A determination is made whether the hand piece/blade exhibits transverse mode behavior based on whether the actual measured power exceeds the established pass/fail threshold level. If this is the case, operation of the generator is inhibited, a ""Transverse Mode Vibrations Present in Hand Piece/Blade"" error code is stored in the generator, and a ""Bad Hand Piece"" message is displayed on a liquid cryst al display on the generator. In addition, a method for detecting transverse mode vibration in anultrasonic hand piece/blade is achieved by monitoring power delivered to the hand piece/blad e to determine if the an extraordinary power increase occurs as the drive frequency is shifted downward and/or upward from a primary intended resonance operating frequency.",ETHICON ENDO SURGERY INC,DONOFRIO WILLIAM T;;FRIEDMAN ALLAN L;;WIENER EITAN,,https://lens.org/167-670-196-401-649,Patent Application,no,0,2,13,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/0003;;A61B2017/0003;;A61B2017/00119;;A61B2017/00119;;A61B2017/00137;;A61B2017/00137;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,,0,0,,,,EXPIRED
335,DE,A1,DE 1545224 A1,179-941-965-889-616,1969-07-10,1969,DE 1545224 A,1966-12-02,US 53098966 A,1966-03-01,Verfahren zur Erhoehung der Octanzahl von fluessigen Kohlenwasserstoffen,,AIR PROD & CHEM,G CRAIG ROBERT;;FRIEDMAN LEE;;A SCHWARTZ WILLIAM,,https://lens.org/179-941-965-889-616,Patent Application,no,0,0,5,5,0,C10G35/085;;C10G59/02;;C10L1/06;;C10G35/085;;C10L1/06;;C10G59/02,C10G35/085;;C10G59/02;;C10L1/06,,0,0,,,,DISCONTINUED
336,AU,B2,AU 617671 B2,006-580-377-829-444,1991-12-05,1991,AU 1988/017182 A,1988-04-15,US 4001387 A,1987-04-17,METHOD FOR DETECTING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS,,UNIV NEW YORK,FRIEDMAN-KIEN ALVIN E;;BORKOWSKY WILLIAM;;CAO YUNZHEN,,https://lens.org/006-580-377-829-444,Granted Patent,no,2,1,15,22,0,G01N33/56988;;Y10S435/81;;Y10S435/974;;Y10S436/811;;Y10S436/808;;C12Q1/70;;G01N33/56988;;Y10S436/808;;Y10S436/811;;Y10S435/81;;Y10S435/974,G01N33/569,,0,0,,,,EXPIRED
337,DE,D1,DE 60137597 D1,079-700-053-186-894,2009-03-19,2009,DE 60137597 T,2001-10-19,US 24189500 P;;US 86694801 A,2000-10-20,Antriebsverfahren für ein Ultraschallsystem mit verbesserter Klingenresonanz während der Anlaufphase,,ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T;;WIENER EITAN,,https://lens.org/079-700-053-186-894,Granted Patent,no,0,0,12,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/00725;;A61B2017/00725;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/32;;A61B17/00,,0,0,,,,EXPIRED
338,CA,C,CA 1340405 C,118-604-972-861-291,1999-02-23,1999,CA 564232 A,1988-04-15,US 4001387 A,1987-04-17,METHOD FOR DETECTING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS,Disclosed herein is a method of screening mammals for antibodies to viral agents by collecting a urine sample from a mammal to be tested and assaying the sample for antibodies directed against the specific viral agent.,UNIV NEW YORK,FRIEDMAN-KIEN ALVIN E;;CAO YUNZHEN;;BORKOWSKY WILLIAM,,https://lens.org/118-604-972-861-291,Granted Patent,no,0,0,15,22,0,G01N33/56988;;Y10S435/81;;Y10S435/974;;Y10S436/811;;Y10S436/808;;C12Q1/70;;G01N33/56988;;Y10S436/808;;Y10S436/811;;Y10S435/81;;Y10S435/974,G01N33/569,,0,0,,,,EXPIRED
339,US,B1,US 8631486 B1,152-577-796-367-105,2014-01-14,2014,US 41484509 A,2009-03-31,US 41484509 A,2009-03-31,Adaptive identity classification,A method is used in identity assurance. A process is executed that is used to verify a user identity. A description of the executed process is stored and is used to determine a level of trust.,FRIEDMAN LAWRENCE N;;ZOLFONOON RIAZ;;DUANE WILLIAM M;;EMC CORP,FRIEDMAN LAWRENCE N;;ZOLFONOON RIAZ;;DUANE WILLIAM M,RSA SECURITY HOLDING INC (2009-12-22);;RSA SECURITY INC (2009-03-25);;RSA SECURITY LLC (2009-12-21);;EMC CORPORATION (2009-12-31);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/152-577-796-367-105,Granted Patent,yes,4,19,1,1,0,G06F21/31;;G06F21/57;;H04L63/08;;H04L63/105;;G06F21/31;;H04L63/105;;H04L63/08;;G06F21/57,G06F21/00,726/19;;726/4;;726/21,0,0,,,,ACTIVE
340,AU,A,AU 1997/014895 A,014-171-172-369-256,1998-08-27,1998,AU 1997/014895 A,1997-02-25,AU 1997/014895 A,1997-02-25,Plastic combined vacuum and holding tank,,SEALAND TECHNOLOGY INC,FRIEDMAN WILLIAM J;;SIGLER JAMES A;;MCKIERNAN EDWARD,,https://lens.org/014-171-172-369-256,Patent Application,no,0,0,2,2,0,Y02A50/30,A47K11/02,,0,0,,,,EXPIRED
341,EP,A3,EP 0302997 A3,018-313-600-639-66X,1990-11-22,1990,EP 88106076 A,1988-04-15,US 4001387 A,1987-04-17,METHOD FOR DETECTING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS,"Disclosed herein is a method of screening mammals for antibodies to viral agents by collecting a urine sample from a mammal to be tested and assaying the sample for antibodies directed against the specific viral agent.  ",NEW YORK UNIVERSITY,"FRIEDMAN-KIEN, ALVIN E.;;CAO, YUNZHEN;;BROKOWSKY, WILLIAM",,https://lens.org/018-313-600-639-66X,Search Report,yes,2,0,15,22,0,G01N33/56988;;Y10S435/81;;Y10S435/974;;Y10S436/811;;Y10S436/808;;C12Q1/70;;G01N33/56988;;Y10S436/808;;Y10S436/811;;Y10S435/81;;Y10S435/974,G01N33/569,,6,1,155-846-435-746-822,10.1016/0009-8981(74)90091-6,JOURNAL OF CLINICAL INVESTIGATION;;BOLLETTINO DELL'ISTITUTO SIEROTERAPICO MILANESE;;BLOOD;;CLINICA CHIMICA ACTA;;LANCET;;AIDS RESEARCH AND HUMAN RETROVIRUSES,DISCONTINUED
342,EP,A3,EP 0959281 A3,168-210-043-058-500,2002-05-29,2002,EP 99710003 A,1999-05-25,US 8328098 A,1998-05-22,Vacuum relief valve for sewage holding tank,"A plastic sewage holding tank (17) in a boat (10), associated with a toilet (14), includes a vent check valve assembly (40) for providing vacuum relief. By mounting the vent check valve (40) in the top of the tank (17), when the tank is being emptied by rapid pumpout implosion or other damage to the tank is prevented. The vent check valve assembly (40) may include a valve body surface (45) operatively connected to the tank (17) and having a plurality of openings (46,47) formed in it, and a flexible material diaphragm (60) covering the openings (46,47) adjacent the inside of the tank (17), and uncovering openings (46,47) to allow air flow through the openings (46,47) substantially only when a vacuum condition exists inside the tank (17). A plastic disk (61) biases the diaphragm (60) into its opening-covering position, but a partial vacuum of at least about 2-5 inches of water allows air to flow through the openings past the diaphragm (60).",SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;FRIEDMAN WILLIAM J;;SIGLER JAMES A,,https://lens.org/168-210-043-058-500,Search Report,yes,4,0,6,6,0,B63B29/16;;F16K24/06;;Y10T137/789;;Y10T137/7897;;Y10T137/784;;Y10T137/7504;;Y10T137/7897;;Y10T137/7504;;F16K24/06;;B63B29/16;;F16K15/148;;F16K15/1402,B63B29/16;;F16K24/06,,0,0,,,,EXPIRED
343,EP,B1,EP 0959281 B1,184-012-320-229-850,2004-08-18,2004,EP 99710003 A,1999-05-25,US 8328098 A,1998-05-22,Vacuum relief valve for sewage holding tank,,SEALAND TECHNOLOGY INC,MCKIERNAN EDWARD;;FRIEDMAN WILLIAM J;;SIGLER JAMES A,,https://lens.org/184-012-320-229-850,Granted Patent,yes,4,0,6,6,0,B63B29/16;;F16K24/06;;Y10T137/789;;Y10T137/7897;;Y10T137/784;;Y10T137/7504;;Y10T137/7897;;Y10T137/7504;;F16K24/06;;B63B29/16;;F16K15/148;;F16K15/1402,B63B29/16;;F16K24/06,,0,0,,,,EXPIRED
344,DE,T2,DE 69511451 T2,104-717-002-507-243,1999-12-09,1999,DE 69511451 T,1995-04-20,US 23506994 A,1994-04-29,Orale Verabreichungsformen von Azithromycin zur Vermeidung von Interaktionen mit der Nahrung,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/104-717-002-507-243,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
345,DZ,A1,DZ 1880 A1,113-586-652-393-478,2002-02-17,2002,DZ 950051 A,1995-05-03,US 23909494 A,1994-05-06,Forme posologique d'azithromycine et son procédé de production.,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/113-586-652-393-478,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
346,US,A1,US 2016/0072787 A1,027-660-638-448-722,2016-03-10,2016,US 201514852473 A,2015-09-11,US 201514852473 A;;US 72920207 A;;US 35892603 A;;US 22409802 A,2002-08-19,METHOD FOR CREATING SECURE SUBNETWORKS ON A GENERAL PURPOSE NETWORK,"Techniques used in a network that includes non-trusted devices, in which packets of information communicated across the network include network address information for a source device and a destination device of the packets of information are described herein. According to one embodiment, a process of establishing a more secure subnetwork includes inserting at least one credential into at least one packet of information issued by the source device, the credential assessable by a plurality of devices on the network, enabling transmission of the at least one packet of information from the source device to at least one destination device on the subnetwork, assessing the credential by at least one of the devices, and permitting the source device to communicate with the destination device conditioned upon the results of the assessing step. Other methods and apparatuses are also described.",BALABINE IGOR V;;FRIEDMAN WILLIAM G;;MINKIN ILYA G,BALABINE IGOR V;;FRIEDMAN WILLIAM G;;MINKIN ILYA G,,https://lens.org/027-660-638-448-722,Patent Application,yes,8,60,1,7,0,H04L63/12;;H04L63/08;;H04L63/08;;H04L63/12,H04L29/06;;H04W12/06,,0,0,,,,DISCONTINUED
347,EP,B1,EP 1201195 B1,029-093-562-399-796,2005-03-23,2005,EP 01308877 A,2001-10-19,US 24225100 P;;US 95300601 A,2000-10-20,Method and systems for detecting transverse vibrations in an ultrasonic hand piece,,ETHICON ENDO SURGERY INC,WIENER EITAN T;;DONOFRIO WILLIAM T;;FRIEDMAN ALLAN L,,https://lens.org/029-093-562-399-796,Granted Patent,yes,4,0,13,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/0003;;A61B2017/0003;;A61B2017/00119;;A61B2017/00119;;A61B2017/00137;;A61B2017/00137;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,,0,0,,,,EXPIRED
348,WO,A3,WO 2004/017552 A3,041-614-204-486-721,2009-06-18,2009,US 0325995 W,2003-08-18,US 22409802 A,2002-08-19,ESTABLISHING AUTHENTICATED NETWORK CONNECTIONS,"A method and apparatus for establishing authenticated network (e.g., TCP/IP) connections augments the network (e.g., TCP/IP) protocol and enables concealment of the presence of network (e.g., TCP/IP) servers on the network. One methodology uses one or more cryptographic techniques, and/or combinations of such techniques, to achieve the goal. A network (e.g., TCP/IP) connection establishment could be authenticated using both shared secret cryptographic and public key cryptographic methods. The trust between peers could be established either directly or via a trusted third party. One methodology allows network (e.g., TCP/IP) server concealment against Internet based eavesdroppers and eavesdroppers staging man-in-the-middle attacks on the local network or in the close proximity to the server. The techniques described herein may be used to protect a network (e.g., TCP/IP) server from establishing unsanctioned connections from both local and remote networks.",SOWL ASSOCIATES INC,BALABINE IGOR V;;FRIEDMAN WILLIAM G;;MINKIN ILYA G,,https://lens.org/041-614-204-486-721,Search Report,yes,3,0,6,7,0,A63F13/12;;A63F2300/401;;A63F2300/402;;A63F2300/50;;A63F2300/532;;A63F2300/5546;;H04L63/0442;;H04L63/08;;H04L63/0823;;H04L63/0869;;H04L63/1466;;H04W4/06;;H04W16/225;;H04W88/12;;H04W88/14;;H04L67/131;;A63F13/30;;H04L63/08;;H04W16/225;;H04L63/0823;;A63F2300/402;;A63F2300/5546;;A63F2300/50;;H04W4/06;;H04L63/0442;;A63F2300/401;;H04W88/12;;H04W88/14;;A63F2300/532;;H04L63/0869;;H04L63/1466;;H04L67/01;;H04L67/131,H04L5/00;;A63F13/12;;H04L7/00;;H04L9/00;;H04L12/56;;H04L29/06,,0,0,,,,PENDING
349,CO,A1,CO 4560547 A1,007-871-224-152-141,1998-02-10,1998,CO 95017782 A,1995-04-28,US 23506994 A,1994-04-29,UNA FORMA DE DOSIS DE AZITROMICINA Y UN METODO DE TRATA- MIENTO DE UNA INFECCION MICROBIANA QUE INVOLUCRA LA ADMINIS- TRACION DE AZITROMICINA,"UNA FORMA DE DOSIS ORAL DE AZITROMICINA QUE NO DE- MUESTRA UN EFECTO ALIMENTICIO CONTRATIO; FORMAS DE DOSIS DE AZITROMICINA ESPECIFICAS INCLUYEN TABLETAS, POLVOS PARA SUSPENSIONES ORALES Y PAQUE- TES UNITARIOS DE DOSIS; METODOS PARA EL TRATAMIEN- TO DE INFECIONES MICROBIANAS CON LAS FORMAS DE DOSIS.",PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/007-871-224-152-141,Patent Application,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,PENDING
350,OA,A,OA 10151 A,079-687-391-230-161,1996-12-18,1996,OA 60654 A,1995-04-28,US 23506994 A,1994-04-29,Method of administering azithromycin,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/079-687-391-230-161,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;A61K9/10;;A61K9/14;;C07H17/00;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
351,WO,A3,WO 2005/057614 A3,076-091-021-404-316,2005-12-15,2005,US 2004/0040055 W,2004-12-01,US 72735303 A,2003-12-03,EXTRACTOR/BUFFER,"An automated material handling system that includes an extractor/buffer apparatus (102) capable of simultaneously accessing multiple Work-In-Process (WIP) parts (116, 117, 124), thereby providing a highly efficient interface between WIP storage locations (103) and transport equipment (140). The extractor/buffer apparatus includes multiple extractor/buffer modules (104), each module being configured to interface with a location for holding WIP parts that is a number of WIP parts deep. Each module includes a platform (130) for holding multiple WIP parts. Further, multiple modules may be disposed side-by-side to form an extractor/buffer apparatus capable of handling multiple rows of WIP parts.",BROOKS AUTOMATION INC,FOSNIGHT WILLIAM JOHN;;BUFANO MICHAEL;;FRIEDMAN GERALD;;SULLIVAN ROBERT,,https://lens.org/076-091-021-404-316,Search Report,yes,5,0,4,4,0,H01L21/67706;;H01L21/6773;;H01L21/67769;;Y10S414/14;;H01L21/67706;;H01L21/6773;;H01L21/67769;;Y10S414/14,B65G1/00;;H01L/;;H01L21/677,,0,0,,,,PENDING
352,ZA,B,ZA 953439 B,123-113-643-967-292,1996-10-28,1996,ZA 953439 A,1995-04-28,US 23506994 A,1994-04-29,Method of administering azithromycin,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/123-113-643-967-292,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;A61K9/10;;C07H17/00;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
353,JP,A,JP 2008231120 A,174-696-246-755-736,2008-10-02,2008,JP 2008139689 A,2008-05-28,US 23506994 A,1994-04-29,METHOD FOR ADMINISTERING AZITHROMYCIN,"<P>PROBLEM TO BE SOLVED: To provide a dosage form of administering azithromycin to a patient which just took foods. <P>SOLUTION: The present invention provides an oral dosage form of azithromycin which can administer to mammals which took foods and contains azithromycin and substantially does not exhibit negative alimentary effect. Solubility of azithromycin is at least about 90% within about 30 min when dosage form in an amount corresponding to 250 mg azithromycin is tested by a method USP-711 in a USP-2 dissolution apparatus with a paddle rotating under the stringent conditions that correspond the following indices: 900 mL phosphoric acid buffer, pH 6.0, at 37°C and at 100 rpm, with the proviso that the dosage form is not a capsule and contains an alkaline earth metal oxide or hydroxide in an amount less than taste-blocking amount and does not exhibit adverse effect of foods. <P>COPYRIGHT: (C)2009,JPO&INPIT",PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/174-696-246-755-736,Patent Application,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K31/7052;;A61K9/00;;C07H17/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K47/02;;A61K47/04;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
354,US,A,US 5860799 A,020-880-703-519-970,1999-01-19,1999,US 80671797 A,1997-02-27,US 80671797 A,1997-02-27,Pulsation damper for marine tank pumpout systems,"A marine tank (such as a toilet system holding tank, or bilge tank) pump out system includes a positive displacement pump connectable at the inlet to a marine tank to be pumped out and connectable at the outlet to a discharge tank or area. A pulsation dampener is connected between the pump outlet and the discharge tank or area, preferably directly to the pump so that a pump check valve is within the pulsation dampener. The pulsation dampener has an open chamber extending upwardly from the pump outlet into which pumped fluent material may flow, and has no moving parts (such as a diaphragm). Typically two different outlets from the dampener are provided for versatility and connecting up to discharge tanks or areas, one of the outlets filled with a plug. The dampener may comprise either a substantially L-shaped or C-shaped (when viewed from the dampener inlet) casing, which nests with the pump motor.",SEALAND TECHNOLOGY INC,SCHEIBE MARK E;;SIGLER JAMES A;;FRIEDMAN WILLIAM J,SEALAND TECHNOLOGYM INC (1997-02-18);;DOMETIC CORPORATION (2008-12-30);;DOMETIC SANITATION CORPORATION (2005-04-07),https://lens.org/020-880-703-519-970,Granted Patent,yes,17,10,7,7,0,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/0025;;Y10T137/3118;;Y10T137/3118;;B63B29/16;;B63B13/00;;F04B11/0025;;E03D5/00,B63B13/00;;B63B29/16;;E03D5/00;;F04B11/00,417/540;;417/543;;137/207;;137/568,0,0,,,,EXPIRED
355,AU,A,AU 1995/017711 A,068-082-953-120-888,1995-11-09,1995,AU 1995/017711 A,1995-04-28,US 23506994 A,1994-04-29,Method of administering azithromycin,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/068-082-953-120-888,Patent Application,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
356,SI,T1,SI 0679400 T1,111-323-696-323-749,1999-10-31,1999,SI 9530303 T,1995-04-20,EP 95302628 A;;US 23506994 A,1994-04-29,Oral dosage forms of azithromycin avoiding drugfood interaction,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/111-323-696-323-749,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;C07H17/00;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
357,US,A1,US 2005/0135906 A1,164-256-500-793-147,2005-06-23,2005,US 72735303 A,2003-12-03,US 72735303 A,2003-12-03,Extractor/buffer,"An automated material handling system that includes an extractor/buffer apparatus capable of simultaneously accessing multiple Work-In-Process (WIP) parts, thereby providing a highly efficient interface between WIP storage locations and transport equipment. The extractor/buffer apparatus includes multiple extractor/buffer modules, each module being configured to interface with a location for holding WIP parts that is a number of WIP parts deep. Each module includes a platform for holding multiple WIP parts. Further, multiple modules may be disposed side-by-side to form an extractor/buffer apparatus capable of handling multiple rows of WIP parts.",FOSNIGHT WILLIAM J.;;BUFANO MICHAEL;;FRIEDMAN GERALD;;SULLIVAN ROBERT,FOSNIGHT WILLIAM J;;BUFANO MICHAEL;;FRIEDMAN GERALD;;SULLIVAN ROBERT,MURATA MACHINERY LTD (2010-02-02);;BROOKS AUTOMATION INC (2003-12-22),https://lens.org/164-256-500-793-147,Patent Application,yes,51,16,4,4,0,H01L21/67706;;H01L21/6773;;H01L21/67769;;Y10S414/14;;H01L21/67706;;H01L21/6773;;H01L21/67769;;Y10S414/14,B65G1/00;;H01L/;;H01L21/677,414/277,0,0,,,,EXPIRED
358,EP,B1,EP 0679400 B1,166-994-610-178-791,1999-08-18,1999,EP 95302628 A,1995-04-20,US 23506994 A,1994-04-29,Oral dosage forms of azithromycin avoiding drugfood interaction,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,PFIZER INC. (2007-10-15),https://lens.org/166-994-610-178-791,Granted Patent,yes,2,5,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,2,0,,,"PHARMACOTHERAPY, vol. 12, no. 3, 1992 pages 161-173, DREW ET AL. 'Azithromycin - Spectrum of activity, Pharmakokinetics and clinical applications';;J. CLIN. PHARMACOL., vol. 32, 1992 pages 32-36, CHU ET AL. 'Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial'",EXPIRED
359,US,B2,US 6626926 B2,173-322-110-781-166,2003-09-30,2003,US 86694801 A,2001-05-29,US 86694801 A;;US 24189500 P,2000-10-20,Method for driving an ultrasonic system to improve acquisition of blade resonance frequency at startup,"
    The ability of an ultrasonic system to sweep and lock onto a resonance frequency of a blade subjected to a heavy load at startup is improved by applying a high drive voltage or a high drive current while systematically increasing the level of the applied signal. Increasing the drive signal to the hand piece results in an improved and more pronounced impedance spectrum. That is, under load, the increased drive signal causes the maximum phase margin to become higher and the minimum/maximum impedance magnitude to become more pronounced. Increasing the excitation drive signal to the hand piece/blade at startup significantly alleviates the limiting factors associated with ultrasonic generators, which results in an increase of the maximum load capability at startup. 
",ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T;;WIENER EITAN T,ETHICON ENDO-SURGERY INC (2001-07-27),https://lens.org/173-322-110-781-166,Granted Patent,yes,21,349,12,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/00725;;A61B2017/00725;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,606/169;;604/22,0,0,,,,EXPIRED
360,DE,D1,DE 60109555 D1,019-206-080-035-59X,2005-04-28,2005,DE 60109555 T,2001-10-19,US 24225100 P;;US 95300601 A,2000-10-20,Verfahren und Systeme zur Erkennung von Quervibrationen in einem Ultraschallhandstück,,ETHICON ENDO SURGERY INC,WIENER EITAN T;;DONOFRIO WILLIAM T;;FRIEDMAN ALLAN L,,https://lens.org/019-206-080-035-59X,Granted Patent,no,0,0,13,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/0003;;A61B2017/0003;;A61B2017/00119;;A61B2017/00119;;A61B2017/00137;;A61B2017/00137;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,,0,0,,,,EXPIRED
361,MX,B,MX 174196 B,022-978-506-877-291,1994-04-26,1994,MX 2281090 A,1990-10-11,MX 2281090 A,1990-10-11,SISTEMA DE ADMINISTRACION DEL ESPACIO DE TRABAJO,"La presente invención se refiere a un sistema de administración de espacios de trabajo, para dividir un espacio en áreas de trabajo separadas, que comprende: un armazón rígido estructural formado por marcos rectangulares de estructura rígida unidos conjuntamente en sus bordes para formar al menos una área de trabajo; cada uno de los marcos teniendo caras externas en sus lados opuestos y medios receptores en los lados opuestos de los marcos; una pluralidad de losetas intercambiables de tamaño modular relativamente igual y altura sustancialmente comun, cada una de las losetas teniendo medios de unión que cooperan con los medios receptores en los marcos para montar las losetas de manera removible en los marcos para facilidad de colocación en y de remoción de los marcos; las losetas estando montadas en las caras externas de los marcos para cubrir sustancialmente ambos lados de los marcos desde una porción inferior a una porción superior, en relación paralela yuxtapuesta; las losetas teniendo una anchura sustancialmente igual a la anchura de los marcos en que se montan losetas, y tienen una altura tal que al menos dos de las losetas sean montadas en yuxtaposición vertical en cada uno de los marcos; algunas de las losetas teniendo una superficie decorativa y otras de las losetas teniendo una estructura para servir para funciones distintas de la decorativa en el área de trabajo definida por el armazón y las losetas; con lo cual las losetas, ya sean decorativas o funcionales, pueden intercambiarse selectivamente en forma rápida y sencilla con losetas montadas dentro del mismo marco y con losetas montadas en diferentes marcos dentro del sistema.",MILLER HERMAN INC,KELLEY JAMES O;;STUMPF WILLIAM E;;FRIEDMAN FRANK A,,https://lens.org/022-978-506-877-291,Granted Patent,no,0,0,1,1,0,,E04H1/06,,0,0,,,,EXPIRED
362,DE,D1,DE 69511451 D1,023-594-199-176-818,1999-09-23,1999,DE 69511451 T,1995-04-20,US 23506994 A,1994-04-29,Orale Verabreichungsformen von Azithromycin zur Vermeidung von Interaktionen mit der Nahrung,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/023-594-199-176-818,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
363,AU,A,AU 1994/070435 A,034-212-966-120-501,1994-12-20,1994,AU 1994/070435 A,1994-05-27,US 6809393 A;;US 9405804 W,1993-05-28,"A polychlorinated biphenyls (pcb) immunoassay method, its components and a kit for use in performing the same",,ENSYS ENVIRONMENT PROD INC,FRIEDMAN STEPHEN B;;STUDABAKER WILLIAM B;;ALLEN RANDY L,,https://lens.org/034-212-966-120-501,Patent Application,no,0,0,4,4,0,C07K16/44;;C07K16/44;;G01N33/5308;;G01N33/5308,C07K16/44;;G01N33/53,,0,0,,,,PENDING
364,AP,A,AP 566 A,133-659-888-577-142,1996-11-22,1996,AP 9500728 A,1995-04-06,US 23506994 A,1994-04-29,Oral dosage forms of azithromycin avoiding drug food interaction.,Oral dosage forms of aziththromycin avoiding drug food interaction.,PFIZER,CURATOLO WILLIAM JOHN;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/133-659-888-577-142,Granted Patent,no,1,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
365,US,A,US 5547877 A,181-121-161-415-835,1996-08-20,1996,US 32909794 A,1994-10-25,US 32909794 A,1994-10-25,Methods for the rapid detection of toxic halogenated hydrocarbons and kits useful in performing the same,"Methods for the detection, identification and/or quantitation of halogenated hydrocarbons in aqueous samples and kits for performing the methods are provided which provide high sensitivity and can provide high selectively for individual halogenated hydrocarbons such as TCE or THMs. An additional method is provided for the sensitive determination of TTHM in an aqueous sample. These methods use a general two step procedure of (1) extracting and concentrating the halogenated hydrocarbons from the aqueous sample and (2) subjecting the concentrated halogenated hydrocarbons to a modified Fujiwara reaction to provide chromophoric products which can be analyzed by absorption spectra of the resulting mixtures.",ENSYS ENVIRONMENT PROD INC,FRIEDMAN STEPHEN B;;STUDABAKER WILLIAM B;;MIZE PATRICK D,MW MONITORING IP LIMITED (2011-12-08);;STRATEGIC DIAGNOSTICS INC (2011-12-08);;ENSYS ENVIRONMENTAL PRODUCTS INC (1994-12-05),https://lens.org/181-121-161-415-835,Granted Patent,yes,5,22,1,1,0,G01N31/22;;G01N33/1826;;Y10T436/196666;;Y10T436/255;;Y10T436/19;;Y10T436/193333;;Y10T436/196666;;Y10T436/255;;Y10T436/19;;Y10T436/193333;;G01N31/22;;G01N33/1826,G01N31/22;;G01N33/18,436/126;;436/124;;436/125;;436/178;;422/68.1;;422/69;;422/59,7,3,133-869-216-175-584;;074-740-753-052-429;;029-633-148-028-652,10.1021/ac00092a008;;10.1021/ac00092a009;;10.1021/ac00092a010,"Fujiwara Reaction and Determination of Carbon Tetrachloride, Chloroform, Tetrachloroethane, and Trichloroethylene in Air, vol. 38, No. 11, Oct. 1966, pp. 1532 1536.;;Multicomponent Determination of Chlorinated Hydrocarbons Using a Reaction Based Chemical Sensor. 1. Multivariate Calibration of Fujiwara Reaction Products, Analytical Chemistry, vol. 66, No. 20, Oct. 15, 1994, pp. 3328 3336.;;Multicomponent Determination of Chlorinated Hydrocarbons Using a Reaction Based Chemical Sensor. 2. Chemical Speciation Using Multivariate Curve Resolution, Analytical Chemistry, vol. 66, No. 20, Oct. 15, 1994, pp. 3337 3344.;;Multicomponent Determination of Chlorinated Hydrocarbons Using a Reaction Based Chemical Sensor. 3. Medium Rank Second Order Calibration with Restricted Turcker Models, Analytical Chemistry, vol. 66, No. 20, Oct. 15, 1994, pp. 3345 3351.;;A Simple Spectrophotometric Method for the Determination of THMs in Drinking Water, by David A. Reckhow and Pamela D. Pierce, AWWA Research Roundation and American Water Works Association.;;Mueller et al., Amer. Lab., (1974),6(5), 49.;;Angel, S. M. et al., Quarterly Technical Report; Jun. 18, 1987, Lawrence Livermore Nat. Lab.",EXPIRED
366,NO,D0,NO 951630 D0,041-144-385-918-082,1995-04-28,1995,NO 951630 A,1995-04-28,US 23506994 A,1994-04-29,Fremgangsmåte for administrering av azithromycin,,PFIZER,CURATOLO WILLIAM JOHN;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/041-144-385-918-082,Patent Application,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;C07H17/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
367,US,A,US 5834222 A,040-157-730-351-256,1998-11-10,1998,US 41184695 A,1995-03-28,US 41184695 A;;US 6809393 A,1993-05-28,"Polychlorinated biphenyls (PCB) immunoassay method, its components and a kit for use in performing the same","An immunoassay method that integrates a sample processing component that enables the testing of a variety of environmental matrixes and the components for performing the method, wherein the immunoassay utilizes a monoclonal anti-PCB antibody to detect the presence or absence of PCB based contamination in a sample when tested in a field or laboratory location.",ENSYS INC,FRIEDMAN STEPHEN B;;STUDABAKER WILLIAM B;;ALLEN RANDY L,MW MONITORING IP LIMITED (2011-12-08);;STRATEGIC DIAGNOSTICS INC (2011-12-08);;ENSYS ENVIRONMENTAL PRODUCTS INC (1991-10-11);;ENSYS INC (1993-06-29),https://lens.org/040-157-730-351-256,Granted Patent,yes,5,10,4,4,0,C07K16/44;;C07K16/44;;G01N33/5308;;G01N33/5308,C07K16/44;;G01N33/53,435/793;;530/388.9;;530/391.1,35,24,028-534-932-329-619;;072-086-251-779-170;;008-410-892-712-823;;026-665-281-084-634;;052-732-608-673-968;;028-506-887-470-753;;020-888-634-457-708;;010-490-060-673-109;;084-745-907-438-689;;024-726-083-230-366;;090-330-563-901-846;;071-843-044-990-706;;099-328-792-170-56X;;031-514-669-719-846;;047-161-509-118-355;;167-678-558-570-519;;168-169-451-365-663;;013-897-624-615-793;;006-106-521-358-627;;075-351-998-288-744;;050-518-578-888-641;;012-421-471-212-810;;139-463-312-844-205;;031-845-305-765-186,10.1002/etc.5620071102;;10.1021/ac00198a018;;386569;;10.1016/0041-008x(79)90501-5;;10.1080/03067318108071553;;6799414;;10.1080/03067318608077121;;3533809;;6774628;;10.1021/ac50059a026;;10.1093/clinchem/38.5.725;;1582026;;4443551;;10.1177/22.12.1084;;10.1021/ja01123a028;;10.1016/s0076-6879(80)70044-7;;6999294;;10.1007/bf01688251;;2001490;;10.1007/bf01697509;;3289646;;10.1002/ps.2780260309;;10.1021/ac00217a027;;2240580;;10.1007/bf01701838;;2383674;;10.1021/jf00082a049;;10.1021/jf00088a080;;10.1021/jf00088a029;;10.1002/1097-0142(19820515)49:10<1953::aid-cncr2820491002>3.0.co;2-h;;6176307;;10.1016/0300-483x(87)90015-1;;3629609;;10.1016/0041-008x(79)90502-7;;115114;;10.1007/978-1-4684-5012-5_2;;10.1021/ac00013a031;;8422524;;10.1007/bf00191725,"E. Sevier et al., Clin. Chem., vol. 27, No. 11, pp. 1797 1802 (1981).;;Improvement and Application of an Immunoassay for Screening Environmental Samples for Dioxin Contanimation, Vanderlaan, et al., Environmental Toxicology and Chemistry, vol. 7, pp. 859 870, 1988.;;Comparison of Screening Techniques for Polychlorinated Biphenyls in Waste Oils, Carol R. Sutcliffe, et al., Anal.chem. 1989, 61, 2682 2868.;;A Radioimmunoassay for Chlorinated Dibenzo p Dioxins, Phillip W. Albro, et al., Toxicology and Applied Pharmacology, 50, 137 146 (1979).;;Radioimmunoassay of PCB S in Milk and Blood, William H. newsome, et al., Intern.J.Environ., Anal.chem., 1981, vol. 10, pp. 295 304.;;Immunoassays in Environmental Analytical Chemistry, Margit Schwalbe Fehl. pp. 295 303. (1986).;;Radioimmunoassay for Quantitiation of 2,3,7,8 Tetrachlorodibenzoruran, Michael I. Luster, et al Anal.Chem. 1980, 52, 1497 1500.;;Direct Time Resolved Fluorosecence Immunoassay of Progesterone in Serum Involving the Biotin streptavidin System and the Immobilized Antibody Approach, S.E. Kakabakos, et al., Clinical Chemistry, vol. 38, No. 5, pp. 725 730.;;Peroxidase Labeled Antibody a New Method of Conjugation, Paul K. Nakane, et al., The Journal of Histochemistry and Cytochemistry, vol. 22, No. 12, pp. 1084 1091, 1974.;;The Preparation of Peptides Using Mixed Carbonic Carboxylic Acid Anhydrides, by James R. Vaughn, et al., J. Am. Chem. Soc., vol. 74, pp. 676 673, 1952.;;5 Production of Reagent Antibodies, B.A.L. Hurn, et al., Methods in Enzymology, vol. 70, pp. 104 142, 1980.;;Enzyme Immunoassay for the Determination of Atrazine Residues in Soil, K.S.Goh, et al., Bull. Environ.Contam.Toxicol.(1991) 46:30 36.;;Determination of Atrazine Residues in Water and Soil by Enzyme Immunoassay, R.J. Bushway, et al Bull.Environ.Contam.Toxicol. (1988) 40:647 654.;;Pesticides, Freia Jung, et al., Pestic.Sci., 1989, pp. 303 317.;;Enzyme Linked Immunosorbent Assay Compared with Gas Chromatography/Mass Spectrometry for the Determination of Triazine Herbicides in Water., E.M. Thurman, et al., Anal.Chem., 1990, 62, 2043 2048.;;Field Leaf Test Kit for Rapid Determination of Dislodgeable Foliar Residues of Organophosphate and M Methyl Carbamate Insecticides, T.C. Blewett, et al., Bull.Environ.Contam.Toxicol. (1990) 45:120 124.;;Immunochemical Techniques in Trade Residue Analysis, Chapter 1, Martin Vanderlaan, et al., American Chemical Society, pp. 1 13, 1991.;;Reliability of Commericial Enzyme Immunoassay in Detection of Atrazine in Water, Chapter 7, James R. Fleeker, et al., American Chemical Society, pp. 78 85, 1991.;;Immunoassay Methods, Jeanette M. Van Emon, Chapter 7, American Chem. Society, pp. 58 64, 1990.;;Development of an Enzyme Linked Immunosorbent Assay for the Analysis of the Thiocarbamate Herbicide Molinate, Shirley J. Gee, et al., J.Argic.Food Chem., 1988, 36, 863 870.;;Development of a Sensitive Enzyme Linked Immunosorbent Assay for the Fungicide Fenpropimorph, F. Jung, et al., J.Agric.Food Chem. 1989, 37, 1183 1187.;;Development of a Monoclomal Antibody Based Enzyme Immunoassay Method for Analysis of Maleic Hydrazide, Robert O. Harrison, et al., J.Agric.Food Chem. 1989, 37, 958 964.;;History and Future Outlook of Enzyme Immunoassay, Eva Engvall, History of Future of EIA, pp. 1 3.;;Monoclonal Antibodies, Cesar Milstein, Cancer, vol. 49, No. 10, pp. 1953 1957, May 15, 1982.;;Chapter 1, Introduction and General Principles, William D. Odell, History of Competative Binding Assays, pp. 1 13.;;Scientific Swapping, Onsite Analytical Technology Uses Medical Technology to Detect Organic Content, Kimberly A. Roy, Hazmat World, Dec. 1991.;;Monoclonal Antibodies for Dioxin: Antibody Characterization and Assay Development, Stanker et al., Toxicology, 45 (1987) 229 243.;;Production and Characterization of Antisera Specific for Chlorinated Biphenyl Species: Initiation of a Readioimmunoassay for Aroclors, Michael I. Luster, Toxicology and Applied Pharmacology 50, 147 155 (1979).;;Enzyme Medicated Immunoassay: an Overview, T.T. Ngo, in Enzyme Mediated Immunoassay eds. Debtor et al., Plenum Press; New York, 3 (1985).;;Immunoassay Technology for on Site Testing, Kevin R. Carter, American Enviromental Laboratory, Feb. 1992.;;Field Analysis Using Rapid Immunoassay Screens, Aisling Scallen, et al., Environmental Lab Magazine.;;Recent Developments in the Periodate Method of Conjugating Horseradish Peroxidase (HRPO) to Antibodies, M. Barbara Wilson, et al., Immunofluorescence and Related Staining Techniques, pp. 215 222, 1978.;;Nonevaporative Preconcentration Technique for volatile and Semivolitile Solutes in Certain Polar Solvents, Thomas F. Jenkins, et al., Anal.Chem. 1991, 63, 1341 1343.;;An on Site Immunoassay for Detecting PCB in Soil, James P. Mapes, et al., Bull.Environ.Contam. Toxicol. 50:219 225, 1993.;;On Site Screening Speeds Sample Analysis, Kevin R.Carter, PhD., Pollution Engineering pp. 36 38, Mar. 15, 1992.",EXPIRED
368,GB,A,GB 1207162 A,064-546-249-736-141,1970-09-30,1970,GB 4810267 A,1967-10-23,GB 4810267 A,1967-10-23,PROCESS FOR PURIFYING SOLID PEROXIDES,"1,207,162. Purifying solid peroxides. ARGUS CHEMICAL CORP. 23 Oct., 1967, No. 48102/67. Heading C2C. Solid fatty acid peroxides having at least 20 carbon atoms are separated from water and other impurities by adjusting the temperature of the mixture to above the melting point of the peroxide but below its decomposition point, separating the aqueous phase with impurities from the liquid peroxide phase while maintaining the liquid phase above its melting point, and then cooling the dry, purified peroxide phase. Temperatures about 2 to 3 degrees above the melting point are generally preferred. Separation may be carried out by conventional means. The process is preferably carried out using an alkaline impure mixture.",ARGUS CHEM,FRIEDMAN RONALD LEROY;;LAWRENCE WHITNEY ELMORE;;NIELSEN WILLIAM WALTER,,https://lens.org/064-546-249-736-141,Granted Patent,no,0,0,1,1,0,C07C407/003;;C07C407/00,C07C407/00,C2C CYR;;C2C C20Y;;C2C C30Y;;C2C C351;;C2C C354;;C2C C356;;C2C C40Y;;C2C C43X;;C2C C540;;C2C C548;;C2C C635;;C2C C655;;C2C C772;;C2C C773,0,0,,,,EXPIRED
369,TW,B,TW 499311 B,129-255-039-284-163,2002-08-21,2002,TW 83109662 A,1994-10-18,US 23506994 A,1994-04-29,Oral dosage form of azithromycin not exhibiting an adverse food effect,"An oral dosage form of azithromycin which does not exhibit an adverse food effect; specific azithromycin oral dosage forms including tablets, powders for oral suspensions and unit dose packets; methods of treating microbial infections with the dosage forms; and therapeutic packages containing the dosage forms.",PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/129-255-039-284-163,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;A61K9/10;;A61K9/14;;C07H17/00;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
370,DE,T8,DE 60109555 T8,043-988-439-385-916,2006-04-27,2006,DE 60109555 T,2001-10-19,US 24225100 P;;US 95300601 A,2000-10-20,Verfahren und Systeme zur Erkennung von Quervibrationen in einem Ultraschallhandstück,,ETHICON ENDO SURGERY INC,WIENER EITAN T;;DONOFRIO WILLIAM T;;FRIEDMAN ALLAN L,,https://lens.org/043-988-439-385-916,Amended Patent,no,0,0,13,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/0003;;A61B2017/0003;;A61B2017/00119;;A61B2017/00119;;A61B2017/00137;;A61B2017/00137;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/32;;A61B17/00,,0,0,,,,EXPIRED
371,AU,A8,AU 2003/259933 A8,063-096-804-310-325,2009-07-30,2009,AU 2003/259933 A,2003-08-18,US 22409802 A;;US 0325995 W,2002-08-19,Establishing authenticated network connections,,SOWL ASSOCIATES INC,FRIEDMAN WILLIAM G;;BALABINE IGOR V;;MINKIN ILYA G,,https://lens.org/063-096-804-310-325,Patent Application,no,0,0,6,7,0,A63F13/12;;A63F2300/401;;A63F2300/402;;A63F2300/50;;A63F2300/532;;A63F2300/5546;;H04L63/0442;;H04L63/08;;H04L63/0823;;H04L63/0869;;H04L63/1466;;H04W4/06;;H04W16/225;;H04W88/12;;H04W88/14;;H04L67/131;;A63F13/30;;H04L63/08;;H04W16/225;;H04L63/0823;;A63F2300/402;;A63F2300/5546;;A63F2300/50;;H04W4/06;;H04L63/0442;;A63F2300/401;;H04W88/12;;H04W88/14;;A63F2300/532;;H04L63/0869;;H04L63/1466;;H04L67/01;;H04L67/131,H04L5/00;;A63F13/12;;H04L7/00;;H04L9/00;;H04L12/56;;H04L29/06,,0,0,,,,DISCONTINUED
372,UY,A1,UY 24614 A1,068-619-621-500-814,1997-12-24,1997,UY 24614 A,1997-07-10,US 23506994 A;;UY 23935 A,1994-04-29,PROCEDIMIENTO PARA PREPARAR FORMAS DE DOSIFICACION DE AZITROMICINA,"La presente invención se refiere a un procedimiento para la preparación de una forma de dosificación oral en forma de tableta que contiene azitromicina, cuya tableta es administrable a un mamífero que se ha alimentado y no exhibe efecto adverso al alimento. La azitromicina es un compuesto antimicrobiano de amplio espectro obtenido a partir de la eritromicina A; por sus propiedades antimicrobianas, la azitromicina es útil como antibiótico.",PFIZER,WILLIAM J CURATOLO;;GEORGE H FOULDS;;HYLAR L FRIEDMAN,,https://lens.org/068-619-621-500-814,Patent Application,no,0,0,1,52,0,,A61P31/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61P31/04,,0,0,,,,DISCONTINUED
373,CA,A,CA 965599 A,084-186-448-383-579,1975-04-08,1975,CA 143752 A,1972-06-02,US 15227771 A,1971-06-11,METHOD AND COMPOSITION FOR SELECTIVE PLUGGING OF WELLS,,GETTY OIL CO,FRIEDMAN ROBERT H;;KRAUSE JULIANNE D;;BRADFORD WILLIAM R,,https://lens.org/084-186-448-383-579,Granted Patent,no,0,0,2,3,0,C09K8/887;;C09K8/887;;C09K8/90;;C09K8/90;;E21B43/261;;E21B43/261,C09K8/88;;C09K8/90;;E21B43/26,31-26,0,0,,,,EXPIRED
374,TN,A1,TN SN95046 A1,089-876-739-051-494,1996-02-06,1996,TN SN95046 A,1995-04-26,US 23506994 A,1994-04-29,FORMES POSOLOGIQUES D'AZITHROMYCINE POUR LE TRAITEMENT D'INFECTIONS MICROBIENNES,"L'INVENTION CONCERNE DES CONDITIONNEMENTS THERAPEUTIQUES COMPRENANT DES FORMES POSOLOGIQSUES ORALES D'AZITHROMYCINE NE PRESENTANT PAS D'EFFET ALIMENTAIRE NEFASTE. CES FORMES POSOLOGIQUES ORALES SPECIFIQUES D'AZITHROMYCINE COMPRENANT DES COMPRIMES, DES POUDRES POUR SUSPENSIONS ORALES ET DES PAQUETS DE DOSES UNITAIRES. APPLICATION : TRAITEMENT D'INFECTIONS MICROBIENNES AU MOYEN DE CES FORMES POSOLOGIQUES",PFIZER,WILLIAM J CURATOLO;;GEORGE H FOULDS;;HYLAR L FRIEDMAN,,https://lens.org/089-876-739-051-494,Patent Application,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,PENDING
375,DE,T2,DE 60109555 T2,174-873-179-302-255,2006-02-16,2006,DE 60109555 T,2001-10-19,US 24225100 P;;US 95300601 A,2000-10-20,Verfahren und Systeme zur Erkennung von Quervibrationen in einem Ultraschallhandstück,,ETHICON ENDO SURGERY INC,WIENER EITAN T;;DONOFRIO WILLIAM T;;FRIEDMAN ALLAN L,,https://lens.org/174-873-179-302-255,Granted Patent,no,0,0,13,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/0003;;A61B2017/0003;;A61B2017/00119;;A61B2017/00119;;A61B2017/00137;;A61B2017/00137;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,,0,0,,,,EXPIRED
376,ES,T3,ES 2136247 T3,056-302-561-574-908,1999-11-16,1999,ES 95302628 T,1995-04-20,US 23506994 A,1994-04-29,FORMAS DE DOSIFICACION ORAL DE AZITROMICINA QUE NO MUESTRAN UN EFECTO ALIMENTO ADVERSO.,LA INVENCION PROPORCIONA EL USO DE AZITROMICINA EN LA FABRICACION DE UNA ADMINISTRACION ORAL QUE SE DESINTEGRE RAPIDAMENTE CON UNA ALTA BIOUTILIDAD PARA EL TRATAMIENTO DE UNA INFECCION MICROBIANA EN UN MAMIFERO QUE HA COMIDO O COMERA EN EL PERIODO QUE COMIENZA 1 HORA ANTES DE LA ADMINISTRACION Y TERMINA 2 HORAS DESPUES DE LA ADMINISTRACION.,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/056-302-561-574-908,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;C07H17/00;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
377,MA,A1,MA 23533 A1,058-413-907-675-584,1995-12-31,1995,MA 23865 A,1995-04-26,US 23506994 A,1994-04-29,FORMES POSOLOGIQUES D'AZITHROMYCINE,,PFIZER,GEORGE H FOULDS;;WILLIAM J CURATOLO;;HYLAR L FRIEDMAN,,https://lens.org/058-413-907-675-584,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;A61K9/10;;A61K9/14;;C07H17/00;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
378,YU,B,YU 49483 B,071-314-374-601-191,2006-08-17,2006,YU 27195 A,1995-04-28,US 23506994 A,1994-04-29,AZITROMICINE ORAL DOSAGE FORM,"Upotreba azitromocina u proizvodnji oralnog doznog oblika koji ne pokazuje neželjene efekte hrane pri lečenju mikrobnih infekcija kod sisara, naznačena time, što dozni oblik obezbeđuje najmanje 90-postotno rastvaranje azitromicina u toku 30 minuta kada se količina doznog oblika ekvivalentna 200 mg azitromicina ispituje prema USP testu (711) uUSP-2 aparatu za rastvaranje pod uslovima koji su najmanje strogi u sledećem: 900 ml fosfatni pufer, pH 6,0, 37C sa lopaticama koje se okreću pri 100 min-1, pod uslovom da ovaj dozni oblik nije u kapsuli i da sadrži količlnu oksida ili hidroksida zemno alkalnog metala, koja maskira ukus. Prijava sadrži još 7 zavisnih patentnih zahteva.",PFIZER,CURATOLO J WILLIAM;;FOULDS H GEORGE;;FRIEDMAN L HYLAR,,https://lens.org/071-314-374-601-191,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
379,US,A,US 3278585 A,152-732-522-500-674,1966-10-11,1966,US 21551162 A,1962-08-08,US 21551162 A,1962-08-08,Process for esterification of secondary alcohols containing an ether group by reaction in the presence of a cation exchange resin catalyst,,SHELL OIL CO,BAKER MARION A;;FRIEDMAN RONALD L;;RAAB WILLIAM J,,https://lens.org/152-732-522-500-674,Granted Patent,no,9,17,5,5,0,B01J31/10;;B01J31/26;;C07C67/08;;B01J31/10;;B01J31/26;;C07C67/08,B01J31/08;;B01J31/10;;B01J31/26;;C07C67/08;;C07C69/83,,0,0,,,,EXPIRED
380,CA,A,CA 738459 A,180-225-273-795-705,1966-07-12,1966,CA 738459D A,,CA 738459T A,,ESTERIFICATION PROCESS,,SHELL OIL CO,FRIEDMAN RONALD L;;RAAB WILLIAM J;;BAKER MARION A,,https://lens.org/180-225-273-795-705,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
381,FI,A,FI 952060 A,009-785-595-757-037,1995-10-30,1995,FI 952060 A,1995-04-28,US 23506994 A,1994-04-29,Menetelmä atsitromysiinin annostamiseksi,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/009-785-595-757-037,Patent Application,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;C07H17/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
382,NO,L,NO 951630 L,055-070-106-820-939,1995-10-30,1995,NO 951630 A,1995-04-28,US 23506994 A,1994-04-29,Fremgangsmåte for administrering av azithromycin,,PFIZER,CURATOLO WILLIAM JOHN;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/055-070-106-820-939,Abstract,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;C07H17/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
383,EP,A1,EP 1201195 A1,133-122-343-614-791,2002-05-02,2002,EP 01308877 A,2001-10-19,US 24225100 P;;US 95300601 A,2000-10-20,Method and systems for detecting transverse vibrations in an ultrasonic hand piece,"A method for detecting transverse mode vibrations in an ultrasonic hand piece/blade is achieved by monitoring the power delivered to the hand piece/blade to determine whether it increases as expected when power levels applied to the hand piece/blade are changed. While the blade is being held in midair, the power delivered to the hand piece/blade and /or the impedance of the hand piece/blade is measured at a first power level. Using the value obtained at the first power level, the expected power at a second power level is calculated and used to set a pass/fail threshold level for an actual measured power. Alternatively, the threshold is set for the impedance. Next, the actual power delivered to the hand piece/blade and/or the impedance of the hand piece/blade is measured at a higher power setting. A determination is made whether the hand piece/blade exhibits transverse mode behavior based on whether the actual measured power exceeds the established pass/fail threshold level. If this is the case, operation of the generator is inhibited, a ""Transverse Mode Vibrations Present in Hand Piece/Blade"" error code is stored in the generator, and a ""Bad Hand Piece"" message is displayed on a liquid crystal display on the generator. In addition, a method for detecting transverse mode vibration in an ultrasonic hand piece/blade is achieved by monitoring power delivered to the hand piece/blade to determine if the an extraordinary power increase occurs as the drive frequency is shifted downward and/or upward from a primary intended resonance operating frequency.",ETHICON ENDO SURGERY INC,WIENER EITAN T;;DONOFRIO WILLIAM T;;FRIEDMAN ALLAN L,,https://lens.org/133-122-343-614-791,Patent Application,yes,5,25,13,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/0003;;A61B2017/0003;;A61B2017/00119;;A61B2017/00119;;A61B2017/00137;;A61B2017/00137;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,,0,0,,,,EXPIRED
384,NO,B1,NO 314386 B1,153-031-559-822-137,2003-03-17,2003,NO 951630 A,1995-04-28,US 23506994 A,1994-04-29,Tablett- og pulverformulering for oral suspenson inneholdende azithromycin,,PFIZER,CURATOLO WILLIAM JOHN;;FOULDS GEORGE H;;FRIEDMAN HYLAR LEWIS,,https://lens.org/153-031-559-822-137,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;A61K9/10;;A61K9/14;;C07H17/00;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
385,AU,B2,AU 744318 B2,198-531-709-369-045,2002-02-21,2002,AU 1999/063157 A,1999-12-06,AU 1999/063157 A,1999-12-06,Method of administering azithromycin,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/198-531-709-369-045,Granted Patent,no,1,0,2,2,0,,A61K9/14;;A61K9/20,,0,0,,,,EXPIRED
386,AU,A,AU 1999/063157 A,066-280-743-741-488,2000-06-01,2000,AU 1999/063157 A,1999-12-06,AU 1999/063157 A,1999-12-06,Method of administering azithromycin,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;FOULDS GEORGE H,,https://lens.org/066-280-743-741-488,Patent Application,no,0,0,2,2,0,,A61K9/14;;A61K9/20,,0,0,,,,EXPIRED
387,AU,A1,AU 2003/259933 A1,097-479-530-338-444,2004-03-03,2004,AU 2003/259933 A,2003-08-18,US 22409802 A;;US 0325995 W,2002-08-19,ESTABLISHING AUTHENTICATED NETWORK CONNECTIONS,,SOWL ASSOCIATES INC,BALABINE IGOR V;;FRIEDMAN WILLIAM G;;MINKIN ILYA G,,https://lens.org/097-479-530-338-444,Patent Application,no,0,0,6,7,0,A63F13/12;;A63F2300/401;;A63F2300/402;;A63F2300/50;;A63F2300/532;;A63F2300/5546;;H04L63/0442;;H04L63/08;;H04L63/0823;;H04L63/0869;;H04L63/1466;;H04W4/06;;H04W16/225;;H04W88/12;;H04W88/14;;H04L67/131;;A63F13/30;;H04L63/08;;H04W16/225;;H04L63/0823;;A63F2300/402;;A63F2300/5546;;A63F2300/50;;H04W4/06;;H04L63/0442;;A63F2300/401;;H04W88/12;;H04W88/14;;A63F2300/532;;H04L63/0869;;H04L63/1466;;H04L67/01;;H04L67/131,A63F13/12;;H04L12/56;;H04L29/06,,0,0,,,,DISCONTINUED
388,GB,A,GB 189808573 A,123-638-508-073-853,1898-08-06,1898,GB 189808573D A,1898-04-12,GB 189808573T A,1898-04-12,Improvements in Means or Appliances for Coupling a Trace or Tug to the Extremity of a Whiffletree.,"8573. Lack, F. E., Friedman, G. J. L., and Paxton, W. F. April 12. Hooks for traces. Fig. 1 shows a plan of the fastening, the dotted lines showing the open position. The trace is fastened at 12 to the hook 6, the shank of which slides in a notch at 4 and beneath a cross-bar 3, and terminates in a T head 10 resting against the cross-bar, which is formed in a piece with the ferrule 1 firmly fixed to the whipple-tree 2. The point 8 of the hook enters a recess in the rear of the ferrule.",LACK FINIS EWING;;FRIEDMAN JOSEPH LEOPOLD;;PAXTON WILLIAM FRANCIS,LACK FINIS EWING;;FRIEDMAN JOSEPH LEOPOLD;;PAXTON WILLIAM FRANCIS,,https://lens.org/123-638-508-073-853,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
389,DE,B1,DE 1643599 B1,135-365-656-721-490,1972-09-21,1972,DE 1643599 A,1967-10-17,DE A0057090 A,1967-10-17,Verfahren zur Isolierung und Reinigung von bei Raumtemperatur festen Diacylperoxyden,,ARGUS CHEM,WALTER NIELSEN WILLIAM;;L FRIEDMAN RONALD;;E LAWRENCE WHITNEY,,https://lens.org/135-365-656-721-490,Patent Application,no,3,3,1,3,0,C07C407/003,C07C409/34,,0,0,,,,DISCONTINUED
390,MC,A1,MC 2013 A1,150-487-090-623-443,1990-02-16,1990,MC 2013 D,1988-04-15,US 4001387 A;;US 8801304 W,1987-04-17,METHODE POUR LA DETECTION DES ANTICORPS DIRIGES CONTRE LE VIRUS D'IMMUNODEFICIENCE HUMAINE,,UNIV NEW YORK,ALVIN E FRIEDMAN-KIEN;;YUNZ-HEN CAO;;WILLIAM BORKOWSKY,,https://lens.org/150-487-090-623-443,Granted Patent,no,0,0,6,22,0,,C12Q/;;C12Q1/70;;G01N/;;G01N33/00;;G01N33/53;;G01N33/569,,0,0,,,,EXPIRED
391,US,A,US 3876438 A,007-095-433-593-657,1975-04-08,1975,US 33242873 A,1973-02-14,US 33242873 A;;US 15227771 A,1971-06-11,COMPOSITION FOR SELECTIVE PLUGGING OF WELLS,,GETTY OIL CO,FRIEDMAN ROBERT H;;KRAUSE JULIANNE D;;BRADFORD WILLIAM R,,https://lens.org/007-095-433-593-657,Granted Patent,no,2,8,1,3,0,C09K8/887;;C09K8/887;;E21B43/261;;E21B43/261,C09K8/88;;E21B43/26,106/189,0,0,,,,EXPIRED
392,EP,A1,EP 0679400 A1,007-862-377-003-871,1995-11-02,1995,EP 95302628 A,1995-04-20,US 23506994 A,1994-04-29,Oral dosage forms of azithromycin avoiding drugfood interaction.,The invention provides the use of azithromycin in the manufacture of a rapidly disintrigrating oral dosage form with high bioavailability for the treatment of a microbial infection in a mammal that has eaten or will eat in the period commencing 1 hour prior to dosing and terminating 2 hours after dosing.,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,PFIZER INC. (2007-10-15),https://lens.org/007-862-377-003-871,Patent Application,yes,3,19,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,2,2,068-577-638-931-060;;052-976-895-993-120,1319048;;10.1002/j.1875-9114.1992.tb04504.x;;10.1002/j.1552-4604.1992.tb03784.x;;1531484,"DREW ET AL.: ""Azithromycin - Spectrum of activity, Pharmakokinetics and clinical applications"", PHARMACOTHERAPY, vol. 12, no. 3, pages 161 - 173;;CHU ET AL.: ""Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial"", J. CLIN. PHARMACOL., vol. 32, pages 32 - 36",EXPIRED
393,LV,B,LV 10918 B,009-769-429-369-83X,1996-06-20,1996,LV 950115 A,1995-04-28,US 23506994 A,1994-04-29,METHOD OF USE OF AZITHROMYCIN,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/009-769-429-369-83X,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;A61K9/10;;C07H17/00;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
394,WO,A1,WO 1994/028422 A1,051-643-601-249-071,1994-12-08,1994,US 9405804 W,1994-05-27,US 6809393 A,1993-05-28,"A POLYCHLORINATED BIPHENYLS (PCB) IMMUNOASSAY METHOD, ITS COMPONENTS AND A KIT FOR USE IN PERFORMING THE SAME","An immunoassay method that integrates a sample processing component that enables the testing of a variety of environmental matrixes and the components for performing the method, wherein the immunoassay utilizes a monoclonal anti-PCB antibody to detect the presence or absence of PCB based contamination in a sample when tested in a field or laboratory location.",ENSYS ENVIRONMENT PROD INC,FRIEDMAN STEPHEN B;;STUDABAKER WILLIAM B;;ALLEN RANDY L,,https://lens.org/051-643-601-249-071,Patent Application,yes,1,2,4,4,0,C07K16/44;;C07K16/44;;G01N33/5308;;G01N33/5308,C07K16/44;;G01N33/53,,4,4,031-845-305-765-186;;036-298-768-763-701;;026-665-281-084-634;;050-518-578-888-641,8422524;;10.1007/bf00191725;;10.1093/clinchem/27.11.1797;;7028317;;10.1080/03067318108071553;;6799414;;10.1016/0041-008x(79)90502-7;;115114,"BULLETIN ENVIRONMENTAL CONTAMINATION TOXICOLOGY, Volume 50, issued 1993, J.P. MAPES et al., ""An On-Site Immunoassay for Detecting PCB in Soil"", pages 219-225.;;CLINICAL CHEMISTRY, Volume 27, Number 11, issued 1981, E. SEVIER et al., ""Monoclonal Antibodies in Clinical Immunology"", pages 1797-1802.;;INTERNATIONAL JOURNAL OF ENVIRONMENTAL AND ANALYTICAL CHEMISTRY, Volume 10, issued 1981, W.H. NEWSOME et al., ""Radioimmunoassay of PCBs in Milk and Blood"", pages 295-304.;;TOXICOLOGY AND APPLIED PHARMACOLOGY, Volume 50, issued 1979, M.I. LUSTER et al., ""Production and Characterization of Antisera Specific for Chlorinated Biphenyl Species: Initiation of a Radioimmunoassay for Aroclors"", pages 147-155.",PENDING
395,US,A1,US 2004/0034773 A1,071-333-049-927-909,2004-02-19,2004,US 22409802 A,2002-08-19,US 22409802 A,2002-08-19,Establishing authenticated network connections,"
   A method and apparatus for establishing authenticated network (e.g., TCP/IP) connections augments the network (e.g., TCP/IP) protocol and enables concealment of the presence of network (e.g., TCP/IP) servers on the network. One methodology uses one or more cryptographic techniques, and/or combinations of such techniques, to achieve the goal. A network (e.g., TCP/IP) connection establishment could be authenticated using both shared secret cryptographic and public key cryptographic methods. The trust between peers could be established either directly or via a trusted third party. One methodology allows network (e.g., TCP/IP) server concealment against Internet based eavesdroppers and eavesdroppers staging man-in-the-middle attacks on the local network or in the close proximity to the server. The techniques described herein may be used to protect a network (e.g., TCP/IP) server from establishing unsanctioned connections from both local and remote networks. 
",BALABINE IGOR V.;;FRIEDMAN WILLIAM G.;;MINKIN ILYA G.,BALABINE IGOR V;;FRIEDMAN WILLIAM G;;MINKIN ILYA G,SOWL ASSOCIATES INC (2002-11-13),https://lens.org/071-333-049-927-909,Patent Application,yes,4,180,6,7,0,A63F13/12;;A63F2300/401;;A63F2300/402;;A63F2300/50;;A63F2300/532;;A63F2300/5546;;H04L63/0442;;H04L63/08;;H04L63/0823;;H04L63/0869;;H04L63/1466;;H04W4/06;;H04W16/225;;H04W88/12;;H04W88/14;;H04L67/131;;A63F13/30;;H04L63/08;;H04W16/225;;H04L63/0823;;A63F2300/402;;A63F2300/5546;;A63F2300/50;;H04W4/06;;H04L63/0442;;A63F2300/401;;H04W88/12;;H04W88/14;;A63F2300/532;;H04L63/0869;;H04L63/1466;;H04L67/01;;H04L67/131,A63F13/12;;H04L12/56;;H04L29/06,713/168,0,0,,,,EXPIRED
396,US,A1,US 2017/0342550 A1,125-913-657-360-73X,2017-11-30,2017,US 201715603161 A,2017-05-23,US 201715603161 A;;US 201662342083 P,2016-05-26,Method for controlled growth of carbon nanotubes in a vertically aligned array,"Template-guided growth of carbon nanotubes using anodized aluminum oxide nanopore templates provides vertically aligned, untangled planarized arrays of multiwall carbon nanotubes with Ohmic back contacts. Growth by catalytic chemical vapor deposition results in multiwall carbon nanotubes with uniform diameters and crystalline quality, but varying lengths. The nanotube lengths can be trimmed to uniform heights above the template surface using ultrasonic cutting, for example. The carbon nanotube site density can be controlled by controlling the catalyst site density. Control of the carbon nanotube site density enables various applications. For example, the highest possible site density is preferred for thermal interface materials, whereas, for field emission, significantly lower site densities are preferable.",NAT TECH & ENG SOLUTIONS SANDIA LLC,SIEGAL MICHAEL P;;FRIEDMAN CAITLIN ROCHFORD;;YELTON WILLIAM G,NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA LLC (2017-06-28),https://lens.org/125-913-657-360-73X,Patent Application,yes,0,11,1,1,0,C25D11/04;;C25D11/20;;C25D11/24;;C23C16/0281;;C23C16/56;;H01J9/025;;C01B32/162;;C01B32/176;;H01L2224/29193;;H01L2924/10253;;H01L23/373;;H01L23/3736;;H01L23/42;;C23C16/26;;C23C16/44;;C25D3/12;;C25D5/022;;C25D11/045;;C25D5/48;;Y10S977/742;;Y10S977/833;;Y10S977/843;;B82Y40/00;;H01J1/304;;C23C16/26;;H01L23/3738;;C23C16/44;;C25D3/12;;C25D5/022;;C25D11/045;;C25D5/48;;Y10S977/742;;Y10S977/833;;Y10S977/843;;B82Y40/00;;H01J1/304;;C25D11/20;;C25D11/04;;H01J2201/30469;;C01B32/176;;C01B32/162;;C23C16/56;;H01J9/025;;C23C16/0281;;C25D11/24;;H01L2924/10253;;H01L23/3736;;H01L23/42;;H01L2224/29193;;H01L23/373,B82Y30/00;;C23C16/26;;B82Y40/00;;C23C16/44;;C25D3/12;;C25D5/02;;C25D5/48;;C25D11/04;;H01J1/304;;H01L23/373,,0,0,,,,DISCONTINUED
397,GR,T3,GR 3031290 T3,173-930-949-803-243,1999-12-31,1999,GR 990402388 T,1999-09-22,US 23506994 A,1994-04-29,Oral dosage forms of azithromycin avoiding drugfood interaction.,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/173-930-949-803-243,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;C07H17/00;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
398,CA,C,CA 2148071 C,049-360-895-599-541,2000-10-17,2000,CA 2148071 A,1995-04-27,US 23506994 A,1994-04-29,METHOD OF ADMINISTERING AZITHROMYCIN,"An oral dosage form of azithromycin which does not exhibit an adverse food effect; Specific azithromycin oral dosage forms including tablets, powders for oral suspensions and unit dose packets; Methods of treating microbial infections with the dosage forms; And therapeutic packages containing the dosage forms.",PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/049-360-895-599-541,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
399,CA,C,CA 1294108 C,070-707-456-205-353,1992-01-14,1992,CA 563031 A,1988-03-31,US 3535187 A,1987-04-07,WORK SPACE MANAGEMENT SYSTEM,"WORK SPACE MANAGEMENT SYSTEM work space management system for dividing a space into separate work areas comprising a wall system having a rigid framework formed of rigid rectangular frames rigidly joined together at the edges thereof to form at least one work area, wire management elements secured to the frames for communication and power wiring and a plurality of selectively relocatable modular tiles removably hanging on the frames. Some of the wire management elements are secured to the bottom or baseline of the frames and some of the wire management elements are removably secured to a waistline or midportion of at least some of the frames. The frames can extend to a waist height, a seated height, to a standing or full floor to ceiling height in a modular stepped fashion. Decorative and functional modular tiles are sized to fit on the frames to substantially cover the frames, and are independently and removably mounted thereto. The tiles are of equal height and of variable modular width to cover the frames. Further, the tiles are easily mounted to and removed from the frames so that the tiles are relocatable and interchangeable with one another within the same frame and along the different frames for ease of customizing work stations within the system. The work space management system provides an architectural wall partition system with flexibility for interchangeable tile panels for different decorative effects and various functional features. The tiles can be painted, fabric, or vinyl covered, or can comprise acoustical tiles, window tiles, work-in-process rail tiles, lighting tiles, tackable tiles, marker tiles, data display tiles, display tiles, shelf tiles, open pass-through tiles, wire management tiles, mail tiles, storage tiles, heater tiles, and cooling and air circulation tiles.",MILLER HERMAN INC,KELLEY JAMES O;;STUMPF WILLIAM E;;FRIEDMAN FRANK A,,https://lens.org/070-707-456-205-353,Granted Patent,no,0,0,1,25,0,,E04B2/00,D302000221   M,0,0,,,,EXPIRED
400,US,A,US 4876835 A,074-109-613-759-399,1989-10-31,1989,US 3535187 A,1987-04-07,US 3535187 A;;US 64890084 A,1984-09-10,Work space management system,"A work space management system for dividing a space into separate work areas comprising a wall system having a rigid framework formed of rigid rectangular frames rigidly joined together at the edges thereof to form at least one work area, wire management elements secured to the frames for communication and power wiring and a plurality of selectively relocatable modular tiles removably hanging on the frames. Some of the wire management elements are secured to the bottom or baseline of the frames and some of the wire management elements are removably secured to a waistline or midportion of at least some of the frames. The frames can extend to a waist height, a seated height, to a standing or full floor to ceiling height in a modular stepped fashion. Decorative and functional modular tiles are sized to fit on the frames to substantially cover the frames, and are independently and removably mounted thereto. The tiles are of equal height and of variable modular width to cover the frames. Further, the tiles are easily mounted to and removed from the frames so that the tiles are relocatable and interchangeable with one another within the same frame and among the different frames for ease of customizing work stations within the system. The work space management system provides an architectural wall partition system with flexibility for interchangeable tile panels for different decorative effects and various functional features. The tiles can be painted, fabric, or vinyl covered, or can comprise acoustical tiles, window tiles, work-in-process rail tiles, lighting tiles, tackable tiles, marker tiles, data display tiles, display tiles, shelf tiles, open pass-through tiles, wire management tiles, mail tiles, storage tiles, heater tiles, and cooling and air circulation tiles.",MILLER HERMAN INC,KELLEY JAMES O;;STUMPF WILLIAM E;;FRIEDMAN FRANK A,HERMAN MILLER INC. ZEELAND OTTAWA MICHIGAN A CORP. OF MI (1987-04-03),https://lens.org/074-109-613-759-399,Granted Patent,yes,44,151,3,25,0,A47B21/06;;A47B83/001;;A47B2037/005;;A47B2083/006;;A47B2200/01;;E04B2/7405;;E04B2/7425;;E04B2002/7483;;E04B2002/7488;;H02G3/288;;A47B21/06;;E04B2/7405;;A47B2037/005;;E04B2002/7483;;E04B2002/7488;;A47B2200/01;;A47B2083/006;;H02G3/288;;A47B83/001;;E04B2/7425,A47B17/00;;A47B21/00;;A47B83/00;;A47B87/00;;E04B2/74;;E04B2/82,52/239;;52/28;;52/36;;52/238.1;;211/190;;211/208;;312/282,0,0,,,,EXPIRED
401,US,B2,US 7069438 B2,109-541-400-700-765,2006-06-27,2006,US 22409802 A,2002-08-19,US 22409802 A,2002-08-19,Establishing authenticated network connections,"A method and apparatus for establishing authenticated network (e.g., TCP/IP) connections augments the network (e.g., TCP/IP) protocol and enables concealment of the presence of network (e.g., TCP/IP) servers on the network. One methodology uses one or more cryptographic techniques, and/or combinations of such techniques, to achieve the goal. A network (e.g., TCP/IP) connection establishment could be authenticated using both shared secret cryptographic and public key cryptographic methods. The trust between peers could be established either directly or via a trusted third party. One methodology allows network (e.g., TCP/IP) server concealment against Internet based eavesdroppers and eavesdroppers staging man-in-the-middle attacks on the local network or in the close proximity to the server. The techniques described herein may be used to protect a network (e.g., TCP/IP) server from establishing unsanctioned connections from both local and remote networks.",SOWL ASSOCIATES INC,BALABINE IGOR V;;FRIEDMAN WILLIAM G;;MINKIN ILYA G,SOWL ASSOCIATES INC (2002-11-13),https://lens.org/109-541-400-700-765,Granted Patent,yes,4,174,6,7,0,A63F13/12;;A63F2300/401;;A63F2300/402;;A63F2300/50;;A63F2300/532;;A63F2300/5546;;H04L63/0442;;H04L63/08;;H04L63/0823;;H04L63/0869;;H04L63/1466;;H04W4/06;;H04W16/225;;H04W88/12;;H04W88/14;;H04L67/131;;A63F13/30;;H04L63/08;;H04W16/225;;H04L63/0823;;A63F2300/402;;A63F2300/5546;;A63F2300/50;;H04W4/06;;H04L63/0442;;A63F2300/401;;H04W88/12;;H04W88/14;;A63F2300/532;;H04L63/0869;;H04L63/1466;;H04L67/01;;H04L67/131,G06F17/00;;A63F13/12;;H04L12/56;;H04L29/06,713/168;;713/151;;726/14,7,3,016-813-927-533-304;;034-295-932-358-681;;040-275-400-323-997,10.1109/jsac.2004.825993;;10.1109/vetecf.2004.1405097;;10.1109/ccst.2004.1405398,"""FOLDOC-IPSec"", May 6, 2002, [Retrieved from Internet Aug. 30, 2004], ""http://foldoc.doc.ic.ac.uk/foldoc/foldoc.cgi?IPsec"".;;""IPSec"", Jun. 15, 2001, [Retrieved from Internet Aug. 30, 2004], ""http://www.forsitesolutions.com/Techstuff/freeswan/ipsec<SUB>-</SUB>overview.html"".;;""Virtual Network Computing"", Jan. 1998, [Retrieved from Internet Aug. 30, 2004], ""http://www.uk.research.att.com/pub/docs/att/tr.98.1.pdf"".;;Bruce Schneier, 1996, John Wiley & Sons, Inc., ""Applied Cryptography"", 75-76, 426, 455.;;A multilayer IP security protocol for TCP performance enhancement in wireless networks Yongguang Zhang; Selected Areas in Communications, IEEE Journal on vol. 22, Issue 4, May 2004 pp. 767-776.;;Analysis of tradeoffs between security strength and energy savings in security protocols for WLANs Prasithsangaree, P.; Krishnamurthy, P.; Vehicular Technology Conference, 2004. VTC2004-Fall. 2004 IEEE 60th vol. 7, Sep. 26-29, 2004 pp.: 5219-5223 V.;;A study of the elliptic curve cryptology applies to the next generation protocol Po-Hsian, H.; Ching-Wei, C.; Security Technology, 2004. 38th Annual 2004 International Carnahan Conference on Oct. 11-14, 2004 pp.: 233-238.",EXPIRED
402,US,A1,US 2002/0049462 A1,139-551-378-049-765,2002-04-25,2002,US 86694801 A,2001-05-29,US 86694801 A;;US 24189500 P,2000-10-20,Method for driving an ultrasonic system to improve acquisition of blade resonance frequency at startup,"
   The ability of an ultrasonic system to sweep and lock onto a resonance frequency of a blade subjected to a heavy load at startup is improved by applying a high drive voltage or a high drive current while systematically increasing the level of the applied signal. Increasing the drive signal to the hand piece results in an improved and more pronounced impedance spectrum. That is, under load, the increased drive signal causes the maximum phase margin to become higher and the minimum/maximum impedance magnitude to become more pronounced. Increasing the excitation drive signal to the hand piece/blade at startup significantly alleviates the limiting factors associated with ultrasonic generators, which results in an increase of the maximum load capability at startup. 
",ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T;;WIENER EITAN T,ETHICON ENDO-SURGERY INC (2001-07-27),https://lens.org/139-551-378-049-765,Patent Application,yes,0,10,12,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/00725;;A61B2017/00725;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,606/169,0,0,,,,EXPIRED
403,WO,A2,WO 2004/017552 A2,177-452-866-968-466,2004-02-26,2004,US 0325995 W,2003-08-18,US 22409802 A,2002-08-19,ESTABLISHING AUTHENTICATED NETWORK CONNECTIONS,"A method and apparatus for establishing authenticated network (e.g., TCP/IP) connections augments the network (e.g., TCP/IP) protocol and enables concealment of the presence of network (e.g., TCP/IP) servers on the network. One methodology uses one or more cryptographic techniques, and/or combinations of such techniques, to achieve the goal. A network (e.g., TCP/IP) connection establishment could be authenticated using both shared secret cryptographic and public key cryptographic methods. The trust between peers could be established either directly or via a trusted third party. One methodology allows network (e.g., TCP/IP) server concealment against Internet based eavesdroppers and eavesdroppers staging man-in-the-middle attacks on the local network or in the close proximity to the server. The techniques described herein may be used to protect a network (e.g., TCP/IP) server from establishing unsanctioned connections from both local and remote networks.",SOWL ASSOCIATES INC,BALABINE IGOR V;;FRIEDMAN WILLIAM G;;MINKIN ILYA G,,https://lens.org/177-452-866-968-466,Patent Application,yes,0,13,6,7,0,A63F13/12;;A63F2300/401;;A63F2300/402;;A63F2300/50;;A63F2300/532;;A63F2300/5546;;H04L63/0442;;H04L63/08;;H04L63/0823;;H04L63/0869;;H04L63/1466;;H04W4/06;;H04W16/225;;H04W88/12;;H04W88/14;;H04L67/131;;A63F13/30;;H04L63/08;;H04W16/225;;H04L63/0823;;A63F2300/402;;A63F2300/5546;;A63F2300/50;;H04W4/06;;H04L63/0442;;A63F2300/401;;H04W88/12;;H04W88/14;;A63F2300/532;;H04L63/0869;;H04L63/1466;;H04L67/01;;H04L67/131,A63F13/12;;H04L12/56;;H04L29/06,,0,0,,,,PENDING
404,DZ,A1,DZ 1877 A1,009-865-599-151-075,2002-02-17,2002,DZ 950046 A,1995-04-26,US 23506994 A,1994-04-29,Forme posologiques d'azithromycine pour le traitement d'infection microbiennes.,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/009-865-599-151-075,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
405,HU,D0,HU 9501206 D0,035-177-694-288-428,1995-06-28,1995,HU 9501206 A,1995-04-27,US 23506994 A,1994-04-29,PHARMACEUTICAL COMPOSITION CONTAINING AZITHROMYCIN,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/035-177-694-288-428,Patent Application,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
406,US,A,US 5605889 A,064-934-783-241-733,1997-02-25,1997,US 23506994 A,1994-04-29,US 23506994 A,1994-04-29,Method of administering azithromycin,"An oral dosage form of azithromycin which does not exhibit an adverse food effect; Specific azithromycin oral dosage forms including tablets, powders for oral suspensions and unit dose packets; Methods of treating microbial infections with the dosage forms; And therapeutic packages containing the dosage forms.",PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,PFIZER INC (1994-07-19),https://lens.org/064-934-783-241-733,Granted Patent,yes,8,127,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;A61K9/10;;A61K9/14;;C07H17/00;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,514/29;;514/960;;424/464;;424/465;;424/474;;424/480;;424/481;;536/7.2,11,7,018-453-661-557-056;;018-408-329-923-98X;;086-510-948-913-390;;068-577-638-931-060;;052-976-895-993-120;;001-077-368-034-121;;031-370-248-311-295,3379590;;10.1002/jps.2600770408;;10.1002/jps.2600670608;;660450;;423080;;10.1002/jps.2600680208;;1319048;;10.1002/j.1875-9114.1992.tb04504.x;;10.1002/j.1552-4604.1992.tb03784.x;;1531484;;10.1146/annurev.pa.20.040180.001133;;6992698;;10.1023/a:1018970323716;;8456064,"Curatolo et al. J. Pharm. Sci., vol. 77 (4), pp. 322 324, (1988).;;Welling et al. J. Pharm. Sci., vol. 67 (6), pp. 764 766, (1978).;;Welling et al. J. Pharm. Sci., vol. 68 (2), pp. 150 155, (1979).;;Malmborg, A. Curr. Med. Res. Opin. vol. 5 (Suppl. 2), pp. 15 18, (1978).;;Drew et al., Pharmacotherapy, 12, 3, 161 173 (1992).;;Chu et al., J. Clin. Pharmacol., 32, 32 36 (1992).;;Hopkins, S., Am. J. Med., 91 (Suppl 3A), 405 455 (1991).;;Toothaker et al., Ann. Rev. Pharmacol. Toxicol. vol. 20, 173 199, 1980.;;Russell et al., Pharmaceutical Research, vol. 10, No. 2, 187 196, 1993.;;CA Abstracts: vol. 120:38194a; 1994.;;Zithromax (Trademark of Pfizer, Inc.) Capsules Package Insert for azithromycin capsule dosage form sold commercially in U.S.",EXPIRED
407,JP,A,JP 2003153919 A,127-468-297-658-603,2003-05-27,2003,JP 2001360101 A,2001-10-22,US 24225100 P,2000-10-20,METHOD FOR DETECTING TRANSVERSE VIBRATION OF ULTRASONIC HAND PIECE,"PROBLEM TO BE SOLVED: To provide a method for detecting transverse vibration of an ultrasonic hand piece capable of preventing undesired effects caused by an overheated blade, such as damage to tissue. SOLUTION: An output supplied to a hand piece/blade is monitored to determine whether or not an output level supplied thereto will increase as expected when it varies. While the blade is being held in air, the output or impedance supplied to the hand piece/blade is measured at a first output level. Using measurements made at the first output level. Outputs expected at a second output level are calculated and a threshold level for acceptance/rejection is actually set for the measurements. The actual outputs and/or impedance supplied to the hand piece/blade is measured in an output environment at a level 5 and a determination is made as to whether it indicates transverse mode action, based on whether or not the actual measurements exceed the acceptance/ rejection threshold. If the threshold is exceeded, the operation of a generator is stopped and an error code is stored in the generator, with a message displayed on the liquid crystal display of the generator.",ETHICON ENDO SURGERY INC,WIENER EITAN T;;DONOFRIO WILLIAM T;;FRIEDMAN ALLAN L,,https://lens.org/127-468-297-658-603,Patent Application,no,0,188,2,15,0,,A61B17/22;;A61B18/00,,0,0,,,,EXPIRED
408,CA,A1,CA 2148071 A1,130-086-655-895-225,1995-10-30,1995,CA 2148071 A,1995-04-27,US 23506994 A,1994-04-29,Method of Administering Azithromycin,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/130-086-655-895-225,Patent Application,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
409,AT,T1,AT E183395 T1,129-976-831-672-522,1999-09-15,1999,AT 95302628 T,1995-04-20,US 23506994 A,1994-04-29,ORALE VERABREICHUNGSFORMEN VON AZITHROMYCIN ZUR VERMEIDUNG VON INTERAKTIONEN MIT DER NAHRUNG,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/129-976-831-672-522,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
410,LV,A,LV 10918 A,137-637-789-124-832,1995-12-20,1995,LV 950115 A,1995-04-28,US 23506994 A,1994-04-29,Azitromicina pielietosanas panemiens,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/137-637-789-124-832,Patent Application,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;A61K9/10;;C07H17/00;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
411,US,A,US 3367951 A,157-184-993-596-470,1968-02-06,1968,US 35870764 A,1964-04-10,US 35870764 A,1964-04-10,Process for purifying solid peroxides,,U S PEROXYGEN CORP,NIELSEN WILLIAM W;;FRIEDMAN RONALD L;;LAWRENCE WHITNEY E,,https://lens.org/157-184-993-596-470,Granted Patent,no,7,8,1,3,0,C07C407/003;;C07C407/003,C07C407/00,260/406,0,0,,,,EXPIRED
412,HR,A2,HR P950277 A2,173-872-218-060-084,1997-10-31,1997,HR P950277 A,1995-05-05,US 23909494 A,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W,,https://lens.org/173-872-218-060-084,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
413,FI,A0,FI 952060 A0,184-532-161-673-856,1995-04-28,1995,FI 952060 A,1995-04-28,US 23506994 A,1994-04-29,Menetelmä atsitromysiinin annostamiseksi,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/184-532-161-673-856,Patent Application,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;C07H17/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
414,DK,T3,DK 0679400 T3,027-722-147-805-941,1999-12-06,1999,DK 95302628 T,1995-04-20,US 23506994 A,1994-04-29,Orale doseringsformer af azithromycin til undgåelse af lægemiddelfødevareinteraktion,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/027-722-147-805-941,Granted Patent,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
415,US,B1,US 6453752 B1,141-553-387-807-207,2002-09-24,2002,US 49868700 A,2000-02-07,US 49868700 A,2000-02-07,Fixture for testing shear strength in tailor welded blanks,"
    A fixture is provided for testing the shear strength of a longitudinal weld which interconnects a plurality of planar blanks forming a tailor welded blank. The fixture includes a first pair of triangular shaped face plates connected to one side of the tailor welded blank and a second pair of triangular shaped face plates connected to the other side of the tailor welded blank. Each of the face plates includes a transverse edge which extends across the longitudinal weld connecting the planar blanks. The fixture further includes each of the transverse edges having a first portion and a second portion spaced from and parallel to the first portion. The fixture also includes an isolation portion interconnecting the first and second portions of the transverse edges adjacent the longitudinal weld for isolating a portion of the weld whereby the isolated portion of the weld is tested for shear resistance by applying a tensile load to the first and second pair of face plates. 
",FORD GLOBAL TECH INC,HOUSTON DANIEL QUINN;;FRIEDMAN PETER A;;STEWART WILLIAM STEVEN,FORD GLOBAL TECHNOLOGIES INC (2000-02-03);;FORD MOTOR COMPANY (2000-02-03),https://lens.org/141-553-387-807-207,Granted Patent,yes,3,12,1,1,0,B23K31/12;;B23K31/12;;B23K2101/185;;B23K2101/185;;G01N3/00;;G01N3/00;;G01N3/04;;G01N3/04;;G01N2203/0296;;G01N2203/0296,B23K31/12;;G01N3/00;;G01N3/04,73/850;;73/841,0,0,,,,EXPIRED
416,US,A,US 5858692 A,167-065-913-103-260,1999-01-12,1999,US 39570595 A,1995-02-28,US 39570595 A;;US 6809393 A,1993-05-28,"Polychlorinated biphenyls (PCB) immunoassay method, its components and a kit for use in performing the same","An immunoassay method that integrates a sample processing component that enables the testing of a variety of environmental matrixes and the components for performing the method, wherein the immunoassay utilizes a monoclonal anti-PCB antibody to detect the presence or absence of PCB based contamination in a sample when tested in a field or laboratory location.",ENSYS INC,FRIEDMAN STEPHEN B;;STUDABAKER WILLIAM B;;ALLEN RANDY L,MW MONITORING IP LIMITED (2011-12-08);;STRATEGIC DIAGNOSTICS INC (2011-12-08);;ENSYS ENVIRONMENTAL PRODUCTS INC (1991-10-11);;ENSYS INC (1993-06-29),https://lens.org/167-065-913-103-260,Granted Patent,yes,4,14,4,4,0,C07K16/44;;C07K16/44;;G01N33/5308;;G01N33/5308,C07K16/44;;G01N33/53,435/7.93;;530/388.9;;530/391.1,34,22,028-534-932-329-619;;072-086-251-779-170;;008-410-892-712-823;;026-665-281-084-634;;052-732-608-673-968;;028-506-887-470-753;;020-888-634-457-708;;010-490-060-673-109;;084-745-907-438-689;;024-726-083-230-366;;090-330-563-901-846;;071-843-044-990-706;;099-328-792-170-56X;;031-514-669-719-846;;047-161-509-118-355;;167-678-558-570-519;;168-169-451-365-663;;013-897-624-615-793;;006-106-521-358-627;;075-351-998-288-744;;050-518-578-888-641;;012-421-471-212-810,10.1002/etc.5620071102;;10.1021/ac00198a018;;386569;;10.1016/0041-008x(79)90501-5;;10.1080/03067318108071553;;6799414;;10.1080/03067318608077121;;3533809;;6774628;;10.1021/ac50059a026;;10.1093/clinchem/38.5.725;;1582026;;4443551;;10.1177/22.12.1084;;10.1021/ja01123a028;;10.1016/s0076-6879(80)70044-7;;6999294;;10.1007/bf01688251;;2001490;;10.1007/bf01697509;;3289646;;10.1002/ps.2780260309;;10.1021/ac00217a027;;2240580;;10.1007/bf01701838;;2383674;;10.1021/jf00082a049;;10.1021/jf00088a080;;10.1021/jf00088a029;;10.1002/1097-0142(19820515)49:10<1953::aid-cncr2820491002>3.0.co;2-h;;6176307;;10.1016/0300-483x(87)90015-1;;3629609;;10.1016/0041-008x(79)90502-7;;115114;;10.1007/978-1-4684-5012-5_2,"PCT/US94/05804, PCT Written Opinion, dated Mar. 23, 1995.;;E. Sevier et al., Clin. Chem., vol. 27, No. 11, pp. 1797 1802 (1981).;;Improvement and Application of an Immunoassay for Screening Environmental Samples for Dioxin Contanimation, Vanderlaan, et al., Environmental Toxicology and Chemistry, vol. 7, pp. 859 870, 1988.;;Comparison of Screening Techniques for Polychlorinated Biphenyls in Waste Oils, Carol R. Sutcliffe, et al., Anal.Chem. 1969, 61, 2682 2868.;;A Radioimmunoassay for Chlorinated Dibenzo p Dioxins, Phillip W. Albro, et al., Toxicology and Applied Pharmacology, 50, 137 146 (1979).;;Radioimmunoassay of PCB s in Milk and Blood, William N. Newsome, et al., Intern.J.Environ., Anal.Chem., 1981, vol. 10, pp. 295 304.;;Immunoassays in Environmental Analytical Chemistry, Margit Schwalbe Fehl, pp. 295 303 (1986).;;Radioimmunoassay for Quantitiation of 2,3,7,8 Tetrachlorodibenzofuran, Michael I. Luster, et al Anal.Chem. 1980, 52, 1497 1500.;;Direct Time Resolved Fluorosecence Immunoassay of Progesterone in Serum Involving the Biotinstreptavidin System and the Immobilized Antibody Approach, S.E. Kakabakos, et al., Clinical Chemistry, vol. 38, No. 5, pp. 725 730.;;Peroxidase Labeled Antibody a New Method of Conjugation, Paul K. Nakane, et al., The Journal of Histochemistry and Cytochemistry, vol. 22, No. 12, pp. 1084 1091, 1974.;;The Preparation of Peptides Using Mixed Carbonic Carboxylic Acid Anhydrides, by James R. Vaughn, et al., J. Am. Chem. Soc., vol. 74, pp. 676 673, 1952.;;5 Production of Reagent Antibodies, B.A.L. Hurn, et al., Methods in Enzymology, vol. 70, pp. 104 142, 1980.;;Enzyme Immunoassay for the Determination of Atrazine Residues in Soil, K.S. Goh, et al., Bull. Environ.Contam.Toxicol.(1991) 46:30 36.;;Determination of Atrazine Residues in Water and Soil by Enzyme Immunoassay, R.J. Bushway, et al Bull.Environ.Contam.Toxicol. (1988) 40:647 654.;;Pesticides, Freia Jung, et al., Pestic.Sci., 1989, pp. 303 317.;;Enzyme Linked Immunosorbent Assay Compared with Gas Chromatography/Mass Spectrometry for the Determination of Triazine Herbicides in Water., E.M. Thurman, et al., Anal. Chem., 1990, 62, 2043 2048.;;Field Leaf Test Kit for Rapid Determination of Dislodgeable Foliar Residues of Organophosphate and N Methyl Carbamate Insecticides, T.C. Blewett, et al., Bull.Environ.Contam.Toxicol. (1990) 45:120 124.;;Immunochemical Techniques in Trade Residue Analysis, Chapter 1, Martin Vanderlaan, et al., American Chemical Society, pp. 1 13, 1991.;;Reliability of Commericial Enzyme Immunoassay in Detection of Atrazine in Water, Chapter 7, James R. Fleeker, et al., American Chemical Society, pp. 78 85, 1991.;;Immunoassay Methods, Jeanette M. Van Emon, Chapter 7, American Chem. Society, pp. 58 64, 1990.;;Development of an Enzyme Linked Immunosorbent Assay for the Analysis of the Thiocarbamate Herbicide Molinate, Shirley J. Gee, et al., J.Agric.Food Chem., 1988, 36, 863 870.;;A Radioimmunoassay for Chlorinated Dibenzo p Dioxins, Phillip W. Albro, et al., Toxicology and Applied Pharmacology, 50, 137 146, (1979).;;Development of a Sensitive Enzyme Linked Immunosorbent Assay for the Fungicide Fenpropimorph, F. Jung, et al., J.Agric.Food Chem. 1989, 37, 1183 1187.;;Development of a Monoclonal Antibody Based Enzyme Immunoassay Method for Analysis of Maleic Hydrazide, Robert O. Harrison, et al., J.Agric.Food Chem. 1989, 37, 958 964.;;History and Future Outlook of Enzyme Immunoassay, Eva Engvall, History of Future of EIA, pp. 1 3.;;Monoclonal Antibodies, Cesar Milstein, Cancer, vol. 49, No. 10, pp. 1953 1957, May 15, 1982.;;Chapter 1, Introduction and General Principles, William D. Odell, History of Competative Binding Assays, pp. 1 13.;;Scientific Shapping, Onsite Analytical Technology Uses Medical Technology to Detect Organic Content, Kimberly A. Roy, Hazmat World, Dec. 1991.;;Monoclonal Antibodies for Dioxin: Antibody Characterization and Assay Development, Stanker et al., Toxicology, 45 (1987) 229 243.;;Production and Characterization of Antisera Specific for Chlorinated Biphenyl Species: Initiation of a Readioimmunoassay for Aroclors, Michael I. Luster, Toxicology and Applied Pharmacology 50, 147 155 (1979).;;Enzyme Mediated Immunoassay: An Overview, T.T. Ngo, in Enzyme Mediated Immunoassay eds. Debtor et al., Plenum Press; New York, 3 (1985).;;Immunoassay Technology for On Site Testing, Kevin R. Carter, American Environmental Laboratory, Feb. 1992.;;Field Analysis Using Rapid Immunoassay Screens, Aisling Scallen, et al., Environmental Lab Magazine.;;Recent Developments in the Periodate Method of Conjugating Norseradism Peroxidase (HRPO) to Antibodies, M. Barbara Wilson, et al., Immunofluorescence and Related Staining Techniques, pp. 215 222, 1978.",EXPIRED
417,AU,B2,AU 709328 B2,073-926-935-959-696,1999-08-26,1999,AU 1995/017711 A,1995-04-28,US 23506994 A,1994-04-29,Method of administering azithromycin,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/073-926-935-959-696,Granted Patent,no,1,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,C07H17/00;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,1,1,068-577-638-931-060,1319048;;10.1002/j.1875-9114.1992.tb04504.x,PHARMACOTHERAPY 12(3) (1992) 161-173,EXPIRED
418,EC,A,EC SP951424 A,139-264-776-968-829,1996-02-28,1996,EC SP951424 A,1995-04-17,EC SP951424 A,1995-04-17,PROCEDIMIENTO PARA LA ADMINISTRACION DE AZITROMICINA,"Esta invención se refiere a una forma de dosificación de azitromicina y además a un procedimiento de tratamiento de una infección microbiana que implica la administración de azitromicina a un animal alimentado, incluyendo a un paciente humano en necesidad de dicho tratamiento.",,CURATOLO WILLIAM JHON;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/139-264-776-968-829,Patent Application,no,0,0,1,1,0,,C07H17/00,,0,0,,,,PENDING
419,UY,A1,UY 23935 A1,158-204-900-406-642,1995-09-12,1995,UY 23935 A,1995-03-15,US 23506994 A,1994-04-29,FORMAS DE DOSIFICACIÓN DE AZITROMICINA QUE NO PRESENTAN EFECTO ALIMENTO ADVERSO CON LA COMIDA,"Se describe una forma de dosificación en la forma de una tableta que comprende azitromicina, en donde dicha tableta es administrable a un mamífero que ha comido y la cual no exhibe efectos adversos a la comida, que incluye: azitromicina, un desintegrante y opcionalmente otros ingredientes, mezclados y granulado en húmedo, previo a la formación de la mencionada tableta, donde dicha tableta lleva adelante la disolución de por lo menos un 90% de la azitromicina en aproximadamente 30 minutos cuando una cantidad de tal forma de dosificación equivalente a 200 mg de azitromicina se ensaya conforme al Ensayo USO < 711 > en un aparato de disolución USP-2 bajo condiciones tan severas como las siguientes: - 900 ml de buffer de fosfato de sodio, - pH 6, - 37º C, - con paletas que giran a 100 rpm, considerando que dicha forma de dosificación contiene una cantidad de un óxido o hidróxido de metal alcalino-terreo menor que la suficienta para quedar enmascarada a gusto. La azitromicina es de utilidad para el tratamiento de infecciones microbianas.",PFIZER,WILLIAM J CURATOLO;;GEORGE H FOULDS;;HYLAR L FRIEDMAN,,https://lens.org/158-204-900-406-642,Patent Application,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61P31/00;;A61K9/00;;C07H17/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
420,US,B2,US 7101138 B2,149-955-013-981-334,2006-09-05,2006,US 72735303 A,2003-12-03,US 72735303 A,2003-12-03,Extractor/buffer,"An automated material handling system that includes an extractor/buffer apparatus capable of simultaneously accessing multiple Work-In-Process (WIP) parts, thereby providing a highly efficient interface between WIP storage locations and transport equipment. The extractor/buffer apparatus includes multiple extractor/buffer modules, each module being configured to interface with a location for holding WIP parts that is a number of WIP parts deep. Each module includes a platform for holding multiple WIP parts. Further, multiple modules may be disposed side-by-side to form an extractor/buffer apparatus capable of handling multiple rows of WIP parts.",BROOKS AUTOMATION INC,FOSNIGHT WILLIAM JOHN;;BUFANO MICHAEL;;FRIEDMAN GERALD;;SULLIVAN ROBERT,MURATA MACHINERY LTD (2010-02-02);;BROOKS AUTOMATION INC (2003-12-22),https://lens.org/149-955-013-981-334,Granted Patent,yes,54,41,4,4,0,H01L21/67706;;H01L21/6773;;H01L21/67769;;Y10S414/14;;H01L21/67706;;H01L21/6773;;H01L21/67769;;Y10S414/14,B65G65/02;;B65G1/00;;H01L/;;H01L21/677,414/222.11;;414/222.09;;414/278;;414/806;;414/940;;198/597,0,0,,,,ACTIVE
421,AU,B2,AU 780276 B2,174-926-518-432-676,2005-03-10,2005,AU 2001/081512 A,2001-10-19,US 24225100 P;;US 95300601 A,2000-10-20,Method for detecting transverse vibrations in an ultrasonic hand piece,,ETHICON ENDO SURGERY INC,WIENER EITAN T;;FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,,https://lens.org/174-926-518-432-676,Granted Patent,no,3,0,13,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/0003;;A61B2017/0003;;A61B2017/00119;;A61B2017/00119;;A61B2017/00137;;A61B2017/00137;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,,0,0,,,,EXPIRED
422,WO,A2,WO 2005/057614 A2,037-050-831-417-973,2005-06-23,2005,US 2004/0040055 W,2004-12-01,US 72735303 A,2003-12-03,EXTRACTOR/BUFFER,"An automated material handling system that includes an extractor/buffer apparatus (102) capable of simultaneously accessing multiple Work-In-Process (WIP) parts (116, 117, 124), thereby providing a highly efficient interface between WIP storage locations (103) and transport equipment (140). The extractor/buffer apparatus includes multiple extractor/buffer modules (104), each module being configured to interface with a location for holding WIP parts that is a number of WIP parts deep. Each module includes a platform (130) for holding multiple WIP parts. Further, multiple modules may be disposed side-by-side to form an extractor/buffer apparatus capable of handling multiple rows of WIP parts.",BROOKS AUTOMATION INC,FOSNIGHT WILLIAM JOHN;;BUFANO MICHAEL;;FRIEDMAN GERALD;;SULLIVAN ROBERT,,https://lens.org/037-050-831-417-973,Patent Application,yes,0,0,4,4,0,H01L21/67706;;H01L21/6773;;H01L21/67769;;Y10S414/14;;H01L21/67706;;H01L21/6773;;H01L21/67769;;Y10S414/14,B65G1/00;;H01L/;;H01L21/677,,0,0,,,,PENDING
423,US,E,US RE039149 E,100-020-579-471-980,2006-06-27,2006,US 4119405 A,2005-01-20,US 23506994 A;;US 4119405 A,1994-04-29,Method of administering azithromycin,"An oral dosage form of azithromycin which does not exhibit an adverse food effect; Specific azithromycin oral dosage forms including tablets, powders for oral suspensions and unit dose packets; Methods of treating microbial infections with the dosage forms; And therapeutic packages containing the dosage forms.",PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/100-020-579-471-980,Amended Patent,yes,15,2,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K31/70;;A61K9/00;;C07H17/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,514/29;;424/464;;424/465;;424/474;;424/480;;424/482;;514/960;;536/7.2;;536/7.4,13,8,018-453-661-557-056;;018-408-329-923-98X;;086-510-948-913-390;;068-577-638-931-060;;052-976-895-993-120;;100-134-512-479-975;;001-077-368-034-121;;031-370-248-311-295,3379590;;10.1002/jps.2600770408;;10.1002/jps.2600670608;;660450;;423080;;10.1002/jps.2600680208;;1319048;;10.1002/j.1875-9114.1992.tb04504.x;;10.1002/j.1552-4604.1992.tb03784.x;;1531484;;1656742;;10.1016/0002-9343(91)90401-i;;10.1146/annurev.pa.20.040180.001133;;6992698;;10.1023/a:1018970323716;;8456064,"CA Abstracts: vol. 120:38194a; (1994).;;Zithromax (Trademark of Pfizer, Inc.) Capsules Package Insert for azithromycin capsule dosage form sold commercially in U.S.;;Curatolo, et al., Perforated Coated Tablets for Controlled Release of Drugs at a Constant Rate, Journal of Pharmaceutical Sciences, vol. 77, No. 4, pp. 322-324, (1988).;;Welling, P. G., et. al., Bioavailability of Erythromycin Stearate: Influence of Food and Fluid Volume, Journal of Pharmaceutical Sciences, vol. 67, No. 6, pp. 764-766, (1978).;;Welling, P. G., et. al., Plasma Levels following Single and Repeated Doses of Erythromycin Estolate and Erythromycin Stearate, Journal of Pharmaceutical Sciences, vol. 68, No. 2, pp. 150-155, (1979).;;Malmborg, A., Absorption of erthromycin stearate after oral administration, Curr. Med. Res. Opin., vol. 5, (Suppl. 2)., pp. 15-18, (1978).;;Drew, R. H., et. al. Azithromycin-Spectrum of Activity, Pharmacokinetics, and Clinical Applications, Pharmacotheraphy, vol. 12, No. 3, pp. 161-173, (1992).;;Chu, S., et. al., Drug-Food Interaction Potential of Clarithromycin, a New Macrolide Antimicrobial, J. Clin. Pharmacol., vol. 32, pp. 32-36, (1992).;;Hopkins, S., Clinical Toleration and Safety of Azithromycin, The American Journal of Medicine, vol. 91 (Suppl. 3A), pp. 40S-45S, (1991).;;Toothaker, R. D., et al., The Effect of Food on Drug Bioavailability, Ann. Rev. Pharmacol, Toxicol., vol. 20, pp. 173-199, (1980).;;Russell, T. L., et al., Upper Gastrointestinal pH in Seventy-nine Healthy, Elderly North American Men and Women, Pharmaceutical Research, vol. 10, No. 2, pp. 187-196, (1993).;;Zithromax (Trademark of Pfizer Inc.) Tablet and Powder for Oral Suspension Package Insert for azithromycin tablets and powder for oral suspension dosage forms sold commercially in Italy (1992).;;Documents relating to the European Patent Office Opposition proceedings regarding EU Patent No. 0 679 400 (Opposition file).",PENDING
424,AU,A,AU 2001/081512 A,128-698-710-062-900,2002-05-02,2002,AU 2001/081512 A,2001-10-19,US 24225100 P;;US 95300601 A,2000-10-20,Method for detecting transverse vibrations in an ultrasonic hand piece,,ETHICON ENDO SURGERY INC,WIENER EITAN T;;FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T,,https://lens.org/128-698-710-062-900,Patent Application,no,0,0,13,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/0003;;A61B2017/0003;;A61B2017/00119;;A61B2017/00119;;A61B2017/00137;;A61B2017/00137;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,,0,0,,,,EXPIRED
425,US,B1,US 4876835 B1,114-590-728-164-558,1992-06-30,1992,US 3535187 A,1987-04-07,US 3535187 A;;US 64890084 A,1984-09-10,US 4876835 B1,,MILLER HERMAN INC,JAMES O KELLY;;WILLIAM E STUMPF;;FRANK A FRIEDMAN,HERMAN MILLER INC. ZEELAND OTTAWA MICHIGAN A CORP. OF MI (1987-04-03),https://lens.org/114-590-728-164-558,Granted Patent,no,0,0,3,25,0,A47B21/06;;A47B83/001;;A47B2037/005;;A47B2083/006;;A47B2200/01;;E04B2/7405;;E04B2/7425;;E04B2002/7483;;E04B2002/7488;;H02G3/288;;A47B21/06;;E04B2/7405;;A47B2037/005;;E04B2002/7483;;E04B2002/7488;;A47B2200/01;;A47B2083/006;;H02G3/288;;A47B83/001;;E04B2/7425,A47B17/00;;A47B21/00;;A47B83/00;;A47B87/00;;E04B2/74;;E04B2/82,,0,0,,,,EXPIRED
426,HU,A,HU T75244 A,156-045-890-908-105,1997-05-28,1997,HU 9501206 A,1995-04-27,US 23506994 A,1994-04-29,PHARMACEUTICAL COMPOSITION CONTAINING AZITHROMYCIN,,PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/156-045-890-908-105,Unknown,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;C07H17/00;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
427,JP,A,JP 2005015466 A,169-820-517-306-583,2005-01-20,2005,JP 2004128641 A,2004-04-23,US 23506994 A,1994-04-29,METHOD FOR ADMINISTERING AZITHROMYCIN,"<P>PROBLEM TO BE SOLVED: To provide a preparation capable of administering azithromycin to a patient just beginning to take a food. <P>SOLUTION: This oral administration preparation of the azithromycin capable of being administered to a mammal capable of taking the food is provided by containing the azithromycin, without showing an disadvantageous effect of the food substantially, and achieving approximately 90 % dissolution of the azithromycin within 30 min in a USP-2 dissolution testing device under a strict condition similar to the below: a preparation corresponding to 250 mg azithromycin is tested in a phosphate buffer of 900 ml of pH6.0 at 37°C with a paddle rotating by 100 rpm, as indicated in the USP test <711>. Provided that, the preparation is not a capsule preparation, but the oral preparation characterized by containing an alkaline earth metal oxide or hydroxide in an amount less than a taste-blocking amount and not exhibiting the bad effect of the food. <P>COPYRIGHT: (C)2005,JPO&NCIPI",PFIZER,CURATOLO WILLIAM J;;FOULDS GEORGE H;;FRIEDMAN HYLAR L,,https://lens.org/169-820-517-306-583,Patent Application,no,0,0,49,52,0,A61K9/0095;;A61K31/70;;A61P31/00;;A61P31/04;;A61K31/7052;;A61K9/20;;A61K9/14;;A61K9/08;;A61K31/70;;A61K9/0095,A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/70;;A61K31/7042;;A61K31/7048;;C07H17/00;;A61K31/7052;;A61K47/02;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,PENDING
428,US,B1,US 9882879 B1,003-232-633-292-501,2018-01-30,2018,US 201313928643 A,2013-06-27,US 201313928643 A,2013-06-27,Using steganography to protect cryptographic information on a mobile device,"Methods, apparatus and articles of manufacture for using steganography to protect cryptographic information on a mobile device are provided herein. A method includes querying a user to select one or more items of data stored on a computing device to be used in connection with one or more cryptographic actions associated with said computing device, and protecting one or more items of cryptographic information within the one or more selected items of data.",EMC IP HOLDING CO LLC,DOTAN YEDIDYA;;FRIEDMAN LAWRENCE N;;DUANE WILLIAM M;;BRAINARD JOHN,EMC CORPORATION (2013-07-24);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/003-232-633-292-501,Granted Patent,yes,5,2,1,1,0,H04L63/083;;H04L63/0428;;H04W12/06;;H04W12/033;;H04L63/0428;;G06T1/00;;H04L63/083;;H04W12/06;;H04W12/033,H04L29/06,,0,0,,,,ACTIVE
429,AT,T1,AT E527690 T1,063-958-483-581-760,2011-10-15,2011,AT 05789226 T,2005-08-23,US 60409904 P;;US 21091805 A;;US 2005/0029840 W,2004-08-23,WERKZEUGLADE- UND PUFFERUNGSSYSTEM AUF LIFTBASIS,"A substrate processing apparatus is provided. The apparatus has a casing, a low port interface and a carrier holding station. The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding station is adapted for holding at least one substrate transport carrier so the at least one substrate transport carrier is capable of being coupled to the load port interface without lifting the at least one substrate transport carrier off the carrier holding station. The carrier holding station is arranged to provide a substantially simultaneous swap section for substantially simultaneous replacement of the substrate transport carrier from the carrier holding station.",MURATA MACHINERY LTD,ULYSSES GILCHRIST;;BUFANO MICHAEL;;WILLIAM FOSNIGHT;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD,,https://lens.org/063-958-483-581-760,Granted Patent,no,0,0,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,,,0,0,,,,INACTIVE
430,US,A1,US 2015/0105762 A1,149-024-468-164-028,2015-04-16,2015,US 201414576422 A,2014-12-19,US 201414576422 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,METHOD FOR PATTERNED PLASMA-MEDIATED MODIFICATION OF THE CRYSTALLINE LENS,"A method of treating a cataractous lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern, delivering the treatment pattern to the lens of the patient's eye to create a plurality of cuts in the form two or more different incisions patterns within the lens to segment the lens tissue into a plurality of patterned pieces, and mechanically breaking the lens into a plurality of pieces along the cuts. A first incision pattern includes two or more crossing cut incision planes. A second incision pattern includes a plurality of laser incision each extending along a first length between a posterior and an anterior surface of the lens capsule.",OPTIMEDICA CORP,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/149-024-468-164-028,Patent Application,yes,6,0,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F9/008,606/6,0,0,,,,ACTIVE
431,US,B2,US 8968375 B2,079-768-737-441-180,2015-03-03,2015,US 70224210 A,2010-02-08,US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,Method for patterned plasma-mediated modification of the crystalline lens,"A method of treating a lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern of the light beam, delivering the treatment pattern to the lens of a patient's eye to create a plurality of cuts in the lens in the form of the treatment pattern to break the lens up into a plurality of pieces, and removing the lens pieces from the patient's eye. The lens pieces can then be mechanically removed. The light beam can be used to create larger segmenting cuts into the lens, as well as smaller softening cuts that soften the lens for easier removal.",CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP;;OPTIMEDICA CORP,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/079-768-737-441-180,Granted Patent,yes,102,23,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61N5/06;;A61F2/16;;A61F9/008;;A61F9/009,607/88;;607/89;;607/92,16,5,097-583-099-978-486;;026-530-457-942-21X;;078-796-045-460-497;;000-548-666-851-615;;054-672-478-733-301,2299571;;10.1016/s0886-3350(13)80870-x;;2005552;;10.1016/s0886-3350(13)81001-2;;9713056;;10.1136/bjo.82.5.504;;pmc1722590;;15342071;;10.1016/j.jcrs.2004.05.018;;7993214;;10.1001/archopht.1994.01090240090031,"Abstract of AU Publication No. 2007292491, Publication date Mar. 13, 2008, which is the AU counterpart of the WO 08/030718 A2 application.;;U.S. Appl. No. 12/510,128, filed Jul. 27, 2009, Blumenkranz et al.;;U.S. Appl. No. 12/048,186, filed Mar. 13, 2008, Culbertson et al.;;U.S. Appl. No. 12/048,182, filed Mar. 13, 2008, Culbertson et al.;;Gimbel. ""Principles of Nuclear Phaco Emulsification"", In Cataract Surgery Techniques Complications and Management, 2nd ed., Edited by Steinert et al., 2004, Ch. 15, pp. 153-181.;;Steinert & Richter. ""Neodymium:Yttrium-Aluminum-Garnet Laser Posterior Capsulotomy"", In Cataract Surgery Techniques Complications and Management, 2nd ed., Edited by Steinert et al., 2004, Ch. 44, pp. 531-544.;;Gimbel & Neuhann, ""Development Advantages and Methods of the Continuous Circular Capsulorhexis Technique"", Journal of Cataract and Refractive Surgery, 1990: 16:31-37.;;Gimbel & Neuhann, ""Continuous Curvilinear Capsulorhexis"", Journal of Cataract and Refractive Surgery, 1991: 17:110-111.;;Geerling, Gerd, et al., Initial Clinical Experience With the Picosecond Nd:YLF Laser for Intraocular Therapeutic Applications, Br F Ophthalmol, 1998, 82:504-509.;;U.S. Appl. No. 12/703,687, filed Feb. 10, 2010, Culbertson.;;U.S. Appl. No. 12/703,689, filed Feb. 10, 2010, Culbertson.;;U.S. Appl. No. 12/510,148, filed Jul. 2009, Blumenkranz et al.;;Georges Baikoff, MD; Eric Lutun, Jay Wei, Caroline Ferraz, MD; ""Contact Between 3 Phakic Intraocular Lens Models and the Crystalline Lens: An Anterior Chamber Optical Coherence Tomography Study""; J Cataract Refract Surg 2004; 30:2007-2012.;;Joseph A. Izatt, PhD; Michael R. Hee, MS; Eric A. Swanson, MS; Charles P. Lin, PhD. et al.; ""Micrometer-Scale Resolution Imaging of the anterior Eye In Vivo With Optical Coherence Tomography"" Arch Ophthalmol. 1994; 112:1584-1589.;;Supplementary European Search Report for Application No. EP08726822, mailed on Apr. 9, 2010, 6 pages.;;Supplementary European Search Report for Application No. EP08726825, mailed on Apr. 30, 2010, 8 pages.",ACTIVE
432,CA,A,CA 1137522 A,102-544-302-818-312,1982-12-14,1982,CA 363242 A,1980-10-24,US 9342379 A,1979-11-13,METHOD OF PRODUCING OLEFINS FROM HYDROCARBONS,"78R24 METHOD OF PRODUCING OLEFINS FROM HYDROCARBONS A method of producing high yields of olefins from hydrocarbon feedstocks which is particularly applicable to heavy hydrocarbons. In accordance with the present method, a stream of gaseous oxygen is introduced into a first reaction zone and a cocurrent flow of hydrogen is introduced about the periphery of the gaseous oxygen stream, the hydrogen being introduced at a temperature at which it will spontaneously react with the oxygen. The hydrogen and oxygen are introduced in amounts to provide a gas stream of reaction products having an average temperature within the range of from about 1000.degree. to 2000.degree.C and which comprises a major amount of hydrogen and a minor amount of water vapor. The gas stream so produced is introduced into a second reaction zone and impinged upon a stream of a hydrocarbon which is heated to a temperature in excess of its melting point but below the temperature at which any substantial coke or tar forms. The gas stream is introduced at a high velocity and in an amount to provide a flowing reaction mixture having a temperature within the range of from 800.degree. to 1800.degree.C. The flowing mixture is maintained at that temperature for a time of from about 1 to 10 milliseconds to form olefins. Thereafter, the flowing mixture is rapidly quenched to arrest the reaction and the olefin products are recovered.",ROCKWELL INTERNATIONAL CORP,FRIEDMAN JOSEPH;;HINES WILLIAM S;;RANIERE FREDERICK D;;SILVERMAN JACOB,,https://lens.org/102-544-302-818-312,Granted Patent,no,0,0,20,20,0,B01J12/005;;B01J19/26;;B01J2219/00119;;B01J2219/00121;;B01J2219/00159;;B01J2219/00164;;C10G2400/20;;B01J19/26;;B01J2219/00121;;B01J2219/00159;;B01J2219/00119;;B01J2219/00164;;B01J12/005;;C10G2400/20,C10G47/00;;B01J12/00;;B01J19/26;;C07C1/00;;C07C4/04;;C07C11/02;;C07C67/00;;C10G9/36;;C10G47/22,260-708.7,0,0,,,,EXPIRED
433,US,B2,US 9402715 B2,157-932-677-906-327,2016-08-02,2016,US 86179810 A,2010-08-23,US 86179810 A;;US 4818508 A;;US 90694407 P,2007-03-13,Method for patterned plasma-mediated modification of the crystalline lens,"A method of treating a lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern of the light beam, delivering the treatment pattern to the lens of a patient's eye to create a plurality of cuts in the lens in the form of the treatment pattern to break the lens up into a plurality of pieces, and removing the lens pieces from the patient's eye. The lens pieces can then be mechanically removed. The light beam can be used to create larger segmenting cuts into the lens, as well as smaller softening cuts that soften the lens for easier removal.",CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILIP;;OPTIMEDICA CORP,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/157-932-677-906-327,Granted Patent,yes,101,0,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61B18/20;;A61B3/10;;A61F2/16;;A61F9/007;;A61F9/008;;A61F9/009,,16,5,000-548-666-851-615;;054-672-478-733-301;;097-583-099-978-486;;026-530-457-942-21X;;078-796-045-460-497,15342071;;10.1016/j.jcrs.2004.05.018;;7993214;;10.1001/archopht.1994.01090240090031;;2299571;;10.1016/s0886-3350(13)80870-x;;2005552;;10.1016/s0886-3350(13)81001-2;;9713056;;10.1136/bjo.82.5.504;;pmc1722590,"Supplementary European Search Report from European Patent Office for EP application No. EP08726822, Applicant Optimedica Corporation, Forms 1503, P0459, and 1703, dated Apr. 9, 2010 (5 pages).;;Supplementary European Search Report from European Patent Office for EP application No. EP08726825, Applicant Optimedica Corporation, Forms 1503, P0459, and 1703, dated Apr. 30, 2010 (7 pages).;;Abstract of AU Publication No. 2007292491, Publication date Mar. 13, 2008, which is the AU counterpart of WO 2008030718 A2 application.;;Georges Baikoff, MD, et al., ""Contact Between 3 Phakic Intraocular Lens Models and the Crystalline lens: An Anterior Chamber Optical Coherence Tomography Study"", Journal of Cataract and Refractive Surgery, Sep. 2004; 30 (9):2007-2012. (6 pages).;;Joseph A. Izatt, PhD, et al., ""Micrometer-Scale Resolution Imaging of the Anterior Eye in Vivo with Optical Coherence Tomography"", Arch Ophthalmol, Dec. 1994; 112(12):1584-1589. (6 pages).;;Gimbel. ""Principles of Nuclear Phaco Emulsification"", In Cataract Surgery Techniques Complications and Management, 2nd ed., Edited by Steinert et al., 2004, Ch. 15, pp. 153-181.;;Steinert & Richter. ""Neodymium: Yttrium-Aluminum-Garnet Laser Posterior Capsulotomy"", In Cataract Surgery Techniques Complications and Management, 2nd ed., Edited by Steinert et al., 2004, Ch. 44, pp. 531-544.;;Gimbel & Neuhann, ""Development Advantages and Methods of the Continuous Circular Capsulorhexis Technique"", Journal of Cataract and Refractive Surgery, 1990: 16:31-37.;;Gimbel & Neuhann, ""Continuous Curvilinear Capsulorhexis"", Journal of Cataract and Refractive Surgery, 1991: 17:110-111.;;Geerling, Gerd, et al., Initial Clinical Experience With the Picosecond Nd:YLF Laser for Intraocular Therapeutic Application, Br F Ophthalmol, 1998, 82:540-509.;;Co-pending U.S. Appl. No. 12/048,182, filed Mar. 13, 2008.;;Co-pending U.S. Appl. No. 12/048,186, filed Mar. 13, 2008.;;Co-pending U.S. Appl. No. 12/510,128, filed Jul. 27, 2009.;;Co-pending U.S. Appl. No. 12/510,148, filed Jul. 27, 2009.;;Co-pending U.S. Appl. No. 12/703,687, filed Feb. 10, 2010.;;Co-pending U.S. Appl. No. 12/703,689, filed Feb. 10, 2010.",ACTIVE
434,US,S,US D0568455 S,091-621-595-740-668,2008-05-06,2008,US 28238507 F,2007-07-18,US 28238507 F,2007-07-18,Device for dispensing volatile liquids,,FRIEDMAN PAMELA;;BROWN COLIN WILLIAM;;GOHIL KISHEN;;NAISH GUY EDWARD,FRIEDMAN PAMELA;;BROWN COLIN WILLIAM;;GOHIL KISHEN;;NAISH GUY EDWARD,GIVAUDAN SUISSE S.A (2008-03-27);;FRIEDMAN PAMELA (2008-03-28),https://lens.org/091-621-595-740-668,Design Right,no,0,0,1,1,0,,,2899;;D23/366,0,0,,,,EXPIRED
435,US,A1,US 2020/0360130 A1,173-070-290-642-260,2020-11-19,2020,US 202016944144 A,2020-07-30,US 202016944144 A;;US 201715726296 A;;US 201414576422 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,METHOD FOR PATTERNED PLASMA-MEDIATED MODIFICATION OF THE CRYSTALLINE LENS,"A method of treating a lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern of the light beam, delivering the treatment pattern to the lens of a patient's eye to create a plurality of cuts in the lens in the form of the treatment pattern to break the lens up into a plurality of pieces, and removing the lens pieces from the patient's eye. The lens pieces can then be mechanically removed. The light beam can be used to create larger segmenting cuts into the lens, as well as smaller softening cuts that soften the lens for easier removal.",AMO DEV LLC,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/173-070-290-642-260,Patent Application,yes,0,0,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F2/16,,0,0,,,,ACTIVE
436,US,B2,US 9782253 B2,140-235-645-474-741,2017-10-10,2017,US 201414576422 A,2014-12-19,US 201414576422 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,Method for patterned plasma-mediated modification of the crystalline lens,"A method of treating a cataractous lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern, delivering the treatment pattern to the lens of the patient's eye to create a plurality of cuts in the form two or more different incisions patterns within the lens to segment the lens tissue into a plurality of patterned pieces, and mechanically breaking the lens into a plurality of pieces along the cuts. A first incision pattern includes two or more crossing cut incision planes. A second incision pattern includes a plurality of laser incision each extending along a first length between a posterior and an anterior surface of the lens capsule.",OPTIMEDICA CORP,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/140-235-645-474-741,Granted Patent,yes,113,7,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F2/16;;A61F9/008,,10,5,000-548-666-851-615;;078-796-045-460-497;;026-530-457-942-21X;;097-583-099-978-486;;054-672-478-733-301,15342071;;10.1016/j.jcrs.2004.05.018;;9713056;;10.1136/bjo.82.5.504;;pmc1722590;;2005552;;10.1016/s0886-3350(13)81001-2;;2299571;;10.1016/s0886-3350(13)80870-x;;7993214;;10.1001/archopht.1994.01090240090031,"Abstract of AU Publication No. 2007292491, Publication Date Mar. 13, 2008, which is the AU counterpart of the WO08030718 A2 application.;;Baikoff G., et al., “Contact Between 3 Phakic Intraocular Lens Models and the Crystalline Lens: An Anterior Chamber Optical Coherence Tomography Study,” Journal of Cataract and Refractive Surgery, 2004, vol. 30 (9), pp. 2007-2012.;;Geerling G., et al., “Initial Clinical Experience with the Picosecond Nd:YLF Laser for Intraocular Therapeutic Applications,” British Journal of Ophthalmology, 1998, vol. 82 (5), pp. 504-509.;;Gimbel H.V., et al., “Continuous Curvilinear Capsulorhexis,” Journal of Cataract and Refractive Surgery, 1991, vol. 17 (1), pp. 110-111.;;Gimbel H.V., et al., “Development, Advantages and Methods of the Continuous Circular Capsulorhexis Technique,” Journal of Cataract and Refractive Surgery, 1990, vol. 16 (1), pp. 31-37.;;Gimbel H.V., et al., “Principles of Nuclear Phaco Emulsification” In: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., 2004, Chap. 15, pp. 153-181.;;Izatt J.A., et al., “Micrometer-Scale Resolution Imaging of the Anterior Eye In Vivo With Optical Coherence Tomography,” Arch Ophthalmology, 1994, vol. 112 (12), pp. 1584-1589.;;Steinert et al., “Neodymium: Yttrium-Aluminum-Garnet Laser Posterior Capsulotomy,” in: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., 2004, Chapter. 44, pp. 531-544.;;Supplementary European Search Report for Application No. EP08726822, mailed on Apr. 9, 2010, 6 pages.;;Supplementary European Search Report for Application No. EP08726825, mailed on Apr. 30, 2010, 8 pages.",ACTIVE
437,US,A1,US 2011/0184395 A1,011-600-703-894-37X,2011-07-28,2011,US 97836710 A,2010-12-23,US 97836710 A;;US 28983709 P,2009-12-23,METHOD FOR LASER CAPSULOTOMY AND LENS CONDITIONING,"A method of creating a capsulotomy and conditioning the crystalline lens is disclosed, wherein a laser is employed that provides improved performance by treating the capsule predominantly prior to treating the lens.",OPTIMEDICA CORP,SCHUELE GEORG;;FRIEDMAN NEIL;;CULBERTSON WILLIAM;;SIEBEL BARRY;;ANDERSEN DAN,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2011-03-16),https://lens.org/011-600-703-894-37X,Patent Application,yes,11,50,1,1,0,A61F9/008;;A61F2009/0087;;A61F2009/00889;;A61F9/008;;A61F2009/0087;;A61F2009/00889,A61B18/20,606/5,0,0,,,,DISCONTINUED
438,US,B2,US 11839536 B2,088-697-051-330-209,2023-12-12,2023,US 202016866362 A,2020-05-04,US 202016866362 A;;US 201715726289 A;;US 201414576422 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,Method for patterned plasma-mediated modification of the crystalline lens,"A method of treating a cataractous lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern, delivering the treatment pattern to the lens of the patient's eye to create a plurality of cuts in the form two or more different incisions patterns within the lens to segment the lens tissue into a plurality of patterned pieces, and mechanically breaking the lens into a plurality of pieces along the cuts. A first incision pattern includes two or more crossing cut incision planes. A second incision pattern includes a plurality of laser incision each extending along a first length between a posterior and an anterior surface of the lens capsule.",AMO DEV LLC,CULBERTSON WILLIAM;;SIEBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/088-697-051-330-209,Granted Patent,yes,124,0,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F9/007;;A61F2/16;;A61F9/00;;A61F9/008;;A61F9/009,,8,5,000-548-666-851-615;;078-796-045-460-497;;026-530-457-942-21X;;097-583-099-978-486;;054-672-478-733-301,15342071;;10.1016/j.jcrs.2004.05.018;;9713056;;10.1136/bjo.82.5.504;;pmc1722590;;2005552;;10.1016/s0886-3350(13)81001-2;;2299571;;10.1016/s0886-3350(13)80870-x;;7993214;;10.1001/archopht.1994.01090240090031,"Abstract of AU Publication No. 2007292491, Publication Date Mar. 13, 2008, which is the AU counterpart of the WO08030718 A2 application.;;Baikoff G., et al., “Contact Between 3 Phakic Intraocular Lens Models and the Crystalline Lens: An Anterior Chamber Optical Coherence Tomography Study,” Journal of Cataract and Refractive Surgery, Sep. 2004, vol. 30 (9), pp. 2007-2012.;;Geerling G., et al., “Initial Clinical Experience with the Picosecond Nd:YLF Laser for Intraocular Therapeutic Applications,” British Journal of Ophthalmology, May 1998, vol. 82 (5), pp. 504-509.;;Gimbel H.V., et al., “Continuous Curvilinear Capsulorhexis,” Journal of Cataract and Refractive Surgery, Jan. 1991, vol. 17 (1), pp. 110-111.;;Gimbel H.V., et al., “Development, Advantages and Methods of the Continuous Circular Capsulorhexis Technique,” Journal of Cataract and Refractive Surgery, Jan. 1990, vol. 16 (1), pp. 31-37.;;Gimbel H.V., et al., “Principles of Nuclear Phaco Emulsification” In: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., Oct. 2003, Chap. 15, pp. 153-181.;;Izatt J.A., et al., “Micrometer-Scale Resolution Imaging Of The Anterior Eye In Vivo With Optical Coherence Tomography,” Arch Ophthalmology, Dec. 1994, vol. 112 (12), pp. 1584-1589.;;Steinert et al., “Neodymium: Yttrium-Aluminum-Garnet Laser Posterior Capsulotomy,” in: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., Oct. 2003, Chapter. 44, pp. 531-544.",ACTIVE
439,US,S,US D0600133 S,101-700-129-461-57X,2009-09-15,2009,US 28011907 F,2007-05-17,US 28011907 F,2007-05-17,Bottle,,FRIEDMAN PAMELA;;BROWN COLIN WILLIAM;;GOHIL KISHEN;;NAISH GUY EDWARD,FRIEDMAN PAMELA;;BROWN COLIN WILLIAM;;GOHIL KISHEN;;NAISH GUY EDWARD,GIVAUDAN SUISSE S.A (2007-06-05);;FRIEDMAN PAMELA (2007-06-12),https://lens.org/101-700-129-461-57X,Design Right,no,0,9,1,1,0,,,0901;;D 9560;;D9/694;;D9/687,0,0,,,,EXPIRED
440,WO,A1,WO 2011/097647 A1,069-814-172-679-475,2011-08-11,2011,US 2011/0024107 W,2011-02-08,US 30243710 P,2010-02-08,SYSTEM FOR PLASMA-MEDIATED MODIFICATION OF TISSUE,"A system comprises a first laser source configured to deliver a first laser beam in a pulsed form at a first pulse energy; a second laser source configured to deliver a second laser beam in a pulsed form at a second pulse energy greater than the first pulse energy; an scanning optical system, configured to: receive the first and second laser beams; and adjust a first focus position of the first laser beam, and a second focus position of the second laser beam, in up to three dimensions to direct the first and second laser beams onto one or more targeted tissue structure portions of the eye of the patient; a controller operatively coupled to the scanning optical system and configured to cause the scanning optical system to adjust the first and second focus positions to controllably photodisrupt a tissue structure portion.",OPTIMEDICA CORP;;FRIEDMAN NEIL;;SEIBEL BARRY;;CULBERTSON WILLIAM;;SCHUELE GEORG;;ANDERSEN DAN,FRIEDMAN NEIL;;SEIBEL BARRY;;CULBERTSON WILLIAM;;SCHUELE GEORG;;ANDERSEN DAN,,https://lens.org/069-814-172-679-475,Patent Application,yes,12,0,7,7,0,A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00825,A61F9/08,,1,1,119-411-786-501-407,8206720,"VOGEL A; CAPON M R; ASIYO-VOGEL M N; BIRNGRUBER R: ""Intraocular photodisruption with picosecond and nanosecond laser pulses: tissue effects in cornea, lens, and retina."", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 35, no. 7, 1 June 1994 (1994-06-01) - 1 June 1994 (1994-06-01), pages 3032 - 3034, XP002631733",PENDING
441,US,A,US 4463874 A,132-379-166-570-683,1984-08-07,1984,US 37930582 A,1982-05-18,US 37930582 A,1982-05-18,Vending machine having card moving fingers,"A dispenser for a stack of horizontally disposed, rectangular cards or the like and a product vending machine incorporating the dispenser. The dispenser features a magazine for the stack of cards and a dispensing chute beneath the magazine. Between the magazine and the chute, on one lateral side thereof, is a slider with a pair of laterally extending front and rear fingers that can be moved frontally and rearwardly against the front and rear edges, repectively, of the bottommost card of the stack. When the dispenser is actuated, the slider moves rearwardly so that its front finger urges the bottommost card to move rearwardly to an intermediate position in which the rear portions of the card are restrained from moving downwardly while the front portions of the card are free to move downwardly into the dispensing chute. Then, the slider moves frontally so that its rear finger urges the bottommost card from the intermediate position frontally so that the rear portions of the card no longer restrain the card from moving downwardly into the dispensing chute.",EB METAL IND INC,FRIEDMAN EVELYN;;BORHO MARTIN A;;CARSWELL WILLIAM R;;KECSETI FRANK,E B METAL INDUSTRIES INC. A CORP OF N Y (1982-05-17),https://lens.org/132-379-166-570-683,Granted Patent,yes,15,10,1,1,0,G07F11/04;;G07F11/72;;G07F11/04;;G07F11/72,G07F11/04;;G07F11/72,221/238;;271/135;;271/137,0,0,,,,EXPIRED
442,US,B2,US 9968439 B2,149-203-663-364-694,2018-05-15,2018,US 201414576467 A,2014-12-19,US 201414576467 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,Method for patterned plasma-mediated modification of the crystalline lens,"A system for treating a cataractous lens of a patient's eye includes a laser source for generating a light beam, a scanning system for deflecting the light beam to form a treatment pattern of the light beam, and a controller operably coupled to the laser source and scanning system and configured to operate the scanner to form the treatment pattern. The treatment pattern is a plurality of cuts in the form two or more different incision patterns for segmenting the lens tissue into a plurality of patterned pieces. The incision pattern includes: a first incision pattern including two or more crossing cut incision planes; and a second incision pattern comprising one or more laser incision each extending along a first length between a posterior and an anterior surface of the lens capsule.",OPTIMEDICA CORP,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/149-203-663-364-694,Granted Patent,yes,113,4,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61B18/20;;A61F2/16;;A61F9/00;;A61F9/008,,10,5,000-548-666-851-615;;078-796-045-460-497;;026-530-457-942-21X;;097-583-099-978-486;;054-672-478-733-301,15342071;;10.1016/j.jcrs.2004.05.018;;9713056;;10.1136/bjo.82.5.504;;pmc1722590;;2005552;;10.1016/s0886-3350(13)81001-2;;2299571;;10.1016/s0886-3350(13)80870-x;;7993214;;10.1001/archopht.1994.01090240090031,"Abstract of AU Publication No. 2007292491, Publication Date Mar. 13, 2008, which is the AU counterpart of the WO08030718 A2 application.;;Baikoff G., et al., “Contact Between 3 Phakic Intraocular Lens Models and the Crystalline Lens: An Anterior Chamber Optical Coherence Tomography Study,” Journal of Cataract and Refractive Surgery, 2004, vol. 30 (9), pp. 2007-2012.;;Geerling G., et al., “Initial Clinical Experience with the Picosecond Nd:YLF Laser for Intraocular Therapeutic Applications,” British Journal of Ophthalmology, 1998, vol. 82 (5), pp. 504-509.;;Gimbel H.V., et al., “Continuous Curvilinear Capsulorhexis,” Journal of Cataract and Refractive Surgery, 1991, vol. 17 (1), pp. 110-111.;;Gimbel H.V., et al., “Development, Advantages and Methods of the Continuous Circular Capsulorhexis Technique,” Journal of Cataract and Refractive Surgery, 1990, vol. 16 (1), pp. 31-37.;;Gimbel H.V., et al., “Principles of Nuclear Phaco Emulsification” In: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., 2004, Chap. 15, pp. 153-181.;;Izatt J.A., et al., “Micrometer-Scale Resolution Imaging of the Anterior Eye In Vivo With Optical Coherence Tomography,” Arch Ophthalmology, 1994, vol. 112 (12), pp. 1584-1589.;;Steinert et al., “Neodymium: Yttrium-Aluminum-Garnet Laser Posterior Capsulotomy,” in: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., 2004, Chapter. 44, pp. 531-544.;;Supplementary European Search Report for Application No. EP08726822, dated Apr. 9, 2010, 6 pages.;;Supplementary European Search Report for Application No. EP08726825, dated Apr. 30, 2010, 8 pages.",ACTIVE
443,US,B2,US 10729538 B2,175-406-119-068-755,2020-08-04,2020,US 201715726296 A,2017-10-05,US 201715726296 A;;US 201414576422 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,Method for patterned plasma-mediated modification of the crystalline lens,"A method of treating a lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern of the light beam, delivering the treatment pattern to the lens of a patient's eye to create a plurality of cuts in the lens in the form of the treatment pattern to break the lens up into a plurality of pieces, and removing the lens pieces from the patient's eye. The lens pieces can then be mechanically removed. The light beam can be used to create larger segmenting cuts into the lens, as well as smaller softening cuts that soften the lens for easier removal.",AMO DEV LLC,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/175-406-119-068-755,Granted Patent,yes,119,2,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F9/008;;A61F2/16;;A61F9/00;;A61F9/007;;A61F9/009,,10,5,000-548-666-851-615;;078-796-045-460-497;;026-530-457-942-21X;;097-583-099-978-486;;054-672-478-733-301,15342071;;10.1016/j.jcrs.2004.05.018;;9713056;;10.1136/bjo.82.5.504;;pmc1722590;;2005552;;10.1016/s0886-3350(13)81001-2;;2299571;;10.1016/s0886-3350(13)80870-x;;7993214;;10.1001/archopht.1994.01090240090031,"Abstract of AU Publication No. 2007292491, Publication Date Mar. 13, 2008, which is the AU counterpart of the WO08030718 A2 application.;;Baikoff G., et al., “Contact Between 3 Phakic Intraocular Lens Models and the Crystalline Lens: An Anterior Chamber Optical Coherence Tomography Study,” Journal of Cataract and Refractive Surgery, 2004, vol. 30 (9), pp. 2007-2012.;;Geerling G., et al., “Initial Clinical Experience with the Picosecond Nd:YLF Laser for Intraocular Therapeutic Applications,” British Journal of Ophthalmology, 1998, vol. 82 (5), pp. 504-509.;;Gimbel H.V., et al., “Continuous Curvilinear Capsulorhexis,” Journal of Cataract and Refractive Surgery, 1991, vol. 17 (1), pp. 110-111.;;Gimbel H.V., et al., “Development, Advantages and Methods of the Continuous Circular Capsulorhexis Technique,” Journal of Cataract and Refractive Surgery, 1990, vol. 16 (1), pp. 31-37.;;Gimbel H.V., et al., “Principles of Nuclear Phaco Emulsification” In: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., 2004, Chap. 15, pp. 153-181.;;Izatt J.A., et al., “Micrometer-Scale Resolution Imaging of the Anterior Eye in Vivo With Optical Coherence Tomography,” Arch Ophthalmology, 1994, vol. 112 (12), pp. 1584-1589.;;Steinert et al., “Neodymium: Yttrium-Aluminum-Garnet Laser Posterior Capsulotomy,” in: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., 2004, Chapter. 44, pp. 531-544.;;Supplementary European Search Report for Application No. EP08726822, dated Apr. 26, 2010, 6 pages.;;Supplementary European Search Report for Application No. EP08726825, dated Apr. 30, 2010, 8 pages.",ACTIVE
444,MX,A,MX 155701 A,178-584-972-617-556,1988-04-14,1988,MX 18465580 A,1980-11-07,US 9342379 A,1979-11-13,MEJORAS EN METODO PARA PRODUCIR ALTOS RENDIMIENTOS DE OLEFINAS A PARTIR DE UNA ALIMENTACION DE HIDROCARBUROS,,ROCKWELL INTERNATIONAL CORP,FRIEDMAN JOSEPH;;HINES WILLIAM STEPHEN;;RANIERE FREDERICK DEAN;;SILVERMAN JACOB,,https://lens.org/178-584-972-617-556,Granted Patent,no,0,0,20,20,0,B01J12/005;;B01J19/26;;B01J2219/00119;;B01J2219/00121;;B01J2219/00159;;B01J2219/00164;;C10G2400/20;;B01J19/26;;B01J2219/00121;;B01J2219/00159;;B01J2219/00119;;B01J2219/00164;;B01J12/005;;C10G2400/20,B01J12/00;;C10G47/00;;B01J19/26;;C07C1/00;;C07C4/04;;C07C11/02;;C07C67/00;;C10G9/36;;C10G47/22,09-3,0,0,,,,EXPIRED
445,US,A1,US 2017/0266048 A1,158-303-022-238-166,2017-09-21,2017,US 201715612920 A,2017-06-02,US 201715612920 A;;US 201514701458 A;;US 201113023483 A;;US 30243710 P,2010-02-08,SYSTEM AND METHOD FOR PLASMA-MEDIATED MODIFICATION OF TISSUE,"A method for cataract surgery on an eye of a patient includes scanning a first focus position of a first pulsed laser beam at a first pulse energy in a first scanning pattern to photodisrupt a tissue structure of a lens with a plurality of pulses of the first laser beam to form one or more cuts within the lens, the cuts being short of reaching a side edge of the lens and being configured to divide the lens into two or more segments which are attached to each other in regions adjacent the side edge of the lens; and afterwards, completely separating the two or more segments of the lens from each other by scanning a second focus position of a second pulsed laser beam having a second pulse energy higher than the first pulse energy in a second scanning pattern that is co-registered to the first scanning pattern.",OPTIMEDICA CORP,FRIEDMAN NEIL;;SEIBEL BARRY;;CULBERTSON WILLIAM;;SCHUELE GEORG;;ANDERSEN DAN,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2011-04-21),https://lens.org/158-303-022-238-166,Patent Application,yes,6,3,7,7,0,A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00825,A61F9/008,,0,0,,,,ACTIVE
446,US,A1,US 2011/0184392 A1,166-455-194-243-634,2011-07-28,2011,US 86179810 A,2010-08-23,US 86179810 A;;US 4818508 A;;US 90694407 P,2007-03-13,METHOD FOR PATTERNED PLASMA-MEDIATED MODIFICATION OF THE CRYSTALLINE LENS,"A method of treating a lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern of the light beam, delivering the treatment pattern to the lens of a patient's eye to create a plurality of cuts in the lens in the form of the treatment pattern to break the lens up into a plurality of pieces, and removing the lens pieces from the patient's eye. The lens pieces can then be mechanically removed. The light beam can be used to create larger segmenting cuts into the lens, as well as smaller softening cuts that soften the lens for easier removal.",CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHULE GEORG;;GOODING PHILIP,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHULE GEORG;;GOODING PHILIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/166-455-194-243-634,Patent Application,yes,99,49,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F9/008,606/4,0,0,,,,ACTIVE
447,US,A1,US 2015/0230987 A1,074-466-875-508-528,2015-08-20,2015,US 201514701458 A,2015-04-30,US 201514701458 A;;US 201113023483 A;;US 30243710 P,2010-02-08,SYSTEM AND METHOD FOR PLASMA-MEDIATED MODIFICATION OF TISSUE,"A method for cataract surgery on an eye of a patient includes scanning a first focus position of a first pulsed laser beam at a first pulse energy of between one-half microjoule and 50 microjoules in a first scanning pattern to photodisrupt a first tissue structure portion with a plurality of pulses of the first laser beam to form an incised surface; and afterwards, scanning a second focus position of a second pulsed laser beam having a second pulse energy being between 50 microjoules and 5,000 microjoules in a second scanning pattern that is co-registered to the first scanning pattern to further photodisrupt the same first tissue structure portion with the second laser beam to further separate segments of the first tissue structure along the incised surface.",FRIEDMAN NEIL;;SEIBEL BARRY;;CULBERTSON WILLIAM;;SCHUELE GEORG;;ANDERSEN DAN;;OPTIMEDICA CORP,FRIEDMAN NEIL;;SEIBEL BARRY;;CULBERTSON WILLIAM;;SCHUELE GEORG;;ANDERSEN DAN,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2011-04-21),https://lens.org/074-466-875-508-528,Patent Application,yes,0,11,7,7,0,A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00825,A61F9/008,,0,0,,,,ACTIVE
448,IT,A0,IT 8050044 A0,096-474-135-191-404,1980-10-30,1980,IT 5004480 A,1980-10-30,US 9342379 A,1979-11-13,METODO PER LA PRODUZIONE DI OLEFINE DA IDROCARBURI CON RESE ELEVATE,,ROCKWELL INTERNATIONAL CORP,FRIEDMAN JOSEPH;;HINES WILLIAM S;;RANIERE FREDERICK D;;SILVERMAN JACOB,,https://lens.org/096-474-135-191-404,Patent Application,no,0,0,20,20,0,B01J12/005;;B01J19/26;;B01J2219/00119;;B01J2219/00121;;B01J2219/00159;;B01J2219/00164;;C10G2400/20;;B01J19/26;;B01J2219/00121;;B01J2219/00159;;B01J2219/00119;;B01J2219/00164;;B01J12/005;;C10G2400/20,B01J12/00;;C10G47/00;;B01J19/26;;C07C1/00;;C07C4/04;;C07C11/02;;C07C67/00;;C10G9/36;;C10G47/22,,0,0,,,,EXPIRED
449,US,B2,US 9668919 B2,163-884-222-591-756,2017-06-06,2017,US 201514701458 A,2015-04-30,US 201514701458 A;;US 201113023483 A;;US 30243710 P,2010-02-08,System and method for plasma-mediated modification of tissue,"A method for cataract surgery on an eye of a patient includes scanning a first focus position of a first pulsed laser beam at a first pulse energy of between one-half microjoule and 50 microjoules in a first scanning pattern to photodisrupt a first tissue structure portion with a plurality of pulses of the first laser beam to form an incised surface; and afterwards, scanning a second focus position of a second pulsed laser beam having a second pulse energy being between 50 microjoules and 5,000 microjoules in a second scanning pattern that is co-registered to the first scanning pattern to further photodisrupt the same first tissue structure portion with the second laser beam to further separate segments of the first tissue structure along the incised surface.",OPTIMEDICA CORP,FRIEDMAN NEIL;;SEIBEL BARRY;;CULBERTSON WILLIAM;;SCHUELE GEORG;;ANDERSEN DAN,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2011-04-21),https://lens.org/163-884-222-591-756,Granted Patent,yes,30,2,7,7,0,A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00825,A61F9/008,,2,1,119-411-786-501-407,8206720,"A. Vogel et al., “Intraocular Photodisruption With Picosecond and Nanosecond Laser Pulses: Tissue Effects in Cornea, Lens, and Retina”, Investigative Ophthalmology & Visual Science, Jun. 1994, vol. 35 No. 7, pp. 3032 to 3044 (13 pages).;;PCT International Search Report and Written Opinion for PCT/US2011/024107, Applicant Optimedica Corporation, Forms PCT/ISA201, 220, and 237, dated Apr. 20, 2011 (10 pages).",ACTIVE
450,US,A1,US 2018/0263758 A1,019-402-301-824-145,2018-09-20,2018,US 201815976751 A,2018-05-10,US 201815976751 A;;US 201414576467 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,METHOD FOR PATTERNED PLASMA-MEDIATED MODIFICATION OF THE CRYSTALLINE LENS,"A method of treating a lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern of the light beam, delivering the treatment pattern to the lens of a patient's eye to create a plurality of cuts in the lens in the form of the treatment pattern to break the lens up into a plurality of pieces, and removing the lens pieces from the patient's eye. The lens pieces can then be mechanically removed. The light beam can be used to create larger segmenting cuts into the lens, as well as smaller softening cuts that soften the lens for easier removal.",OPTIMEDICA CORP,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/019-402-301-824-145,Patent Application,yes,3,2,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F2/16;;A61F9/00;;A61F9/008,,0,0,,,,ACTIVE
451,US,S,US D0590270 S,041-811-093-442-947,2009-04-14,2009,US 28238707 F,2007-07-18,US 28238707 F,2007-07-18,Bottle,,FRIEDMAN PAMELA;;BROWN COLIN WILLIAM;;GOHIL KISHEN;;NAISH GUY EDWARD,FRIEDMAN PAMELA;;BROWN COLIN WILLIAM;;GOHIL KISHEN;;NAISH GUY EDWARD,,https://lens.org/041-811-093-442-947,Design Right,no,0,4,1,1,0,,,0901;;D 9658;;D9/522,0,0,,,,EXPIRED
452,US,B2,US 10828149 B2,049-519-364-633-669,2020-11-10,2020,US 201815976751 A,2018-05-10,US 201815976751 A;;US 201414576467 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,Method for patterned plasma-mediated modification of the crystalline lens,"A method of treating a lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern of the light beam, delivering the treatment pattern to the lens of a patient's eye to create a plurality of cuts in the lens in the form of the treatment pattern to break the lens up into a plurality of pieces, and removing the lens pieces from the patient's eye. The lens pieces can then be mechanically removed. The light beam can be used to create larger segmenting cuts into the lens, as well as smaller softening cuts that soften the lens for easier removal.",AMO DEV LLC,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/049-519-364-633-669,Granted Patent,yes,120,2,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F2/16;;A61F9/00;;A61F9/007;;A61F9/008;;A61F9/009,,10,5,000-548-666-851-615;;078-796-045-460-497;;026-530-457-942-21X;;097-583-099-978-486;;054-672-478-733-301,15342071;;10.1016/j.jcrs.2004.05.018;;9713056;;10.1136/bjo.82.5.504;;pmc1722590;;2005552;;10.1016/s0886-3350(13)81001-2;;2299571;;10.1016/s0886-3350(13)80870-x;;7993214;;10.1001/archopht.1994.01090240090031,"Abstract of AU Publication No. 2007292491, Publication Date Mar. 13, 2008, which is the AU counterpart of the WO08030718 A2 application.;;Baikoff G., et al., “Contact Between 3 Phakic Intraocular Lens Models and the Crystalline Lens: An Anterior Chamber Optical Coherence Tomography Study,” Journal of Cataract and Refractive Surgery, 2004, vol. 30 (9), pp. 2007-2012.;;Geerling G., et al., “Initial Clinical Experience with the Picosecond Nd:YLF Laser for Intraocular Therapeutic Applications,” British Journal of Ophthalmology, 1998, vol. 82 (5), pp. 504-509.;;Gimbel H.V., et al., “Continuous Curvilinear Capsulorhexis,” Journal of Cataract and Refractive Surgery, 1991, vol. 17 (1), pp. 110-111.;;Gimbel H.V., et al., “Development, Advantages and Methods of the Continuous Circular Capsulorhexis Technique,” Journal of Cataract and Refractive Surgery, 1990, vol. 16 (1), pp. 31-37.;;Gimbel H.V., et al., “Principles of Nuclear Phaco Emulsification” In: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., 2004, Chap. 15, pp. 153-181.;;Izatt J.A., et al., “Micrometer-Scale Resolution Imaging of the Anterior Eye in Vivo With Optical Coherence Tomography,” Arch Ophthalmology, 1994, vol. 112 (12), pp. 1584-1589.;;Steinert et al., “Neodymium: Yttrium-Aluminum-Garnet Laser Posterior Capsulotomy,” in: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., 2004, Chapter. 44, pp. 531-544.;;Supplementary European Search Report for Application No. EP08726822, dated Apr. 26, 2010, 6 pages.;;Supplementary European Search Report for Application No. EP08726825, dated Apr. 30, 2010, 8 pages.",ACTIVE
453,US,S,US D0561887 S,082-863-623-369-823,2008-02-12,2008,US 28012007 F,2007-05-17,US 28012007 F,2007-05-17,Device for dispensing volatile liquids,,FRIEDMAN PAMELA;;BROWN COLIN WILLIAM;;GOHIL KISHEN;;NAISH GUY EDWARD,FRIEDMAN PAMELA;;BROWN COLIN WILLIAM;;GOHIL KISHEN;;NAISH GUY EDWARD,GIVAUDAN SULSSE S.A (2007-06-05);;FRIEDMAN PAMELA (2007-06-12),https://lens.org/082-863-623-369-823,Design Right,no,0,14,1,1,0,,,2899;;D23/366,0,0,,,,EXPIRED
454,FR,B1,FR 2469446 B1,101-620-168-681-292,1986-01-03,1986,FR 8024026 A,1980-11-12,US 9342379 A,1979-11-13,PROCEDE DE PRODUCTION RAPIDE D'OLEFINES PAR CONVERSION THERMIQUE D'HYDROCARBURES EN PRESENCE D'HYDROGENE,,ROCKWELL INTERNATIONAL CORP,FRIEDMAN JOSEPH;;HINES WILLIAM STEPHEN;;RANIERE FREDERICK DEAN;;SILVERMAN JACOB,,https://lens.org/101-620-168-681-292,Granted Patent,no,0,0,20,20,0,B01J12/005;;B01J19/26;;B01J2219/00119;;B01J2219/00121;;B01J2219/00159;;B01J2219/00164;;C10G2400/20;;B01J19/26;;B01J2219/00121;;B01J2219/00159;;B01J2219/00119;;B01J2219/00164;;B01J12/005;;C10G2400/20,B01J12/00;;B01J19/26;;C10G47/00;;C07C1/00;;C07C4/04;;C07C11/02;;C07C67/00;;C10G9/36;;C10G47/22,,0,0,,,,EXPIRED
455,US,A1,US 2015/0105763 A1,140-391-304-849-650,2015-04-16,2015,US 201414576467 A,2014-12-19,US 201414576467 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,METHOD FOR PATTERNED PLASMA-MEDIATED MODIFICATION OF THE CRYSTALLINE LENS,"A system for treating a cataractous lens of a patient's eye includes a laser source for generating a light beam, a scanning system for deflecting the light beam to form a treatment pattern of the light beam, and a controller operably coupled to the laser source and scanning system and configured to operate the scanner to form the treatment pattern. The treatment pattern is a plurality of cuts in the form two or more different incision patterns for segmenting the lens tissue into a plurality of patterned pieces. The incision pattern includes: a first incision pattern including two or more crossing cut incision planes; and a second incision pattern comprising one or more laser incision each extending along a first length between a posterior and an anterior surface of the lens capsule.",OPTIMEDICA CORP,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/140-391-304-849-650,Patent Application,yes,1,7,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F9/008,606/6,0,0,,,,ACTIVE
456,US,B2,US 10639140 B2,124-451-943-872-285,2020-05-05,2020,US 201715726289 A,2017-10-05,US 201715726289 A;;US 201414576422 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,Method for patterned plasma-mediated modification of the crystalline lens,"A method of treating a cataractous lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern, delivering the treatment pattern to the lens of the patient's eye to create a plurality of cuts in the form two or more different incisions patterns within the lens to segment the lens tissue into a plurality of patterned pieces, and mechanically breaking the lens into a plurality of pieces along the cuts. A first incision pattern includes two or more crossing cut incision planes. A second incision pattern includes a plurality of laser incision each extending along a first length between a posterior and an anterior surface of the lens capsule.",OPTIMEDICA CORP;;AMO DEV LLC,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/124-451-943-872-285,Granted Patent,yes,118,0,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F9/008;;A61F2/16;;A61F9/00;;A61F9/007;;A61F9/009,,10,5,000-548-666-851-615;;078-796-045-460-497;;026-530-457-942-21X;;097-583-099-978-486;;054-672-478-733-301,15342071;;10.1016/j.jcrs.2004.05.018;;9713056;;10.1136/bjo.82.5.504;;pmc1722590;;2005552;;10.1016/s0886-3350(13)81001-2;;2299571;;10.1016/s0886-3350(13)80870-x;;7993214;;10.1001/archopht.1994.01090240090031,"Abstract of AU Publication No. 2007292491, Publication Date Mar. 13, 2008, which is the AU counterpart of the WO08030718 A2 application.;;Baikoff G., et al., “Contact Between 3 Phakic Intraocular Lens Models and the Crystalline Lens: An Anterior Chamber Optical Coherence Tomography Study,” Journal of Cataract and Refractive Surgery, 2004, vol. 30 (9), pp. 2007-2012.;;Geerling G., et al., “Initial Clinical Experience with the Picosecond Nd:YLF Laser for Intraocular Therapeutic Applications,” British Journal of Ophthalmology, 1998, vol. 82 (5), pp. 504-509.;;Gimbel H.V., et al., “Continuous Curvilinear Capsulorhexis,” Journal of Cataract and Refractive Surgery, 1991, vol. 17 (1), pp. 110-111.;;Gimbel H.V., et al., “Development, Advantages and Methods of the Continuous Circular Capsulorhexis Technique,” Journal of Cataract and Refractive Surgery, 1990, vol. 16 (1), pp. 31-37.;;Gimbel H.V., et al., “Principles of Nuclear Phaco Emulsification” In: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., 2004, Chap. 15, pp. 153-181.;;Izatt J.A., et al., “Micrometer-Scale Resolution Imaging of the Anterior Eye in Vivo With Optical Coherence Tomography,” Arch Ophthalmology, 1994, vol. 112 (12), pp. 1584-1589.;;Steinert et al., “Neodymium: Yttrium-Aluminum-Garnet Laser Posterior Capsulotomy,” in: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., 2004, Chapter. 44, pp. 531-544.;;Supplementary European Search Report for Application No. EP08726822, dated Apr. 26, 2010, 6 pages.;;Supplementary European Search Report for Application No. EP08726825, dated Apr. 30, 2010, 8 pages.",ACTIVE
457,US,B2,US 9278028 B2,014-998-086-513-800,2016-03-08,2016,US 201113023483 A,2011-02-08,US 201113023483 A;;US 30243710 P,2010-02-08,System and method for plasma-mediated modification of tissue,"A system for cataract surgery on an eye of a patient is described. In one embodiment, the system comprises a first laser source configured to deliver a first laser beam in a pulsed form at a first pulse energy; a second laser source configured to deliver a second laser beam in a pulsed form at a second pulse energy greater than the first pulse energy; an scanning optical system, configured to: receive the first and second laser beams; and adjust a first focus position of the first laser beam, and a second focus position of the second laser beam, in up to three dimensions to direct the first and second laser beams onto one or more targeted tissue structure portions of the eye of the patient; a controller operatively coupled to the scanning optical system and configured to cause the scanning optical system to adjust the first focus position to photodisrupt a first tissue structure portion with the first laser beam, and subsequently adjust the second focus position to further photodisrupt the first tissue structure portion with the second laser beam.",FRIEDMAN NEIL;;SEIBEL BARRY;;CULBERTSON WILLIAM;;SCHUELE GEORG;;ANDERSEN DAN;;OPTIMEDICA CORP,FRIEDMAN NEIL;;SEIBEL BARRY;;CULBERTSON WILLIAM;;SCHUELE GEORG;;ANDERSEN DAN,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2011-04-21),https://lens.org/014-998-086-513-800,Granted Patent,yes,31,4,7,7,0,A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00825,A61B18/20;;A61F9/008,,2,1,119-411-786-501-407,8206720,"A. Vogel et al., ""Intraocular Photodisruption With Picosecond and Nanosecond Laser Pulses: Tissue Effects in Cornea, Lens, and Retina"", Investigative Ophthalmology & Visual Science, Jun. 1994, vol. 35 No. 7, pp. 3032 to 3044 (13 pages).;;PCT International Search Report and Written Opinion for PCT/US2011/024107, Applicant Optimedica Corporation, Forms PCT/ISA/210, 220, and 237, dated Apr. 20, 2011 (10 pages).",ACTIVE
458,AU,B2,AU 533979 B2,018-088-188-331-306,1983-12-22,1983,AU 1980/064340 A,1980-11-13,US 9342379 A,1979-11-13,METHOD OF PRODUCING OLEFINS FROM HYDROCARBONS,,ROCKWELL INTERNATIONAL CORP,FRIEDMAN JOSEPH;;HINES WILLIAM STEPHEN;;RANIERE FREDERICK DEAN;;SILVERMAN JACOB,,https://lens.org/018-088-188-331-306,Granted Patent,no,0,0,20,20,0,B01J12/005;;B01J19/26;;B01J2219/00119;;B01J2219/00121;;B01J2219/00159;;B01J2219/00164;;C10G2400/20;;B01J19/26;;B01J2219/00121;;B01J2219/00159;;B01J2219/00119;;B01J2219/00164;;B01J12/005;;C10G2400/20,C10G47/00;;B01J12/00;;B01J19/26;;C07C1/00;;C07C4/04;;C07C11/02;;C07C67/00;;C10G9/36;;C10G47/22,,0,0,,,,EXPIRED
459,US,B2,US 10478341 B2,156-386-355-160-057,2019-11-19,2019,US 201715612920 A,2017-06-02,US 201715612920 A;;US 201514701458 A;;US 201113023483 A;;US 30243710 P,2010-02-08,System and method for plasma-mediated modification of tissue,"A method for cataract surgery on an eye of a patient includes scanning a first focus position of a first pulsed laser beam at a first pulse energy in a first scanning pattern to photodisrupt a tissue structure of a lens with a plurality of pulses of the first laser beam to form one or more cuts within the lens, the cuts being short of reaching a side edge of the lens and being configured to divide the lens into two or more segments which are attached to each other in regions adjacent the side edge of the lens; and afterwards, completely separating the two or more segments of the lens from each other by scanning a second focus position of a second pulsed laser beam having a second pulse energy higher than the first pulse energy in a second scanning pattern that is co-registered to the first scanning pattern.",OPTIMEDICA CORP,FRIEDMAN NEIL;;SEIBEL BARRY;;CULBERTSON WILLIAM;;SCHUELE GEORG;;ANDERSEN DAN,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2011-04-21),https://lens.org/156-386-355-160-057,Granted Patent,yes,32,0,7,7,0,A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00825,A61F9/008,,2,1,119-411-786-501-407,8206720,"International Search Report and Written Opinion for Application No. PCT/US2011/024107, dated Apr. 20, 2011, 10 pages.;;Vogel A., et al., “Intraocular Photodisruption with Picosecond and Nanosecond Laser Pulses: Tissue Effects in Cornea, Lens and Retina,” Investigative Ophthalmology & Visual Science, 1994, vol. 35 (7), pp. 3032-3044.",ACTIVE
460,US,A1,US 2009/0012507 A1,178-797-183-155-618,2009-01-08,2009,US 4818508 A,2008-03-13,US 4818508 A;;US 90694407 P,2007-03-13,METHOD FOR PATTERNED PLASMA-MEDIATED MODIFICATION OF THE CRYSTALLINE LENS,"A method of treating a lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern of the light beam, delivering the treatment pattern to the lens of a patient's eye to create a plurality of cuts in the lens in the form of the treatment pattern to break the lens up into a plurality of pieces, and removing the lens pieces from the patient's eye. The lens pieces can then be mechanically removed. The light beam can be used to create larger segmenting cuts into the lens, as well as smaller softening cuts that soften the lens for easier removal.",CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHULE GEORG;;GOODING PHILIP,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHULE GEORG;;GOODING PHILIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/178-797-183-155-618,Patent Application,yes,83,153,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F9/008,606/6;;606/107;;128/898,0,0,,,,DISCONTINUED
461,US,A1,US 2020/0261215 A1,029-126-488-539-882,2020-08-20,2020,US 202016866362 A,2020-05-04,US 202016866362 A;;US 201715726289 A;;US 201414576422 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,METHOD FOR PATTERNED PLASMA-MEDIATED MODIFICATION OF THE CRYSTALLINE LENS,"A method of treating a cataractous lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern, delivering the treatment pattern to the lens of the patient's eye to create a plurality of cuts in the form two or more different incisions patterns within the lens to segment the lens tissue into a plurality of patterned pieces, and mechanically breaking the lens into a plurality of pieces along the cuts. A first incision pattern includes two or more crossing cut incision planes. A second incision pattern includes a plurality of laser incision each extending along a first length between a posterior and an anterior surface of the lens capsule.",AMO DEV LLC,CULBERTSON WILLIAM;;SIEBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/029-126-488-539-882,Patent Application,yes,4,0,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F2/16,,0,0,,,,ACTIVE
462,CN,A,CN 1261793 A,053-193-044-525-703,2000-08-02,2000,CN 98806696 A,1998-06-15,US 5149897 P;;US 5142097 P;;US 5140297 P;;US 5141497 P,1997-07-01,Sertraline salts and substained-release dosage forms of sertraline,,PFIZER,ENDE MARY T AM;;CURATOLO WILLIAM J;;FRIEDMAN HYLAR L,,https://lens.org/053-193-044-525-703,Patent Application,no,0,2,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
463,US,A1,US 2018/0042715 A1,078-336-072-072-361,2018-02-15,2018,US 201715726289 A,2017-10-05,US 201715726289 A;;US 201414576422 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,METHOD FOR PATTERNED PLASMA-MEDIATED MODIFICATION OF THE CRYSTALLINE LENS,"A method of treating a cataractous lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern, delivering the treatment pattern to the lens of the patient's eye to create a plurality of cuts in the form two or more different incisions patterns within the lens to segment the lens tissue into a plurality of patterned pieces, and mechanically breaking the lens into a plurality of pieces along the cuts. A first incision pattern includes two or more crossing cut incision planes. A second incision pattern includes a plurality of laser incision each extending along a first length between a posterior and an anterior surface of the lens capsule.",OPTIMEDICA CORP,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/078-336-072-072-361,Patent Application,yes,2,0,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F2/16;;A61F9/00;;A61F9/008,,0,0,,,,ACTIVE
464,US,A1,US 2010/0137850 A1,187-426-099-006-605,2010-06-03,2010,US 70224210 A,2010-02-08,US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,Method For Patterned Plasma-Mediated Modification Of The Crystalline Lens,"A method of treating a lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern of the light beam, delivering the treatment pattern to the lens of a patient's eye to create a plurality of cuts in the lens in the form of the treatment pattern to break the lens up into a plurality of pieces, and removing the lens pieces from the patient's eye. The lens pieces can then be mechanically removed. The light beam can be used to create larger segmenting cuts into the lens, as well as smaller softening cuts that soften the lens for easier removal.",CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHULE GEORG;;GOODING PHILIP,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHULE GEORG;;GOODING PHILIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/187-426-099-006-605,Patent Application,yes,36,59,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F9/008,606/6,0,0,,,,ACTIVE
465,DE,A1,DE 3042878 A1,022-421-535-186-686,1981-09-03,1981,DE 3042878 A,1980-11-13,US 9342379 A,1979-11-13,VERFAHREN ZUR HERSTELLUNG VON OLEFINEN AUS KOHLENWASSERSTOFFEN,,ROCKWELL INTERNATIONAL CORP,FRIEDMAN JOSEPH;;HINES WILLIAM S;;RANIERE FREDERICK D;;SILVERMAN JACOB,,https://lens.org/022-421-535-186-686,Patent Application,no,0,1,20,20,0,B01J12/005;;B01J19/26;;B01J2219/00119;;B01J2219/00121;;B01J2219/00159;;B01J2219/00164;;C10G2400/20;;B01J19/26;;B01J2219/00121;;B01J2219/00159;;B01J2219/00119;;B01J2219/00164;;B01J12/005;;C10G2400/20,C10G47/00;;B01J12/00;;B01J19/26;;C07C1/00;;C07C4/04;;C07C11/02;;C07C67/00;;C10G9/36;;C10G47/22,,0,0,,,,DISCONTINUED
466,FR,A1,FR 2469446 A1,047-757-292-814-153,1981-05-22,1981,FR 8024026 A,1980-11-12,US 9342379 A,1979-11-13,PROCEDE DE PRODUCTION RAPIDE D'OLEFINES PAR CONVERSION THERMIQUE D'HYDROCARBURES EN PRESENCE D'HYDROGENE,"<P>PROCEDE THERMIQUE POUR TRANSFORMER AVEC RENDEMENT ELEVE DES HYDROCARBURES (LOURDS) EN DES OLEFINES.</P><P>ON INTRODUIT DANS UNE 1 ZONE REACTIONNELLE 22 UN COURANT D'OXYGENE GAZEUX ENTOURE D'UN COURANT PARALLELE D'HYDROGENE CHAUD. ON OBTIENT UN COURANT GAZEUX A ENVIRON 1000-2000C, COMPRENANT DE L'HYDROGENE ET UN PEU DE VAPEUR D'EAU, QUI EST INTRODUIT DANS UNE SECONDE ZONE REACTIONNELLE 33 ET Y HEURTE UN COURANT D'HYDROCARBURES H, CHAUFFE. MAINTENU A 800-1000C PENDANT QUELQUES MILLISECONDES, LE MELANGE FORME DES OLEFINES ET EST RAPIDEMENT REFROIDI.</P>",ROCKWELL INTERNATIONAL CORP,FRIEDMAN JOSEPH;;HINES WILLIAM STEPHEN;;RANIERE FREDERICK DEAN;;SILVERMAN JACOB,,https://lens.org/047-757-292-814-153,Patent Application,no,11,0,20,20,0,B01J12/005;;B01J19/26;;B01J2219/00119;;B01J2219/00121;;B01J2219/00159;;B01J2219/00164;;C10G2400/20;;B01J19/26;;B01J2219/00121;;B01J2219/00159;;B01J2219/00119;;B01J2219/00164;;B01J12/005;;C10G2400/20,B01J12/00;;B01J19/26;;C07C1/00;;C10G47/00;;C07C4/04;;C07C11/02;;C07C67/00;;C10G9/36;;C10G47/22,,0,0,,,,EXPIRED
467,US,A1,US 2011/0196350 A1,161-885-460-585-855,2011-08-11,2011,US 201113023483 A,2011-02-08,US 201113023483 A;;US 30243710 P,2010-02-08,SYSTEM AND METHOD FOR PLASMA-MEDIATED MODIFICATION OF TISSUE,"A system for cataract surgery on an eye of a patient is described. In one embodiment, the system comprises a first laser source configured to deliver a first laser beam in a pulsed form at a first pulse energy; a second laser source configured to deliver a second laser beam in a pulsed form at a second pulse energy greater than the first pulse energy; an scanning optical system, configured to: receive the first and second laser beams; and adjust a first focus position of the first laser beam, and a second focus position of the second laser beam, in up to three dimensions to direct the first and second laser beams onto one or more targeted tissue structure portions of the eye of the patient; a controller operatively coupled to the scanning optical system and configured to cause the scanning optical system to adjust the first focus position to photodisrupt a first tissue structure portion with the first laser beam, and subsequently adjust the second focus position to further photodisrupt the first tissue structure portion with the second laser beam.",OPTIMEDICA CORP,FRIEDMAN NEIL;;SEIBEL BARRY;;CULBERTSON WILLIAM;;SCHUELE GEORG;;ANDERSEN DAN,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2011-04-21),https://lens.org/161-885-460-585-855,Patent Application,yes,16,113,7,7,0,A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00834;;A61F2009/00851;;A61F2009/0087;;A61F2009/00887;;A61F2009/00897;;A61F9/008;;A61F9/00825,A61B18/20,606/6,0,0,,,,ACTIVE
468,US,B2,US 11826245 B2,001-050-006-140-103,2023-11-28,2023,US 202016944144 A,2020-07-30,US 202016944144 A;;US 201715726296 A;;US 201414576422 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,Method for patterned plasma-mediated modification of the crystalline lens,"A method of treating a lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern of the light beam, delivering the treatment pattern to the lens of a patient's eye to create a plurality of cuts in the lens in the form of the treatment pattern to break the lens up into a plurality of pieces, and removing the lens pieces from the patient's eye. The lens pieces can then be mechanically removed. The light beam can be used to create larger segmenting cuts into the lens, as well as smaller softening cuts that soften the lens for easier removal.",AMO DEV LLC,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/001-050-006-140-103,Granted Patent,yes,117,0,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F9/008;;A61F2/16;;A61F9/00;;A61F9/007;;A61F9/009,,8,5,000-548-666-851-615;;078-796-045-460-497;;026-530-457-942-21X;;097-583-099-978-486;;054-672-478-733-301,15342071;;10.1016/j.jcrs.2004.05.018;;9713056;;10.1136/bjo.82.5.504;;pmc1722590;;2005552;;10.1016/s0886-3350(13)81001-2;;2299571;;10.1016/s0886-3350(13)80870-x;;7993214;;10.1001/archopht.1994.01090240090031,"Abstract of AU Publication No. 2007292491, Publication Date Mar. 13, 2008, which is the AU counterpart of the WO08030718 A2 application.;;Baikoff G., et al., “Contact Between 3 Phakic Intraocular Lens Models and the Crystalline Lens: An Anterior Chamber Optical Coherence Tomography Study,” Journal of Cataract and Refractive Surgery, Sep. 2004, vol. 30 (9), pp. 2007-2012.;;Geerling G., et al., “Initial Clinical Experience with the Picosecond Nd:YLF Laser for Intraocular Therapeutic Applications,” British Journal of Ophthalmology, May 1998, vol. 82 (5), pp. 504-509.;;Gimbel H.V., et al., “Continuous Curvilinear Capsulorhexis,” Journal of Cataract and Refractive Surgery, Jan. 1991, vol. 17 (1), pp. 110-111.;;Gimbel H.V., et al., “Development, Advantages and Methods of the Continuous Circular Capsulorhexis Technique,” Journal of Cataract and Refractive Surgery, Jan. 1990, vol. 16 (1), pp. 31-37.;;Gimbel H.V., et al., “Principles of Nuclear Phaco Emulsification”In: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., Oct. 2003, Chap. 15, pp. 153-181.;;Izatt J.A., et al., “Micrometer-Scale Resolution Imaging of the Anterior Eye In Vivo With Optical Coherence Tomography,” Arch Ophthalmology, Dec. 1994, vol. 112 (12), pp. 1584-1589.;;Steinert et al., “Neodymium: Yttrium-Aluminum-Garnet Laser Posterior Capsulotomy,” in: Cataract Surgery Techniques Complications and Management, 2nd edition., Steinert et al., Oct. 2003, Chapter. 44, pp. 531-544.",ACTIVE
469,US,A1,US 2018/0042716 A1,114-410-840-955-447,2018-02-15,2018,US 201715726296 A,2017-10-05,US 201715726296 A;;US 201414576422 A;;US 70224210 A;;US 4818508 A;;US 90694407 P,2007-03-13,METHOD FOR PATTERNED PLASMA-MEDIATED MODIFICATION OF THE CRYSTALLINE LENS,"A method of treating a lens of a patient's eye includes generating a light beam, deflecting the light beam using a scanner to form a treatment pattern of the light beam, delivering the treatment pattern to the lens of a patient's eye to create a plurality of cuts in the lens in the form of the treatment pattern to break the lens up into a plurality of pieces, and removing the lens pieces from the patient's eye. The lens pieces can then be mechanically removed. The light beam can be used to create larger segmenting cuts into the lens, as well as smaller softening cuts that soften the lens for easier removal.",OPTIMEDICA CORP,CULBERTSON WILLIAM;;SEIBEL BARRY;;FRIEDMAN NEIL;;SCHUELE GEORG;;GOODING PHILLIP,AMO DEVELOPMENT LLC (2019-12-30);;OPTIMEDICA CORPORATION (2008-09-13),https://lens.org/114-410-840-955-447,Patent Application,yes,5,0,136,136,0,A61F2009/00859;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F9/00825;;A61F2009/0087;;A61F9/00;;A61F2/16;;A61F2220/0016;;A61F2/1637;;A61F2/1648;;A61F9/00;;A61F9/00825;;A61F2009/00859;;A61F2009/0087;;A61F2009/00872;;A61F2009/0088;;A61F2009/00897;;A61F2/16;;A61F2/1613;;A61F2009/00887;;A61F2002/1683;;A61F2220/0016;;A61F2/1662;;A61F9/00754;;A61F9/008;;A61F9/009;;A61F2002/16901;;A61F9/00812,A61F2/16;;A61F9/00;;A61F9/008,,0,0,,,,ACTIVE
470,US,A,US 4256565 A,195-690-949-706-329,1981-03-17,1981,US 9342379 A,1979-11-13,US 9342379 A,1979-11-13,Method of producing olefins from hydrocarbons,"A method of producing high yields of olefins from hydrocarbon feedstocks which is particularly applicable to heavy hydrocarbons. In accordance with the present method, a stream of gaseous oxygen is introduced into a first reaction zone and a cocurrent flow of hydrogen is introduced about the periphery of the gaseous oxygen stream, the hydrogen being introduced at a temperature at which it will spontaneously react with the oxygen. The hydrogen and oxygen are introduced in amounts to provide a gas stream of reaction products having an average temperature within the range of from about 1,000.degree. to 2,000.degree. C. and which comprises a major amount of hydrogen and a minor amount of water vapor. The gas stream so produced is introduced into a second reaction zone and impinged upon a stream of hydrocarbon which is heated to a temperature in excess of its melting point but below the temperature at which any substantial coke or tar forms. The gas stream is introduced at a high velocity and in an amount to provide a flowing reaction mixture having a temperature within the range of from 800.degree. to 1,800.degree. C. The flowing mixture is maintained at that temperature for a time of from about 1 to 10 milliseconds to form olefins. Thereafter, the flowing mixture is rapidly quenched to arrest the reaction and the olefin products are recovered.",ROCKWELL INTERNATIONAL CORP,FRIEDMAN JOSEPH;;HINES WILLIAM S;;RANIERE FREDERICK D;;SILVERMAN JACOB,ROCKWELL INTERNATIONAL CORPORATION (1979-11-06),https://lens.org/195-690-949-706-329,Granted Patent,yes,5,44,20,20,0,B01J12/005;;B01J19/26;;B01J2219/00119;;B01J2219/00121;;B01J2219/00159;;B01J2219/00164;;C10G2400/20;;B01J19/26;;B01J2219/00121;;B01J2219/00159;;B01J2219/00119;;B01J2219/00164;;B01J12/005;;C10G2400/20,B01J12/00;;C10G47/00;;B01J19/26;;C07C1/00;;C07C4/04;;C07C11/02;;C07C67/00;;C10G9/36;;C10G47/22,208/129,0,0,,,,EXPIRED
471,IT,B,IT 1146059 B,138-253-111-503-242,1986-11-12,1986,IT 5004480 A,1980-10-30,US 9342379 A,1979-11-13,METODO PER LA PRODUZIONE DI OLEFINE DA IDROCARBURI CON RESE ELEVATE,,ROCKWELL INTERNATIONAL CORP,FRIEDMAN JOSEPH;;HINES WILLIAM S;;RANIERE FREDERICK D;;SILVERMAN JACOB,,https://lens.org/138-253-111-503-242,Granted Patent,no,0,0,20,20,0,B01J12/005;;B01J19/26;;B01J2219/00119;;B01J2219/00121;;B01J2219/00159;;B01J2219/00164;;C10G2400/20;;B01J19/26;;B01J2219/00121;;B01J2219/00159;;B01J2219/00119;;B01J2219/00164;;B01J12/005;;C10G2400/20,B01J12/00;;C10G47/00;;B01J19/26;;C07C1/00;;C07C4/04;;C07C11/02;;C07C67/00;;C10G9/36;;C10G47/22,,0,0,,,,EXPIRED
472,AU,B2,AU 764768 B2,008-797-439-225-962,2003-08-28,2003,AU 2000/063690 A,2000-07-21,US 14521299 P;;US 0020103 W,1999-07-23,Ultrasonic guidance of target structures for medical procedures,,UNIV FLORIDA,BOVA FRANK J;;BUATTI JOHN M;;MEEKS SANFORD L;;FRIEDMAN WILLIAM,,https://lens.org/008-797-439-225-962,Granted Patent,no,2,0,9,9,0,A61B8/5238;;A61B8/5238;;A61B5/7285;;A61B5/7285;;A61B6/5247;;A61B6/5247;;A61B6/541;;A61B6/541;;A61B8/08;;A61B8/08;;A61B8/4245;;A61B8/4245;;A61N5/1049;;A61N5/1049;;A61N2005/1058;;A61N2005/1058;;A61N2005/1059;;A61N2005/1059;;Y10S128/916;;Y10S128/916,G01R33/28;;A61B5/055;;A61B5/06;;A61B6/00;;A61B6/03;;A61B8/00;;A61B8/08;;A61B19/00;;G01S15/89,,0,0,,,,EXPIRED
473,US,B2,US 10920592 B2,081-810-889-349-955,2021-02-16,2021,US 201715844065 A,2017-12-15,US 201715844065 A,2017-12-15,System and method for assembling gas turbine rotor using localized inductive heating,"A method of assembling a rotor is provided, in which each rotor disk comprising a connecting element. The method includes: (a) applying heat to a localized region of a first rotor disk of a plurality of rotor disks to selectively deflect a first connecting element of the first rotor disk, wherein the first rotor disk is stationary during heating; (b) installing the first rotor disk onto a rotor stack containing at least one rotor disk; and (c) repeating steps (a) and (b) for each rotor disk of the plurality of rotor disks; and (d) allowing the rotor disks, when stacked, to cool. When cooled, the respective connecting element of each rotor disk that has been selectively deflected contracts into an interference fit with an adjacent rotor disk. A system for selectively heating a localized region of a rotor disk is also provided.",GEN ELECTRIC,FRIEDMAN MICHAEL ERICSON;;SYED MINHAJUDDIN;;MICHAUD WILLIAM MICHAEL;;LUM LAMONT JOSEPH,GE INFRASTRUCTURE TECHNOLOGY LLC (2023-11-10);;GENERAL ELECTRIC COMPANY (2017-12-15),https://lens.org/081-810-889-349-955,Granted Patent,yes,21,3,2,2,0,F04D19/02;;F04D29/053;;F04D29/644;;F01D5/06;;F01D5/026;;F05D2230/642;;F01D25/285;;H05B6/102;;H05B6/36;;F01D5/026;;F01D5/025;;F04D29/644;;H05B6/102;;F05D2230/64;;F05D2240/24;;F04D29/329;;F05D2230/232;;F04D19/02;;F04D29/053,F01D5/02;;F04D19/02;;F04D29/053;;F04D29/32;;F04D29/64;;H05B6/10,,0,0,,,,ACTIVE
474,EP,A1,EP 2213225 A1,145-387-171-533-694,2010-08-04,2010,EP 10151702 A,2010-01-26,US 36294209 A,2009-01-30,Systems and methods for integrating hemodynamic and imaging examinations,"Hemodynamic data and imaging data are obtained about a patient, and the data is combined to generate a single report integrating same (480. While a hemodynamic system (12) obtains the hemodynamic data, an imaging system (14) obtains the imaging data. Preferably, the report confirms the absence or presence (and/or severity) of peripheral arterial disease, including quantitative data. The hemodynamic system (12) and the imaging system (14) can communicate directly, indirectly, and/or wirelessly. They may be contained within a common enclosure (50) and/or integrated into a single apparatus (50). Either or both of the hemodynamic system (12) and/or the imaging system (14) can also be configured to measure the blood pressure of the patient. Preferably, the imaging system (14) is an ultrasound imaging system (14), and improved workflows for diagnosing peripheral arterial disease result.
",GEN ELECTRIC,EVERETT DEBORAH ANN;;FRIEDMAN BRUCE;;MULLEN PAUL LAWRENCE;;ZANG WILLIAM ALPHONSUS,,https://lens.org/145-387-171-533-694,Patent Application,yes,4,1,6,6,0,A61B5/02007;;A61B5/022;;A61B8/06;;A61B5/022;;A61B8/06;;A61B5/02007,A61B5/0205;;A61B8/00,,0,0,,,,DISCONTINUED
475,AU,A,AU 2000/063690 A,006-508-777-735-926,2001-02-13,2001,AU 2000/063690 A,2000-07-21,US 14521299 P;;US 0020103 W,1999-07-23,Ultrasonic guidance of target structures for medical procedures,,UNIV FLORIDA,BOVA FRANK J;;BUATTI JOHN M;;MEEKS SANFORD L;;FRIEDMAN WILLIAM,,https://lens.org/006-508-777-735-926,Patent Application,no,0,0,9,9,0,A61B5/7285;;A61B6/5247;;A61B6/541;;A61B8/08;;A61B8/4245;;A61B8/5238;;A61N5/1049;;A61N2005/1058;;A61N2005/1059;;Y10S128/916;;A61B8/5238;;A61N5/1049;;A61B6/541;;A61B8/08;;A61B5/7285;;A61N2005/1059;;A61N2005/1058;;A61B6/5247;;A61B8/4245;;Y10S128/916,G01R33/28;;A61B5/055;;A61B5/06;;A61B6/00;;A61B6/03;;A61B8/00;;A61B8/08;;A61B19/00;;G01S15/89,,0,0,,,,EXPIRED
476,EP,A1,EP 1217947 A1,026-657-759-736-735,2002-07-03,2002,EP 00950608 A,2000-07-21,US 0020103 W;;US 14521299 P,1999-07-23,ULTRASONIC GUIDANCE OF TARGET STRUCTURES FOR MEDICAL PROCEDURES,,UNIV FLORIDA,BOVA FRANK J;;BUATTI JOHN M;;MEEKS SANFORD L;;FRIEDMAN WILLIAM,,https://lens.org/026-657-759-736-735,Patent Application,yes,0,0,9,9,0,A61B8/5238;;A61B8/5238;;A61B5/7285;;A61B5/7285;;A61B6/5247;;A61B6/5247;;A61B6/541;;A61B6/541;;A61B8/08;;A61B8/08;;A61B8/4245;;A61B8/4245;;A61N5/1049;;A61N5/1049;;A61N2005/1058;;A61N2005/1058;;A61N2005/1059;;A61N2005/1059;;Y10S128/916;;Y10S128/916,G01R33/28;;A61B5/055;;A61B5/06;;A61B6/00;;A61B6/03;;A61B8/00;;A61B8/08;;A61B19/00;;G01S15/89,,0,0,,,,DISCONTINUED
477,US,A1,US 2010/0198062 A1,090-330-533-401-656,2010-08-05,2010,US 36294209 A,2009-01-30,US 36294209 A,2009-01-30,SYSTEMS AND METHODS FOR INTEGRATING HEMODYNAMIC AND IMAGING EXAMINATIONS,"Hemodynamic data and imaging data are obtained about a patient, and the data is combined to generate a single report integrating same. While a hemodynamic system obtains the hemodynamic data, an imaging system obtains the imaging data. Preferably, the report confirms the absence or presence (and/or severity) of peripheral arterial disease, including quantitative data. The hemodynamic system and the imaging system can communicate directly, indirectly, and/or wirelessly. They may be contained within a common enclosure and/or integrated into a single apparatus. Either or both of the hemodynamic system and/or the imaging system can also be configured to measure the blood pressure of the patient. Preferably, the imaging system is an ultrasound imaging system, and improved workflows for diagnosing peripheral arterial disease result.",GEN ELECTRIC,EVERETT DEBORAH ANN;;FRIEDMAN BRUCE;;MULLEN PAUL LAWRENCE;;ZANG WILLIAM ALPHONSUS,GENERAL ELECTRIC COMPANY (2009-01-27),https://lens.org/090-330-533-401-656,Patent Application,yes,15,9,6,6,0,A61B5/02007;;A61B5/022;;A61B8/06;;A61B5/022;;A61B8/06;;A61B5/02007,A61B5/02;;A61B8/00,600/437;;600/490,0,0,,,,ACTIVE
478,US,B1,US 11806711 B1,064-588-348-194-574,2023-11-07,2023,US 202217647807 A,2022-01-12,US 202217647807 A;;US 202163228023 P;;US 202163203820 P;;US 202163201062 P;;US 202163199696 P;;US 202163199610 P,2021-01-12,"Systems, devices, and methods for fluidic processing of biological or chemical samples using flexible fluidic circuits","Various fluidic structures are described that may be implemented between two portions of material, at least one of which may be made of a flexible but inelastic material, such as Mylar. Such fluidic circuits may be configured such that applying a clamping pressure zone to such fluidic circuits and then moving the clamping pressure zone along the fluidic circuit and along a particular axis may cause the fluidic circuit to operate in a particular manner, thereby driving fluids contained within the fluidic circuit around the fluidic circuit according to a desired flow sequence.",HOUND LABS INC,FRIEDMAN DANIEL H;;D'AMBROSIO MICHAEL V;;WELCH WILLIAM;;NGUYEN THU M,HOUND LABS INC (2022-01-21);;TRIPLE RING TECHNOLOGIES INC (2023-07-24),https://lens.org/064-588-348-194-574,Granted Patent,yes,159,1,1,1,0,B01L2400/0481;;B01L2400/0683;;B01L2300/0816;;B01L2300/087;;B01L2300/123;;B01L3/505;;B01L3/502738;;B01L2400/0688;;B01L3/50273,B01L3/00,,258,207,049-466-383-422-676;;079-563-448-675-707;;048-743-207-280-601;;080-048-418-399-974;;037-132-335-634-388;;055-115-853-851-17X;;076-510-803-459-198;;017-069-168-307-894;;051-708-714-464-629;;038-474-779-115-470;;076-784-131-400-940;;076-507-647-794-842;;096-593-689-720-226;;005-730-200-314-327;;007-191-056-117-064;;074-159-413-719-566;;059-991-870-664-902;;021-892-729-339-788;;084-128-032-306-240;;034-829-199-514-867;;039-793-417-332-528;;009-171-032-174-325;;025-242-880-299-206;;069-999-941-667-334;;022-191-680-240-473;;133-963-873-702-39X;;007-342-222-116-282;;022-671-984-647-072;;026-654-600-542-281;;049-216-272-797-254;;012-996-977-927-896;;001-431-766-640-943;;043-245-974-755-037;;034-428-867-749-550;;148-330-034-230-496;;066-452-309-737-759;;022-842-608-244-345;;135-285-137-875-615;;193-601-936-470-118;;005-175-844-634-713;;169-786-093-426-648;;005-097-744-645-625;;020-776-201-626-055;;101-903-348-344-293;;022-427-786-066-838;;000-949-853-808-775;;083-171-732-612-721;;008-933-505-153-703;;071-405-081-158-660;;008-016-511-528-032;;081-726-735-890-894;;004-131-523-529-655;;017-354-371-712-871;;014-755-155-592-578;;082-020-497-441-656;;111-127-593-042-452;;027-987-249-892-074;;030-316-109-388-889;;014-232-843-242-042;;082-250-439-788-081;;044-169-128-332-136;;039-695-933-492-465;;005-390-228-551-027;;037-260-983-987-911;;037-118-509-525-579;;007-831-702-063-332;;046-489-700-031-656;;022-165-061-242-171;;071-459-158-136-851;;119-948-986-485-86X;;012-773-870-627-094;;067-152-104-292-807;;133-406-584-175-034;;034-234-314-175-272;;048-771-102-136-388;;040-187-446-664-148;;033-418-665-391-057;;073-882-433-217-498;;086-949-631-447-871;;096-877-937-211-696;;072-165-373-905-53X;;103-475-553-796-875;;012-083-063-644-930;;023-292-397-742-258;;104-700-346-803-440;;016-673-746-328-297;;127-139-661-302-703;;004-285-715-433-49X;;063-327-945-949-603;;040-342-915-462-379;;012-778-042-919-609;;113-568-654-931-533;;008-870-648-164-471;;109-004-952-663-794;;046-331-024-240-099;;003-829-733-851-608;;101-135-909-384-529;;110-159-856-944-061;;015-517-614-064-735;;070-866-407-877-055;;023-977-736-705-745;;023-951-008-461-29X;;067-051-330-271-948;;011-276-097-669-364;;064-342-530-521-914;;022-415-571-600-994;;002-343-906-831-167;;015-018-075-636-549;;076-940-109-247-267;;035-793-118-591-102;;046-504-095-632-690;;014-610-940-049-354;;059-307-049-848-49X;;008-013-891-911-661;;013-638-794-960-614;;096-176-835-117-146;;019-072-171-899-034;;158-231-103-588-934;;077-984-158-739-218;;064-438-798-298-107;;017-081-925-352-169;;020-574-332-001-711;;043-890-900-430-936;;017-949-905-974-933;;040-929-663-126-442;;016-900-706-909-844;;083-370-334-802-468;;093-765-162-543-373;;024-426-334-637-116;;058-296-534-753-665;;000-771-747-316-042;;007-479-749-250-477;;008-213-584-884-460;;122-386-127-402-022;;030-616-634-582-780;;075-071-668-135-298;;100-343-590-683-710;;013-052-503-973-389;;076-473-289-796-668;;114-079-335-496-14X;;060-494-303-754-694;;120-354-693-074-888;;010-238-824-977-117;;079-965-982-665-412;;011-830-961-874-121;;007-697-675-758-07X;;091-167-399-773-887;;102-859-041-244-504;;088-580-986-013-138;;091-373-141-408-951;;014-906-864-380-733;;074-123-659-060-015;;091-959-426-265-091;;020-259-610-727-281;;136-208-570-906-66X;;030-576-566-513-201;;053-939-850-114-077;;073-827-615-882-681;;027-343-186-748-433;;032-850-615-442-641;;051-946-601-235-348;;034-492-605-831-745;;012-495-789-498-531;;125-736-394-500-942;;003-881-682-645-051;;019-054-392-384-238;;101-212-030-110-961;;076-000-457-549-106;;117-684-703-722-484;;032-091-248-899-900;;040-967-257-151-658;;053-554-350-708-824;;042-240-669-007-762;;097-690-499-073-110;;009-764-407-103-755;;040-142-603-108-606;;071-415-543-564-970;;016-678-081-099-380;;006-373-366-756-727;;129-031-926-887-080;;069-138-914-800-625;;053-102-275-743-103;;029-998-561-211-102;;025-080-585-444-563;;011-136-685-192-22X;;019-285-537-051-863;;001-094-696-940-419;;027-156-889-616-118;;026-141-567-909-059;;007-820-852-337-972;;085-188-338-104-028;;019-259-129-702-947;;007-747-832-713-012;;024-776-520-768-005;;013-285-310-692-617;;025-059-359-682-567;;006-899-664-484-471;;083-008-960-752-435;;014-069-643-793-424;;021-791-080-374-091;;110-921-223-767-263;;031-728-575-315-035;;088-252-171-644-18X;;003-056-888-906-851;;016-028-490-207-94X;;115-580-747-262-097;;010-641-713-713-979,10.1002/anie.201305784;;24127124;;10.1016/j.electacta.2009.01.081;;10.1093/jat/30.8.614;;17132261;;18965558;;10.1016/0039-9140(92)80130-6;;10.1093/jat/34.4.196;;20465865;;10.1016/j.mehy.2005.08.026;;16209908;;27221203;;10.1016/j.cca.2016.05.013;;19110408;;10.1016/j.rmed.2008.11.009;;10.1007/s004140050287;;10876986;;16414979;;10.1152/ajplung.00371.2005;;10.1038/jid.1967.11;;6018244;;10.1001/archpedi.1985.02140130031024;;3904404;;10.1373/clinchem.2008.122119;;19833841;;pmc3196989;;1662560;;10.1093/clinchem/37.12.2062;;10.1021/acssensors.9b00476;;10.1021/acssensors.9b00476.s001;;30907578;;11955826;;10.1016/s0379-0738(02)00023-3;;6294525;;10.1038/s41598-019-49185-y;;pmc6722119;;31481686;;10.1146/annurev.anchem.1.031207.112814;;20636091;;10.1211/0022357022791;;15025853;;10.1093/jat/34.4.210;;20465867;;24854188;;pmc4031072;;10.1371/journal.pone.0095330;;20740278;;10.1007/s00216-010-4109-6;;10.1016/j.aca.2004.12.018;;10.1093/jat/34.4.216;;20465868;;6991645;;10.1021/np50008a001;;8787723;;10.1093/clinchem/42.9.1518;;15067692;;10.1002/jps.20036;;18645719;;10.1080/08958370802013559;;3231372;;10.1038/clpt.1983.179;;6309462;;6271823;;10.1002/j.1552-4604.1981.tb02594.x;;14606995;;10.1093/jat/27.7.429;;24153334;;10.1038/pr.2013.142;;pmc4758820;;26900428;;10.3390/ma8063024;;2848522;;10.1016/s0006-291x(88)80013-5;;1493;;10.1111/j.2042-7158.1975.tb10227.x;;10.26616/nioshhhe201701743335;;6105177;;8990229;;10.1093/clinchem/43.1.100;;10.1300/j175v04n01_04;;20083251;;10.1016/j.chroma.2009.12.053;;pmc2849720;;10.1520/jfs13282j;;1324293;;10.2478/cttr-2013-0834;;16959131;;10.1093/jat/30.7.409;;16803651;;10.1093/jat/30.3.171;;16959132;;10.1093/jat/30.7.413;;10.1093/jat/25.7.555;;11599599;;10.1520/jfs11041j;;2999292;;3386204;;10.1093/jat/12.3.113;;10216980;;10.1093/jat/29.8.842;;16356342;;16356335;;10.1093/jat/29.8.782;;16306858;;10.1097/01.ftd.0000177223.19294.5c;;12404700;;10.1002/hup.369;;11499881;;10.1093/jat/25.5.289;;16419389;;10.1093/jat/29.7.607;;10.1371/journal.pone.0174802;;28384298;;pmc5383041;;6250760;;10.1038/clpt.1980.181;;10.1002/bms.1200090103;;6277407;;10.1103/physrevb.86.235147;;6258825;;10.1093/clinchem/27.4.619;;10.1016/j.snb.2015.02.008;;6366113;;10.1520/jfs11650j;;10.1038/clpt.1982.86;;6280918;;4558903;;10.1126/science.177.4049.633;;10.1002/j.1552-4604.1981.tb02596.x;;6271825;;2176276;;10.1037/e496372006-005;;31321969;;10.1021/acssensors.9b00762.s001;;10.1021/acssensors.9b00762;;10.1016/j.saa.2018.01.030;;29453097;;10.1016/j.aca.2016.08.033;;27639147;;10.1046/j.1360-0443.1996.911115852.x;;10.1111/j.1360-0443.1996.tb02264.x;;8972919;;10.1016/j.clinbiochem.2016.06.003;;27288550;;10.1093/jat/34.4.177;;20465864;;10.1186/s41479-016-0009-7;;28702287;;pmc5471930;;10.2165/00003088-198814040-00003;;3292101;;1313866;;10.1016/0041-008x(87)90338-3;;2820086;;10.4236/jasmi.2013.31004;;10.1038/35003583;;10716447;;2241828;;10.1016/0026-265x(83)90030-9;;10.1038/nmeth.f.230;;10.1088/1752-7155/7/2/026006;;23619392;;10.1093/anatox/35.8.541;;22004672;;10.1038/clpt.1980.139;;7389248;;8394791;;10.1093/clinchem/39.8.1705;;6278139;;10.1021/tx9800598;;9778318;;1352216;;8897084;;10.1016/j.forsciint.2006.04.018;;16859848;;10.1126/science.176.4033.422;;5026162;;10.1016/0091-3057(91)90330-5;;1664106;;9872202;;10.1378/chest.114.6.1653;;10.1016/j.scitotenv.2015.08.051;;26360454;;12100860;;10.1016/s0378-5173(02)00262-4;;10.1093/jat/34.4.169;;20465863;;3932862;;10.1037/e496922006-001;;10.1093/jat/10.4.129;;3018361;;10.1038/s41467-019-10147-7;;pmc6506515;;31068594;;10.1093/jat/20.1.13;;8837945;;10.1093/jat/22.6.460;;9788521;;3184885;;10.1093/jat/12.4.169;;3037193;;10.1093/jat/11.3.89;;15975256;;10.1093/jat/29.4.244;;15899565;;10.1016/j.forsciint.2005.02.028;;10.1126/scitranslmed.aaa3480;;25947164;;10.1093/jat/30.9.645;;17137523;;28412574;;10.1016/j.forsciint.2017.03.023;;10.1038/sj.npp.1300496;;15173844;;10.1038/clpt.1985.226;;3902318;;10.1520/jfs14636j;;10641915;;10.1103/physrevb.91.235137;;10.1016/s0140-6736(03)14738-1;;14615106;;10.1016/j.jaci.2003.10.046;;14767439;;10.1016/j.aca.2017.09.021;;29137702;;16439618;;10.1124/jpet.105.098541;;10.1038/363215a0;;8387642;;10.1007/bf00432554;;6285406;;10.1378/chest.120.4.1136;;11591550;;10999345;;10.1093/jat/24.6.395;;12451292;;10.1097/00007691-200212000-00011;;10.1016/j.forsciint.2004.02.034;;10.1016/s0379-0738(04)00209-9;;15240035;;10.1016/j.forsciint.2003.07.011;;14609657;;4853640;;10.1002/jps.2600630705;;10.1002/jps.2600660322;;845807;;8357462;;10.1016/0001-4575(93)90078-b;;20465866;;10.1093/jat/34.4.204;;16885723;;10.1097/00007691-200608000-00010;;10.1016/j.bpj.2013.02.011;;pmc3602784;;23528085;;9394029;;21386165;;10.1088/1752-7155/2/3/037004;;pmc3058888;;2984463;;10.1093/jat/9.1.1;;10.2165/00003088-200342040-00003;;12648025;;10.1016/j.jchromb.2003.09.022;;14630369;;10.1373/49.7.1114;;12816908;;15107145;;10.1093/jat/28.3.160;;10.1300/j175v03n04_02;;10.1021/ac971228g;;9599579;;6126323;;9653176;;pmc20965;;10.1073/pnas.95.14.8268;;6304423;;10.1093/jat/7.2.96;;9112136;;10.3109/00498259009046849;;2336840;;10.1097/pcc.0b013e3182231644;;pmc4078922;;21666533;;10.1037/e497082006-001;;10.1016/0091-3057(89)90369-9;;2560548;;pmc4537523;;24046200;;10.1373/clinchem.2013.207407;;10.1093/jat/25.7.531;;11599596;;10.1038/clpt.1992.100;;1320536;;10.1093/jat/16.5.276;;1338215;;1338216;;10.1093/jat/16.5.283;;pmc2274831;;10.1016/j.forsciint.2006.08.005;;16963215;;8926739;;10.1093/jat/19.6.443;;10.1093/jat/22.6.445;;9788519;;16223887;;10.1373/clinchem.2005.056838;;10.1093/jat/28.6.394;;15516285;;8889681;;10.1093/jat/20.6.441;;17712819;;10.1002/cbdv.200790152;;pmc2689518;;6270295;;10.1007/bf01059266;;6256518;;10.1021/tx950116m;;8839037;;11569567;;10.1520/jfs15123j;;1338115;;10.1093/jat/16.6.401;;10.1007/bf00679783;;2558889;;2539872;;10.1002/bmc.1130030109;;10.1111/j.2042-7158.1988.tb05272.x;;2899638;;10.1093/jat/13.4.218;;2550702;;10.1371/journal.pone.0139484;;26421725;;pmc4589536;;14519710;;10.1001/jama.290.13.1757;;1323733;;10.1093/jat/16.4.228;;7500614;;10.1093/jat/19.5.285;;7500615;;10.1093/jat/19.5.292;;9700555;;10.1016/s0378-4347(97)00572-0;;7595299;;10.1520/jfs13837j;;11043659;;10.1093/jat/24.7.557;;9166224;;10.1093/clinchem/43.5.736;;pmc3826294;;10.1155/2013/539568;;24288492;;10.1016/b978-0-12-404630-6.00012-9;;20465870;;10.1093/jat/34.4.229;;24339443;;10.1002/ppul.22953;;4682965;;10.1126/science.179.4071.391;;10.2165/00003088-199426020-00007;;8162658;;10.1093/clinchem/37.11.1927;;1934467;;10.1016/j.forsciint.2006.03.033;;16842950;;6145762;;10.1111/j.2042-7158.1984.tb04376.x;;10.1021/jp0687908;;20465869;;10.1093/jat/34.4.222;;10.1126/science.177.4043.62;;5041775;;5087483;;10.1126/science.173.3991.72;;5479011;;10.1126/science.170.3964.1320;;6267648;;10.1007/bf00427095;;10920191;;pmc16904;;10.1073/pnas.160105897;;10.1093/jat/25.7.538;;11599597;;6311456;;10.1016/s0009-9120(83)90070-x;;897339;;2993473;;10.1520/jfs10998j;;6502125;;10.1520/jfs11768j;;10.1016/0024-3205(95)00193-a;;7776836;;8383856;;10.1016/0091-3057(93)90194-x;;10.1016/0091-3057(94)90475-8;;7816872;;10.1093/jat/10.2.56;;3009969;;10.1016/s0009-3084(02)00144-5;;12505688;;pmc1751232;;10.1038/sj.bjp.0706415;;16205721;;9157527;;1851311;;10.1007/bf02244217,"“Pexa—The importance of early diagnosis”, downloaded on Mar. 25, 2019 from http://pexa.se/en/respiratory-research/the-importance-of-early-diagnosis/.;;“Pexa—The search for new biomarkers”, downloaded on Mar. 25, 2019 from http://pexa.se/en/respiratory-research/the-search-for-new-biomarkers/.;;Piao, Wen et al., “Development of azo-based fluorescent probes to detect different levels of hypoxia,” Angew. Chem. Int. Ed. 2013, 52, 13028-13032.;;Prodromidis, M.I., “Impedimetric immunosensors—A review”, Electrochimica Acta, (May 30, 2010), 55(14):4227-33.;;Quintela, Oscar et al., “Recovery of drugs of abuse from the immunalysis quantisal oral fluid collection device,” Journal of Analytical Toxicology, vol. 30, Oct. 2006.;;Rahim S.A. et al., “Colorimetric determination of ethanol in the presence of methanol and other species in aqueous solution,” Taianta. Nov. 1992;39(11):1489-91, PubMed abstract 18965558.;;Rohrich, J. et al., “Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to cannabis smoke in a coffee shop,” Journal of Analytical Toxicology, vol. 34, May 2010.;;Russo, E. et al., “A tale of two cannabinoids: the therapeutic rational for combining tetrahydrocannabinol and cannabidiol,” Med Hypotheses. 2006;66(2):234-46, PubMed abstract 16209908.;;Saalberg, Yannick and Marcus Wolff, “VOC breath biomarkers in lung cancer”, Clinica Chimica Acta, (Aug. 1, 2016), 459:5-9.;;Samitas, K., et al., “Exhaled cysteinyl-leukotrienes and 8-isoprostane in patients with asthma and their relation to clinical severity”, Respiratory medicine, (May 1, 2009), 103(5):750-6.;;Samyn N. et al., “On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users,” Int J Legal Med. 2000;113(3):150-4, PubMed abstract 10876986.;;Sarafian, Theodor et al., “Inhaled marijuana smoke disrupts mitochondrial energetics in pulmonary epithelial cells in vivo,” Am J Physiol Lung Cell Mol Physiol, 2006, 290. L1202-L1209. (Year:2006).;;Scheuplein, Robert J., “Mechanism of percutaneous absorption. II. Transient diffusion and the relative importance of various routes of skin penetration,” J. Invest. Dermatol 1967;48:79.;;Schwartz, Richard H. et al., “Laboratory detection of marijuana use, Experience with a photometric immunoassay to measure urinary cannabinoids,” Aj J Dis Child. 1985;139(11): 1093-1096, abstract.;;Schwilke, Eugene W. et al., “Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC,” Clinical Chemistry 55:12 2180-2189 (2009).;;Shaw, Leslie M. et al., “Ultrasensitive measurement of delta-9-tetrahydrocannabinol with a high energy dynode detector and electron-capture negative chemical-ionization mass spectrometry,” Clin. Chem. 37/12, 2062-2068 (1991).;;Sigma, “How Proximity Ligation Assays (PLA) Work”.;;Sivashanmugan K, Squire K, Tan A, Zhao Y, Kraai JA, Rorrer GL, Wang AX. Trace detection of tetrahydrocannabinol in body fluid via surface-enhanced Raman scattering and principal component analysis. ACS sensors. Mar. 25, 2019;4(4):1109-17.;;Skopp, G. et al., “Partition coefficient, blood to plasma ratio, protein binding and short-term stability of 11-nor-Delta(9)-carboxy tetrahydrocannabinol glucuronide,” Forensic Sci Int. Mar. 28, 2002;126(1):17-23, PubMed abstract 11955826.;;Soares, J.R. et al., “Significant developments in radioimmune methods applied to delta9-THC and its 9-substituted metabolites,” Analysis of Cannabinoids Research Monograph 42, NIDA 1982.;;“Drug detection, health monitoring etc.”, SensAbues AB—Innovation, downloaded on Mar. 25, 2019 from http://sensabues.com/innovation.;;“Exhaled breath sampling company”, SensAbues AB—About, downloaded on Mar. 25, 2019 from http://sensabues.com/about.;;Stevenson H, Bacon A, Joseph KM, Gwandaru WR, Bhide A, Sankhala D, Dhamu VN, Prasad S. A rapid response electrochemical biosensor for detecting THC in saliva. Scientific reports. Sep. 3, 2019; 9(1):1-11. (11 pages) //9:12701 https://doi.org/10.1038/s41598-019-49185-y.;;Stiles PL, Dieringer JA, Shah NC, Van Duyne RP. Surface-enhanced Raman spectroscopy. Annu. Rev. Anal. Chem . . . Jul. 19, 2008;1:601-26.;;Stinchcomb, A.L. et al., “Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannbinol,”J Pharm Pharmacol. Mar. 2004;56(3):291-7, PubMed abstract 15025853.;;Strano-Rossi, Sabina et al., “Analysis of stimulants in oral fluid and urine by gas chromatography-mass spectrometry II: Pseudophedrine,” Journal of Analytical Toxicology, vol. 34, May 2010.;;Switz, N. A., et al., “Low-Cost Mobile Phone Microscopy with a Reversed Mobile Phone Camera Lens”, PloS one, (May 22, 2014), 9(5):e95330. 7 pages.;;Tan, Chongxiao et al., “Direct detection of delta9-tetrahydrocannabinol in aqueous samples using a homogeneous increasing fluorescence immunoassay (HiFi),” Anal Bioaanal Chem, 2010. 8 pgs.;;Teshima, N. et al., “Determination of acetone in breath”, Analytica Chimica Acta, 2005, 535, pp. 189-199.;;“The Chemistry of Phenols,” Zvi Rappoport, editor, © 2003 John Wiley & Sons, Ltd. ISBN: 0-471-49737-1.;;Toennes, Stefan W et al., “Pharmacokinetic properties of delta9-tetrahydrocannabinol in oral fluid of occasional and chronic users,” Journal of Analytical Toxicology, vol. 34, May 2010.;;Townsend, Doug, Ian Eustis, Mark Lewis, Steven Rodgers, Kevin Smith, Ariel Bohman, C. T. Shelton, and C. A. Sacramento. “The Determination of Total THC and CBD Content in Cannabis Flower by Fourier Transform Near Infrared Spectroscopy.” (2018); Document No. 014329_01, 5 pages, accessed at perkinelmer.com/lab-solutions/resources/docs/app_determination_of_thc_and_cbd_cannabisflower.pdf.;;Turner, Carton E. et al., “Constituents of cannabis sativa I. XVII. A review of the natural constituents,” J. Nat. Prod. 1980;43:169.;;Ullman EF, Kirakossian H, Switchenko AC, Ishkanian J, Ericson M, Wartchow CA, Pirio M, Pease J, Irvin BR, Singh S, Singh R. Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method. Clinical chemistry. Sep. 1, 1996;42(9):1518-26.;;Vahimaa P et al., “Surface-Enhanced Raman Spectroscopy (SERS),” Institute of Photonics at the University of Eastern Finland, accessible at sway.com/s/XtgAoh8F5QewSEFL/embed.;;Valiveti, S. et al., “In vitro/in vivo correlation studies for transdermal delta 8-THC development,” J Pharm Sci. May 2004;93(5):1154-64, PubMed abstract 15067692.;;Van der Kooy, F. et al., “Cannabis smoke condensate I: The effect of different preparation methods on tetrahydrocannabinol levels,” Inhalation Toxicology, 20:801-804, 2008.;;Vinciguerra, V. et al., “Inhalation marijuana as an antiemetic for cancer chemotherapy,” NY State J Med. Oct. 1988;88(10):525-7.;;“Volatile Organic Compounds (VOC) as non-invasive biomarkers for a range of diseases”, downloaded on Mar. 25, 2019 from https://www.owlstonemedical.com/science-technology/voc-biomarkers/.;;Wall, M.E. et al., “Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women,” Clin Pharmacol Ther. Sep. 1983;34(3):352-63, PubMed abstract 6309462.;;Wall, M.E. et al., “The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man,” J Clin Pharmacol. Aug.-Sep. 1981;21 (8-9 Suppl):178S-189S, PubMed abstract 6271823.;;Walsh, J. Michael et al., “An evaluation of rapid point-of-collection oral fluid drug-testing devices,” Journal of Analytical Toxicology, vol. 27, Oct. 2003.;;Wan, G.H., et al., “Cysteinyl leukotriene levels correlate with 8-isoprostane levels in exhaled breath condensates of atopic and healthy children”, Pediatric research (Nov. 2013), 74(5):584.;;Wang, AX, Kong X. Review of recent progress of plasmonic materials and nano-structures for surface-enhanced Raman scattering. Materials. Jun. 2015;8(6):3024-52.;;Watanabe, K. et al., “Brain microsomal oxidation of delta 8- and delta 9- tetrahydrocannabinol,” Biochem Biophys Res Commun. Nov. 30, 1988;157(1):75-80, PubMed abstract 2848522.;;Widman, M. et al., “Metabolism of delta 1-tetrahydrocannabinol by the isolated perfused dog lung. Comparison with in vitro liver matabolism.” J Phar Pharmacol. Nov. 1975;27(11):842-8, PubMed abstract 1493.;;Wiegand, D.M. et al., “Evaluation of police officers exposure to secondhand cannabis smoke at open-air stadium events”, NIOSH health hazard evaluation report; HHE 2017-0174-335, (Mar. 2019), https://www.cdc.gov/niosh/hhe/reports/pdfs/2017-0174-3335.pdf.;;Williams, P.L. et al., “Identification in human urine of delta 9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite,” J Pharm Pharmacol. Jul. 1980;32(7):445-8, PubMed abstract 6105177.;;Wingert, William E., “Lowering cutoffs for initial and confirmation testing for cocaine and marijuana: large-scale study of effects on the rates of drug-positive results,” Clinical Chemistry 43:1 100-103 (1997).;;Written Opinion of the Searching Authority dated Apr. 6, 2020, for International Patent Application No. PCT/US2020/13553, 7 pages.;;Mikuriya, Tod H., “Cannabis as a substitute for alcohol: a harm-reduction approach,” Journal of Cannabis Therapeutics, vol. 4(1) 2004.;;Milman, Garry et al., “Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry,” J Chromatogr A. Feb. 26, 2010; 1217(9): 1513-1521.;;Moeller, M.R et al., “Simultaneous quantitation of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) in serum by GC/MS using deuterated internal standards and its application to a smoking study and forensic cases,” J Forensic Sci. Jul. 1992;37(4):969-83, PubMed abstract 1324293.;;Moldoveanu, Serban C. et al., “Differences in the chemical composition of the particulate phase of inhaled and exhaled cigarette mainstream smoke,” Contributions to Tobacco Research 22(4), 290 (2007).;;Moore, Christine et al., “Analytical procedure for the determination of the marijuana metabolite 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in oral fluid specimens,” Journal of Analytical Toxicology, vol. 30, Sep. 2006.;;Moore, Christine et al., “Application of two-dimensional gas chromatography with electron capture chemical ionization mass spectrometry to the detection of 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in hair,” Journal of Analytical Toxicology, vol. 30, Apr. 2006.;;Moore, Christine et al., “Detection of the marijuana metabolite 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in oral fluid specimens and its contribution to positive results in screening assays,” Journal of Analytical Toxicology, vol. 30, Sep. 2006.;;Moore, Christine et al., “The determination of 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in hair using negative ion gas chromatography-mass spectrometry and high-volume injection,” Journal of Analytical Toxicology, vol. 25, Oct. 2001.;;Morland, J. et al., “Cannabinoids in blood and urine after passive inhalation of cannabis smoke,” J Forensic Sci. 1985 0ct;30(4):997-1002, PubMed abstract 2999292.;;Mule, S.J. et al., “Active and realistic passive marijuana exposure tested by three immunoassays and GC/MS in urine,” Journal of Analytical Toxicology, vol. 12, May/Jun. 1988.;;Mura, P. et al., “Evaluation of six rapid tests for screening of cannabis in sweat, saliva and tears,” Acta Clin Belg. 1999;53 Suppl 1:35-8, PubMed abstract 10216980.;;Mura, P. et al., “THC can be detected in brain while absent in blood,” Letter to the Editor, Journal of Analytical Toxicology, vol. 29, Nov./Dec. 2005.;;Nadulski T. et al., “Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract,” Journal of Analytical Toxicology, vol. 29, Nov./Dec. 2005.;;Nadulski T. et al., “Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delat9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract,” Ther Drug Monit. Dec. 2005;27(6):799-810.;;Nahas, Gabriel G. et al., “Pharmacokinetics of THC in brain and testis, male gametotoxicity and premature apoptosis of spermatozoa,” Human Psycopharmacology: Clinical and Experimental, vol. 17, Issue 2, pp. 103-113, Mar. 2002, abstract.;;Niedbala, R. Sam et al., “Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana,” Journal of Analytical Toxicology, vol. 25, Jul./Aug. 2001.;;Niedbala, R. Sam et al., “Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle,” Journal of Analytical Toxicology, vol. 29, Oct. 2005.;;“N.S. woman who tested positive for pot when she wasnt high to challenge roadside testing laws,” CBC Radio, posted Apr. 3, 2019. 6 pages.;;Oguma, T., et al., “Clinical contributions of exhaled volatile organic compounds in the diagnosis of lung cancer”, PloS one, (Apr. 6, 2017), 12(4):e0174802.;;Ohlsson, A. et al., “Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking,” Clin Pharmacol Ther. Sep. 1980;28(3):409-16, PubMed abstract 6250760.;;Ohlsson, Agneta et al., “Single dose kinetics of deuterium labelled delta1-tetrahydrocnnabinol in heavy and light cannabis users,” Biological Mass Spectrometry, vol. 9, Issue 1, pp. 6-10, Jan. 1982, abstract.;;Olmon RL, Slovick B, Johnson TW, Shelton D, Oh SH, Boreman GD, Raschke MB. “Optical dielectric function of gold”, Physical Review B. Dec. 28, 2012;86(23):235147.;;Owens, S. Michael et al., I Radioimmunoassay of delta-9-tetrahydrocannabinol in blood and plasma with a solid-phase second-antibody separation method, Clin. Chem. 27/4, 619-624 (1981).;;“Owlstone—About”, downloaded on Mar. 25, 2019 from https://www.owlstonemedical.com/about/.;;“Owlstone—EVOC Probes”, downloaded on Mar. 25, 2019 from https://www.owlstonemedical.com/science-technology/evoc-probes/.;;“Owlstone—FAIMS technology”, downloaded on Mar. 25, 2019 from https://www.owlstonemedical.com/science-technology/faims-technology/.;;“Owlstone—Research case studies”, downloaded on Mar. 25, 2019 from https://www.owlstonemedical.com/science-technology/research-case-studies/.;;“Owlstone Medical—Active Clinical Pipeline”, downloaded on Mar. 25, 2019 from https://www.owlstonemedical.com/clinical-pipeline/.;;“Owlstone Medical—Products”, downloaded on Mar. 21, 2019 from https://www.owlstonemedical.com/products/.;;“Owlstone Medical—The Home of Breath Biopsy: A Breathalyzer for Disease”, downloaded on Mar. 25, 2019 from https://www.owlstonemedical.com/#.;;“Owlstone Medical—The Home of Breath Biopsy: Breath Biopsy—VOC Biomarkers”, downloaded on Mar. 25, 2019 from https://www.owlstonemedical.com/#.;;Pardon, G, et al., “Aerosol sampling using an electrostatic precipitator integrated with a microfluidic interface”, Sensors and Actuators B: Chemical. Feb. 2015, vol. 212, pp. 344-352.;;Peel, H.W. et al., “Detection of drugs in saliva of impaired drivers,” J Forensic Sci. Jan. 1984;29(1):185-9, PubMed abstract 6366113.;;Perez-Reyes, M. et al., “Comparison of effects of marihuana cigarettes to three different potencies,” Clin Pharmacol Ther. May 1982;31(5):617-24, PubMed abstract 6280918.;;Perez-Reyes, M. et al., “Intravenous injection in man of 9-tetrahydrocannabinol and 11-OH-9-tetrahydrocannabinol,” Science. Aug. 18, 1972;177(4049):633-5, PubMed abstract 4558903.;;Perez-Reyes, M. et al., “The clinical pharmacology and dynamics of marihuana cigarette smoking,” J Clin Pharmacol. Aug.-Sep. 1981;21(8-9 Suppl):201S-207S, PubMed abstract 6271825.;;Perez-Reyes, Mario, “Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol,” NIDA Monograph 1990;99:42.;;PerkinElmer Inc., “TSA Signal Amplification (TSA) Systems,” Document No. 007703_01, 16 pages, accessed at perkinelmer.com/lab-solutions/resources/docs/BRO_tsasignalamplification systems.pdf.;;“Pexa—About PExA”, downloaded on Mar. 25, 2019 from http://pexa.se/en/about-pexa/.;;“Pexa—Analysis”, downloaded on Mar. 25, 2019 from http://pexa.se/en/product-services/analysis/.;;“Pexa—Business Concept & Vision”, downloaded on Mar. 25, 2019 from http://pexa.se/en/about-pexa/business-concept-vision/.;;“Pexa—History”, downloaded on Mar. 25, 2019 from http://pexa.se/en/about-pexa/history/.;;“Pexa—How PExA works”, downloaded on Mar. 25, 2019 from http://pexa.se/en/product-services/how-pexa-works/.;;“Pexa—Particles in Exhaled Air”, downloaded on Mar. 25, 2019 from http://pexa.se/en/.;;“Pexa—PExA 2.0”, downloaded on Mar. 25, 2019 from http://pexa.se/en/product-services/pexa-2-0/.;;“Pexa—Product Services”, downloaded on Mar. 25, 2019 from http://pexa.se/en/product-services/.;;“Pexa—Product-Sheet”, Sep. 2016.;;“Pexa—Research & Development”, downloaded on Mar. 25, 2019 from http://pexa.se/en/product-services/research-development/.;;“Pexa—Research areas”, downloaded on Mar. 25, 2019 from http://pexa.se/en/respiratory-research/research-areas/.;;“Pexa—Respiratory Research Needs”, downloaded on Mar. 25, 2019 from http://pexa.se/en/respiratory-research/.;;Sean I. Hwang, “Tetrahydrocannabinol Detection Using Semiconductor-Enriched Single-Walled Carbon Nanotube Chemiresistors”, 2019 hereafter Hwang (Year: 2019).;;Sarah Milliken, “Self-assembled vertically aligned Au nanorod arrays for surface-enhanced Raman scattering (SERS) detection of Cannabinol”, Jan. 12, 2018 (Year: 2018).;;Sezin Yuksel, “Trace detection of tetrahydrocannabinol (THC) with a SERS-based capillary platform prepared by the in situ microwave synthesis of AgNPs”, May 24, 2016 (Year: 2016).;;Massachusetts Probation Service, “Probation″s Plan to Strengthen Drug Testing”, Apr. 15, 2016 (Year: 2016).;;Adams, I.B. et al., “Cannabis: pharmacology and toxicology in animals and humans,” Addiction, Nov. 1996;91 (11):1585-614, PubMed abstract 8972919.;;Coucke et al., “Tetrahydrocannabinol concentrations in exhaled breath and physiological effects following cannabis intake—A pilot study using illicit cannabis”, Clinical Biochemistry, 2016, pp. 1072-1077.;;Al-Asmari, Ahmed et al., “Method for the quantification of diamorphine and its metabolites in pediatric plasma samples by liquid chromatography-tandem mass spectrometry,” Journal of Analytical Toxicology, vol. 34, May 2010.;;Alexander, Brentan R., “Design of a microbreather for two-phase microchannel devices”, Dissertation submitted to Massachusetts Institute of Technology. Dept. of Mechanical Engineering, (Jun. 2008), 59 pages.;;Aliberti, S, et al., “Serum and exhaled breath condensate inflammatory cytokines in community-acquired pneumonia: a prospective cohort study”, Pneumonia (Nathan), (Jun. 23, 2016), 8:8. doi: 10.1186/s41479-016-0009-7. eCollection 2016.;;Andrews, Travis M., “Breathalyzers of the Future Today,” The Atlantic, Jun. 27, 2013. Downloaded from the Internet on Feb. 4, 2019, http://www.theatlantic.com/health/archive/2013/06/breathalyzers-of-the-future-today/277249/.;;Atkinson, H.C. et al., “Drugs in human milk. Clinical pharmacokinetic considerations.” Clin Pharmacokinet. Apr. 1988;14 (4):217-40, PubMed abstract 3292101.;;Azorlosa, J.L. et al., “Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs,” J. Pharmacol. Exper. Ther 1992;261:114, abstract.;;Bailey, J.R. et al., “Fetal disposition of delta 9-tetrahydrocannabinol (THC) during late pegnancy in the rhesus monkey,” Toxicol Appl Pharmacol. Sep. 15, 1987;90(2):315-21, abstract.;;Bajaj, P., and F.T. Ishmael, “Exhaled breath condensates as a source for biomarkers for characterization of inflammatory lung diseases”, Journal of Analytical Sciences, Methods and Instrumentation, (Mar. 20, 2013), 3(01):17.;;Baker, D. et al., “Cannabinoids control spasticity and tremor in a multiple sclerosis model,” Nature, Mar. 2, 2000;404(6773):84-7, abstract.;;Balabanova, S. et al., “Detection of drugs in sweat,” Belt Gerichtl Med. 1990;48:45-9, abstract.;;Bashir, W. et al., “Spectrophotometric Determination of Acetone in Acetic Acid”, Microchemical Journal, 1983, 28, pp. 77-81.;;Beaudet L, Rodriguez-Suarez R, Venne MH, Caron M, Bedard J, Brechler V, Parent S, Bielefeld-Sevigny M. “AlphaLISA immunoassays: the no-wash alternative to ELISAs for research and drug discovery”, Nature Methods, (Dec. 2008), 5(12):an8-9.;;Beck, O., et al., “Detection of drugs of abuse in exhaled breath using a device for rapid collection: comparison with plasma, urine and self-re porting in 47 drug users” Journal of breath research, (Apr. 25, 2013), 7(2):026006.;;Beck, Olof et al., “Detection of Delta9-tetrahydrocannabinol in exhaled breath collected from cannabis users,” Journal of Analytical Toxicology, vol. 35, Oct. 2011.;;Benowitz, Neal L. et al., “Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction,” Clinical Pharmacology and Therapeutics (1980) 28, 115-120, abstract.;;Blanc, Jennifer A. et al., “Adsorption losses from urine-based cannabinoid calibrators during routine use,” Clin. Chem. 39/8, 1705-1712 (1993).;;Bloom, A.S., Effect of delta9-tetrahydrocannabinol on the synthesis of dopamine and norepinephrine in mouse brain synaptosomes, J Pharmocol Exp Ther. Apr. 1982;221(1):97-103.;;Bornheim, Lester M. et al., “Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator,” Chem. Res. Toxicol., 1998, 11 (10), pp. 1209-0450.;;Bornheim, L.M. et al., “Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol,” Drug Metab Dispos. Mar.-Apr. 1992;20(2):241-6, PubMed abstract 1352216.;;Brenneisen, R. et al., “The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spaticity: a pilot study with 2 patients,” Int J Clin Pharmocol Ther. Oct. 1996;34(10):446-52.;;Brunet, B. et al., “Validation of large white pig as an animal model for the study of cannabinoids metabolism: application to the study of THC distribution in issues,” Forensic Sci Int. Sep. 12, 2006;161(2-3):169-74, PubMed abstract 16859848.;;Burstein, S. et al., “Isolation and characterization of two major urinary metabolites of 1-tetrahydrocannabinol,” Science, Apr. 28, 1972;176(4033):422-3, PubMed abstract 5026162.;;Cami, J. et al., “Effect of subject expectancy on the THC intoxication and disposition from smoked hashish cigarettes,” Pharmacology Biochemistry and Behavior, vol. 40, Issue 1, Sep. 1991, pp. 115-119.;;Carpenter, C.T., Price PV, Christman BW. Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury or ARDS. Chest. Dec. 1, 1998;114(6):1653-9.;;Cecinato, A., Balducci C, Perilli M., “Illicit psychotropic substances in the air: The state-of-art”, Sci Total Environ, (Jan. 1, 2016), 539:1-6. doi: 10.1016/j.scitotenv.2015.08.051. Epub Sep. 8, 2015. PMID: 26360454.;;Challapalli, P.V. et al., “In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation,” Int J Pharm. Jul. 25, 2002;241(2):329-39, PubMed abstract 12100860.;;Chaturvedi, Arvind K., “Postmortem aviation forensic toxicology: an overview,” Journal of Analytical Toxicology, vol. 34, May 2010.;;Chiang, C. Nora et al., “Prenatal drug exposure: kinetics and dynamics,” NIDA Research Monograph 60, 1985.;;Christophersen, Asbjorg Solberg et al., “Tetrahydrocannabinol stability in whole blood: plastic versus glass containers,” Journal of Analytical Toxicology, vol. 10, Jul./Aug. 1986.;;Chuah K, Wu Y, Vivekchand SR, Gaus K, Reece PJ, Micolich AP, Gooding JJ. “Nanopore blockade sensors for ultrasensitive detection of proteins in complex biological samples”, Nature communications, (May 8, 2019), 10(1):1-9. (9 pages).;;Cirimele, V. et al., “Testing human hair for cannabis. III. Rapid screening procedure for the simultaneous identification of delta9-tetrahydrocannabinol, cannabinol, and cannabidiol,” Journal of Analytical Toxicology, vol. 20, Jan./Feb. 1996.;;Cone, Edward J. et al., “In vivo adulteration: excess fluid ingestion causes false-negative marijuana and cocaine urine test results,” Journal of Analytical Toxicology, vol. 22, Oct. 1998.;;Cone, Edward J. et al., “Marijuana-laced brownies: behavioral effects, physiologic effects, and urinalysis in humans following ingestion,” Journal of Analytical Toxicology, vol. 12, Jul./Aug. 1988.;;Cone, EJ, Johnson RE, Darwin WD, Yousefnejad D, Mell LD, Paul BD, Mitchell J., “Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol”, J Anal Toxicol. (May-Jun 1987), 11 (3):89-96. doi: 10.1093/jat/11.3.89. PMID: 3037193.;;Crouch, Dennis J. et al., “An evaluation of selected oral fluid point-of-collection drug-testing devices,” Journal of Analytical Toxicology, vol. 29, May/Jun. 2005.;;Crouch, D.J., “Oral fluid collection: the neglected variable in oral fluid testing,” Forensic Sci Int. Jun. 10, 2005;150(2-3):165-73, PubMed abstract 15899565.;;D'Ambrosio, M. et al., “Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope”, Science Translational Medicine (May 6, 2015), vol. 7, Issue 286, p. 286re4. 10 pages.;;Day, David et al., “Detection of THCA in oral fluid by GC-MS-MS,” Journal of Analytical Toxicology, vol. 30, Nov./Dec. 2006.;;Doran, GS, Deans R, De Filippis C, Kostakis C, Howitt JA., “Work place drug testing of police officers after THC exposure during large volume cannabis seizures”, Forensic Sci Int. (Jun. 2017), 275:224-233. doi: 10.1016/j.forsciint.2017.03.023. Epub Apr. 2, 2017. PMID: 28412574.;;D'Souza, Deepak Cyril et al., “The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis,” Neuropsychopharmacology (2004) 29, 1558-1572.;;Dunk, et al., “Development of a Portable Marijuana Breathalyzer”, (Mar. 2018), URL=http://https://houndlabs.com/wp-content/uploads/2018/03/Hound-TRT-Pittcon-Poster.pdf.;;Ellis, George M. Jr. et al. “Excretion patterns of cannabinoid metabilites after last use,” 420 Magazine, Oct. 4, 2011, downloaded from https://www.420magazine.com/forums/drug-testing-urine/153724.;;Ellis, G.M. Jr. et al., “Excretion patterns of cannabiniod metabolites after last use in a group of chronic users,” Clin Pharmacol Ther. Nov. 1985;38(5):572-8, PubMed abstract 3902318.;;ElSohly, M. et al., “Potency trends of Delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997,” Journal of Forensic Sciences, vol. 45, No. 1, 2000, pp. 24-30.;;Written Opinion of the Searching Authority dated Jan. 23, 2020, for International Patent Application No. PCT/US2019/060342, 9 pages.;;Yang HU, DArchangel J, Sundheimer ML, Tucker E, Boreman GD, Raschke MB. “Optical dielectric function of silver”, Physical Review B. Jun. 22, 2015;91(23):235137.;;Zajicek, J. et al., “Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial,” Lancet. Nov. 8, 2003;362(9395):1517-26, abstract.;;Zanconato, S., et al., “Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma”, Journal of Allergy and Clinical Immunology, (Feb. 1, 2004), 113(2):257-63.;;Zhou, J., “Review of recent developments in determining volatile organic compounds in exhaled breath as biomarkers for lung cancer diagnosis”, Analytica chimica acta, (Dec. 15, 2017), 996:1-9.;;Zhu, H.J., Wang JS, Markowitz JS, Donovan JL, Gibson BB, Gefroh HA, DeVane CL., “Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana”, Journal of Pharmacology and Experimental Therapeutics. May 1, 2006;317(2):850-7.;;Zias, Joe et al., “Early medical use of cannabis,” Nature; May 20, 1993; 363,6426; Research Library Core p. 215.;;Zuardi, A.W. et al., “Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects,” Psychopharmacology (Berl). 1982;76(3):245-50, PubMed abstract 6285406.;;Emelyanov, A., et al., “Elevated concentrations of exhaled hydrogen peroxide in asthmatic patients”, Chest, (Oct. 1, 2001), 120(4):1136-9.;;“SensAbues AB—Next generation drug detection and health monitoring”, SensAbues AB—Home, downloaded on Mar. 25, 2019 from http://sensabues.com/home.;;“Exhaled breath biological sample matrix. EB”, SensAbues AB—Product, downloaded on Mar. 25, 2019 from http://sensabues.com/product.;;“FAIMS Breathalyzer Device”, downloaded on Mar. 25, 2019 from https://algernonpharmaceuticals.com/faims-breathalyzer-device/.;;Feng, Shixia et al., “Simultaneous analysis of Delta9-THC and its major metabolites in urine, plasma, and meconium by GC-MS using an immunoaffinity extraction procedure,” Journal of Analytical Toxicology, vol. 24, Sep. 2000.;;Fraser, A.D. et al., “Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabiniod-to-creatinine ratio study,” Ther Drug Monit. Dec. 2002;24(6):746-50, PubMed abstract 12451292.;;Fraser, A.D. et al., “Urinary excretion profiles of 11-nor9-carboxy-delta9-tetrahydrocannabinol and 11-hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio study IV,” Forensic Sci Int. Jul. 16, 2004;143(2-3):147-52, PubMed abstract 15240035.;;Fraser, A.D. et al., “Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol. Study III. A Delta9-THC-COOH to creatinine ratio study,” Forensic Sci Int. Nov. 26, 2003;137(2-3):196-202, PubMed abstract 14609657.;;Garrett, Edward R. et al., “Physicochemical properties, solubility, and protein binding of Delta9-tetrahydrocannabinol,” J Pharm Sci. Jul. 1974;63(7):1056-64, abstract.;;Garrett, E.R. et al., “Pharmacokinetics of delta9-tetrahydrocannabinol in dogs,” J Pharm Sci. Mar. 1977;66(3):395-407, PubMed abstract 845807.;;Gjerde, H. et al., “Incidence of alcohol and drugs in fatally injured car drivers in Norway,” Accid Anal Prev. Aug. 1993;25(4):479-83, PubMed abstract 8357462.;;Gjerde, Hallvard et al., “Comparison of drug concentrations in blood and oral fluid collected with the Intercept® sampling device,” Journal of Analytical Toxicology, vol. 34, May 2010.;;Goodwin, R.S. et al., “Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids,” Ther Drug Monit. Aug. 2006;28(4):545-51, PubMed abstract 16885723.;;Gramse G, Dols-Perez A, Edwards MA, Fumagalli L, Gomila G. Nanoscale measurement of the dielectric constant of supported lipid bilayers in aqueous solutions with electrostatic force microscopy. Biophysical journal. Mar. 19, 2013;104(6):1257-62.;;Green, Mitchell D. et al., “Glucuronidation of opioids, carboxylic acid-containing drugs, and hydroxylated xenobiotics catalyzed by expressed monkey UDP-glucuronosyltransferase 2B9 protein,” Drug Metabolism and Disposition, vol. 25, No. 12, (1997).;;Grob NM, Aytekin M, Dweik RA. “Biomarkers in exhaled breath condensate: a review of collection, processing and analysis”, Journal of breath research, (Sep. 8, 2008), 2(3):037004.;;Gross, Stanley J. et al., “Detection of recent cannabis use by saliva Delta9-THC radioimmunoassay,” Journal of Analytical Toxicology, vol. 9, Jan./Feb. 1985.;;Grotenhermen, F., “Pharmacokinetics and pharmacodynamics of cannabinids,” Clin Pharmacokinet. 2003;42(4):327-60, PubMed abstract 12648025.;;Gustafson, R.A. et al., “Validated method for the simultaneous determination of Delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in human plasma using solid phase extraction and gas chromatography-mass spectrometry with positive chemical ionization,” J. Chromatogr B Analyt Technol Biomed Life Sci, Dec. 5, 2003;798(1):145-54, PubMed abstract 14630369. et al.",ACTIVE
479,US,A1,US 2019/0186265 A1,042-761-843-707-902,2019-06-20,2019,US 201715844065 A,2017-12-15,US 201715844065 A,2017-12-15,SYSTEM AND METHOD FOR ASSEMBLING GAS TURBINE ROTOR USING LOCALIZED INDUCTIVE HEATING,"A method of assembling a rotor is provided, in which each rotor disk comprising a connecting element. The method includes: (a) applying heat to a localized region of a first rotor disk of a plurality of rotor disks to selectively deflect a first connecting element of the first rotor disk, wherein the first rotor disk is stationary during heating; (b) installing the first rotor disk onto a rotor stack containing at least one rotor disk; and (c) repeating steps (a) and (b) for each rotor disk of the plurality of rotor disks; and (d) allowing the rotor disks, when stacked, to cool. When cooled, the respective connecting element of each rotor disk that has been selectively deflected contracts into an interference fit with an adjacent rotor disk. A system for selectively heating a localized region of a rotor disk is also provided.",GEN ELECTRIC,FRIEDMAN MICHAEL ERICSON;;SYED MINHAJUDDIN;;MICHAUD WILLIAM MICHAEL;;LUM LAMONT JOSEPH,GE INFRASTRUCTURE TECHNOLOGY LLC (2023-11-10);;GENERAL ELECTRIC COMPANY (2017-12-15),https://lens.org/042-761-843-707-902,Patent Application,yes,6,4,2,2,0,F04D19/02;;F04D29/053;;F04D29/644;;F01D5/06;;F01D5/026;;F05D2230/642;;F01D25/285;;H05B6/102;;H05B6/36;;F01D5/026;;F01D5/025;;F04D29/644;;H05B6/102;;F05D2230/64;;F05D2240/24;;F04D29/329;;F05D2230/232;;F04D19/02;;F04D29/053,F01D5/02;;F04D29/64,,0,0,,,,ACTIVE
480,JP,A,JP 2010172704 A,160-177-406-379-686,2010-08-12,2010,JP 2010017775 A,2010-01-29,US 36294209 A,2009-01-30,SYSTEM AND METHOD FOR INTEGRATING HEMODYNAMIC AND IMAGING EXAMINATION,"<P>PROBLEM TO BE SOLVED: To provide a system and a method for integrating hemodynamic and imaging examinations. <P>SOLUTION: Hemodynamic data and imaging data are obtained about a patient, and the data is combined to generate a single report (48) integrating same. While a hemodynamic system (12) obtains the hemodynamic data, an imaging system (14) obtains the imaging data. Preferably, the report (48) confirms the absence or presence (and/or severity) of peripheral arterial disease, including quantitative data. The hemodynamic system (12) and the imaging system (14) can communicate wirelessly. The hemodynamic system (12) and the imaging system (14) may be contained within a common enclosure (50) and integrated into a single apparatus (50). The hemodynamic system (12) and the imaging system (14) can also be configured to measure the blood pressure of the patient. Preferably, the imaging system (14) is an ultrasound imaging system (14). <P>COPYRIGHT: (C)2010,JPO&INPIT",GEN ELECTRIC,EVERETT DEBORAH ANN;;FRIEDMAN BRUCE;;MULLEN PAUL LAWRENCE;;ZANG WILLIAM ALPHONSUS,,https://lens.org/160-177-406-379-686,Patent Application,no,5,1,6,6,0,A61B5/02007;;A61B5/022;;A61B8/06;;A61B5/022;;A61B8/06;;A61B5/02007,A61B5/0205;;A61B8/06,,0,0,,,,PENDING
481,CA,A1,CA 2377190 A1,041-824-458-364-340,2001-02-01,2001,CA 2377190 A,2000-07-24,US 14521299 P;;US 0020103 W,1999-07-23,ULTRASONIC GUIDANCE OF TARGET STRUCTURES FOR MEDICAL PROCEDURES,"An ultrasound device such as a 3D ultrasound probe (22) provides 3D imaging data to the processor (20). A reference device (24) is fixed to the probe (22), and has probe position markers (26). The reference device (24) is fixe d to the probe (22), and has probe position markers (26). The markers (16, 26) are tracked using infrared (IR) camera system (28) which is connected to processor (20), that can covert the ultrasound data into data relative to th e frame of reference of the device (14). The display (30) shows images combini ng the ultrasound data from probe (22), and imaging data from imaging subsystem (18).",UNIV FLORIDA,FRIEDMAN WILLIAM;;BOVA FRANK J;;MEEKS SANFORD L;;BUATTI JOHN M,,https://lens.org/041-824-458-364-340,Patent Application,no,0,0,9,9,0,A61B8/5238;;A61B8/5238;;A61B5/7285;;A61B5/7285;;A61B6/5247;;A61B6/5247;;A61B6/541;;A61B6/541;;A61B8/08;;A61B8/08;;A61B8/4245;;A61B8/4245;;A61N5/1049;;A61N5/1049;;A61N2005/1058;;A61N2005/1058;;A61N2005/1059;;A61N2005/1059;;Y10S128/916;;Y10S128/916,G01R33/28;;A61B5/055;;A61B5/06;;A61B6/00;;A61B6/03;;A61B8/00;;A61B8/08;;A61B19/00;;G01S15/89,,0,0,,,,DISCONTINUED
482,US,A,US 5633565 A,184-722-344-041-728,1997-05-27,1997,US 30072794 A,1994-09-02,US 30072794 A;;IL 10040691 A;;US 90551392 A,1991-12-18,Electronic flasher circuit,"An electrical flasher circuit has improved operating characteristics, in particular by providing continuous illumination for a long period of time from a fully charged solar battery. The circuit employs a solar battery recharging circuit component that achieves full charge in a short period of time. The flasher circuit may be used in roadside warning device having a sign member with a warning image. Placed around the warning image are a plurality of light emitters for providing a visual warning during evening and night hours. The light emitters are powered by a solar energy source connected to a flasher circuit including an oscillator for causing the light emitters to be energized in a particular sequence. When the device is exposed to sunlight, the battery is disconnected to avoid unnecessary draining of the battery.",INTERPLEX SOLAR INC,FRIEDMAN RONI;;CHACHAM CHAIM;;RICHARDSON JR WILLIAM F;;RAYMOND BRIAN N,INTERPLEX SOLAR INC (1995-01-29),https://lens.org/184-722-344-041-728,Granted Patent,yes,11,26,1,10,0,F21S9/037;;G08B5/38;;Y10S136/291;;F21S9/037;;G08B5/38,G08B5/38,315200A;;315/150;;315/152;;315/159;;362/275;;40/442;;136/291,1,0,,,"555 Timer Appl. Source Book with Experiments by H. M. Berlin, Howard Sams & Coi, Inc 1979 pp. 126 127 & 68 69.",EXPIRED
483,US,A,US 4747478 A,088-922-164-360-111,1988-05-31,1988,US 83852686 A,1986-03-11,US 83852686 A;;US 48984883 A,1983-04-29,Coin sorter and totalizer,"A coin sorter is described for sorting coins of different denominations by means of ramps and flaps, the sorted coins being directed to different chutes, one chute being provided for each coin denomination, the chutes and coin exit openings at the ends of chutes as well as the ramps being formed in two complementary parts of the coin sorter. The sorter may be provided either in a coin operated assembly for use in an existing coin operated vending machine or in a new machine and in either case is best used in conjunction with a coin totalizer having a ratchet wheel, a price cam and at least two circular cams, the price cam and circular cams being rotatable with the ratchet wheel when the latter is rotated by a trip wire-lever, the degree of rotation being determined by the chute through which a given coin passes. The assembly is further provided with an operating and a reset lever operable to reset the coin totalizer after dispensing a commodity from the machine in response to insertion of the correct amount of coins. Also described is a lock-out mechanism which prevents the return of coins if a purchaser operates a coin return button of the machine simultaneously with the attempted opening of a front door of the machine after depositing the correct coins required for vending the commodity.",FRIEDMAN EVELYN,FRIEDMAN EVELYN;;CARSWELL WILLIAM R;;BORHO MARTIN A;;FRANDINO NICHOLAS J,FRIEDMAN EVELYN (1986-03-11),https://lens.org/088-922-164-360-111,Granted Patent,yes,8,6,1,2,0,G07F5/08;;G07F11/045;;G07F5/08;;G07F11/045,G07F5/08;;G07F11/04,194/227;;194/346;;453/5,0,0,,,,EXPIRED
484,DE,B2,DE 3000744 B2,124-849-667-991-48X,1981-02-19,1981,DE 3000744 A,1980-01-10,US 252579 A,1979-01-11,DE 3000744 B2,,"BORG-WARNER CORP., CHICAGO, ILL. (V.ST.A.)","HORN JUN., WILLIAM E., VINCENT, OHIO;;FRIEDMAN, LESTER, LONG BEACH, CALIF.",,https://lens.org/124-849-667-991-48X,Patent Application,no,0,0,9,9,0,C08K5/526,C08L51/00;;C08K5/52;;C08K5/526;;C08L51/04;;C08L55/00;;C08L55/02,,0,0,,,,EXPIRED
485,EP,A4,EP 1217947 A4,142-650-125-383-695,2005-01-19,2005,EP 00950608 A,2000-07-21,US 0020103 W;;US 14521299 P,1999-07-23,ULTRASONIC GUIDANCE OF TARGET STRUCTURES FOR MEDICAL PROCEDURES,,UNIV FLORIDA,BOVA FRANK J;;BUATTI JOHN M;;MEEKS SANFORD L;;FRIEDMAN WILLIAM,,https://lens.org/142-650-125-383-695,Search Report,no,3,0,9,9,0,A61B8/5238;;A61B8/5238;;A61B5/7285;;A61B5/7285;;A61B6/5247;;A61B6/5247;;A61B6/541;;A61B6/541;;A61B8/08;;A61B8/08;;A61B8/4245;;A61B8/4245;;A61N5/1049;;A61N5/1049;;A61N2005/1058;;A61N2005/1058;;A61N2005/1059;;A61N2005/1059;;Y10S128/916;;Y10S128/916,G01R33/28;;A61B5/055;;A61B5/06;;A61B6/00;;A61B6/03;;A61B8/00;;A61B8/08;;A61B19/00;;G01S15/89,,2,1,049-612-329-058-28X,9310978;;10.1097/00006123-199709000-00020;;10.1227/00006123-199709000-00020,"HATA N ET AL: ""Development of a frameless and armless stereotactic neuronavigation system with ultrasonographic registration."", NEUROSURGERY, vol. 41, no. 3, September 1997 (1997-09-01), pages 608 - 613 ; dis, XP008038713, ISSN: 0148-396X;;See also references of WO 0106924A1",DISCONTINUED
486,WO,A1,WO 2001/006924 A1,181-702-809-148-393,2001-02-01,2001,US 0020103 W,2000-07-21,US 14521299 P,1999-07-23,ULTRASONIC GUIDANCE OF TARGET STRUCTURES FOR MEDICAL PROCEDURES,"An ultrasound device such as a 3D ultrasound probe (22) provides 3D imaging data to the processor (20). A reference device (24) is fixed to the probe (22), and has probe position markers (26). The reference device (24) is fixed to the probe (22), and has probe position markers (26). The markers (16, 26) are tracked using infrared (IR) camera system (28) which is connected to processor (20), that can covert the ultrasound data into data relative to the frame of reference of the device (14). The display (30) shows images combining the ultrasound data from probe (22), and imaging data from imaging subsystem (18).",UNIV FLORIDA,BOVA FRANK J;;BUATTI JOHN M;;MEEKS SANFORD L;;FRIEDMAN WILLIAM,,https://lens.org/181-702-809-148-393,Patent Application,yes,2,32,9,9,0,A61B8/5238;;A61B8/5238;;A61B5/7285;;A61B5/7285;;A61B6/5247;;A61B6/5247;;A61B6/541;;A61B6/541;;A61B8/08;;A61B8/08;;A61B8/4245;;A61B8/4245;;A61N5/1049;;A61N5/1049;;A61N2005/1058;;A61N2005/1058;;A61N2005/1059;;A61N2005/1059;;Y10S128/916;;Y10S128/916,G01R33/28;;A61B5/055;;A61B5/06;;A61B6/00;;A61B6/03;;A61B8/00;;A61B8/08;;A61B19/00;;G01S15/89,,1,0,,,See also references of EP 1217947A4,PATENTED
487,CN,A,CN 101822536 A,101-398-807-571-07X,2010-09-08,2010,CN 201010114913 A,2010-01-29,US 36294209 A,2009-01-30,Systems and methods for integrating hemodynamic and imaging examinations,"Hemodynamic data and imaging data are obtained about a patient, and the data is combined to generate a single report integrating same (480. While a hemodynamic system (12) obtains the hemodynamic data, an imaging system (14) obtains the imaging data. Preferably, the report confirms the absence or presence (and/or severity) of peripheral arterial disease, including quantitative data. The hemodynamic system (12) and the imaging system (14) can communicate directly, indirectly, and/or wirelessly. They may be contained within a common enclosure (50) and/or integrated into a single apparatus (50). Either or both of the hemodynamic system (12) and/or the imaging system (14) can also be configured to measure the blood pressure of the patient. Preferably, the imaging system (14) is an ultrasound imaging system (14), and improved workflows for diagnosing peripheral arterial disease result.",GEN ELECTRIC,ANN EVERETT DEBORAH;;BRUCE FRIEDMAN;;LAWRENCE MULLEN PAUL;;ALPHONSUS ZANG WILLIAM,,https://lens.org/101-398-807-571-07X,Patent Application,no,0,2,6,6,0,A61B5/02007;;A61B5/022;;A61B8/06;;A61B5/022;;A61B8/06;;A61B5/02007,A61B5/022;;A61B8/00,,0,0,,,,ACTIVE
488,WO,A9,WO 2001/006924 A9,026-904-997-232-669,2002-07-11,2002,US 0020103 W,2000-07-21,US 14521299 P,1999-07-23,ULTRASONIC GUIDANCE OF TARGET STRUCTURES FOR MEDICAL PROCEDURES,"An ultrasound device such as a 3D ultrasound probe (22) provides 3D imaging data to the processor (20). A reference device (24) is fixed to the probe (22), and has probe position markers (26). The reference device (24) is fixed to the probe (22), and has probe position markers (26). The markers (16, 26) are tracked using infrared (IR) camera system (28) which is connected to processor (20), that can covert the ultrasound data into data relative to the frame of reference of the device (14). The display (30) shows images combining the ultrasound data from probe (22), and imaging data from imaging subsystem (18).",UNIV FLORIDA,BOVA FRANK J;;BUATTI JOHN M;;MEEKS SANFORD L;;FRIEDMAN WILLIAM,,https://lens.org/026-904-997-232-669,Patent Application,no,0,0,9,9,0,A61B8/5238;;A61B8/5238;;A61B5/7285;;A61B5/7285;;A61B6/5247;;A61B6/5247;;A61B6/541;;A61B6/541;;A61B8/08;;A61B8/08;;A61B8/4245;;A61B8/4245;;A61N5/1049;;A61N5/1049;;A61N2005/1058;;A61N2005/1058;;A61N2005/1059;;A61N2005/1059;;Y10S128/916;;Y10S128/916,G01R33/28;;A61B5/055;;A61B5/06;;A61B6/00;;A61B6/03;;A61B8/00;;A61B8/08;;A61B19/00;;G01S15/89,,0,0,,,,PATENTED
489,CN,B,CN 101822536 B,050-231-504-993-547,2015-05-13,2015,CN 201010114913 A,2010-01-29,US 36294209 A,2009-01-30,Systems and methods for integrating hemodynamic and imaging examinations,,GEN ELECTRIC,EVERETT DEBORAH ANN;;FRIEDMAN BRUCE;;MULLEN PAUL LAWRENCE;;ZANG WILLIAM ALPHONSUS,,https://lens.org/050-231-504-993-547,Granted Patent,no,0,0,6,6,0,A61B5/02007;;A61B5/022;;A61B8/06;;A61B5/022;;A61B8/06;;A61B5/02007,A61B5/022;;A61B8/00,,0,0,,,,ACTIVE
490,US,B2,US 8137273 B2,176-923-642-950-795,2012-03-20,2012,US 36294209 A,2009-01-30,US 36294209 A,2009-01-30,Systems and methods for integrating hemodynamic and imaging examinations,"Hemodynamic data and imaging data are obtained about a patient, and the data is combined to generate a single report integrating same. While a hemodynamic system obtains the hemodynamic data, an imaging system obtains the imaging data. Preferably, the report confirms the absence or presence (and/or severity) of peripheral arterial disease, including quantitative data. The hemodynamic system and the imaging system can communicate directly, indirectly, and/or wirelessly. They may be contained within a common enclosure and/or integrated into a single apparatus. Either or both of the hemodynamic system and/or the imaging system can also be configured to measure the blood pressure of the patient. Preferably, the imaging system is an ultrasound imaging system, and improved workflows for diagnosing peripheral arterial disease result.",EVERETT DEBORAH ANN;;FRIEDMAN BRUCE;;MULLEN PAUL LAWRENCE;;ZANG WILLIAM ALPHONSUS;;GEN ELECTRIC,EVERETT DEBORAH ANN;;FRIEDMAN BRUCE;;MULLEN PAUL LAWRENCE;;ZANG WILLIAM ALPHONSUS,GENERAL ELECTRIC COMPANY (2009-01-27),https://lens.org/176-923-642-950-795,Granted Patent,yes,15,10,6,6,0,A61B5/02007;;A61B5/022;;A61B8/06;;A61B5/022;;A61B8/06;;A61B5/02007,A61B8/00,600/437;;600/485;;600/500,1,0,,,"Unetixs, MultiLab Series II LHS-IMG, retrieved from the internet on Jan. 28, 2009 via URL: http://www.unetixs.com/multilab-2-lhs-img.html.",ACTIVE
491,RS,B1,RS 54651 B1,009-944-052-188-179,2016-08-31,2016,RS P20160064 A,2009-10-01,US 10224208 P;;US 2009/0059203 W,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"Agens za upotrebu u lečenju poremećaja suvog oka kod pacijenta, naznačen time što je pomenuti agens 3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1il]propannitril, ili njegova farmaceutski prihvatljiva so.Prijava sadrži još 13 patentnih zahteva.",INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/009-944-052-188-179,Granted Patent,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/437;;A61K31/519;;A61P27/00,,0,0,,,,ACTIVE
492,US,A1,US 2011/0142575 A1,012-977-964-239-417,2011-06-16,2011,US 89744010 A,2010-10-04,US 89744010 A;;US 21091805 A;;US 60409904 P,2004-08-23,ELEVATOR-BASED TOOL LOADING AND BUFFERING SYSTEM,"A substrate processing apparatus is provided. The apparatus has a casing, a low port interface and a carrier holding station. The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding station is adapted for holding at least one substrate transport carrier so the at least one substrate transport carrier is capable of being coupled to the load port interface without lifting the at least one substrate transport carrier off the carrier holding station. The carrier holding station is arranged to provide a substantially simultaneous swap section for substantially simultaneous replacement of the substrate transport carrier from the carrier holding station.",BROOKS AUTOMATION INC,FRIEDMAN GERALD M;;BUFANO MICHAEL L;;HOFMEISTER CHRISTOPHER;;GILCHRIST ULYSSES;;FOSNIGHT WILLIAM,BROOKS AUTOMATION US LLC (2021-10-01);;BROOKS AUTOMATION HOLDING LLC (2021-10-01),https://lens.org/012-977-964-239-417,Patent Application,yes,47,4,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,H01L21/677,414/222.01,0,0,,,,ACTIVE
493,WO,A2,WO 2006/024035 A2,030-237-378-848-577,2006-03-02,2006,US 2005/0030617 W,2005-08-24,US 60440604 P;;US 21123605 A,2004-08-24,TRANSPORTATION SYSTEM,An exemplary embodiment a substrate transport system is provided. The system has a guideway and at least one transport vehicle. The transport vehicle is adapted for holding at least one substrate and capable of being supported from and moving along the guideway. The guideway comprises at least one travel lane for the vehicle and at least one access lane offset from the travel lane allowing the vehicle selectable access on and off the travel lane.,BROOKS AUTOMATION INC,GILCHRIST ULYSSES;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/030-237-378-848-577,Patent Application,yes,0,15,9,12,0,H01L21/67715;;H01L21/67736;;H01L21/67775;;H01L21/68;;H01L21/67715;;H01L21/67736;;H01L21/67775,B60L13/00,,0,0,,,,PENDING
494,TW,A,TW 200619121 A,095-465-554-733-879,2006-06-16,2006,TW 94128322 A,2005-08-19,US 60336104 P,2004-08-19,Reduced capacity carrier and method of use,"An apparatus and method is disclosed for a reduced-capacity substrate carriers for use within an IC fab. Side-opening carriers with a capacity of fewer than the conventional 13 Or 25 wafers may be constructed in a manner similar to the FOUP defined in SEMI E47, but characterized by reduced height and weight. The present invention describes such carriers for use in a fab and methods of using such carriers within a fab.",BROOKS AUTOMATION INC,GILCHRIST ULYSSES;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/095-465-554-733-879,Patent of Addition,no,0,0,2,19,0,,,,0,0,,,,ACTIVE
495,KR,A,KR 20070054683 A,120-529-362-707-54X,2007-05-29,2007,KR 20077006624 A,2007-03-22,US 21091805 A;;US 60409904 P,2004-08-23,ELEVATOR-BASED TOOL LOADING AND BUFFERING SYSTEM,"A substrate processing apparatus is provided. The apparatus has a casing, a low port interface and a carrier holding station. The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding station is adapted for holding at least one substrate transport carrier so the at least one substrate transport carrier is capable of being coupled to the load port interface without lifting the at least one substrate transport carrier off the carrier holding station. The carrier holding station is arranged to provide a substantially simultaneous swap section for substantially simultaneous replacement of the substrate transport carrier from the carrier holding station.",BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;BUFANO MICHAEL L;;WILLIAM FOSNIGHT;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/120-529-362-707-54X,Patent Application,no,0,0,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,H01L21/677,,0,0,,,,DISCONTINUED
496,AU,A,AU 1995/021131 A,130-735-916-427-794,1995-11-29,1995,AU 1995/021131 A,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,Controlled-release dosage forms of azithromycin,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LEMOTT STEVEN R,,https://lens.org/130-735-916-427-794,Patent Application,no,0,1,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
497,US,A1,US 2006/0099054 A1,199-003-881-843-13X,2006-05-11,2006,US 21091805 A,2005-08-23,US 21091805 A;;US 60409904 P,2004-08-23,Elevator-based tool loading and buffering system,"A substrate processing apparatus is provided. The apparatus has a casing, a low port interface and a carrier holding station. The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding station is adapted for holding at least one substrate transport carrier at the load port interface. The carrier holding station is arranged to provide a fast swap section for replacement of the substrate transport carrier from the carrier holding station.",FRIEDMAN GERALD M;;BUFANO MICHAEL L;;HOFMEISTER CHRISTOPHER;;GILCHRIST ULYSSES;;FOSNIGHT WILLIAM,FRIEDMAN GERALD M;;BUFANO MICHAEL L;;HOFMEISTER CHRISTOPHER;;GILCHRIST ULYSSES;;FOSNIGHT WILLIAM,BROOKS AUTOMATION INC (2005-11-30);;BROOKS AUTOMATION US LLC (2021-10-01);;BROOKS AUTOMATION HOLDING LLC (2021-10-01),https://lens.org/199-003-881-843-13X,Patent Application,yes,35,46,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,H01L21/677,414/217,0,0,,,,INACTIVE
498,WO,A3,WO 2006/024035 A3,009-740-964-326-04X,2007-05-03,2007,US 2005/0030617 W,2005-08-24,US 60440604 P;;US 21123605 A,2004-08-24,TRANSPORTATION SYSTEM,An exemplary embodiment a substrate transport system is provided. The system has a guideway and at least one transport vehicle. The transport vehicle is adapted for holding at least one substrate and capable of being supported from and moving along the guideway. The guideway comprises at least one travel lane for the vehicle and at least one access lane offset from the travel lane allowing the vehicle selectable access on and off the travel lane.,BROOKS AUTOMATION INC,GILCHRIST ULYSSES;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/009-740-964-326-04X,Search Report,yes,1,0,9,12,0,H01L21/67715;;H01L21/67736;;H01L21/67775;;H01L21/68;;H01L21/67715;;H01L21/67736;;H01L21/67775,B60L13/00,,0,0,,,,PENDING
499,WO,A3,WO 2006/023838 A3,033-422-732-826-746,2006-08-17,2006,US 2005/0029757 W,2005-08-19,US 60336104 P;;US 20723105 A,2004-08-19,REDUCED CAPACITY CARRIER AND METHOD OF USE,"A substrate transport apparatus (10) is provided. The apparatus has a casing (11) and a door (13). The casing is adapted to form a controlled environment therein. The casing has supports (12, 14) therein for holding at least one substrate (s) in the casing. The casing defines a substrate transfer opening through which a substrate transport system accesses the substrate in the casing. The door is connected to the casing for closing the substrate transfer opening in the casing. The casing has structure forming a fast swap element allowing replacement of the substrate from the apparatus with another substrate without retraction of the substrate transport system and independent of substrate loading in the casing.",BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/033-422-732-826-746,Search Report,yes,6,0,17,19,0,B65G49/07;;H01L21/67763;;H01L21/67763;;H01L21/67326;;H01L21/67353;;H01L21/67353;;H01L21/67369;;H01L21/67369;;H01L21/67373;;H01L21/67373;;H01L21/67376;;H01L21/67376;;H01L21/67383;;H01L21/67389;;H01L21/67393;;H01L21/67393;;H01L21/67772;;H01L21/67772;;H01L21/67778;;H01L21/67778;;H01L21/6779;;H01L21/6779;;Y10S414/139;;Y10S414/139,B65G49/07,,1,0,,,See also references of EP 1786710A4,PENDING
500,TW,A,TW 201018689 A,059-871-742-991-304,2010-05-16,2010,TW 98133430 A,2009-10-01,US 10224208 P,2008-10-02,Janus kinase inhibitors for treatment of dry eye and other eye related diseases,"Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.",INCYTE CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/059-871-742-991-304,Patent of Addition,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,C07D471/22;;A61K31/437;;A61K31/519;;A61K31/55;;A61P27/02;;C07D471/04;;C07D487/04,,0,0,,,,ACTIVE
501,KR,A,KR 20070045322 A,061-913-457-317-69X,2007-05-02,2007,KR 20077006063 A,2005-08-19,US 20723105 A;;US 60336104 P;;US 2005/0029757 W,2004-08-19,REDUCED CAPACITY CARRIER AND METHOD OF USE,,BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/061-913-457-317-69X,Patent Application,no,0,1,17,19,0,B65G49/07;;H01L21/67763;;H01L21/67763;;H01L21/67326;;H01L21/67353;;H01L21/67353;;H01L21/67369;;H01L21/67369;;H01L21/67373;;H01L21/67373;;H01L21/67376;;H01L21/67376;;H01L21/67383;;H01L21/67389;;H01L21/67393;;H01L21/67393;;H01L21/67772;;H01L21/67772;;H01L21/67778;;H01L21/67778;;H01L21/6779;;H01L21/6779;;Y10S414/139;;Y10S414/139,B65G49/07,,0,0,,,,ACTIVE
502,US,A1,US 2015/0155192 A1,069-378-599-270-259,2015-06-04,2015,US 201414541934 A,2014-11-14,US 201414541934 A;;US 20723105 A;;US 60336104 P,2004-08-19,REDUCED CAPACITY CARRIER AND METHOD OF USE,A substrate transport apparatus is provided. The apparatus has a casing and a door. The casing is adapted to form a controlled environment therein. The casing has supports therein for holding at least one substrate in the casing. The casing defines a substrate transfer opening through which a substrate transport system accesses the substrate in the casing. The door is connected to the casing for closing the substrate transfer opening in the casing. The casing has structure forming a fast swap element allowing replacement of the substrate from the apparatus with another substrate without retraction of the substrate transport system and independent of substrate loading in the casing.,BROOKS AUTOMATION INC,GILCHRIST ULYSSES;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERARLD M,BROOKS AUTOMATION. INC (2015-04-28);;BROOKS AUTOMATION US LLC (2021-10-01);;BROOKS AUTOMATION HOLDING LLC (2021-10-01),https://lens.org/069-378-599-270-259,Patent Application,yes,0,2,17,19,0,B65G49/07;;H01L21/67763;;H01L21/67763;;H01L21/67326;;H01L21/67353;;H01L21/67353;;H01L21/67369;;H01L21/67369;;H01L21/67373;;H01L21/67373;;H01L21/67376;;H01L21/67376;;H01L21/67383;;H01L21/67389;;H01L21/67393;;H01L21/67393;;H01L21/67772;;H01L21/67772;;H01L21/67778;;H01L21/67778;;H01L21/6779;;H01L21/6779;;Y10S414/139;;Y10S414/139,H01L21/677;;H01L21/673,,0,0,,,,ACTIVE
503,CN,B,CN 101044074 B,193-974-879-401-088,2014-04-02,2014,CN 200580035790 A,2005-08-19,US 2005/0029757 W;;US 20723105 A;;US 60336104 P,2004-08-19,Reduced capacity carrier and method of use,,BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M;;FOSNIGHT WILLIAM;;BUFANO MICHAEL L,,https://lens.org/193-974-879-401-088,Granted Patent,no,0,0,17,19,0,B65G49/07;;H01L21/67763;;H01L21/67763;;H01L21/67326;;H01L21/67353;;H01L21/67353;;H01L21/67369;;H01L21/67369;;H01L21/67373;;H01L21/67373;;H01L21/67376;;H01L21/67376;;H01L21/67383;;H01L21/67389;;H01L21/67393;;H01L21/67393;;H01L21/67772;;H01L21/67772;;H01L21/67778;;H01L21/67778;;H01L21/6779;;H01L21/6779;;Y10S414/139;;Y10S414/139,B65G49/07,,0,0,,,,ACTIVE
504,US,A1,US 2017/0087158 A1,002-483-941-248-449,2017-03-30,2017,US 201615156125 A,2016-05-16,US 201615156125 A;;US 201213564271 A;;US 57183409 A;;US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"The present application relates to Janus kinase (JAK) inhibitors, including 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, for the treatment of a dry eye disorder or ameliorating a particular symptom of a dry eye disorder, such as eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface, as well as kits and compositions, including topical compositions, related thereto.",INCYTE CORP;;INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,INCYTE CORPORATION (2015-01-07);;INCYTE HOLDINGS CORPORATION (2015-01-07),https://lens.org/002-483-941-248-449,Patent Application,yes,4,32,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/519;;A61K9/00,,2,0,,,"Winfield, Pharmaceutical Practice, Ophthalmic Products-pH adjustment, Churchill Livingstone, 2004, 264-271;;Winfield, Pharmaceutical Practice, Ophthalmic Products-pH adjustment, Churchill Livingstone, 2004, 264-271",DISCONTINUED
505,JP,A,JP 2020050682 A,053-163-056-837-256,2020-04-02,2020,JP 2020002245 A,2020-01-09,US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"To treat dry eye disorders and other related eye diseases.SOLUTION: Methods, kits and compositions for treating dry eye disorders and other related eye diseases are provided, where the methods, kits and compositions utilize a JAK inhibitor.SELECTED DRAWING: None",INCYTE HOLDINGS CORP,PAUL A FRIEDMAN;;JORDAN S FRIDMAN;;MONICA E LUCHI;;WILLIAM V WILLIAMS,,https://lens.org/053-163-056-837-256,Patent Application,no,2,0,34,34,0,A61K31/437;;A61K31/519;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/437;;A61K31/519;;A61K9/0048,A61K31/519;;A61K9/06;;A61K9/08;;A61K9/10;;A61K9/16;;A61K31/047;;A61K31/717;;A61K31/728;;A61K31/765;;A61K31/77;;A61K45/00;;A61K47/32;;A61K47/34;;A61K47/42;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,,1,0,,,"LAB. INVEST., vol. 86, JPN7015001039, 2006, pages 1243 - 1260, ISSN: 0004615063",PENDING
506,US,A1,US 2006/0104712 A1,064-595-254-109-098,2006-05-18,2006,US 21123605 A,2005-08-24,US 21123605 A;;US 60440604 P,2004-08-24,Transportation system,An exemplary embodiment a substrate transport system is provided. The system has a guideway and at least one transport vehicle. The transport vehicle is adapted for holding at least one substrate and capable of being supported from and moving along the guideway. The guideway comprises at least one travel lane for the vehicle and at least one access lane offset from the travel lane allowing the vehicle selectable access on and off the travel lane.,BUFANO MICHAEL L;;FRIEDMAN GERALD M;;HOFMEISTER CHRISTOPHER;;GILCHRIST ULYSSES;;FOSNIGHT WILLIAM,BUFANO MICHAEL L;;FRIEDMAN GERALD M;;HOFMEISTER CHRISTOPHER;;GILCHRIST ULYSSES;;FOSNIGHT WILLIAM,BROOKS AUTOMATION INC (2005-11-30);;BROOKS AUTOMATION US LLC (2021-10-01);;BROOKS AUTOMATION HOLDING LLC (2021-10-01),https://lens.org/064-595-254-109-098,Patent Application,yes,26,67,9,12,0,H01L21/67715;;H01L21/67736;;H01L21/67775;;H01L21/68;;H01L21/67715;;H01L21/67736;;H01L21/67775,E01C1/00,404/1,0,0,,,,DISCONTINUED
507,PL,T3,PL 2349260 T3,080-622-062-243-461,2016-07-29,2016,PL 09737257 T,2009-10-01,US 10224208 P;;EP 09737257 A;;US 2009/0059203 W,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,,INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/080-622-062-243-461,Patent Application,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/437;;A61K31/519;;A61P27/00,,0,0,,,,PENDING
508,ES,T3,ES 2564203 T3,124-352-536-548-871,2016-03-18,2016,ES 09737257 T,2009-10-01,US 10224208 P;;US 2009/0059203 W,2008-10-02,Inhibidores de quinasas Jano para el tratamiento de ojo seco y otras enfermedades relacionadas con el ojo,"Un agente para su uso para el tratamiento de la enfermedad de ojos secos en un paciente donde dicho agente es 3-ciclopentil-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propanenitrilo, o una de sus sales farmacéuticamente aceptables.",INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/124-352-536-548-871,Granted Patent,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/437;;A61K31/519;;A61P27/00,,0,0,,,,ACTIVE
509,JP,A,JP 2017189866 A,137-603-570-305-561,2017-10-19,2017,JP 2017073362 A,2017-04-03,US 201615097082 A,2016-04-12,APPARATUS AND METHOD FOR PEENING OF MACHINE COMPONENTS,"PROBLEM TO BE SOLVED: To provide an apparatus and method for peening of machine components.SOLUTION: A peening device for treating a component includes a shot media propulsion source configured to propel a quantity of shot media. The device also includes a plurality of treatment enclosures each selectively coupleable to the shot media propulsion source. Each of the treatment enclosures has a shape complementary to a corresponding one of a plurality of portions of the component, so that each treatment enclosure and the corresponding portion cooperate to enclose the shot media.SELECTED DRAWING: Figure 1",GENERAL ELECTRIC CO GE,MICHAEL ERICSON FRIEDMAN;;COLIN BECKWITH SPELLMEYER;;BRIAN EDWARD WILLIAM;;PAUL LAWRENCE KALMAR,,https://lens.org/137-603-570-305-561,Patent Application,no,5,1,13,13,0,B24C3/32;;B24C9/00;;B24C3/065;;B24C3/32;;B24C9/00;;B24C1/10;;B24C1/10;;B24C7/0046;;B24C5/06;;B21D31/06;;B24C9/00;;B24C3/065;;B24C3/32;;B24C3/02;;B24C1/10,B24C5/00;;B24C3/06;;B24C3/32;;B24C5/04,,0,0,,,,ACTIVE
510,US,A1,US 2010/0147181 A1,159-934-109-837-118,2010-06-17,2010,US 69622410 A,2010-01-29,US 69622410 A;;US 21123605 A;;US 60440604 P,2004-08-24,Elevator-based tool loading and buffering system,An exemplary embodiment a substrate transport system is provided. The system has a guideway and at least one transport vehicle. The transport vehicle is adapted for holding at least one substrate and capable of being supported from and moving along the guideway. The guideway comprises at least one travel lane for the vehicle and at least one access lane offset from the travel lane allowing the vehicle selectable access on and off the travel lane.,BROOKS AUTOMATION INC,BUFANO MICHAEL L;;FRIEDMAN GERALD M;;HOFMEISTER CHRISTOPHER;;GILCHRIST ULYSSES;;FOSNIGHT WILLIAM,MURATA MACHINERY LTD (2010-02-03);;BROOKS AUTOMATION INC (2010-02-02),https://lens.org/159-934-109-837-118,Patent Application,yes,12,2,9,12,0,H01L21/67715;;H01L21/67736;;H01L21/67775;;H01L21/68;;H01L21/67715;;H01L21/67736;;H01L21/67775,E01B25/00,104/130.01,0,0,,,,DISCONTINUED
511,US,B2,US 7806643 B2,166-825-196-666-345,2010-10-05,2010,US 21091805 A,2005-08-23,US 21091805 A;;US 60409904 P,2004-08-23,Elevator-based tool loading and buffering system,"A substrate processing apparatus is provided. The apparatus has a casing, a low port interface and a carrier holding station. The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding station is adapted for holding at least one substrate transport carrier at the load port interface. The carrier holding station is arranged to provide a fast swap section for replacement of the substrate transport carrier from the carrier holding station.",BROOKS AUTOMATION INC,FRIEDMAN GERALD M;;BUFANO MICHAEL L;;HOFMEISTER CHRISTOPHER;;GILCHRIST ULYSSES;;FOSNIGHT WILLIAM,BROOKS AUTOMATION INC (2005-11-30);;BROOKS AUTOMATION US LLC (2021-10-01);;BROOKS AUTOMATION HOLDING LLC (2021-10-01),https://lens.org/166-825-196-666-345,Granted Patent,yes,43,26,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,B65G65/00;;B65H1/00,414/222.01;;414/277;;414/217;;414/940,4,4,151-048-311-925-245;;077-076-406-863-020;;144-969-703-121-046;;048-775-054-246-133,10.1109/asmc.1997.630764;;10.1109/asmc.1997.630762;;10.1007/s001700200137;;10.1109/asmc.1998.731633,"Campbell, ""Overhead Intrabay Automation and Microstocking-a virtual fab case study,"" IEEE/SEMI Advance dSemiconductor Manufacturing Conference, pp. 368-372 (1997).;;Kaempf , ""Automated Wafer Transport in the Wafer Fab,"" IEEE/SEMI Advanced Semiconductor Manufacturing Conference, pp. 356-361 (1997).;;Kuo, ""Modelling and Performance Evaluation of an Overhead Hoist Trasnport System in a 300 mm Fabrication Plant,"" Int. J. Adv. Manuf. Technol., vol. 20, pp. 153-161 (2002).;;Sikich, ""Development and Implementation of an Automated Wafer Transport System,"" IEEE/SEMI Advanced Semiconductor Manufacturing Conference, pp. 400-404 (1998).",INACTIVE
512,EP,A1,EP 2349260 A1,176-085-262-004-158,2011-08-03,2011,EP 09737257 A,2009-10-01,US 2009/0059203 W;;US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,,INCYTE CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,INCYTE HOLDINGS CORPORATION (2015-12-09);;INCYTE CORPORATION (2015-03-11),https://lens.org/176-085-262-004-158,Patent Application,yes,0,1,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/437;;A61K31/519;;A61P27/00,,1,0,,,See references of WO 2010039939A1,ACTIVE
513,EP,A2,EP 1789630 A2,199-498-703-361-805,2007-05-30,2007,EP 05792415 A,2005-08-24,US 2005/0030617 W;;US 60440604 P;;US 21123605 A,2004-08-24,TRANSPORTATION SYSTEM,,BROOKS AUTOMATION INC,GILCHRIST ULYSSES;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,"MURATA MACHINERY, LTD. (2010-06-02)",https://lens.org/199-498-703-361-805,Patent Application,yes,0,0,9,12,0,H01L21/67715;;H01L21/67736;;H01L21/67775;;H01L21/68;;H01L21/67715;;H01L21/67736;;H01L21/67775,B60L13/00,,0,0,,,,DISCONTINUED
514,US,A1,US 2012/0301464 A1,195-732-080-526-526,2012-11-29,2012,US 201213564271 A,2012-08-01,US 201213564271 A;;US 57183409 A;;US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.",FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V;;INCYTE CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,INCYTE CORPORATION (2010-05-17);;INCYTE HOLDINGS CORPORATION AND INCYTE CORPORATION (2015-01-07),https://lens.org/195-732-080-526-526,Patent Application,yes,2,69,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/519;;A61K31/58;;A61K31/65;;A61K31/7072;;A61K38/13;;A61K38/16;;A61K39/395;;A61P27/02,424/133.1;;514/265.1;;514/210.21;;514/171;;514/20.5;;514/154;;514/51;;514/20.8,3,1,000-770-213-683-433,10.1016/s0039-6257(00)00203-4;;11587144,"Rolando et al., The Ocular Surface and Tear Film and Their Dysfunction in Dry eye Disease, Survey of Ophthalmology, March 2001, Vol 45, Supplement 2, S203-S210;;Webster's New World Medical Dictionary, Sjogren's syndrome, 2003, Wiley Publishing, printed from http://www.credoreference.com/entry/webstermed/sjogren_s_syndrome, 2 pages;;Mosby's Dictionary of Medicine, Nursing, & Health Professions, sicca complex, 2009, Elsevier, printed from http://www.credoreference.com/entry/ehsmosbymed/sicca_complex, 2 pages",DISCONTINUED
515,TW,B,TW I591068 B,020-867-729-521-255,2017-07-11,2017,TW 98133430 A,2009-10-01,US 10224208 P,2008-10-02,Janus kinase inhibitors for treatment of dry eye and other eye related diseases,,INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/020-867-729-521-255,Granted Patent,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,,,0,0,,,,ACTIVE
516,US,B2,US 8678734 B2,069-130-664-370-186,2014-03-25,2014,US 89744010 A,2010-10-04,US 89744010 A;;US 21091805 A;;US 60409904 P,2004-08-23,Elevator-based tool loading and buffering system,"A substrate processing apparatus is provided. The apparatus has a casing, a low port interface and a carrier holding station. The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding station is adapted for holding at least one substrate transport carrier so the at least one substrate transport carrier is capable of being coupled to the load port interface without lifting the at least one substrate transport carrier off the carrier holding station. The carrier holding station is arranged to provide a substantially simultaneous swap section for substantially simultaneous replacement of the substrate transport carrier from the carrier holding station.",FRIEDMAN GERALD M;;BUFANO MICHAEL L;;HOFMEISTER CHRISTOPHER;;GILCHRIST ULYSSES;;FOSNIGHT WILLIAM;;BROOKS AUTOMATION INC,FRIEDMAN GERALD M;;BUFANO MICHAEL L;;HOFMEISTER CHRISTOPHER;;GILCHRIST ULYSSES;;FOSNIGHT WILLIAM,BROOKS AUTOMATION US LLC (2021-10-01);;BROOKS AUTOMATION HOLDING LLC (2021-10-01),https://lens.org/069-130-664-370-186,Granted Patent,yes,55,1,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,B65G54/02;;B65G54/00;;H01L21/67;;H01L21/677,414/222.01;;414/279;;414/591;;414/940;;198/465.2,4,4,151-048-311-925-245;;077-076-406-863-020;;144-969-703-121-046;;048-775-054-246-133,10.1109/asmc.1997.630764;;10.1109/asmc.1997.630762;;10.1007/s001700200137;;10.1109/asmc.1998.731633,"Campbell, ""Overhead Intrabay Automation and Microstocking-a virtual fab case study,"" IEEE/SEMI Advance Dsemiconductor Manufacturing Conference, pp. 368-372 (1997).;;Kaempf, ""Automated Wafter Transport in the Wafer Fab"", IEEE/SEMI Advanced Semiconductor Manufacturing Conference, pp. 356-361 (1997).;;Kuo, ""Modelling and Performance Evlaluation of an Overhead Hoist Transport System in a 300 mm Fabrication Plant,"" Int. J. Adv. Manuf. Technol., vol. 20, pp. 153-161 (2002).;;Sikich, ""Development and Implementation of an Automated Wafer Transport System"", IEEE/SEMI Advanced Semiconductor Manufacturing Conference, pp. 400-404 (1998).",ACTIVE
517,US,B2,US 8156304 B2,079-102-009-847-851,2012-04-10,2012,US 63173709 A,2009-12-04,US 63173709 A,2009-12-04,Dynamic data storage repartitioning,"Embodiments of the present invention enable dynamic repartitioning of data storage in response to one or more triggers. In embodiments, a trigger may be a user-initiated action, a system-generated action, and/or an inference based on storage usage parameters. Applications of the present invention are its use in embodiments of a storage management system comprising a file system manager and a volume manager, where the placement of data into a partition (data storage region) may be specified by matching one or more disk region placement data attributes assigned to data with corresponding disk region attributes. In embodiments, dynamic repartitioning comprises adjustment of the location of the boundary between adjacent disk partitions and, if necessary, rebalancing of the data stored within the partitions by identifying mismatched data and relocating it to the partition with which it is associated.",FRIEDMAN DAVID;;BAGAL PRASAD V;;BRIDGE JR WILLIAM HAVINDEN;;LONG RICHARD L;;ORACLE INT CORP,FRIEDMAN DAVID;;BAGAL PRASAD V;;BRIDGE JR WILLIAM HAVINDEN;;LONG RICHARD L,ORACLE INTERNATIONAL CORPORATION (2009-12-04),https://lens.org/079-102-009-847-851,Granted Patent,yes,19,12,2,2,0,G06F3/0613;;G06F3/0644;;G06F3/0676;;G06F3/0644;;G06F3/0613;;G06F3/0676,G06F12/00,711/173;;711/153;;711/156;;707/770,0,0,,,,ACTIVE
518,PT,E,PT 2349260 E,114-029-122-367-031,2016-03-07,2016,PT 09737257 T,2009-10-01,US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,,INCYTE HOLDINGS CORP,PAUL A FRIEDMAN;;JORDAN S FRIDMAN;;MONICA E LUCHI;;WILLIAM V WILLIAMS,,https://lens.org/114-029-122-367-031,Granted Patent,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/437;;A61K31/519;;A61P27/00,,0,0,,,,ACTIVE
519,US,A1,US 2010/0113416 A1,106-922-508-628-902,2010-05-06,2010,US 57183409 A,2009-10-01,US 57183409 A;;US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.",FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,INCYTE CORPORATION (2010-05-05),https://lens.org/106-922-508-628-902,Patent Application,yes,98,125,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/519,514/210.21;;514/265.1,3,1,000-770-213-683-433,10.1016/s0039-6257(00)00203-4;;11587144,"Rolando et al., The Ocular Surface and Tear Film and Their Dysfunction in Dry eye Disease, Survey of Ophthalmology, March 2001, Vol 45, Supplement 2, S203-S210;;Webster's New World Medical Dictionary, Sjogren's syndrome, 2003, Wiley Publishing, printed from http://www.credoreference.com/entry/webstermed/sjogren_s_syndrome, 2 pages;;Mosby's Dictionary of Medicine, Nursing, & Health Professions, sicca complex, 2009, Elsevier, printed from http://www.credoreference.com/entry/ehsmosbymed/sicca_complex, 2 pages",DISCONTINUED
520,CA,A1,CA 2351902 A1,136-238-742-374-178,2001-12-29,2001,CA 2351902 A,2001-06-27,US 21497900 P,2000-06-29,USE OF GROWTH HORMONE SECRETAGOGUES FOR STIMULATING OR INCREASING APPETITE,"Disclosed herein is a drug for increasing or stimulating appetite in a patient, which comprises an effective amount of a certain growth hormone secretagogue, a prodrug thereof or a pharmaceutically acceptable salt of the secretagogue or the prodrug. More preferably, the growth hormone secretagogue is a compound of Formula I: (see formula I) (in which HET is a heterocyclic moiety; R3 is alkyl or the like; R4 is H, alkyl or the like; X4 is H or alkyl; R6 is a bond, alkylene or the like; R7 and R8 are H, alkyl or the like) such as 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7- hexahydropyrazolo[4,3-c]pyridin-5-yl)-l-(R)-benzyloxymethyl-2- oxo-ethyl]isobutylamide, a prodrug thereof or a pharmaceutically acceptable salt of the secretagogue or the prodrug.",PFIZER PROD INC,FRIEDMAN HYLAR LEWIS;;GARDNER MARK JAMES;;LANDSCHULZ WILLIAM HARRAS;;PAN LYDIA CODETTA,,https://lens.org/136-238-742-374-178,Patent Application,no,0,0,13,13,0,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/55;;A61K49/0004;;A61P1/14;;A61P3/00;;A61P3/02;;A61P3/04;;A61P43/00;;A61K31/519;;A61K49/0004;;A61K31/55;;A61K31/437;;A61K31/444;;A61K31/438,C07D471/04;;A61K31/437;;A61K31/438;;A61K31/444;;A61K31/4985;;A61K31/519;;A61K31/55;;A61K49/00;;A61P1/14;;A61P3/00;;A61P43/00,,0,0,,,,DISCONTINUED
521,KR,A,KR 20070049675 A,150-192-017-062-178,2007-05-11,2007,KR 20077006749 A,2007-03-23,US 21123605 A;;US 60440604 P,2004-08-24,TRANSPORTATION SYSTEM,,BROOKS AUTOMATION INC,GILCHRIST ULYSSES;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/150-192-017-062-178,Patent Application,no,0,2,9,12,0,H01L21/67715;;H01L21/67736;;H01L21/67775;;H01L21/68;;H01L21/67715;;H01L21/67736;;H01L21/67775,H01L21/68,,0,0,,,,DISCONTINUED
522,EP,A4,EP 1786710 A4,003-412-897-475-887,2011-10-12,2011,EP 05791673 A,2005-08-19,US 2005/0029757 W;;US 60336104 P;;US 20723105 A,2004-08-19,REDUCED CAPACITY CARRIER AND METHOD OF USE,,BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/003-412-897-475-887,Search Report,no,2,0,17,19,0,B65G49/07;;H01L21/67763;;H01L21/67763;;H01L21/67326;;H01L21/67353;;H01L21/67353;;H01L21/67369;;H01L21/67369;;H01L21/67373;;H01L21/67373;;H01L21/67376;;H01L21/67376;;H01L21/67383;;H01L21/67389;;H01L21/67393;;H01L21/67393;;H01L21/67772;;H01L21/67772;;H01L21/67778;;H01L21/67778;;H01L21/6779;;H01L21/6779;;Y10S414/139;;Y10S414/139,H01L21/68,,0,0,,,,PENDING
523,HU,T2,HU E028499 T2,032-085-508-428-574,2016-12-28,2016,HU E09737257 A,2009-10-01,US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,,INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/032-085-508-428-574,Amended Patent,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61P27/00,,0,0,,,,PENDING
524,CA,A1,CA 2738520 A1,033-959-802-260-136,2010-04-08,2010,CA 2738520 A,2009-10-01,US 10224208 P;;US 2009/0059203 W,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.",INCYTE CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/033-959-802-260-136,Patent Application,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/437;;A61K31/519;;A61P27/00,,0,0,,,,ACTIVE
525,EP,A2,EP 1803151 A2,047-043-430-992-173,2007-07-04,2007,EP 05789226 A,2005-08-23,US 2005/0029840 W;;US 60409904 P;;US 21091805 A,2004-08-23,ELEVATOR-BASED TOOL LOADING AND BUFFERING SYSTEM,"A substrate processing apparatus is provided. The apparatus has a casing, a low port interface and a carrier holding station. The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding station is adapted for holding at least one substrate transport carrier so the at least one substrate transport carrier is capable of being coupled to the load port interface without lifting the at least one substrate transport carrier off the carrier holding station. The carrier holding station is arranged to provide a substantially simultaneous swap section for substantially simultaneous replacement of the substrate transport carrier from the carrier holding station.",BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;BUFANO MICHAEL L;;WILLIAM FOSNIGHT;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,"MURATA MACHINERY, LTD. (2010-06-02)",https://lens.org/047-043-430-992-173,Patent Application,yes,0,0,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,H01L21/677;;H01L21/00,,0,0,,,,ACTIVE
526,US,B1,US 6390982 B1,041-399-156-140-857,2002-05-21,2002,US 62186800 A,2000-07-21,US 62186800 A;;US 14521299 P,1999-07-23,Ultrasonic guidance of target structures for medical procedures,"
    A system comprising a combination of an ultrasound probe and both passive and active infrared tracking systems. The combined system enables a real time image display of the entire region of interest without probe movement; real time tracking of the target region permitting physiological gating; and probe placement during image acquisition so that all external displacements introduced by the probe can be accounted for at the time of treatment planning. This system may be used in the surgical arena for image guidance during radiation therapy and surgery. 
",UNIV FLORIDA,BOVA FRANK J;;FRIEDMAN WILLIAM A;;MEEKS SANFORD L;;BUATTI JOHN M,FLORIDA RESEARCH FOUNDATION INC. UNIVERSITY OF (2003-04-02);;UNIVERSITY OF FLORIDA (2002-02-24),https://lens.org/041-399-156-140-857,Granted Patent,yes,13,270,9,9,0,A61B8/5238;;A61B8/5238;;A61B5/7285;;A61B5/7285;;A61B6/5247;;A61B6/5247;;A61B6/541;;A61B6/541;;A61B8/08;;A61B8/08;;A61B8/4245;;A61B8/4245;;A61N5/1049;;A61N5/1049;;A61N2005/1058;;A61N2005/1058;;A61N2005/1059;;A61N2005/1059;;Y10S128/916;;Y10S128/916,G01R33/28;;A61B5/055;;A61B5/06;;A61B6/00;;A61B6/03;;A61B8/00;;A61B8/08;;A61B19/00;;G01S15/89,600/443;;600/424;;128/916,0,0,,,,EXPIRED
527,ZA,B,ZA 200105259 B,104-863-638-699-135,2003-01-02,2003,ZA 200105259 A,2001-06-26,US 21497900 P,2000-06-29,Use of growth hormone secretagogues for stimulating or increasing appetite.,,PFIZER PROD INC,FRIEDMAN HYLAR LEWIS;;GARDNER MARK JAMES;;LANDSCHULZ WILLIAM HARRAS;;PAN LYDIA CODETTA,,https://lens.org/104-863-638-699-135,Granted Patent,no,0,0,13,13,0,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/55;;A61K49/0004;;A61P1/14;;A61P3/00;;A61P3/02;;A61P3/04;;A61P43/00;;A61K31/519;;A61K49/0004;;A61K31/55;;A61K31/437;;A61K31/444;;A61K31/438,A61K31/437;;A61K31/438;;C07D471/04;;A61K31/444;;A61K31/4985;;A61K31/519;;A61K31/55;;A61K49/00;;A61P1/14;;A61P3/00;;A61P43/00,,0,0,,,,EXPIRED
528,US,A1,US 2011/0138148 A1,127-441-204-964-741,2011-06-09,2011,US 63173709 A,2009-12-04,US 63173709 A,2009-12-04,Dynamic Data Storage Repartitioning,"Embodiments of the present invention enable dynamic repartitioning of data storage in response to one or more triggers. In embodiments, a trigger may be a user-initiated action, a system-generated action, and/or an inference based on storage usage parameters. Applications of the present invention are its use in embodiments of a storage management system comprising a file system manager and a volume manager, where the placement of data into a partition (data storage region) may be specified by matching one or more disk region placement data attributes assigned to data with corresponding disk region attributes. In embodiments, dynamic repartitioning comprises adjustment of the location of the boundary between adjacent disk partitions and, if necessary, rebalancing of the data stored within the partitions by identifying mismatched data and relocating it to the partition with which it is associated.",FRIEDMAN DAVID;;BAGAL PRASAD V;;BRIDGE JR WILLIAM HAVINDEN;;LONG RICHARD L,FRIEDMAN DAVID;;BAGAL PRASAD V;;BRIDGE JR WILLIAM HAVINDEN;;LONG RICHARD L,ORACLE INTERNATIONAL CORPORATION (2009-12-04),https://lens.org/127-441-204-964-741,Patent Application,yes,19,143,2,2,0,G06F3/0613;;G06F3/0644;;G06F3/0676;;G06F3/0644;;G06F3/0613;;G06F3/0676,G06F12/00;;G06F12/02,711/173;;X711E12001;;X711E12002,0,0,,,,ACTIVE
529,CN,A,CN 103771034 A,133-598-098-402-667,2014-05-07,2014,CN 201310692043 A,2005-08-19,US 60336104 P;;US 20723105 A,2004-08-19,Capacity reduced carrier and method of use,A substrate transport apparatus is provided. The apparatus has a casing and a door. The casing is adapted to form a controlled environment therein. The casing has supports therein for holding at least one substrate in the casing. The casing defines a substrate transfer opening through which a substrate transport system accesses the substrate in the casing. The door is connected to the casing for closing the substrate transfer opening in the casing. The casing has structure forming a fast swap element allowing replacement of the substrate from the apparatus with another substrate without retraction of the substrate transport system and independent of substrate loading in the casing.,BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/133-598-098-402-667,Patent Application,no,4,2,17,19,0,B65G49/07;;H01L21/67763;;H01L21/67763;;H01L21/67326;;H01L21/67353;;H01L21/67353;;H01L21/67369;;H01L21/67369;;H01L21/67373;;H01L21/67373;;H01L21/67376;;H01L21/67376;;H01L21/67383;;H01L21/67389;;H01L21/67393;;H01L21/67393;;H01L21/67772;;H01L21/67772;;H01L21/67778;;H01L21/67778;;H01L21/6779;;H01L21/6779;;Y10S414/139;;Y10S414/139,B65D85/48;;B65G49/07,,0,0,,,,ACTIVE
530,EP,A1,EP 3042655 A1,000-535-718-699-81X,2016-07-13,2016,EP 15195683 A,2009-10-01,US 10224208 P;;EP 09737257 A,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.",INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/000-535-718-699-81X,Patent Application,yes,25,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/437;;A61K31/519;;A61P27/00,,138,116,024-348-911-056-434;;057-173-326-142-652;;090-322-747-879-890;;034-608-382-953-068;;106-780-162-547-046;;084-979-194-358-014;;137-961-190-704-720;;090-086-830-586-608;;007-143-850-789-152;;035-076-098-142-753;;176-245-138-008-207;;046-630-001-594-388;;076-476-628-456-988;;038-383-222-303-307;;053-543-065-487-432;;001-562-499-690-427;;042-477-483-455-546;;001-562-499-690-427;;024-598-170-491-974;;036-881-306-556-837;;039-120-133-000-672;;102-518-442-406-433;;075-815-069-233-901;;038-383-222-303-307;;026-807-817-100-358;;000-358-912-762-822;;037-600-713-643-527;;076-112-938-501-855;;076-112-938-501-855;;038-557-964-711-067;;074-741-408-513-321;;024-944-860-685-791;;052-328-524-903-602;;159-571-531-716-354;;084-287-385-757-037;;060-897-303-684-434;;004-204-497-121-457;;053-543-065-487-432;;017-172-514-022-687;;026-592-001-636-015;;074-463-460-883-015;;136-667-038-397-232;;033-236-259-741-456;;042-755-578-896-472;;008-758-921-951-813;;030-431-017-603-397;;049-191-752-276-038;;039-157-713-393-352;;013-614-246-427-046;;117-626-506-578-158;;011-953-395-707-774;;037-054-911-923-284;;133-457-029-718-407;;053-599-875-782-313;;050-497-887-668-626;;022-359-876-177-53X;;003-308-169-206-11X;;124-457-072-659-637;;019-016-859-411-897;;019-013-475-112-675;;054-148-239-979-610;;050-497-887-668-626;;044-832-260-120-403;;104-752-547-912-808;;011-688-243-581-530;;031-343-998-356-958;;034-845-425-237-213;;033-663-103-112-465;;001-232-267-433-833;;053-357-915-381-599;;081-910-357-624-045;;003-828-317-789-791;;145-442-345-753-187;;127-954-213-567-813;;045-540-789-801-251;;101-847-103-871-526;;178-062-975-666-152;;010-273-866-104-537;;032-752-454-014-929;;082-665-399-734-576;;045-689-222-680-730;;053-357-915-381-599;;021-882-492-539-458;;110-883-686-474-972;;071-404-706-565-780;;000-225-607-052-163;;061-571-098-250-288;;000-439-411-681-340;;041-599-068-697-467;;011-447-908-660-616;;088-661-502-447-955;;042-477-483-455-546;;056-763-180-134-265;;076-301-101-311-26X;;085-144-843-087-092;;050-088-328-804-241;;067-693-411-161-454;;015-223-841-206-066;;024-507-295-068-866;;075-793-181-797-980;;110-743-209-182-77X;;009-603-734-219-07X;;019-910-308-262-625;;110-018-535-893-727;;139-802-247-246-535;;007-357-946-033-88X;;110-018-535-893-727;;110-018-535-893-727;;110-018-535-893-727;;152-775-282-589-250;;001-554-355-117-226;;034-974-911-550-038;;101-965-755-278-506;;014-461-200-232-958;;030-267-489-757-034;;050-909-963-813-345,10.1128/cdli.9.6.1153-1159.2002;;12414743;;pmc130124;;10.1073/pnas.91.14.6374;;pmc44204;;8022790;;11094415;;pmc129988;;10.1186/ar66;;10.1046/j.1600-6143.2003.00225.x;;14525593;;10.1016/s1521-6616(02)00049-9;;12706408;;9590172;;10.1016/s0092-8674(00)81166-6;;10.1016/s0092-8674(00)81168-x;;9590174;;10.1016/s0092-8674(00)81167-8;;9590173;;10.1182/blood.v90.10.3996;;9354668;;17508116;;10.1016/s1542-0124(12)70081-2;;10.1016/s1542-0124(12)70083-6;;17508118;;12352083;;10.1097/00003226-200210000-00007;;10.1097/00003226-199901000-00007;;9894936;;9894935;;8565190;;10.1097/00003226-200404000-00010;;15084861;;14508260;;10.1097/00003226-200310000-00008;;12614039;;10.1007/978-1-4615-0717-8_157;;14508260;;10.1097/00003226-200310000-00008;;8430006;;10.1097/00006324-199301000-00007;;10.1046/j.1475-1313.1995.9500071k.x;;8594528;;10.1016/0275-5408(95)00071-k;;10.1136/bjo.74.9.519;;pmc1042197;;1697478;;10.1111/j.1755-3768.1992.tb08579.x;;1636398;;16160497;;10.1097/01.ico.0000154378.67495.40;;8565190;;10.3109/02713689408995787;;8033588;;3776509;;10.1111/j.1755-3768.1986.tb06950.x;;9436879;;10.1097/00003226-199801000-00007;;pmc1005429;;10.1136/ard.53.10.637;;7979575;;pmc1005429;;10.1136/ard.53.10.637;;7979575;;4183019;;10.1001/archopht.1969.00990020012003;;10.1007/978-1-4615-2417-5_83;;8030524;;10.3109/02713688609015135;;3769529;;8249586;;10.1111/j.1755-3768.1993.tb04630.x;;12883343;;10.1097/00003226-200308000-00006;;10.1046/j.1475-1313.2003.00081.x;;12535050;;10.1167/iovs.03-0685;;14638706;;10.3109/02713689609008906;;8670769;;10.1097/00003226-200404000-00010;;15084861;;15502475;;10.1097/01.ico.0000133997.07144.9e;;10.1097/00003226-200007000-00019;;10928766;;15106919;;10.1016/j.exer.2003.09.020;;9019372;;10.1111/j.1600-0420.1995.tb00324.x;;10.1097/00006324-198906000-00008;;2771324;;14578388;;10.1167/iovs.03-0260;;10.1001/archopht.121.2.173;;12583782;;12714621;;10.1167/iovs.02-0818;;10.1016/s0141-7037(82)80022-0;;10030612;;10.1097/00006324-199901000-00025;;8030491;;10.1007/978-1-4615-2417-5_50;;16044071;;10.1097/01.opx.0000171818.01353.8c;;9071529;;10.1097/00003226-199703000-00008;;15277478;;10.1167/iovs.03-1185;;10.3109/02713688609029242;;3780283;;8956636;;10.1016/s0002-9394(14)70378-2;;10369581;;10.1001/archopht.117.6.723;;10.1097/01.ico.0000136685.88489.70;;15448483;;10.1016/s0002-9394(03)00901-2;;14700653;;15111590;;10.1167/iovs.03-0712;;8482113;;10.3109/02713689308999470;;8482114;;10.3109/02713689308999471;;10.1007/978-1-4615-0717-8_73;;12613955;;10369581;;10.1001/archopht.117.6.723;;10.1007/s00417-004-0868-0;;14963716;;7076409;;8155046;;10.1001/archopht.1994.01090160022008;;4069605;;10.1016/s0161-6420(85)33848-4;;10.1016/s0161-6420(98)98033-2;;9709762;;10.1007/s10384-006-0397-y;;17295142;;8256669;;9407208;;10.1002/(sici)1097-0339(199712)17:6<456::aid-dc15>3.0.co;2-l;;10.1097/00003226-200110000-00014;;11588428;;pmc1772414;;15548799;;10.1136/bjo.2004.047167;;1695061;;2321456;;10.1097/00003226-199111000-00011;;1782781;;9191610;;10634610;;9990333;;10.1006/exer.1998.0566;;10798650;;11133852;;15106926;;10.1016/j.exer.2003.08.005;;9407208;;10.1002/(sici)1097-0339(199712)17:6<456::aid-dc15>3.0.co;2-l;;10.1016/s0161-6420(00)00347-x;;11013183;;15111589;;10.1167/iovs.03-1067;;8012142;;10.1097/00003226-199401000-00010;;8131408;;7976270;;10.1111/j.1755-3768.1994.tb02775.x;;10.1016/s0275-5408(99)00087-3;;10962696;;10.1046/j.1475-1313.2000.00523.x;;9734804;;10.1097/00006324-199808000-00025;;3817685;;10.1159/000309944;;3231427;;12614039;;10.1007/978-1-4615-0717-8_157;;10.1007/978-1-4615-0717-8_152;;12614034;;1477640;;1428718;;10.1001/archopht.1965.00970030235017;;14237794;;5947945;;8618768;;10.1016/s0161-6420(96)30637-4;;8713923;;10.1097/00003226-199605000-00001;;15106917;;10.1016/s0014-4835(03)00199-4;;7721117;;10.1007/bf00177778;;9624695;;10.1097/00006324-199805000-00020;;10.1097/00006324-200101010-00011;;11233332;;10.4103/0973-8398.41558;;11733117;;10.1016/s0169-409x(01)00220-4;;10.1128/aac.48.9.3396-3401.2004;;pmc514778;;15328102;;10.4103/0973-8398.41558;;10.4103/0973-8398.41558;;10.4103/0973-8398.41558;;15500820;;10.1016/j.exer.2004.07.002;;10.1046/j.1440-1711.1998.00783.x;;9893027;;14616119;;10.1046/j.1398-9995.2003.00326.x;;10.1006/abio.1999.4029;;10094779;;15793561;;10.1038/nature03546;;10.1074/jbc.c500358200;;16239216;;10.1007/bf02027222;;8480531,"SCOTT, M. J.; C. J. GODSHALL ET AL.: ""Jaks, STATs, Cytokines, and Sepsis"", CLIN DIAGN LAB IMMUNOLOGY, vol. 9, no. 6, 2002, pages 1153 - 1159;;KAWAMURA, M.; D. W. MCVICAR ET AL.: ""Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes"", PROC NATL ACAD SCI U S A, vol. 91, no. 14, 1994, pages 6374 - 6378;;ORTMANN, R. A.; T. CHENG ET AL.: ""Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation"", ARTHRITIS RES, vol. 2, no. 1, 2000, pages 16 - 32;;SAEMANN, M. D.; C. DIAKOS ET AL.: ""Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3"", AM J TRANSPLANT, vol. 3, no. 11, 2003, pages 1341 - 1349;;CETKOVIC-CVRLJE, M.; A. L. DRAGT ET AL.: ""Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice"", CLIN IMMUNOL, vol. 106, no. 3, 2003, pages 213 - 225;;RODIG, S. J.; M. A. MERAZ ET AL.: ""Disruption of the Jakl gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses"", CELL, vol. 93, no. 3, 1998, pages 373 - 383;;NEUBAUER, H.; A. CUMANO ET AL., CELL, vol. 93, no. 3, 1998, pages 397 - 409;;PARGANAS, E.; D. WANG ET AL., CELL, vol. 93, no. 3, 1998, pages 385 - 395;;CANDOTTI, F.; S. A. OAKES ET AL.: ""Structural and functional basis for JAK3-deficient severe combined immunodeficiency"", BLOOD, vol. 90, no. 10, 1997, pages 3996 - 4003;;LEMP: ""The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop"", THE OCULAR SURFACE, vol. 5, no. 2, April 2007 (2007-04-01), pages 75 - 92;;BRON ET AL.: ""Methodologies to Diagnose and Monitor Dry Eye Disease: Report of the Diagnostic Methodology Subcommittee of the International Dry Eye Workshop (2007"", THE OCULAR SURFACE, vol. 5, no. 2, April 2007 (2007-04-01), pages 108 - 152;;BEGLEY ET AL.: ""Use of the dry eye questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye"", CORNEA, vol. 21, 2002, pages 664 - 670;;BARR ET AL.: ""Corneal scarring in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study: baseline prevalence and repeatability of detection"", CORNEA, vol. 18, no. 1, 1999, pages 34 - 46;;LEMP: ""Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes"", CLAO J, vol. 21, no. 4, 1995, pages 221 - 231;;NICHOLS ET AL.: ""The repeatability of clinical measurements of dry eye"", CORNEA, vol. 23, 2004, pages 272 - 285;;BRON ET AL.: ""Grading of corneal and conjunctival staining in the context of other dry eye tests"", CORNEA, vol. 22, no. 7, 2003, pages 640 - 650;;ABELSON ET AL.: ""Alternate reference values for tear film break-up time in normal and dry eye populations"", ADV EXP MED BIOL, vol. 506, no. B, 2002, pages 1121 - 1125;;BRON AJ ET AL.: ""Grading of corneal and conjunctival staining in the context of other dry eye tests"", CORNEA, vol. 22, 2003, pages 640 - 650;;CHO ET AL.: ""Review of the tear break-up time and a closer look at the tear break-up time of Hong Kong Chinese"", OPTOM VIS SCI, vol. 70, no. 1, 1993, pages 30 - 38;;CRAIG ET AL.: ""Tear lipid layer structure and stability following expression of the meibomian glands"", OPHTHALMIC PHYSIOL OPT, vol. 15, no. 6, 1995, pages 569 - 574;;ELIASON ET AL.: ""Staining of the conjunctiva and conjunctival tear film"", BR J OPHTHALMOL, vol. 74, 1990, pages 519 - 522, XP000430653;;FARRELL ET AL.: ""A classification for dry eyes following comparison of tear thinning time with Schirmer tear test"", ACTA OPHTHALMOL (COPENH), vol. 70, no. 3, 1992, pages 357 - 360;;JOHNSON ET AL.: ""The effect of instilled fluorescein solution volume on the values and repeatability of TBUT measurements"", CORNEA, vol. 24, 2005, pages 811 - 817;;LEMP ET AL.: ""Corneal desiccation despite normal tear volume"", ANN OPHTHALMOL, vol. 284, 1970, pages 258 - 261;;LEMP: ""Report of National Eye Institute/Industry Workshop on clinical trials in dry eyes"", CLAO J, vol. 21, 1995, pages 221 - 232, XP000933694;;MADDEN ET AL.: ""Comparative study of two non-invasive tear film stability techniques"", CURR EYE RES, vol. 13, no. 4, 1994, pages 263 - 269;;MARQUARDT ET AL.: ""Modification of tear film break-up time test for increased reliability"", THE PREOCULAR TEAR FILM INHEALTH, DISEASE AND CONTACT LENS WEAR, 1986, pages 57 - 63, XP001207044;;MENGHER ET AL.: ""Non-invasive tear film break-up time: sensitivity and specificity"", ACTA OPHTHALMOL (COPENH, vol. 64, no. 4, 1986, pages 441 - 444;;PFLUGFELDER ET AL.: ""Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation"", CORNEA, vol. 17, no. L, 1998, pages 38 - 56, XP000933607, DOI: doi:10.1097/00003226-199801000-00007;;VITALI: ""Sensitivity and specificity of tests for ocular and oral involvement in Sjogren's syndrome"", 1992, THE EUROPEAN COMMUNITY STUDY GROUP ON DIAGNOSTIC CRITERIA FOR SJOGREN'S SYNDROME, article ""The European Community Study Group on diagnostic criteria for Sjogren's syndrome"";;ANN RHEUM DIS, vol. 53, no. 10, pages 637 - 647;;WELCH ET AL.: ""An approach to a more standardized method of evaluating tear film break-up time"", INVEST OPHTHALMOL VIS SCI, vol. 2485, 2003, pages B324;;VAN BIJSTERVELD: ""Diagnostic tests in the sicca syndrome"", ARCH OPHTHALMOL, vol. 82, 1969, pages 10 - 14;;HOLLY ET AL.: ""The preocular tear film"", 1986, LUBBOCK TX, LUBBOCK DRY EYE INSTITUTE, article ""Lacrimation kinetics as determined by a novel technique"", pages: 76 - 88;;FARRIS: ""Tear osmolarity--a new gold standard?"", ADV EXP MED BIOL, vol. 350, 1994, pages 495 - 503;;NELSON ET AL.: ""Tear film osmolality determination: an evaluation of potential errors in measurement"", CURR EYE RES, vol. 5, no. 9, September 1986 (1986-09-01), pages 677 - 681;;SULLIVAN ET AL., 4TH INTERNATIONAL CONFERENCE ON THE LACRIMAL GLAND, TEAR FILM & OCULAR SURFACE AND DRY EYE SYNDROMES, 20 November 2004 (2004-11-20);;WHITE ET AL.: ""Human basic tear fluid osmolality. I. Importance of sample collection strategy"", ACTA OPHTHALMOL (COPENH, vol. 71, no. 4, August 1993 (1993-08-01), pages 524 - 529;;CENNAK ET AL.: ""Is complete androgen insensitivity syndrome associated with alterations in the meibomium gland and ocular surface"", CORNEA, vol. 22, 2003, pages 516 - 521;;FARRELL ET AL.: ""A clinical procedure to predict the value of temporary occlusion therapy in keratoconjunctivitis sicca"", OPHTHAL PHYSIOL OPT, vol. 23, 2003, pages 1 - 8;;GLASSON ET AL.: ""Differences in clinical parameters and tear film of tolerant and intolerant contact lens wearers"", INVEST OPHTHALMOL VIS SCI, vol. 44, 2003, pages 5116 - 5124;;MAINSTONE ET AL.: ""Tear meniscus measurement in the diagnosis of dry eye"", CURR EYE RES, vol. 15, 1996, pages 653 - 661, XP002105229;;NICHOLS ET AL.: ""The repeatability of clinical measurements of dry eye"", CORNEA, vol. 23, 2004, pages 272 - 285;;NICHOLS ET AL.: ""The lack of association between signs and symptoms in patients with dry eye disease"", CORNEA, vol. 23, 2004, pages 762 - 770;;OGUZ ET AL.: ""The height and radius of the tear meniscus and methods for examining these parameters"", CORNEA, vol. 19, 2000, pages 497 - 500;;YOKOI ET AL.: ""Non-invasive methods of assessing the tear film"", EXP EYE RES, vol. 78, 2004, pages 399 - 407;;DANJO ET AL.: ""Observation of precorneal tear film in patients with Sjogren's syndrome"", ACTA OPHTHALMOL SCAND, vol. 73, 1995, pages 501 - 505;;DOANE: ""An instrument for in vivo tear film interferometry"", OPTOM VIS SCI, vol. 66, 1989, pages 383 - 388, XP009103794, DOI: doi:10.1097/00006324-198906000-00008;;GOTO ET AL.: ""Computer-synthesis of an interference color chart of human tear lipid layer by a colorimetric approach"", INVEST OPHTHALMOL VIS SCI, vol. 44, 2003, pages 4693 - 4697, XP055016265, DOI: doi:10.1167/iovs.03-0260;;GOTO ET AL.: ""Differentiation of lipid tear deficiency dry eye by kinetic analysis of tear interference images"", ARCH OPHTHALMOL, vol. 121, 2003, pages 173 - 180;;GOTO E ET AL.: ""Kinetic analysis of tear interference images in aqueous tear deficiency dry eye before and after punctal occlusion"", INVEST OPHTHALMOL VIS SCI, vol. 44, 2003, pages 1897 - 1905, XP002391239, DOI: doi:10.1167/iovs.02-0818;;GOTO ET AL.: ""Color mapping of tear lipid layer thickness distribution from the image analysis in DR-1 tear lipid layer interference images (ARVO abstract"", ARVO, 2004;;GUILLON: ""Tear film photography and contact lens wear"", J BR CONTACT LENS ASSOC, vol. 5, 1982, pages 84 - 87;;KING-SMITH ET AL.: ""Three interferometric methods for measuring the thickness of layers of the tear film"", OPTOM VIS SCI, vol. 76, 1999, pages 19 - 32, XP000955906;;KORB: ""Increase in tear film lipid layer thickness following treatment of meibomian gland dysfunction"", ADV EXP MED BIOL, vol. 350, 1994, pages 293 - 298, XP009135249;;KORB ET AL.: ""The effect of two novel lubricant eye drops on tear film lipid layer thickness in subjects with dry eye symptoms"", OPTOM VIS SCI, vol. 82, 2005, pages 594 - 601, XP009103830, DOI: doi:10.1097/01.opx.0000171818.01353.8c;;MATHERS ET AL.: ""Assessment of the tear film with tandem scanning confocal microscopy"", CORNEA, vol. 16, 1997, pages 162 - 168;;MARUYAMA ET AL.: ""Effect of environmental conditions on tear dynamics in soft contact lens wearers"", INVEST OPHTHALMOL VIS SCI, vol. 45, no. 8, 2004, pages 2563 - 2568;;TIFFANY: ""Refractive index of meibomian and other lipids"", CURR EYE RES, vol. 5, 1986, pages 887 - 889;;TIFFANY ET AL.: ""Meniscometry using the Tearscope-plus (ARVO abstract"", INVEST OPHTHALMOL VIS SCI, vol. 42, 2001, pages S37;;YOKOI ET AL.: ""Correlation of tear lipid layer interference patterns with the diagnosis and severity of dry eye"", AM J OPHTHALMOL, vol. 122, 1996, pages 818 - 824, XP029017123, DOI: doi:10.1016/S0002-9394(14)70378-2;;YOKOI ET AL.: ""Assessment of meibomian gland function in dry eye using meibometry"", ARCH OPHTHALMOL, vol. 117, 1999, pages 723 - 729, XP009163048, DOI: doi:10.1001/archopht.117.6.723;;GOTO ET AL.: ""Tear Film Stability Analysis System: Introducing a new application for videokeratography"", CORNEA, vol. 23, no. 8, November 2004 (2004-11-01), pages S65 - S70;;GOTO ET AL.: ""Evaluation of the tear film stability after laser in situ keratomileusis using the tear film stability analysis system"", AM J OPHTHALMOL, vol. 137, no. L, January 2004 (2004-01-01), pages 116 - 120, XP004918171, DOI: doi:10.1016/S0002-9394(03)00901-2;;KOJIMA ET AL.: ""A new noninvasive tear stability analysis system for the assessment of dry eyes"", INVEST OPHTHALMOL VIS SCI, vol. 45, no. 5, May 2004 (2004-05-01), pages 1369 - 1374;;CHEW ET AL.: ""An instrument for quantifying meibomian lipid on the lid margin: the Meibometer"", CURR EYE RES, vol. 12, 1993, pages 247 - 254;;CHEW ET AL.: ""The casual level of meibomian lipids in humans"", CURRENT EYE RESEARCH, vol. 12, 1993, pages 255 - 259;;KOMURO ET AL.: ""Assessment of meibomian gland function by a newly developed laser meibometer"", ADV EXP MED BIOL, vol. 506, 2002, pages 517 - 520;;YOKOI ET AL.: ""Assessment of meibomian gland function in dry eye using meibometry"", ARCH OPHTHALMOL, vol. 117, 1999, pages 723 - 729, XP009163048, DOI: doi:10.1001/archopht.117.6.723;;KAERCHER: ""Ocular symptoms and signs in patients with ectodermal dysplasia symdromes"", GRAFES ARCH CLIN EXP OPHTHALMOL, 2004, pages 495 - 500;;JESTER ET AL.: ""In vivo biomcroscopy and photography of meibomian glands in a rabbit model of meibomian gland dysfunction"", INVEST OPHTHALMOL VIS SCI, vol. 22, 1982, pages 660 - 667;;MATHERS ET AL.: ""Video imaging of the meibomian gland"", ARCH OPHTHALMOL, vol. 112, 1994, pages 448 - 449;;ROBIN ET AL.: ""In vivo transillumination biomicroscopy and photography of meibomian gland dysfunction"", OPHTHALMOLOGY, vol. 92, 1985, pages 1423 - 1426;;SHIMAZAKI ET AL.: ""Meibomian gland dysfunction in patients with Sjogren syndrome"", OPHTHALMOLOGY, vol. 105, no. 8, 1998, pages 1485 - 1488;;YOKOI ET AL.: ""A newly developed video-meibography system featuring a newly designed probe"", JPN J OPHTHALMOL, vol. 51, 2007, pages 53 - 56, XP019476892, DOI: doi:10.1007/s10384-006-0397-y;;FUKAGAWA ET AL.: ""Histological evaluation of brush cytology of rabbit conjunctiva"", NIPPON GANKA GAKKAI ZASSHI, vol. 97, 1993, pages 1173 - 1178;;FUJIHARA ET AL.: ""Evaluation of human conjunctival epithelium by a combination of brush cytology and flow cytometry: an approach to the quantitative technique"", DIAGN CYTOPATHOL, vol. 17, 1997, pages 456 - 460;;MIYOSHI: ""Intcrlcukin-8 concentrations in conjunctival epithelium brush cytology samples correlate with neutrophil, eosinophil infiltration, and corneal damage"", CORNEA, vol. 20, 2001, pages 743 - 747;;TAKANO ET AL.: ""Tnflammatory cells in brush cytology samples correlate with the severity of corneal lesions in atopic keratoconjunctivitis"", BR J OPHTHALMOL, vol. 88, 2004, pages 1504 - 1505;;TSUBOTA ET AL.: ""Brush cytology for the evaluation of dry-eye"", NIPPON GANKA GAKKAI ZASSHI, vol. 94, 1990, pages 224 - 230;;TSUBOTA ET AL.: ""Conjunctival brush cytology"", ACTA CYTOL, vol. 34, 1990, pages 233 - 235;;TSUBOTA ET AL.: ""Detection by brush cytology of mast cells and eosinophils in allergic and vernal conjunctivitis"", CORNEA, vol. 10, 1991, pages 525 - 531;;BAUDOUIN ET AL.: ""Flow cytometry in impression cytology specimens. A new method for evaluation of conjunctival Inflammation"", INVEST OPHTHALMOL VIS SCI, vol. 38, 1997, pages 1458 - 1464;;BOURCIER ET AL.: ""Expression of CD40 and CD40 ligand in the human conjunctival epithelium"", INVEST OPHTHALMOL VIS SCI, vol. 41, 2000, pages 120 - 126;;BRIGNOLE ET AL.: ""Expression of Fas antigen (CD95) in the human conjunctival epithelium. Positive correlation with class II HLA DR expression in inflammatory conditions"", EXP EYE RES, vol. 67, 1998, pages 687 - 697;;BRIGNOLE ET AL.: ""Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes"", INVEST OPHTHALMOL VIS SCI, vol. 41, 2000, pages 1356 - 1363;;BRIGNOLE ET AL.: ""Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A"", INVEST OPHTHALMOL VIS SCI, vol. 42, 2001, pages 90 - 95, XP002490490;;BRIGNOLE ET AL.: ""Flow cytometry in conjunctival impression cytology: a new tool for exploring ocular surface pathologies"", EXP EYE RES, vol. 78, 2004, pages 473 - 481;;FUJIHARA ET AL.: ""Evaluation of human conjunctival epithelium by a combination of brush cytology and flow cytometry: an approach to the quantitative technique"", DIAGN CYTOPATHOL, vol. 17, 1997, pages 456 - 460;;PISELLA ET AL.: ""Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca"", OPHTHALMOLOGY, vol. 107, 2000, pages 1841 - 1849;;PISELLA ET AL.: ""Conjunctival proinflammatory and proapoptotic effects of latanoprost, preserved timolol and unpreserved timolol: an ex vivo and in vitro study"", INVEST OPHTHALMOL VIS SCI, vol. 45, 2004, pages 1360 - 1368;;ALBACH ET AL.: ""Diagnosis of keratoconjunctivitis sicca in rheumatoid arthritis. The value of various tests"", OPHTHALMOLOGE, vol. 91, no. 2, April 1994 (1994-04-01), pages 229 - 234;;GOLDING ET AL.: ""X-ray and scanning electron microscopic analysis of the structural composition of tear ferns"", CORNEA, vol. 13, no. L, January 1994 (1994-01-01), pages 58 - 66;;NORN: ""Quantitative tear ferning. Clinical investigations"", ACTA OPHTHALMOL (COPENH, vol. 72, no. 3, June 1994 (1994-06-01), pages 369 - 372;;PEARCE ET AL.: ""Spatial location studies on the chemical composition of human tear ferns"", OPHTHALMIC PHYSIOL OPT, vol. 20, no. 4, July 2000 (2000-07-01), pages 306 - 313;;PENSYL ET AL.: ""The repeatability of tear mucus ferning grading"", OPTOM VIS SCI, vol. 75, no. 8, August 1998 (1998-08-01), pages 600 - 604;;ROLANDO: ""Tear mucus ferning test in normal and keratoconjunctivitis sicca eyes"", CHIBRET INT J OPHTHALMOL, vol. 2, no. 4, 1984, pages 32 - 41;;ROLANDO ET AL.: ""Thepreocular tear film in health, disease, and contact lens wear"", 1986, LUBBOK, article ""Tear mucus ferning test in keratoconjunctivitis sicca"", pages: 203 - 210;;ROLANDO ET AL.: ""The effect of hyperosmolarity on tear mucus ferning"", FORTSCHR OPHTHALMOL, vol. 83, 1986, pages 644 - 646;;ROLANDO: ""Tear mucus crystallization in children with cystic fibrosis"", OPHTHALMOLOGICA, vol. 197, no. 4, 1988, pages 202 - 206;;OUSLER ET AL.: ""Factors that influence the inter-blink interval (IBI) as measured by the ocular protection index (OPI"", POSTER PRESENTATION) ARVO, 2002;;NALLY ET AL.: ""Ocular discomfort and tear film break-up time in dry eye patients: A correlation"", INVEST OPHTHALMOL VIS SCI, vol. 41, no. 4, 2000, pages 1436;;ABELSON ET AL.: ""Alternate reference values for tear film break-up time in normal and dry eye populations'', Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3 Part B"", ADV EXP MED BIOL, vol. 506, 2002, pages 1121 - 1125;;ABELSON ET AL.: ""Dry eye syndrome: diagnosis, clinical trials, and pharmaceutical treatment-'improving clinical trials'. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3 Part B"", ADV EXP MED BIOL, vol. 506, 2002, pages 1079 - 1086;;GOBBELS ET AL.: ""Tear secretion in dry eyes as assessed by objective fluorophotometry"", GER J OPHTHALMOL, vol. 1, 1992, pages 350 - 353;;KUPPENS ET AL.: ""Basal tear turnover and topical timolol in glaucoma patients and healthy controls by Fluorophotometry"", INVEST OPHTHALMOL VIS SCI, vol. 33, 1992, pages 3442 - 3448;;MISHIMA: ""Some physiological aspects of the precorneal tear film"", ARCH OPHTHALMOL, vol. 73, 1965, pages 233 - 241;;MISHIMA S: ""Determination of tear volume and tear flow"", INVEST OPHTHALMOL, vol. 5, 1966, pages 264 - 275;;MATHERS ET AL.: ""Tear film and evaporation in patients with and without dry eye"", OPHTHALMOLOGY, vol. 103, 1996, pages 664 - 669;;MATHERS ET AL.: ""Tear film changes associated with normal aging"", CORNEA, vol. 15, 1996, pages 229 - 334;;MATHERS: ""Evaporation from the ocular surface"", EXP EYE RES, vol. 78, 2004, pages 389 - 394;;VAN BEST ET AL.: ""Measurement of basal tear turnover using a standardized protocol"", GRAEFE'S ARCH CLIN EXP OPHTHALMOL, vol. 233, 1995, pages 1 - 7;;MCNAMARA ET AL.: ""Fluorometry in contact lens research: The next step"", OPTOM VIS SCI, vol. 75, 1998, pages 316 - 322;;PEARCE: ""An improved fluorophotometric method for tear turnover assessment"", OPTOM VIS SCI, vol. 78, 2001, pages 30 - 36;;WAGH: ""Polymers used in ocular dosage form and drug delivery systems"", ASIAN J. PHARM., January 2008 (2008-01-01), pages 12 - 17;;EINMAHL, ADV. DRUG. DELIV. REV., vol. 53, 2001, pages 45 - 73;;GHELARDI ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 48, 2004, pages 3396 - 3401;;WAGH ET AL.: ""Polymers used in ocular dosage form and drug delivery systems"", ASIAN J. PHARM., January 2008 (2008-01-01), pages 12 - 17;;WAGH ET AL.: ""Polymers used in ocular dosage form and drug delivery systems"", ASIAN J. PHARM.., January 2008 (2008-01-01), pages 12 - 17;;WAGH ET AL.: ""Polymers used in ocular dosage form and drug delivery systems"", ASIAN .7. PHARM., January 2008 (2008-01-01), pages 12 - 17;;FABRIZIO, ADVANCED DRUG DELIVERY REVIEWS, vol. 16, 1998, pages 95 - 106;;WAGH ET AL.: ""Polymers used in ocular dosage form and drug delivery systems"", ASIAN J. PHAR I., January 2008 (2008-01-01), pages 12 - 17;;REMINGTON'S: ""Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY, pages: 1418;;JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2;;T. HIGUCHI; V. STELLA: ""Pro-drugs as Novel Delivery Systems"", vol. 14, A.C.S. SYMPOSIUM SERIES;;""Bioreversible Carriers in Drug Design"", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS;;T.W. GREEN; P.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1999, WILEY & SONS, INC.;;BARABINO ET AL., EXPERIMENTAL EYE RESEARCH, vol. 79, 2004, pages 613 - 621;;SCHRADER ET AL.: ""Developmental Opthalmology"", vol. 41, 2008, KARGER, pages: 298 - 312;;SMITH ET AL., IMMUNOLOGY AND CELL BIOLOGY, vol. 76, 1998, pages 497 - 512;;GRONEBERG, D.A. ET AL., ALLERGY, vol. 58, 2003, pages 1101 - 1113;;PARK ET AL., ANALYTICAL BIOCHEMISTRY, vol. 269, 1999, pages 94 - 104;;JAMES, C. ET AL., NATURE, vol. 434, pages 1144 - 1148;;STAERK, J. ET AL., JBC, vol. 280, pages 41893 - 41899;;IMMUNOL TODAY., vol. 19, no. 1, January 1998 (1998-01-01), pages 37 - 44;;AGENTS ACTIONS., vol. 38, no. 1-2, January 1993 (1993-01-01), pages 116 - 121;;COLIGAN, J.E.: ""Current Protocols in Immunology"", vol. 3, WILEY PRESS.;;WINYARD, P.G.; WILLOUGHBY, D.A.: ""Inflammation Protocols."", vol. 225, 2003, HUMANA PRESS, article ""Methods in Molecular Biology""",DISCONTINUED
531,HU,D0,HU 0102696 D0,070-254-501-386-378,2001-08-28,2001,HU P0102696 A,2001-06-28,US 21497900 P,2000-06-29,USE OF GROWTH HORMONE SECRETAGOGUES FOR STIMULATING OR INCREASING APPETITE,,PFIZER PROD INC,FRIEDMAN HYLAR LEWIS;;GARDNER MARK JAMES;;LANDSCHULZ WILLIAM HARRAS;;PAN LYDIA CODETTA,,https://lens.org/070-254-501-386-378,Patent Application,no,0,0,13,13,0,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/55;;A61K49/0004;;A61P1/14;;A61P3/00;;A61P3/02;;A61P3/04;;A61P43/00;;A61K31/519;;A61K49/0004;;A61K31/55;;A61K31/437;;A61K31/444;;A61K31/438,A61K31/437;;C07D471/04;;A61K31/438;;A61K31/444;;A61K31/4985;;A61K31/519;;A61K31/55;;A61K49/00;;A61P1/14;;A61P3/00;;A61P43/00,,0,0,,,,DISCONTINUED
532,TW,B,TW I643622 B,106-193-418-572-792,2018-12-11,2018,TW 106111786 A,2009-10-01,US 10224208 P,2008-10-02,Janus kinase inhibitors for treatment of dry eye and other eye related diseases,,INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/106-193-418-572-792,Granted Patent,no,3,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,,,0,0,,,,ACTIVE
533,EP,B1,EP 2349260 B1,122-477-888-610-428,2016-01-06,2016,EP 09737257 A,2009-10-01,US 2009/0059203 W;;US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,,INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,INCYTE HOLDINGS CORPORATION (2015-12-09);;INCYTE CORPORATION (2015-03-11),https://lens.org/122-477-888-610-428,Granted Patent,yes,1,1,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/437;;A61K31/519;;A61P27/00,,2,2,040-104-972-510-10X;;106-822-378-308-186,22525048;;10.1016/j.ophtha.2012.01.028;;pmc3419278;;22819198;;10.1016/j.coph.2012.06.008,"SHIAO HUI (MELISSA) LIEW ET AL: ""Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease"", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 119, no. 7, 13 January 2012 (2012-01-13), pages 1328 - 1335, XP028504561, ISSN: 0161-6420, [retrieved on 20120118], DOI: 10.1016/J.OPHTHA.2012.01.028;;APOSTOLOS KONTZIAS ET AL: ""Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease"", CURRENT OPINION IN PHARMACOLOGY, vol. 12, no. 4, 1 August 2012 (2012-08-01), pages 464 - 470, XP055160926, ISSN: 1471-4892, DOI: 10.1016/j.coph.2012.06.008",ACTIVE
534,EP,A4,EP 1803151 A4,187-477-739-302-470,2010-05-26,2010,EP 05789226 A,2005-08-23,US 2005/0029840 W;;US 60409904 P;;US 21091805 A,2004-08-23,ELEVATOR-BASED TOOL LOADING AND BUFFERING SYSTEM,"A substrate processing apparatus is provided. The apparatus has a casing, a low port interface and a carrier holding station. The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding station is adapted for holding at least one substrate transport carrier so the at least one substrate transport carrier is capable of being coupled to the load port interface without lifting the at least one substrate transport carrier off the carrier holding station. The carrier holding station is arranged to provide a substantially simultaneous swap section for substantially simultaneous replacement of the substrate transport carrier from the carrier holding station.",BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;BUFANO MICHAEL L;;WILLIAM FOSNIGHT;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,"MURATA MACHINERY, LTD. (2010-06-02)",https://lens.org/187-477-739-302-470,Search Report,no,4,0,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,H01L21/677;;H01L21/00,,0,0,,,,ACTIVE
535,US,A1,US 2020/0093825 A1,001-716-306-470-09X,2020-03-26,2020,US 201916686934 A,2019-11-18,US 201916686934 A;;US 201615156125 A;;US 201213564271 A;;US 57183409 A;;US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.",INCYTE CORP;;INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,INCYTE CORPORATION (2015-01-07);;INCYTE HOLDINGS CORPORATION (2015-01-07),https://lens.org/001-716-306-470-09X,Patent Application,yes,0,10,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/519;;A61K9/00;;A61K31/437,,0,0,,,,DISCONTINUED
536,CN,B,CN 101048861 B,051-500-241-917-997,2010-05-26,2010,CN 200580036308 A,2005-08-23,US 2005/0029840 W;;US 60409904 P;;US 21091805 A,2004-08-23,Elevator-based tool loading and buffering system,"A substrate processing apparatus is provided. The apparatus has a casing, a load port interface and a carrier holding station The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding statio is adapted for holding at least one substrate transport carrier at the load port interface. The carrier holding station is arranged to provide a fast swap section for replacement of the substrate transport carrier from the carrier holding station.",BROOKS AUTOMATION INC,GILCHRIST ULYSSES;;FOSNIGHT WILLIAM;;CHRISTOPHER HOFMEISTER;;FRIEDMAN GERALD M;;BUFANO MICHAEL L,"MURATA MACHINERY CO., LTD. (2010-04-28)",https://lens.org/051-500-241-917-997,Granted Patent,no,0,0,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,H01L21/673,,0,0,,,,INACTIVE
537,US,A1,US 2012/0149994 A1,055-058-218-376-682,2012-06-14,2012,US 96725610 A,2010-12-14,US 96725610 A,2010-12-14,METHOD AND SYSTEM FOR CONTROLLING NON-INVASIVE BLOOD PRESSURE DETERMINATION BASED ON OTHER PHYSIOLOGICAL PARAMETERS,"A system and method for processing a cuff pressure waveform to determine the blood pressure of a patient. The processing unit of the NIBP monitoring system receives status signals from one or more physiological parameter monitors. The physiological parameter monitors each include an operating algorithm that causes the physiological parameter monitor to generate a status signal indicating whether artifacts are present that prevent the determination of the physiological parameter. When the processing unit receives the monitoring signal from the physiological parameter monitor indicating the presence of artifacts, the processing unit adjusts the operation of the NIBP monitor. The adjustment of the NIBP monitor may be to delay the beginning of the NIBP determination cycle until artifacts are no longer present from the physiological parameter monitor or to control the cuff pressure in such a manner as to keep the patient safe and comfortable until the artifacts are no longer present.",LUCZYK WILLIAM J;;HERSH LAWRENCE T;;DONEHOO ROBERT F;;FRIEDMAN BRUCE A;;GEN ELECTRIC,LUCZYK WILLIAM J;;HERSH LAWRENCE T;;DONEHOO ROBERT F;;FRIEDMAN BRUCE A,GENERAL ELECTRIC COMPANY (2010-12-09),https://lens.org/055-058-218-376-682,Patent Application,yes,13,23,2,2,0,A61B5/02255;;A61B5/02255;;A61B5/02225;;A61B5/02225;;A61B5/14542;;A61B5/14542;;A61B5/349;;A61B5/349;;A61B5/7203;;A61B5/7203;;A61B5/721;;A61B5/721;;A61B5/7221;;A61B5/7221,A61B5/02;;A61B5/022,600/301;;600/490,0,0,,,,DISCONTINUED
538,HU,A2,HU P0102696 A2,085-853-790-159-604,2002-04-29,2002,HU P0102696 A,2001-06-28,US 21497900 P,2000-06-29,USE OF GROWTH HORMONE SECRETAGOGUES FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS STIMULATING OR INCREASING APPETITE,"(I) ltal nos képletű vegyületek, vagy pedig ezek tautomerjei gyógyszatilag elfogadható sói alkalmaz sa ""nmag ban vagy egy tov bbihatóanyaggal, péld ul egy n""vekedési hormon szekretagóg anyaggal,antidepressz nssal, antiemetikummal és/vagy antipszichotikummal együttegy kezelt egyed étv gy nak serkentésére vagy fokoz s ra haszn lhatógyógy szati készítmények elő llít s ra, ahol az (I) ltal nos képletbena szubsztituensek főbb jelentései HET jelentése (a), (b), (c), (d)vagy (e) ltal nos képletű heterociklusos csoport; Y2 jelentéseoxigénatom vagy kénatom; A jelentése kétértékű csoport, péld ul 2-4-tagú, adott esetben oxigénatomot, kénatomot vagy nitrogénatomottartalmazó csoport; Q jelentése egy kovalens k""tés vagymetiléncsoport; W jelentése metincsoport vagy nitrogénatom; Xjelentése adott esetben helyettesített metiléncsoport; Y jelentéseadott esetben helyettesített metiléncsoport, oxigénatom vagy NR2 ltalnos képletű csoport; Z jelentése karbonilcsoport, tiokarbonilcsoportvagy szulfonilcsoport; R3 jelentése adott esetben helyettesített ésadott esetben a szénl ncba ékelve heteroatomo(ka)t tartalmazóalkilcsoport, cikloalkilcsoport, cikloalkenilcsoport, fenilcsoportvagy heterociklusos csoport; R4 jelentése hidrogénatom, alkilcsoportvagy cikloalkilcsoport; vagy pedig R4 és R3 együtt, tov bb azzal aszénatommal együtt, amelyhez kapcsolódnak, cikloalkilcsoportot,cikloalkenilcsoportot, vagy mono- vagy biciklusos heterociklusoscsoportot képez; X4 jelentése hidrogénatom vagy alkilcsoport; vagypedig X4 és R4 együtt, tov bb azzal a nitrogénatommal együtt, amelyhezX4 kapcsolódik, valamint azzal a szénatommal együtt, amelyhez R4kapcsolódik, egy gyűrűs csoportot képez; R6 jelentése egy k""tés vagy -Z1-(CH2)a-C(X5X5a)-(CH2)b-, -(CRaRb)a-E-(CRaRb)b- ltal nos képletűcsoport, R7 és R8 jelentése egym stól függetlenül hidrogénatom vagyadott esetben helyettesített alkilcsoport; vagy R7 és R8 együttesjelentése lehet -(CH2)r-L-(CH2)r- ltal nos képletű csoport. Ó",PFIZER PROD INC,FRIEDMAN HYLAR LEWIS;;GARDNER MARK JAMES;;LANDSCHULZ WILLIAM HARRAS;;PAN LYDIA CODETTA,,https://lens.org/085-853-790-159-604,Patent Application,no,0,0,13,13,0,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/55;;A61K49/0004;;A61P1/14;;A61P3/00;;A61P3/02;;A61P3/04;;A61P43/00;;A61K31/519;;A61K49/0004;;A61K31/55;;A61K31/437;;A61K31/444;;A61K31/438,A61K31/437;;C07D471/04;;A61K31/438;;A61K31/444;;A61K31/4985;;A61K31/519;;A61K31/55;;A61K49/00;;A61P1/14;;A61P3/00;;A61P43/00,,0,0,,,,DISCONTINUED
539,WO,A2,WO 2006/023873 A2,092-830-885-141-628,2006-03-02,2006,US 2005/0029840 W,2005-08-23,US 60409904 P;;US 21091805 A,2004-08-23,ELEVATOR-BASED TOOL LOADING AND BUFFERING SYSTEM,"A substrate processing apparatus (10) is provided. The apparatus has a casing, a load port interface (I) and a carrier holding station (16) The casing has processing devices (12) within for processing substrates. The load port interface (I) is connected to the casing for loading substrates into the processing device (12). The carrier holding station (16) is connected to the casing. The carrier holding statio (16) is adapted for holding at least one substrate transport carrier (C) at the load port interface (I). The carrier holding station (16) is arranged to provide a fast swap section for replacement of the substrate transport carrier (C) from the carrier holding station (16).",BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;BUFANO MICHAEL L;;WILLIAM FOSNIGHT;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/092-830-885-141-628,Patent Application,yes,0,4,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,H01L21/673,,0,0,,,,PENDING
540,AU,A,AU 2001/054108 A,185-278-751-172-555,2002-01-03,2002,AU 2001/054108 A,2001-06-28,US 21497900 P,2000-06-29,Use of growth hormone secretagogues for stimulating or increasing appetite,,PFIZER PROD INC,FRIEDMAN HYLAR LEWIS;;PAN LYDIA CODETTA;;LANDSCHULZ WILLIAM HARRAS;;GARDNER MARK JAMES,,https://lens.org/185-278-751-172-555,Patent Application,no,0,0,13,13,0,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/55;;A61K49/0004;;A61P1/14;;A61P3/00;;A61P3/02;;A61P3/04;;A61P43/00;;A61K31/519;;A61K49/0004;;A61K31/55;;A61K31/437;;A61K31/444;;A61K31/438,C07D471/04;;A61K31/437;;A61K31/438;;A61K31/444;;A61K31/4985;;A61K31/519;;A61K31/55;;A61K49/00;;A61P1/14;;A61P3/00;;A61P43/00,,0,0,,,,PENDING
541,JP,A,JP 2012015550 A,199-809-757-603-625,2012-01-19,2012,JP 2011221201 A,2011-10-05,US 60336104 P;;US 20723105 A,2004-08-19,USAGE OF LOW STORAGE CARRIER,"PROBLEM TO BE SOLVED: To provide a usage method of a substrate transport device (10).SOLUTION: The device has a casing (11) and a door (13). The casing has an adjusted environment formed in the inside thereof. The casing has support parts (12 and 14) inside thereof to hold at least one substrate(s) in the casing. The casing defines a substrate transport aperture. A substrate transport system accesses to the substrate in the casing via the aperture. The door is connected to the casing to close the substrate transport aperture in the casing. The casing has a structure which forms components for performing quick replacement, thereby the substrate in the device can be replaced with another substrate independently from loading of the substrate in the casing without retreating the substrate transport system.",BROOKS AUTOM INC,ULYSSES GILCHRIST;;MICHAEL L BUCHANAN;;WILLIAM FOSNIGHT;;CHRISTOPHER HOFMEISTER;;GERALD M FRIEDMAN,,https://lens.org/199-809-757-603-625,Patent Application,no,1,12,17,19,0,B65G49/07;;H01L21/67763;;H01L21/67763;;H01L21/67326;;H01L21/67353;;H01L21/67353;;H01L21/67369;;H01L21/67369;;H01L21/67373;;H01L21/67373;;H01L21/67376;;H01L21/67376;;H01L21/67383;;H01L21/67389;;H01L21/67393;;H01L21/67393;;H01L21/67772;;H01L21/67772;;H01L21/67778;;H01L21/67778;;H01L21/6779;;H01L21/6779;;Y10S414/139;;Y10S414/139,H01L21/673;;B65G49/07,,0,0,,,,PENDING
542,WO,A9,WO 2006/023873 A9,020-249-468-772-911,2006-06-22,2006,US 2005/0029840 W,2005-08-23,US 60409904 P;;US 21091805 A,2004-08-23,ELEVATOR-BASED TOOL LOADING AND BUFFERING SYSTEM,"A substrate processing apparatus is provided. The apparatus has a casing, a low port interface and a carrier holding station. The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding station is adapted for holding at least one substrate transport carrier at the load port interface. The carrier holding station is arranged to provide a fast swap section for replacement of the substrate transport carrier from the carrier holding station.",BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;BUFANO MICHAEL L;;WILLIAM FOSNIGHT;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/020-249-468-772-911,Patent Application,no,0,0,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,,,0,0,,,,PENDING
543,US,A1,US 2002/0044965 A1,020-351-554-596-943,2002-04-18,2002,US 80362801 A,2001-03-09,US 80362801 A;;US 57705900 A;;US 72763496 A;;IB 9500264 W;;US 23909494 A,1994-05-06,Controlled- release dosage forms of azithromycin,"
   A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment. 
",CURATOLO WILLIAM J.;;FRIEDMAN HYLAR L.;;KORESMEYER RICHARD W.;;LEMOTT STEVEN R.,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORESMEYER RICHARD W;;LEMOTT STEVEN R,,https://lens.org/020-351-554-596-943,Patent Application,yes,4,20,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;C07H15/252;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,424/468;;514/28,0,0,,,,EXPIRED
544,JP,A,JP 2017057231 A,025-075-919-687-949,2017-03-23,2017,JP 2017000685 A,2017-01-05,US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"PROBLEM TO BE SOLVED: To treat dry eye disorders and other related eye diseases.SOLUTION: Methods, kits and compositions for treating dry eye disorders and other related eye diseases are provided, where the methods, kits and compositions utilize a JAK inhibitor.SELECTED DRAWING: None",INCYTE HOLDINGS CORP,PAUL A FRIEDMAN;;JORDAN S FRIDMAN;;MONICA E LUCHI;;WILLIAM V WILLIAMS,,https://lens.org/025-075-919-687-949,Patent Application,no,2,0,34,34,0,A61K31/437;;A61K31/519;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/437;;A61K31/519;;A61K9/0048,A61K31/437;;A61K9/06;;A61K9/08;;A61K9/10;;A61K31/047;;A61K31/519;;A61K31/573;;A61K31/717;;A61K31/728;;A61K31/765;;A61K45/00;;A61K47/32;;A61K47/34;;A61K47/42;;A61P27/02;;A61P27/04;;A61P29/00,,1,0,,,"LAB. INVEST., vol. 86, JPN7015001039, 2006, pages 1243 - 1260, ISSN: 0003487472",PENDING
545,JP,A,JP 2018044012 A,024-493-538-304-153,2018-03-22,2018,JP 2017246134 A,2017-12-22,US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"PROBLEM TO BE SOLVED: To treat dry eye disorders and other related eye diseases.SOLUTION: Methods, kits and compositions for treating dry eye disorders and other related eye diseases are provided, where the methods, kits and compositions utilize a JAK inhibitor.SELECTED DRAWING: None",INCYTE HOLDINGS CORP,PAUL A FRIEDMAN;;JORDAN S FRIDMAN;;MONICA E LUCHI;;WILLIAM V WILLIAMS,,https://lens.org/024-493-538-304-153,Patent Application,no,2,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/519;;A61K9/06;;A61K9/08;;A61K9/10;;A61K9/16;;A61K31/047;;A61K31/717;;A61K31/728;;A61K31/765;;A61K31/77;;A61K45/00;;A61K47/32;;A61K47/34;;A61K47/42;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,,1,1,053-583-065-206-860,10.1038/labinvest.3700487;;17075579,"LAB. INVEST., vol. 86, JPN7015001039, 2006, pages 1243 - 1260, ISSN: 0004109496",PENDING
546,SM,B,SM T201600080 B,067-812-632-809-874,2016-07-01,2016,SM 201600080 T,2016-03-22,US 10224208 P;;US 2009/0059203 W,2008-10-02,INIBITORI DI CHINASI JANUS PER IL TRATTAMENTO DI OCCHIO SECCO E ALTRE MALATTIE OCULARI,,INCYTE CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/067-812-632-809-874,Unknown,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,,,0,0,,,,PENDING
547,CA,A1,CA 3064247 A1,087-673-818-159-978,2010-04-08,2010,CA 3064247 A,2009-10-01,US 10224208 P;;CA 2738520 A,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"Methods, kits, and compositions for treating dye eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.",INCYTE HOLDINGS CORP,FRIDMAN JORDAN S;;FRIEDMAN PAUL A;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/087-673-818-159-978,Patent Application,no,0,0,34,34,0,A61K31/437;;A61K31/519;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/437;;A61K31/519;;A61K9/0048,A61K31/519;;A61K9/00;;A61P27/02,,0,0,,,,DISCONTINUED
548,EP,B1,EP 1803151 B1,089-762-800-640-63X,2011-10-05,2011,EP 05789226 A,2005-08-23,US 2005/0029840 W;;US 60409904 P;;US 21091805 A,2004-08-23,ELEVATOR-BASED TOOL LOADING AND BUFFERING SYSTEM,"A substrate processing apparatus is provided. The apparatus has a casing, a low port interface and a carrier holding station. The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding station is adapted for holding at least one substrate transport carrier so the at least one substrate transport carrier is capable of being coupled to the load port interface without lifting the at least one substrate transport carrier off the carrier holding station. The carrier holding station is arranged to provide a substantially simultaneous swap section for substantially simultaneous replacement of the substrate transport carrier from the carrier holding station.",MURATA MACHINERY LTD,ULYSSES GILCHRIST;;BUFANO MICHAEL L;;WILLIAM FOSNIGHT;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,"MURATA MACHINERY, LTD. (2010-06-02)",https://lens.org/089-762-800-640-63X,Granted Patent,yes,6,0,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,H01L21/677;;H01L21/00,,0,0,,,,ACTIVE
549,JP,A,JP 2002293743 A,108-982-098-792-95X,2002-10-09,2002,JP 2001193024 A,2001-06-26,US 21497900 P,2000-06-29,USE OF GROWTH HORMONE SECRETION-ACCELERATING SUBSTANCE FOR STIMULATING OR ENHANCING APPETITE,"PROBLEM TO BE SOLVED: To provide a method for using a growth hormone secretion- accelerating substance for stimulating or enhancing the appetite of a patient. SOLUTION: This method for stimulating or enhancing the appetite of the patient includes administering the growth hormone secretion-accelerating substance, its prodrug, or the pharmacologically acceptable salt of the secretion- accelerating substance or the prodrug. In more detail, this invention provides the method for stimulating or enhancing the appetite of the patient wherein the growth hormone secretion-accelerating substance is a compound represented by formula I (the substituents are the same as defined in the present specification).",PFIZER PROD INC,FRIEDMAN HYLAR L;;GARDNER MARK J;;LANDSHULZ WILLIAM H;;PAN LYDIA C,,https://lens.org/108-982-098-792-95X,Patent Application,no,0,0,13,13,0,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/55;;A61K49/0004;;A61P1/14;;A61P3/00;;A61P3/02;;A61P3/04;;A61P43/00;;A61K31/519;;A61K49/0004;;A61K31/55;;A61K31/437;;A61K31/444;;A61K31/438,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/4985;;A61K31/519;;A61K31/55;;C07D471/04;;A61K49/00;;A61P1/14;;A61P3/00;;A61P43/00,,0,0,,,,PENDING
550,WO,A3,WO 2006/023873 A3,085-907-980-542-680,2007-02-01,2007,US 2005/0029840 W,2005-08-23,US 60409904 P;;US 21091805 A,2004-08-23,ELEVATOR-BASED TOOL LOADING AND BUFFERING SYSTEM,"A substrate processing apparatus (10) is provided. The apparatus has a casing, a load port interface (I) and a carrier holding station (16) The casing has processing devices (12) within for processing substrates. The load port interface (I) is connected to the casing for loading substrates into the processing device (12). The carrier holding station (16) is connected to the casing. The carrier holding statio (16) is adapted for holding at least one substrate transport carrier (C) at the load port interface (I). The carrier holding station (16) is arranged to provide a fast swap section for replacement of the substrate transport carrier (C) from the carrier holding station (16).",BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;BUFANO MICHAEL L;;WILLIAM FOSNIGHT;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/085-907-980-542-680,Search Report,yes,2,0,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,H01L21/673,,0,0,,,,PENDING
551,TW,A,TW 200626460 A,118-687-159-101-851,2006-08-01,2006,TW 94128694 A,2005-08-23,US 60409904 P,2004-08-23,Elevator-based tool loading and buffering system,"A substrate processing apparatus comprising: a casing with a processing device within for processing substrates; a load port interface connected to the casing for loading substrates into the processing device; and a carrier holding station connected to the casing, the carrier holding station being adapted for holding at least one substrate transport carrier at the load port interface, wherein the carrier holding station is arranged to provide a fast swap section for replacement of the at least one substrate transport carrier from the carrier holding station.",BROOKS AUTOMATION INC,GILCHRIST ULYSSES;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/118-687-159-101-851,Patent of Addition,no,0,1,1,18,0,,,,0,0,,,,PENDING
552,KR,A,KR 20020002271 A,168-205-770-378-432,2002-01-09,2002,KR 20010037527 A,2001-06-28,US 21497900 P,2000-06-29,Use of Growth Hormone Secretagogues for Stimulating or Increasing Appetite,"PURPOSE: A method for increasing or stimulating appetite in a patient which comprises administering a certain growth hormone secretagogue, a prodrug thereof or a pharmaceutically acceptable salt of the secretagogues or the prodrug is provided. Whereby, the medicine is effective in the treatment of a patient suffering from an eating disorder or a nutritional disorder or the like. CONSTITUTION: This medicine contains a compound of formula 1 or a stereoisomer mixture thereof, a partially stereoisomerically superior, partially stereoisomerically pure, enantiomerically superior, enantiomerically pure isomer thereof, a prodrug of the compound, mixture or isomer, or a pharmaceutically acceptable salt of the compound, mixture or isomer, or a tautomer of the compound.",PFIZER PROD INC,FRIEDMAN HYLAR LEWIS;;GARDNER MARK JAMES;;LANDSCHULZ WILLIAM H;;PAN LYDIA CODETTA,,https://lens.org/168-205-770-378-432,Patent Application,no,5,0,13,13,0,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/55;;A61K49/0004;;A61P1/14;;A61P3/00;;A61P3/02;;A61P3/04;;A61P43/00;;A61K31/519;;A61K49/0004;;A61K31/55;;A61K31/437;;A61K31/444;;A61K31/438,A61K31/437;;C07D471/04;;A61K31/438;;A61K31/444;;A61K31/4985;;A61K31/519;;A61K31/55;;A61K49/00;;A61P1/14;;A61P3/00;;A61P43/00,,0,0,,,,EXPIRED
553,EP,A2,EP 1786710 A2,155-474-439-205-084,2007-05-23,2007,EP 05791673 A,2005-08-19,US 2005/0029757 W;;US 60336104 P;;US 20723105 A,2004-08-19,REDUCED CAPACITY CARRIER AND METHOD OF USE,,BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/155-474-439-205-084,Patent Application,yes,0,0,17,19,0,B65G49/07;;H01L21/67763;;H01L21/67763;;H01L21/67326;;H01L21/67353;;H01L21/67353;;H01L21/67369;;H01L21/67369;;H01L21/67373;;H01L21/67373;;H01L21/67376;;H01L21/67376;;H01L21/67383;;H01L21/67389;;H01L21/67393;;H01L21/67393;;H01L21/67772;;H01L21/67772;;H01L21/67778;;H01L21/67778;;H01L21/6779;;H01L21/6779;;Y10S414/139;;Y10S414/139,H01L21/68,,0,0,,,,PENDING
554,NZ,A,NZ 512664 A,176-253-379-508-202,2002-11-26,2002,NZ 51266401 A,2001-06-28,US 21497900 P,2000-06-29,Use of growth hormone secretagogues for stimulating or increasing appetite,"Described is the use of compounds of formula (I) in the manufacture of a medicament for stimulating or increasing appetite in a patient, wherein HET is a heterocyclic moiety selected from the group consisting of formula (II) -formula (VI), and the remaining substituents are defined in the specification. The medicament may also include a recombinant growth hormone or a growth hormone secretagogue, an antidepressant or an antipsychotic agent.",PFIZER PROD INC,PAN LYDIA CODETTA;;FRIEDMAN HYLAR LEWIS;;GARDNER MARK JAMES;;LANDSCHULZ WILLIAM HARRAS,,https://lens.org/176-253-379-508-202,Patent Application,no,0,0,13,13,0,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/55;;A61K49/0004;;A61P1/14;;A61P3/00;;A61P3/02;;A61P3/04;;A61P43/00;;A61K31/519;;A61K49/0004;;A61K31/55;;A61K31/437;;A61K31/444;;A61K31/438,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/4985;;A61K31/519;;A61K31/55;;C07D471/04;;A61K49/00;;A61P1/14;;A61P3/00;;A61P43/00,,0,0,,,,PENDING
555,CN,A,CN 102551694 A,023-378-291-502-691,2012-07-11,2012,CN 201110463088 A,2011-12-14,US 96725610 A,2010-12-14,Method and system for controlling non-invasive blood pressure determination based on other physiological parameters,"The invention is a method and system for controlling non-invasive blood pressure determination based on other physiological parameters. A system and method for processing a cuff pressure waveform to determine the blood pressure of a patient. The processing unit of the NIBP monitoring system receives status signals from one or more physiological parameter monitors. The physiological parameter monitors each include an operating algorithm that causes the physiological parameter monitor to generate a status signal indicating whether artifacts are present that prevent the determination of the physiological parameter. When the processing unit receives the monitoring signal from the physiological parameter monitor indicating the presence of artifacts, the processing unit adjusts the operation of the NIBP monitor. The adjustment of the NIBP monitor may be to delay the beginning of the NIBP determination cycle until artifacts are no longer present from the physiological parameter monitor or to control the cuff pressure in such a manner as to keep the patient safe and comfortable until the artifacts are no longer present.",GEN ELECTRIC,LUCZYK WILLIAM J;;HERSH LAWRENCE T;;DONEHOO ROBERT F;;FRIEDMAN BRUCE A,,https://lens.org/023-378-291-502-691,Patent Application,no,8,1,2,2,0,A61B5/02255;;A61B5/02255;;A61B5/02225;;A61B5/02225;;A61B5/14542;;A61B5/14542;;A61B5/349;;A61B5/349;;A61B5/7203;;A61B5/7203;;A61B5/721;;A61B5/721;;A61B5/7221;;A61B5/7221,A61B5/022,,0,0,,,,DISCONTINUED
556,MA,A1,MA 23537 A1,069-056-599-839-722,1995-12-31,1995,MA 23869 A,1995-05-03,US 23909494 A,1994-05-06,PROCEDE DE PRODUCTION D'UNE FORME D'AZITHROMYCINE,,PFIZER,RICHARD W KORSMEYER;;WILLIAM J CURATOLO;;HYLAR L FRIEDMAN;;STEVEN R LEMOTT,,https://lens.org/069-056-599-839-722,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;C07H15/252;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
557,US,A1,US 2002/0086865 A1,079-847-064-580-412,2002-07-04,2002,US 89301401 A,2001-06-27,US 89301401 A;;US 21497900 P,2000-06-29,Use of growth hormone secretagogues for stimulating or increasing appetite,"
    This invention is directed to methods for increasing or stimulating appetite in a patient which comprises administering certain growth hormone secretagogues, prodrugs thereof or pharmaceutically acceptable salts of said secretagogues or said prodrugs. More preferably, the present invention provides such methods wherein the growth hormone secretagogue is a compound of Formula I: 

   a prodrug thereof or a pharmaceutically acceptable salt of said secretagogue or said prodrug. 
",FRIEDMAN HYLAR L.;;GARDNER MARK J.;;LANDSHULZ WILLIAM H.;;PAN LYDIA C.,FRIEDMAN HYLAR L;;GARDNER MARK J;;LANDSHULZ WILLIAM H;;PAN LYDIA C,,https://lens.org/079-847-064-580-412,Patent Application,yes,0,13,13,13,0,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/55;;A61K49/0004;;A61P1/14;;A61P3/00;;A61P3/02;;A61P3/04;;A61P43/00;;A61K31/519;;A61K49/0004;;A61K31/55;;A61K31/437;;A61K31/444;;A61K31/438,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/4985;;A61K31/519;;C07D471/04;;A61K31/55;;A61K49/00;;A61P1/14;;A61P3/00;;A61P43/00,514/248;;514/249;;X51422;;514/256;;514/259.41;;514/262.1,0,0,,,,DISCONTINUED
558,EP,A3,EP 1181933 A3,090-517-131-509-998,2002-04-10,2002,EP 01305039 A,2001-06-08,US 21497900 P,2000-06-29,Use of growth hormone secretagogues for stimulating or increasing appetite,"This invention is directed to methods for increasing or stimulating appetite in a patient which comprises administering certain growth hormone secretagogues, prodrugs thereof or pharmaceutically acceptable salts of said secretagogues or said prodrugs. More preferably, the present invention provides such methods wherein the growth hormone secretagogue is a compound of Formula I:  a prodrug thereof or a pharmaceutically acceptable salt of said secretagogue or said prodrug.",PFIZER PROD INC,FRIEDMAN HYLAR LEWIS;;GARDNER MARK JAMES;;LANDSCHULZ WILLIAM H;;PAN LYDIA CODETTA,,https://lens.org/090-517-131-509-998,Search Report,yes,6,0,13,13,0,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/55;;A61K49/0004;;A61P1/14;;A61P3/00;;A61P3/02;;A61P3/04;;A61P43/00;;A61K31/519;;A61K49/0004;;A61K31/55;;A61K31/437;;A61K31/444;;A61K31/438,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/4985;;A61K31/519;;C07D471/04;;A61K31/55;;A61K49/00;;A61P1/14;;A61P3/00;;A61P43/00,,2,1,023-329-456-188-805,10.1159/000054491;;10567856,"DATABASE WPI Section Ch Week 199406, Derwent World Patents Index; Class B04, AN 1994-043356, XP002185542;;DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 1999 (1999-11-01), WILLESEN METTE GEORGI ET AL: ""Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat."", XP002185562, Database accession no. PREV200000076110",DISCONTINUED
559,TW,A,TW 201801731 A,147-287-118-536-92X,2018-01-16,2018,TW 106111786 A,2009-10-01,US 10224208 P,2008-10-02,JANUS kinase inhibitors for treatment of dry eye and other eye related diseases,"Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.",INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/147-287-118-536-92X,Patent of Addition,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/519;;A61P27/02;;C07D487/04,,0,0,,,,ACTIVE
560,JP,A,JP 2015127332 A,190-411-648-038-99X,2015-07-09,2015,JP 2015042933 A,2015-03-04,US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"PROBLEM TO BE SOLVED: To treat dry eye disorders and other related eye diseases.SOLUTION: Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, where the methods, kits, and compositions utilize a JAK inhibitor.",INCYTE CORP,PAUL A FRIEDMAN;;JORDAN S FRIDMAN;;MONICA E LUCHI;;WILLIAM V WILLIAMS,,https://lens.org/190-411-648-038-99X,Patent Application,no,2,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/437;;A61K9/06;;A61K9/08;;A61K9/10;;A61K31/047;;A61K31/519;;A61K31/573;;A61K31/717;;A61K31/728;;A61K31/765;;A61K45/00;;A61K47/32;;A61K47/34;;A61K47/42;;A61P27/02;;A61P27/04;;A61P29/00,,0,0,,,,PENDING
561,US,A1,US 2010/0158643 A1,033-323-779-502-171,2010-06-24,2010,US 69626810 A,2010-01-29,US 69626810 A;;US 21123605 A;;US 21091805 A;;US 60440604 P;;US 60409904 P,2004-08-23,ELEVATOR-BASED TOOL LOADING AND BUFFERING SYSTEM,"A substrate processing apparatus is provided. The apparatus has a casing, a low port interface and a carrier holding station. The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding station is adapted for holding at least one substrate transport carrier at the load port interface. The carrier holding station is arranged to provide a fast swap section for replacement of the substrate transport carrier from the carrier holding station.",BROOKS AUTOMATION INC,FRIEDMAN GERALD M;;BUFANO MICHAEL L;;HOFMEISTER CHRISTOPHER;;GILCHRIST ULYSSES;;FOSNIGHT WILLIAM,MURATA MACHINERY LTD (2010-02-03);;BROOKS AUTOMATION INC (2010-02-02),https://lens.org/033-323-779-502-171,Patent Application,yes,14,1,9,12,0,H01L21/67715;;H01L21/67736;;H01L21/67775;;H01L21/68;;H01L21/67715;;H01L21/67736;;H01L21/67775,H01L21/677,414/222.01,0,0,,,,DISCONTINUED
562,WO,A2,WO 2006/023838 A2,075-726-015-526-78X,2006-03-02,2006,US 2005/0029757 W,2005-08-19,US 60336104 P;;US 20723105 A,2004-08-19,REDUCED CAPACITY CARRIER AND METHOD OF USE,"A substrate transport apparatus (10) is provided. The apparatus has a casing (11) and a door (13). The casing is adapted to form a controlled environment therein. The casing has supports (12, 14) therein for holding at least one substrate (s) in the casing. The casing defines a substrate transfer opening through which a substrate transport system accesses the substrate in the casing. The door is connected to the casing for closing the substrate transfer opening in the casing. The casing has structure forming a fast swap element allowing replacement of the substrate from the apparatus with another substrate without retraction of the substrate transport system and independent of substrate loading in the casing.",BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/075-726-015-526-78X,Patent Application,yes,0,5,17,19,0,B65G49/07;;H01L21/67763;;H01L21/67763;;H01L21/67326;;H01L21/67353;;H01L21/67353;;H01L21/67369;;H01L21/67369;;H01L21/67373;;H01L21/67373;;H01L21/67376;;H01L21/67376;;H01L21/67383;;H01L21/67389;;H01L21/67393;;H01L21/67393;;H01L21/67772;;H01L21/67772;;H01L21/67778;;H01L21/67778;;H01L21/6779;;H01L21/6779;;Y10S414/139;;Y10S414/139,B65G49/07,,1,0,,,See references of EP 1786710A4,PENDING
563,SI,T1,SI 2349260 T1,116-935-577-416-191,2016-05-31,2016,SI 200931388 A,2009-10-01,US 10224208 P;;US 2009/0059203 W;;EP 09737257 A,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,,INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/116-935-577-416-191,Granted Patent,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/00;;A61P27/00,,0,0,,,,ACTIVE
564,TW,B,TW I359754 B,126-343-856-411-354,2012-03-11,2012,TW 94128861 A,2005-08-24,US 60440604 P,2004-08-24,Transportation system,,MURATA MACHINERY LTD,ULYSSES GILCHRIST;;MICHAEL L BUFANO;;WILLIAM FOSNIGHT;;CHRISTOPHER HOFMEISTER;;GERALD M FRIEDMAN,,https://lens.org/126-343-856-411-354,Granted Patent,no,0,0,3,12,0,,,,0,0,,,,ACTIVE
565,US,B2,US 7108865 B2,041-754-408-317-481,2006-09-19,2006,US 80362801 A,2001-03-09,US 80362801 A;;US 57705900 A;;US 72763496 A;;IB 9500264 W;;US 23909494 A,1994-05-06,Controlled-release dosage forms of azithromycin,"A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.",PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LEMOTT STEVEN R,,https://lens.org/041-754-408-317-481,Granted Patent,yes,39,16,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K9/14;;A61K/;;C07H15/252;;A61K9/00;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,424/489;;424/400;;424/464;;424/468;;424/469;;424/489;;424/490;;514/29;;514/964,36,14,087-650-378-258-881;;107-902-963-989-556;;017-537-299-622-725;;087-650-378-258-881;;059-083-335-093-489;;034-709-537-661-282;;146-890-078-021-12X;;119-514-352-967-383;;091-880-199-493-657;;056-294-396-662-834;;007-770-676-215-526;;139-294-802-068-646;;065-188-897-690-056;;051-370-294-976-98X,1930622;;10.1007/978-1-4613-2745-5_16;;8383944;;10.1128/aac.37.2.314;;pmc187659;;1930622;;1394712;;10.1248/cpb.40.1902;;10.1093/jac/25.suppl_a.39;;2154437;;10.1016/0378-5173(91)90357-t;;2801679;;4005135;;pmc1463760;;10.1111/j.1365-2125.1985.tb02749.x;;2137217;;10.1023/a:1015835609333;;10.1023/a:1016423404636;;3508560;;10.1111/j.1365-2125.1985.tb02756.x;;4005117;;pmc1463757;;10.1097/00007435-199403000-00010;;9071422;;10.2165/00003088-198916040-00001;;2656049,"Morishita et al., Controlled Release Microspheres Based on Eudragit L100 for the Oral Administration of Erythromycin, 1991, Drug, Design and Delivery, vol. 7, pp. 309-319.;;Martindale, The Extra Pharmacopoiea, 30<SUP>th</SUP>, The Pharm. Press, London, 1963, p. 1197.;;PDR, 48<SUP>th</SUP>, Med. L994, N.Y. p. 1789.;;The Merck Index, 11<SUP>th</SUP>, Merck & Co., N.Y., 1989, p. 146 Remington Pharmaceutical Science, 16<SUP>th </SUP>Merck Pub.;;Farmacia Practica de Remington, second Spanish edition, UTEHA, Mexico, 1965, pp. 471 and 525.;;Laegemiddelkataloget, Copenhagen 1992, p. 229, and p. 356.;;Farmaceuten, No. 12, 1990, p. 402-405.;;Hon-Leung Lee et al., ""Drug Properties Influencing The Design of Sustained or Controlled Release Drug Delivery"".;;Chapters 88, 90, and 91 from Remington Pharmaceutical Science, 16<SUP>th </SUP>Merck Pub., Co., Pennsylvania (1980), pp. 1535, 1585, 1594.;;Scott Hopkins, The American Journal of Medicine, vol. 91, (Suppl 3A) Sep. 12, 1991, 3A-40S-3A-45S.;;J. R. Cardinal, Plenum Publishing Corp., 1984, Drug Release From Matrix Devices.;;Richard H. Drew, Pharmacotherapy, vol. 12, No. 3, 1992, pp. 162-173.;;Chem. Abstr., Yoshitomi, H., et al., V 119, No. 8, p. 496, abst. No. 79946v, ""Evaluation of Enteric Coated Tablet Sensitive to Pancreatic Lipase I. In Vitro Disintegration Test"".;;Farmaceitisk Tidente, No. 35/36, 1988, p. 537-548.;;Milap C. Nahata et al., Antimicrobial Agents and Chemotherapy, vol. 37/2, Feb. 1993, pp. 314-316.;;Gazzetta Ufficiale Della Repubblica Italiana, No. 103 of May 5, 1992 along with English translation.;;H. Sucker, et al, Pharmazeutische Technologie, 2<SUP>nd </SUP>Edition 1991, Sections 4.4.1 to 4.4.3 along with English translation.;;Physician's Desk Reference, 47<SUP>th </SUP>Ed. 1993, entry zithromax.;;H. N. Nellans, et al., Abstract 518, 31<SUP>st </SUP>Interscience Conf. on Antimicrobial Agents and Chemotherapy, Chicago, IL, Sep. 1991.;;Isao Morishita et al., Drug Design and Delivery, vol. 7, 1991, pp. 309-319.;;Farmacia Practica DeRemington, Second Spanish Ed., Uteha, Mexico, 1965, Chapters 36 and 38.;;Remington's Pharm Sciences, 19Ed Spanish Farmacia Practica DeRemington, p. 2228 and 2229 (translation being obtained).;;Yoshitomi, et al., Chem. Pharm. Bull, 40(7), 1902-1905, 1992.;;Fiese, et al., Jml of Antimicrobial Chemotherapy, 1990, 25, suppl. A. pp. 39-47.;;Anie, et al., Intml Jml of Pharmaceutics, 76, 1991, pp. 183-185.;;Khosla, et al., Intrnl Jrnl of Pharmaceutics, 62, 1990, pp. R9-R11.;;Knutson, et al., The Am Jrnl of Gastroenterology, 1989, vol. 84, No. 10, pp. 1278-1284.;;Jobin, et al., Br. J. Clin. Pharmac, 1985, 19, pp. 97S-105S.;;Blankenhom, Socl. Exp. Boil. Med, 1955, 88, pp. 356-362.;;Graffner, et al., Pharm Research, vol. 7, No. 1, 1990, pp. 54-58.;;Fischer, et al., Pharm Research, vol. 4, No. 6, 1987, pp. 480-485.;;Welling, P., 1986, ACS Monograph 185, American Chemical Society, pp. 173-178.;;Langenbucher, et al., Br. J. Clin. Pharmac, 1985, 19, pp. 151S-162S.;;Handsfield Abstract from the 31<SUP>st</SUP>Interscience Conference on Antimicrobial Agents & Chemotherapy, 1991.;;H. H. Handsfield et al., Sexually Transmitted Diseases, vol. 21(2), pp. 107-111, 1994.;;Piero Periti, et al., Clinical Pharmacokinetics, vol. 16, pp. 193-214, 1989.",EXPIRED
566,US,A1,US 2014/0341679 A1,055-228-198-268-930,2014-11-20,2014,US 201414223553 A,2014-03-24,US 201414223553 A;;US 89744010 A;;US 21091805 A;;US 60409904 P,2004-08-23,ELEVATOR-BASED TOOL LOADING AND BUFFERING SYSTEM,"A substrate processing apparatus is provided. The apparatus has a casing, a low port interface and a carrier holding station. The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding station is adapted for holding at least one substrate transport carrier so the at least one substrate transport carrier is capable of being coupled to the load port interface without lifting the at least one substrate transport carrier off the carrier holding station. The carrier holding station is arranged to provide a substantially simultaneous swap section for substantially simultaneous replacement of the substrate transport carrier from the carrier holding station.",FRIEDMAN GERALD M;;BUFANO MICHAEL L;;HOFMEISTER CHRISTOPHER;;GILCHRIST ULYSSES;;FOSNIGHT WILLIAM;;BROOKS AUTOMATION INC,FRIEDMAN GERALD M;;BUFANO MICHAEL L;;HOFMEISTER CHRISTOPHER;;GILCHRIST ULYSSES;;FOSNIGHT WILLIAM,BROOKS AUTOMATION US LLC (2021-10-01);;BROOKS AUTOMATION HOLDING LLC (2021-10-01),https://lens.org/055-228-198-268-930,Patent Application,yes,10,2,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,H01L21/677,414/222.01,0,0,,,,ACTIVE
567,US,B1,US 6287605 B1,189-888-798-629-755,2001-09-11,2001,US 29375899 A,1999-04-16,US 29375899 A;;US 8215998 P,1998-04-17,Compositions and methods useful in treatment and prevention of HIV-1 infection,"The invention includes compositions comprising substantially purified salivary glycoproteins and carbohydrate ligands thereof which are useful in methods for the treatment and prevention of HIV-1 infection. The invention also includes methods for the treatment and prevention of HIV-1 infection comprising contacting a composition of the invention with a human patient. Additionally, the invention includes antibodies and kits useful in the treatment and prevention of HIV-1 infection.",UNIV PENNSYLVANIA,MALAMUD DANIEL;;NAGASHUNMUGAM THANDAVARAYAN;;FRIEDMAN HARVEY M;;ABRAMS WILLIAM;;BERGEY EARL J,TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA THE (1999-05-21),https://lens.org/189-888-798-629-755,Granted Patent,yes,3,6,1,1,0,A61L2/0082;;A61L2/0082;;A61K31/70;;A61K31/70;;A61K38/1709;;A61K38/1709;;A61K45/06;;A61K45/06;;Y10S435/975;;Y10S435/975,A61K38/17;;A61L2/00,424/550;;424/537;;436/518;;435/975,61,55,134-945-919-810-116;;012-887-606-996-080;;080-255-364-508-718;;005-621-823-855-370;;058-969-994-262-617;;017-150-654-990-340;;015-350-059-706-767;;074-012-521-734-695;;051-507-802-045-896;;005-556-076-662-859;;075-885-479-864-945;;076-463-987-790-512;;006-552-678-996-600;;048-237-738-197-127;;025-032-496-209-987;;006-971-742-435-610;;038-783-738-913-395;;022-930-467-216-366;;028-188-265-049-912;;072-088-384-557-570;;002-481-869-668-860;;035-045-312-356-364;;004-208-991-566-863;;002-264-966-090-625;;036-625-097-637-426;;106-728-157-859-485;;062-648-004-577-570;;114-045-495-938-773;;007-256-557-541-108;;116-310-248-735-159;;032-231-905-355-746;;024-627-430-003-587;;033-541-680-627-500;;040-639-010-790-260;;021-301-310-330-525;;014-889-022-639-17X;;001-370-737-964-790;;053-607-213-075-289;;011-354-209-070-235;;035-490-791-518-900;;070-214-015-072-81X;;004-683-367-356-048;;020-624-946-643-594;;011-597-853-530-593;;017-080-000-118-317;;038-237-102-772-218;;055-938-198-128-125;;068-904-980-333-918;;098-495-130-906-218;;031-471-521-611-110;;018-440-221-586-838;;005-175-383-026-001;;088-121-602-928-513;;014-862-474-742-629;;008-999-116-616-972,2078420;;10.1089/aid.1990.6.1425;;10.1126/science.272.5267.1486;;8633242;;8083829;;8373999;;10.1177/10454411930040033001;;1910004;;10.1128/iai.59.10.3492-3497.1991;;pmc258911;;3140379;;10.1126/science.3140379;;10.1006/geno.1996.0049;;8838308;;9189219;;8633228;;10.1126/science.272.5267.1421;;8145792;;10.1056/nejm199405053301815;;8145790;;8145791;;8145793;;pmc2199189;;9419208;;10.1084/jem.187.1.25;;10.1016/s1367-5931(98)80041-0;;9667913;;10.1128/iai.56.9.2484-2490.1988;;3410546;;pmc259592;;10.1016/s0021-9258(19)39087-8;;2185241;;1719051;;10.1177/00220345910700100201;;10.1111/j.1432-1033.1983.tb07456.x;;6852037;;3467077;;10.1001/jama.257.5.640;;10.1001/jama.1987.03390050066020;;3164028;;10.14219/jada.archive.1988.0002;;10.1056/nejm198602063140604;;3456076;;2877344;;10.1089/aid.1991.7.343;;2064831;;6093247;;10.1126/science.6093247;;2999597;;4069172;;10.1056/nejm198512193132512;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1016/s1367-5931(98)80106-3;;9914191;;1692672;;10.1016/0003-2697(90)90302-p;;10.1128/jvi.66.4.2232-2239.1992;;pmc289016;;1548759;;2903974;;8970677;;10.1097/00002030-199612000-00001;;10.1089/aid.1993.9.633;;8396401;;8373998;;10.1177/10454411930040032901;;10.1016/s0008-6215(97)10001-5;;9648259;;pmc185219;;10.1172/jci118056;;7615818;;9080928;;10.1001/archpedi.1997.02170400014003;;1995942;;pmc239879;;10.1128/jvi.65.3.1133-1140.1991;;10.1126/science.2251501;;2251501;;10.14219/jada.archive.1993.0197;;8409011;;10.1006/abio.1995.1268;;7668379;;10.1271/bbb.61.1059;;9255967;;10.1089/dna.1996.15.353;;8924209;;10.1089/aid.1997.13.371;;9075477;;9815215;;10.1086/314511;;7946087;;10.1097/00002030-199407000-00021;;10.1093/infdis/171.1.190;;7798662;;8104046;;10.1177/10454411930040030901;;8397002;;10.1177/10454411930040032801;;10.7326/0003-4819-125-4-199608150-00001;;8678387;;1612175;;10.1016/0020-711x(92)90111-d;;2129627;;10.1177/10454411900010040201;;10.1146/annurev.ph.57.030195.002555;;7778877;;10.1002/ar.1092300303;;1714258;;pmc1858155;;9094984;;8986758;;10.1073/pnas.93.26.15030;;pmc26350;;1512690;;8450244;;10.1093/infdis/167.4.803,"Archibald and Cole, 1990, AIDS Res. Hum. Retroviruses 6:1425-1432.*;;Baba et al., 1996, Science 272:1486-1489.*;;Barr et al., 1992, J. Am. Dent. Assoc. 123:37-48.*;;Bergey et al., 1994 J. Acquired Immune Defic. Syndr. 7:995-1002.*;;Bergey et al., 1993, Critic Rev. Oral Biol. 4:467-474.*;;Biesbrock et al., 1991, Infect. Immun. 59:3492-3497.*;;Bird et al., 1988, Science 242:423-426.*;;Bobek et al., 1996, Genomics 31:277-282.*;;Chebbi et al., 1997, AIDS 11:927-928.*;;Cohen, 1996, Science 272:1421-1422.*;;Coppenhaver et al., 1994, N. Engl. J. Med. 330:1314-1315.*;;Crombie et al., 1998, J. Exp. Med. 187:25-35.*;;Crout et al., 1998, Curr. Opin. Chem. Biol. 2:98-111.*;;Demuth et al., 1988, Inf. Immun. 56:2484-2490.*;;Demuth et al., 1990, J. Biol. Chem. 265:7120-7126.*;;Denny et al., 1991, J. Dent. Res. 70:1320-1327.;;Erickson et al., 1983, European J. Biochem. 133:255-261.;;Fischl et al., 1987, JAMA 257:640-644.;;Fox and Baum, 1986, N. Engl. J. Med. 31:1387.;;Fox et al., 1988, J. Am. Dent. Assoc. 116:635-637.;;Friedland et al., 1986, N. Engl. J. Med. 314:344-349.;;Fultz, 1986, Lancet 2:1215.;;Goto et al., 1991, AIDS Res. Human Retro. 7:343-347.;;Groopman et al., 1984, Science 226:447-449.;;Ho et al., 1985, N. Engl. J. Med. 313:1606.;;Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883.;;Ito et al., 1998, Curr. Opin. Chem. Biol. 2(6):701-708.;;Jay et al., 1990, Anal. Biochem. 185:324-330.;;Kimpton and Emerman, 1992, J. Virol. 66:2232-2239.;;Levy et al., 1988, Lancet 2:1248.;;Liuzzi et al., 1996, AIDS 10:F51-56.;;Malamud et al., 1993, AIDS Res. Hum. Retroviruses 9:633-637.;;Malamud et al., 1997, Oral Diseases, 3:S58-S63.;;Malamud and Friedman, 1993, Crit. Rev. Oral Biol. Med. 4:461-466.;;Matsuo et al., 1997, Carboyhdr. Res. 305:401-413.;;McNeely et al., 1995, J. Clin. Invest. 96:456-464.;;Melvin et al., 1997, Arch. Pediatr. Adolesc. Med. 151:228-232.;;Moore et al., 1991, J. Virol. 65:1133-1140.;;Moore et al., 1990, Science 250:1139-1142.;;Moore et al., 1993, J. Am. Dent. Assoc. 124:67-74.;;Morton et al., 1995, Anal. Biochem. 227:176-185.;;Murata et al., 1997, Biosci. Biotech. and Biochem. 61:1059-1066.;;Nagashunmugam and Friedman, 1996, DNA Cell Biol. 15:353-361.;;Nagashunmugam et al., 1997, AIDS Res. Human Retroviruses 13:371-776.;;Nagashunmugam et al., 1998, J Inf. Dis 178:1635-1641.;;O'Shea et al., 1990, J. Med. Virol. 4:291-296.;;Phillips et al., 1994, AIDS 8:1011-1012.;;Qureshi et al., 1995, J. Infect. Dis. 171:190-193.;;Ramasubba et al., 1991, Biochem. J. 280:341-352.;;Reddy and Levine, 1993, Crit. Rev. Oral Biol. Med. 4:315-323.;;Robinovitch and Iverson, 1993, Crit. Rev. Oral Biol. Med. 4:455-459.;;Schacker et al., 1996, Ann. Intern Med. 125:257-264.;;Slomiany et al., 1992, Intl. J. Biochem, 24:1003-1015.;;Tabak, 1990, Crit. Rev. Oral Biol. CRC Press, pp. 229-234.;;Tabak, 1995, Annu. Rev. Physiol. 57:547-564.;;Takano et al., 1992, Anat. Rec. 230:307-318.;;Wahl et al., 1997, Oral Diseases 3:S64-S69.;;Wahl, et al., 1997, Am. J. Pathol. 150:1275-1284.;;Wu et al., 1996, Proc. Natl. Acad. Sci. 93:15030-15035.;;Yeh et al., 1992, J.Acq. Defic. Synd. 5:898-903.;;Yeung et al., 1993, J. Infect Dis. 167:803-809.",EXPIRED
568,DK,T3,DK 2349260 T3,075-240-512-716-648,2016-01-25,2016,DK 09737257 T,2009-10-01,US 10224208 P;;US 2009/0059203 W,2008-10-02,JANUS KINASE-INHIBITORER TIL BEHANDLING AF TØRRE ØJNE OG ANDRE ØJEN-BESLÆGTEDE SYGDOMME,,INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/075-240-512-716-648,Granted Patent,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/437;;A61K31/519;;A61P27/00,,0,0,,,,ACTIVE
569,EP,A2,EP 1181933 A2,081-244-879-686-938,2002-02-27,2002,EP 01305039 A,2001-06-08,US 21497900 P,2000-06-29,Use of growth hormone secretagogues for stimulating or increasing appetite,"This invention is directed to methods for increasing or stimulating appetite in a patient which comprises administering certain growth hormone secretagogues, prodrugs thereof or pharmaceutically acceptable salts of said secretagogues or said prodrugs. More preferably, the present invention provides such methods wherein the growth hormone secretagogue is a compound of Formula I:
   a prodrug thereof or a pharmaceutically acceptable salt of said secretagogue or said prodrug.",PFIZER PROD INC,FRIEDMAN HYLAR LEWIS;;GARDNER MARK JAMES;;LANDSCHULZ WILLIAM H;;PAN LYDIA CODETTA,,https://lens.org/081-244-879-686-938,Patent Application,yes,2,1,13,13,0,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/55;;A61K49/0004;;A61P1/14;;A61P3/00;;A61P3/02;;A61P3/04;;A61P43/00;;A61K31/519;;A61K49/0004;;A61K31/55;;A61K31/437;;A61K31/444;;A61K31/438,A61K31/437;;A61K31/438;;A61K31/444;;A61K31/4985;;A61K31/519;;C07D471/04;;A61K31/55;;A61K49/00;;A61P1/14;;A61P3/00;;A61P43/00,,1,1,023-329-456-188-805,10.1159/000054491;;10567856,"WILLESEN: ""Co-Localization of Growth Hormone Secretagogue Receptor and NPY mRNA in the Aruate Nucleus of the Rat"", NEUROENDOCINOLOGY, vol. 70, 1999, pages 306 - 316",DISCONTINUED
570,US,B2,US 9881825 B2,199-453-920-900-992,2018-01-30,2018,US 201414541934 A,2014-11-14,US 201414541934 A;;US 20723105 A;;US 60336104 P,2004-08-19,Reduced capacity carrier and method of use,A substrate transport apparatus is provided. The apparatus has a casing and a door. The casing is adapted to form a controlled environment therein. The casing has supports therein for holding at least one substrate in the casing. The casing defines a substrate transfer opening through which a substrate transport system accesses the substrate in the casing. The door is connected to the casing for closing the substrate transfer opening in the casing. The casing has structure forming a fast swap element allowing replacement of the substrate from the apparatus with another substrate without retraction of the substrate transport system and independent of substrate loading in the casing.,BROOKS AUTOMATION INC,GILCHRIST ULYSSES;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERARLD M,BROOKS AUTOMATION. INC (2015-04-28);;BROOKS AUTOMATION US LLC (2021-10-01);;BROOKS AUTOMATION HOLDING LLC (2021-10-01),https://lens.org/199-453-920-900-992,Granted Patent,yes,41,0,17,19,0,B65G49/07;;H01L21/67763;;H01L21/67763;;H01L21/67326;;H01L21/67353;;H01L21/67353;;H01L21/67369;;H01L21/67369;;H01L21/67373;;H01L21/67373;;H01L21/67376;;H01L21/67376;;H01L21/67383;;H01L21/67389;;H01L21/67393;;H01L21/67393;;H01L21/67772;;H01L21/67772;;H01L21/67778;;H01L21/67778;;H01L21/6779;;H01L21/6779;;Y10S414/139;;Y10S414/139,H01L21/677;;H01L21/673,,1,0,,,"European Search Report, EP Application No. 05791673, dated Aug. 30, 2011.",ACTIVE
571,US,B2,US 8888433 B2,068-231-374-152-187,2014-11-18,2014,US 20723105 A,2005-08-19,US 20723105 A;;US 60336104 P,2004-08-19,Reduced capacity carrier and method of use,A substrate transport apparatus is provided. The apparatus has a casing and a door. The casing is adapted to form a controlled environment therein. The casing has supports therein for holding at least one substrate in the casing. The casing defines a substrate transfer opening through which a substrate transport system accesses the substrate in the casing. The door is connected to the casing for closing the substrate transfer opening in the casing. The casing has structure forming a fast swap element allowing replacement of the substrate from the apparatus with another substrate without retraction of the substrate transport system and independent of substrate loading in the casing.,GILCHRIST ULYSSES;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M;;BUFANO MICHAEL L;;BROOKS AUTOMATION INC,GILCHRIST ULYSSES;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M;;BUFANO MICHAEL L,BROOKS AUTOMATION INC (2005-11-30);;BROOKS AUTOMATION US LLC (2021-10-01);;BROOKS AUTOMATION HOLDING LLC (2021-10-01),https://lens.org/068-231-374-152-187,Granted Patent,yes,37,5,17,19,0,B65G49/07;;H01L21/67763;;H01L21/67763;;H01L21/67326;;H01L21/67353;;H01L21/67353;;H01L21/67369;;H01L21/67369;;H01L21/67373;;H01L21/67373;;H01L21/67376;;H01L21/67376;;H01L21/67383;;H01L21/67389;;H01L21/67393;;H01L21/67393;;H01L21/67772;;H01L21/67772;;H01L21/67778;;H01L21/67778;;H01L21/6779;;H01L21/6779;;Y10S414/139;;Y10S414/139,H01L21/677;;H01L21/673,414/217.1;;414/939,5,0,,,"TW Office Action, Application No. 94128322, Jun. 2011.;;EP Office Action, Application No. 05791673.6, dated Sep. 20, 2011.;;CN Office Action, Application No. 200580035790.6, dated Jan. 12, 2012.;;JP Office Action, Application No. 2007-528083, dated Apr. 5, 2011.;;JP Office Action, Application No. 2007-528083, dated Mar. 6, 2012.",ACTIVE
572,US,A1,US 2006/0088272 A1,097-878-566-697-172,2006-04-27,2006,US 20723105 A,2005-08-19,US 20723105 A;;US 60336104 P,2004-08-19,Reduced capacity carrier and method of use,A substrate transport apparatus is provided. The apparatus has a casing and a door. The casing is adapted to form a controlled environment therein. The casing has supports therein for holding at least one substrate in the casing. The casing defines a substrate transfer opening through which a substrate transport system accesses the substrate in the casing. The door is connected to the casing for closing the substrate transfer opening in the casing. The casing has structure forming a fast swap element allowing replacement of the substrate from the apparatus with another substrate without retraction of the substrate transport system and independent of substrate loading in the casing.,GILCHRIST ULYSSES;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M;;BUFANO MICHAEL L,GILCHRIST ULYSSES;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M;;BUFANO MICHAEL L,BROOKS AUTOMATION INC (2005-11-30);;BROOKS AUTOMATION US LLC (2021-10-01);;BROOKS AUTOMATION HOLDING LLC (2021-10-01),https://lens.org/097-878-566-697-172,Patent Application,yes,30,25,17,19,0,B65G49/07;;H01L21/67763;;H01L21/67763;;H01L21/67326;;H01L21/67353;;H01L21/67353;;H01L21/67369;;H01L21/67369;;H01L21/67373;;H01L21/67373;;H01L21/67376;;H01L21/67376;;H01L21/67383;;H01L21/67389;;H01L21/67393;;H01L21/67393;;H01L21/67772;;H01L21/67772;;H01L21/67778;;H01L21/67778;;H01L21/6779;;H01L21/6779;;Y10S414/139;;Y10S414/139,G02B6/00,385/147,0,0,,,,ACTIVE
573,US,A,US 1857374 A,175-369-891-938-330,1932-05-10,1932,US 35071329 A,1929-03-28,US 35071329 A,1929-03-28,Cryptograph enciphering and deciphering device,,GRAHAM GEORGE A;;FRIEDMAN WILLIAM F;;NATIONAL BANK CITIZENS;;EVANS MARY E,GRAHAM GEORGE A;;FRIEDMAN WILLIAM F;;NATIONAL BANK CITIZENS;;EVANS MARY E,,https://lens.org/175-369-891-938-330,Granted Patent,no,0,1,1,1,0,G09C3/02;;G09C3/02,G09C3/00,,0,0,,,,EXPIRED
574,WO,A1,WO 2010/039939 A1,052-051-081-555-813,2010-04-08,2010,US 2009/0059203 W,2009-10-01,US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.",INCYTE CORP;;FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/052-051-081-555-813,Patent Application,yes,6,119,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/437;;A61K31/519;;A61P27/00,,0,0,,,,PENDING
575,EP,A4,EP 1789630 A4,063-826-741-908-427,2009-07-22,2009,EP 05792415 A,2005-08-24,US 2005/0030617 W;;US 60440604 P;;US 21123605 A,2004-08-24,TRANSPORTATION SYSTEM,,BROOKS AUTOMATION INC,GILCHRIST ULYSSES;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,"MURATA MACHINERY, LTD. (2010-06-02)",https://lens.org/063-826-741-908-427,Search Report,no,0,0,9,12,0,H01L21/67715;;H01L21/67736;;H01L21/67775;;H01L21/68;;H01L21/67715;;H01L21/67736;;H01L21/67775,B60L13/00,,1,0,,,No further relevant documents disclosed,DISCONTINUED
576,HR,T1,HR P20160330 T1,154-793-699-763-375,2016-05-06,2016,HR P20160330 T,2016-04-01,US 10224208 P;;EP 09737257 A;;US 2009/0059203 W,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,,INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/154-793-699-763-375,Granted Patent,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/437;;A61K31/519;;A61P27/00,,0,0,,,,ACTIVE
577,US,A,US 6068859 A,024-711-952-720-219,2000-05-30,2000,US 72763496 A,1996-11-04,US 72763496 A;;IB 9500264 W;;US 23909494 A,1994-05-06,Controlled-release dosage forms of Azithromycin,"A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.",PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LEMOTT STEVEN R,PFIZER INC (1999-09-16),https://lens.org/024-711-952-720-219,Granted Patent,yes,21,196,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;C07H15/252;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,424/490;;424/489;;424/464;;424/484;;424/465,13,1,107-902-963-989-556,10.1007/978-1-4613-2745-5_16,"Chem. Abstr., Yoshitomi, H., et al., V 119, No. 8, p. 496, abst. No. 79946v, Evaluation of Enteric Coated Tablet Sensitive to Pancreatic Lipase I. In vitro Disintegration Test .;;Martindale, The Extra Pharmacopoiea, 30th, The Pharm. Press, London, 1963, p. 1197.;;PDR, 48th, Med. L994, N.Y. p. 1789.;;The Merck Index, 11th, Merck & Co., N.Y., 1989, p. 146 Remington Pharmaceutical Science, 16th Merck Pub.;;Farmacia Practica de Remington, second Spanish edition, UTEHA, Mexico, 1965, pp. 471 and 525.;;Laegemiddelkataloget, Copenhagen 1992, p. 229, and p. 356 (including English Translation thereof).;;Farmaceitisk Tidende, No. 35/36, 1988, p. 537 548 (including English Translation thereof).;;Farmaceuten, No. 12, 1990, p. 402 405 (including English Translation thereof).;;Hon Leung Lee et al., Drug Properties Influencing The Design of Sustained or Controlled Release Drug Delivery .;;Chapters 88, 90, and 91 from Remington Pharmaceutical Science, 16th Merck Pub. Co., Pennsylvania (1980), pp. 1535, 1585, 1594.;;Scott Hopkins, The American Journal of Medicine, vol. 91, (Suppl 3A) Sep. 12, 1991, 3A 40S 3A 45S.;;J. R. Cardinal, Plenum Publishing Corp., 1984, Drug Release From Matrix Devices.;;Richard H. Drew, Pharmacotherapy, vol. 12, No. 3, 1992, pp. 162 173.",EXPIRED
578,HK,A1,HK 1160607 A1,039-887-208-801-487,2012-08-10,2012,HK 12101002 A,2012-02-02,US 2009/0059203 W;;US 10224208 P,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES JANUS,,INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/039-887-208-801-487,Patent Application,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K/;;A61P/,,0,0,,,,PENDING
579,CL,A1,CL 2009001884 A1,053-438-101-260-530,2010-05-14,2010,CL 2009001884 A,2009-09-23,US 10224208 P,2008-10-02,"Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.","Un método para el tratamiento del ojo seco que comprende la administración de un compuesto heterocíclico bicíclico sustituido, inhibidor de quinasa janus; inserto oftálmico que comprende a dicho compuesto y kit.",INCYTE HOLDINGS CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/053-438-101-260-530,Patent Application,no,0,0,34,34,0,A61K31/519;;A61K31/519;;A61K9/0048;;A61K31/437;;A61K31/437;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00,A61K31/519;;A61P27/02,,0,0,,,,PENDING
580,CA,C,CA 2738520 C,051-348-280-132-152,2020-03-10,2020,CA 2738520 A,2009-10-01,US 10224208 P;;US 2009/0059203 W,2008-10-02,JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES,"Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.",INCYTE CORP,FRIEDMAN PAUL A;;FRIDMAN JORDAN S;;LUCHI MONICA E;;WILLIAMS WILLIAM V,,https://lens.org/051-348-280-132-152,Granted Patent,no,0,0,34,34,0,A61K31/437;;A61K31/519;;A61P27/00;;A61P27/02;;A61P27/04;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/437;;A61K31/519;;A61K9/0048,A61K31/519;;A61K31/437,,0,0,,,,ACTIVE
581,US,B2,US 9368382 B2,048-740-847-309-560,2016-06-14,2016,US 201414223553 A,2014-03-24,US 201414223553 A;;US 89744010 A;;US 21091805 A;;US 60409904 P,2004-08-23,Elevator-based tool loading and buffering system,"A substrate processing apparatus is provided. The apparatus has a casing, a low port interface and a carrier holding station. The casing has processing devices within for processing substrates. The load port interface is connected to the casing for loading substrates into the processing device. The carrier holding station is connected to the casing. The carrier holding station is adapted for holding at least one substrate transport carrier so the at least one substrate transport carrier is capable of being coupled to the load port interface without lifting the at least one substrate transport carrier off the carrier holding station. The carrier holding station is arranged to provide a substantially simultaneous swap section for substantially simultaneous replacement of the substrate transport carrier from the carrier holding station.",BROOKS AUTOMATION INC,FRIEDMAN GERALD M;;BUFANO MICHAEL L;;HOFMEISTER CHRISTOPHER;;GILCHRIST ULYSSES;;FOSNIGHT WILLIAM,BROOKS AUTOMATION US LLC (2021-10-01);;BROOKS AUTOMATION HOLDING LLC (2021-10-01),https://lens.org/048-740-847-309-560,Granted Patent,yes,65,3,17,18,0,H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;H01L21/67276;;H01L21/67346;;H01L21/67379;;H01L21/67769;;H01L21/67772;;H01L21/67775;;Y10S414/14;;B65G47/50;;Y10S414/14;;H01L21/67276;;H01L21/67769;;H01L21/67772;;H01L21/67775;;H01L21/677,B65G47/10;;B65G47/50;;H01L21/67;;H01L21/677,,4,3,151-048-311-925-245;;077-076-406-863-020;;048-775-054-246-133,10.1109/asmc.1997.630764;;10.1109/asmc.1997.630762;;10.1109/asmc.1998.731633,"Campbell, Philip L. ""Overhead Intrabay Automation and Microstocking-A Virtual Fab Case Study"". IEEE/SEMI Publications; Advanced Semiconductor Manufacturing Conference 1997, pp. 368-372.;;Kaempf, Ulrich. ""Automated Wafer Transport in the Wafer Fab"". IEEE/SEMI Publications; Advanced Semiconductor Manufacturing Conference 1997, pp. 356-361.;;Kuo, C.H. ""Modelling and Performance Evaluation of an Overhead Hoist Transport System in a 300mm Fabrication Plant"". International Journal of Advanced Manufacturing Technology, 2002, vol. 20, pp. 153-161.;;Sikich, Joe. ""Development and Implementation of an Automated Wafer Transport System"". IEEE/SEMI Publications; Advanced Semiconductor Manufacturing Conference 1998, pp. 400-404.",ACTIVE
582,NO,B1,NO 315453 B1,109-040-510-302-72X,2003-09-08,2003,NO 964678 A,1996-11-05,IB 9500264 W;;US 23909494 A,1994-05-06,"Kontrollert frigivings-doseformer av azitromycin, fremgangsmåte for fremstilling av en flerpartikkeldoseringsform av azitromycin oganvendelse av en azitomycinholdig doseringsform for fremstilling av et farmasöytiskpreparat",,PFIZER,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;KORSMEYER RICHARD WILKER;;LEMOTT STEVEN R,,https://lens.org/109-040-510-302-72X,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;C07H15/252;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
583,US,A,US 3878073 A,122-377-665-380-17X,1975-04-15,1975,US 27178672 A,1972-07-14,US 27178672 A,1972-07-14,Oxygen exchange with liquid metals,"Oxygen, which is dissolved in liquid metals, is rapidly withdrawn by electrochemical pumping through a solid electrolyte cell while the melt is turbulently circulated past the electrolyte wall. Heating and stirring of the melt by induction or other means additionally permit a further increased deoxidation rate by allowing application of pumping voltages in excess of the electrolyte decomposition voltage for stagnant melts. A programmed reduction of pumping voltage as oxygen is withdrawn optimizes the deoxidation rate. Oxygen may similarly be pumped into the melt.",UNIV OHIO STATE RES FOUND,BOORSTEIN WILLIAM M;;FRIEDMAN LAWRENCE M;;RAPP ROBERT A;;OBERG KARL E,,https://lens.org/122-377-665-380-17X,Granted Patent,no,8,7,1,1,0,C22B9/00;;C22B9/00,C22B9/00,204/140,0,0,,,,EXPIRED
584,TW,A,TW 200616877 A,180-647-388-146-182,2006-06-01,2006,TW 94128861 A,2005-08-24,US 60440604 P,2004-08-24,Transportation system,A substrate transport system comprising: a guideway; and at least one transport vehicle adapted for holding at least one substrate and capable of being supported from and moving along the guideway; wherein the guideway comprises at least one travel lane for the at least one vehicle and at least one access lane offset from the travel lane allowing the vehicle selectable access on and off the travel land.,BROOKS AUTOMATION INC,GILCHRIST ULYSSES;;BUFANO MICHAEL L;;FOSNIGHT WILLIAM;;HOFMEISTER CHRISTOPHER;;FRIEDMAN GERALD M,,https://lens.org/180-647-388-146-182,Patent of Addition,no,0,1,3,12,0,,,,0,0,,,,ACTIVE
585,TW,B,TW I365841 B,176-099-930-244-964,2012-06-11,2012,TW 94128322 A,2005-08-19,US 60336104 P,2004-08-19,Reduced capacity carrier and method of use,,BROOKS AUTOMATION INC,ULYSSES GILCHRIST;;MICHAEL L BUFANO;;WILLIAM FOSNIGHT;;CHRISTOPHER HOFMEISTER;;GERALD M FRIEDMAN,,https://lens.org/176-099-930-244-964,Granted Patent,no,0,0,2,19,0,,,,0,0,,,,ACTIVE
586,AT,T1,AT E209497 T1,104-371-804-645-853,2001-12-15,2001,AT 95913923 T,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,AZITHROMYCIN ENTHALTENDE ARZNEIVERABREICHUNGSFORMEN MIT GESTEUERTER WIRKSTOFFABGABE,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/104-371-804-645-853,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
587,DE,D1,DE 69524214 D1,182-433-436-977-626,2002-01-10,2002,DE 69524214 T,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,AZITHROMYCIN ENTHALTENDE ARZNEIVERABREICHUNGSFORMEN MIT GESTEUERTER WIRKSTOFFABGABE,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/182-433-436-977-626,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
588,FI,A0,FI 964452 A0,198-697-879-573-444,1996-11-05,1996,FI 964452 A,1996-11-05,IB 9500264 W;;US 23909494 A,1994-05-06,Atsitromysiinin kontrolloidun vapautumisen annostusmuotoja,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/198-697-879-573-444,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;C07H15/252;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
589,SK,B6,SK 282854 B6,006-024-106-959-899,2002-12-03,2002,SK 143296 A,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,Controlled-release dosage forms of azithromycin,"A controlled-release dosage form of azithromycin and pharmaceutically suitable carrier, which after administering to a mammal, which needs and application for such form, releases azithromycin into the gastrointestinal tract, so that the total amount of the released azithromycin is not more than approximately 4 mg of azithromycin per 1 kg of the mammal weight during the first 15 minutes after administering, is not more than approximately 10 mg of azithromycin per 1 kg of the mammal weight during the first hour after administering, is not more than approximately 20 mg of azithromycin per 1 kg of the mammal weight during the first two hours after administering, is not more than 30 mg of azithromycin per 1 kg of the mammal weight during the first four hours after administering and is not more than 40 mg of azithromycin per 1 kg of the mammal weight during the first six hours after administering.",PFIZER,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/006-024-106-959-899,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
590,KR,B1,KR 100232297 B1,082-300-390-631-384,1999-12-01,1999,KR 19960706244 A,1996-11-05,US 23909494 A;;IB 9500264 W,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,"개선된 부작용 프로필을 갖는 아지트로마이신의 제어된-방출 투여형 제제: 투여형 제제를 제조하기 위한 공정; 및 미생물 감염 치료가 요구되는 사람 환자를 포함하는 포유동물에게 아지트로마이신을 이러한 제어된 방출 투여형 제제로 투여함을 포함하는, 상기 미생물적 감염을 치료하는 방법.",PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/082-300-390-631-384,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
591,DE,T2,DE 69524214 T2,111-870-292-134-485,2002-05-23,2002,DE 69524214 T,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,AZITHROMYCIN ENTHALTENDE ARZNEIVERABREICHUNGSFORMEN MIT GESTEUERTER WIRKSTOFFABGABE,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/111-870-292-134-485,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
592,AP,A,AP 548 A,073-021-136-041-508,1996-10-30,1996,AP 9500735 A,1995-04-27,US 23909494 A,1994-05-06,Controlled-release dosage forms of azithromycin.,A controlled-release dosage form of azithromycin,PFIZER,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/073-021-136-041-508,Granted Patent,no,2,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
593,FI,A,FI 964452 A,191-139-338-524-753,1996-11-05,1996,FI 964452 A,1996-11-05,IB 9500264 W;;US 23909494 A,1994-05-06,Atsitromysiinin kontrolloidun vapautumisen annostusmuotoja,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/191-139-338-524-753,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;C07H15/252;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
594,BR,A,BR 9501929 A,192-759-467-212-514,1996-03-05,1996,BR 9501929 A,1995-05-05,US 23909494 A,1994-05-06,Forma de dosagem de liberação controlada método de administração de azitromicina processo para a preparação de uma forma de dosagem e método de trata mento de um mamifero,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KOSMEYER RICHARD W;;MOTT STEVEN R LE,,https://lens.org/192-759-467-212-514,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
595,ZA,B,ZA 953627 B,014-453-943-310-574,1996-11-05,1996,ZA 953627 A,1995-05-05,US 23909494 A,1994-05-06,Controlled-release dosage forms of azithromycin,,PFIZER,FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;MOTT STEVEN R LE;;CURATOLO WILLIAM J,,https://lens.org/014-453-943-310-574,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;C07H15/252;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
596,ES,T3,ES 2163504 T3,190-755-381-225-17X,2002-02-01,2002,ES 95913923 T,1995-04-13,US 23909494 A,1994-05-06,FORMAS DE DOSIFICACION DE LIBERACION CONTROLADA DE AZITROMICINA.,"FORMULA DE DOSIFICACION CON ADMINISTRACION CONTROLADA DE AZITROMICINA CON UN MEJOR PERFIL DE EFECTOS SECUNDARIOS; PROCESO PARA PREPARAR LA FORMULA DE DOSIFICACION; Y UN METODO PARA TRATAR UNA INFECCION MICROBIANA, QUE INCLUYE LA ADMINISTRACION DE AZITROMICINA DOSIFICADA DE FORMA CONTROLADA A UN MAMIFERO, INCLUIDO EL SER HUMANO, QUE NECESITE ESTE TRATAMIENTO.",PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/190-755-381-225-17X,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
597,EP,B1,EP 0758244 B1,052-495-134-989-648,2001-11-28,2001,EP 95913923 A,1995-04-13,US 23909494 A;;IB 9500264 W,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,PFIZER INC. (2007-10-15),https://lens.org/052-495-134-989-648,Granted Patent,yes,3,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
598,OA,A,OA 10320 A,098-636-775-387-124,1997-10-07,1997,OA 60919 A,1996-11-06,US 23909494 A,1994-05-06,Controlled-release dosage forms of azithromycin,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/098-636-775-387-124,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
599,US,B1,US 9407441 B1,096-492-423-601-69X,2016-08-02,2016,US 201313927386 A,2013-06-26,US 201313927386 A,2013-06-26,Adding entropy to key generation on a mobile device,"Methods, apparatus and articles of manufacture for adding entropy to key generation on a mobile device are provided herein. A method includes generating a prompt via a computing device interface in connection with an authentication request to access a protected resource associated with the computing device; processing input cryptographic information entered via the computing device interface in response to the prompt against a pre-determined set of cryptographic information, wherein said pre-determined set of cryptographic information comprises one or more input elements and one or more interface manipulation measures associated with the one or more input elements; and resolving the authentication request based on said processing.",EMC CORP,DOTAN YEDIDYA;;FRIEDMAN LAWRENCE N;;BAILEY DANIEL V;;BRAINARD JOHN;;DUANE WILLIAM M,RSA SECURITY LLC (2020-09-01);;EMC CORPORATION (2013-07-25);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/096-492-423-601-69X,Granted Patent,yes,13,1,1,1,0,H04L63/083;;H04W12/06;;G06F21/35;;H04L9/3226;;H04L9/3226;;G06F21/35;;H04W12/06;;H04L63/083,G06F21/00;;H04L9/32,,1,0,,,"U.S. Appl. No. 14/036,498, filed Sep. 25, 2013, entitled: Increasing Entropy for Password and Key Generation on a Mobile Device.",ACTIVE
600,HR,B1,HR P950277 B1,129-635-856-785-288,2002-06-30,2002,HR P950277 A,1995-05-05,US 23909494 A,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;MOTT STEVEN R LE,,https://lens.org/129-635-856-785-288,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
601,DE,T3,DE 69524214 T3,033-957-778-760-990,2008-05-15,2008,DE 69524214 T,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,AZITHROMYCIN ENTHALTENDE ARZNEIVERABREICHUNGSFORMEN MIT GESTEUERTER WIRKSTOFFABGABE,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/033-957-778-760-990,Amended Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K31/70;;C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
602,CA,A1,CA 2189658 A1,050-857-316-953-155,1995-11-16,1995,CA 2189658 A,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,Controlled-Release Dosage Forms of Azithromycin,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/050-857-316-953-155,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
603,IS,A,IS 4282 A,167-647-381-295-723,1995-11-07,1995,IS 4282 A,1995-05-02,US 23909494 A,1994-05-06,Leysnistýrð skammtaform af Azithromycín,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;MOTT STEVEN R LE,,https://lens.org/167-647-381-295-723,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,PENDING
604,LV,B,LV 11729 B,026-686-222-961-679,1997-08-20,1997,LV 960429 A,1996-11-11,IB 9500264 W;;US 23909494 A,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/026-686-222-961-679,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
605,NO,L,NO 964678 L,034-415-048-657-043,1997-01-06,1997,NO 964678 A,1996-11-05,IB 9500264 W;;US 23909494 A,1994-05-06,Kontrollert frigivings-dose former azithromycin,,PFIZER,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD WILKER;;LE MOTT STEVEN R,,https://lens.org/034-415-048-657-043,Abstract,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;C07H15/252;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
606,PL,A1,PL 317106 A1,102-455-871-971-216,1997-03-17,1997,PL 31710695 A,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,CONTROLLABLE RELEASE DOSING FORMS OF AZITROMYCIN,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/102-455-871-971-216,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;C07H15/252;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
607,EC,A,EC SP951438 A,126-438-309-843-993,1996-05-10,1996,EC SP951438 A,1995-05-05,EC SP951438 A,1995-05-05,FORMAS DE DOSIFICACION DE LIBERACION CONTROLADA DE AZITROMICINA,"El invento se refiere a una forma de dosificación de liberación controlada de azitromicina que tiene un perfil de efectos secundarios mejorado; un procedimiento para la preparación de la forma de dosificación, y un procedimiento de tratamiento de infección microbiana que comprende la administración de azitromicina en dicha forma de dosificación de liberación controlada a un mamífero, incluyendo a un humano, en necesidades de dicho tratamiento.",,KORSMEYER RICHARD WILKER;;CURATOLO WILLIAM JHON;;FRIEDMAN HYLAR L;;LE MOTT STEVEN R,,https://lens.org/126-438-309-843-993,Patent Application,no,0,0,1,1,0,,A61J3/00,,0,0,,,,PENDING
608,PE,A1,PE 4796 A1,015-557-086-986-811,1996-03-09,1996,PE 26765195 A,1995-05-03,US 23909494 A,1994-05-06,FORMAS DE DOSIFICACION DE LIBERACION CONTROLADA DE AZITROMICINA,"CARACTERIZADAS POR REDUCIR LA EXPOSICION LOCALIZADA DE AZITROMICINA A TRAVES DEL TRACTO GASTROINTESTINAL, ESPECIALMENTE A NIVEL DEL DUODENO, POR LO QUE PUEDEN PRODUCIRSE MENORES EFECTOS SECUNDARIOS GASTROINTESTINALES, SE REFIERE ASI A: A) UNA MATRIZ QUE LIBERA AZITROMICINA, COMPRENDIENDO LA MATRIZ EXCIPIENTES TALES COMO HIDROXIPROPILMETILCELULOSA, HIDROXIPROPILCELULOSA, POLI(OXIDO DE ETILENO), ACIDO POLIACRILICO; DONDE LA MATRIZ PUEDE TENER DOS ZONAS: UNA ZONA CON UN RECUBRIMIENTO IMPERMEABLE Y UNA ZONA NO RECUBIERTA EN LA FORMA DE UNA ABERTURA O VIA DE PASO APROPIADA PARA EL TRANSPORTE DEL FARMACO B) UN RESERVORIO DE AZITROMICINA, TAL COMO UN COMPRIMIDO, RECUBIERTO POR UNA MEMBRANA; PUEDE CONTENER UN AGENTE OSMOTICO; C) UN MULTIPARTICULADO DE AZITROMICINA QUE COMPRENDE PARTICULAS RECUBIERTAS CON UNA MEMBRANA, PUEDE CONTENER UN AGENTE OSMOTICO; LAS MEMBRANAS DE B Y C COMPRENDEN UN POLIMERO GASTRORRESISTENTE Y ENTEROSOLUBLE TAL COMO ACETATO FTALATO DE CELULOSA, POLI(ACETATO FTALATO DE VINILO), FTALATO DE HIDROXIPROPILMETILCELULOSA, COPOLIMEROS DE ACIDO ACRILICO, ESTER DE ACRILATO",PFIZER,CURATOLO WILLIAM J;;LE MOTT STEVEN R;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W,,https://lens.org/015-557-086-986-811,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
609,EP,B2,EP 0758244 B2,041-466-760-040-681,2008-02-13,2008,EP 95913923 A,1995-04-13,US 23909494 A;;IB 9500264 W,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,PFIZER INC. (2007-10-15),https://lens.org/041-466-760-040-681,Granted Patent,yes,3,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K31/70;;C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,22,11,017-537-299-622-725;;087-650-378-258-881;;139-294-802-068-646;;007-770-676-215-526;;056-294-396-662-834;;037-670-274-220-98X;;091-880-199-493-657;;119-514-352-967-383;;009-017-982-681-667;;146-890-078-021-12X;;034-709-537-661-282,8383944;;10.1128/aac.37.2.314;;pmc187659;;1930622;;10.1111/j.1365-2125.1985.tb02756.x;;4005117;;pmc1463757;;10.1023/a:1016423404636;;3508560;;2137217;;10.1023/a:1015835609333;;10.3181/00379727-88-21588;;14371635;;4005135;;pmc1463760;;10.1111/j.1365-2125.1985.tb02749.x;;2801679;;10.1016/0378-5173(90)90243-w;;10.1016/0378-5173(91)90357-t;;10.1093/jac/25.suppl_a.39;;2154437,"Milap C. Nahata et al., ""Pharmacokinetics of Azithromycin in Pediatric Patients after Oral Administration of Multiple Doses of Suspension"", Antimicrobial Agents and Chemotherapy, Bd. 37/2, Feb. 1993, S. 314-316;;""Gazzetta Ufficiale Della Republica Italiana"" No. 103, 05. Mai 1992;;H. Sucker et al., ""Pharmazeutische Technologie"", 2. Aufl. 1991, Abschnitte 4.4.1 bis 4.4.3;;""Physician's Desk Reference"", 47. Aufl. 1993, Stichwort ""Zithromax"";;H.N. Nellans et al., ""Gastrointestinal side effects: clarithromycin superior to azithromycin in reduced smooth muscle contration and binding"", Abstract 518, 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 1991;;Isao Morishita et al., ""Controlled Release Microspheres Based on Eudragit L100 for the Oral Administration of Erythromycin"", Drug Design and Delivery, Bd. 7, 1991, S. 309-319;;Welling, P. (1986) ""Pharmacokinetics: Processes and Mathematics""; ACS Monograph 185, American Chemical Society, Wash., D.C., pp. 173-175;;Langenbucher and Mysicka (1985); In vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations; Br. J. Clin. Pharmacol. (1985), 19, 151S - 162S;;Fischer, W. et al. (1987); Investigation of the gastrointestinal transit and in vivo drug release of isosorbide-5-nitrate pellets; Pharm. Res. 4, 480-485;;Graffner, C. et al. (1990); Plasma concentrations of remoxipride and the gastrointestinal transit of 111In-marked extended release coated spheres; Pharm. Res. 7, 54-58;;Blankerhorn, D. et al.(1955); Transintestinal intubation: technique for measurement of gut length and physiological sampling at known loci; Proc. Soc. Exp. Biol. Med. 88, 356-362;;Jobin, G. et al. (1985); Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum, and jejunum; Br. J. Clin. Pharmacol. 19, 97S-105S;;Knutson, L. et al. (1989); A new technique for segmental jejunal perusion in man; Amer. J. Gastroenterology 84, 1278-1284;;Khosia, R. and Davis, S.S. (1990); The effect of tablet size on the gastric epmtying of non-disintegrating tablets; Int. J. Pharmaceut. 62, R9-R11;;Anie, S. et al. (1991); Gastrointestinal transit studies in the rat using 19F-NMR; Int. J. Pharmaceut 76, 183-185;;Fiese and Steffen; Journal of Antimicrobial Chemotherapy, 1990, 25, Suppl. A, 39-47;;Clin. Pharmacology of Antibiotics, vol 13, n°6 (Jun 1992);;Eur. J. Clin. Microbiol. Infect. Dis., vol. 10 (1991);;Drug Safety, vol. 9, n° 5 (1993);;Gastroenterology, vol.105 (1993);;Treatment Issues, vol. 8, n° 1 (Mar 1994);;Med. Klin., vol. 76 (1981)",EXPIRED
610,HU,A,HU T77530 A,093-070-242-934-357,1998-05-28,1998,HU 9603076 A,1995-04-13,US 23909494 A,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/093-070-242-934-357,Unknown,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
611,BG,A,BG 100960 A,124-027-879-696-885,1997-08-29,1997,BG 10096096 A,1996-11-05,IB 9500264 W;;US 23909494 A,1994-05-06,DOSAGE FORMS FOR CONTROLLED RELEASE OF AZITROMYCIN,"The dosage form has improved profile of side effects. The invention also relates to a method for the preparation of a dosage form and to a method for the treatment of a microbial infection including the application of azitromycin in such a form for controlled release in mammals, including humans, requiring such a treatment.",PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/124-027-879-696-885,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
612,EP,A1,EP 0758244 A1,122-391-720-441-395,1997-02-19,1997,EP 95913923 A,1995-04-13,US 23909494 A;;IB 9500264 W,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,PFIZER INC. (2007-10-15),https://lens.org/122-391-720-441-395,Patent Application,yes,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
613,MY,A,MY 113059 A,034-149-310-635-722,2001-11-30,2001,MY PI19951187 A,1995-05-04,US 23909494 A,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,"A CONTROLLED-RELEASE DOSAGE FORM OF AZITHROMYCIN HAVING AN IMPROVED SIDE EFFECT PROFILE; A PROCESS FOR PREPARING THE DOSAGE FORM; AND A METHOD OF TREATING A MICROBIAL INFECTION, COMPRISING ADMINISTERING AZITHROMYCIN IN SUCH A CONTROLLED-RELEASE DOSAGE FORM TO A MAMMAL, INCLUDING A HUMAN PATIENT, IN NEED OF SUCH TREATMENT.",PFIZER,STEVEN R LE MOTT;;RICHARD W KORSMEYER;;WILLIAM J CURATOLO;;HYLAR L FRIEDMAN,,https://lens.org/034-149-310-635-722,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K9/16;;A61K/;;C07H15/252;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
614,HU,D0,HU 9603076 D0,151-076-358-189-132,1997-01-28,1997,HU 9603076 A,1995-04-13,US 23909494 A,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/151-076-358-189-132,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
615,CA,C,CA 2189658 C,005-317-979-766-677,2000-10-31,2000,CA 2189658 A,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,"A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.",PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/005-317-979-766-677,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
616,DE,C2,DE 3000745 C2,056-471-564-820-50X,1982-12-23,1982,DE 3000745 A,1980-01-10,US 252679 A,1979-01-11,DE 3000745 C2,,"BORG-WARNER CHEMICALS, INC.(N.D.GES.DES STAATES DELAWARE), 26101 PARKERSBURG, W.VA., US","HORN JUN., WILLIAM E., VINCENT, OHIO, US;;FRIEDMAN, LESTER, LONG BEACH, CALIF., US","GE SPECIALTY CHEMICALS, INC. (N.D.GES.D.STAATES DE (1993-01-21);;BORG-WARNER CHEMICALS, INC.(N.D.GES.DES STAATES DE (1982-07-29)",https://lens.org/056-471-564-820-50X,Granted Patent,no,0,0,8,8,0,C08K5/526,C08L23/00;;C08K5/52;;C08K5/526;;C08L7/00;;C08L21/00;;C08L101/00,,0,0,,,,EXPIRED
617,LV,A,LV 11729 A,080-882-013-912-797,1997-04-20,1997,LV 960429 A,1996-11-11,IB 9500264 W;;US 23909494 A,1994-05-06,Azitromicina zalu forma ar programmetu aktivas vielas izdalisanos,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;MOTT STEVEN R LE,,https://lens.org/080-882-013-912-797,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
618,SK,A3,SK 143296 A3,053-024-583-189-385,1998-07-08,1998,SK 143296 A,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,"A controlled-release dosage form of azithromycin and pharmaceutically suitable carrier, which after administering to a mammal, which needs and application for such form, releases azithromycin into the gastrointestinal tract, so that the total amount of the released azithromycin is not more than approximately 4 mg of azithromycin per 1 kg of the mammal weight during the first 15 minutes after administering, is not more than approximately 10 mg of azithromycin per 1 kg of the mammal weight during the first hour after administering, is not more than approximately 20 mg of azithromycin per 1 kg of the mammal weight during the first two hours after administering, is not more than 30 mg of azithromycin per 1 kg of the mammal weight during the first four hours after administering and is not more than 40 mg of azithromycin per 1 kg of the mammal weight during the first six hours after administering.",PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/053-024-583-189-385,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
619,PT,E,PT 758244 E,099-771-511-673-539,2002-04-29,2002,PT 95913923 T,1995-04-13,US 23909494 A,1994-05-06,FORMAS DE DOSAGEM LIBERTACAO CONTROLADA DE AZITROMICINA,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;MOTT STEVEN R LE,,https://lens.org/099-771-511-673-539,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
620,UA,C2,UA 41995 C2,154-946-042-055-563,2001-10-15,2001,UA 96114330 A,1995-04-13,US 23909494 A;;IB 9500264 W,1994-05-06,"SUSTAINED RELEASE DOSAGE FORM OF AZITHROMYCIN (VARIANTS), METHOD OF USE, METHOD OF MANUFACTURE AND METHOD FOR TREATING INFECTIOUS DISEASES IN MAMMALS (VARIANTS)",The invention relates to the sustained release dosage form of Azithromycin containing Azithromycin and the pharmaceutically acceptable carrier. The rate of the release in gastrointestinal tract upon swallowing the tablet provides for the following uptake of the drug: no more than 4 mg of Azithromycin per 1 kg of body mass within the first 15 minutes; no more than 10 mg of Azithromycin per 1 kg of body mass within the first one hour; no more than 20 mg of Azithromycin per 1 kg of body mass within two hours; no more than 30 mg of Azithromycin per 1 kg of body mass within four hours; and no more than 40 mg of Azithromycin per 1 kg of body mass within six hours.,PFIZER,KURATOLO WILLIAM G;;FRIEDMAN HILAR L;;CORSMEYER RICHARD V;;LE MOTT STEVEN R,,https://lens.org/154-946-042-055-563,Limited Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
621,NZ,A,NZ 283160 A,137-894-861-226-284,1998-07-28,1998,NZ 28316095 A,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,AZITHROMYCIN IN A CONTROLLED RELEASE DOSAGE FORM FOR TREATING MICROBIOL INFECTIONS,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/137-894-861-226-284,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
622,BG,B1,BG 63152 B1,172-073-706-427-968,2001-05-31,2001,BG 10096096 A,1996-11-05,IB 9500264 W;;US 23909494 A,1994-05-06,DOSAGE FORMS FOR CONTROLLED RELEASE OF AZITROMYCIN,"The dosage form has improved profile of side effects. The invention also relates to a method for the preparation of a dosage form and to a method for the treatment of a microbial infection including the application of azitromycin in such a form for controlled release in mammals, including humans, requiring such a treatment. 71 claims",PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/172-073-706-427-968,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
623,UY,A1,UY 23958 A1,180-703-419-474-298,1995-10-31,1995,UY 23958 A,1995-05-05,US 23909494 A,1994-05-06,PROCEDIMIENTO PARA LA PREPARACIÓN DE FORMAS DE DOSIFICACIÓN DE LIBERACIÓN CONTROLADA DE AZITROMICINA,"Se describe un procedimiento para la preparación de una forma de dosificación multiparticulada de azitromicina que comprende las etapas de: a) granulación de la sustancia de fármaco de azitromicina en masa con un ligante para obtener una granulación que tiene un tamaño de partícula medio de 50 a 300 micrómetros; b) recubrimiento de forma sustancial de la azitromicina granulada con un material que forma membrana de liberación sostenida en una cantidad del 5 al 30% del peso total del producto recubierto; y c) después de esto, adicionalmente el recubrimiento del producto de la etapa (b) con un polímero adicional hasta que la cantidad total de polímero de recubrimento sea de entre el 25 y 70% del peso total del producto recubierto. La azitromicina es de utilidad para el tratamiento de infecciones microbianas.",PFIZER,WILLIAM J CURATOLO;;HYLAR L FRIEDMAN;;RICHARD W KORSMEYER;;STEVEN R LE MOTT,,https://lens.org/180-703-419-474-298,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61P31/00;;A61K/;;C07H15/252;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K9/52;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
624,ES,T5,ES 2163504 T5,147-046-484-369-079,2008-05-16,2008,ES 95913923 T,1995-04-13,US 23909494 A,1994-05-06,FORMAS DE DOSIFICACION DE LIBERACION CONTROLADA DE AZITROMICINA.,"FORMULA DE DOSIFICACION CON ADMINISTRACION CONTROLADA DE AZITROMICINA CON UN MEJOR PERFIL DE EFECTOS SECUNDARIOS; PROCESO PARA PREPARAR LA FORMULA DE DOSIFICACION; Y UN METODO PARA TRATAR UNA INFECCION MICROBIANA, QUE INCLUYE LA ADMINISTRACION DE AZITROMICINA DOSIFICADA DE FORMA CONTROLADA A UN MAMIFERO, INCLUIDO EL SER HUMANO, QUE NECESITE ESTE TRATAMIENTO.",PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/147-046-484-369-079,Amended Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K31/70;;A61K/;;C07H15/252;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
625,TN,A1,TN SN95051 A1,146-955-210-745-884,1996-02-06,1996,TN SN95051 A,1995-05-03,US 23909494 A,1994-05-06,PROCEDE DE PRODUCTION D'UNE FORME PHARMACEUTIQUE D'AZITHROMYCINE,"L'INVENTION CONCERNE UN PROCEDE DE PRODUCTION D'UNE FORME PHARMACEUTIQUE D'AZITHROMYCINE A LIBERATION CONTROLEE, DESTINEE AU TRAITEMENT D'INFECTIONS MICROBIENNES",PFIZER,WILLIAM J CURATOLO;;HYLAR L FRIEDMAN;;RICHARD W KORSMEYER;;STEVEN R LE MOTT,,https://lens.org/146-955-210-745-884,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,PENDING
626,NO,D0,NO 964678 D0,181-812-248-548-06X,1996-11-05,1996,NO 964678 A,1996-11-05,IB 9500264 W;;US 23909494 A,1994-05-06,Kontrollert-frigivings-dose former azithromycin,,PFIZER,CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD WILKER;;LE MOTT STEVEN R,,https://lens.org/181-812-248-548-06X,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;C07H15/252;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
627,DK,T4,DK 0758244 T4,013-979-177-692-98X,2008-06-16,2008,DK 95913923 T,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,Doseringsformer af azithromycin med styret frigivelse,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/013-979-177-692-98X,Amended Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K31/70;;C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
628,TW,B,TW 420616 B,090-396-641-401-188,2001-02-01,2001,TW 84104175 A,1995-04-27,US 23909494 A,1994-05-06,Controlled-release dosage forms of azithromycin,"A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage from; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.",PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/090-396-641-401-188,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;C07H15/252;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
629,SI,A,SI 9520049 A,155-577-083-393-492,1997-12-31,1997,SI 9520049 A,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/155-577-083-393-492,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
630,WO,A1,WO 1995/030422 A1,189-205-401-298-797,1995-11-16,1995,IB 9500264 W,1995-04-13,US 23909494 A,1994-05-06,CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN,"A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.",PFIZER;;CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/189-205-401-298-797,Patent Application,yes,3,77,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,PATENTED
631,RO,B1,RO 114740 B1,190-578-937-663-323,1999-07-30,1999,RO 9602092 A,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,"CONTROLLED RELEASE COMPOSITION, PROCESS FOR PREPARING THE SAME AND METHOD OF TREATMENT",,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/190-578-937-663-323,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;C07H15/252;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
632,AU,B2,AU 680356 B2,027-041-056-780-765,1997-07-24,1997,AU 1995/021131 A,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,Controlled-release dosage forms of azithromycin,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;MOTT STEVEN R LE,,https://lens.org/027-041-056-780-765,Granted Patent,no,3,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
633,CO,A1,CO 4290346 A1,029-744-729-438-926,1996-04-17,1996,CO 95018844 A,1995-05-05,US 23909494 A,1994-05-06,FORMAS DE DOSIFICACION DE LIBERACION CONTROLADA DE AZITROMICINA,"UNA FORMA DE DOSIFICACION DE LIBERACION CONTROLADA DE AZITROMICINA QUE TIENE UN PERFIL DE EFECTOS SE- CUNDARIOS MEJORADO; UN PROCEDIMIENTO PARA LA PRE- PARACION DE LA FORMA DE DOSIFICACION; Y UN PROCE- DIMIENTO DE TRATAMIENTO DE UNA INFECCION MICROBIA- NA QUE COMPRENDE LA ADMINSITRACION DE AZITROMICINA EN DICHA FORMA DE DOSIFICACION DE LIBERACION CON- TROLADA A UN MAMIFERO, INCLUYENDO A UN HUMANO, EN NECESIDAD DE DICHO TRATAMIENTO. FIGURA 1",PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/029-744-729-438-926,Patent Application,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,PENDING
634,DK,T3,DK 0758244 T3,123-272-944-577-19X,2002-02-11,2002,DK 95913923 T,1995-04-13,IB 9500264 W;;US 23909494 A,1994-05-06,Doseringsformer af azithromycin med styret frigivelse,,PFIZER,CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;KORSMEYER RICHARD W;;LE MOTT STEVEN R,,https://lens.org/123-272-944-577-19X,Granted Patent,no,0,0,69,69,0,A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073;;A61K31/7048;;A61P31/00;;A61P31/04;;A61K31/70;;A61K9/20;;A61K9/28;;A61K9/00;;A61K31/7048;;A61K9/0004;;A61K9/2054;;A61K9/5047;;A61K9/5073,C07H15/252;;A61K/;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/50;;A61K31/00;;A61K31/70;;A61K31/7016;;A61K31/7028;;A61K31/7034;;A61K31/704;;A61K31/7048;;A61K47/30;;A61P31/00;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
635,US,A1,US 2022/0330948 A1,006-731-271-579-85X,2022-10-20,2022,US 202217716073 A,2022-04-08,US 202217716073 A;;US 202163177052 P,2021-04-20,"OCCLUSIVE MATERIAL FOR MEDICAL DEVICE, SYSTEM, AND METHOD THEREOF","Medical devices, systems and methods for forming an occlusive material for occluding a left atrial appendage of a heart are provided. In one embodiment, the occlusive material includes a foam portion that extends as a single piece, seamless monolithic structure that is sized to couple to an external side of a framework of a medical device. In another embodiment, the occlusive material may include a polymeric laminate. Such polymeric laminate may be adhered to an outer side of the foam portion. Further, various embodiments for forming a polymer laminate are provided.",COHEREX MEDICAL INC,LEE SUNG K;;LEE ANNABEL;;DITTER TOM;;TAYLOR WILLIAM J Z;;FRIEDMAN ROBERT S,COHEREX MEDICAL INC (2022-04-12),https://lens.org/006-731-271-579-85X,Patent Application,yes,3,2,1,5,0,A61B17/12122;;A61B2017/1205;;A61B17/12172;;A61B17/12177;;A61B2017/00526;;A61B17/12122;;A61B2017/00575;;A61B17/12172;;A61B17/0057,A61B17/12;;A61B17/00,,0,0,,,,PENDING
636,EP,A1,EP 1214306 A1,049-159-813-657-580,2002-06-19,2002,EP 00962671 A,2000-09-15,GB 0003545 W;;GB 9922179 A;;GB 0009267 A,1999-09-21,LIQUID CRYSTAL COMPOUNDS,,QINETIQ LTD,GOODBY JOHN WILLIAM;;TOYNE KENNETH JOHNSON;;HIRD MICHAEL;;FRIEDMAN MARK RICHARD;;JONES JOHN CLIFFORD,,https://lens.org/049-159-813-657-580,Patent Application,yes,0,0,3,5,0,C07D307/79;;C07D307/83;;C07D307/84;;C07D333/70;;C07D405/04;;C09K19/3466;;C09K19/3491;;C09K2019/3408,G02F1/13;;C07D307/79;;C07D307/83;;C07D307/84;;C07D307/85;;C07D333/70;;C07D405/04;;C09K19/34,,1,0,,,See references of WO 0121606A1,DISCONTINUED
637,WO,A2,WO 2023/147087 A2,111-515-220-187-573,2023-08-03,2023,US 2023/0011785 W,2023-01-27,US 202263304607 P,2022-01-29,SYSTEM AND METHOD FOR DISPENSING AND MIXING A FOOD AND BEVERAGE PRODUCT,An apparatus and system for dispensing a food and beverage product where a flowable product is extracted from a flexible pouch and where an opening exists through which the flowable product evacuates the flexible pouch. The opening has a lock seal that locks the flowable product within the flexible pouch when a pressure is applied to the flexible pouch. There is also a zip seal located in the opening that is configured to lock the flowable product within the flexible pouch after the lock seal has been removed when pressure is applied to the flexible pouch.,PLANT TAP LLC,SUH WILLIAM D;;LEWIS DANIEL T;;SAVINO JOSEPH CAMILLO;;FRIEDMAN LENNIE;;TOLWIN SHLOMO ARI,,https://lens.org/111-515-220-187-573,Patent Application,yes,0,0,2,15,0,B01F23/41;;B01F27/808;;B01F27/88;;A47J31/407;;B01F33/5014;;A23L2/52;;A23C11/00;;B67D1/0001;;B67D1/0462;;B67D1/0888;;B67D1/12;;B67D1/0028;;B67D1/0032;;B67D1/0047;;B67D1/0804;;B67D1/0857;;B67D1/0894;;B67D1/1218;;B67D2001/0091;;B67D2001/0098;;B67D2001/0811;;B67D2001/0814;;B67D2001/0828;;B67D2210/0001;;B67D2210/00031;;G07F9/105;;G07F13/065;;G07F17/0064,B01F23/41,,0,0,,,,PENDING
638,CA,A1,CA 2744704 A1,172-327-119-362-765,2010-06-17,2010,CA 2744704 A,2009-11-25,US 20017208 P;;US 20375808 P;;US 20963509 P;;US 2009/0065923 W,2008-11-25,"DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF SLEEP APNEA","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,,https://lens.org/172-327-119-362-765,Patent Application,no,0,0,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56,,0,0,,,,ACTIVE
639,EP,A1,EP 2349140 A1,022-982-775-299-647,2011-08-03,2011,EP 09832364 A,2009-11-25,US 2009/0065923 W;;US 20963509 P;;US 20017208 P;;US 20375808 P,2008-11-25,MEDICAL DEVICE FOR A PATIENT,,LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,,https://lens.org/022-982-775-299-647,Patent Application,yes,0,0,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56,,0,0,,,,ACTIVE
640,IL,A,IL 307862 A,178-817-304-866-498,2023-12-01,2023,IL 30786223 A,2023-10-19,US 202163177052 P;;US 202217716073 A;;IB 2022053611 W,2021-04-20,"Occlusive material for medical device, system, and method thereof",,COHEREX MEDICAL INC;;LEE SUNG K;;LEE ANNABEL;;DITTER TOM;;TAYLOR WILLIAM J Z;;FRIEDMAN ROBERT S,LEE SUNG K;;LEE ANNABEL;;DITTER TOM;;TAYLOR WILLIAM J Z;;FRIEDMAN ROBERT S,,https://lens.org/178-817-304-866-498,Patent Application,no,0,0,3,5,0,A61B17/12122;;A61B17/12177;;A61B17/12172;;A61B2017/00526;;A61B17/12122;;A61B17/12172;;A61B17/12177;;A61B2017/00526,A61B17/00;;A61B17/12,,0,0,,,,PENDING
641,US,A1,US 2011/0226264 A1,188-116-612-722-008,2011-09-22,2011,US 200913130869 A,2009-11-25,US 200913130869 A;;US 20017208 P;;US 20375808 P;;US 20963509 P;;US 2009/0065923 W,2008-11-25,"DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF SLEEP APNEA","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",FRIEDMAN MICHAEL;;IRWIN JOHN J;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,FRIEDMAN MICHAEL;;IRWIN JOHN J;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,LUMEN DEVICES LLC (2010-03-12),https://lens.org/188-116-612-722-008,Patent Application,yes,12,44,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56,128/848,0,0,,,,ACTIVE
642,CA,C,CA 2911748 C,055-385-450-775-360,2018-11-06,2018,CA 2911748 A,2009-11-25,US 20017208 P;;US 20375808 P;;US 20963509 P;;CA 2744704 A,2008-11-25,"DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF SLEEP APNEA","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,,https://lens.org/055-385-450-775-360,Granted Patent,no,0,0,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56,,0,0,,,,ACTIVE
643,US,B2,US 9707126 B2,000-928-412-981-844,2017-07-18,2017,US 201213665495 A,2012-10-31,US 201213665495 A;;US 90922810 A;;US 25373609 P;;US 201261699226 P;;US 201261671798 P,2009-10-21,Systems and methods for corneal cross-linking with pulsed light,"A method for controlling activation of Riboflavin applied to an eye includes applying the Riboflavin to a selected region of a cornea of the eye and initiating cross-linking activity in the selected region by activating the Riboflavin with pulsed light illumination. The pulsed light illumination has an irradiance, dose, and an on/off duty cycle. The irradiance, the dose, and the on/off duty cycle are adjusted in response to a determination of photochemical kinetic pathways for Riboflavin cross-linking activity and to control photochemical efficiency.",AVEDRO INC,FRIEDMAN MARC D;;KAMAEV PAVEL;;SHERR EVAN;;EDDINGTON WILLIAM;;ROOD-OJALVO SARA;;MULLER DAVID,AVEDRO INC (2013-01-31),https://lens.org/000-928-412-981-844,Granted Patent,yes,240,15,14,27,0,A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61K31/525;;A61F9/0008;;A61P27/10;;A61K31/525;;A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61F9/0008,A61M37/00;;A61F9/00;;A61F9/007;;A61F9/008;;A61F9/013;;A61K31/525;;A61K41/00;;A61N5/06,,109,75,025-145-871-483-285;;079-223-349-038-496;;078-582-516-506-84X;;050-659-417-825-796;;058-396-261-852-42X;;031-951-025-920-400;;024-433-252-581-636;;091-405-567-936-990;;003-590-578-739-058;;059-998-718-973-876;;009-139-125-944-464;;074-465-466-043-075;;025-358-884-642-811;;121-102-227-128-987;;060-845-613-700-538;;001-657-005-458-321;;027-760-743-636-184;;019-498-712-391-89X;;124-373-916-529-595;;020-513-459-942-472;;002-815-968-975-61X;;026-145-447-386-001;;000-320-297-659-706;;045-350-281-152-978;;010-346-167-225-887;;000-310-730-091-72X;;024-067-377-256-67X;;017-794-216-203-013;;004-261-073-890-958;;034-659-786-497-185;;050-521-998-142-755;;026-822-038-587-078;;058-971-025-531-657;;052-494-322-721-935;;020-941-553-246-837;;090-697-587-451-57X;;100-125-824-768-739;;074-506-854-081-055;;019-053-567-239-215;;020-266-521-561-465;;025-145-871-483-285;;027-980-370-663-79X;;154-008-544-694-217;;114-203-961-656-564;;139-063-259-346-473;;029-300-368-667-864;;023-465-584-107-615;;000-410-543-137-209;;020-620-616-680-52X;;080-374-751-252-101;;093-412-774-954-903;;010-553-409-184-179;;018-135-504-358-607;;095-655-905-657-941;;008-349-319-736-013;;021-726-002-847-42X;;004-758-386-490-65X;;015-710-886-922-945;;026-217-922-922-425;;129-647-388-907-165;;067-870-398-931-753;;030-786-054-939-829;;029-808-187-424-684;;057-009-769-557-641;;004-898-834-572-486;;033-513-993-800-37X;;015-881-453-955-537;;035-798-317-253-731;;050-183-377-154-850;;138-295-607-486-947;;045-801-777-979-821;;025-752-963-652-861;;029-873-524-928-041;;040-885-868-657-472;;024-842-394-595-731,10.1167/iovs.11-9385;;22427580;;15106954;;10.1016/s0014-4835(03)00215-x;;10.1016/j.jcrs.2009.03.035;;19631120;;10.17925/eor.2009.03.02.67;;18952911;;10.1167/iovs.08-1960;;20954581;;10.3928/1081597x-20100930-01;;pmc3075647;;21335557;;10.1074/jbc.m110.169813;;12929744;;10.1562/0031-8655(2003)078<0023:apdcaf>2.0.co;2;;10.1562/0031-8655(2003)0780023apdcaf2.0.co2;;10.1364/oe.19.010153;;21643273;;10.1364/ol.37.001625;;22627517;;22076271;;10.1364/boe.2.003109;;pmc3207379;;10.1016/s0886-3350(03)00407-3;;14522301;;10.1167/iovs.09-3669;;19516010;;7216676;;1898043;;10.1016/0003-9861(91)90223-6;;22792444;;10.1155/2012/303459;;pmc3391900;;10.3928/1081597x-20090901-02;;19731884;;10.1007/978-0-387-73906-9_13;;22167358;;10.1055/s-0031-1281952;;pmc3149515;;10.1364/boe.2.002144;;21833354;;22159012;;10.1167/iovs.11-8281;;pmc3292356;;10.1016/s0032-3861(99)00832-0;;10.1167/iovs.05-1504;;17003420;;17068461;;10.1097/01.ico.0000220769.19402.86;;pmc1518628;;16751234;;10.1529/biophysj.106.082388;;4310146;;10.1016/0006-291x(69)90288-5;;10.1109/10.983453;;11876285;;14686588;;10.1007/bf02349970;;9125305;;10.1016/s0021-9150(96)05947-3;;10.1167/iovs.10-7105;;21508101;;pmc3175975;;18640085;;10.1016/j.actbio.2008.06.007;;1508020;;10.1002/lsm.1900120305;;10.1006/exer.2000.0959;;11180974;;10.3928/1081597x-20090401-02;;19431928;;2243004;;21303258;;10.1089/ten.tec.2010.0368;;pmc3065732;;13898430;;pmc1243559;;10.1042/bj0830368;;10.1167/iovs.08-1724;;18676633;;19304080;;10.1016/j.jcrs.2008.10.060;;17265796;;10.1167/iovs.11-9385;;22427580;;20207972;;10.1167/iovs.09-4524;;20673048;;10.3109/02713683.2010.481068;;17846959;;10.1055/s-2007-963492;;10.1016/s0021-9258(17)31664-2;;8077188;;10.1136/bjo.85.4.437;;pmc1723934;;11264134;;11006222;;16765788;;10.1016/j.jcrs.2006.01.062;;17960755;;10.1002/lsm.20548;;16129286;;10.1016/j.jcrs.2005.01.032;;10.1016/j.jcrs.2009.01.022;;19465292;;10.1167/iovs.03-1066;;15223792;;10.3928/1081597x-20080901-20;;18811123;;18811120;;10.3928/1081597x-20080901-15;;10.3928/1081597x-20080901-17;;18811118;;1959777;;10.1159/000213267;;21317670;;10.1097/opx.0b013e31820f1585;;7041308;;10.1016/0039-6257(82)90081-9;;4293497;;10.1111/j.1751-1097.1967.tb08735.x;;16431951;;10.1167/iovs.05-0889;;9487761;;10.1007/s003470050219;;10.1006/exer.1997.0410;;9533835;;10.3928/1081-597x-19991101-21;;10590015;;10.1097/ico.0b013e3180334f78;;17457183;;11758987;;10.3928/1081-597x-20011101-08;;10.1038/382275a0;;8717046;;11822407;;10.1002/1529-0131(200201)46:1<114::aid-art10025>3.0.co;2-p;;10.1016/j.jcrs.2003.11.032;;15050269;;12719068;;10.1016/s0002-9394(02)02220-1;;10.1111/j.1600-0420.2005.00447.x;;16029274;;16900027;;10.1097/01.icu.0000233954.86723.25;;10.1016/j.jcrs.2006.11.015;;17321404;;19251149;;10.1016/j.jcrs.2008.11.036;;10.1167/iovs.07-0349;;pmc2764532;;17898283;;10.1021/j100699a032;;10.7863/jum.2004.23.10.1349;;15448325;;15502482;;10.1097/01.ico.0000134189.33549.cc,"Kamaev et al. (“Photochemical Kinetics of Corneal Cross-Linking with Riboflavin”, Investigative Ophthalmology & Visual Science, Apr. 2012, vol. 53, No. 4).;;Frucht-Pery, et al. “Iontophoresis—gentamicin delivery into the rabbit cornea, using a hydrogel delivery probe,” Jun. 20, 2003 (5 pages).;;International Search Report and Written Opinion mailed Feb. 6, 2014 which issued in International Patent Application No. PCT/US2013/068588 (6 pages).;;Koller, T. et. Al., “Complication and failure rates after corneal crosslinking,” Journal Cataract and refractive surgery, vol. 35, No. 8, Aug. 2009, pp. 1358-1362.;;Averianova, O. S., “Nastoyaschee I buduschee kross-linkage.” Mir Ofalmologii, 2010, [online] [retrieved on Feb. 13, 2014] Retrieved from the internet: http://miroft.org.ua/publications/.html (3 pages).;;Marzouky, et. al., Tensioactive-mediated Transepithelial Corneal Cross-linking—First Laboratory Report, European Ophthalmic Review, 2009, 3(2), pp. 67-70.;;O.V. Shilenskaya et al., “Vtorichnaya katarakta posle implantatsii myagkikh IOL,” [online] Aug. 21, 2008 [retrieved Mar. 4, 2013] Retrieved from the Internet: <URL:http://www.reper.ru/rus/index.php?catid=210> (4 pages).;;Thorton, I. et. al., “Biomechancial Effects of Intraocular Pressure Elevation on Optic Berve/Lamina Cribrosa before and after Peripapillary Scleral Collagen Cross-Linking.” Invest. Ophthalm,ol. Vis. Sci., Mar. 2009, 50(3): pp. 1227-1233.;;Zhang, Y. et al., “Effect of the Synthetic NC-1059 Peptide on Diffusion of Riboflavin Across an Intact Corneal Epithelium”, May 6, 2012 ARBO 2012 Annual Meeting Abstract, 140 Stroma and Keratocytes, program No. 1073, poster board number: A109 (1 page).;;Kornilovsky, I. M. “Novye neinvazivnye tekhnologii lazernoy modifikatsii optiko-refraksionnykk struktur glaza. Refraktsionnaya khirurgiya I oftalmologiya.” vol. 9, No. 3, 2006 (pp. 17-26).;;Reinstein, D. Z. et al. “Epithelial Thickness Profile as a Method to Evaluate the Effectiveness of Collagen Cross-Linking Treatment After Corneal Ectasis.” Journal of Refractive Surgery. vol. 27, No. 5, May 2011 (pp. 356-363). [Abstract only].;;International Search Report and Written Opinion mailed Jul. 18, 2013 which issued in International Patent Application No. PCT/US2013/032567 (6 pages).;;Zang, Y. et al., “Effects of Ultraviolet—A and Riboflavin on the Interaction of Collagen and Proteoglycans during Corneal Cross-linking”, Journal of Biological Chemistry, vol. 286, No. 15, dated Apr. 15, 2011 (pp. 13011-13022).;;Search report and written opinion for Int'l Appl. No. PCT/US2012/062843, dated Apr. 11, 2013 (8 pages).;;Givens et al. “A Photoactivated Diazpryruvoyl Cross-Linking Agent for Bonding Tissue Containing Type-I Collagen.” Photochemistry and Photobiology. vol. 78, No. 1, 2003 (pp. 23-29).;;Nesterov, A. P. “Transpalpebralny Tonometr Dlya Izmereniya Vnutriglaznogo Davleniya.” Feb. 2, 2006. [online] [Retrieved Dec. 17, 2012] Retrieved from the Internet: <URL: http://grpz.ru/images/publication—pdf/27.pdf>.;;International Search Report and Written Opinion mailed Dec. 21, 2010 which issued in corresponding International Patent Application No. PCT/US2010/053551 (14 pages).;;Li, C. et al. “Elastic Properties of Soft Tissue-Mimicking Phantoms Assessed by Combined Use of Laser Ultrasonics and Low Coherence Interferometry.” Optics Express. vol. 19, No. 11, May 9, 2011 (pp. 10153-10163).;;Li, C. et al. “Noncontact All-Optical Measurement of Corneal Elasticity.” Optics Letters. vol. 37, No. 10, May 15, 2012 (pp. 1625-1627).;;Li, P. et al. “In Vivo Microstructural and Microvascular Imaging of the Human Corneo-Scleral Limbus Using Optical Coherence Tomography.” Biomedical Optics Express. vol. 2, No. 11, Oct. 18, 2011 (pp. 3109-3118).;;Pinelli, R. “Corneal Cross-Linking with Riboflavin: Entering a New Era in Ophthalmology.” Ophthalmology Times Europe. vol. 2, No. 7, Sep. 1, 2006 (3 pages).;;Wollensak, G. et al. “Laboratory Science: Stress-Strain Measurements of Human and Porcine Corneas after Riboflavin-Ultraviolet-A-Induced Cross-Linking.” Journal of Cataract and Refractive Surgery. vol. 29, No. 9, Sep. 2003 (pp. 1780-1785).;;Abahussin, M. “3D Collagen Orientation Study of the Human Cornea Using X-ray Diffraction and Femtosecond Laser Technology” Investigative Ophthalmology & Visual Science, Nov. 2009, vol. 50, No. 11, pp. 5159-5164 (6 pages).;;Barbarino, S. et al., “Post-LASIK ectasia: Stabilization and Effective Management with Riboflavin / ultraviolet A-induced collagen cross-linking,” Association for Research in Vision and Ophthalmology, 2006 (1 page).;;Burke, JM et al., Abstract for “Retinal proliferation in response to vitreous hemoglobin or iron”, Investigative Ophthalmology & Visual Science, May 1981, 20(5), pp. 582-592 (1 page).;;Chace, KV. et al., Abstract for “The role of nonenzymatic glycosylation, transition metals, and free radicals in the formation of collagen aggregates”, Arch Biochem Biophys., Aug. 1, 1991, 288(2), pp. 473-480 (1 page).;;Friedman, M. et al. “Advanced Corneal Cross-Linking System with Fluorescence Dosimetry”, Journal of Ophthalmology, vol. 2012, Article ID 303459, dated May 7, 2012 (6 pages).;;Kanellopoulos, A. J., “Collagen Cross-linking in Early Keratoconus With Riboflavin in a Femtosecond Laser-created Pocket: Initial Clinical Results”, Journal of Refractive Surgery, Aug. 18, 2009.;;Kanellopoulos, A. J., “Keratoconus management: UVA-induced collagen cross-linking followed by a limited topo-guided surface excimer ablation,” American Academy of Ophthalmology, 2006 (25 pages).;;Kanellopoulos, A. J., “Ultraviolet a cornea collagen cross-linking, as a pre-treatment for surface excimer ablation in the management of keratoconus and post-LASIK ectasia,” American Academy of Ophthalmology, 2005 (28 pages).;;Meek, K.M. et al. “The Cornea and Sclera”, Collagen: Structure and Mechanics, Chapter 13, pp. 359-396, 2008 (38 pages).;;Pinelli, R., “Panel Discussion: Epithelium On/Off, Corneal abrasion for CCL contra”, presented at the 3° International Congress of Corneal Cross Linking on Dec. 7-8, 2007 in Zurich (36 pages).;;Pinelli R., “Resultados de la Sociedad de Cirugia Refractiva Italiana (SICR) utilizando el C3-R” presented at the Istitutor Laser Microchirurgia Oculare in 2007 in Italy (23 pages).;;Pinelli R., “The Italian Refractive Surgery Society (SICR) results using C3-R” presented Jun. 22-23, 2007 in Italy (13 pages).;;Randall, J. et al., “The Measurementand Intrepretation of Brillouin Scattering in the Lens of the Eye,” The Royal Society, Abstract only, published 2013 [available online at http://rspb.royalsocietypublishing.org/content/214/1197/449.short] (1 page).;;Reiss, S. et al., “Non-Invasive, ortsaufgeloeste Bestimmung von Gewebeeigenschaften derAugenlinse, Dichte undProteinkonzentration unter Anwendung der Brillouin-spektroskopie”, Klin Monatsbl Augenheilkd, vol. 228, No. 12, pp. 1079-1085, Dec. 13, 2011 (7 pages).;;Reiss, S. et al., “Spatially resolved Brillouin Spectroscopy to determine the rheological properties of the eye lens”, Biomedical Optics Express, vol. 2, No. 8, p. 2144, Aug. 1, 2011 (1 page).;;Scarcelli, G. et al., “Brillouin Optical Microscopy for Corneal Biomechanics”, Investigative Ophthalmology & Visual Science, Jan. 2012, vol. 53, No. 1, pp. 185-190 (6 pages).;;Sun, G.J. et al., Abstract for “Properties of 2,3-butanedione and 1-phenyl-1,2-propanedione as new photosensitizers for visible light cured dental resin composites”, Polymer 41, pp. 6205-6212, published in 2000 (1 page).;;Tomlinson, A. “Tear Film Osmolarity: Determination of a Referent for Dry Eye Diagnosis”, Investigative Ophthalmology & Visual Science, Oct. 2006, vol. 47, No. 10, pp. 4309-4315 (7 pages).;;Turgunbaev N. A. et al. Fotomodifikatsiya sklery u bolnykh s progressiruyuschei blizorukostyu (predvaritelnoe soobschenie). 2010 [online] Retrieved from the Internet:<URL: http://www.eyepress.ru/article.aspx?7484>(2 pages).;;Wong, J. et al., “Post-Lasik ectasia: PRK following previous stablization and effective management with Riboflavin / ultraviolet A-induced collagen cross-linking,” Association for Research in Vision and Ophthalmology, 2006 (1 page).;;Acosta A. et al., “Corneal Stroma Regeneration in Felines After Supradescemetic Keratoprothesis Implantation,” Cornea, vol. 25, No. 7, pp. 830-838; Aug. 2006 (9 pages).;;Baier J. et al., “Singlet Oxygen Generation by UVA Light Exposure of Endogenous Photosensitizers,” Biophysical Journal, vol. 91(4), pp. 1452-1459; Aug. 15, 2006 (8 pages).;;Ballou, D. et al., “Direct Demonstration of Superoxide Anion Production During The Oxidation of Reduced Flavin and of Its Catalytic Decomposition by Erythrocuprein,” Biochemical and Biophysical Research Communications vol. 36, No. 6, pp. 898-904, Jul. 11, 1969 (7 pages).;;Berjano E., et al., “Radio-Frequency Heating of the Cornea: Theoretical Model and in Vitro Experiments,” IEEE Transactions on Biomedical Engineering, vol. 49, No. 3, pp. 196-205; Mar. 2002 (10 pages).;;Berjano E., et al., “Ring Electrode for Radio-frequency Heating of the Cornea: Modelling and in vitro Experiments,” Medical & Biological Engineering & Computing, vol. 41, pp. 630-639; Jun. 2003 (10 pages).;;Brüel, A., “Changes in Biomechanical Properties, Composition of Collagen and Elastin, and Advanced Glycation Endproducts of The Rat Aorta in Relation to Age,” Atherosclerosis 127, Mar. 14, 1996 (11 pages).;;Chai, D. et al., “Quantitative Assessment of UVA-Riboflavin Corneal Cross-Linking Using Nonlinear Optical Microscopy,” Investigative Ophthalmology & Visual Science, Jun. 2011, vol. 52, No. 7, 4231-4238 (8 pages).;;Chan B.P., et al., “Effects of photochemical crosslinking on the microstructure of collagen and a feasibility study on controlled protein release;” Acta Biomaterialia, vol. 4, Issue 6, pp. 1627-1636; Jul. 1, 2008 (10 pages).;;Chandonnet, “CO2 Laser Annular Thermokeratoplasty: A Preliminary Study,” Lasers in Surgery and Medicine, vol. 12, pp. 264-273; 1992 (10 pages).;;Clinical Trials.gov, “Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus (CCL),” University Hospital Freiburg, Feb. 20, 2008; retrieved from http://www.clinicaltrials.gov/ct2/show/NCT00626717, on Apr. 26, 2011 (3 pages).;;Corbett M., et al., “Effect of Collagenase Inhibitors on Corneal Haze after PRK,” Exp. Eye Res., vol. 72, Issue 3, pp. 253-259; Jan. 2001 (7 pages).;;Coskenseven E. et al., “Comparative Study of Corneal Collagen Cross-linking With Riboflaving and UVA Irradiation in Patients With Keratoconus,” Journal of Refractive Surgery, vol. 25, issue 4, pp. 371-376; Apr. 2009 (6 pages).;;“Definity (perflutren) injection, suspension [Bristol-Myers Squibb Medical Imaging],” http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8338, revised Sep. 2008, retrieved via the internet archive from http://web.archive.org/web/20100321105500/http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8338, on Dec. 14, 2011 (15 pages).;;Ehlers W., et al., “Factors Affecting Therapeutic Concentration of Topical Aminocaproic Acid in Traumatic Hyphema,” Investigative Ophthalmology & Visual Science, vol. 31, No. 11, pp. 2389-2394; Nov. 1990 (6 pages).;;Erskine H., “Avedro Becomes Sponsor of US FDA Clinical Trials of Corneal Collagen Crosslinking,” Press Release, Mar. 16, 2010 (1 page).;;Fite et al. Noninvasive Multimodal Evaluation of Bioengineered Cartilage Constructs Combining Time-Resolved Fluorescence and Ultrasound Imaging. Tissue Eng: Part C vol. 17, No. 4, 2011 (10 pages).;;Gibson, Q. et al., “The Oxidation of Reduced Flavin Mononucleotide by Molecular Oxygen,” Biochem. J. (1962) 83, 368-377 (10 pages).;;Glenn J.V., et al., “Advanced Glycation End Product (AGE) Accumulation on Bruch's Membrane: Links to Age-Related RPE Dysfunction;” Investigative Ophthalmology & Visual Science, vol. 50, No. 1, pp. 441-451; Jan. 2009 (11 pages).;;Gravitz L., “Laser Show in the Surgical Suite: Lasers and a century-old dye could supplant needles and thread;” technology review, MIT, Mar./Apr. 2009; retrieved from http://www.technologyreview.com/biomedicine/22088/?nlid=1767, on Sep. 26, 2011 (2 pages).;;Hafezi F., et al., “Collagen Crosslinking with Ultraviolet-A and Hypoosmolar Riboflavin Solution in Thin Corneas,” J. Catract Refract. Surg., vol. 35, No. 1, pp. 621-624; Apr. 2009 (4 pages).;;Hitzenberger et al., “Birefringence Properties of the Human Cornea Measured With Polarization Sensitive Optical Coherence Tomography,” Bull. Soc. Beige Ophtalmol., 302, 153-168, 2006 (16 pages).;;Holmström, B. et al., “Riboflavin as an Electron Donor in Photochemical Reactions,” 1867-1871, Nov. 29, 1960 (5 pages).;;How to Use Definity: “Frequently Asked Questions;” retrieved from http://www.definityimaging.com/how-faq.html, on Sep. 26, 2011 (date unknown, prior to Apr. 26, 2010) (3 pages).;;IMEX, “KXL System: Crosslinking Para Cirugia Corneal Bibliografia Cientifica,” Product Literature, Nov. 23, 2010 (24 pages).;;Kamaev et al., “Photochemical Kinetics of Corneal Cross-Linking With Riboflavin,” Investigative Ophthalmology & Visual Science, Apr. 2012, vol. 53, No. 4, pp. 2360-2367 (8 pages).;;Kampik D. et al., “Influence of Corneal Collagen Crosslinking With Riboflavin and Ultraviolet-A Irradiation on Excimer Laser Surgery,” Investigative Opthalmology & Visual Science, vol. 51, No. 8, pp. 3929-3934; Aug. 2010 (6 pages).;;Kissner Anja, et al., “Pharmacological Modification of the Epithelial Permeability by Benzalkonium Chloride in UVA/Riboflavin Corneal Collagen Cross-Linking,” Current Eye Research 35(8), pp. 715-721; Mar. 2010 (7 pages).;;Koller T., et al., “Therapeutische Quervernetzung der Hornhaut mittels UVA and Riboflavin: Therapeutic Cross-Linking of the Cornea Using Riboflavin/UVA,” Klinische Monatsblätter für Augenheilkunde, vol. 224, No. 9, pp. 700-706; Sep. 2007 (7 pages).;;Krueger, Ronald R., “Rapid VS Standard Collagen CXL with Equivalent Energy Dosing,” presentation slides, (26 pages); available at http://www.slideshare.net/logen/krueger-herekar-rapid-cross-linking (date unknown, prior to Nov. 9, 2009).;;Krueger, R. et al., “Rapid vs. Standard Collagen CXL With Equivalent Energy Dosing,” posted Nov. 9, 2009 (26 pages).;;Massey, V., “Activation of Molecular Oxygen by Flavins and Flavoproteins,” The Journal of Biological Chemistry vol. 269, No. 36, Issue of Sep. 9, pp. 22459-22462, 1994 (4 pages).;;Mi S., et al., “The adhesion of LASIK-like flaps in the cornea: effects of cross-linking, stromal fibroblasts and cytokine treatment,” presented at British Society for Matrix Biology annual Meeting, Cardiff, UK, Sep. 8-9, 2008 (17 pages).;;Muller L., et al., “The Specific Architecture of the Anterior Stroma Accounts for Maintenance of Corneal Curvature,” Br. J. Opthalmol., vol. 85, pp. 437-443; Apr. 2001 (8 pages).;;Mulroy L., et al., “Photochemical Keratodesmos for repair of Lamellar corneal Incisions;” Investigative Ophthalmology & Visual Science, vol. 41, No. 11, pp. 3335-3340; Oct. 2000 (6 pages).;;Naoumidi T., et al., “Two-Year Follow-up of Conductive Keratoplasty for the Treatment of Hyperopic Astigmatism,” J. Cataract Refract. Surg., vol. 32(5), pp. 732-741; May 2006 (10 pages).;;O'Neil A.C., et al., “Microvascular Anastomosis Using a Photochemical Tissue Bonding Technique;” Lasers in Surgery and Medicine, vol. 39, Issue 9, pp. 716-722; Oct. 2007 (7 pages).;;Paddock C., Medical News Today: “Metastatic Melanoma PV-10 Trial Results Encouraging Says Drug Company;” Jun. 9, 2009; retrieved from http://www.medicalnewstoday.com/articles/153024.php, on Sep. 26, 2011 (2 pages).;;Pallikaris I., et al., “Long-term Results of Conductive Keratoplasty for low to Moderate Hyperopia,” J. Cataract Refract. Surg., vol. 31(8), pp. 1520-1529; Aug. 2005 (10 pages).;;Pinelli R., et al., “C3-Riboflaving Treatments: Where Did We Come From? Where Are We Now?” Cataract & Refractive Surgery Today Europe, Summer 2007, pp. 36-46; Jun. 2007 (10 pages).;;Ponce C., et al., “Central and Peripheral Corneal Thickness Measured with Optical Coherence Tomography, Scheimpflug Imaging, and Ultrasound Pachymetry in Normal, Keratoconus-suspect and Post-laser in situ Keratomileusis Eyes,” J. Cataract Refract. Surgery, vol. 35, No. 6, pp. 1055-1062; Jun. 2009 (8 pages).;;Proano C.E., et al., “Photochemical Keratodesmos for Bonding Corneal Incisions;” Investigative Ophthalmology & Visual Science, vol. 45, No. 7, pp. 2177-2181; Jul. 2004 (5 pages).;;Rocha K., et al., “Comparative Study of Riboflavin-UVA Cross-linking and “Flash-linking” Using Surface Wave Elastometry,” Journal of Refractive Surgery, vol. 24 Issue 7, pp. S748-S751; Sep. 2008 (4 pages).;;Rolandi et al. Correlation of Collagen-Linked Fluorescence and Tendon Fiber Breaking Time. Gerontology 1991;27:240-243 (4 pages).;;RxList: “Definity Drug Description;” The Internet Drug Index, revised Jun. 16, 2008, retrieved from http://www.rxlist.com/definity-drug.htm, on Sep. 26, 2011 (4 pages).;;Sheehan M., et al., “Illumination System for Corneal Collagen Crosslinking,” Optometry and Vision Science, vol. 88, No. 4, pp. 512-524; Apr. 2011 (13 pages).;;Shell, J., “Pharmacokinetics of Topically Applied Ophthalmic Drugs,” Survey of Ophthalmology, vol. 26, No. 4, pp. 207-218; Jan.-Feb. 1982 (12 pages).;;Song P., Metzler D. Photochemical Degradation of Flavins—IV. Studies of the Anaerobic Photolysis of Riboflavin. Photochemistry and Photobiology, vol. 6, pp. 691-709, 1967 (21 pages).;;Sonoda S., “Gene Transfer to Corneal Epithelium and Keratocytes Mediated by Ultrasound with Microbubbles,” Investigative Ophthalmology & Visual Science, vol. 47, No. 2, pp. 558-564; Feb. 2006 (7 pages).;;Spoerl E., et al., “Artificial Stiffening of the Cornea by Induction of Intrastromal Cross-links,” Der Ophthalmologe, vol. 94, No. 12, pp. 902-906; Dec. 1997 (5 pages).;;Spoerl E., et al., “Induction of Cross-links in Corneal Tissue,” Experimental Eye Research, vol. 66, Issue 1, pp. 97-103; Jan. 1998 (7 pages).;;Spoerl E., et al., “Techniques for Stiffening the Cornea,” Journal of Refractive Surgery, vol. 15, Issue 6, pp. 711-713; Nov.-Dec. 1999 (4 pages).;;Spoerl E. et al., “Safety of UVA-Riboflavin Cross-Linking of the Cornea,” Cornea, vol. 26, No. 4, pp. 385-389; May 2007 (5 pages).;;Tessier FJ, et al., “Rigidification of Corneas Treated in vitro with Glyceraldehyde: Characterization of Two Novel Crosslinks and Two Chromophores,” Investigative Opthalmology & Visual Science, vol. 43, E-Abstract; 2002 (2 pages).;;Trembly et al., “Microwave Thermal Keratoplasty for Myopia: Keratoscopic Evaluation in Porcine Eyes,” Journal of Refractive Surgery, vol. 17, No. 6, pp. 682-688; Nov./Dec. 2001 (8 pages).;;“UV-X: Radiation System for Treatment of Keratokonus,” PESCHKE Meditrade GmbH; retrieved from http://www.peschkemed.ch/ on Sep. 27, 2011 (date unknown, prior to Sep. 16, 2008) (1 page).;;Vasan S., et al., “An agent cleaving glucose-derived protein crosslinks in vitro and in vivo;” Letters to Nature, vol. 382, pp. 275-278; Jul. 18, 1996 (4 pages).;;Verzijl et al. Crosslinking by Advanced Glycation End Products Increases the Stiffness of the Collagen Network in Human Articular Cartilage. Arthritis & Rheumatism vol. 46, No. 1, Jan. 2002, pp. 114-123 (10 pages).;;Wollensak G., et al., “Collagen Crosslinking of Human and Porcine Sclera,” J. Cataract Refract. Surg., vol. 30, Issue 3, pp. 689-695; Mar. 2004 (7 pages).;;Wollensak G., et al., “Riboflavin/Ultraviolet-A-induced Collagen Crosslinking for the Treatment of Keratoconus,” American Journal of Ophthalmology, vol. 135, No. 5, pp. 620-627; May 2003 (8 pages).;;Wollensak G., et al., “Cross-linking of Scleral Collagen in the Rabbit Using Riboflavin and UVA,” Acta Ophtalmologica Scandinavica, vol. 83(4), pp. 477-482; Aug. 2005 (6 pages).;;Wollensak G., “Crosslinking Treatment of Progressive Keratoconus: New Hope,” Current Opinion in Ophthalmology, vol. 17(4), pp. 356-360; Aug. 2006 (5 pages).;;Wollensak G., et al., “Hydration Behavior of Porcine Cornea Crosslinked with Riboflavin and Ultraviolet,” A.J. Cataract Refract. Surg., vol. 33, Issue 3, pp. 516-521; Mar. 2007 (6 pages).;;Wollensak G., et al., “Biomechanical and Histological Changes After Corneal Crosslinking With and Without Epithelial Debridement,” J. Cataract Refract. Surg., vol. 35, Issue 3, pp. 540-546; Mar. 2009 (7 pages).;;Yang H., et al., “3-D Histomorphometry of the Normal and Early Glaucomatous Monkey Optic Nerve Head: Lamina Cribrosa and Peripapillary Scleral Position and Thickness,” Investigative Ophthalmology & Visual Science, vol. 48, No. 10, pp. 4597-4607; Oct. 2007 (11 pages).;;Yang N., Oster G. Dye-sensitized photopolymerization in the presence of reversible oxygen carriers. J. Phys. Chem. 74, 856-860 (1970) (5 pages).;;Zderic V., et al., “Drug Delivery Into the Eye With the Use of Ultrasound,” J. Ultrasound Med, vol. 23(10), pp. 1349-1359; Oct. 2004 (11 pages).;;Zderic V., et al., “Ultrasound-enhanced Transcorneal Drug Delivery,” Cornea vol. 23, No. 8, pp. 804-811; Nov. 2004 (8 pages).",ACTIVE
644,AU,B2,AU 2009/324904 B2,054-803-363-460-283,2014-03-06,2014,AU 2009/324904 A,2009-11-25,US 20017208 P;;US 20375808 P;;US 20963509 P;;US 2009/0065923 W,2008-11-25,"Devices, systems and methods for the treatment of sleep apnea","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,,https://lens.org/054-803-363-460-283,Granted Patent,no,2,0,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56,,0,0,,,,INACTIVE
645,EP,A1,EP 4074294 A1,066-814-578-130-897,2022-10-19,2022,EP 22174910 A,2012-10-31,US 201261671798 P;;US 201261699226 P;;EP 12842319 A;;US 2012/0062843 W,2012-07-16,SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT,"A method for controlling activation of Riboflavin applied to an eye includes applying the Riboflavin to a selected region of a cornea of the eye and initiating cross-linking activity in the selected region by activating the Riboflavin with pulsed light illumination. The pulsed light illumination has an irradiance, dose, and an on/off duty cycle. The irradiance, the dose, and the on/off duty cyclc arc adjusted in response to a determination of photochemical kinetic pathways for Riboflavin cross-linking activity and to control photochemical efficiency.
",AVEDRO INC,FRIEDMAN MARC D;;KAMAEV PAVEL;;SHERR EVAN;;EDDINGTON WILLIAM;;ROOD-OJALVO SARA;;MULLER DAVID,,https://lens.org/066-814-578-130-897,Patent Application,yes,7,0,14,27,0,A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61K31/525;;A61F9/0008;;A61P27/10;;A61K31/525;;A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61F9/0008,A61F9/007;;A61B18/18;;A61F9/008;;A61N5/06,,9,9,025-145-871-483-285;;005-436-614-630-197;;139-063-259-346-473;;029-873-524-928-041;;034-659-786-497-185;;095-655-905-657-941;;090-697-587-451-57X;;004-898-834-572-486;;004-758-386-490-65X,10.1167/iovs.11-9385;;22427580;;10.1201/9781420014372;;10.1016/s0021-9258(17)31664-2;;8077188;;10.1021/j100699a032;;10.1167/iovs.10-7105;;21508101;;pmc3175975;;1959777;;10.1159/000213267;;21303258;;10.1089/ten.tec.2010.0368;;pmc3065732;;11822407;;10.1002/1529-0131(200201)46:1<114::aid-art10025>3.0.co;2-p;;4293497;;10.1111/j.1751-1097.1967.tb08735.x,"KAMAEV ET AL., INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 53, no. 4, 2012, pages 2360 - 2367;;HELDMAN ET AL.: ""Handbook of Food Engineering"", 2006, CRC PRESS;;MASSEY, V: ""Activation of molecular oxygen by flavins and flavoproteins"", J. BIOL. CHEM., vol. 269, 1994, pages 22459 - 22462;;YANG N.OSTER G: ""Dye-sensitized photopolymerization in the presence of reversible oxygen carriers"", J. PHYS. CHEM., vol. 74, 1970, pages 856 - 860;;CHAI ET AL.: ""Quantitative Assessment of UVA-Riboflavin Corneal Cross-Linking Using Nonlinear Optical Microscopy"", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, vol. 52, June 2011 (2011-06-01);;ROLANDI ET AL.: ""Correlation of Collagen-Linked Fluorescence and Tendon Fiber Breaking Time"", GERONTOLOGY, vol. 27, 1991, pages 240 - 243;;FITE ET AL.: ""Noninvasive Multimodal Evaluation of Bioengineered Cartilage Constructs Combining Time-Resolved Fluorescence and Ultrasound Imaging"", TISSUE ENG: PART C, vol. 17, no. 4, 2011;;VERZIJL ET AL.: ""Crosslinking by Advanced Glycation End Products Increases the Stiffness of the Collagen Network in Human Articular Cartilage"", ARTHRITIS & RHEUMATISM, vol. 46, 1 January 2002 (2002-01-01), pages 114 - 123;;SONG PMETZLER D: ""Photochemical Degradation of Flavins - IV. Studies of the Anaerobic Photolysis of Riboflavin"", PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. 6, 1967, pages 691 - 709",PENDING
646,US,B2,US 9132028 B2,080-093-981-738-034,2015-09-15,2015,US 200913130869 A,2009-11-25,US 200913130869 A;;US 20017208 P;;US 20375808 P;;US 20963509 P;;US 2009/0065923 W,2008-11-25,"Devices, systems and methods for the treatment of sleep apnea","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",FRIEDMAN MICHAEL;;IRWIN JOHN J;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER;;LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN JOHN J;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,LUMEN DEVICES LLC (2010-03-12),https://lens.org/080-093-981-738-034,Granted Patent,yes,13,4,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61M16/00;;A61B1/00;;A61B1/233;;A61B1/267;;A61F5/00;;A61F5/37;;A61F5/56;;A61F9/00;;A61F11/00;;A61M15/08;;A61M16/04;;A61M16/08;;A61M16/20;;A62B7/08;;A62B18/02,,4,0,,,"European Search Report dated Jan. 17, 2013 from corresponding International Patent Application No. PCT/US2009/065923, 7 pages.;;Office Action dated Aug. 29, 2013 corresponding to Australian Patent Application No. 2009324904, 3 pp.;;European Office Action dated Jul. 3, 2014 corresponding to European Patent App. No. 09 832 364.5-1654, 4 pp.;;Canadian Office Action dated Aug. 13, 2014 corresponding to Canadian Patent App. No. 2,744,704, 3 pp.",ACTIVE
647,EP,A1,EP 4326169 A1,067-622-535-977-588,2024-02-28,2024,EP 22720043 A,2022-04-18,US 202163177052 P;;US 202217716073 A;;IB 2022053611 W,2021-04-20,"OCCLUSIVE MATERIAL FOR MEDICAL DEVICE, SYSTEM, AND METHOD THEREOF",,COHEREX MEDICAL INC,LEE SUNG K;;LEE ANNABEL;;DITTER TOM;;TAYLOR WILLIAM J Z;;FRIEDMAN ROBERT S,,https://lens.org/067-622-535-977-588,Patent Application,yes,0,0,3,5,0,A61B17/12122;;A61B17/12177;;A61B17/12172;;A61B2017/00526;;A61B17/12122;;A61B17/12172;;A61B17/12177;;A61B2017/00526,A61B17/00;;A61B17/12,,0,0,,,,PENDING
648,US,A,US 5003577 A,074-749-834-574-73X,1991-03-26,1991,US 33405089 A,1989-04-05,US 33405089 A,1989-04-05,Voice and data interface to a voice-mail service system,A user-access interface to a voice message service system (16) includes a voice channel (13) and a data channel (14). The data channel enables the user to interact with the voice-mail service system via a video terminal or display-equipped computer (11) and to print message headers on the terminal or display. The user can then visually scan the headers. The user can then listen to the messages or record new messages via the voice channel. The interactive interface between the terminal or computer and the voice message service system over the data channel is provided by a function (30) executing on the terminal or computer and a function (31) executing on the voice-message service system.,AT & T BELL LAB,ERTZ DOUGLAS J;;FRIEDMAN LARRY A;;KATAMURA WILLIAM;;KWOK CHEUK W;;MARINELLI DAVID J,AMERICAN TELEPHONE AND TELEGRAPH COMPANY A CORP. OF NY (1989-03-24);;AVAYA TECHNOLOGY CORP (2000-09-29);;AT&T INFORMATION SYSTEMS INC. A CORP. OF DE (1989-03-24);;LUCENT TECHNOLOGIES INC (1996-03-29),https://lens.org/074-749-834-574-73X,Granted Patent,yes,12,311,2,2,0,H04M3/5307;;H04M3/5307;;H04M2201/60;;H04M2201/60,H04M3/42;;H04M3/53,379/89;;370/60.1;;370/61;;370/105.2;;379/94;;379/96,5,0,,,"Integrated Digital Switching System with Queing Storage Facility , S. Hattori et al., ICC 80, Seattle, Wash., Jun. 1980, pp. 27.4.1 27.4.5.;;ISDN in the Office HICOM , Special Issue Telecom Report and Siemens Magazine COM, Dec. 1985, pp. 1 111.;;S. Girishankar, Northern to Deliver Better Meridian Mail , Communications Week, 5 23 88, p. 32.;;Northern Telecom MBS Consultant Programs, Consultant Bulletin, Meredian Mail MP, p. 31 (undated).;;Convergence Column, Wang Adds Voice Products , Communications Week, Issue No. 229 (Jan. 2, 1989), p. 8.",EXPIRED
649,US,A1,US 2013/0060187 A1,147-862-185-488-321,2013-03-07,2013,US 201213665495 A,2012-10-31,US 201213665495 A;;US 90922810 A;;US 25373609 P;;US 201261699226 P;;US 201261671798 P,2009-10-21,SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT,"A method for controlling activation of Riboflavin applied to an eye includes applying the Riboflavin to a selected region of a cornea of the eye and initiating cross-linking activity in the selected region by activating the Riboflavin with pulsed light illumination. The pulsed light illumination has an irradiance, dose, and an on/off duty cycle. The irradiance, the dose, and the on/off duty cycle are adjusted in response to a determination of photochemical kinetic pathways for Riboflavin cross-linking activity and to control photochemical efficiency.",AVERDO INC;;AVEDRO INC,FRIEDMAN MARC D;;KAMAEV PAVEL;;SHERR EVAN;;EDDINGTON WILLIAM;;ROOD-OJALVO SARA;;MULLER DAVID,AVEDRO INC (2013-01-31),https://lens.org/147-862-185-488-321,Patent Application,yes,2,48,14,27,0,A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61K31/525;;A61F9/0008;;A61P27/10;;A61K31/525;;A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61F9/0008,A61M37/00,604/20,1,1,025-145-871-483-285,10.1167/iovs.11-9385;;22427580,"Kamaev et al. (“Photochemical Kinetics of Corneal Cross-Linking with Riboflavin”, Investigative Ophthalmology & Visual Science, April 2012, Vol. 53, No. 4).",ACTIVE
650,EP,B1,EP 3045154 B1,018-060-740-758-959,2022-01-05,2022,EP 15195168 A,2009-11-25,US 20017208 P;;US 20375808 P;;US 20963509 P;;EP 09832364 A;;US 2009/0065923 W,2008-11-25,MEDICAL APPLIANCE FOR THE TREATMENT OF SLEEP APNEA,,LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,,https://lens.org/018-060-740-758-959,Granted Patent,yes,1,0,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56;;A61B1/00;;A61B1/233;;A61F5/00;;A61M16/04,,0,0,,,,ACTIVE
651,WO,A3,WO 2023/147087 A3,035-623-344-239-308,2023-09-07,2023,US 2023/0011785 W,2023-01-27,US 202263304607 P,2022-01-29,SYSTEM AND METHOD FOR DISPENSING AND MIXING A FOOD AND BEVERAGE PRODUCT,An apparatus and system for dispensing a food and beverage product where a flowable product is extracted from a flexible pouch and where an opening exists through which the flowable product evacuates the flexible pouch. The opening has a lock seal that locks the flowable product within the flexible pouch when a pressure is applied to the flexible pouch. There is also a zip seal located in the opening that is configured to lock the flowable product within the flexible pouch after the lock seal has been removed when pressure is applied to the flexible pouch.,PLANT TAP LLC,SUH WILLIAM D;;LEWIS DANIEL T;;SAVINO JOSEPH CAMILLO;;FRIEDMAN LENNIE;;TOLWIN SHLOMO ARI,,https://lens.org/035-623-344-239-308,Search Report,yes,5,0,2,15,0,B01F23/41;;B01F27/808;;B01F27/88;;A47J31/407;;B01F33/5014;;A23L2/52;;A23C11/00;;B67D1/0001;;B67D1/0462;;B67D1/0888;;B67D1/12;;B67D1/0028;;B67D1/0032;;B67D1/0047;;B67D1/0804;;B67D1/0857;;B67D1/0894;;B67D1/1218;;B67D2001/0091;;B67D2001/0098;;B67D2001/0811;;B67D2001/0814;;B67D2001/0828;;B67D2210/0001;;B67D2210/00031;;G07F9/105;;G07F13/065;;G07F17/0064,B01F35/32;;A47J43/08;;B01D25/00,,0,0,,,,PENDING
652,AU,A1,AU 2009/324904 A1,067-530-480-884-203,2011-06-23,2011,AU 2009/324904 A,2009-11-25,US 20017208 P;;US 20375808 P;;US 20963509 P;;US 2009/0065923 W,2008-11-25,"Devices, systems and methods for the treatment of sleep apnea","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",LUMEN DEVICES LLC,MICHAEL FRIEDMAN;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;CHRISTOPHER FLAHERTY J,,https://lens.org/067-530-480-884-203,Patent Application,no,0,0,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56,,0,0,,,,INACTIVE
653,EP,A4,EP 2349140 A4,167-682-463-663-060,2013-02-20,2013,EP 09832364 A,2009-11-25,US 2009/0065923 W;;US 20963509 P;;US 20017208 P;;US 20375808 P,2008-11-25,"DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF SLEEP APNEA",,LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,,https://lens.org/167-682-463-663-060,Search Report,no,2,0,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56,,0,0,,,,ACTIVE
654,WO,A1,WO 2010/062952 A1,012-064-905-235-735,2010-06-03,2010,US 2009/0065914 W,2009-11-25,US 20963509 P;;US 20017208 P;;US 20375808 P,2008-11-25,"DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF SLEEP APNEA","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",LUMEN DEVICES LLC;;FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,,https://lens.org/012-064-905-235-735,Patent Application,yes,8,14,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56,,0,0,,,,DISCONTINUED
655,EP,A4,EP 2872081 A4,059-899-347-280-021,2016-03-30,2016,EP 12842319 A,2012-10-31,US 201261671798 P;;US 201261699226 P;;US 2012/0062843 W,2012-07-16,SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT,,AVEDRO INC,FRIEDMAN MARC D;;KAMAEV PAVEL;;SHERR EVAN;;EDDINGTON WILLIAM;;ROOD-OJALVO SARA;;MULLER DAVID,"AVEDRO, INC. (2017-07-26)",https://lens.org/059-899-347-280-021,Search Report,no,2,0,14,27,0,A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61K31/525;;A61F9/0008;;A61P27/10;;A61K31/525;;A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61F9/0008,A61F9/00;;A61F9/007;;A61F9/008;;A61K31/525;;A61N5/06;;A61N5/067;;A61P27/10,,2,1,025-145-871-483-285,10.1167/iovs.11-9385;;22427580,"PAVEL KAMAEV ET AL: ""Photochemical Kinetics of Corneal Cross-Linking with Riboflavin"", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, vol. 53, no. 4, 30 April 2012 (2012-04-30), US, pages 2360, XP055248371, ISSN: 1552-5783, DOI: 10.1167/iovs.11-9385;;See also references of WO 2013059837A2",ACTIVE
656,CA,C,CA 2744704 C,077-502-387-441-752,2016-01-26,2016,CA 2744704 A,2009-11-25,US 20017208 P;;US 20375808 P;;US 20963509 P;;US 2009/0065923 W,2008-11-25,"DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF SLEEP APNEA","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,,https://lens.org/077-502-387-441-752,Granted Patent,no,0,0,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56,,0,0,,,,ACTIVE
657,EP,B1,EP 2872081 B1,032-293-027-358-444,2022-06-08,2022,EP 12842319 A,2012-10-31,US 201261671798 P;;US 201261699226 P;;US 2012/0062843 W,2012-07-16,SYSTEMS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT,,AVEDRO INC,FRIEDMAN MARC D;;KAMAEV PAVEL;;SHERR EVAN;;EDDINGTON WILLIAM;;ROOD-OJALVO SARA;;MULLER DAVID,"AVEDRO, INC. (2017-07-26)",https://lens.org/032-293-027-358-444,Granted Patent,yes,5,0,14,27,0,A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61K31/525;;A61F9/0008;;A61P27/10;;A61K31/525;;A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61F9/0008,A61F9/00;;A61F9/007;;A61F9/008;;A61K31/525;;A61N5/06;;A61N5/067;;A61P27/10,,0,0,,,,ACTIVE
658,WO,A3,WO 2013/059837 A3,122-133-742-463-075,2013-06-27,2013,US 2012/0062843 W,2012-10-31,US 201261671798 P;;US 201261699226 P,2012-07-16,SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT,"A method for controlling activation of Riboflavin applied to an eye includes applying the Riboflavin to a selected region of a cornea of the eye and initiating cross-linking activity in the selected region by activating the Riboflavin with pulsed light illumination. The pulsed light illumination has an irradiance, dose, and an on/off duty cycle. The irradiance, the dose, and the on/off duty cycle are adjusted in response to a determination of photochemical kinetic pathways for Riboflavin cross-linking activity and to control photochemical efficiency.",AVEDRO INC,FRIEDMAN MARC D;;KAMAEV PAVEL;;SHERR EVAN;;EDDINGTON WILLIAM;;ROOD-OJALVO SARA;;MULLER DAVID,,https://lens.org/122-133-742-463-075,Search Report,no,3,0,14,27,0,A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61K31/525;;A61F9/0008;;A61P27/10;;A61K31/525;;A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61F9/0008,A61F9/00;;A61F9/008;;A61K31/525;;A61N5/06;;A61N5/067;;A61P27/10,,1,1,024-433-252-581-636,pmc3075647;;21335557;;10.1074/jbc.m110.169813,"YUNTAO ZHANG ET AL.: ""Effects of Ultraviolet-A and Riboflavin on the Interaction of in Collagen and Proteoglycans during Corneal Cross-linking"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 15, April 2011 (2011-04-01), pages 13011 - 13021, XP055072350",PENDING
659,AU,B9,AU 2009/324904 B9,032-748-919-337-874,2014-07-10,2014,AU 2009/324904 A,2009-11-25,US 20017208 P;;US 20375808 P;;US 20963509 P;;US 2009/0065923 W,2008-11-25,"Devices, systems and methods for the treatment of sleep apnea",,LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,,https://lens.org/032-748-919-337-874,Amended Patent,no,0,0,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,,,0,0,,,,INACTIVE
660,WO,A1,WO 2010/068493 A1,087-281-021-389-175,2010-06-17,2010,US 2009/0065923 W,2009-11-25,US 20963509 P;;US 20017208 P;;US 20375808 P,2008-11-25,"DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF SLEEP APNEA","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",LUMEN DEVICES LLC;;FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,,https://lens.org/087-281-021-389-175,Patent Application,yes,23,7,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56,,0,0,,,,PENDING
661,WO,A2,WO 2013/059837 A2,190-817-798-122-61X,2013-04-25,2013,US 2012/0062843 W,2012-10-31,US 201261671798 P;;US 201261699226 P,2012-07-16,SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT,"A method for controlling activation of Riboflavin applied to an eye includes applying the Riboflavin to a selected region of a cornea of the eye and initiating cross-linking activity in the selected region by activating the Riboflavin with pulsed light illumination. The pulsed light illumination has an irradiance, dose, and an on/off duty cycle. The irradiance, the dose, and the on/off duty cycle are adjusted in response to a determination of photochemical kinetic pathways for Riboflavin cross-linking activity and to control photochemical efficiency.",AVEDRO INC,FRIEDMAN MARC D;;KAMAEV PAVEL;;SHERR EVAN;;EDDINGTON WILLIAM;;ROOD-OJALVO SARA;;MULLER DAVID,,https://lens.org/190-817-798-122-61X,Patent Application,yes,1,20,14,27,0,A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61K31/525;;A61F9/0008;;A61P27/10;;A61K31/525;;A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61F9/0008,,,0,0,,,,PENDING
662,WO,A1,WO 2001/021606 A1,068-098-250-606-925,2001-03-29,2001,GB 0003545 W,2000-09-15,GB 9922179 A;;GB 0009267 A,1999-09-21,LIQUID CRYSTAL COMPOUNDS,"A liquid crystal compound of general formula (I) where X is O, S or Se, and R?1, R2, R3, R4¿, m, n, p and q are as specified in the application. Liquid crystal devices comprising said compounds are also claimed.",SECR DEFENCE;;GOODBY JOHN WILLIAM;;TOYNE KENNETH JOHNSON;;HIRD MICHAEL;;FRIEDMAN MARK RICHARD;;JONES JOHN CLIFFORD,GOODBY JOHN WILLIAM;;TOYNE KENNETH JOHNSON;;HIRD MICHAEL;;FRIEDMAN MARK RICHARD;;JONES JOHN CLIFFORD,,https://lens.org/068-098-250-606-925,Patent Application,yes,6,18,3,5,0,C07D307/79;;C07D307/83;;C07D307/84;;C07D333/70;;C07D405/04;;C09K19/3466;;C09K19/3491;;C09K2019/3408,G02F1/13;;C07D307/79;;C07D307/83;;C07D307/84;;C07D307/85;;C07D333/70;;C07D405/04;;C09K19/34,,2,1,040-950-892-628-733,10.1021/jo962325x,"DATABASE WPI Section Ch Week 199537, Derwent World Patents Index; Class E19, AN 1995-281175, XP002153297;;SHTAREV, ALEXANDER B. ET AL: ""Synthesis of Conjugated F-Polyenes Containing Thienyl Ring Systems"", J. ORG. CHEM. (1997), 62(16), 5608-5614, XP002153296",PENDING
663,EP,B1,EP 2349140 B1,189-969-008-669-109,2016-06-22,2016,EP 09832364 A,2009-11-25,US 2009/0065923 W;;US 20963509 P;;US 20017208 P;;US 20375808 P,2008-11-25,MEDICAL DEVICE FOR A PATIENT,,LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,,https://lens.org/189-969-008-669-109,Granted Patent,yes,11,0,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56,,0,0,,,,ACTIVE
664,EP,A2,EP 2872081 A2,046-607-800-482-803,2015-05-20,2015,EP 12842319 A,2012-10-31,US 201261671798 P;;US 201261699226 P;;US 2012/0062843 W,2012-07-16,SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT,,AVEDRO INC,FRIEDMAN MARC D;;KAMAEV PAVEL;;SHERR EVAN;;EDDINGTON WILLIAM;;ROOD-OJALVO SARA;;MULLER DAVID,"AVEDRO, INC. (2017-07-26)",https://lens.org/046-607-800-482-803,Patent Application,yes,0,0,14,27,0,A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61K31/525;;A61F9/0008;;A61P27/10;;A61K31/525;;A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61F9/0008,A61F9/00;;A61F9/007;;A61F9/008;;A61K31/525;;A61N5/06;;A61N5/067;;A61P27/10,,0,0,,,,ACTIVE
665,WO,A1,WO 2022/224125 A1,127-775-343-912-378,2022-10-27,2022,IB 2022053611 W,2022-04-18,US 202163177052 P;;US 202217716073 A,2021-04-20,"OCCLUSIVE MATERIAL FOR MEDICAL DEVICE, SYSTEM, AND METHOD THEREOF","Medical devices, systems and methods for forming an occlusive material for occluding a left atrial appendage of a heart are provided. In one embodiment, the occlusive material includes a foam portion that extends as a single piece, seamless monolithic structure that is sized to couple to an external side of a framework of a medical device. In another embodiment, the occlusive material may include a polymeric laminate. Such polymeric laminate may be adhered to an outer side of the foam portion. Further, various embodiments for forming a polymer laminate are provided.",COHEREX MEDICAL INC,LEE SUNG K;;LEE ANNABEL;;DITTER TOM;;TAYLOR WILLIAM J Z;;FRIEDMAN ROBERT S,,https://lens.org/127-775-343-912-378,Patent Application,yes,7,0,3,5,0,A61B17/12122;;A61B17/12177;;A61B17/12172;;A61B2017/00526;;A61B17/12122;;A61B17/12172;;A61B17/12177;;A61B2017/00526,A61B17/00;;A61B17/12,,0,0,,,,PENDING
666,EP,A1,EP 3045154 A1,140-762-389-110-221,2016-07-20,2016,EP 15195168 A,2009-11-25,US 20017208 P;;US 20375808 P;;US 20963509 P;;EP 09832364 A;;US 2009/0065923 W,2008-11-25,"DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF SLEEP APNEA","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.
",LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,,https://lens.org/140-762-389-110-221,Patent Application,yes,48,1,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56;;A61B1/00;;A61B1/233;;A61F5/00;;A61M16/04,,0,0,,,,ACTIVE
667,CA,A1,CA 2911748 A1,161-445-152-405-112,2010-06-17,2010,CA 2911748 A,2009-11-25,US 20017208 P;;US 20375808 P;;US 20963509 P;;CA 2744704 A,2008-11-25,"DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF SLEEP APNEA",,LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,,https://lens.org/161-445-152-405-112,Patent Application,no,0,0,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56,,0,0,,,,ACTIVE
668,US,A1,US 2023/0276992 A1,170-202-122-049-321,2023-09-07,2023,US 202318160549 A,2023-01-27,US 202318160549 A;;US 202117303471 A;;US 202017131632 A;;US 201916409759 A;;US 202263304607 P,2019-05-10,SYSTEM AND METHOD FOR DISPENSING AND MIXING A FOOD AND BEVERAGE PRODUCT,An apparatus and system for dispensing a food and beverage product where a flowable product is extracted from a flexible pouch and where an opening exists through which the flowable product evacuates the flexible pouch. The opening has a lock seal that locks the flowable product within the flexible pouch when a pressure is applied to the flexible pouch. There is also a zip seal located in the opening that is configured to lock the flowable product within the flexible pouch after the lock seal has been removed when pressure is applied to the flexible pouch.,PLANT TAP LLC,SUH WILLIAM D;;LEWIS DANIEL T;;SAVINO JOSEPH CAMILLO;;FRIEDMAN LENNIE;;TOLWIN SHLOMO ARI,,https://lens.org/170-202-122-049-321,Patent Application,yes,0,0,1,15,0,A47J31/407;;A47J43/046;;A47J43/0722;;A47J43/0727;;A47J43/085;;B65D75/5805;;B65D33/2508;;B65D33/02;;B65D85/80;;B01F35/71795;;B01F27/808;;B01F23/43;;A47J43/046;;A23C11/10;;A47J43/085;;A47J43/0722;;A47J43/0727;;B01F27/2723;;B01F27/808;;B01F35/4112;;B01F23/43;;B65D85/80;;B65D23/04;;B65D75/566;;B65D75/5811;;B65D83/0055;;B01F35/71795;;B01F2101/14;;A47J31/407,A47J43/046;;A47J31/40;;A47J43/07;;A47J43/08;;B01F23/43;;B01F27/272;;B01F27/808;;B01F35/41;;B65D23/04;;B65D75/56;;B65D75/58;;B65D83/00;;B65D85/80,,0,0,,,,PENDING
669,US,B2,US 10441457 B2,016-491-874-699-917,2019-10-15,2019,US 201514818914 A,2015-08-05,US 201514818914 A;;US 201113130869 A;;US 2009/0065923 W;;US 20963509 P;;US 20375808 P;;US 20017208 P,2008-11-25,"Devices, systems and methods for the treatment of sleep apnea","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN III JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,LUMEN DEVICES LLC (2015-08-10),https://lens.org/016-491-874-699-917,Granted Patent,yes,34,4,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56;;A61B1/00;;A61B1/233;;A61B1/267;;A61F5/00;;A61M16/00;;A61M16/04;;A61M16/08;;A61M16/20,,9,0,,,"Supplemental European Search Report dated Feb. 5, 2013 corresponding to European Application No. 09832364.5, 7 pages.;;Office Action dated Aug. 29, 2013 corresponding to Australian Patent Application No. 2009324904, 3 pages.;;European Office Action dated Jul. 3, 2014 corresponding to European Patent App. No. 09832364.5-1654, 4 pages.;;Canadian Office Action dated Aug. 13, 2014 corresponding to Canadian Patent App. No. 2744704, 3 pages.;;Extended European Search Report dated Jun. 20, 2016 issued in corresponding European Application No. 15195168.8.;;Canadian Office Action dated Sep. 6, 2016 issued in corresponding Canadian application No. 2911748.;;Canadian Office Action dated Jun. 6, 2017 issued in related Canadian Application No. 2,911,748.;;Canadian Office Action dated Feb. 14, 2018 issued in Canadian Application No. 2,911,748.;;European Office Action dated Nov. 8, 2017, issued in Euorpean Application No. 15195168.8.",ACTIVE
670,US,B2,US 7238147 B2,049-008-387-512-793,2007-07-03,2007,US 1686604 A,2004-12-21,US 1686604 A;;US 81911604 A,2004-04-07,Exercise device with removable weight,"An exercise device in which removable weight may be provided in a housing of the device. Two rotatable handles may be provided in the housing, permitting various hand orientations during exercise. The removable weight may be received within and/or removed from a cavity of the device.",PT METRICS LLC,MILLS ALDEN MORRIS;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM PATRICK;;THOMASON RODGER DALE,PT METERICS LLC (2004-12-17);;IMPLUS FOOTCARE LLC (2011-10-25);;PERFECT PUSHUP LLC (2008-04-22),https://lens.org/049-008-387-512-793,Granted Patent,yes,16,78,9,11,0,A63B21/0605;;A63B21/072;;A63B21/0724;;A63B21/0728;;A63B21/075;;A63B23/12;;A63B21/4017;;A63B21/4001;;A63B21/0004;;A63B23/03525;;A63B21/4043;;A63B21/4035;;A63B23/12;;A63B21/072;;A63B21/0605;;A63B21/075;;A63B21/0724;;A63B21/0728;;A63B21/4001;;A63B21/4017;;A63B21/0004;;A63B23/03525;;A63B21/4035;;A63B21/4043,A63B21/075;;A63B21/00;;A63B21/005;;A63B21/06;;A63B21/072;;A63B23/12,482/106;;482/92;;482/93,1,0,,,"International Search Report dated Aug. 29, 2006.",INACTIVE
671,CA,A1,CA 2295609 A1,123-906-168-859-910,1999-11-25,1999,CA 2295609 A,1999-05-19,US 8593198 P;;US 9910952 W,1998-05-19,HEMOSTATIC SANDWICH BANDAGE,The present invention relates to a haemostatic multilayer bandage that comprises preferably a thrombin layer between two fibrinogen layers. The dressing may contain other resorbable materials such as glycolic acid or lactic acid based polymers or copolymers. The inventive haemostatic sandwich bandage is useful for the treatment of wounded tissue.,AMERICAN NAT RED CROSS,TUTHILL DAVID;;DROHAN WILLIAM N;;MACPHEE MARTIN J;;BAYER VLADISLAV;;BEALL DAWSON;;FRIEDMAN STANLEY A,,https://lens.org/123-906-168-859-910,Patent Application,no,0,0,13,14,0,A61L15/225;;A61L15/26;;A61L15/32;;A61L15/64;;A61L26/0042;;A61L26/0047;;A61L2400/04;;A61P17/02,A61F13/00;;A61L15/22;;A61L15/26;;A61L15/32;;A61L15/44;;A61L15/64;;A61L26/00,,0,0,,,,EXPIRED
672,US,B2,US 11517471 B2,047-289-825-021-320,2022-12-06,2022,US 202016851218 A,2020-04-17,US 202016851218 A;;US 201715611085 A;;US 201313985977 A;;US 2012/0025458 W;;US 201161443839 P,2011-02-17,Apparatus and methods for the treatment of sleep apnea,"A medical apparatus for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient is provided. The apparatus has an elongate member with a middle portion, a first fixation element and a second fixation element. The middle portion applies a force to a segment of a patient's airway.",LUMEN DEVICES LLC,FLAHERTY J CHRISTOPHER;;GARIBOTTO JOHN T;;GORMAN WILLIAM J;;IRWIN III JOHN N;;FRIEDMAN MICHAEL,LUMEN DEVICES LLC (2012-02-23),https://lens.org/047-289-825-021-320,Granted Patent,yes,123,0,7,7,0,A61F5/566;;A61F5/566,A61F5/56,,6,0,,,"Canadian Office Action dated Sep. 6, 2016 issued in corresponding Canadian Application No. 2,911,748.;;International Preliminary Report on Patentability dated Aug. 29, 2013 corresponding to PCT/US2012/025458, 27pp.;;International Search Report and Written Opinion dated Jul. 16, 2012 from PCT/US2012/025458; 41 pages.;;“Aparatus and Methods for the Treatment of Sleep Apnea” Specification, Drawings and Prosecution History of U.S. Appl. No. 13/985,977, filed Aug. 16, 2013, now U.S. Pat. No. 9,668,911, issued Jun. 6, 2017, by J. Christopher Flaherty, et al., which is stored in the United States Patent and Trademark Office (USPTO).;;“Aparatus and Methods for the Treatment of Sleep Apnea” Specification, Drawings and Prosecution History of U.S. Appl. No. 15/611,085, filed Jun. 1, 2017, now U.S. Pat. No. 10,660,787, issued May 26, 2020, by J. Christopher Flaherty, et al., which is stored in the United States Patent and Trademark Office (USPTO).;;European Office Action dated Jan. 22, 2021 issued in corresponding European Application No. 15195168.8.",ACTIVE
673,US,B2,US 11510806 B2,065-605-403-236-895,2022-11-29,2022,US 201916564295 A,2019-09-09,US 201916564295 A;;US 201514818914 A;;US 201113130869 A;;US 2009/0065923 W;;US 20963509 P;;US 20375808 P;;US 20017208 P,2008-11-25,"Devices, systems and methods for the treatment of sleep apnea","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN III JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,LUMEN DEVICES LLC (2015-08-10),https://lens.org/065-605-403-236-895,Granted Patent,yes,123,1,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61B1/00;;A61F5/56;;A61B1/233;;A61B1/267;;A61F5/00;;A61M16/00;;A61M16/04;;A61M16/08;;A61M16/20,,1,0,,,"European Office Action dated Jan. 22, 2021 issued in corresponding European Application No. 15195168.8.",ACTIVE
674,CA,C,CA 2295609 C,064-644-826-749-145,2009-09-29,2009,CA 2295609 A,1999-05-19,US 8593198 P;;US 9910952 W,1998-05-19,HEMOSTATIC SANDWICH BANDAGE,The present invention relates to a haemostatic multilayer bandage that comprises preferably a thrombin layer between two fibrinogen layers. The dressing may contain other resorbable materials such as glycolic acid or lactic acid based polymers or copolymers. The inventive haemostatic sandwich bandage is useful for the treatment of wounded tissue.,AMERICAN NAT RED CROSS,FRIEDMAN STANLEY A;;TUTHILL DAVID;;MACPHEE MARTIN J;;DROHAN WILLIAM N;;BEALL DAWSON;;BAYER VLADISLAV,,https://lens.org/064-644-826-749-145,Granted Patent,no,0,0,13,14,0,A61L15/225;;A61L15/26;;A61L15/32;;A61L15/64;;A61L26/0042;;A61L26/0047;;A61L2400/04;;A61P17/02,A61F13/00;;A61L15/32;;A61L15/22;;A61L15/26;;A61L15/44;;A61L15/64;;A61L26/00,,0,0,,,,EXPIRED
675,US,B2,US 10660787 B2,073-187-582-588-60X,2020-05-26,2020,US 201715611085 A,2017-06-01,US 201715611085 A;;US 201313985977 A;;US 2012/0025458 W;;US 201161443839 P,2011-02-17,Apparatus and methods for the treatment of sleep apnea,"A medical apparatus for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient is provided. The apparatus has an elongate member with a middle portion, a first fixation element and a second fixation element. The middle portion applies a force to a segment of a patient's airway.",LUMEN DEVICES LLC,FLAHERTY J CHRISTOPHER;;GARIBOTTO JOHN T;;GORMAN WILLIAM J;;IRWIN III JOHN N;;FRIEDMAN MICHAEL,LUMEN DEVICES LLC (2012-02-23),https://lens.org/073-187-582-588-60X,Granted Patent,yes,44,3,7,7,0,A61F5/566;;A61F5/566,A61F5/56,,4,0,,,"Canadian Office Action dated Sep. 6, 2016 issued in corresponding Canadian Application No. 2,911,748.;;International Search Report and Written Opinion dated Jul. 16, 2012 from PCT/US2012/025458; 41 pages.;;International Preliminary Report on Patentability dated Aug. 21, 2013 from PCT/US2012/025458; 26 pages.;;“Aparatus and Methods for the Treatment of Sleep Apnea” Specification, Drawings and Prosecution History of U.S. Appl. No. 13/985,977, filed Aug. 16, 2013 by J. Christopher Flaherty, et al.",ACTIVE
676,JP,A,JP 2005296633 A,144-008-220-622-441,2005-10-27,2005,JP 2005060308 A,2005-03-04,US 81911604 A;;US 1686604 A,2004-04-07,EXERCISER WITH REMOVABLE WEIGHT,"<P>PROBLEM TO BE SOLVED: To provide an exerciser having removable weights. <P>SOLUTION: The exerciser can be provided with removable weights in its housing. It is provided with two rotatable handles in its housing, permitting various hand orientations during exercise. The removable weights can be received into or taken out of the cavity of the exerciser. <P>COPYRIGHT: (C)2006,JPO&NCIPI",PT METRICS LLC,MILLS ALDEN MORRIS;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM PATRICK;;THOMASON RODGER DALE,,https://lens.org/144-008-220-622-441,Patent Application,no,2,0,9,11,0,A63B21/0605;;A63B21/072;;A63B21/0724;;A63B21/0728;;A63B21/075;;A63B23/12;;A63B21/4017;;A63B21/4001;;A63B21/0004;;A63B23/03525;;A63B21/4043;;A63B21/4035;;A63B23/12;;A63B21/072;;A63B21/0605;;A63B21/075;;A63B21/0724;;A63B21/0728;;A63B21/4001;;A63B21/4017;;A63B21/0004;;A63B23/03525;;A63B21/4035;;A63B21/4043,A63B21/075;;A63B21/005;;A63B21/06;;A63B21/072;;A63B23/12,,0,0,,,,PENDING
677,WO,A2,WO 2005/102464 A2,101-280-922-551-951,2005-11-03,2005,US 2005/0001882 W,2005-01-21,US 81911604 A;;US 1686604 A,2004-04-07,EXERCISE DEVICE WITH REMOVABLE WEIGHT,"An exercise device in which removable weight may be provided in a housing of the device. Two rotatable handles may be provided in the housing, permitting various hand orientations during exercise. The removable weight may be received within and/or removed from a cavity of the device.",PT METRICS LLC;;MILLS ALDEN MORRIS;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM PATRICK;;THOMASON RODGER DALE,MILLS ALDEN MORRIS;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM PATRICK;;THOMASON RODGER DALE,,https://lens.org/101-280-922-551-951,Patent Application,yes,3,1,9,11,0,A63B21/0605;;A63B21/072;;A63B21/0724;;A63B21/0728;;A63B21/075;;A63B23/12;;A63B21/4017;;A63B21/4001;;A63B21/0004;;A63B23/03525;;A63B21/4043;;A63B21/4035;;A63B23/12;;A63B21/072;;A63B21/0605;;A63B21/075;;A63B21/0724;;A63B21/0728;;A63B21/4001;;A63B21/4017;;A63B21/0004;;A63B23/03525;;A63B21/4035;;A63B21/4043,A63B21/005;;A63B21/075;;A63B21/06;;A63B21/072;;A63B23/12,,1,0,,,See also references of EP 1809390A4,PENDING
678,US,A1,US 2005/0003931 A1,153-475-844-856-755,2005-01-06,2005,US 81911604 A,2004-04-07,US 81911604 A;;US 48363303 P,2003-07-01,"Exercise device, method of fabricating exercise device, and method and system for interaction with an exercise device","An exercise device, method of making the device and a method and system for interaction with an exercise device, in which removable, variable weight may be provided in a housing of the device. Two rotatable handles may be provided in the housing, permitting various hand orientations during exercise. The removable weight may be provided near the center of the exercise device, with the handles substantially outboard the weight. Weight may thus be efficiently added or removed in a central area of the housing between the handles.",MILLS ALDEN MORRIS;;FRIEDMAN MARK B.;;HAUSER STEPHEN G.;;CONLEY WILLIAM PATRICK;;THOMASON RODGER DALE,MILLS ALDEN MORRIS;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM PATRICK;;THOMASON RODGER DALE,PT METRICS LLC (2004-04-02),https://lens.org/153-475-844-856-755,Patent Application,yes,3,72,2,11,0,A63B21/00065;;A63B21/0601;;A63B21/0724;;A63B21/0728;;A63B21/075;;A63B21/4035;;A63B21/4017;;A63B21/075;;A63B21/0724;;A63B21/0728;;A63B21/00065;;A63B21/0601;;A63B21/4017;;A63B21/4035,A63B21/06;;A63B21/072;;A63B21/075;;A63B23/12,482/5;;482/92,0,0,,,,DISCONTINUED
679,AU,A1,AU 2005/235519 A1,082-004-277-222-267,2005-11-03,2005,AU 2005/235519 A,2005-01-21,US 1686604 A;;US 81911604 A;;US 2005/0001882 W,2004-04-07,Exercise device with removable weight,,PERFECT PUSHUP LLC,HAUSER STEPHEN G;;THOMASON RODGER DALE;;FRIEDMAN MARK B;;CONLEY WILLIAM PATRICK;;MILLS ALDEN MORRIS,,https://lens.org/082-004-277-222-267,Patent Application,no,0,0,9,11,0,A63B21/0605;;A63B21/072;;A63B21/0724;;A63B21/0728;;A63B21/075;;A63B23/12;;A63B21/4017;;A63B21/4001;;A63B21/0004;;A63B23/03525;;A63B21/4043;;A63B21/4035;;A63B23/12;;A63B21/072;;A63B21/0605;;A63B21/075;;A63B21/0724;;A63B21/0728;;A63B21/4001;;A63B21/4017;;A63B21/0004;;A63B23/03525;;A63B21/4035;;A63B21/4043,A63B21/00;;A63B21/075;;A63B21/005;;A63B21/06;;A63B21/072;;A63B23/12,,0,0,,,,DISCONTINUED
680,AU,A,AU 1999/040016 A,099-967-575-552-140,1999-12-06,1999,AU 1999/040016 A,1999-05-19,US 8593198 P;;US 9910952 W,1998-05-19,Hemostatic sandwich bandage,The present invention relates to a haemostatic multilayer bandage that comprises preferably a thrombin layer between two fibrinogen layers. The dressing may contain other resorbable materials such as glycolic acid or lactic acid based polymers or copolymers. The inventive haemostatic sandwich bandage is useful for the treatment of wounded tissue.,AMERICAN NATIONAL RED CROSS THE,MACPHEE MARTIN J;;DROHAN WILLIAM N;;BEALL DAWSON;;FRIEDMAN STANLEY A;;TUTHILL DAVID;;BAYER VLADISLAV,,https://lens.org/099-967-575-552-140,Patent Application,no,0,0,13,14,0,A61L15/225;;A61L15/26;;A61L15/32;;A61L15/64;;A61L26/0042;;A61L26/0047;;A61L2400/04;;A61P17/02,A61F13/00;;A61L15/22;;A61L15/26;;A61L15/32;;A61L15/44;;A61L15/64;;A61L26/00,,0,0,,,,EXPIRED
681,US,A1,US 2020/0138621 A1,130-168-856-662-152,2020-05-07,2020,US 201916564295 A,2019-09-09,US 201916564295 A;;US 201514818914 A;;US 201113130869 A;;US 2009/0065923 W;;US 20963509 P;;US 20375808 P;;US 20017208 P,2008-11-25,"DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF SLEEP APNEA","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN III JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,LUMEN DEVICES LLC (2015-08-10),https://lens.org/130-168-856-662-152,Patent Application,yes,0,0,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61B1/00;;A61F5/56;;A61B1/233;;A61B1/267;;A61F5/00;;A61M16/00;;A61M16/04;;A61M16/08;;A61M16/20,,0,0,,,,ACTIVE
682,EP,A1,EP 0973374 A1,032-911-904-311-724,2000-01-26,2000,EP 98907352 A,1998-01-30,US 9801864 W;;US 79722697 A,1997-02-07,DNA SEQUENCES ENCODING SOLANIDINE UDP-GLUCOSE GLUCOSYLTRANSFERASE AND USE TO REDUCE GLYCOALKALOIDS IN SOLANACEOUS PLANTS,,US AGRICULTURE,MOEHS CHARLES P;;ALLEN PAUL V;;ROCKHOLD DAVID R;;STAPLETON ANDREW;;FRIEDMAN MENDEL;;BELKNAP WILLIAM,,https://lens.org/032-911-904-311-724,Patent Application,yes,0,0,4,4,2,C12N9/1051;;C12N9/1051;;C12N15/8243;;C12N15/8243,C12N9/10;;C12N15/29;;C12N15/82,,1,0,,,See references of WO 9834471A1,DISCONTINUED
683,US,A1,US 2021/0085514 A1,185-343-753-795-21X,2021-03-25,2021,US 202016851218 A,2020-04-17,US 202016851218 A;;US 201715611085 A;;US 201313985977 A;;US 2012/0025458 W;;US 201161443839 P,2011-02-17,APPARATUS AND METHODS FOR THE TREATMENT OF SLEEP APNEA,"A medical apparatus for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient is provided. The apparatus has an elongate member with a middle portion, a first fixation element and a second fixation element. The middle portion applies a force to a segment of a patient's airway.",LUMEN DEVICES LLC,FLAHERTY J CHRISTOPHER;;GARIBOTTO JOHN T;;GORMAN WILLIAM J;;IRWIN III JOHN N;;FRIEDMAN MICHAEL,LUMEN DEVICES LLC (2012-02-23),https://lens.org/185-343-753-795-21X,Patent Application,yes,0,0,7,7,0,A61F5/566;;A61F5/566,A61F5/56,,0,0,,,,ACTIVE
684,EP,B1,EP 0998311 B1,133-358-684-449-916,2003-11-26,2003,EP 99923189 A,1999-05-19,US 9910952 W;;US 8593198 P,1998-05-19,HEMOSTATIC SANDWICH BANDAGE COMPRISING A THROMBIN LAYER BETWEEN TWO FIBRINOGEN LAYERS,The present invention relates to a haemostatic multilayer bandage that comprises preferably a thrombin layer between two fibrinogen layers. The dressing may contain other resorbable materials such as glycolic acid or lactic acid based polymers or copolymers. The inventive haemostatic sandwich bandage is useful for the treatment of wounded tissue.,AMERICAN NAT RED CROSS,MACPHEE MARTIN J;;DROHAN WILLIAM N;;BEALL DAWSON;;FRIEDMAN STANLEY A;;TUTHILL DAVID;;BAYER VLADISLAV,,https://lens.org/133-358-684-449-916,Granted Patent,yes,4,1,13,14,0,A61L15/225;;A61L15/26;;A61L15/32;;A61L15/64;;A61L26/0042;;A61L26/0047;;A61L2400/04;;A61P17/02,A61F13/00;;A61L15/22;;A61L15/26;;A61L15/32;;A61L15/44;;A61L15/64;;A61L26/00,,1,0,,,"HOLCOMB J.B. ET AL.: ""Implications of new dry fibrin sealant technology for trauma surgery"" SURGICAL CLINICS OF NORTH AMERICA, vol. 77, no. 4, 1997, pages 943-950, XP002113927",EXPIRED
685,US,A1,US 2003/0130678 A1,164-071-365-492-729,2003-07-10,2003,US 32622302 A,2002-12-20,US 32622302 A;;US 86694801 A;;US 24189500 P,2000-10-20,Method for driving an ultrasonic system to improve acquisition of blade resonance frequency at startup,"
   The ability of an ultrasonic system to sweep and lock onto a resonance frequency of a blade subjected to a heavy load at startup is improved by applying a high drive voltage or a high drive current while systematically increasing the level of the applied signal. Increasing the drive signal to the hand piece results in an improved and more pronounced impedance spectrum. That is, under load, the increased drive signal causes the maximum phase margin to become higher and the minimum/maximum impedance magnitude to become more pronounced. Increasing the excitation drive signal to the hand piece/blade at startup significantly alleviates the limiting factors associated with ultrasonic generators, which results in an increase of the maximum load capability at startup. 
",ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T;;WIENER EITAN T;;BROTZ JOSEPH A;;HEIN JOHN E,,https://lens.org/164-071-365-492-729,Patent Application,yes,7,0,12,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/00725;;A61B2017/00725;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/00;;A61B17/32,606/169,0,0,,,,EXPIRED
686,UY,A1,UY 25067 A1,018-420-762-970-711,2000-12-29,2000,UY 25067 A,1998-06-29,US 5140297 P;;US 5149897 P;;US 5142097 P;;US 5141497 P,1997-07-01,"ACETATO DE SERTRALINA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN Y PROCEDIMIENTOS DE PREPARACIÓN.","Formas de dosificación de liberación sostenida de sertralina que liberan sertralina a una velocidad entre 1 mgA/h y 40 mgA/h. La presente invención refiere además a una sal de acetato, una sal de L-lactato y una sal de L-aspartato de sertralina, a sus composiciones farmacéuticas y a procedimientos de uso de la sal para tratamientos de varios trastornos y afecciones, principalmente para la depresión. La presente invención también se refiere a los procedimientos para la preparación del acetato de sertralina, del L-lactato de sertralina y del L-aspartato de sertralina.",PFIZER,FRIEDMAN HYLAR LEWIS;;HERBIG SCOTT MAX;;SHANKER RAVI MYSORE;;CURATOLO WILLIAM;;ENDE MARY TANYA AM,,https://lens.org/018-420-762-970-711,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
687,AT,T1,AT E254934 T1,080-003-094-266-905,2003-12-15,2003,AT 99923189 T,1999-05-19,US 8593198 P;;US 9910952 W,1998-05-19,"BLUTSTILLENDE MEHRSCHICHTIGE BANDAGE, DIE EINE THROMBINSCHICHT ZWISCHEN ZWEI FIBRINOGENSCHICHTEN ENTHÄLT",The present invention relates to a haemostatic multilayer bandage that comprises preferably a thrombin layer between two fibrinogen layers. The dressing may contain other resorbable materials such as glycolic acid or lactic acid based polymers or copolymers. The inventive haemostatic sandwich bandage is useful for the treatment of wounded tissue.,AMERICAN NAT RED CROSS,MACPHEE MARTIN J;;DROHAN WILLIAM N;;BEALL DAWSON;;FRIEDMAN STANLEY A;;TUTHILL DAVID;;BAYER VLADISLAV,,https://lens.org/080-003-094-266-905,Granted Patent,no,0,0,13,14,0,A61L15/225;;A61L15/26;;A61L15/32;;A61L15/64;;A61L26/0042;;A61L26/0047;;A61L2400/04;;A61P17/02,A61F13/00;;A61L15/22;;A61L15/26;;A61L15/32;;A61L15/44;;A61L15/64;;A61L26/00,,0,0,,,,DISCONTINUED
688,WO,A3,WO 2004/027562 A3,125-573-906-150-779,2004-06-24,2004,US 0329226 W,2003-09-15,US 41133602 P;;US 41961302 P;;US 27447802 A,2002-09-17,SERVER-BASED MESSAGE PROTOCOL TRANSLATION,"A system and method are presented in which a plurality of transport protocol objects (TPOs) are instantiated at a server. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",BELLSOUTH INTELLECT PTY CORP,DANIELL WILLIAM TODD;;DAIGLE BRIAN KEITH;;KENT LARRY GRAHAM;;DAVIS JOEL A;;FRIEDMAN LEE G,,https://lens.org/125-573-906-150-779,Search Report,yes,2,0,10,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L69/08;;H04L51/234,G06Q10/10;;H04L12/58;;H04L29/06,,1,0,,,"JOHN D. RAMSDELL: ""Simple instant messaging and presence 1.3 protocol"", MITRE CORPORATION, June 2001 (2001-06-01), pages 1 - 19, XP002976932",PENDING
689,WO,A3,WO 2005/102464 A3,177-012-418-131-436,2006-11-02,2006,US 2005/0001882 W,2005-01-21,US 81911604 A;;US 1686604 A,2004-04-07,EXERCISE DEVICE WITH REMOVABLE WEIGHT,"An exercise device in which removable weight may be provided in a housing of the device. Two rotatable handles may be provided in the housing, permitting various hand orientations during exercise. The removable weight may be received within and/or removed from a cavity of the device.",PT METRICS LLC;;MILLS ALDEN MORRIS;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM PATRICK;;THOMASON RODGER DALE,MILLS ALDEN MORRIS;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM PATRICK;;THOMASON RODGER DALE,,https://lens.org/177-012-418-131-436,Search Report,yes,6,0,9,11,0,A63B21/0605;;A63B21/072;;A63B21/0724;;A63B21/0728;;A63B21/075;;A63B23/12;;A63B21/4017;;A63B21/4001;;A63B21/0004;;A63B23/03525;;A63B21/4043;;A63B21/4035;;A63B23/12;;A63B21/072;;A63B21/0605;;A63B21/075;;A63B21/0724;;A63B21/0728;;A63B21/4001;;A63B21/4017;;A63B21/0004;;A63B23/03525;;A63B21/4035;;A63B21/4043,A63B21/00;;A63B21/005;;A63B21/075;;A63B21/06;;A63B21/072;;A63B23/12,,0,0,,,,PENDING
690,CA,A1,CA 2587024 A1,071-188-234-529-496,2005-11-03,2005,CA 2587024 A,2005-01-21,US 81911604 A;;US 1686604 A;;US 2005/0001882 W,2004-04-07,EXERCISE DEVICE WITH REMOVABLE WEIGHT,,PT METRICS LLC,CONLEY WILLIAM PATRICK;;MILLS ALDEN MORRIS;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;THOMASON RODGER DALE,,https://lens.org/071-188-234-529-496,Patent Application,no,0,5,9,11,0,A63B21/0605;;A63B21/072;;A63B21/0724;;A63B21/0728;;A63B21/075;;A63B23/12;;A63B21/4017;;A63B21/4001;;A63B21/0004;;A63B23/03525;;A63B21/4043;;A63B21/4035;;A63B23/12;;A63B21/072;;A63B21/0605;;A63B21/075;;A63B21/0724;;A63B21/0728;;A63B21/4001;;A63B21/4017;;A63B21/0004;;A63B23/03525;;A63B21/4035;;A63B21/4043,A63B21/00;;A63B21/075;;A63B21/005;;A63B21/06;;A63B21/072;;A63B23/12,,0,0,,,,DISCONTINUED
691,EP,A4,EP 1809390 A4,130-972-898-179-65X,2009-04-29,2009,EP 05705973 A,2005-01-21,US 2005/0001882 W;;US 81911604 A;;US 1686604 A,2004-04-07,EXERCISE DEVICE WITH REMOVABLE WEIGHT,,PERFECT PUSHUP LLC,MILLS ALDEN MORRIS;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM PATRICK;;THOMASON RODGER DALE,"PERFECT PUSHUP, LLC (2008-08-20)",https://lens.org/130-972-898-179-65X,Search Report,no,4,0,9,11,0,A63B21/0605;;A63B21/072;;A63B21/0724;;A63B21/0728;;A63B21/075;;A63B23/12;;A63B21/4017;;A63B21/4001;;A63B21/0004;;A63B23/03525;;A63B21/4043;;A63B21/4035;;A63B23/12;;A63B21/072;;A63B21/0605;;A63B21/075;;A63B21/0724;;A63B21/0728;;A63B21/4001;;A63B21/4017;;A63B21/0004;;A63B23/03525;;A63B21/4035;;A63B21/4043,A63B21/005;;A63B21/075;;A63B21/06;;A63B21/072;;A63B23/12,,1,0,,,See also references of WO 2005102464A2,DISCONTINUED
692,EP,A2,EP 1809390 A2,175-623-302-782-819,2007-07-25,2007,EP 05705973 A,2005-01-21,US 2005/0001882 W;;US 81911604 A;;US 1686604 A,2004-04-07,EXERCISE DEVICE WITH REMOVABLE WEIGHT,,PT METRICS LLC,MILLS ALDEN MORRIS;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM PATRICK;;THOMASON RODGER DALE,"PERFECT PUSHUP, LLC (2008-08-20)",https://lens.org/175-623-302-782-819,Patent Application,yes,0,0,9,11,0,A63B21/0605;;A63B21/072;;A63B21/0724;;A63B21/0728;;A63B21/075;;A63B23/12;;A63B21/4017;;A63B21/4001;;A63B21/0004;;A63B23/03525;;A63B21/4043;;A63B21/4035;;A63B23/12;;A63B21/072;;A63B21/0605;;A63B21/075;;A63B21/0724;;A63B21/0728;;A63B21/4001;;A63B21/4017;;A63B21/0004;;A63B23/03525;;A63B21/4035;;A63B21/4043,A63B21/005;;A63B21/075;;A63B21/06;;A63B21/072;;A63B23/12,,0,0,,,,DISCONTINUED
693,AU,A8,AU 2003/272487 A8,167-465-146-121-531,2004-04-08,2004,AU 2003/272487 A,2003-09-15,US 41133602 P;;US 41961302 P;;US 27447802 A;;US 0329226 W,2002-09-17,Server-based message protocol translation,,BELLSOUTH INTELLECT PTY CORP,FRIEDMAN LEE G;;KENT LARRY GRAHAM;;DANIELL WILLIAM TODD;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,,https://lens.org/167-465-146-121-531,Patent Application,no,0,0,10,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L69/08;;H04L51/234,G06Q10/10;;H04L12/58;;H04L29/06,,0,0,,,,DISCONTINUED
694,US,S,US D0532465 S,169-369-264-914-500,2006-11-21,2006,US 21983904 F,2004-12-23,US 21983904 F,2004-12-23,Exercise device with removable weight,,PT METRICS LLC,MILLS ALDEN MORRIS;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM PATRICK;;THOMASON RODGER DALE,IMPLUS FOOTCARE LLC (2011-10-25);;PERFECT PUSHUP LLC DBA PERFECT FITNESS (2005-04-18),https://lens.org/169-369-264-914-500,Design Right,no,0,4,1,1,0,,,2102;;D21/680;;D21/681,0,0,,,,EXPIRED
695,US,A,US 5943427 A,087-957-555-334-352,1999-08-24,1999,US 42511995 A,1995-04-21,US 42511995 A,1995-04-21,Method and apparatus for three dimensional audio spatialization,A digital audio spatialization system that incorporates accurate synthesis of three-dimensional audio spatialization cues responsive to a desired simulated location and/or velocity of one or more emitters relative to a sound receiver. Cue synthesis may also simulate the location of one or more reflective surfaces in the receiver's simulated acoustic environment. The cue synthesis techniques are suitable for economical implementation in a personal computer add-on card.,CREATIVE TECH LTD,MASSIE DANA C;;SUN JOHN D;;FRIEDMAN SOL D;;MARTENS WILLIAM L;;ROSSUM DAVID P,CREATIVE TECHNOLOGY LTD (1995-06-01),https://lens.org/087-957-555-334-352,Granted Patent,yes,15,163,1,1,0,H04S1/007;;H04S1/007,H04S1/00,381/17;;381/1;;381/63,22,9,050-027-658-244-495;;035-230-360-673-254;;011-204-466-922-546;;058-286-091-282-489;;058-299-660-927-770;;032-038-047-198-11X;;101-964-977-563-391;;020-275-189-992-718;;005-496-094-610-874,2262632;;10.1121/1.400250;;4424970;;10.1121/1.1903351;;5907617;;10.1121/1.1909913;;893803;;10.1121/1.381470;;5659494;;10.1121/1.1910977;;4706183;;10.1121/1.1913336;;10.1177/154193128803200218;;10.1121/1.397557;;2926000;;10.1121/1.1910976;;5659493,"Loomis et al., Active Localization of Virtual Sounds, J. Acoust. Soc. Am., vol. 88, No. 4, Oct. 1990, pp. 1757 1764.;;Wallach et al., The Precedence Effect in Sound Localization, J. Audio Eng. Soc., vol. 21, No. 10, Dec. 1973, pp. 817 826.;;Rodgers, Pinna Transformations and Sound Reproduction, J. Audio Eng. Soc., vol. 29, No. 4, Apr. 1981, pp. 226 234.;;Madsen, Extraction of Ambiance Information from Ordinary Recordings, J. Audio Eng. Soc., vol. 18, NO. 5, Oct. 1970, pp. 490 496.;;Wiener, On the Diffraction of a Progressive Sound Wave by the Human Head, J. Acoust. Soc. Am., vol. 19, No. 1, Jan. 1947, pp. 143 146.;;Hebrank et al., Are Two Ears Necessary for Localization of Sound Sources on the Median Plane , J. Acoust. Soc. Am., vol. 56, No. 3, Sep. 1974, pp. 935 938.;;Shaw, Earcanal Pressure Generated by a Free Sound Field, J. Acoust. Soc. Am., vol. 39, No. 3, 1966, pp. 465 470.;;Megrgardt, Transformation Characteristics of the External Human Ear, J. Acoust. Soc. Am. vol. 61, No. 6, Jun. 1977, pp. 1567 1576.;;Roffler et al., Localization of Tonal Stimuli in the Vertical Plane, J. Acoust. Soc. Am., vol. 43, No. 6, 1968, pp. 1260 1266.;;Gardner, et al., Problems of Localization in the Median Plane: Effect of Pinnae Cavity Occlusion, J. Acoust. Soc. Am., vol. 53, No. 2, 1973, pp. 400 408.;;Handbook for Sound Engineers: The New Audio Cyclopedia, Acoustics Psychoacoustics, 1987 by Howard W. Sams & Co., pp. 25 35.;;McGreevy, Virtual Reality and Planetary Exploration, 29th AAS Goddard Memorial Symposium, Mar. 1991, pp. 1 13.;;Wenzel et al., A Virtual Display System for Conveying Three Dimensional Acoustic Information, Proceedings of the Human Factors Society 32nd Annual Meeting, 1988, pp. 86 90.;;Wightman et al., Headphone Simulation of Free Field Listening. I: Stimulus Synthesis, J. Acoust. Soc. Am., vol. 85, No. 2, Feb. 1989, pp. 858 867.;;Linkwitz, Improved Headphone Listening: Build a Stereo Crossfeed Circuit, Audio, Dec. 1971, pp. 42 43.;;Eargle, An Earing Earing, Audio, Sep. 1990, pp. 25 32.;;Pohlmann, Psycho What Psychoacoustics, Stereo Review, Sep. 1989, pp. 117 120.;;Klein, Audio Update Can You Believe Your Ears , Radio Electronics, Dec.1987, pp. 40 45.;;Feldman, Beyond Stereo: The Sound Retrieval System Adds a New Dimension to Audio Reproduction, Radio Electronics, Sep. 1989, pp. 51 54.;;Vaughan, How We Hear Direction, Audio, Dec. 1983, pp. 51 55.;;Roeffler et al., Factors that Influence the Localization of Sound in the Vertical Plane, J. Acoust. Soc. Am., vol. 43, No. 6, 1968, pp. 1255 1259.;;Chamberlin, Musical applications of microprocessors, Hayden Book CO., pp. 446 459, 1980 91.",EXPIRED
696,US,A1,US 2013/0312768 A1,180-727-376-148-607,2013-11-28,2013,US 201213985977 A,2012-02-16,US 201213985977 A;;US 201161443839 P;;US 2012/0025458 W,2011-02-17,APPARATUS AND METHODS FOR THE TREATMENT OF SLEEP APNEA,"A medical apparatus for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient is provided. The apparatus comprises an elongate member with a middle portion, a first fixation element and a second fixation element. The middle portion applies a force to a segment of a patient's airway.",FLAHERTY CHRISTOPHER J;;GARIBOTTO JOHN T;;GORMAN WILLIAM J;;IRWIN III JOHN N;;FRIEDMAN MICHAEL;;LUMEN DEVICES LLC,FLAHERTY CHRISTOPHER J;;GARIBOTTO JOHN T;;GORMAN WILLIAM J;;IRWIN III JOHN N;;FRIEDMAN MICHAEL,LUMEN DEVICES LLC (2012-02-23),https://lens.org/180-727-376-148-607,Patent Application,yes,5,13,7,7,0,A61F5/566;;A61F5/566,A61F5/56,128/848,0,0,,,,ACTIVE
697,US,A1,US 2005/0227831 A1,184-482-872-905-972,2005-10-13,2005,US 1686604 A,2004-12-21,US 1686604 A;;US 81911604 A,2004-04-07,Exercise device with removable weight,"An exercise device in which removable weight may be provided in a housing of the device. Two rotatable handles may be provided in the housing, permitting various hand orientations during exercise. The removable weight may be received within and/or removed from a cavity of the device.",MILLS ALDEN M;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM P;;THOMASON RODGER D,MILLS ALDEN M;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM P;;THOMASON RODGER D,PT METERICS LLC (2004-12-17);;IMPLUS FOOTCARE LLC (2011-10-25);;PERFECT PUSHUP LLC (2008-04-22),https://lens.org/184-482-872-905-972,Patent Application,yes,16,54,9,11,0,A63B21/0605;;A63B21/072;;A63B21/0724;;A63B21/0728;;A63B21/075;;A63B23/12;;A63B21/4017;;A63B21/4001;;A63B21/0004;;A63B23/03525;;A63B21/4043;;A63B21/4035;;A63B23/12;;A63B21/072;;A63B21/0605;;A63B21/075;;A63B21/0724;;A63B21/0728;;A63B21/4001;;A63B21/4017;;A63B21/0004;;A63B23/03525;;A63B21/4035;;A63B21/4043,A63B21/005;;A63B21/06;;A63B21/075;;A63B21/072;;A63B23/12,482/106,0,0,,,,INACTIVE
698,JP,A,JP 2010115504 A,097-841-150-402-060,2010-05-27,2010,JP 2010000835 A,2010-01-05,US 8593198 P,1998-05-19,HEMOSTATIC SANDWICH BANDAGE,"<P>PROBLEM TO BE SOLVED: To provide a hemostatic sandwich bandage which can be used to heal a wound. <P>SOLUTION: The hemostatic sandwich bandage relates to a hemostatic multi-layered bandage which is preferably designed to sandwich a thrombin layer between two fibrinogen layers, and may contain another absorptive substance such as a glycolic acid or lactic acid base polymer or copolymer, and further is useful to treat a wounded tissue. The hemostatic sandwich bandage, which is used to treat the wounded tissue of a patient, includes: (i) a first fibrinogen layer; (ii) a thrombin layer adjoining to the first fibrinogen layer; and (iii) a second fibrinogen layer adjoining to the thrombin layer. <P>COPYRIGHT: (C)2010,JPO&INPIT",AMERICAN NAT RED CROSS,MACPHEE MARTIN J;;DROHAN WILLIAM N;;BEALL DAWSON;;FRIEDMAN STANLEY A;;TUTHILL DAVID;;BAYER VLADISLAV,,https://lens.org/097-841-150-402-060,Patent Application,no,0,2,13,14,0,A61L15/225;;A61L15/26;;A61L15/32;;A61L15/64;;A61L26/0042;;A61L26/0047;;A61L2400/04;;A61P17/02,A61F13/00;;A61L15/22;;A61L15/16;;A61L15/26;;A61L15/32;;A61L15/44;;A61L15/64;;A61L26/00,,0,0,,,,DISCONTINUED
699,AU,B2,AU 755486 B2,034-163-545-940-79X,2002-12-12,2002,AU 1999/040016 A,1999-05-19,US 8593198 P;;US 9910952 W,1998-05-19,Hemostatic sandwich bandage,The present invention relates to a haemostatic multilayer bandage that comprises preferably a thrombin layer between two fibrinogen layers. The dressing may contain other resorbable materials such as glycolic acid or lactic acid based polymers or copolymers. The inventive haemostatic sandwich bandage is useful for the treatment of wounded tissue.,AMERICAN NAT RED CROSS,MACPHEE MARTIN J;;DROHAN WILLIAM N;;BEALL DAWSON;;FRIEDMAN STANLEY A;;TUTHILL DAVID;;BAYER VLADISLAV,,https://lens.org/034-163-545-940-79X,Granted Patent,no,3,0,13,14,0,A61L15/225;;A61L15/26;;A61L15/32;;A61L15/64;;A61L26/0042;;A61L26/0047;;A61L2400/04;;A61P17/02,A61F13/00;;A61L15/22;;A61L15/26;;A61L15/32;;A61L15/44;;A61L15/64;;A61L26/00,,0,0,,,,EXPIRED
700,AU,A1,AU 2003/272487 A1,051-960-226-228-381,2004-04-08,2004,AU 2003/272487 A,2003-09-15,US 41133602 P;;US 41961302 P;;US 27447802 A;;US 0329226 W,2002-09-17,SERVER-BASED MESSAGE PROTOCOL TRANSLATION,,BELLSOUTH INTELLECT PTY CORP,DANIELL WILLIAM TODD;;DAIGLE BRIAN KEITH;;KENT LARRY GRAHAM;;DAVIS JOEL A;;FRIEDMAN LEE G,,https://lens.org/051-960-226-228-381,Patent Application,no,0,0,10,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L69/08;;H04L51/234,G06Q10/10;;H04L12/58;;H04L29/06,,0,0,,,,DISCONTINUED
701,US,A1,US 2015/0342779 A1,137-237-109-870-40X,2015-12-03,2015,US 201514818914 A,2015-08-05,US 201514818914 A;;US 201113130869 A;;US 2009/0065923 W;;US 20963509 P;;US 20375808 P;;US 20017208 P,2008-11-25,"DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF SLEEP APNEA","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN III JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,LUMEN DEVICES LLC (2015-08-10),https://lens.org/137-237-109-870-40X,Patent Application,yes,25,6,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56,,0,0,,,,ACTIVE
702,EP,A1,EP 0998311 A1,063-549-369-679-02X,2000-05-10,2000,EP 99923189 A,1999-05-19,US 9910952 W;;US 8593198 P,1998-05-19,HEMOSTATIC SANDWICH BANDAGE,The present invention relates to a haemostatic multilayer bandage that comprises preferably a thrombin layer between two fibrinogen layers. The dressing may contain other resorbable materials such as glycolic acid or lactic acid based polymers or copolymers. The inventive haemostatic sandwich bandage is useful for the treatment of wounded tissue.,AMERICAN NAT RED CROSS,MACPHEE MARTIN J;;DROHAN WILLIAM N;;BEALL DAWSON;;FRIEDMAN STANLEY A;;TUTHILL DAVID;;BAYER VLADISLAV,,https://lens.org/063-549-369-679-02X,Patent Application,yes,0,1,13,14,0,A61L15/225;;A61L15/26;;A61L15/32;;A61L15/64;;A61L26/0042;;A61L26/0047;;A61L2400/04;;A61P17/02,A61F13/00;;A61L15/22;;A61L15/26;;A61L15/32;;A61L15/44;;A61L15/64;;A61L26/00,,0,0,,,,EXPIRED
703,US,B2,US 9668911 B2,098-004-937-408-093,2017-06-06,2017,US 201213985977 A,2012-02-16,US 201213985977 A;;US 201161443839 P;;US 2012/0025458 W,2011-02-17,Apparatus and methods for the treatment of sleep apnea,"A medical apparatus for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient is provided. The medical apparatus has an elongate member with a middle portion, a first fixation element and a second fixation element. The middle portion applies a force to a segment of a patient's airway.",FLAHERTY CHRISTOPHER J;;GARIBOTTO JOHN T;;GORMAN WILLIAM J;;IRWIN III JOHN N;;FRIEDMAN MICHAEL;;LUMEN DEVICES LLC,FLAHERTY CHRISTOPHER J;;GARIBOTTO JOHN T;;GORMAN WILLIAM J;;IRWIN III JOHN N;;FRIEDMAN MICHAEL,LUMEN DEVICES LLC (2012-02-23),https://lens.org/098-004-937-408-093,Granted Patent,yes,33,3,7,7,0,A61F5/566;;A61F5/566,A61F5/56,,3,0,,,"International Preliminary Report on Patentability dated Aug. 29, 2013 corresponding to PCT/US2012/025458, 27 pp.;;International Search Report and Written Opinion dated Jul. 16, 2012 from PCT/US2012/025458; 41 pages.;;Canadian Office Action dated Sep. 6, 2016 issued in corresponding Canadian Application No. 2,911,748.",ACTIVE
704,US,B2,US 7179271 B2,038-070-129-510-697,2007-02-20,2007,US 32622302 A,2002-12-20,US 32622302 A;;US 86694801 A;;US 24189500 P,2000-10-20,Method for driving an ultrasonic system to improve acquisition of blade resonance frequency at startup,"The ability of an ultrasonic system to sweep and lock onto a resonance frequency of a blade subjected to a heavy load at startup is improved by applying a high drive voltage or a high drive current while systematically increasing the level of the applied signal. Increasing the drive signal to the hand piece results in an improved and more pronounced “impedance spectrum.” That is, under load, the increased drive signal causes the maximum phase margin to become higher and the minimum/maximum impedance magnitude to become more pronounced. Increasing the excitation drive signal to the hand piece/blade at startup significantly alleviates the limiting factors associated with ultrasonic generators, which results in an increase of the maximum load capability at startup.",ETHICON ENDO SURGERY INC,FRIEDMAN ALLAN L;;DONOFRIO WILLIAM T;;WIENER EITAN T;;BROTZ JOSEPH A;;HEIN JOHN E,,https://lens.org/038-070-129-510-697,Granted Patent,yes,13,389,12,15,0,A61B17/320068;;A61B17/320068;;A61B2017/00026;;A61B2017/00026;;A61B2017/00725;;A61B2017/00725;;A61B2017/320069;;A61B2017/320069;;A61B2017/320071;;A61B2017/320071;;A61B2017/320089;;A61B2017/320089,A61B17/32;;A61B17/00,606/169;;606/1;;702/106,1,0,,,"EPO Communication dated Jul. 28, 2005 for corresponding patent application, European Patent Application No. EP 01 308 910.",EXPIRED
705,WO,A1,WO 1999/059647 A1,085-936-928-072-223,1999-11-25,1999,US 9910952 W,1999-05-19,US 8593198 P,1998-05-19,HEMOSTATIC SANDWICH BANDAGE,The present invention relates to a haemostatic multilayer bandage that comprises preferably a thrombin layer between two fibrinogen layers. The dressing may contain other resorbable materials such as glycolic acid or lactic acid based polymers or copolymers. The inventive haemostatic sandwich bandage is useful for the treatment of wounded tissue.,AMERICAN NAT RED CROSS;;MACPHEE MARTIN J;;DROHAN WILLIAM N;;BEALL DAWSON;;FRIEDMAN STANLEY A;;TUTHILL DAVID;;BAYER VALDISLAV,MACPHEE MARTIN J;;DROHAN WILLIAM N;;BEALL DAWSON;;FRIEDMAN STANLEY A;;TUTHILL DAVID;;BAYER VALDISLAV,,https://lens.org/085-936-928-072-223,Patent Application,yes,4,73,13,14,0,A61L15/225;;A61L15/26;;A61L15/32;;A61L15/64;;A61L26/0042;;A61L26/0047;;A61L2400/04;;A61P17/02,A61L15/22;;A61L15/26;;A61F13/00;;A61L15/32;;A61L15/44;;A61L15/64;;A61L26/00,,1,1,011-357-808-224-578,10.1016/s0039-6109(05)70596-x;;9291993,"HOLCOMB J.B. ET AL.: ""Implications of new dry fibrin sealant technology for trauma surgery"", SURGICAL CLINICS OF NORTH AMERICA, vol. 77, no. 4, 1997, pages 943 - 950, XP002113927",PATENTED
706,US,A1,US 2017/0266034 A1,115-313-885-981-915,2017-09-21,2017,US 201715611085 A,2017-06-01,US 201715611085 A;;US 201313985977 A;;US 2012/0025458 W;;US 201161443839 P,2011-02-17,APPARATUS AND METHODS FOR THE TREATMENT OF SLEEP APNEA,"A medical apparatus for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient is provided. The apparatus comprises an elongate member with a middle portion, a first fixation element and a second fixation element. The middle portion applies a force to a segment of a patient's airway.",LUMEN DEVICES LLC,FLAHERTY J CHRISTOPHER;;GARIBOTTO JOHN T;;GORMAN WILLIAM J;;IRWIN III JOHN N;;FRIEDMAN MICHAEL,LUMEN DEVICES LLC (2012-02-23),https://lens.org/115-313-885-981-915,Patent Application,yes,4,3,7,7,0,A61F5/566;;A61F5/566,A61F5/56,,0,0,,,,ACTIVE
707,US,B1,US 6762336 B1,191-089-785-235-678,2004-07-13,2004,US 89079502 A,2002-03-22,US 89079502 A;;US 8593198 P;;US 9910952 W,1998-05-19,Hemostatic sandwich bandage,"
    The present invention relates to a haemostatic multilayer bandage that comprises preferably a thrombin layer between two fibrinogen layers. The dressing may contain other resorbable materials such as glycolic acid or lactic acid based polymers or copolymers. The inventive haemostatic bandage is useful for the treatment of wounded tissue. 
",AMERICAN NAT RED CROSS,MACPHEE MARTIN J;;DROHAN WILLIAM N;;BEALL DAWSON;;FRIEDMAN STANLEY A;;TUTHILL DAVID;;BAYER VALDISLAV,THE AMERICAN NATIONAL RED CROSS (2002-05-14),https://lens.org/191-089-785-235-678,Granted Patent,yes,100,144,1,14,0,A61L15/32;;A61L15/32;;A61L15/225;;A61L15/225;;A61L15/26;;A61L15/26;;A61L2400/04;;A61L2400/04,A61L15/22;;A61L15/26;;A61L15/32;;A61L15/64;;A61L26/00,602/48;;602/42;;602/43,99,88,011-357-808-224-578;;054-761-271-598-661;;035-580-799-773-729;;085-229-193-125-327;;047-642-252-769-343;;129-573-254-125-361;;051-081-881-216-749;;031-823-064-166-176;;041-392-736-422-664;;072-341-907-345-400;;103-519-576-757-395;;034-321-956-199-722;;089-499-623-386-021;;055-196-942-859-234;;035-958-605-459-662;;148-478-453-072-120;;002-911-456-533-439;;061-191-090-939-297;;051-713-213-812-070;;029-097-789-036-613;;005-309-007-010-744;;126-384-438-432-92X;;095-163-015-743-716;;024-277-889-286-165;;055-994-635-903-465;;031-945-956-858-202;;030-563-040-050-764;;048-628-838-341-462;;016-211-023-381-848;;076-437-673-330-24X;;082-944-611-153-245;;098-850-198-430-483;;023-620-295-834-979;;052-365-914-379-888;;040-772-437-870-051;;052-387-422-195-369;;040-572-504-138-869;;054-310-498-662-418;;078-910-698-376-942;;002-475-901-422-211;;018-861-067-407-293;;060-489-267-240-250;;037-619-930-702-247;;003-076-604-905-549;;025-446-123-002-684;;017-271-025-337-083;;072-132-644-949-278;;008-420-938-757-517;;016-368-347-417-97X;;043-344-285-039-493;;086-336-719-442-205;;037-712-184-693-073;;000-724-971-353-479;;008-872-273-137-977;;057-937-750-535-903;;147-231-611-702-546;;027-449-012-247-423;;149-751-371-842-92X;;017-906-956-061-413;;013-687-251-803-592;;017-801-352-633-838;;072-447-826-926-268;;109-270-513-405-12X;;038-592-919-512-599;;015-936-534-082-593;;138-991-779-752-411;;080-905-507-136-643;;115-679-521-048-493;;109-951-220-582-759;;041-055-399-124-334;;083-042-581-202-256;;088-359-481-222-353;;074-827-543-031-71X;;031-450-037-915-54X;;019-273-790-723-231;;059-873-053-174-770;;054-291-865-062-73X;;036-505-593-321-467;;087-980-411-360-215;;081-655-232-838-984;;005-516-077-530-085;;002-867-986-848-133;;014-716-808-813-365;;110-634-124-236-510;;107-757-446-995-394;;011-357-808-224-578;;079-675-708-493-157;;084-530-983-034-725,10.1016/s0039-6109(05)70596-x;;9291993;;8150838;;10.1097/00004630-199401000-00005;;2351154;;150066;;10.1055/s-0028-1096612;;10.3109/17453678208992288;;7136585;;10.1046/j.1537-2995.1995.35996029166.x;;7570942;;6384560;;10.1016/0741-5214(84)90201-5;;10.1067/mva.1984.avs0010224;;3876217;;10.1159/000128477;;7020640;;10.1007/bf00632975;;14914563;;10.1172/jci101528;;pmc435377;;16695139;;pmc435378;;10.1172/jci101529;;16695140;;20260247;;10.3171/jns.1947.4.5.0465;;2480829;;10.1093/oxfordjournals.bmb.a072333;;10.1097/00000658-197201000-00018;;pmc1355166;;5060850;;2421948;;339885;;10.1007/bf00415894;;384681;;10.1007/bf00457781;;7000033;;7023075;;10.1016/s0022-5223(19)38982-2;;6981733;;10.1001/archsurg.1992.01420040046007;;1558491;;10.1146/annurev.bi.58.070189.003043;;10.1146/annurev.biochem.58.1.575;;2549857;;1714789;;10.1002/bjs.1800780723;;3380851;;10.1016/s0140-6736(45)90653-2;;1709215;;10.1016/0741-5214(91)90367-4;;3706490;;pmc1888315;;10.1001/jama.1944.02850140022006;;3289048;;10.1097/00007611-194303000-00001;;10.1016/s0022-5347(17)70580-0;;pmc435374;;16695136;;10.1172/jci101525;;10.1016/s0022-5347(17)69808-2;;21000047;;6084332;;10.1055/s-2007-1023425;;10.1016/s0003-4975(10)60074-4;;3876814;;10.1097/00005373-199103000-00018;;2002531;;10.1097/00005373-199004000-00028;;2325186;;10.1067/mva.1984.avs0010171;;6207313;;10.1016/0741-5214(84)90196-4;;10.1097/00005373-199001000-00016;;2404129;;10.1097/00005373-199007000-00020;;2381006;;10.1016/0003-4975(90)90080-p;;2369228;;10.1001/jama.1979.03290420016016;;10.1001/jama.241.16.1690;;430729;;1728869;;10.1093/ajcp/97.1.84;;10.1016/s0887-7963(96)80085-x;;8721966;;10.1097/00005373-198207000-00151;;10.1016/0267-6605(92)90097-d;;10149967;;10.1001/jama.1995.03530170048031;;10.1001/jama.274.17.1368;;7563562;;8578510;;10.1055/s-0038-1642725;;3873716;;2447216;;10.1017/s0022215100103469;;2447383;;10.1177/000348948609500109;;2418738;;10.1172/jci101523;;pmc435372;;16695134;;10.1016/0022-4804(86)90021-1;;2945052;;2986538;;10.1146/annurev.physiol.47.1.443;;10.1146/annurev.ph.47.030185.002303;;10.1097/00003226-199209000-00006;;1424666;;10.1288/00005537-198510000-00028;;2413324;;10.1046/j.1537-2995.1990.30891020337.x;;2219264;;20988494;;10.1210/edrv-8-2-95;;2440668;;6138969;;7071743;;10.1002/jbm.820250104;;2019611;;2356856;;pmc1877595;;3535846;;2950245;;10.1016/0741-5214(87)90151-0;;10.1067/mva.1987.avs0050393;;1641764;;2439776;;10.1016/0022-4804(87)90049-7;;411428;;pmc1396310;;10.1097/00000658-197711000-00009;;10.1016/s0002-9610(44)90342-9;;10.1016/s0022-5347(17)68877-3;;18151893;;1988283;;10.1016/0014-4827(91)90050-5;;2412249;;10.1097/00006534-198510000-00030;;2230431;;10.1055/s-2007-1023489;;6179195;;6182630;;10.1055/s-2007-1022390;;10.1016/s0003-4975(10)60766-7;;6231896;;2519992;;10.1111/j.1540-8191.1989.tb00269.x;;1530824;;10.1067/mva.1992.30301;;10.1016/0741-5214(92)70027-i;;10.1172/jci101526;;pmc435375;;16695137;;10.1016/0006-291x(87)91011-4;;2443140;;3612959;;10.1067/mva.1987.avs0060114;;2129006;;10.1016/0002-9610(50)90269-8;;10.1016/s0039-6109(05)70596-x;;9291993;;6408315;;10.1002/jso.2930230303;;10.1001/jama.1944.02850460010003,"Holcomb, J.B. et al., ""Implications of New Dry Fibrin Sealant Technology for Trauma Surgery,"" Damage Control Surg. 77:943-952, W.B. Saunders, Inc. (1997).;;Dialog File 351, Accession No. 3793917, Derwent WPI English language abstract for EP 0 090 997 A2 (Document AL1).;;International Search Report for International Application No. PCT/US99/10952, mailed Sep. 17, 1999.;;Achauer, B.M., et al., ""The Hemostatic Effect of Fibrin Glue on Graft Donor Sites,"" J. Burn. Care Rehabil. 15:24-28, Burn Science Publishers, Inc. (1994).;;Adelmann-Grill, B.C., et al., ""Chemotactic migration of normal dermal fibroblasts towards epidermal growth factor and its modulation by platelet-derived growth factor and transforming growth factor-beta,"" Eur. J. Cell. Biol. 51:322-326, Wissenschaftliche Verlagsgesellschaft mbH (1990).;;Akrami, R., et al., ""Replacement of the Thoraric Aorta by Sealed Dacron Prostheses,"" Thoraxchirurgie 26:144-147, Georg Thieme Verlag Stuttgart (1978) Summary Only.;;Albrektsson, T., et al., ""Fibrin Adhesive System (FAS) Influence on Bone Healing Rate,"" Acta orthop. scand. 53:757-763, Munksgaard (1982).;;Alving, B.M., et al., ""Fibrin sealant: summary of a conference on characteristics and clinical uses,"" Transfusion 35:783-790, The American Association of Blood Banks (1995).;;Allen, B.T., et al., ""Influence of endothelial cell seeding on platelet deposition and patency in small-diameter Dacron arterial grafts,"" J. Vasc. Surg. 1:224-233, Mosby-Year Book Inc. (1984).;;The American Red Cross, ""Growth Factor-Supplemented Fibrin Glue,"" in The American Red Cross Biomedical Research and Development Report, p. 21, The American Red Cross (1989).;;The American Red Cross, ""Growth Factor-Supplemented Fibrin Glue,"" in The American Red Cross Biomedical Research and Development Report, p. 20, The American Red Cross (1990).;;Andreassen, T.T., and Jorgensen, P.H., ""Biomechanical Properties and Collagen Formation in Subcutaneously Implanted Cellulose Sponges Treated with Fibrin Sealant,"" Eur. surg. Res. 17:264-268, S.Karger AG (1985).;;Arbes, H., et al., ""First Clinical Experience with Heterologous Cancellous Bone Grafting Combined with the Fibrin Adhesive System (F.A.S.),"" Arch. Orthop. Traumat. Surg. 98:183-188, J.F.Bergmann Verlag (1981).;;Bagdy, D., et al., ""Application of Bovine Fibrin Foam and of a Mixture of Thrombin and Fibrin Powders as Haemostatic Agents,"" Acta. Physiol. Acad. Sci. Hung. 2:493-504, Magyar Tudományos Akadémia (1951).;;Bailey, O.T., and Ingraham, F.D., ""Chemical, Clinical, and Immunological Studies on the Products of Human Plasma Fractionation. XXI. The Use of Fibrin Foam as Hemostatic Agent in Neurosurgery: Clinical and Pathological Studies,"" J. Clin. Invest. 23:591-596, The American Society for Clinical Investigation (1944).;;Bailey, O.T., and Ingraham, F.D., ""Chemical, Clinical, and Immunological Studies on the Products of Human Plasma Fractionation. XXII. Fibrin Films in Neurosurgery, with Special Reference to Their Use in the Repair of Dural Defects and in the Prevention of Meningocerebral Adhesions,"" J. Clin. Invest. 23:597-600, The American Society for Clinical Investigation (1944).;;Bailey, O.T., et al., ""Fibrin Film in Neurosurgery, Further Studies: The Insertion of Fibrin Film Between the Sutured Dura and The Intact Leptomeninges; The Effect of Roentgen Therapy on Tissue Reactions to Fibrin Film,"" J. Neurosurg. 4:465-471, American Association of Neurosurgical Surgeons (1947).;;Baird, A., and Walicke, P.A., ""Fibroblast growth factors,"" Brit. Med. Bull. 45:438-452, The British Council (1989).;;Berger, K., et al., ""Healing of Arterial Prostheses in Man: Its Incompleteness,"" Ann. Surg. 175:118-127, J.B. Lippincott Company (1972).;;Bishara, S.E., et al., ""Effects of a Fibrin-Sealant Wound Dressing on the Healing of Full-Thickness Wounds of the Hard Palate: Preliminary Report,"" Cleft Palate J. 23:144-152, Allen Press Inc. (1986).;;Bösch, P., et al., ""The Technic of Fibrin Glue in Cancellous Bone Transplants,"" Arch. orthop. Unfall-Chir. 90:63-75, J.F. Bergmann-Verlag (1977) Summary Only.;;Bösch, P., et al., ""Autologous Cancellous Bone Grafting in Rabbits Using a Fibrinogen Adhesive System,"" Wiener klinische Wochenschrift 91:628-634, Springer-Verlag Wien (1979) Summary Only.;;Bösch, P., ""Experimental Investigations of the Effect of the Fibrin Adhesive on the Kiel Heterologous Bone Graft,"" Arch. Orthop. Traumat. Surg. 96:177-185, J.F. Bergmann Verlag (1980).;;Bösch, P., ""Bone Grafting with Fibrin-Glue,"" Weiner klinische Wochenschrift 93:3-26, Springer-Verlag Wien (1981).;;Borst, H.G., et al., ""Fibrin adhesive: An important hemostatic adjunct in cardiovascular operations,"" J. Thorac. Cardiovasc. Surg. 84:548-553, The C.V. Mosby Co. (1982).;;Brown, D.M,. et al., ""Decreased Wound Contraction With Fibrin Glue-Treated Skin Grafts,"" Arch. Surg. 127:404-406, American Medical Association (1992).;;Burgess, W.H., and Maciag, T., ""The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins,"" Annu. Rev. Biochem. 58:575-606, Annual Reviews Inc. (1989).;;Byrne, D.J., et al., ""Effect of fibrin glues on the mechanical properties of healing wounds,"" Br. J. Surg. 78:841-843, Butterworth-Heinemann Ltd. (1991).;;Carter, D.M., et al., ""Clinical Experience with Crude Preparations of Growth Factors in Healing of Chronic Wounds in Human Subjects,"" Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Implications, Alan R. Liss, Inc., pp. 303-317 (1988).;;Clark, A.M., et al., ""Fixation of Skin-Grafts with Human Plasma and Thrombin,"" Lancet 1:498-500, The Lancet Ltd. (1945).;;Clowes, A.W., and Kohler, T., ""Graft Endothelialization: The Role of Angiogenic Mechanisms,"" J. Vasc. Surg. 13:734-736, Mosby-Year Book, Inc. (1991).;;Clowes, A.W., et al., ""Mechanisms of Arterial Graft Healing. Rapid Transmural Capillary Ingrowth Provides a Source of Intimal Endothelium and Smooth Muscle in Porous PTFE Prostheses,"" Am. J. Pathol. 123:220-230, American Society of Investigative Pathology (1986).;;Conant, M., et al., ""Treatment of Condylomata Acuminata with Intralesional 5-Fluorouracil Therapeutic Implant (MPI 5003),"" Clinical Res. 39:818A, The American Federation for Clinical Research (1991).;;Cronkite, E.P., et al., ""Use of Thrombin and Fibrinogen in Skin Grafting: Preliminary Report,"" J.A.M.A. 124:976-978, The American Medical Association (1944).;;Cziperle, D., et al., ""Enhanced Endothelialization of Expanded Polytetrafluoroethylene Grafts by Heparin Binding Growth Factor-Type I (HBGF-1) Pretreatment,"" Presented at the Society of University Surgeons (Feb. 1992).;;Davidson, J., et al., ""Mechanisms of Accelerated Wound Repair Using Epidermal Growth Factor and Basic Fibroblast Growth Factor,"" in Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Implications, Alan R. Liss, Inc., pp. 63-75 (1988).;;Dees, J.E., ""The Use of an Intrapelvic Coagulum in Pyelolithotomy: Preliminary Report,"" South. Med. J. 36:167-175, The Southern Medical Association (1943).;;Dees, J.E., and Fox, H., ""The Properties of Human Fibrinogen Coagulum-Preliminary Report,"" J. Urol. 49:503-511, The Williams & Wilkins Company (1943).;;Dees, J.E., ""Chemical, Clinical, and Immunological Studies on the Products of Human Plasma Fractionation. XVIII. Fibrinogen Coagulum as an Aid in the Operative Removal of Renal Calculi,"" J. Clin. Invest. 23:576-579, The American Society for Clinical Investigation (1944).;;Dees, J.E., ""The Use of a Fibrinogen Coagulum in Pyelolithotomy,"" J. Urol. 56:271-283, The Williams & Wilkins Company (1946).;;Deyerling, W., et al., ""A Suspension of Fibrin Glue and Antibiotic for Local Treatment of Myocotic Aneurysms in Endocarditis-An Experimental Study,"" Thorac. cardiovasc. Surgeon 32:369-372, Georg Thieme Verlag Stuttgart (1984).;;Dresdale, A., et al., ""Hemostatic Effectiveness of Fibrin Glue Derived from Single-Donor Fresh Frozen Plasma,"" Ann. Thorac. Surg. 40:385-387, The Society of Thoracic Surgeons (1985).;;Berguer, R., et al., ""Warning: Fatal Reaction to the Use of Fibrin Glue in Deep Hepatic Wounds. Case Reports,"" J. Trauma 31:408-411, Williams & Wilkens Company (1991).;;de la Garza, J.L., and Rumsey Jr., E., ""Fibrin Glue and Hemostatis in Liver Trauma: A Case Report,"" J. Trauma 30:512-513, Williams & Wilkens Company (1990).;;Jakob, H., et al., ""Use of fibrin sealant for reinforcing arterial anastomoses,"" J. Vasc. Surg. 1:171-180, C.V. Mosby Company (1984).;;Kendrick, D.B., et al., ""Plasma Fractionation,"" in Blood Program in World War II, Coates, Jr., J.B., and McFetridge, E.M., eds., Office of the Surgeon General, Dept. of the Army, Washington, D.C. pp. 363-369 (1964).;;Kram, H.B., et al., ""Techniques of Splenic Preservation Using Fibrin Glue,"" J. Trauma 30:97-101, Williams & Wilkens Company (1990).;;Ochsner, M.G., et al., ""Fibrin Glue as a Hemostatic Agent in Hepatic and Splenic Trauma,"" J. Trauma 30:884-887, Williams & Wilkens Company (1990).;;Matthew, T.L., et al., ""Four Years Experience With Fibrin Sealant in Thoracic and Cardiovascular Surgery,"" Ann. Thorac. Surg. 50:40-44, Elsevier (1990).;;Ness, P.M., and Perkins, H.A., ""Cryoprecipitate as a Reliable Source of Fibrinogen Replacement,"" JAMA 241:1690-1691, American Medical Association (1979).;;Rapaport, S.I., ""Clinical Significance of Antibodies to Bovine and Human Thrombin and Factor V After Surgical Use of Bovine Thrombin,"" Am. J. Clin. Pathol. 97:84-91, J.B. Lippincott Company (1992).;;Reiss, R.F., and Oz, M.C., ""Autologous Fibrin Glue: Production and Clinical Use,"" Transfus. Med. Rev. 10:85-92, W.B. Saunders Company (1996).;;Rocko, J.M., et al., ""A.A.S.T. Abstracts: Exsanguination in public-a preventable death,"" J. Trauma 22:635, Williams & Wilkens Company (1982).;;Schiele, U., et al., ""Haemostyptic Preparations on the Basis of Collagen alone and as fixed Combination with Fibrin Glue,"" Clin. Mater. 9:169-177, Elsevier Science Publishers, Ltd. (1992).;;Sloand, E.M., et al., ""Safety of the Blood Supply,"" JAMA 274:1368-1373, American Medical Association (1995).;;Spotnitz, W.D., ""Fibrin Sealant in the United States: Clinical Use at the University of Virginia,"" Thromb. Haemost. 74:482-485, Stuttgart F.K. Schattauer Verlag (1995).;;Zimmerman, L.M., and Veith, I., ""Celsus and the Alexandrians,"" in Great Ideas in the History of Surgery, Zimmerman, L.M., and Veith, I., eds., Norman Publishing, San Francisco, CA, p. 31 (1993).;;Dresdale, A., et al., ""Preparation of fibrin glue from single-donor fresh-frozen plasma,"" Surgery 97:750-755, Mosby-Year Book, Inc. (1985).;;Durham, L.H., et al., ""A method for preparation of fibrin glue,"" J. Laryngol. Otol. 101:1182-1186, Headley Brothers Ltd. (1987).;;Dvorak, H.F., et al., ""Fibrin Containing Gels Induce Angiogenesis. Implications for Tumor Stroma Generation and Wound Healing,"" Lab. Invest. 57:673-686, The United States and Canadian Academy of Pathology, Inc. (1987).;;Epstein, G.H., et al., ""A New Autologous Fibrinogen-Based Adhesive for Otologic Surgery,"" Ann. Otol. Rhinol. Laryngol. 95:40-45, Annals Publishing Company (1986).;;Ferry, J.D., and Morrison, P.R., ""Chemical, Clinical, and Immunological Studies on the Products of Human Plasma Fractionation. XVI. Fibrin Clots, Fibrin Films, and Fibrinogen Plastics,"" J. Clin. Invest. 23:566-572, The American Society for Clinical Investigation (1944).;;Foxall, T.L., et al., ""Adult Human Endothelial Cell Coverage of Small-Caliber Dacron and Polytetrafluoroethylene Vascular Protheses in Vitro,"" J. Surg. Res. 41:158-172, Academic Press, Inc. (1986).;;Froesch, R.R., et al., ""Actions of Insulin-Like Growth Factors,"" Ann. Rev. Physiol. 47:443-467, Annual Reviews, Inc. (1985).;;Frucht-Perry, J., et al., ""Fibrin-Enmeshed Tobramycin Liposomes: Single Application Topical Therapy of Pseudonas Keratitis,"" Cornea 11:393-397, Raven Press, Ltd. (1992).;;Gerendás, M., ""Fibrin Products as Aids in Hemostatis and Wound Healing,"" in Fibrinogen, Chapter 13, Laki, K., Ed., Marcel Dekker, New York, pp. 277-316 (1968).;;Gersdorff, M.C.H., and Robillard, T.A.J., ""'How I do It'-Otology and Neurotology. A Specific Issue and Its Solution. A New Procedure for Bone Reconstruction in Oto-Microsurgery: A Mixture of Bone Dust And Fibrinogen Adhesive,"" Laryngoscope 95:1278-1280, The Laryngoscope Company (1985).;;Gibble, J.W., and Ness, P.M., ""Fibrin glue: the perfect operative sealant?,"" Transfusion 30:741-747, American Association of Blood Banks (1990).;;Glynn, J.H., and Richardson, J.H., ""The Antigenic Properties of Fibrin Films and Foams Prepared from Human and from Bovine Blood Plasma,"" J. Immunol. 53:143-150, The Williams & Wilkens Company (1946).;;Gospodarowicz, D., et al., ""Structural Characterization and Biological Functions of Fibroblast Growth Factor,"" Endocr. Rev. 8:95-114, The Endocrine Society (1987).;;Goudarzi, Y.M., ""Clinical Experiences with a Fibrin-Nebacetin Bone Marrow Combination in the Treatment of Chronic Bone Infections and as Local Infection Prophylaxis in Non-Infected Bone Diseases,"" Akt. Traumatol. 13:205-209, Georg Thieme Verlag Stuttgart (1983) Summary Only.;;Graham, L.M., et al., ""Expanded polytetrafluoroethylene vascular protheses seeded with enzymatically derived and cultured canine endothelial cells,"" Surgery 91:550-559, The C.V. Mosby Co. (1982).;;Greco, F., et al., ""Fibrin-antibiotic mixtures: An in vitro study assessing the possibility of using a biologic carrier for local drug delivery,"" J. Biomed. Mater. Res. 25:39-51, John Wiley & Sons, Inc. (1991).;;Greenhalgh, D.G., et al., ""PDGF and FGF Stimulate Wound Healing in the Genetically Diabetic Mouse,"" Am. J. Path. 136:1235-1246, American Association of Pathologists (1990).;;Greisler, H.P., et al., ""Endothelial Cell Growth Factor Attachment to Biomaterials,"" Trans. Am. Soc. Artif. Intern. Organs 32:346-349, American Society for Artificial Internal Organs (1986).;;Greisler, H.P., et al., ""Biomaterial pretreatment with ECGF to augment endothelial cell proliferation,"" J. Vasc. Surg. 5:393-399 and 402, Mosby-Year Book, Inc. (1987).;;Greisler, H.P., et al., ""Enhanced endothelialization of expanded polytetrafluoroethylene grafts by fibroblast growth factor type 1 pretreatment,"" Surgery 112:244-255, Mosby-Year Book, Inc. (1992).;;Greisler, H.P., et al., ""Enhancement of Polytetrafluoroethylene Endothelialization by Pretreatment with Fibrin Glue Containing Heparin Binding Growth Factor-Type I (HBGF-1),"" presented at the Proceedings of the Cardiovascular Science and Technology Conference, p. 50 (Dec. 2-4, 1991).;;Gundry, S.R., and Behrendt, D.M., ""A Quantitative and Qualitative Comparison of Fibrin Glue, Albumin, and Blood as Agents to Pretreat Porous Vascular Grafts,"" J. Surg. Res. 43:75-77, Academic Press, Inc. (1987).;;Harker, L.A., et al., ""Platelet Consumption by Arterial Prostheses: The Effects of Endothelization and Pharmacologic Inhibition of Platelet Function,"" Ann. Surg. 186:594-601, Lippincott Williams & Wilkins (1977).;;Harris, H.I., ""Heterogenous Skin Grafts by Coagulum Contact Method,"" Am. J. Surg. 65:315-320, The American Journal of Surgery, Inc. (1944).;;Harrison, J.H., and Trichel, B. E., ""Experiences with Fibrin Coagulum in Pyelolithotomy,"" j. Urol. 62:1-12, The Williams & Wilkins Company (1949).;;Harrison, E.T., et al., ""Osteogenin Promotes Reexpression of Cartilage Phenotype by Dedifferentiated Articular Chondrocytes in Serum-Free Medium,"" Exp. Cell Res. 192:340-345, Academic Press, Inc. (1991).;;Härting, F., et al., ""Glued Fixation of Split-Skin Graft to the Bony Orbit Following Exenteration,"" Plas. Reconstruc. Surg. 76:633-635, Lippincott Williams & Wilkins (1985).;;Hattori, T., ""Experimental Investigations of Osteogenesis and Chondrogenesis by Implant of BMP-Fibrin Glue Mixture,"" J. Jpn. Orthop. Assoc. 64:824-834, Japanese Orthopedic Association (1990) Summary and Figures Only.;;Haverich, A., et al., ""The Use of Fibrin Glue for Sealing Vascular Protheses of High Porosity,"" Thorac. cardiovasc. Surgeon 29:252-254, Georg Thieme Verlag Stuttgart (1981).;;Haverich, A., et al., ""Evaluation of Fibrin Seal in Animal Experiments,"" Thorac. cardiovasc. Surgeion 30:215-222, Georg Thieme Verlag Stuttgart (1982).;;Haverich, A., et al., ""Histopathological Evaluation of Woven and Knitted Dacron Grafts for Right Ventricular Conduits: A Comparative Experimental Study,"" Ann. Thorac. Surg. 37:404-411, Elsevier Science Inc. (1984).;;Haverich, A., et al., ""Pericardial Flap-Plasty for Protection of the Tracheal Anastomosis in Heart-Lung Transplantation,"" J. Card. Surg. 4:136-139, Futura Publishing Company, Inc (1989).;;Haverich, A., et al., ""Prevention of graft infection by bonding of gentamycin to Dacron prostheses,"" J. Vasc. Surg. 15:187-193, Mosby-Year Book, Inc. (1992).;;Hawn, C.v.Z, et al., ""Chemical, Clinical and Immunological Studies on the Products of Human Plasma Fractionation. XIX. A Note on the Use of Fibrinogen and Thrombin in the Surface Treatment of Burns,"" J. Clin. Invest. 23:580-585, The American Society for Clinical Investigation (1944).;;Hayek, A., et al., ""An in Vivo Model for Study of the Angiogenic Effects of Basic Fibroblast Growth Factor,"" Biochem. Biophys. Res. Commun. 147:876-880, Academic Press, Inc. (1987).;;Herring, M.B., et al., ""Endothelial Seeding of Polytetrafluoroethylene Popliteal bypasses,"" J. Vasc. Surg. 6:114-118, Mosby-Year Book, Inc. (1987).;;Ho, H.-O., et al., ""Drug Release From Glutaraldehyde-Treated Fibrin Gels,"" Drug Des. Del. 7:65-73, Harwood Academic Publishers GmbH (1990).;;Hoffman, H.A., ""Coagulum Pyelolithotomy,"" Am. J. Surg. 79:598-602, Excerpta Medica, Inc. (1950).;;Holcomb, J.B., et al., ""Implications of New Dry Fibrin Sealant Technology for Trauma Surgery,"" Surg. Clin. North Am. 77:943-952, W.B. Saunders Company (Aug. 1997).;;Ikossi-O'Connor, M.G., et al., ""The Role of Fibrin Adhesive in Vascular Surgery,"" J. Surg. Oncol. 23:151-152, Alan R. Liss, Inc. (1983).;;Ingraham, F.D., and Bailey, O.T., ""Clinical Use of Products of Human Plasma Fractionation. III. The Use of Products of Fibrinogen and Thrombin in Surgery,"" J.A.M.A. 126:680-685, The American Medical Association (1944).;;Ingraham, F.D., and Bailey, O.T., ""The Use of Products Prepared from Human Fibrinogen and Human Thrombin in Neurosurgery. Fibrin Foams as Hemostatic Agents; Fibrin Films in Repair of Dural Defects and in Prevention of Meningocerebral Adhesions,"" J. Neurosurg. 1:23-39, Charles C. Thomas (1944).",EXPIRED
708,WO,A1,WO 2012/112783 A1,064-224-015-564-39X,2012-08-23,2012,US 2012/0025458 W,2012-02-16,US 201161443839 P,2011-02-17,APPARATUS AND METHODS FOR THE TREATMENT OF SLEEP APNEA,"A medical apparatus for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient is provided. The apparatus comprises an elongate member with a middle portion, a first fixation element and a second fixation element. The middle portion applies a force to a segment of a patient's airway.",LUMEN DEVICES LLC;;FLAHERTY J CHRISTOPHER;;GARIBOTTO JOHN T;;GORMAN WILLIAM J;;IRWIN III JOHN N;;FRIEDMAN MICHAEL,FLAHERTY J CHRISTOPHER;;GARIBOTTO JOHN T;;GORMAN WILLIAM J;;IRWIN III JOHN N;;FRIEDMAN MICHAEL,,https://lens.org/064-224-015-564-39X,Patent Application,yes,28,0,7,7,0,A61F5/566;;A61F5/566,A61F5/56;;A61F2/20;;A61F11/00,,0,0,,,,PENDING
709,WO,A2,WO 2004/027562 A2,123-315-982-942-052,2004-04-01,2004,US 0329226 W,2003-09-15,US 41133602 P;;US 41961302 P;;US 27447802 A,2002-09-17,SERVER-BASED MESSAGE PROTOCOL TRANSLATION,"A system and method are presented in which a plurality of transport protocol objects (TPOs) are instantiated at a server. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",BELLSOUTH INTELLECT PTY CORP,DANIELL WILLIAM TODD;;DAIGLE BRIAN KEITH;;KENT LARRY GRAHAM;;DAVIS JOEL A;;FRIEDMAN LEE G,,https://lens.org/123-315-982-942-052,Patent Application,yes,0,30,10,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L69/08;;H04L51/234,G06Q10/10;;H04L12/58;;H04L29/06,,0,0,,,,PENDING
710,WO,A1,WO 2005/004996 A1,158-112-383-719-799,2005-01-20,2005,US 2004/0013812 W,2004-04-30,US 48363303 P;;US 81911604 A,2003-07-01,"EXERCISE DEVICE, METHOD OF FABRICATING EXERCISE DEVICE, AND METHOD AND SYSTEM FOR INTERACTION WITH AN EXERCISE DEVICE","An exercise device, method of making the device and a method and system for interaction with an exercise device, in which removable, variable weight may be provided in a housing of the device. Two rotatable handles may be provided in the housing, permitting various hand orientations during exercise. The removable weight may be provided near the center of the exercise device, with the handles substantially outboard the weight. Weight may thus be efficiently added or removed in a central area of the housing between the handles.",PT METRICS LLC;;MILLS ALDEN MORRIS;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM PATRICK;;THOMASON RODGER DALE,MILLS ALDEN MORRIS;;FRIEDMAN MARK B;;HAUSER STEPHEN G;;CONLEY WILLIAM PATRICK;;THOMASON RODGER DALE,,https://lens.org/158-112-383-719-799,Patent Application,yes,3,0,2,11,0,A63B21/00065;;A63B21/0601;;A63B21/0724;;A63B21/0728;;A63B21/075;;A63B21/4035;;A63B21/4017;;A63B21/075;;A63B21/0724;;A63B21/0728;;A63B21/00065;;A63B21/0601;;A63B21/4017;;A63B21/4035,A63B21/06;;A63B21/072;;A63B21/075;;A63B23/12,,0,0,,,,PENDING
711,CA,A1,CA 2280027 A1,157-399-369-259-700,1998-08-13,1998,CA 2280027 A,1998-01-30,US 79722697 A;;US 9801864 W,1997-02-07,DNA SEQUENCES ENCODING SOLANIDINE UDP-GLUCOSE GLUCOSYLTRANSFERASE AND USE TO REDUCE GLYCOALKALOIDS IN SOLANACEOUS PLANTS,"DNA sequences which encode the enzyme solanidine UDP-glucose glucosyltransferase (SGT) are disclosed. Recombinant DNA molecules containing the sequences, and use thereof, in particular, use of an antisense DNA construct to inhibit the production of SGT and thereby reduce glycoalkaloid levels in solanaceous plants, e.g., potato, are described.",US HEALTH,ROCKHOLD DAVID R;;ALLEN PAUL V;;FRIEDMAN MENDEL;;MOEHS CHARLES P;;BELKNAP WILLIAM;;STAPLETON ANDREW,,https://lens.org/157-399-369-259-700,Patent Application,no,0,0,4,4,2,C12N9/1051;;C12N9/1051;;C12N15/8243;;C12N15/8243,C12N9/10;;C12N15/29;;C12N15/82,,0,0,,,,DISCONTINUED
712,US,A1,US 2023/0310203 A1,066-627-326-372-44X,2023-10-05,2023,US 202217982703 A,2022-11-08,US 202217982703 A;;US 201916564295 A;;US 201514818914 A;;US 201113130869 A;;US 2009/0065923 W;;US 20963509 P;;US 20375808 P;;US 20017208 P,2008-11-25,"DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF SLEEP APNEA","A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth. In a particular configuration, both the soft palate and tongue are biased to prevent obstruction of the flow of air in the nasopharyngeal airway.",LUMEN DEVICES LLC,FRIEDMAN MICHAEL;;IRWIN III JOHN N;;GORMAN WILLIAM J;;GARIBOTTO JOHN T;;FLAHERTY J CHRISTOPHER,LUMEN DEVICES LLC (2015-08-10),https://lens.org/066-627-326-372-44X,Patent Application,yes,3,0,21,21,0,A61M16/021;;A61F5/566;;A61F5/00;;A61F5/56;;A61M16/08;;A61B1/233;;A61M16/0497;;A61F5/00;;A61M16/0463;;A61M16/0488;;A61B1/00;;A61M16/0461;;A61M16/0465;;A61M16/20;;A61B1/267;;A61M16/0468;;A61M16/04;;A61F5/56;;A61M16/021;;A61F5/566,A61F5/56;;A61B1/00;;A61B1/233;;A61B1/267;;A61F5/00;;A61M16/00;;A61M16/04;;A61M16/08;;A61M16/20,,0,0,,,,PENDING
713,WO,A1,WO 1998/034471 A1,183-508-389-955-060,1998-08-13,1998,US 9801864 W,1998-01-30,US 79722697 A,1997-02-07,DNA SEQUENCES ENCODING SOLANIDINE UDP-GLUCOSE GLUCOSYLTRANSFERASE AND USE TO REDUCE GLYCOALKALOIDS IN SOLANACEOUS PLANTS,"DNA sequences which encode the enzyme solanidine UDP-glucose glucosyltransferase (SGT) are disclosed. Recombinant DNA molecules containing the sequences, and use thereof, in particular, use of an antisense DNA construct to inhibit the production of SGT and thereby reduce glycoalkaloid levels in solanaceous plants, e.g., potato, are described.",US AGRICULTURE,MOEHS CHARLES P;;ALLEN PAUL V;;ROCKHOLD DAVID R;;STAPLETON ANDREW;;FRIEDMAN MENDEL;;BELKNAP WILLIAM,,https://lens.org/183-508-389-955-060,Patent Application,yes,0,15,4,4,0,C12N9/1051;;C12N9/1051;;C12N15/8243;;C12N15/8243,C12N9/10;;C12N15/29;;C12N15/82,,5,4,069-580-479-149-98X;;102-220-737-763-815;;097-127-097-686-210;;011-691-036-848-658,9076990;;10.1046/j.1365-313x.1997.11020227.x;;10.1016/0168-9452(92)90205-z;;10.1021/jf00006a040;;1422219;;10.1016/s1046-5928(05)80023-3;;10.1016/s1046-5928(05)80090-7,"MOEHS C P, ET AL.: ""CLONING AND EXPRESSION OF SOLANIDINE UDP-GLUCOSE GLUCOSYLTRANSFERASE FROM POTATO"", THE PLANT JOURNAL, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD., GB, vol. 11, no. 02, 1 February 1997 (1997-02-01), GB, pages 227 - 236, XP002910721, ISSN: 0960-7412, DOI: 10.1046/j.1365-313X.1997.11020227.x;;BERGENSTRAEHLE A, TILLBERG E, JONSSON L: ""CHARACTERIZATION OF UDP-GLUCOSE:SOLANIDINE GLUCOSYLTRANSFERASE AND UDP-GALACTOSE:SOLANIDINE GALACTOSYLTRANSFERASE FROM POTATO TUBER"", PLANT SCIENCE, ELSEVIER IRELAND LTD, IE, vol. 84, 1 January 1992 (1992-01-01), IE, pages 35 - 44, XP002910722, ISSN: 0168-9452, DOI: 10.1016/0168-9452(92)90205-Z;;STAPLETON A, ET AL.: ""PURIFICATION AND CHARACTERIZATION OF SOLANIDINE GLUCOSYLTRANSFERASE FROM THE POTATO (SOLANUM TUBEROSUM)"", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 39, 1 January 1991 (1991-01-01), US, pages 1187 - 1193, XP002910723, ISSN: 0021-8561, DOI: 10.1021/jf00006a040;;BIOLOGICAL ABSTRACTS, 1 January 1900, Philadelphia, PA, US; PACZKOWSKI C, KALINOWSKA M, WOJCIECHOWSKI Z A: ""UDP-GLUCOSE:SOLASODINE GLUCOSYLTRANSFERASE FROM EGGPLANT (SOLANUM MELONGEN L.) LEAVES: PARTIAL PURIFICATION AND CHARACTERIZATION"" XP002910724;;BIOLOGICAL ABSTRACTS, 1 January 1900, Philadelphia, PA, US; STAPLETON A, ET AL.: ""PARTIAL AMINO ACID SEQUENCE OF POTATO SOLANIDINE UDP-GLUCOSE GLUCOSYLTRANSFERASE PURIFIED BY NEW ANION-EXCHANGE AND SIZE EXCLUSION MEDIA"" XP002910725",PENDING
714,US,B1,US 6708053 B1,109-605-532-739-776,2004-03-16,2004,US 51819500 A,2000-03-03,US 51819500 A;;US 12302499 P,1999-03-04,Biochemical markers of brain function,"
    The present invention provides methods for determining brain functioning in an individual by measuring the amount of either N-acetylaspartate or choline in an individual's brain. The present invention also provides methods for determining a change in an individual's brain functioning due to a change in the concentration of N-acetylaspartate or choline in the individual's brain. 
",SCIENCE AND TECHNOLOGY CORP UN,BROOKS WILLIAM M;;JUNG REX;;FRIEDMAN SETH DAVID;;PETROPOULOS HELEN;;YEO RONALD A;;SIBBITT WILMER L,UNIVERSITY OF NEW MEXICO (2003-08-21),https://lens.org/109-605-532-739-776,Granted Patent,yes,6,21,1,4,0,G01R33/483;;Y10T436/24;;Y10T436/24;;G01R33/483,G01R33/483,600/410;;436/173,32,30,098-048-905-803-114;;028-801-920-417-009;;040-939-737-120-000;;100-640-948-079-86X;;152-415-830-370-147;;036-967-110-890-494;;144-105-578-736-00X;;054-206-077-006-842;;101-146-035-664-442;;136-718-865-584-653;;089-119-049-014-479;;088-494-596-129-476;;162-372-372-734-358;;034-786-758-676-583;;003-023-646-723-859;;056-809-146-645-177;;040-177-407-701-787;;106-422-569-212-483;;047-981-874-988-731;;095-808-874-870-938;;059-825-802-422-238;;037-856-024-141-010;;112-035-611-174-925;;056-729-094-671-858;;036-834-205-871-705;;003-910-081-723-093;;053-893-751-536-839;;026-611-764-609-868;;010-357-379-588-480;;003-026-381-932-172,10.1016/s0730-725x(97)00079-9;;9285801;;10.1016/0730-725x(94)00113-h;;7791555;;10.1016/s0022-510x(97)86460-x;;10.1016/s0160-2896(99)80054-3;;10.1176/ajp.150.1.130;;8417555;;10.1002/mrm.1910320202;;7968436;;8856684;;10.1097/00001756-199605310-00014;;9918245;;10.1002/(sici)1522-2594(199901)41:1<193::aid-mrm27>3.0.co;2-p;;10025629;;10.1037//0003-066x.52.10.1051;;10.1007/bf00867424;;8530981;;9246731;;10.1016/s0166-2236(97)01070-9;;pmc8337737;;9874540;;10227622;;10.1212/wnl.52.7.1384;;10.1212/wnl.46.4.974;;8780075;;pmc8337488;;9802491;;10.1097/00006842-199809000-00006;;9773757;;10.1073/pnas.94.18.9854;;pmc23281;;9275215;;7485820;;10.1111/j.1530-0277.1995.tb00992.x;;10.1037//0003-066x.47.8.1007;;1510328;;10.1002/ana.410280502;;2260847;;10.1016/s0022-510x(98)00190-7;;9849797;;9674775;;10.1212/wnl.51.1.33;;8805839;;10.1098/rspb.1996.0156;;pmc8337358;;9403453;;10.1093/brain/119.5.1763;;8931596;;7873353;;9702884;;10.1002/jmri.1880080412;;10.1007/bf01074266;;3753376;;8441018;;pmc6576593;;10.1523/jneurosci.13-03-00981.1993,"Cruz et al. ""Proton MR Spectroscopic Imaging of the Striatum in Parkinson's Disease,"" Dec. 1996, Magnetic Resonance Imaging, vol. 15, No. 6, pp. 619-624.*;;Christiansen et al. ""Reduced N-Acetylaspartate Content in the Frontal Part of the Brain in Patients with Probable Alzheimer's Disease,"" Jan. 1994, Magnetic Resonance Imaging, vol. 13, No. 3, pp. 457-462.*;;Ryou et al. ""Dementia in Parkinson's diease-Examination according to Wechsler adult intelligence scale"", Sep. 1997, Journal of the Neurological Sciences, vol. 150, Issue 1001, p. S319.*;;Lucivero et al. ""Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders,"" Journal of the Neurological Sciences, vol. 150, Issue 1001, p. S316.*;;Anderson et al., ""Temporal Lobe pHi and IQ: No Consistent Correlation."" Intellegence 1998; 26(2): 75-79.;;Andreasen et al., ""Intelligence and Brain Structure in Normal Individuals."" Am. J. Psychiatry 1993; 150:130-134.;;Barker et al., ""Quantitative Proton Spectroscopy of Canine Brain: in Vivo and in Vitro Correlations."" MRM 1994; 32: 157-163.;;Bates et al., ""Inhibition of N-acetylaspartate production: implications for <1>H MRS studies in vivo."" NeuroReport 1996; 7:1397-1400.;;Brooks et al., ""Relationship Between Neurometabolite Derangement and Neurocognitive Dysfunction in Systematic Lupus Erythematosus."" The Journal of Rheumatology 1999; 26:81-85.;;Brooks et al., ""Reproducibility of <1>H-MRS In Vivo."" Magnetic Resonance in Medicine 1999; 41:193-197.;;Ceci et al., ""Schooling, Intelligence, and Income."" American Psychologist 1997; 52(10): 1051-1058.;;Davie et al., ""Proton Magnetic Resonance Spectroscopy of Systemic Lupus Erythematosus Involving the Central Nervous System."" J. Neurol. 1995; 242: 522-528.;;Deary et al., ""Neuroscience and Human Intelligence Differences."" TINS 1997; 20(8): 365-370.;;Friedman et al., ""Proton MR Spectroscopic Findings Correspond ot Neuropsychological Function in Traumatic Brain Injury."" AJNR Am. J. Neuroradiol 1998; 19:1879-1885.;;Freidman et al., ""Quantitative proton MRS predicts outcome after traumatic brain injury."" Neurology 1999; 52: 1384-1391.;;Gadian et al., ""Lateralization of brain function in childhood revealed by magnetic resonance spectroscopy."" Neurology 1996; 46:974-977.;;Haseler et al., ""Proton MR Spectroscopic Meaurement of Neurometabolites in Hepatic Encephalopathy during Oral Lactulose Therapy."" AJNR Am. J. Neuroradiol 1998; 19: 1681-1686.;;Huda et al., ""Clinical Correlation of Neuropsychological Tests With <1>H Magnetic Resonance Spectroscopy in Hepatic Encephalopathy."" Psychosomatic Medicine 1998; 60: 550-556.;;Lopez-Villegas et al., ""Biochemical changes in the frontal lobe of HIV-infected individuals detected by magnetic resonance spectroscopy."" Proc. Natl. Acad. Sci. USA 1997; 94, 9854-9859.;;Martin et al., ""Brain Proton Magnetic Resonance Spectroscopy Studies in Recently Abstinent Alcoholics."" Alcohol Clin. Exp. Res. 1995; 19(4): 1078-1082.;;Matarazzo, ""Psychological Testing and Assessment in the 21<st >Century."" American Psychologist 1992; 47(8): 1007-1018.;;Mesulam, ""Large Scale Neurocognitive Networks and Distributed Processing for Attention, Language, and Memory."" Ann. Neurol. 1990; 28: 597-613.;;Rae et al., ""Brain biochemistry in Duchenne muscular dystrophy: A <1>H magnetic resonance and neuropsychological study."" Journal of Neurological Science 1998; 160: 148-157.;;Rae et al., ""Brain biochemistry in Williams syndrome: Evidence for a role of the cerebellum in cognition?"" Neurology 1998; 51:33-40.;;Rae et al., ""Is pH a Biochemical Marker of IQ?"" Proc. R. Soc. Lond. B 1996; 263: 1061-1064.;;Rajanayagam et al., ""Proton MR Spectroscopy and Neruopsychological Testing in Adrenoleukodystrophy."" AJNR Am. J. Neuroradiol 1997; 18: 1909-1914.;;Reiss et al., ""Brain development, gender and IQ in children: A volumetric imaging study."" Brain 1996; 119: 1763-1774.;;Ross et al., ""Clinical Applications of Magnetic Resonance Spectroscopy."" Magnetic Resonance Quarterly, 1994; 10(4): 191-247.;;Ross et al., ""<1>H MRS in Acute Traumatic Brian Injury."" JMRI 1998; 8:829-840.;;Tambs et al., ""Genetic and Environmental Contributions to the Covariation Between the Wechsler Adult Intelligence Scale (WAIS) Subtests: A Study of Twins."" Behavior Genetics 1986; 16(4): 475-491.;;Urenjak et al., ""Proton Nuclear Magnetic Resonance Spectroscopy Unambiguously Identifies Different Neural Cell Types."" The Journal of Neuroscience, 1993; 13(3): 981-989.;;Wechsler, ""Wais-III Administration and Scoring Manual.""",EXPIRED
715,US,A1,US 2009/0132726 A1,147-485-545-846-815,2009-05-21,2009,US 34324808 A,2008-12-23,US 34324808 A;;US 30559605 A;;US 27447802 A;;US 41133602 P;;US 41961302 P,2002-09-17,Server-Based Message Protocol Translation,"A system and method are presented in which a plurality of transport protocol objects (TPOs) are instantiated at a server. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",AT & T IP I LP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,AT&T INTELLECTUAL PROPERTY I L.P (2016-12-13);;UBER TECHNOLOGIES INC (2017-01-13);;AT&T DELAWARE INTELLECTUAL PROPERTY INC (2007-11-01),https://lens.org/147-485-545-846-815,Patent Application,yes,15,24,10,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L69/08;;H04L51/234,G06F15/16;;G06Q10/10;;H04L12/58;;H04L29/06,709/246;;709/206,0,0,,,,EXPIRED
716,TW,B,TW I241188 B,154-249-409-580-214,2005-10-11,2005,TW 87110253 A,1998-06-25,US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,Sertraline salts and sustained-release dosage forms of sertraline,"Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr. The present invention is further directed to an acetate salt, an L-lactate salt and an L-aspartate salt of sertraline, pharmaceutical compositions thereof and methods of using that salt for treating various conditions and disorders. The present invention is also directed to processes for preparing sertraline acetate, sertraline L-lactate and sertraline L-aspartate.",PFIZER,AM ENDE MARY TANYA;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX,,https://lens.org/154-249-409-580-214,Granted Patent,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/00;;A61K9/22;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
717,US,B2,US 7757003 B2,011-794-790-436-016,2010-07-13,2010,US 34324808 A,2008-12-23,US 34324808 A;;US 30559605 A;;US 27447802 A;;US 41133602 P;;US 41961302 P,2002-09-17,Server-based message protocol translation,"A system and method are presented in which a plurality of transport protocol objects (TPOs) are instantiated at a server. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",AT & T IP II LP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KIETH,AT&T INTELLECTUAL PROPERTY I L.P (2016-12-13);;UBER TECHNOLOGIES INC (2017-01-13);;AT&T DELAWARE INTELLECTUAL PROPERTY INC (2007-11-01),https://lens.org/011-794-790-436-016,Granted Patent,yes,15,3,10,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L69/08;;H04L51/234,G06F15/16;;G06Q10/10;;H04L12/58;;H04L29/06,709/246;;709/202;;709/227,0,0,,,,EXPIRED
718,US,A,US 5959180 A,029-573-870-955-179,1999-09-28,1999,US 79722697 A,1997-02-07,US 79722697 A,1997-02-07,DNA sequences from potato encoding solanidine UDP-glucose glucosyltransferase and use to reduce glycoalkaloids in solanaceous plants,"DNA sequences from potato which encode the enzyme solanidine UDP-glucose glucosyltransferase (SGT) are disclosed. Recombinant DNA molecules containing the sequences, and use thereof, in particular, use of an antisense DNA construct to inhibit the production of SGT and thereby reduce glycoalkaloid levels in solanaceous plants, e.g., potato, are described.",US AGRICULTURE,MOEHS CHARLES P;;ALLEN PAUL V;;ROCKHOLD DAVID R;;STAPLETON ANDREW;;FRIEDMAN MENDEL;;BELKNAP WILLIAM R,AGRICULTURE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE (1998-06-10),https://lens.org/029-573-870-955-179,Granted Patent,yes,2,13,4,4,2,C12N9/1051;;C12N9/1051;;C12N15/8243;;C12N15/8243,C12N9/10;;C12N15/29;;C12N15/82,800/298;;435/320.1;;435/419;;435/468;;536/23.2;;536/23.6;;800/278;;800/286;;800/317.2;;800/317.4,20,17,081-255-427-440-869;;009-493-670-126-565;;069-580-479-149-98X;;014-356-869-951-503;;046-809-189-832-068;;024-987-234-948-97X;;159-663-736-822-749;;102-220-737-763-815;;049-680-266-692-914;;011-691-036-848-658;;164-140-986-626-714;;009-565-502-956-252;;071-995-913-708-120;;003-821-280-324-074;;011-542-575-483-820;;031-001-200-915-475;;037-037-786-808-265,10.18388/abp.1997_4438;;9241353;;10.1007/bf00040724;;8843948;;9076990;;10.1046/j.1365-313x.1997.11020227.x;;10.1080/07352689709701946;;10.1007/bf00237428;;24197257;;10.1021/jf00023a023;;10.1016/s0176-1617(11)81078-3;;10.1016/0168-9452(92)90205-z;;1515610;;10.1007/bf00029145;;1422219;;10.1016/s1046-5928(05)80023-3;;10.1016/s1046-5928(05)80090-7;;1912493;;10.1007/bf00037054;;1886609;;10.1007/bf00282472;;1966276;;10.1007/bf00018567;;10.1073/pnas.85.12.4300;;16593941;;pmc280416;;pmc340566;;3029718;;10.1093/nar/15.4.1543;;10.1073/pnas.83.15.5372;;pmc386288;;16593734;;10.1007/bf02851505,"C. Paczkowski et al., UDP Glucose: Solasodine Glucosyltransferase from Eggplant ( Solanum melongena L.) Leaves: Partial Purification and Characterization, Acta Biochimical Polonica 44(1):43 54 (1997) (Abstract) (BIOSIS, An 97:309475).;;Horvath DM, et al. Identification of an immediate early salicyclic acid inducible tobacco gene and characterization of induction by other compounds. Plant Mol. Biol. 31: 1061 1072, 1996.;;Horvath DM, et al. GenBank Accession No. U32644, 1995.;;Moehs, C.P. et al., Cloning and expression of solanidine UDP glucose glucosyltransferase from potato , The Plant Journal (1997), vol. 11(2):227 236.;;Friedman, M. and G.M. McDonald, Potato Glycoalkaloids: Chemistry, Analysis, Safety, and Plant Physiology , Critical Reviews in Plant Sciences (1997), vol. 16(1):55 132.;;Moehs, C.P., et al., Cloning of solanidine UDP glucose glucosyltransferase from potato by functional expression in yeast , Phytochemical Society of North America (Jul. 1996), vol. 36, p. 11.;;Snyder, G.W. and W.R. Belknap, A modified method for routine Agrobacterium mediated transformation of in vitro grown potato microtubers , Plant Cell Reports (1993), vol. 12:324 327.;;Friedman, M. and C.E. Levin, Reversed phase high performance liquid chromatographic separation of potato glycoalkaloids and hydrolysis products on acidic columns , J. Agric. Food Chem. (1992), vol. 40:2157 2163.;;Bergenstrahle, A., et al., Regulation of glycoalkaloid accumulation in potato tuber discs , J. Plant Physiol. (1992), vol 140:269 275.;;Berenstrahle, A., et al., Characterization of UDP glucose: solanidine glucosyltransferase and UDP galactose: solanidine galactosyltransferase from potato tuber , Plant Science (1992), vol. 84:35 44.;;van der Steege, G., et al., Potato granule bound starch synthase promoter controlled GUS expression: regulation of expression after transient and stable transformation , Plant Molecular Biology (1992), vol. 20:19 30.;;Stapleton, A., et al, Partial amino acid sequence of potato solanidine UDP glucose glucosyltransferase purified by new anion exchange and size exclusion media , Protein Expression and Purification (1992), vol. 3(2):85 92.;;Stapleton, A., et al., Purification and characterization of solanidine glycosyltransferase from the potato ( Solanum tuberosum ) , Journal of Agricultural & Food Chemistry (Jun. 1991), vol. 39(6):1187 1193.;;Visser, R.G.F., et al., Expresion of a chimaeric granule bound starch synthase GUS gene in transgenic potato plants , Plant Molecular Biology (1991), vol. 17:691 699.;;van der Leij, F.R., et al., Sequence of the structural gene for granule bound starch synthase of potato ( Solanum tuberosum L.) and evidence for a single point deletion in the amf allele , Mol. Gen. Genet. (1991), vol. 228:240 248.;;McBride, K.E. and K.R. Summerfelt, Improved binary vectors for Agrobacterium mediated plant transformation , Plant Molecular Biology (1990), vol. 14:269 276.;;Delauney, A.J., et al., A Stable bifunctional antisense transcript inhibiting gene expression in transgenic plants , Proc. Natl. Acad. Sci. USA (Jun. 1988), vol. 85:4300 4304.;;Sanders, P.R., et al., Comparison of cauliflower mosaic virus 35S and nopaline synthase promoters in transgenic plants , Nucleic Acids Research (1987), vol. 15(4):1543 1558.;;Ecker, J.R. and R.W. Davis, Inhibition of gene expression in plant cells by expression of antisense RNA , Proc, Natl. Acad. Sci. USA (Aug. 1986), vol. 83:5372 5376.;;Fitzpatrick, T.J. and S.F. Osman, A comprehensive method for the determination of total potato glycoalkaloids , American Potato Journal (1974), vol. 51:318 323.",EXPIRED
719,US,B2,US 7849220 B2,159-111-309-905-78X,2010-12-07,2010,US 28427308 A,2008-09-19,US 28427308 A;;US 21018705 A;;US 27440802 A;;US 41133602 P;;US 41961302 P,2002-09-17,System using transport protocol objects located at a user agent location to provide translation between different instant messaging protocols,"A system and method are presented in which a plurality of transport protocol objects (TPOs) are instantiated at an IM user agent. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",AT & T IP I LP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,AT&T INTELLECTUAL PROPERTY I L.P (2009-05-29);;UBER TECHNOLOGIES INC (2017-01-12);;AT&T DELAWARE INTELLECTUAL PROPERTY INC (2007-11-01);;BELLSOUTH INTELLECTUAL PROPERTY CORPORATION (2002-12-16),https://lens.org/159-111-309-905-78X,Granted Patent,yes,5,2,9,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L67/14;;H04L69/08;;H04L51/234;;H04L67/565;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L67/14;;H04L69/08;;H04L67/565;;H04L51/234,G06F15/16;;G06Q10/10;;H04L12/58;;H04L29/06,709/246;;709/227;;709/202,0,0,,,,EXPIRED
720,AU,A8,AU 2003/278822 A8,196-329-509-930-836,2004-04-08,2004,AU 2003/278822 A,2003-09-15,US 41133602 P;;US 41961302 P;;US 27440502 A;;US 0329066 W,2002-09-17,Message client with multiple message system consolidation,,BELLSOUTH INTELLECT PTY CORP,FRIEDMAN LEE G;;DAVIS JOEL A;;DAIGLE BRIAN KEITH;;DANIELL WILLIAM TODD;;KENT LARRY GRAHAM JR,,https://lens.org/196-329-509-930-836,Patent Application,no,0,0,5,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234,G06Q10/00;;H04L12/58;;H04L29/06,,0,0,,,,DISCONTINUED
721,US,A1,US 2006/0013205 A1,024-439-159-650-26X,2006-01-19,2006,US 21018705 A,2005-08-23,US 21018705 A;;US 27440802 A;;US 41133602 P;;US 41961302 P,2002-09-17,Client-based message protocol translation,"A system and method are presented in which a plurality of transport protocol objects (TPOs) are instantiated at an IM user agent. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY G JR;;DAVIS JOEL A;;DAIGLE BRIAN K,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY G JR;;DAVIS JOEL A;;DAIGLE BRIAN K,AT&T INTELLECTUAL PROPERTY I L.P (2008-08-28);;UBER TECHNOLOGIES INC (2017-01-12);;AT&T DELAWARE INTELLECTUAL PROPERTY INC (2007-11-01);;BELLSOUTH INTELLECTUAL PROPERTY CORPORATION (2002-12-16),https://lens.org/024-439-159-650-26X,Patent Application,yes,20,21,9,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L67/14;;H04L69/08;;H04L51/234;;H04L67/565;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L67/14;;H04L69/08;;H04L67/565;;H04L51/234,H04L12/66;;G06Q10/10;;H04L12/58;;H04L29/06,370/352,0,0,,,,EXPIRED
722,US,A1,US 2009/0024692 A1,160-620-164-913-084,2009-01-22,2009,US 28427308 A,2008-09-19,US 28427308 A;;US 21018705 A;;US 27440802 A;;US 41133602 P;;US 41961302 P,2002-09-17,Client-based message protocol translation,"A system and method are presented in which a plurality of transport protocol objects (TPOs) are instantiated at an IM user agent. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVID JOEL A;;DAIGLE BRIAN KEITH,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVID JOEL A;;DAIGLE BRIAN KEITH,AT&T INTELLECTUAL PROPERTY I L.P (2009-05-29);;UBER TECHNOLOGIES INC (2017-01-12);;AT&T DELAWARE INTELLECTUAL PROPERTY INC (2007-11-01);;BELLSOUTH INTELLECTUAL PROPERTY CORPORATION (2002-12-16),https://lens.org/160-620-164-913-084,Patent Application,yes,5,5,9,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L67/14;;H04L69/08;;H04L51/234;;H04L67/565;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L67/14;;H04L69/08;;H04L67/565;;H04L51/234,G06F15/16;;G06Q10/10;;H04L9/32;;H04L12/58;;H04L29/06,709/202;;709/246;;709/227;;726/6,0,0,,,,EXPIRED
723,WO,A3,WO 2004/027561 A3,022-704-581-327-486,2004-07-29,2004,US 0329225 W,2003-09-15,US 41133602 P;;US 41961302 P;;US 27440802 A,2002-09-17,CLIENT-BASED MESSAGE PROTOCOL TRANSLATION,"A system and method are presented in which a plurality of transport protocol objects (TPOs) (220, 221, 222, 223, 224, 225, 226 and 227) are instantiated at an IM user agent (115). In one embodiment, each of the plurality of TPOs (220, 221, 222, 223, 224, 225, 226, and 227) is adapted to provide a translation between a first IM protocol and a different IM protocol.",BELLSOUTH INTELLECT PTY CORP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,,https://lens.org/022-704-581-327-486,Search Report,yes,1,0,9,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L67/14;;H04L69/08;;H04L51/234;;H04L67/565;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L67/14;;H04L69/08;;H04L67/565;;H04L51/234,G06Q10/10;;H04L12/58;;H04L29/06,,1,0,,,"PETER SAINT-ANDRE: ""Jabber FAQ"", JABBER.ORG, 13 May 2001 (2001-05-13), pages 33 - 35, XP002976958",PENDING
724,US,B1,US 6976092 B1,190-850-160-818-938,2005-12-13,2005,US 27440802 A,2002-10-18,US 27440802 A;;US 41133602 P,2002-09-17,System that using transport protocol objects located at agent location to generate session ID and to provide translation between different instant messaging protocols,"A system and method are presented in which a plurality of transport protocol objects (TPOs) are instantiated at an IM user agent. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",BELLSOUTH INTELLECT PTY CORP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT JR LARRY GRAHAM;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,AT&T INTELLECTUAL PROPERTY I L.P (2008-08-28);;UBER TECHNOLOGIES INC (2017-01-12);;AT&T DELAWARE INTELLECTUAL PROPERTY INC (2007-11-01),https://lens.org/190-850-160-818-938,Granted Patent,yes,8,105,1,119,0,H04L51/04;;H04L51/066;;H04L67/14;;H04L67/565;;H04L67/14;;H04L51/04;;H04L51/066;;H04L67/565,G06F15/16;;H04L12/58;;H04L29/08,709/246;;709/227;;709/202,23,5,062-895-497-242-485;;075-725-963-794-587;;135-805-492-258-431;;075-725-963-794-587;;135-805-492-258-431,10.17487/rfc2779;;10.17487/rfc2778;;10.17487/rfc3862;;10.17487/rfc2778;;10.17487/rfc3862,"Peter Saint-Andre, Jabber.org Jabber FAQ and User Guide, May 13, 2001.;;Peter saint-Andre, XML Messaging with Jabber, Oct. 6, 2000.;;Instant Messaging / Presence Protocol Requirements Day et al.; Feb. 2000.;;A Model for Presence and Instant Messaging Day et al.; Feb. 2000.;;Extensible Markup Language (XML) 1.0 (Second Edition) W3C XML Core Working Group (WG); Oct. 6, 2000.;;Common Presence and Instant Messaging: Message Format Atkins et al.; Feb. 20, 2002.;;Common Presence and Instant Messaging (CPIM) Presence Information Data Format Sugano et al.; May 2002.;;Common Presence and Instant Messaging (CPIM) Crocker et al.; Aug. 14, 2002.;;Daniell, et al., patent application entitled ""Server-Based Message Protocol Translation,"" filed Oct. 18, 2002, (s.n. 10/274,478), 52 pages (combined spec. and figures).;;Daniell, et al., patent application entitled ""Message Client with Multiple Message System Consolidation,"" filed Oct. 18, 2002 (s.n. 10/274,405), 51 pages (combined spec. and figures).;;http://www.malvino.com/ep/startup.htm, entitled: Startup Programs, printed Mar. 2, 2004, pages 7.;;http://download.com.com./3000-2150-10148311.html?tag=1st-0-1, entitled: C/Net Download.com; Trillian 0.74 popular, printed Mar. 2, 2004, pages 2.;;J.D. Ramsdell, The MITRE Corporation, entitled: Simple Instant Messaging and Presence 1.3 Protocol, dated Jun. 2001, p. 19.;;http://www.ceruleanstudios.com/, entitled: Trillian-Communicate with Flexibility and Style, printed Mar. 2, 2004, p. 15.;;PCT International Search Report-Int'l Appl. No.: PCT.US03/29225, mailed Jun. 21, 2004, p. 6.;;PCT International Search Report-Int'l Appl. No.: PCT/US03/29066, mailed May 11, 2004, p. 7.;;PCT International Search Report-Int'l Appl. No.: PCT/US03/29226, mailed May 5, 2004, p. 6.;;Instant Messaging/Presence Protocol Requirements Day et al.; Feb. 2000.;;A Model for Presence and Instant Messaging Day et al.; Feb. 2000.;;Extensible Markup Language (XML) 1.0 (Second Edition) W3C XML Core Working Group (WG); Oct. 6, 2000.;;Common Presence and Instant Messaging: Message Format Atkins et al.; Feb. 20, 2002.;;Common Presence and Instant Messaging (CPIM) Presence Information Data Format Sugano et al.; May 2002.;;Common Presence and Instant Messaging (CPIM) Crocker et al.; Aug. 14, 2002.",EXPIRED
725,US,B2,US 7444429 B2,187-359-448-044-937,2008-10-28,2008,US 21018705 A,2005-08-23,US 21018705 A;;US 27440802 A;;US 41133602 P;;US 41961302 P,2002-09-17,System uses transport protocol objects locate at user agent location to provide translation between different instant messaging protocols,"A system and method are presented in which a plurality of transport protocol objects (TPOs) are instantiated at an IM user agent. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,AT&T INTELLECTUAL PROPERTY I L.P (2008-08-28);;UBER TECHNOLOGIES INC (2017-01-12);;AT&T DELAWARE INTELLECTUAL PROPERTY INC (2007-11-01);;BELLSOUTH INTELLECTUAL PROPERTY CORPORATION (2002-12-16),https://lens.org/187-359-448-044-937,Granted Patent,yes,23,3,9,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L67/14;;H04L69/08;;H04L51/234;;H04L67/565;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L67/14;;H04L69/08;;H04L67/565;;H04L51/234,G06F15/16;;G06Q10/10;;H04L12/58;;H04L29/06,709/246;;709/227;;709/202,36,3,075-725-963-794-587;;135-805-492-258-431;;062-895-497-242-485,10.17487/rfc2778;;10.17487/rfc3862;;10.17487/rfc2779,"Peter Saint-Andre, ""Jabber FAQ"", May 13, 2001, jabber.org, pp. 1-36.;;Peter Saint-Andre, ""XML Messaging With Jabber"" Oct. 6, 2000, O'Reilly Media, Inc., pp. 1-3.;;Trillian 74, www.download.com, Sep. 2002, 2 pages.;;Startup Programs, www.Malvino.com, Nov. 1998, 7 pages.;;Trillian 71, www.ceruleanstudios.com, 2001, pp. 1-15.;;M. Day, A Model for Presence and Instant Messaging; Feb. 2002, pp. 1-17.;;Second Edition-W3C Recommendation, Oct. 2000.;;Atkins et al., Common Presence and Instant Messaging: Message Format, Feb. 2002.;;Sugano et al., Common Presence and Instant Messaging (CPIM) Presence Information Data Format, May 2002.;;Crocker et al., Common Presence and Instant Messaging (CPIM), Aug. 2002.;;Simple Instant Messaging and Presence 1.3 Protocol, Jun. 2001.;;PCT International Search Report, International Application No. PCT/US03/29226, mailed May 5, 2004, pp. 1-6.;;PCT International Search Report, International Application No. PCT/US03/29066, mailed May 11, 2004, pp. 1-7.;;PCT International Search Report, International Application No. PCT/US03/29225, mailed Jun. 21, 2004, pp. 1-6.;;Daniell, W. Todd, Non Final Office Action, mailed Mar. 25, 2004, filed Oct. 18, 2002, U.S. Appl. No. 10/274,478.;;Daniell, W. Todd, Non Final Office Action, mailed Oct. 7, 2004, filed Oct. 18, 2002, U.S. Appl. No. 10/274,478.;;Daniell, W. Todd, Final Office Action, mailed Jul. 27, 2005, filed Oct. 18, 2002, U.S. Appl. No. 10/274,478.;;Malik, Dale, Non Final Office Action, mailed Jun. 22, 2005, filed Apr. 29, 2002, U.S. Appl. No. 10/135,929.;;Daniell, W. Todd, Non Final Action, mailed Mar. 26, 2004, filed Oct. 18 , 2002, U.S. Appl. No. 10/274,408.;;Daniell, W. Todd, Patent Application, filed Oct. 18, 2002, U.S. Appl. No. 10/274,408, Patent No. 6,976,092 Dec. 13, 2005;;Day; Instant Messaging / Presence Protocol Requirements; Feb. 2000; pp. 1-26.;;Daniell; U.S. Appl. No. 11/210,187, filed Aug. 23, 2005.;;Daniell; U.S. Appl. No. 11/305,596, filed Dec. 16, 2005.;;Daniell; U.S. Appl. No. 11/352,435, filed Feb. 10, 2006.;;Daniell; Non-Final Rejection mailed Oct. 5, 2007 for U.S. Appl. No. 11/210,187, filed Aug. 23, 2005.;;Malik; Examiner Interview Summary Record mailed Dec. 29, 2005 for U.S. Appl. No. 10/135,929, filed Apr. 29, 2002.;;Malik; Notice of Allowance and Fees Due mailed Dec. 29, 2005 for U.S. Appl. No. 10/135,929, filed Apr. 29, 2002.;;Daniell; Examiner Interview Summary Record Summary mailed Oct. 4, 2004 for U.S. Appl. No. 10/274,408, filed Oct. 18, 2002.;;Daniell; Notice of Allowance and Fees Due mailed Jan. 6, 2005 for U.S. Appl. No. 10/724,408, filed Oct. 18, 2002.;;Daniell; Notice of Allowance and Fees Due mailed May 23, 2005 for U.S. Appl. No. 10/724,408, filed Oct. 18, 2002.;;Daniell; Notice of Allowance and Fees Due mailed Sep. 21, 2005 for U.S. Appl. No. 10/724,408, filed Oct. 18, 2002.;;Daniell; Notice of Allowance and Fees Due mailed Nov. 16, 2005 for U.S. Appl. No. 10/274,478, filed Oct. 18, 2002.;;Daniell; Non-Final Rejection mailed Apr. 9, 2007 for U.S. Appl. No. 11/305,596, filed Dec. 16, 2005.;;Daniell; Final Rejection mailed Sep. 25, 2007 for U.S. Appl. No. 11/305,596, filed Dec. 16, 2005.;;Daniell; Examiner Interview Summary Record mailed May 15, 2008 for U.S. Appl. No. 11/305,596, filed Dec. 16, 2005.;;Malik; Non-Final Rejection mailed Apr. 30, 2008 for U.S. Appl. No. 11/352,435, filed Feb. 10, 2006.",EXPIRED
726,US,B2,US 7035942 B2,065-635-934-983-344,2006-04-25,2006,US 27447802 A,2002-10-18,US 27447802 A;;US 41133602 P;;US 41961302 P,2002-09-17,Server-based message protocol translation,"A system and method are presented in which a plurality of transport protocol objects (TPOs) are instantiated at a server. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",BELLSOUTH INTELLECT PTY CORP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,AT&T INTELLECTUAL PROPERTY I L.P (2008-08-28);;UBER TECHNOLOGIES INC (2017-01-13);;AT&T DELAWARE INTELLECTUAL PROPERTY INC (2007-11-01);;BELLSOUTH INTELLECTUAL PROPERTY CORPORATION (2003-01-07),https://lens.org/065-635-934-983-344,Granted Patent,yes,8,32,10,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L69/08;;H04L51/234,G06F15/16;;G06Q10/10;;H04L12/58;;H04L29/06,709/246;;227/202,18,3,062-895-497-242-485;;075-725-963-794-587;;135-805-492-258-431,10.17487/rfc2779;;10.17487/rfc2778;;10.17487/rfc3862,"Ramsdell, John D., Simple Instant Messaging and Presence 1.3 Protocol, Mitre Corporation, Jun. 2001.;;Instant Messaging / Presence Protocol Requirements Day et al.; Feb. 2000.;;A Model for Presence and Instant Messaging Day et al.; Feb. 2000.;;Extensible Markup Language (XML) 1.0 (Second Edition), W3C XML Core Working Group (WG); Oct. 6, 2000.;;Common Presence and Instant Messaging: Message Format Atkins et al.; Feb. 20, 2002.;;Common Presence and Instant Messaging (CPIM) Presence Information Data Format Sugano et al.; May 2002.;;Common Presence and Instant Messaging (CPIM) Crocker et al.; Aug. 14, 2002.;;Jabber FAQ, by Peter Saint-Andre, dated May, 13, 2001, printed from the website address: http://web.archive.org/web/20010603135226/docs. Jabber.org/general/html/faz.html; pp. 1-39.;;Startup Programs, printed from website address: http://www.malvino.com/ep/startup.htm; pp. 1-7.;;XML Messaging with Jabber, by Peter Saint-Andre, dated Oct. 6, 2000; printed from website address: http://www.openp2p.com/pub/a/p2p/2000/10/06/jabber<SUB>13 </SUB>xml.htmp?page=1; pp. 1-8.;;C/net download.com, Trillian 0.74 popular; printed from website address: http://download.com.com/3000-2150-10148311.html?tag=1st-0-1; pp. 1-2.;;Trillian-Communicate with Flexibility and Style; printed from website address: http://web.archive.org/web/20020124064915/http://www.ceruleanstudios.com/; pp. 1-15.;;Daniell, et al., patent application entitled: ""Client-Based Message Protocol Translation,"" filed Oct. 18, 2002, (U.S. Appl. No. 10/274,408), 52 pages.;;Daniell, et al., patent application entitled: ""Message Client with Multiple Message System Consolidation,"" filed Oct. 18, 2002, (U.S. Appl. No. 10/274,405), 51 pages.;;PCT International Search Report-Int'l Appl. No.: PCT/US03/29226, mailed May 5, 2004, p. 6.;;PCT International Search Report-Int'l Appl. No.: PCT/US03/29066, mailed May 11, 2004, p. 7.;;PCT International Search Report-Int'l Appl. No.: PCT/US03/29225, mailed Jun. 21, 2004, p. 6.;;J.D. Ramsdell, MITRE Corporation; Simple Instant Messaging and Presence 1.3 Protocol, Jun. 2001, pp. 1-19.",EXPIRED
727,US,A1,US 2006/0095530 A1,090-660-193-844-793,2006-05-04,2006,US 30559605 A,2005-12-16,US 30559605 A;;US 27447802 A;;US 41133602 P;;US 41961302 P,2002-09-17,Server-based message protocol translation,"A system and method are presented in which a plurality of transport protocol objects (TPOs) are instantiated at a server. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY G JR;;DAVIS JOEL A;;DAIGLE BRIAN K,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY G JR;;DAVIS JOEL A;;DAIGLE BRIAN K,AT&T INTELLECTUAL PROPERTY I L.P (2008-08-28);;UBER TECHNOLOGIES INC (2017-01-13);;AT&T DELAWARE INTELLECTUAL PROPERTY INC (2007-11-01);;BELLSOUTH INTELLECTUAL PROPERTY CORPORATION (2003-01-07),https://lens.org/090-660-193-844-793,Patent Application,yes,20,26,10,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L69/08;;H04L51/234,G06F15/16;;G06Q10/10;;H04L12/58;;H04L29/06,709/206;;709/246,0,0,,,,EXPIRED
728,WO,A3,WO 2004/027559 A3,089-073-303-889-051,2004-07-15,2004,US 0329066 W,2003-09-15,US 41133602 P;;US 41961302 P;;US 27440502 A,2002-09-17,MESSAGE CLIENT WITH MULTIPLE MESSAGE SYSTEM CONSOLIDATION,"Systems and methods are presented in which a single user interface provides a user with information on multiple messaging sessions, each having a different messaging protocol.",BELLSOUTH INTELLECT PTY CORP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,,https://lens.org/089-073-303-889-051,Search Report,yes,0,0,5,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234,G06Q10/00;;H04L12/58;;H04L29/06,,5,0,,,"PETER SAINT-ANDRE: ""Jabber FAQ and User guide"", JABBER.ORG, 13 May 2001 (2001-05-13), pages 1 - 39, XP002976958, Retrieved from the Internet <URL:http://www.jabber.org>;;""Startup programs"", 22 November 1998 (1998-11-22), pages 1 - 3, XP002976959, Retrieved from the Internet <URL:http://www.malvino.com/ep/startup.htm>;;PETER SAINT-ANDRE: ""XML messaging with jabber"", OPENP2P.COM, 6 October 2000 (2000-10-06), pages 1 - 8, XP002976960, Retrieved from the Internet <URL:http://www.openp2p.com>;;""Trillian 0.74 popular"", 10 September 2002 (2002-09-10), pages 1 - 2, XP002976961, Retrieved from the Internet <URL:http://www.download.com>;;""Trillian 0.71"", 24 January 2002 (2002-01-24), pages 1 - 15, XP002976962, Retrieved from the Internet <URL:http://www.ceruleanstudios.com>",PENDING
729,WO,A2,WO 2004/027561 A2,143-687-445-695-220,2004-04-01,2004,US 0329225 W,2003-09-15,US 41133602 P;;US 41961302 P;;US 27440802 A,2002-09-17,CLIENT-BASED MESSAGE PROTOCOL TRANSLATION,"A system and method are presented in which a plurality of transport protocol objects (TPOs) (220, 221, 222, 223, 224, 225, 226 and 227) are instantiated at an IM user agent (115). In one embodiment, each of the plurality of TPOs (220, 221, 222, 223, 224, 225, 226, and 227) is adapted to provide a translation between a first IM protocol and a different IM protocol.",BELLSOUTH INTELLECT PTY CORP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,,https://lens.org/143-687-445-695-220,Patent Application,yes,0,7,9,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L67/14;;H04L69/08;;H04L51/234;;H04L67/565;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L67/14;;H04L69/08;;H04L67/565;;H04L51/234,G06Q10/10;;H04L12/58;;H04L29/06,,0,0,,,,PENDING
730,WO,A2,WO 2004/027559 A2,152-160-851-741-179,2004-04-01,2004,US 0329066 W,2003-09-15,US 41133602 P;;US 41961302 P;;US 27440502 A,2002-09-17,MESSAGE CLIENT WITH MULTIPLE MESSAGE SYSTEM CONSOLIDATION,"Systems and methods are presented in which a single user interface provides a user with information on multiple messaging sessions, each having a different messaging protocol.",BELLSOUTH INTELLECT PTY CORP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,,https://lens.org/152-160-851-741-179,Patent Application,yes,0,23,5,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234,G06Q10/00;;H04L12/58;;H04L29/06,,0,0,,,,PENDING
731,WO,A3,WO 2000/052465 A3,192-256-950-252-255,2001-07-26,2001,US 0005592 W,2000-03-03,US 12302499 P,1999-03-04,BIOCHEMICAL MARKERS OF BRAIN FUNCTION,The present invention provides methods for determining brain functioning in an individual by measuring the amount of either N-acetylaspartate or choline in an individual's brain. The present invention also provides methods for determining a change in an individual's brain functioning due to a change in the concentration of N-acetylaspartate or choline in the individual's brain.,UNIV NEW MEXICO;;BROOKS WILLIAM M;;FRIEDMAN SETH D;;JUNG REX J;;PETROPOULOS HELEN;;SIBBITT WILMER L;;YEO RONALD,BROOKS WILLIAM M;;FRIEDMAN SETH D;;JUNG REX J;;PETROPOULOS HELEN;;SIBBITT WILMER L;;YEO RONALD,,https://lens.org/192-256-950-252-255,Search Report,yes,1,0,3,4,0,G01R33/483;;G01R33/4806,G01R33/28;;G01R33/48,,6,3,054-206-077-006-842;;002-630-289-523-59X;;077-071-674-810-280,9918245;;8898669;;10.1097/00042560-199611010-00006;;10445292;;pmc1690078;;10.1098/rspb.1999.0790,"DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, RAE CAROLINE ET AL: ""Is pH a biochemical marker of IQ?"", XP002157604, Database accession no. PREV199699235073;;DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 1998 (1998-11-01), FRIEDMAN SETH D ET AL: ""Proton MR spectroscopic findings correspond to neuropsychological function in traumatic brain injury."", XP002157605, Database accession no. PREV199900061841;;DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 1999 (1999-01-01), BROOKS WILLIAM M ET AL: ""Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus."", XP002157606, Database accession no. PREV199900089766;;DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, JARVIK JEFFREY G ET AL: ""Proton spectroscopy in asymptomatic HIV-infected adults: Initial results in a prospective Cohort Study."", XP002157607, Database accession no. PREV199799293480;;DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 8 November 1999 (1999-11-08), JUNG REX E ET AL: ""Biochemical markers of cognition: A proton MR spectroscopy study of normal human brain."", XP002157608, Database accession no. PREV200000066238;;DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 7 July 1999 (1999-07-07), JUNG REX E ET AL: ""Biochemical markers of intelligence: A proton MR spectroscopy study of normal human brain."", XP002157609, Database accession no. PREV199900382319",PENDING
732,US,B2,US 7469301 B2,016-201-078-398-947,2008-12-23,2008,US 30559605 A,2005-12-16,US 30559605 A;;US 27447802 A;;US 41133602 P;;US 41961302 P,2002-09-17,Server-based message protocol translation,"A system and method are presented in which a plurality of transport protocol objects (TPOs) are instantiated at a server. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",AT & T IP I LP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,AT&T INTELLECTUAL PROPERTY I L.P (2008-08-28);;UBER TECHNOLOGIES INC (2017-01-13);;AT&T DELAWARE INTELLECTUAL PROPERTY INC (2007-11-01);;BELLSOUTH INTELLECTUAL PROPERTY CORPORATION (2003-01-07),https://lens.org/016-201-078-398-947,Granted Patent,yes,23,28,10,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L69/08;;H04L51/234,G06F15/16;;G06Q10/10;;H04L12/58;;H04L29/06,709/246;;709/227;;709/202,32,2,075-725-963-794-587;;062-895-497-242-485,10.17487/rfc2778;;10.17487/rfc2779,"Jabber.org; Jabber FAQ by Peter Saint-Andre, 20010513.;;Atkins; Common Presence and Instant Messaging (CPIM), Aug. 14, 2002, pp. 1-30.;;Ramsdell; The MITRE Corporation, entitled: Simple Instant Messaging and Presence 1.3 Protocol, dated Jun. 2001, pp. 19.;;Sugano; ""Common Presence and Instant Messaging (CPIM) Presence Information Data Format"", May 2002, pp. 1-23.;;Day; ""A Model for Presence and Instant Messaging"", Feb. 2000, pp. 1-17.;;Day; Instant Messaging / Presence Protocol Requirements; Feb. 2000; pp. 1-26.;;Saint-Andre; Jabber FAQ, May 13, 2001, printed from the website address: http://web.qarchive.org/web/20010603135226/docs. Jabber.org/general/html/faz.html; pp. 1-39.;;Saint-Andre; XML Messaging with Jabber, Oct. 6, 2000; printed from website address: http://www.openp2p.com/pub.a/p2p/2000/10/06/jabber-xml.htmp?page-1; pp. 1-8.;;W3C; Extensible Markup Language (XML) 1.0 (Second Edition-W3C Recommendation; Oct. 6, 2000; pp. 1-59.;;Website: http://download.com.com/3000-2150-10148311.html?gtag=1st-0-1, entitled: C/Net Download.com; Trillian 0.74 popular, printed Mar. 2, 2004, pp. 2.;;Website: http://www.ceruleanstudios.com/, entitled: Trillian-Communicate with Flexibility and Style, printed Mar. 2, 2004, pp. 15.;;Website: http://www.malvino.com/ep/startup.htm, entitled: Startup Programs, printed Mar. 2, 2004, pp. 7.;;Malik; U.S. Appl. No. 10/135,929, filed Apr. 29, 2002.;;Daniell; U.S. Appl. No. 10/274,405, filed Oct. 18, 2002.;;Daniell; U.S. Appl. No. 10/274,408, filed Oct. 18, 2002.;;Daniell; U.S. Appl. No. 10/274,478, filed Oct. 18, 2002.;;Daniell; U.S. Appl. No. 11/210,178, filed Aug. 23, 2005.;;Malik; U.S. Appl. No. 11/352,435, filed Feb. 10, 2006.;;Malik; Non-Final Rejection mailed Jun. 22, 2005 for U.S. Appl. No. 10/135,929, filed Apr. 29, 2002.;;Malik; Examiner Interview Summary Record mailed Dec. 29, 2005 for U.S. Appl. No. 10/135,929, filed Apr. 29, 2002.;;Malik; Notice of Allowance and Fees Due mailed Dec. 29, 2005 for U.S. Appl. No. 10/135,929, filed Apr. 29, 2002.;;Daniell; Non-Final Rejection mailed Mar. 26, 2004 for U.S. Appl. No. 10/274,408, filed Oct. 18, 2002.;;Daniell; Examiner Interview Summary Record mailed Oct. 4, 2004 for U.S. Appl. No. 10/274,408, filed Oct. 18, 2002.;;Daniell; Notice of Allowance and Fees Due mailed Jan. 6, 2005 for U.S. Appl. 10/274,408, filed Oct. 18, 2002.;;Daniell; Notice of Allowance and Fees Due mailed May 23, 2005 for U.S. Appl. No. 10/274,408, filed Oct. 18, 2002.;;Daniell; Notice of Allowance and Fees Due mailed Sep. 21, 2005 for U.S. Appl. No. 10/274,408, filed Oct. 18, 2002.;;Daniell; Non-Final Rejection mailed Mar. 25, 2004 for U.S. Appl. No. 10/274,478, filed Oct. 18, 2002.;;Daniell; Non-Final Rejection mailed Oct. 7, 2004 for U.S. Appl. No. 10/274,478, filed Oct. 18, 2002.;;Daniell; Final Rejection mailed Jul. 27, 2005 for U.S. Appl. No. 10/274,478, filed Oct. 18, 2002.;;Daniell; Notice of Allowance and Fees Due mailed Nov. 16, 2005 for U.S. Appl. No. 10/274,478, filed Oct. 18, 2002.;;Daniell; Non-Final Rejection mailed Oct. 5, 2007 for U.S. Appl. No. 11/210,187, filed Aug. 23, 2005.;;Malik; Non-Final Rejection mailed Apr. 30, 2008 for U.S. Appl. No. 11/352,435, filed Feb. 10, 2006.",EXPIRED
733,US,B1,US 9667611 B1,143-060-972-782-386,2017-05-30,2017,US 201414230359 A,2014-03-31,US 201414230359 A,2014-03-31,Situationally aware authentication,"Improved techniques involve selecting a set of authentication factors from among multiple factors based on a current situation and information about how well the multiple authentication factors have worked in similar situations in the past. Along these lines, when an authentication system performs an authentication operation on a requesting party, the authentication system first assesses a situational environment. Based on the assessment of the situational environment, the authentication system decides that it is necessary to re-authenticate the requesting party. In some arrangements, the authentication system may determine which set of factors has the highest likelihood of successfully verifying the user's identity when compared with other authentication factors. The authentication system then carries out an authentication operation on the selected set of factors and bases a successful authentication result on whether the selected set of factors can be verified.",EMC CORP;;EMC IP HOLDING CO LLC,FRIEDMAN LAWRENCE N;;DOTAN YEDIDYA;;RICHARDS GARETH;;BAILEY DANIEL V;;DUANE WILLIAM M;;BRAINARD JOHN G,EMC CORPORATION (2014-09-18);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/143-060-972-782-386,Granted Patent,yes,3,18,1,1,0,G06F21/32;;H04L63/083;;H04L63/0861;;G06F2221/2111;;H04L63/08;;H04L63/08;;H04L63/083;;H04L63/0861;;G06F2221/2111;;G06F21/32,H04L29/06,,0,0,,,,ACTIVE
734,AU,A,AU 2000/037204 A,083-290-119-255-22X,2000-09-21,2000,AU 2000/037204 A,2000-03-03,US 12302499 P;;US 0005592 W,1999-03-04,Biochemical markers of brain function,,UNIV NEW MEXICO,BROOKS WILLIAM M;;FRIEDMAN SETH D;;JUNG REX J;;PETROPOULOS HELEN;;SIBBITT WILMER L;;YEO RONALD,,https://lens.org/083-290-119-255-22X,Patent Application,no,0,0,3,4,0,G01R33/483;;G01R33/4806,G01R33/28;;G01R33/48,,0,0,,,,DISCONTINUED
735,US,E,US RE041848 E,155-397-498-109-539,2010-10-19,2010,US 28613608 A,2008-09-24,US 28613608 A;;US 27440802 A;;US 41961302 P;;US 41133602 P,2002-09-17,System using transport protocol objects located at agent location to generate session ID and to provide translation between different instant messaging protocols,"A system and method are presented in which a plurality of transport protocol objects (TPOs) are instantiated at an IM user agent. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",AT & T IP I LP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,,https://lens.org/155-397-498-109-539,Amended Patent,yes,11,46,9,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L67/14;;H04L69/08;;H04L51/234;;H04L67/565;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L67/14;;H04L69/08;;H04L67/565;;H04L51/234,G06F15/16;;G06Q10/10;;H04L12/58;;H04L29/06,709/246;;709/227;;709/202,23,5,062-895-497-242-485;;075-725-963-794-587;;135-805-492-258-431;;062-895-497-242-485;;075-725-963-794-587,10.17487/rfc2779;;10.17487/rfc2778;;10.17487/rfc3862;;10.17487/rfc2779;;10.17487/rfc2778,"Peter Saint-Andre, ""Jabber FAQ"" May 13, 2001, jabber.org, pp. 1-36.;;Peter Saint-Andre, ""XML Messaging With Jabber"" Oct. 6, 2000, O'Reilly Media, Inc. pp. 1-3.;;Instant Messaging/Presence Protocol Requirements Day et al.; Feb. 2000.;;A Model for Presence and Instant Messaging Day et al., Feb. 2000.;;Extensible Markup Language (XML) 1.0 (Second Edition) W3C XML Core Working Group (WG); Oct. 6, 2000.;;Common Presence and Instant Messaging: Message Format Atkins et al., Feb. 20, 2002.;;Common Presence and Instant Messaging (CPIM) Presence Information Data Format Sugano et al.; May 2002.;;Common Presence and Instant Messaging (CPIM) Crocker et al.; Aug. 14, 2002.;;Daniell, et al., patent application entitled ""Server-Based Message Protocol Translation,"" filed Oct. 18, 2002, (s.n. 10/274,478), 52 pages (combined spec. and figures).;;Daniell, et al., patent application entitled ""Message Client with Multiple Message System Consolidation,"" filed Oct. 18, 2002 (s.n. 10/274,405), 51 pages (combined spec. and figures).;;http://www.malvino.com/ep/startup.htm, entitled: Startup Programs, printed Mar. 2, 2004, pp. 7.;;http://download.com.com./3000-2150-10148311.html?tag=1st-0-1, entitled: C/Net Download.com; Trillian 0.74 popular, printed Mar. 2, 2004, pp. 2.;;J.D. Ramsdell, The MITRE Corporation, entitled: Simple Instant Messaging and Presence 1.3 Protocol, dated Jun. 2001, p. 19.;;http://www.ceruleanstudios.com/, entitled: Trillian-Communicate with Flexibility and Style, printed Mar. 2, 2004, p. 15.;;PCT International Search Report-Int'l Appl. No.: PCT.US03/29225, mailed Jun. 21, 2004, p. 6.;;PCT International Search Report-Int'l Appl. No.: PCT/US03/29066, mailed May 11, 2004, p. 7.;;PCT International Search Report-Int'l Appl. No. PCT/US03/29226, mailed May 5, 2004, p. 6.;;Instant Messaging/Presence Protocol Requirements Day et al.; Feb. 2000.;;A Model for Presence and Instant Messaging Day et al., Feb. 2000.;;Extensible Markup Language (XML) 1.0 (Second Edition) W3C XML Core Working Group (WG); Oct. 6, 2000.;;Common Presence and Instant Messaging: Message Format Atkins et al.; Feb. 20, 2002.;;Common Presence and instant Messaging (CPIM) Presence Information Data Format Sugano et al.; May 2002.;;Common Presence and Instant Messaging (CPIM) Crocker et al.; Aug. 14, 2002.",PENDING
736,AU,A1,AU 2003/272486 A1,091-619-553-228-356,2004-04-08,2004,AU 2003/272486 A,2003-09-15,US 41133602 P;;US 41961302 P;;US 27440802 A;;US 0329225 W,2002-09-17,CLIENT-BASED MESSAGE PROTOCOL TRANSLATION,,BELLSOUTH INTELLECT PTY CORP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,,https://lens.org/091-619-553-228-356,Patent Application,no,0,0,9,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L67/14;;H04L69/08;;H04L51/234;;H04L67/565;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L67/14;;H04L69/08;;H04L67/565;;H04L51/234,G06Q10/10;;H04L12/58;;H04L29/06,,0,0,,,,DISCONTINUED
737,WO,A2,WO 2000/052465 A2,140-603-710-283-092,2000-09-08,2000,US 0005592 W,2000-03-03,US 12302499 P,1999-03-04,BIOCHEMICAL MARKERS OF BRAIN FUNCTION,The present invention provides methods for determining brain functioning in an individual by measuring the amount of either N-acetylaspartate or choline in an individual's brain. The present invention also provides methods for determining a change in an individual's brain functioning due to a change in the concentration of N-acetylaspartate or choline in the individual's brain.,UNIV NEW MEXICO;;BROOKS WILLIAM M;;FRIEDMAN SETH D;;JUNG REX J;;PETROPOULOS HELEN;;SIBBITT WILMER L;;YEO RONALD,BROOKS WILLIAM M;;FRIEDMAN SETH D;;JUNG REX J;;PETROPOULOS HELEN;;SIBBITT WILMER L;;YEO RONALD,,https://lens.org/140-603-710-283-092,Patent Application,yes,0,2,3,4,0,G01R33/483;;G01R33/4806,G01R33/28;;G01R33/48,,0,0,,,,PENDING
738,US,A1,US 2006/0041684 A1,199-670-561-610-360,2006-02-23,2006,US 27447802 A,2002-10-18,US 27447802 A;;US 41133602 P;;US 41961302 P,2002-09-17,SERVER-BASED MESSAGE PROTOCOL TRANSLATION,"A system and method are presented in which a plurality of transport protocol objects (TPOS) are instantiated at a server. In one embodiment, each of the plurality of TPOs is adapted to provide a translation between a first IM protocol and a different IM protocol.",BELLSOUTH INTELLECT PTY CORP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY G JR;;DAVIS JOEL A;;DAIGLE BRIAN K,AT&T INTELLECTUAL PROPERTY I L.P (2008-08-28);;UBER TECHNOLOGIES INC (2017-01-13);;AT&T DELAWARE INTELLECTUAL PROPERTY INC (2007-11-01);;BELLSOUTH INTELLECTUAL PROPERTY CORPORATION (2003-01-07),https://lens.org/199-670-561-610-360,Patent Application,yes,8,53,10,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L69/08;;H04L51/234,G06F15/16;;G06Q10/10;;H04L12/58;;H04L29/06,709/246,0,0,,,,EXPIRED
739,WO,A8,WO 2004/027559 A8,012-565-403-652-294,2004-08-19,2004,US 0329066 W,2003-09-15,US 41133602 P;;US 41961302 P;;US 27440502 A,2002-09-17,MESSAGE CLIENT WITH MULTIPLE MESSAGE SYSTEM CONSOLIDATION,"Systems and methods are presented in which a single user interface provides a user with information on multiple messaging sessions, each having a different messaging protocol.",BELLSOUTH INTELLECT PTY CORP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,,https://lens.org/012-565-403-652-294,Patent Application,no,0,0,5,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234,G06Q10/00;;H04L12/58;;H04L29/06,,0,0,,,,PENDING
740,AU,A8,AU 2003/272486 A8,076-778-389-482-874,2004-04-08,2004,AU 2003/272486 A,2003-09-15,US 41133602 P;;US 41961302 P;;US 27440802 A;;US 0329225 W,2002-09-17,Client-based message protocol translation,,BELLSOUTH INTELLECT PTY CORP,KENT LARRY GRAHAM JR;;DAIGLE BRIAN KEITH;;FRIEDMAN LEE G;;DAVIS JOEL A;;DANIELL WILLIAM TODD,,https://lens.org/076-778-389-482-874,Patent Application,no,0,0,9,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L67/14;;H04L69/08;;H04L51/234;;H04L67/565;;G06Q10/107;;H04L63/0428;;H04L51/066;;H04L51/04;;H04L67/14;;H04L69/08;;H04L67/565;;H04L51/234,G06Q10/10;;H04L12/58;;H04L29/06,,0,0,,,,DISCONTINUED
741,AU,A1,AU 2003/278822 A1,152-331-599-391-595,2004-04-08,2004,AU 2003/278822 A,2003-09-15,US 41133602 P;;US 41961302 P;;US 27440502 A;;US 0329066 W,2002-09-17,MESSAGE CLIENT WITH MULTIPLE MESSAGE SYSTEM CONSOLIDATION,,BELLSOUTH INTELLECT PTY CORP,DANIELL WILLIAM TODD;;FRIEDMAN LEE G;;KENT LARRY GRAHAM JR;;DAVIS JOEL A;;DAIGLE BRIAN KEITH,,https://lens.org/152-331-599-391-595,Patent Application,no,0,0,5,119,0,G06Q10/107;;H04L51/04;;H04L51/066;;H04L63/0428;;H04L69/08;;H04L51/234,G06Q10/00;;H04L12/58;;H04L29/06,,0,0,,,,DISCONTINUED
742,EP,A4,EP 2872082 A4,156-161-152-964-517,2016-03-23,2016,EP 13819425 A,2013-03-15,US 201261671798 P;;US 201261699226 P;;US 201213665495 A;;US 2013/0032567 W,2012-07-16,SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT,,AVEDRO INC,FRIEDMAN MARC D;;SHERR EVAN;;KAMAEV PAVEL;;EDDINGTON WILLIAM;;MULLER DAVID;;USHER DAVID;;PERTAUB RADHA;;HEREKAR SATISH,"AVEDRO, INC. (2017-07-26)",https://lens.org/156-161-152-964-517,Search Report,no,2,0,14,27,0,A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61K31/525;;A61F9/0008;;A61P27/10;;A61K31/525;;A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61F9/0008,A61F9/007;;A61B18/18;;A61F9/008;;A61N5/06,,1,0,,,See also references of WO 2014014521A1,ACTIVE
743,WO,A1,WO 2014/014521 A1,019-389-046-052-534,2014-01-23,2014,US 2013/0032567 W,2013-03-15,US 201261671798 P;;US 201261699226 P;;US 201213665495 A,2012-07-16,SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT,"A method for controlling activation of a cross-linking agent applied to an eye includes applying the cross-linking agent to a selected region of a cornea of the eye and initiating cross-linking activity in the selected region by activating the cross-linking agent with pulsed light illumination. The pulsed light illumination has a selectable wavelength, irradiance, dose, and on/off duty cycle. The wavelength, the irradiance, the dose, and the on/off duty cycle are adjusted in response to a determination of photochemical kinetic pathways for cross-linking activity and to control photochemical efficiency, depth of cross-linking, and density of cross-linking.",AVEDRO INC,FRIEDMAN MARC D;;SHERR EVAN;;KAMAEV PAVEL;;EDDINGTON WILLIAM;;MULLER DAVID;;USHER DAVID;;PERTAUB RADHA;;HEREKAR SATISH,,https://lens.org/019-389-046-052-534,Patent Application,yes,2,16,14,27,0,A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61K31/525;;A61F9/0008;;A61P27/10;;A61K31/525;;A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61F9/0008,A61F9/007;;A61B18/18,,3,1,031-951-025-920-400,20954581;;10.3928/1081597x-20100930-01,"I.M. KORNILOVSKY.: ""Novye neinvazivnye tekhnologii lazemoy modifikatsii optiko-refraktsionnykh struktur glaza."", REFRAKTSIONNAYA KHIRURGIYA I OFTALMOLOGIYA, vol. 9, no. 3, 2009, pages 17 - 26, XP055189190;;REINSTEIN D.Z. ET AL.: ""Epithelial thickness profile as a method to evaluate the effectiveness of collagen cross-linking treatment after corneal ectasia."", J REFRACT SURG., vol. 27, no. 5, May 2011 (2011-05-01), pages 356 - 363, XP008176252, Retrieved from the Internet <URL:doi:10.3928/1081597X-20100930-01.>;;See also references of EP 2872082A4",PENDING
744,US,A1,US 2016/0174908 A1,083-076-822-503-021,2016-06-23,2016,US 201514735887 A,2015-06-10,IN 6498CH2014 A,2014-12-23,DEVICE AND METHOD FOR HIGHLIGHTING PATIENT DATA AND TRENDS,"A monitoring or diagnostic device including a display having a display screen on which incoming data from sensors attached to the item or object being monitored by the device is illustrated. The incoming data is represented on the display screen to enable an individual viewing the display screen to determine the current operating condition or parameters of the item or object, such as a patient. The device and display screen can also illustrate various alarm conditions or events, as determined by the device to draw the attention of the individual to those alarm conditions. To assist in this function, the device represents the incoming data from a sensor giving rise to the alarm condition or event, as well as additional incoming data from other sensors corresponding in some manner to the alarm condition, on the display screen in a visually different or distinct manner from the rest of the incoming data not relating to the alarm condition or event.",GEN ELECTRIC,NAIR RENJITH S;;GENC SAHIKA;;TREACY STEPHEN THOMAS;;FRIEDMAN BRUCE ARNOLD;;SITZMAN DAVID ALAN;;BALLONI WILLIAM JAMES,GENERAL ELECTRIC COMPANY (2015-02-24),https://lens.org/083-076-822-503-021,Patent Application,yes,2,3,1,1,0,A61B5/0205;;G16H40/63;;A61B5/742;;A61B5/746;;G16Z99/00;;A61B5/742;;A61B5/746;;G16H40/63;;A61B5/0205;;G16Z99/00,A61B5/00;;A61B5/0215;;A61B5/026;;A61B5/04;;A61B5/0452;;A61B5/1455;;G16Z99/00,,0,0,,,,DISCONTINUED
745,EP,A3,EP 0135435 A3,010-197-044-995-180,1987-03-25,1987,EP 84401696 A,1984-08-21,US 52534583 A,1983-08-22,IMMUNOGENIC HBSAG DERIVED FROM TRANSFORMED YEAST,"@ The surface antigen protein of human Hepatitis B virus is synthesized in Saccharomyces cerevisiae as a 23,000-26,000 dalton polypeptide, essentially free of intermolecular disulfide bonds. This antigen is a poor immunogen in animals and man. No prior precedent or method exists for efficiently converting the non-disulfide bonded antigen to a fully intermolecular disulfide bonded particle. We describe the first example of such a conversion in vitro and show that the act of this conversion enhances the immunogenicity of the antigen about 10-fold. The in vitro conversion makes practical the production of hepatitis B surface antigen from microorganisms using recombinant DNA methods.",MERCK & CO. INC.,"FRIEDMAN, ARTHUR;;LEHMAN, E. DALE;;MCALEER, WILLIAM J.;;SCHAEFER, TED F.;;SCOLNICK, EDWARD M.;;WAMPLER, EUGENE D.",,https://lens.org/010-197-044-995-180,Search Report,yes,1,0,4,5,0,A61K39/00;;C07K14/005;;C12N2730/10122;;C12N15/00;;A61K39/00,A61K39/29;;A61K39/00;;C07K14/02,,8,6,123-700-699-980-708;;097-773-387-318-439;;044-774-028-384-962;;045-020-822-822-638;;053-298-124-616-235;;142-932-773-999-338,7045698;;10.1038/298347a0;;6337369;;10.1073/pnas.80.1.1;;pmc393297;;pmc325921;;10.1093/nar/11.9.2745;;6344021;;10.1002/jmv.1890100109;;7130967;;10.1016/0141-8130(79)90045-x;;6154075,"NATURE, vol. 298, July 22, 1982 pages 347-350 P. VALENZUELA et al.: ""Synthesis and assembly of hepatitis B virus surface antigen particles in yeast"". Page 349-350: ""Nature of viral antigen gene in yeast"" and ""Conclusions"";;PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 80, no. 1, January 1983, pages 1-5; Washington, US A. MIYANOHARA et al.: ""Expression of hepatitis B surface antigen gene in yeast"". Pages 3-5, paragraph: ""Introduction and production of HBsAg on yeast cells"", ""Some properties of the HBsAG producedin yeast cells"" and ""discussion"";;NUCLEIC ACIDS RESEARCH, vol. 11, no. 9, 1983, pages 2745-2763 R.A. HITZEMAN et al.: ""Expression of hepatitis B virus Surface antigen in yeast"": Whole article;;BIOLOGICAL ABSTRACTS, vol. 75, 1983, ref. no. 49348 E. TABOR et al.: ""Immunogenicity in chimpanzees of experimental hepatitis B vaccines prepared from intact hepatitis B virus, purified polypeptides, or polypeptide micells"" & J. MED. VIROL, 10(1), 65-74, 1982. Abstract;;CHEMICAL ABSTRACTS, vol. 92, no. 3, January 21, 1980, page 248, ref.no. 17460x; Columbus, Ohio, US H.P. JENNISSEN et al.: ""Protein binding to two-dimensional hydrophobic binding-site lattices: adsorption hysteresis on immobilized butyl-residues"". & INT. J. BIOL. MACROMOL. 1979, 1(4), 171-9. Abstract;;CHEMICAL ABSTRACTS, vol. 92, no. 13, March 31, 1980, page 290, ref. no. 106622u; Columbus, Ohio, US H.P. JENNISSEN: ""Cooperative, multivalent protein binding on two-dimensional, hydrophobic binding-site lattices: a model for the mechanism of protein adsorption on hydrophobic agareses"" & COLLOQ.-INST. NATL. SANTE RECH. MED: 1979, 86(Chromatogr. Affinite Interact. Mol.), 253-64. Abstract;;CHEMICAL ABSTRACTS, vol. 95, no. 15, October 12, 1981, page 271, ref.no. 128372b; Columbus, Ohio, US H.P. JENNISSEN: ""The binding and regulation of biologically active proteins on cellular interfaces"" & ADV. ENZYME REGUL. 1981, 19, 377-406. Abstract;;THE JOURNAL OF IMMUNOLOGY, vol. 124, no. 4 April 1980, pages 1589-1593; The Williams & Wilkins Co., US SHUNJI MISHITO et al.: ""A 49,000 Dalton polypeptide bearing all antigenic determinants and full immunogenicity of 22-nm hepatitis B surface antigen particles""",DISCONTINUED
746,US,B2,US 11468608 B2,080-483-078-482-988,2022-10-11,2022,US 202017247015 A,2020-11-24,US 202017247015 A,2020-11-24,Machine architecture for computerized plan analysis with provenance,"A computing machine accesses a directed graph representing one or more sequences of actions. The directed graph comprises nodes and edges between the nodes. Each node is either a beginning node, an intermediate node, or an end node. Each intermediate is downstream from at least one beginning node and upstream from at least one end node. Each beginning node in at least a subset of the beginning nodes has an explainability value vector. The computing machine computes, for each first node from among a plurality of first nodes that are intermediate nodes or end nodes, a provenance value representing dependency of an explainability value vector of the first node on the one or more nodes upstream from the first node. The computing machine computes, for each first node, the explainability value vector. The computing machine provides a graphical output representing at least an explainability value vector of an end node.",SMART INFORMATION FLOW TECH LLC,FRIEDMAN SCOTT EHRLICH;;GOLDMAN ROBERT PRESCOTT;;FREEDMAN RICHARD GABRIEL;;KUTER UGUR;;GEIB CHRISTOPHER WILLIAM;;RYE JEFFREY M,SMART INFORMATION FLOW TECHNOLOGIES LLC D/B/A SIFT L.L.C (2020-11-18),https://lens.org/080-483-078-482-988,Granted Patent,yes,7,0,2,2,0,G06F3/04842;;G06F3/0482;;G06F9/451;;G06T11/206;;G06N5/022;;G06N7/01;;G06T11/206;;G06F3/04855;;G06T2200/24;;G06N20/00;;G06F3/04842,G06N20/20;;G06F3/04842;;G06F3/04855;;G06N20/00;;G06T11/20,,0,0,,,,ACTIVE
747,EP,A1,EP 2872082 A1,006-526-555-530-828,2015-05-20,2015,EP 13819425 A,2013-03-15,US 201261671798 P;;US 201261699226 P;;US 201213665495 A;;US 2013/0032567 W,2012-07-16,SYSTEMS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT,,AVEDRO INC,FRIEDMAN MARC D;;SHERR EVAN;;KAMAEV PAVEL;;EDDINGTON WILLIAM;;MULLER DAVID;;USHER DAVID;;PERTAUB RADHA;;HEREKAR SATISH,"AVEDRO, INC. (2017-07-26)",https://lens.org/006-526-555-530-828,Patent Application,yes,0,1,14,27,0,A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61K31/525;;A61F9/0008;;A61P27/10;;A61K31/525;;A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61F9/0008,A61F9/007;;A61B18/18;;A61F9/008;;A61N5/06,,0,0,,,,ACTIVE
748,US,A1,US 2022/0165007 A1,107-835-239-640-356,2022-05-26,2022,US 202017247015 A,2020-11-24,US 202017247015 A,2020-11-24,MACHINE ARCHITECTURE FOR COMPUTERIZED PLAN ANALYSIS WITH PROVENANCE,"A computing machine accesses a directed graph representing one or more sequences of actions. The directed graph comprises nodes and edges between the nodes. Each node is either a beginning node, an intermediate node, or an end node. Each intermediate is downstream from at least one beginning node and upstream from at least one end node. Each beginning node in at least a subset of the beginning nodes has an explainability value vector. The computing machine computes, for each first node from among a plurality of first nodes that are intermediate nodes or end nodes, a provenance value representing dependency of an explainability value vector of the first node on the one or more nodes upstream from the first node. The computing machine computes, for each first node, the explainability value vector. The computing machine provides a graphical output representing at least an explainability value vector of an end node.",SMART INFORMATION FLOW TECH LLC D/B/A SIFT L L C,FRIEDMAN SCOTT EHRLICH;;GOLDMAN ROBERT PRESCOTT;;FREEDMAN RICHARD GABRIEL;;KUTER UGUR;;GEIB CHRISTOPHER WILLIAM;;RYE JEFFREY M,SMART INFORMATION FLOW TECHNOLOGIES LLC D/B/A SIFT L.L.C (2020-11-18),https://lens.org/107-835-239-640-356,Patent Application,yes,0,1,2,2,0,G06F3/04842;;G06F3/0482;;G06F9/451;;G06T11/206;;G06N5/022;;G06N7/01;;G06T11/206;;G06F3/04855;;G06T2200/24;;G06N20/00;;G06F3/04842,G06T11/20;;G06F3/0484;;G06F3/0485,,0,0,,,,ACTIVE
749,EP,B1,EP 2872082 B1,026-899-453-169-688,2020-09-09,2020,EP 13819425 A,2013-03-15,US 201261671798 P;;US 201261699226 P;;US 201213665495 A;;US 2013/0032567 W,2012-07-16,SYSTEMS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT,,AVEDRO INC,FRIEDMAN MARC D;;SHERR EVAN;;KAMAEV PAVEL;;EDDINGTON WILLIAM;;MULLER DAVID;;USHER DAVID;;PERTAUB RADHA;;HEREKAR SATISH,"AVEDRO, INC. (2017-07-26)",https://lens.org/026-899-453-169-688,Granted Patent,yes,4,3,14,27,0,A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61K31/525;;A61F9/0008;;A61P27/10;;A61K31/525;;A61F9/0079;;A61F9/013;;A61F2009/00872;;A61N5/062;;A61K41/00;;A61F9/0008,A61F9/00;;A61B18/18;;A61F9/007;;A61F9/008;;A61F9/013;;A61K31/525;;A61K41/00;;A61N5/06,,2,0,,,"I.M. KORNILOVSKY.: 'Novye neinvazivnye tekhnologii lazemoy modifikatsii optiko-refraktsionnykh struktur glaza.' REFRAKTSIONNAYA KHIRURGIYA I OFTALMOLOGIYA vol. 9, no. 3, 2009, pages 17 - 26, XP055189190;;REINSTEIN D.Z. ET AL.: 'Epithelial thickness profile as a method to evaluate the effectiveness of collagen cross-linking treatment after corneal ectasia.' J REFRACT SURG. vol. 27, no. 5, May 2011, pages 356 - 363, XP008176252 Retrieved from the Internet: <URL:doi: 10.3928/1081597X-20100930-01.> & DATABASE PUBMED [Online] XP055188058 Retrieved from NCBI Database accession no. 0954581",ACTIVE
750,US,A1,US 2013/0245536 A1,158-466-680-329-306,2013-09-19,2013,US 201313841617 A,2013-03-15,US 201313841617 A;;US 201213665495 A;;US 90922810 A;;US 25373609 P;;US 201261699226 P;;US 201261671798 P,2009-10-21,SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT,"A method for controlling activation of a cross-linking agent applied to an eye includes applying the cross-linking agent to a selected region of a cornea of the eye and initiating cross-linking activity in the selected region by activating the cross-linking agent with pulsed light illumination. The pulsed light illumination has a selectable wavelength, irradiance, dose, and on/off duty cycle. The wavelength, the irradiance, the dose, and the on/off duty cycle are adjusted in response to a determination of photochemical kinetic pathways for cross-linking activity and to control photochemical efficiency, depth of cross-linking, and density of cross-linking.",AVEDRO INC,FRIEDMAN MARC D;;SHERR EVAN;;KAMAEV PAVEL;;EDDINGTON WILLIAM;;MULLER DAVID;;USHER DAVID;;PERTAUB RADHA;;HEREKAR SATISH,AVEDRO INC (2013-04-04),https://lens.org/158-466-680-329-306,Patent Application,yes,3,53,1,27,0,A61K41/00;;A61F9/0008;;A61F9/0079;;A61F9/013;;A61K31/14;;A61F2009/00872;;A61F2210/0085;;A61K41/0042;;A61N5/062;;A61N5/062;;A61F2009/00872;;A61F9/013;;A61K31/14;;A61F9/0008;;A61F9/0079;;A61K41/00;;A61F2210/0085;;A61K41/0042,A61N5/06,604/20,0,0,,,,DISCONTINUED
751,US,A,US 4707542 A,172-173-923-523-591,1987-11-17,1987,US 63651484 A,1984-08-01,US 63651484 A;;US 52534583 A,1983-08-22,Immunogenic HbsAg derived from transformed yeast,"The surface antigen protein of human Hepatitis B virus is synthesized in Saccharomyces cerevisiae as a 23,000-26,000 dalton polypeptide, essentially free of intermolecular disulfide bonds. This antigen is a poor immunogen in animals and man. No prior precedent or method exists for efficiently converting the non-disulfide bonded antigen to a fully intermolecular disulfide bonded particle. We describe the first example of such a conversion in vitro and show that the act of this conversion enhances the immunogenicity of the antigen about 10-fold. The in vitro conversion makes practical the production of hepatitis B surface antigen from microorganisms using recombinant DNA methods.",MERCK & CO INC,FRIEDMAN ARTHUR;;LEHMAN E DALE;;MCALEER WILLIAM J;;SCHAEFER TED F;;SCOLNICK EDWARD M;;WAMPLER D EUGENE,MERCK & CO. INC (1984-08-08),https://lens.org/172-173-923-523-591,Granted Patent,yes,4,23,1,5,0,A61K39/00;;A61K39/292;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;Y10S530/806;;Y10S530/826;;Y10S435/803;;Y10S436/82;;A61K2039/55505;;A61K39/12;;C07K14/005;;A61K39/00;;C12N2730/10122;;A61K39/292;;C12N2730/10134;;Y10S436/82;;Y10S530/806;;Y10S435/803;;Y10S530/826;;A61K39/12;;A61K2039/55505,A61K39/00;;A61K39/29;;C07K14/02,530/371;;530/395;;530/417;;530/415;;530/806;;530/826;;424/89;;436/820;;210/635;;210/502.1;;210/198.2;;435/5;;435/68;;435/70;;435/172.3;;435/235;;435/239;;435/255;;435/803,11,4,142-932-773-999-338;;123-700-699-980-708;;044-774-028-384-962;;097-773-387-318-439,6154075;;7045698;;10.1038/298347a0;;pmc325921;;10.1093/nar/11.9.2745;;6344021;;6337369;;10.1073/pnas.80.1.1;;pmc393297,"Jennissen, H. P., Collog. Inst. Natl. Sante Recher. Med. 86:253 264 (1979) cited in Chem. Abstract CA92(13):106622u.;;Vukovich, T. et al, Folia Haematol. (Leipzig) 107(1):148 151 (1980) cited in Chem. Abstract CA93(5):40663v.;;Andersson, L. O. et al, Canadian Pat. No. 1076956, May 6, 1980, cited in Chem. Abstract CA93(22):210240z.;;Einarsson, M. et al, J. Virol. Methods 3(4):213 228 (1981), cited in Chem. Abstract CA96(12):91530u.;;Austen, D. E. et al, Thromb. Haemostas. 48(1):46 48 (1982) cited in Chem. Abstract CA97(20):168767g.;;Dubois, M. F. et al, Ann. Virol. 134E(1):87 96 (1983) cited in Chem. Abstract CA98(25):213811a.;;Einarsson, M. et al, J. Virol. Methods 8(3):233 241 (5 1984) cited in Chem. Abstract CA101(15):128495m.;;Mishiro, S. et al. J. of Immunology 124:1589 1593 (1980).;;Valenzuela, P. et al, Nature 298:347 350 (1982).;;Hitzeman, R. A. et al, Nucleic Acids Research 11:2745 2763 (1983).;;Miyanohara, A. et al, Proc. Natl. Acad. Sci. USA 80:1 5 (1983).",EXPIRED
752,EP,A2,EP 0135435 A2,126-974-017-249-123,1985-03-27,1985,EP 84401696 A,1984-08-21,US 52534583 A,1983-08-22,Immunogenic HBsAg derived from transformed yeast.,"@ The surface antigen protein of human Hepatitis B virus is synthesized in Saccharomyces cerevisiae as a 23,000-26,000 dalton polypeptide, essentially free of intermolecular disulfide bonds. This antigen is a poor immunogen in animals and man. No prior precedent or method exists for efficiently converting the non-disulfide bonded antigen to a fully intermolecular disulfide bonded particle. We describe the first example of such a conversion in vitro and show that the act of this conversion enhances the immunogenicity of the antigen about 10-fold. The in vitro conversion makes practical the production of hepatitis B surface antigen from microorganisms using recombinant DNA methods.",MERCK & CO INC,FRIEDMAN ARTHUR;;LEHMAN E DALE;;MCALEER WILLIAM J;;SCHAEFER TED F;;SCOLNICK EDWARD M;;WAMPLER EUGENE D,,https://lens.org/126-974-017-249-123,Patent Application,yes,0,12,4,5,0,A61K39/00;;C07K14/005;;C12N2730/10122;;C12N15/00;;A61K39/00,A61K39/29;;A61K39/00;;C07K14/02,,0,0,,,,DISCONTINUED
753,EC,A,EC SP982571 A,054-931-182-338-613,1999-01-26,1999,EC SP982571 A,1998-06-30,EC SP982571 A,1998-06-30,SALES DE SERTRALINA Y FORMAS DE DOSIFICACION DE LIBERACION SOSTENIDA DE SERTRALINA,"Formas de dosificación de liberación sostenida d esertralina que liberan sertralina a una velocidad entre 1 mgA/h y 40mgA/h. Las formas de dosificación pueden presentar un periodo de retraso inicial durante el cual, la sertralina se libera a una velocidad menor que 1 mgA/h. La presente invención se refiere además a una sal de acetato, a una sal de L-lactato y a una sal de L-aspartato de sertralina, a las composiciones farmacéuticas de las mismas y a los procedimientos de uso de la sal para el tratamiento de varios trastornos y afecciones. La presente invención también se refiere a los procedimientos para la preparación del acetato de sertralina, del L-lactato de sertralina y del L-aspartato de sertralina.",,SHANKER RAVI MYSORE;;CURATOLO WILLIAM JHON;;FRIEDMAN HYLAR L;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/054-931-182-338-613,Patent Application,no,0,0,1,1,0,,A61K9/22;;C07C211/58,,0,0,,,,PENDING
754,US,A1,US 2003/0217089 A1,115-588-661-129-726,2003-11-20,2003,US 15138102 A,2002-05-20,US 15138102 A,2002-05-20,Multiple task wait system for use in a data warehouse environment,"
   A multiple task wait system and associated method allow a client application to wait for multiple tasks to be successfully or conditionally implemented before running subsequent tasks. Two mechanisms can be used to accomplish this multiple wait process: The first mechanism uses a multi-wait grouping process that is visible to the client, and the second mechanism uses a graphical representation to identify the tasks to be completed. The multi-wait grouping process allows a client to group a related set of tasks together for both control and documentation purposes. The client can add as many tasks as the resources of the computer allow to a group while defining the data flows and control flows between the tasks in the group using various graphical tools. The multi-wait system allows the client to define the constraints and conditions for a set of tasks to be considered complete, and further allows the system to define the constraints and conditions for considering all the tasks within the group to be completed. By utilizing the group concept, the system can selectively control the tasks to be included in the completion decision based on predefined rules. 
",IBM,BAKOW LINNETTE;;FARRINGTON SHANNON MATTHEW;;FRIEDMAN DIANA;;JACOPI TOM WILLIAM;;LABRIE JACQUES JOSEPH;;NGUYEN THANH VU;;WU CHEUNG-YUK,INTERNATIONAL BUSINESS MACHINES CORPORATION (2002-05-16),https://lens.org/115-588-661-129-726,Patent Application,yes,6,16,2,2,0,G06F9/4843;;G06F9/4843;;G06F9/5038;;G06F9/5038,G06F9/00;;G06F9/48;;G06F9/50,7091,0,0,,,,EXPIRED
755,US,B2,US 7174551 B2,068-824-031-523-912,2007-02-06,2007,US 15138102 A,2002-05-20,US 15138102 A,2002-05-20,Multiple task wait system for use in a data warehouse environment,"A multiple task wait system and associated method allow a client application to wait for multiple tasks to be successfully or conditionally implemented before running subsequent tasks. Two mechanisms can be used to accomplish this multiple wait process: The first mechanism uses a multi-wait grouping process that is visible to the client, and the second mechanism uses a graphical representation to identify the tasks to be completed. The multi-wait grouping process allows a client to group a related set of tasks together for both control and documentation purposes. The client can add as many tasks as the resources of the computer allow to a group while defining the data flows and control flows between the tasks in the group using various graphical tools. The multi-wait system allows the client to define the constraints and conditions for a set of tasks to be considered complete, and further allows the system to define the constraints and conditions for considering all the tasks within the group to be completed. By utilizing the group concept, the system can selectively control the tasks to be included in the completion decision based on predefined rules.",IBM,BAKOW LINNETTE;;FARRINGTON SHANNON MATTHEW;;FRIEDMAN DIANE;;JACOPI TOM WILLIAM;;LABRIE JACQUES JOSEPH;;NGUYEN THANH VU;;WU CHEUNG-YUK,INTERNATIONAL BUSINESS MACHINES CORPORATION (2002-05-16),https://lens.org/068-824-031-523-912,Granted Patent,yes,11,8,2,2,0,G06F9/4843;;G06F9/4843;;G06F9/5038;;G06F9/5038,G06F9/46;;G06F9/00;;G06F9/48;;G06F9/50,718/100;;718/107,3,0,,,"""Method for Network-Aware, Asynchronous, Process-Com{grave over (){grave over (})}pletion, Notification,"" Research Disclosure, Dec. 1999, p. 1670.;;R.G. Mustain et al., ""Virtual List Multiple Event Wait,"" IBM Technical Disclosure Bulletin, vol. 21, No. 5, Oct. 1978.;;R.L. Obermack, ""Deadlock Detection for all Resource Classes,"" IBM Technical Disclosure Bulletin, vol. 22, No. 11, Apr. 1980.",INACTIVE
756,US,B2,US 6810707 B2,010-303-170-557-954,2004-11-02,2004,US 6375702 A,2002-05-10,US 6375702 A,2002-05-10,Compressed-radius hem-forming process and tool,"
    A tool and process utilizing the tool for forming a compressed-radius hem on a sheet metal assembly is provided. A concave portion on the tool is formed by at least two surfaces that together define a cavity. A flange on the perimeter of an outer panel is initially formed to an approximate perpendicular angle and is then formed to about 45. In a final forming step, an intermediate portion of the flange is engaged by the cavity and is formed into a compressed-radius hem. 
",FORD MOTOR CO;;UNOVA IND AUTOMATION SYS INC,FRIEDMAN PETER A;;FAITEL WILLIAM;;SAMANT JAIDEEP;;COUGHLIN PATRICK;;WIENS PHIL;;SCHRANDT DOUG;;MILLER CRAIG EUGENE;;XIA ZHIYONG CEDRIC,UNOVA INDUSTRIAL AUTOMATION SYSTEMS INC (2002-04-22);;FORD MOTOR COMPANY (2002-05-03),https://lens.org/010-303-170-557-954,Granted Patent,yes,19,15,9,9,0,B21D39/021;;B21D39/021;;Y10T29/53791;;Y10T29/53791,B21D39/02,72/220;;29/243.58,0,0,,,,EXPIRED
757,US,A1,US 2003/0209048 A1,194-586-734-146-102,2003-11-13,2003,US 6375702 A,2002-05-10,US 6375702 A,2002-05-10,Compressed-radius hem-forming process and tool,"
   A tool and process utilizing the tool for forming a compressed-radius hem on a sheet metal assembly is provided. A concave portion on the tool is formed by at least two surfaces that together define a cavity. A flange on the perimeter of an outer panel is initially formed to an approximate perpendicular angle and is then formed to about 45. In a final forming step, an intermediate portion of the flange is engaged by the cavity and is formed into a compressed-radius hem. 
",FORD MOTOR CO;;UNOVA IND AUTOMATION SYS INC,FRIEDMAN PETER A;;FAITEL WILLIAM;;SAMANT JAIDEEP;;COUGHLIN PATRICK;;WIENS PHIL;;SCHRANDT DOUG;;MILLER CRAIG EUGENE;;XIA ZHIYONG CEDRIC,UNOVA INDUSTRIAL AUTOMATION SYSTEMS INC (2002-04-22);;FORD MOTOR COMPANY (2002-05-03),https://lens.org/194-586-734-146-102,Patent Application,yes,1,16,9,9,0,B21D39/021;;B21D39/021;;Y10T29/53791;;Y10T29/53791,B21D39/02,07222,0,0,,,,EXPIRED
758,CN,A,CN 116323424 A,090-223-506-684-482,2023-06-23,2023,CN 202180041960 A,2021-05-28,US 202063032308 P;;US 202063126292 P;;US 202017131632 A;;US 2021/0035013 W,2020-05-29,SYSTEM AND METHOD FOR DISPENSING FOOD AND BEVERAGE PRODUCTS,"An apparatus and system for dispensing food and beverage products in which a flowable product is extracted from a flexible bag, and in which there is a nozzle region through which the flowable product exits the flexible bag. The nozzle region has a locking seal that closes the flowable product within the flexible pouch when a pressure less than a first threshold is applied to the flexible pouch. There is also a frangible seal positioned above the nozzle region, the frangible seal configured to close the flowable product within the flexible pouch when a pressure less than a second threshold is applied to the flexible pouch and when the first threshold is greater than the second threshold.",PLANT WATER FAUCETS CORP,SAVINO JOHN C;;FRIEDMAN LORI;;TOWEN SIMON ANDREW;;SU WILLIAM D;;SHEPPARD JAMES;;KARLINGS ZOLTAN;;PANONE ANDREA;;LEWIS DAVID T,,https://lens.org/090-223-506-684-482,Patent Application,no,0,0,5,15,0,B65D75/30;;B65D75/5811;;B65D75/566;;B65D75/5855;;B65D85/72;;A23L2/52;;A23L2/385,B65D75/30,,0,0,,,,PENDING
759,US,A1,US 2012/0153909 A1,027-257-105-860-714,2012-06-21,2012,US 201113213368 A,2011-08-19,US 201113213368 A;;US 42392310 P,2010-12-16,HYBRID FAST-SLOW PASSGATE CONTROL METHODS FOR VOLTAGE REGULATORS EMPLOYING HIGH SPEED COMPARATORS,"Voltage regulator circuits and methods implementing hybrid fast-slow passgate control circuitry are provided to minimize the ripple amplitude of a regulated voltage output. In one aspect, a voltage regulator circuit includes a comparator, a first passgate device, a second passgate device, and a bandwidth limiting control circuit. The comparator compares a reference voltage to a regulated voltage at an output node of the voltage regulator circuit and generates a first control signal on a first gate control path based on a result of the comparing. The first and second passgate devices are connected to the output node of the regulator circuit. The first passgate device is controlled in a bang-bang mode of operation by the first control signal to supply current to the output node. The bandwidth limiting control circuit has an input connected to the first gate control path and an output connected to the second passgate device. The bandwidth limiting control circuit generates a second control signal based on the first control signal, wherein the second control signal is a slew rate limited version of the first control signal, and wherein the second passgate is controlled by the second control signal to supply current to the output node.",BUCOSSI WILLIAM L;;BULZACCHELLI JOHN F;;CHHABRA MOHAK;;TOPRAK-DENIZ ZEYNEP;;FRIEDMAN DANIEL J;;IADANZA JOSEPH A;;RASMUS TODD M;;IBM,BUCOSSI WILLIAM L;;BULZACCHELLI JOHN F;;CHHABRA MOHAK;;TOPRAK-DENIZ ZEYNEP;;FRIEDMAN DANIEL J;;IADANZA JOSEPH A;;RASMUS TODD M,INTERNATIONAL BUSINESS MACHINES CORPORATION (2011-07-19),https://lens.org/027-257-105-860-714,Patent Application,yes,4,22,1,1,0,H02M1/15;;H02M3/1563;;H02M3/1566;;H02M3/1563;;H02M1/15;;H02M3/1566,G05F1/10,323/271,0,0,,,,DISCONTINUED
760,EP,A1,EP 4157742 A1,034-675-803-801-100,2023-04-05,2023,EP 21813728 A,2021-05-28,US 202063032308 P;;US 202063126292 P;;US 202017131632 A;;US 2021/0035013 W,2020-05-29,SYSTEM AND METHOD FOR DISPENSING A FOOD AND BEVERAGE PRODUCT,,PLANT TAP LLC,SAVINO JOSEPH CAMILLO;;FRIEDMAN LENNIE;;TOLWIN SCHLOMO A;;SUH WILLIAM D;;SHEPARD JAMES;;CARLINS ZACHARY;;PANONE AARON;;LEWIS DANIEL T,,https://lens.org/034-675-803-801-100,Patent Application,yes,0,0,5,15,0,B65D75/30;;B65D75/5811;;B65D75/566;;B65D75/5855;;B65D85/72;;A23L2/52;;A23L2/385,B65D75/30;;A23L2/04;;B65D35/44,,0,0,,,,PENDING
761,WO,A1,WO 2003/095123 A1,140-466-849-095-581,2003-11-20,2003,IB 0301815 W,2003-05-09,US 6375702 A,2002-05-10,A TOOL AND PROCESS FOR FORMING A HEM,"A tool and process utilizing the tool for forming a compressed-radius hem on a sheet metal assembly is disclosed. The tool 30, 40, 50, 60, 70, 88, 100 includes a concave portion formed by at least two surfaces 34, 36; 44, 46; 64, 66; 54, 55; 92, 93; 104, 106 that together define a cavity. A flange 26 on the perimeter of an outer panel 18 is initially formed to an approximate perpendicular angle and is then formed to about 45°. In a final forming step, an intermediate portion 74 of the flange 26 is engaged by the cavity and is formed into a compressed-radius hem.",FORD MOTOR CO;;UNOVA IND AUTOMATION SYS INC,WIENS PHIL V;;SAMANT JAIDEEP;;COUGHLIN PATRICK;;FAITEL WILLIAM;;MILLER CRAIG EUGENE;;FRIEDMAN PETER;;XIA ZHIYONG CEDRIC;;SCHRANDT DOUGLAS J,,https://lens.org/140-466-849-095-581,Patent Application,yes,3,0,9,9,0,B21D39/021;;B21D39/021;;Y10T29/53791;;Y10T29/53791,B21D39/02,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 2002, no. 08 5 August 2002 (2002-08-05);;PATENT ABSTRACTS OF JAPAN vol. 1996, no. 03 29 March 1996 (1996-03-29)",PENDING
762,CA,A1,CA 3180358 A1,174-257-115-180-878,2021-12-02,2021,CA 3180358 A,2021-05-28,US 202063032308 P;;US 202063126292 P;;US 202017131632 A;;US 2021/0035013 W,2020-05-29,SYSTEM AND METHOD FOR DISPENSING A FOOD AND BEVERAGE PRODUCT,"An apparatus and system for dispensing a food and beverage product where a flowable product is extracted from a flexible pouch, and where a nozzle region exists through which the flowable product evacuates the flexible pouch. The nozzle region has a lock seal that locks the flowable product within the flexible pouch when a pressure less than a first threshold value is applied to the flexible pouch. There is also a frangible seal located above the nozzle region that is configured to lock the flowable product within the flexible pouch when pressure less than a second threshold value is applied to the flexible pouch and when the first threshold value is larger than the second threshold value.",PLANT TAP LLC,SAVINO JOSEPH CAMILLO;;FRIEDMAN LENNIE;;TOLWIN SCHLOMO A;;SUH WILLIAM D;;SHEPARD JAMES;;CARLINS ZACHARY;;PANONE AARON;;LEWIS DANIEL T,,https://lens.org/174-257-115-180-878,Patent Application,no,0,0,5,15,0,B65D75/30;;B65D75/5811;;B65D75/566;;B65D75/5855;;B65D85/72;;A23L2/52;;A23L2/385,B65D75/30;;A23L2/04;;B65D35/44,,0,0,,,,PENDING
763,GB,B,GB 2403924 B,143-011-100-013-853,2005-09-14,2005,GB 0424428 A,2003-05-09,IB 0301815 W;;US 6375702 A,2002-05-10,A tool and process for forming a hem,,FORD MOTOR CO;;UNOVA IND AUTOMATION SYS INC,WIENS PHIL V;;SAMANT JAIDEEP;;COUGHLIN PATRICK;;FAITEL WILLIAM;;MILLER CRAIG EUGENE;;FRIEDMAN PETER;;XIA ZHIYONG CEDRIC;;SCHRANDT DOUGLAS J,,https://lens.org/143-011-100-013-853,Granted Patent,no,5,0,9,9,0,B21D39/021;;B21D39/021;;Y10T29/53791;;Y10T29/53791,B21D39/02,B3J J1B           J,0,0,,,,EXPIRED
764,AU,A8,AU 2003/224362 A8,195-842-418-477-061,2003-11-11,2003,AU 2003/224362 A,2003-05-09,IB 0301815 W;;US 6375702 A,2002-05-10,A tool and process for forming a hem,,UNOVA IND AUTOMATION SYS INC;;FORD MOTOR CO,COUGHLIN PATRICK;;FAITEL WILLIAM;;MILLER CRAIG EUGENE;;FRIEDMAN PETER;;XIA ZHIYONG CEDRIC;;SCHRANDT DOUGLAS J;;WIENS PHIL V;;SAMANT JAIDEEP,,https://lens.org/195-842-418-477-061,Patent Application,no,0,0,9,9,0,B21D39/021;;B21D39/021;;Y10T29/53791;;Y10T29/53791,B21D39/02,,0,0,,,,DISCONTINUED
765,WO,A1,WO 2021/243299 A1,092-516-095-150-874,2021-12-02,2021,US 2021/0035013 W,2021-05-28,US 202063032308 P;;US 202063126292 P;;US 202017131632 A,2020-05-29,SYSTEM AND METHOD FOR DISPENSING A FOOD AND BEVERAGE PRODUCT,"An apparatus and system for dispensing a food and beverage product where a flowable product is extracted from a flexible pouch, and where a nozzle region exists through which the flowable product evacuates the flexible pouch. The nozzle region has a lock seal that locks the flowable product within the flexible pouch when a pressure less than a first threshold value is applied to the flexible pouch. There is also a frangible seal located above the nozzle region that is configured to lock the flowable product within the flexible pouch when pressure less than a second threshold value is applied to the flexible pouch and when the first threshold value is larger than the second threshold value.",PLANT TAP LLC,SAVINO JOSEPH CAMILLO;;FRIEDMAN LENNIE;;TOLWIN SCHLOMO A;;SUH WILLIAM D;;SHEPARD JAMES;;CARLINS ZACHARY;;PANONE AARON;;LEWIS DANIEL T,,https://lens.org/092-516-095-150-874,Patent Application,yes,4,0,5,15,0,B65D75/30;;B65D75/5811;;B65D75/566;;B65D75/5855;;B65D85/72;;A23L2/52;;A23L2/385,B65D75/30;;A23L2/04;;B65D35/44,,0,0,,,,PENDING
766,US,A1,US 2021/0284417 A1,159-542-913-529-463,2021-09-16,2021,US 202117303471 A,2021-05-28,US 202117303471 A;;US 202017131632 A;;US 201916409759 A;;US 202063032308 P;;US 202063126292 P,2019-05-10,SYSTEM AND METHOD FOR DISPENSING A FOOD AND BEVERAGE PRODUCT,"An apparatus and system for dispensing a food and beverage product where a flowable product is extracted from a flexible pouch, and where a nozzle region exists through which the flowable product evacuates the flexible pouch. The nozzle region has a lock seal that locks the flowable product within the flexible pouch when a pressure less than a first threshold value is applied to the flexible pouch. There is also a frangible seal located above the nozzle region that is configured to lock the flowable product within the flexible pouch when pressure less than a second threshold value is applied to the flexible pouch and when the first threshold value is larger than the second threshold value.",PLANT TAP LLC,SAVINO JOSEPH CAMILLO;;FRIEDMAN LENNIE;;TOLWIN SCHLOMO A;;SUH WILLIAM D;;SHEPARD JAMES;;CARLINS ZACHARY;;PANONE AARON;;LEWIS DANIEL T,PLANT TAP INC (2021-12-09),https://lens.org/159-542-913-529-463,Patent Application,yes,0,0,1,15,0,A23C11/02;;B65D75/5822;;B65D75/5861;;B65D75/008;;B65D75/566;;B65D75/58;;B65D83/0055,B65D75/58;;B65D75/00;;B65D83/00,,0,0,,,,PENDING
767,GB,A,GB 2403924 A,068-913-485-461-773,2005-01-19,2005,GB 0424428 A,2003-05-09,IB 0301815 W;;US 6375702 A,2002-05-10,A tool and process for forming a hem,"A tool and process utilizing the tool for forming a compressed-radius hem on a sheet metal assembly is disclosed. The tool 30, 40, 50, 60, 70, 88, 100 includes a concave portion formed by at least two surfaces 34, 36; 44, 46; 64, 66; 54, 55; 92, 93; 104, 106 that together define a cavity. A flange 26 on the perimeter of an outer panel 18 is initially formed to an approximate perpendicular angle and is then formed to about 45{. In a final forming step, an intermediate portion 74 of the flange 26 is engaged by the cavity and is formed into a compressed-radius hem.",FORD MOTOR CO;;UNOVA IND AUTOMATION SYS INC,WIENS PHIL V;;SAMANT JAIDEEP;;COUGHLIN PATRICK;;FAITEL WILLIAM;;MILLER CRAIG EUGENE;;FRIEDMAN PETER;;XIA ZHIYONG CEDRIC;;SCHRANDT DOUGLAS J,,https://lens.org/068-913-485-461-773,Patent Application,no,5,1,9,9,0,B21D39/021;;B21D39/021;;Y10T29/53791;;Y10T29/53791,B21D39/02,B3J J1B           J,0,0,,,,EXPIRED
768,AU,A1,AU 2003/224362 A1,135-571-045-968-408,2003-11-11,2003,AU 2003/224362 A,2003-05-09,IB 0301815 W;;US 6375702 A,2002-05-10,A TOOL AND PROCESS FOR FORMING A HEM,,FORD MOTOR CO,COUGHLIN PATRICK;;FAITEL WILLIAM;;MILLER CRAIG EUGENE;;FRIEDMAN PETER;;XIA ZHIYONG CEDRIC;;SCHRANDT DOUGLAS J;;WIENS PHIL V;;SAMANT JAIDEEP,,https://lens.org/135-571-045-968-408,Patent Application,no,0,0,9,9,0,B21D39/021;;B21D39/021;;Y10T29/53791;;Y10T29/53791,B21D39/02,,0,0,,,,DISCONTINUED
769,WO,A1,WO 2016/209990 A1,013-606-335-163-011,2016-12-29,2016,US 2016/0038804 W,2016-06-22,US 201514752201 A,2015-06-26,PRESENTING OPPORTUNITIES FOR INSTANT TRANSACTIONS,"In some examples, a customer is identified that is associated with an item that is eligible for instant sell. The item may be eligible for instant sell because the item is popular on an electronic marketplace. A selling opportunity for the customer to sell the item may be presented to the customer. The selling opportunity may include an offer to sell the item via an instant payment transaction when the customer is qualified for the instant payment transaction. The instant payment transaction may enable the customer to receive instant credit for accepting the terms of the offer. A selection indicating acceptance of the offer by the customer may be received and, in response, a notification may be provided to the customer.",AMAZON TECH INC,PANAGUITON DAMIAN JEFFERY ROSS;;BODAPTI SANDEEP;;FRIEDMAN CHERYL STAAB;;LEVINE JASON WILLIAM;;CHAKRAVORTY MAMIDI SREE KALYAN;;MOTTET NICOLAS JEAN;;SINGH VIKRAM,,https://lens.org/013-606-335-163-011,Patent Application,yes,1,0,2,2,0,G06Q30/06;;G06Q30/0253;;G06Q30/0633;;G06Q30/06;;G06Q20/10;;G06Q30/0253;;G06Q30/0633,G06Q30/06,,4,0,,,"WIKIPEDIA: ""Mobile Web"", INTERNET ARTICLE, 27 March 2015 (2015-03-27), XP055292399, Retrieved from the Internet <URL:https://en.wikipedia.org/w/index.php?title=Mobile_Web&oldid=653815098> [retrieved on 20160801];;ANDREW S. TANENBAUM ET AL: ""Distributed Systems: Principles and Paradigms (2nd Edition)"", 12 October 2006, PRENTICE HALL, ISBN: 978-0-13-239227-3, pages: ToC,Ch01 - Ch03,Ch10,Ch12, XP055272991;;PHILLIP J. WINDLEY: ""The Live Web: Building Event-Based Connections in the Cloud"", 21 December 2011, COURSE TECHNOLOGY PTR, ISBN: 978-1-133-68668-2, pages: ToC,Ch01 - Ch02,Ch10, XP055258627;;RICHARD FERRARO ET AL: ""Location-Aware Applications"", 28 July 2011, MANNING PUBLICATIONS, ISBN: 978-1-935182-33-7, pages: 0 - 298, XP055223427",PENDING
770,US,B1,US 6971197 B1,193-231-036-921-723,2005-12-06,2005,US 66991300 A,2000-09-25,US 66991300 A;;US 18299998 A,1998-10-30,Display board system,"A mounting structure including at least one display board including a first mounting interface and a second mounting interface, a first pivotal interface including a first projection forming a retaining slot adapted to engage the first mounting interface of the display board wherein the first projection is a hook and the second pivotal interface adapted to engage the second mounting interface of the display board so that the display board is adapted to be removably pivotally coupled to the mounting structure at both the first pivotal interface and the second pivotal interface.",STEELCASE DEV CORP,SEIBER CHARLES ANTHONY;;ARKO ROBERT PETER;;DERUNTZ OTTO DANIEL;;STEWART WILLIAM CHARLES;;TAKAYAMA STEVEN RYUTARO;;FRIEDMAN FRANK;;CHAN-LIZARDO KRISTINE RENE,STEELCASE DEVELOPMENT CORPORATION (2001-04-17);;STEELCASE INC (2007-10-17),https://lens.org/193-231-036-921-723,Granted Patent,yes,107,8,1,7,0,G09F7/18;;G09F7/18;;G09F15/00;;G09F15/00;;G09F15/0068;;G09F15/0068;;H05K5/0204;;H05K5/0204,G06F15/00;;G09F7/18;;G09F15/00;;H05K5/02,40/606.01;;40/530;;40/606.15,30,0,,,"US 5,252,368, 10/1993, Blake (withdrawn);;Promotional Materials for ""A World of Possibilities Introducing Contrada(TM), The Next Generatation in Office Furniture"", By Trendway Corporation of Holland, Michigan, bearing a designation ""(C)1998"".;;Promotional Materials for ""Village Wall"" by Tellus Furniture a Paoli Company of Orleans, Indiana, bearing a designation ""(C)1998 Tellus Furniture"", 8 color sheets.;;Yate, JoAnne, ""Graphic ROI Reporting,"" Knowledge Management at 106, Oct. 1998.;;Brochure for ""TooGo New Workplace Solutions"", by Egan Visual, bearing a designation ""(C)Copyright Egan Visual 1999"", 16 color sheets.;;Details-Mar. 2001, 5 pages.;;Brochure by UNIFOR titled ""Pannelli PL"" (undated) (37 sheets).;;Brochure by UNIFOR titled ""Progetto 25.90"" (undated) (19 sheets).;;Promotional material (chart) by Dowing Displays of Milford, Ohio, showing display models (no date), color.;;Promotional material for ""The Office Of The Future"", by Tarrant Interiors-of Fort Worth, Texas, (no date), 4 sheets.;;Innamorati, Francesco, ""The Telematic Tree"", Habitat Ufficio, bearing a designation 1991.;;Advertisement for ""Ameriwood Oak Armoire"", by Office Max, bearing a designation ""Nov. 11, 1995"", 1 sheet.;;Gertsakis, John, ""Durable Yet Future Proof"", bearing a designation ""(C)1996, National Key Centre for Design at RMIT"", 4 sheets, printed from Internet site: www.cfd.rmit.edu.au/outcomes/erdnews/ERD6/HOTdesk.html on Oct. 27, 1998.;;Peter Piper Products Inc. sales materials, Undated.;;Steelcase Inc. sales materials, Undated.;;Sunrise Business Products sales materials, Undated.;;K.O.H. sales materials, Undated.;;Best-Rite Manufacturing sales materials, Undated.;;Peter Piper Products Inc. sales materials, Undated.;;K.O.H. sales materials, Undated.;;Quartet(TM) sales materials, shown in Corporate Express office supplies catalogue, bearing a designation ""Printed in the U.S.A. (R) 1997"".;;Quartet(TM) sales materials, shown in Redwood office supplies catalogue, Undated.;;Bretford(TM) sales materials, Undated.;;Egan sales materials, bearing a desgnation ""Printed in Canada (R) Copyright Egan Visual 1994"".;;Egan sales materials, Undated.;;3M sales materials, Undated.;;Teknion sales materials, Undated.;;Stanrite sales materials, Undated.;;Quartet (TM) sales materials, in BT Office Products International catalogue, Undated.;;Wilkahn sales materials, Undated.",EXPIRED
771,CO,A1,CO 4940402 A1,060-391-990-186-729,2000-07-24,2000,CO 98037140 A,1998-07-01,US 5149897 P;;US 5141497 P;;US 5140297 P;;US 5142097 P,1997-07-01,SALES DE SERTRALINA Y FORMAS DE DOSIFICACION DE LIBERACION SOSTENIDA DE SERTRALINA,"Formas de dosificación de liberación sostenida de sertralinaque liberan sertralina a una velocidad entre 1 mgA/h y 40 mgA/h. Las formas de dosificación pueden presentar un período de retraso inicial durante el cual, la sertralina se libera a una velocidad menor que 1 mgA/h. La presente invención se refiere además a una sal de acetato, a una sal de L-lactato y una sal de L-aspartato de sertralina, a las composiciones farmacéuticas de las mismas y a los procedimientos de uso de la sal para el tratamiento de varios trastornos y afecciones. La presente invención también se refiere a los procedimientos para la preparación del acetato de sertralina, del L-lactato de sertralina y del L-aspartato de sertralina.",PFIZER,AMENDE MARY TANYA;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;DWAYNE THOMAS FRIESEN;;BLAIR WEST JAMES,,https://lens.org/060-391-990-186-729,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,PENDING
772,EP,A1,EP 3814373 A1,145-893-040-659-512,2021-05-05,2021,EP 19744936 A,2019-06-27,US 201862691428 P;;US 201962811710 P;;US 2019/0039557 W,2018-06-28,METHODS OF PRODUCING ANTI-C5 ANTIBODIES,,ALEXION PHARMA INC,MALANSON HUNTER F;;ZINGARO KYLE A;;GIRI ANJIL;;WEAVER JUSTIN;;FRIEDMAN ABRAHAM;;HUNTER JEFFREY WILLIAM;;SIVANANDAM SARANYA;;ZUGATES JEFFREY;;GODAWAT RAHUL,,https://lens.org/145-893-040-659-512,Patent Application,yes,0,0,4,4,0,B01D15/362;;B01D15/362;;B01D15/363;;B01D15/363;;B01D15/3809;;B01D15/3809;;C07K16/065;;C07K16/18;;C07K16/065;;C07K16/18;;C07K2317/565;;C07K2317/92;;C07K2317/94,C07K16/06;;B01D15/08;;B01D15/36;;B01D15/38;;C07K16/18,,1,0,,,See references of WO 2020006266A1,PENDING
773,KR,A,KR 20010014043 A,157-116-720-450-113,2001-02-26,2001,KR 19997012073 A,1998-06-15,IB 9800934 W;;US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE,"Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr. The present invention is further directed to an acetate salt, an L-lactate salt and an L-aspartate salt of sertraline, pharmaceutical compositions thereof and methods of using that salt for treating various conditions and disorders. The present invention is also directed to processes for preparing sertraline acetate, sertraline L- lactate and sertraline L-aspartate.",PFIZER,AMENDE MARY TANYA;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/157-116-720-450-113,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
774,US,A1,US 2016/0379248 A1,080-399-071-668-278,2016-12-29,2016,US 201514752201 A,2015-06-26,US 201514752201 A,2015-06-26,PRESENTING OPPORTUNITIES FOR INSTANT TRANSACTIONS,"In some examples, a customer is identified that is associated with an item that is eligible for instant sell. The item may be eligible for instant sell because the item is popular on an electronic marketplace. A selling opportunity for the customer to sell the item may be presented to the customer. The selling opportunity may include an offer to sell the item via an instant payment transaction when the customer is qualified for the instant payment transaction. The instant payment transaction may enable the customer to receive instant credit for accepting the terms of the offer. A selection indicating acceptance of the offer by the customer may be received and, in response, a notification may be provided to the customer.",AMAZON TECH INC,PANAGUITON DAMIAN JEFFREY ROSS;;BODAPTI SANDEEP;;FRIEDMAN CHERYL STAAB;;LEVINE JASON WILLIAM;;CHAKRAVORTY MAMIDI SREE KALYAN;;MOTTET NICOLAS JEAN;;SINGH VIKRAM,AMAZON TECHNOLOGIES INC (2015-07-09),https://lens.org/080-399-071-668-278,Patent Application,yes,0,7,2,2,0,G06Q30/0253;;G06Q30/0253;;G06Q20/10;;G06Q30/06;;G06Q30/06;;G06Q30/0633;;G06Q30/0633,G06Q30/02;;G06Q20/10;;G06Q30/06,,0,0,,,,DISCONTINUED
775,US,A1,US 2021/0122806 A1,189-850-181-815-757,2021-04-29,2021,US 201917254508 A,2019-06-27,US 201917254508 A;;US 201962811710 P;;US 201862691428 P;;US 2019/0039557 W,2018-06-28,METHODS OF PRODUCING ANTI-C5 ANTIBODIES,"The present application relates to a method of producing an anti-C5 antibody (ravulizumab). wherein the method comprises: —culturing mammalian cells comprising a nucleic acid encoding the anti-C5 antibody in a cell culture production medium—Performing two or more steps selected from the group consisting of: a recovery step; purification by Protein A affinity chromatography, a low pH viral inactivation step; Purification by cation exchange chromatography; Purification by anion exchange chromatography; a virus reduction filtration step; and a concentration and diafiltration step",ALEXION PHARMA INC,MALANSON HUNTER F;;ZINGARO KYLE A;;GIRI ANJIL;;WEAVER JUSTIN;;FRIEDMAN ABRAHAM;;HUNTER JEFFREY WILLIAM;;SIVANANDAM SARANYA;;ZUGATES JEFFREY;;GODAWAT RAHUL,ALEXION PHARMACEUTICALS INC (2019-07-24),https://lens.org/189-850-181-815-757,Patent Application,yes,0,1,4,4,50,B01D15/362;;B01D15/362;;B01D15/363;;B01D15/363;;B01D15/3809;;B01D15/3809;;C07K16/065;;C07K16/18;;C07K16/065;;C07K16/18;;C07K2317/565;;C07K2317/92;;C07K2317/94,C07K16/06;;B01D15/36;;B01D15/38;;C07K16/18,,0,0,,,,PENDING
776,US,B1,US 6272779 B1,008-685-004-432-261,2001-08-14,2001,US 18299998 A,1998-10-30,US 18299998 A,1998-10-30,Display board system,A mounting structure for at least one display board is disclosed. The Display board includes a first mounting interface and a second mounting interface. The mounting structure includes a first pivotal interface including a barb adapted to engage the first mounting interface of the display board. The mounting structure also includes a second pivotal interface including a protruding member adapted to engage the second mounting interface of the display board. The display board may be removably pivotally mounted within the mounting structure at the first pivotal interface and the second pivotal interface. A mounting structure for display of at least one display board is also disclosed. The mounting structure includes a frame. The mounting structure also includes a platform for the display board coupled to the frame. The mounting structure also includes a compliant retaining system for the display board coupled to the frame. The display board can be placed on the platform and pressed into secure engagement with the compliant retaining system. A mounting structure associated with an existing structure and for use with at least one display board is also disclosed. The mounting structure includes an articulating frame pivotally coupled to the existing structure for movement between a fully deployed position and a fully stowed position. The mounting structure also includes at least one display rack coupled to the articulating frame and providing a first and second interface for pivotal coupling of a plurality of display boards.,STEELCASE DEV INC,SEIBER CHARLES ANTHONY;;ARKO ROBERT PETER;;DERUNTZ OTTO DANIEL;;STEWART WILLIAM CHARLES;;TAKAYAMA STEVEN RYUTARO;;FRIEDMAN FRANK;;CHAN-LIZARDO KRISTINE RENE,STEELCASE DEVELOPMENT CORPORATION (2001-04-17);;STEELCASE DEVELOPMENT INC. A CORP. OF MICHIGAN (1999-07-01);;STEELCASE INC (2007-10-17),https://lens.org/008-685-004-432-261,Granted Patent,yes,101,46,3,7,0,G09F7/18;;G09F15/00;;G09F15/0012;;G09F15/0056;;G09F15/0062;;G09F15/0087;;G09F7/18;;G09F15/00;;G09F15/0087;;G09F15/0012;;G09F15/0062;;G09F15/0056,G09F7/18;;G09F15/00,40/606;;40/617;;248/453,7,0,,,"Brochure by UNIFOR titled ""Pannelli PL"" (undated) (37 sheets).;;Brochure by UNIFOR titled ""Progetto 25.90"" (undated) (19 sheets).;;Promotional material (chart) by Dowing Displays of Milford, Ohio, showing display models (no date), color. (undated).;;Promotional material for ""The Office of the Future"", by Tarrant Interiors-of Fort Worth, Texas, (no date), 4 sheets. (undated).;;Innamorati, Francesco, ""The Telematic Tree"", Habitat Ufficio, bearing a designation 1991.;;Advertisement for ""Ameriwood Oak Armoire"", by Office Max, bearing a designation ""Nov. 11, 1995"", 1 sheet.;;Gertsakis, John, ""Durable Yet Future Proof"", bearing a designation ""(C)1996, National Key Centre for Design at RMIT"", 3 sheets, printed from Internet site: www.cfd.rmit.edu.au/outcomes/erdnews/ERD6/HOTdesk.html on Oct. 27, 1998.",EXPIRED
777,EA,B1,EA 002482 B1,129-734-659-135-167,2002-06-27,2002,EA 199900964 A,1998-06-15,IB 9800934 W;;US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE,"1. A sustained-release dosage form suitable for oral administration to a mammal, comprising sertraline, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier which dosage form releases sertraline into a use environment at a rate not exceeding 0.8 mgA/hr/kg, provided said dosage form (1) releases not more than 70% of the sertraline contained therein within the first hour following entry into said use environment and (2) releases sertraline at a rate of at least 0.02 mgA/hr/kg. 2. A dosage form as defined in claim 1, wherein said sertraline is present as sertraline free base, sertraline hydrochloride, sertraline aspartate, sertraline acetate or sertraline lactate. 3. A dosage form as defined in claim 1, wherein said mammal is a human. 4. A dosage form as defined in claim 1, in the form of a matrix tablet which remains substantially intact during the period of sustained release. 5. A dosage form as defined in claim 1, in the form of a disintegrating matrix tablet. 6. A dosage form as defined in claim 1, in the form of a matrix tablet partially coated with a polymer which impedes the release of sertraline. 7. A dosage form as defined in claim 1, in the form of an osmotic tablet. 8. A dosage form as defined in claim 1, in the form of a membranecoated hydrogel tablet. 9. A dosage form as defined in claim 1, which is multiparticulate. 10. A dosage form as defined in claim 1, in the form of a membranecoated diffusion-based, capsule, tablet or multiparticulate. 11. A sustained-release dosage form suitable for administration to a mammal, comprising sertraline, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, which dosage form releases sertraline into a use environment at a rate not exceeding 40 mgA/hr, provided said dosage form (1) releases not more than 70% of the sertraline contained therein within the first hour following entry into said use environment and (2) releases sertraline at a rate of at least 1 mgA/hr. 12. A dosage form as defined in claim 11 wherein said sertraline is present as sertraline free base, sertraline hydrochloride, sertraline aspartate, sertraline acetate or sertraline lactate. 13. A dosage form as defined in claim 11, wherein said mammal is a human. 14. A dosage form as defined in claim 11, in the form of a matrix tablet which remains substantially intact during the period of sustained release. 15. A dosage form as defined in claim 11, in the form of a disintegrating matrix tablet. 16. A dosage form as defined in claim 11, in the form of a matrix tablet partially coated with a polymer which impedes the release of sertraline. 17. A dosage form as defined in claim 11, in the form of an osmotic tablet. 18. A dosage form as defined in claim 11, in the form of a membranecoated hydrogel tablet. 19. A dosage form as defined in claim It, which is multiparticulate. 20. A dosage form as defined in claim 11, in the form of a membranecoated fiffusion-based tablet or multiparticulate. 21. A sustained release dosage form suitable for oral administration to a mammal, comprising sertraline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, which dosage form releases sertraline at a rate less than 40 mgA/hr in vitro when dissolution tested in a USP-2 apparatus containing 900 ml of acetate buffer, pH 4.0, which is 0.075 M in NaCI, as follows: (1) if said dosage form is a sustained release tablet or a nontisintegrating sustained release capsule, said USP-2 apparatus is equipped with a paddle stirring at 50 rpm; (2) if said dosage form is a multiparticulate, said USP-2 apparatus is equipped with a paddle stirring at 100 rpm; provided said dosage form (a) releases not more than 70% of the sertraline contained therein within the first hour following initiation of testing and (b) releases sertraline at a rate of at least 1 mgA/hr. 22. A dosage form as defined in claim 21, wherein said sertraline is present as sertraline free base, sertraline hydrochloride, sertraline aspartate, sertraline acetate or sertraline lactate. 23. A dosage form as defined in claim 21, wherein said mammal is a human. 24. A dosage form as defined in claim 21, in the form of a matrix tablet which remains substantially intact during the period of sustained release. 25. A dosage form as defined in claim 21, in the form of a disintegrating matrix tablet. 26. A dosage form as defined in claim 21, in the form of a matrix tablet partially coated with a polymer which impedes the release of sertraline. 27. A dosage form as defined in claim 21, in the form of an osmotic tablet. 28. A dosage form as defined in claim 21, in the form of a membranecoated hydrogel tablet. 29. A dosage form as defined in claim 21, which is multiparticulate. 30. A dosage form as defined in claim 21, in the form of a membranecoated diffusion-based tablet or multiparticulate. 31. A temporally delayed plus sustained release dosage form suitable for oral administration to a mammal, comprising sertraline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, which dosage form, following ingestion by said mammal, releases sertraline into said mammal's Gl tract at a rate less than 1 mgA/hr for an initial delay period of up to 3 hours, and which thereafter releases sertraline at a rate of from 1 mgA/hr to 40 mgA/hr, provided said dosage form releases not more than 70 % of the sertraline contained therein within the first hour after said delay period. 32. A dosage form as defined in claim 31, wherein said delay period is up to two hours. 33. A dosage form as defined in claim 31, wherein the rate of release following said delay period is from 1 mgA/hr to 30 mgA/hr. 34. A dosage form as defined in claim 31, wherein said sertraline is present as sertraline free base, sertraline hydrochloride, sertraline aspartate, sertraline acetate or sertraline lactate. 35. A dosage form as defined in claim 31, wherein said mammal is a human. 36. A temporally delayed plus sustained release dosage form suitable for administration to a mammal, said dosage form having an initial temporal delay period of up to 3 hours, comprising sertraline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, which dosage form, when dissolution tested in vitro in a USP-2 apparatus containing 900 ml of acetate buffer, pH 4.0, which is 0.075 M in NaCI, releases sertraline at a rate less than 1 mgA/hr for a period corresponding to said delay period and, thereafter, releases sertraline at a rate of from 1 mgA/hr to 40 mgA/hr, provided the dosage form releases not more than 70 % of the remaining sertraline contained therein within the first hour following said delay. 37. A dosage form as defined in claim 36, wherein said delay period is up to two hours. 38. A dosage form as defined in claim 36, wherein the rate of release following said delay period is from 1 mgA/hr to 30 mgA/hr. 39. A dosage form as defined in claim 36, wherein said sertraline is present as sertraline free base, sertraline hydrochloride, sertraline aspartate, sertraline acetate or sertraline lactate. 40. A dosage form as defined in claim 36, wherein said mammal is a human. 41. A dosage form as defined in claim 36, in the form of a tablet. 42. A dosage form as defined in claim 36, which is multiparticulate. 43. A spatially delayed plus sustained release dosage form suitable for oral administration to a mammal, comprising sertraline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, which dosage form, following ingestion by said mammal, releases sertraline into said mammal's stomach at a rate less than 1 mgAlhr, and which, after having passed into said mammal's small intestine, effects sustained release at a rate of from 1 mgA/hr to 40 mgA/hr, provided said dosage form releases not more than 70 % of the sertraline contained therein within the first hour after passing into said mammal's small intestine. 44. A dosage form as defined in claim 43, wherein the onset of sustained release is pH-triggered. 45. A dosage form as defined in claim 44, comprising a sustained release dosage form coated with a polymer that prevents release of sertraline at the pH of the stomach, but which is permeable to sertraline at the pH of the small intestine. 46. A dosage form as defined in claim 44, wherein said sustained release dosage form is multiparticulate. 47. A dosage form as defined in claim 44 wherein said sustained release dosage form is a tablet. 48. A dosage form as defined in claim 43, which is enzyme-triggered. 49. A dosage form as defined in claim 48, comprising a sustained release dosage form coated with a membrane having a hydrophobic liquid entrained within the pores thereof, said hydrophobic liquid being substantially impermeable to water and sertraline, but capable of changing, through enzymatic degradation, so that said membrane becomes substantially permeable to water and sertraline when said dosage form moves into the environment of the small intestinal lumen. 50. A dosage form as defined in claim 48, wherein said sustained release dosage form is multiparticulate. 51. A dosage form as defined in claim 48, wherein said sustained release dosage form is a matrix. 52. A dosage form as defined in claim 43, wherein said sertraline is present as sertraline free base, sertraline hydrochloride, sertraline aspartate, sertraline acetate or sertraline lactate. 53. A dosage form as defined in claim 43, wherein said mammal is a human. 54. A sustained release pH-triggered dosage form suitable for oral administration to a mammal, said dosage form having an initial delay period prior to the onset of sustained release, comprising sertraline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, which dosage form, when tested in vitro in a USP-2 apparatus, releases sertraline into 0.1 N HCI at a rate less than 1 mgA/hr for 1 hou",PFIZER,AMENDE MARY TANYA;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/129-734-659-135-167,Granted Patent,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
778,ID,A,ID 23503 A,177-414-369-634-521,2000-04-27,2000,ID 991704 A,1998-06-15,US 5140297 P;;US 5142097 P;;US 5141497 P;;US 5149897 P,1997-07-01,GARAM-GARAM SERTRALINA DAN BENTUK-BENTUK SEDIAAN LEPAS-LAMBAT DARI SERTRALINA,,PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/177-414-369-634-521,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,PENDING
779,PL,A1,PL 337806 A1,094-171-473-921-94X,2000-09-11,2000,PL 33780698 A,1998-06-15,IB 9800934 W;;US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,SERTRALIN SALTS AND SERTALIN DOSAGE FORMS OF PROLONGED RELEASE,,PFIZER,AM ENDE MARY TANYA;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/094-171-473-921-94X,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/00;;A61K9/22;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,PENDING
780,AU,B2,AU 761618 B2,109-180-334-403-808,2003-06-05,2003,AU 2001/095218 A,2001-11-30,AU 2001/095218 A;;AU 1998/075449 A,1998-06-15,Sertraline salts and sustained-release dosage forms of sertraline,,PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/109-180-334-403-808,Granted Patent,no,1,0,2,2,0,,A61K31/135,,0,0,,,,EXPIRED
781,TN,A1,TN SN98125 A1,159-419-652-813-648,2005-03-15,2005,TN SN98125 A,1998-06-30,US 5140297 P;;US 5141497 P;;US 5142097 P;;US 5149897 P,1997-07-01,"SELS DE SERTRALINE, ET FORMES POSOLOGIQUES DE SERTRALINE A LIBERATION PROLONGEE, ET PROCEDES POUR LEUR PREPARATION","L’INVENTION CONCERNE DES FORMES POSOLOGIQUES DE SERTRALINE A LIBERATION PROLONGEES, POUVANT PRESENTER UNE PERIODE DE RETARD INITIALE. ELLE CONCERNE EN OUTRE UNE ACETATE DE SERTRALINE, UN L – LACTATE DE SERTRALINE ET UN L – ASPARTATE DE SERTRALINE, DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET DES PROCEDES POUR LEUR PREPARATION. APPLICATION : UTILISATION POUR LE TRAITEMENT DE DIVERSES MALADIES ET AFFECTIONS.",PFIZER,MARY TANYA AM ENDE;;WILLIAM JOHN CURATOLO;;HYLAR LEWIS FRIEDMAN;;RAVI MYSORE SHANKER;;SCOTT MAX HERBIG;;DWAYNE THOMAS FRIESEN;;JAMES BLAIR WEST,,https://lens.org/159-419-652-813-648,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,PENDING
782,AU,B2,AU 739261 B2,062-465-009-013-457,2001-10-11,2001,AU 1998/075449 A,1998-06-15,IB 9800934 W;;US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,Sertraline salts and sustained-release dosage forms of sertraline,,PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/062-465-009-013-457,Granted Patent,no,3,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
783,AU,A,AU 2001/095218 A,072-383-698-554-569,2002-01-24,2002,AU 2001/095218 A,2001-11-30,AU 2001/095218 A;;AU 1998/075449 A,1998-06-15,Sertraline salts and sustained-release dosage forms of sertraline,,PFIZER,ENDE MARY TANYA ARM;;WEST JAMES BLAIR;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;SHANKER RAVI MYSORE;;FRIEDMAN HYLAR LEWIS;;CURATOLO WILLIAM JOHN,,https://lens.org/072-383-698-554-569,Patent Application,no,0,0,2,2,0,,A61K31/135,,0,0,,,,EXPIRED
784,CZ,A3,CZ 9904640 A3,107-006-970-677-571,2000-10-11,2000,CZ 464099 A,1998-06-15,CZ 464099 A,1998-06-15,Sertraline salts and setraline dosage forms with permanent setraline release,,PFIZER,AM ENDE MARY TANYA;;CURATALO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/107-006-970-677-571,Patent Application,no,0,0,1,1,0,,A61K31/136;;A61P3/04;;A61P15/00;;A61P25/00;;A61P25/30,,0,0,,,,PENDING
785,CA,C,CA 2290966 C,197-709-754-079-409,2005-12-20,2005,CA 2290966 A,1998-06-15,IB 9800934 W;;US 5149897 P;;US 5141497 P;;US 5140297 P;;US 5142097 P,1997-07-01,SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE,"Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr. The present invention is further directed to an acetate salt, an L-lactate salt and an L-aspartate salt of sertraline, pharmaceutical compositions thereof and methods of using that salt for treating various conditions and disorders. The present invention is also directed to processes for preparing sertraline acetate, sertraline L-lactate and sertraline L-aspartate.",PFIZER LTD,HERBIG SCOTT MAX;;WEST JAMES BLAIR;;FRIESEN DWAYNE THOMAS;;AM ENDE MARY TANYA;;SHANKER RAVI MYSORE;;FRIEDMAN HYLAR LEWIS;;CURATOLO WILLIAM JOHN,,https://lens.org/197-709-754-079-409,Granted Patent,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
786,UY,A1,UY 27128 A1,026-630-709-060-749,2002-03-22,2002,UY 27128 A,2002-01-21,UY 27128 A,2002-01-21,"L-ASPARTATO DE SERTRALINA, ALGUNAS OTRAS SALES DERIVADAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y PROCEDIMIENTOS DE PREPARACIÓN","Refiere L-aspartato de sertralina, composiciones que lo contienen y procedimientos para su preparación.",PFIZER,SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIEDMAN HYLAR LEWIS;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR;;ENDE MARY TANYA AM,,https://lens.org/026-630-709-060-749,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
787,AP,A0,AP 2002002662 A0,084-364-358-453-27X,2002-12-31,2002,AP 2002002662 A,1998-06-25,US 5149897 P,1997-07-01,SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE,"The invention provides a sustained-release dosage form suitable for administration to a mammal comprising as active ingredient sertraline of Formula I. In a pharmaceutically acceptable form, at an effective rate of between 1mgA/hr and 40mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1mgA/hr. The present invention is further directed to an acetate salt, an L-lactate salt and an L-aspartate salt of sertraline, pharmaceutical compositions thereof and methods of using that salt for treating various conditions and disorders. The present invention is also directed to processed for preparing sertraline acetate, sertraline L-lactate and sertraline L-aspartate.",PFIZER,VAN ENDE MARY TAMYS;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR L;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/084-364-358-453-27X,Patent Application,no,0,0,5,54,0,,A61K/;;C07D/,,0,0,,,,PENDING
788,US,A1,US 2023/0203202 A1,092-369-397-991-145,2023-06-29,2023,US 202218062453 A,2022-12-06,US 202218062453 A;;US 202263375826 P;;US 202163287524 P,2021-12-08,"PROTEINS BINDING NKG2D, CD16 AND 5T4","Multispecific binding proteins that bind NKG2D receptor, CD16, and 5T4 are described, as well as pharmaceutical compositions, formulations, and therapeutic methods of the multispecific binding proteins useful for the treatment of cancer.",DRAGONFLY THERAPEUTICS INC,BIGELOW MITCHELL;;DEROSE MARK;;DU JINYAN;;FRIEDMAN ROBIN;;HEIN PYAE P;;HICKS STUART WILLIAM;;JUO ZONG SEAN;;LI XINBI;;MORGAN CHRISTOPHER RYAN,,https://lens.org/092-369-397-991-145,Patent Application,yes,0,0,3,3,0,C07K16/2851;;C07K16/30;;C07K2317/31;;C07K2317/92;;C07K2317/73;;C07K2317/94;;C07K2317/71;;C07K2317/64;;A61K39/39591;;A61P35/04;;C07K16/468;;C07K2317/31;;C07K2317/53;;C07K2317/55;;C07K2317/565;;C07K2317/622,C07K16/46;;A61P35/04,,0,0,,,,PENDING
789,TW,A,TW 202340247 A,156-056-871-252-466,2023-10-16,2023,TW 111147115 A,2022-12-08,US 202163287524 P;;US 202263375826 P,2021-12-08,"Proteins binding NKG2D, CD16 and 5T4","Multispecific binding proteins that bind NKG2D receptor, CD16, and 5T4 are described, as well as pharmaceutical compositions, formulations, and therapeutic methods of the multispecific binding proteins useful for the treatment of cancer.",DRAGONFLY THERAPEUTICS INC,BIGELOW MITCHELL;;DEROSE MARK;;DU JINYAN;;FRIEDMAN ROBIN;;HEIN PYAE P;;HICKS STUART WILLIAM;;JUO ZONG SEAN;;LI XINBI;;MORGAN CHRISTOPHER RYAN,,https://lens.org/156-056-871-252-466,Patent of Addition,no,0,0,3,3,0,C07K16/2851;;C07K16/30;;C07K2317/31;;C07K2317/92;;C07K2317/73;;C07K2317/94;;C07K2317/71;;C07K2317/64;;A61K39/39591;;A61P35/04;;C07K16/468;;C07K2317/31;;C07K2317/53;;C07K2317/55;;C07K2317/565;;C07K2317/622,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/46;;C07K19/00,,0,0,,,,PENDING
790,EP,A2,EP 1736150 A2,157-937-682-771-052,2006-12-27,2006,EP 06008738 A,1998-06-15,EP 98923020 A;;US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,Sertraline salts and sustained-release dosage forms of sertraline,"Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr. The present invention is further directed to an acetate salt, an L-lactate salt and an L-aspartate salt of sertraline, pharmaceutical compositions thereof and methods of using that salt for treating various conditions and disorders. The present invention is also directed to processes for preparing sretraline acetate, sertraline L-lactate and sertraline L-aspartate.",PFIZER,AM ENDE MARY TANYA;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/157-937-682-771-052,Patent Application,yes,0,0,1,54,0,A61K9/2054;;A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P3/04;;A61P25/24,A61K9/22;;A61K31/135;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61P3/04;;A61P25/24,,0,0,,,,DISCONTINUED
791,ZA,B,ZA 985707 B,030-381-062-903-150,2000-01-10,2000,ZA 985707 A,1998-06-30,US 5149897 P,1997-07-01,Sertraline salts and sustained-release dosage forms of sertraline.,,PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/030-381-062-903-150,Granted Patent,no,0,0,5,54,0,,A61K/;;C07D/,,0,0,,,,EXPIRED
792,AU,A,AU 1998/075449 A,139-103-478-752-58X,1999-01-25,1999,AU 1998/075449 A,1998-06-15,IB 9800934 W;;US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,Sertraline salts and sustained-release dosage forms of sertraline,,PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/139-103-478-752-58X,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
793,US,B1,US 6517866 B1,158-183-897-405-605,2003-02-11,2003,US 38089799 A,1999-09-07,US 38089799 A;;IB 9800934 W;;US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,Sertraline salts and sustained-release dosage forms of sertraline,"
    Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr. 
",PFIZER,AM ENDE MARY TANYA;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;SHANKAR RAVI MYSORE;;WEST JAMES BLAIR,,https://lens.org/158-183-897-405-605,Granted Patent,yes,49,62,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,424/457;;424/458;;424/468;;424/469;;424/473;;424/474;;424/484;;424/490;;424/463,5,0,,,"Remington's Pharmaceutical Sciences, 16th, Mack Publishers, Pennyslvania, 1980, pps. 1585-1594.;;The Merck Index, 12th Merck & Co., NJ, 1996, pp. 1455.;;Drug Facts and Comparison, 1997, pp. 1564 and 1574.;;Merck Index 12th Merck & Co. NJ 1996, p. 1455.;;Rem. Pharm. Sciences, 16th Mack Publisher, Pennsylvania, 1980, pp. 1576, 1585.",EXPIRED
794,CA,A1,CA 2290966 A1,034-871-766-163-709,1999-01-14,1999,CA 2290966 A,1998-06-15,IB 9800934 W;;US 5149897 P;;US 5141497 P;;US 5140297 P;;US 5142097 P,1997-07-01,SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE,"Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr. The present invention is further directed to an acetate salt, an L-lactate salt and an L-aspartate salt of sertraline, pharmaceutical compositions thereof and methods of using that salt for treating various conditions and disorders. The present invention is also directed to processes for preparing sertraline acetate, sertraline L-lactate and sertraline L-aspartate.",PFIZER,FRIEDMAN HYLAR LEWIS;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR;;SHANKER RAVI MYSORE;;AM ENDE MARY TANYA;;CURATOLO WILLIAM JOHN,,https://lens.org/034-871-766-163-709,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
795,HR,B1,HR P980379 B1,163-731-606-633-591,2003-04-30,2003,HR P980379 A,1998-07-01,US 5140297 P;;US 5141497 P;;US 5142097 P;;US 5149897 P,1997-07-01,SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE,,PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/163-731-606-633-591,Granted Patent,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
796,AP,A,AP 1526 A,039-546-229-333-728,2006-01-03,2006,AP 9801281 A,1998-06-25,US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,Sertraline salts and sustained-release dosage forms of sertraline.,"The invention provides a sustained-release dosage form suitable for administration to a mammal comprising as active ingredient sertraline of Formula I. In a pharmaceutically acceptable form, at an effective rate of between 1mgA/hr and 40mgA/hr. The dosage forms may exhibit an initial delay period during which setraline is released at a rate less than 1mgA/hr. The present invention is further directed to an acetate salt, an L-lactate salt and an L-aspartate salt of sertraline, pharmaceutical compositions thereof and methods of using that salt for treating various conditions and disorders. The present invention is also directed to processed for preparing sertraline acetate, sertraline L-lactate and sertraline L-aspartate.",PFIZER,ENDE MARY TANYS AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR L;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/039-546-229-333-728,Granted Patent,no,2,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K31/00;;A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
797,UY,A1,UY 27129 A1,196-188-286-583-85X,2002-03-22,2002,UY 27129 A,2002-01-21,UY 27129 A,2002-01-21,"L-LACTATO DE SERTRALINA, ALGUNAS OTRAS SALES DERIVADAS COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y PROCEDIMIENTOS DE PREPARACIÓN","Se refiere a L-lactato de sertralina, composiciones que lo contienen y procedimientos para su preparación.",PFIZER,ENDE MARY TANYA AM;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIEDMAN HYLAR LEWIS;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/196-188-286-583-85X,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
798,MY,A,MY 129175 A,074-327-418-691-080,2007-03-30,2007,MY PI9802948 A,1998-06-29,US 5149897 P;;US 5141497 P;;US 5140297 P;;US 5142097 P,1997-07-01,SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE,"SUSTAINED RELEASE DOSAGE FORMS OF SERTRALINE WHICH RELEASE SERTRALINE AT A RATE BETWEEN 1MGA/HR AND 40MGA/HR. THE DOSAGE FORMS MAY EXHIBIT AN INITIAL DELAY PERIOD DURING WHICH SERTRALINE IS RELEASED AT A RATE LESS THAN 1 MGA/HR. THE PRESENT INVENTION IS FURTHER DIRECTED TO AN ACETATE SALT, AN L-LACTATE SLAT AND AN L-ASPARTATE SALT OF SERTRALINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USING THAT SALT FOR TREATING VARIOUS CONDITIONS AND DISORDERS. THE PRESENT INVENTION IS ALSO DIRECTED TO PROCESSES FOR PREPARING SERTRALINE ACETATE, SERTRALINE L-LACTATE AND SERTRALINE L-ASPARTATE.",PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/074-327-418-691-080,Granted Patent,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K/;;A61K31/145;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
799,AP,A0,AP 2003002905 A0,175-481-210-402-013,2003-12-31,2003,AP 2003002905 A,1998-06-25,US 5149897 P,1997-07-01,Sertraline salts and sustained-release dosage forms of sertraline.,"The invention provides a sustained-release dosage form suitable for administration to a mammal comprising as active ingredient sertraline of Formula I. In a pharmaceutically acceptable form, at an effective rate of between 1mgA/hr and 40mgA/hr. The dosage forms may exhibit an initial dalay period during which setraline is released at a rate less than 1mgA/hr. The present invention is further directed to an acetate salt, an L-lactate salt and an L-aspartate salt of sertraline, pharmaceutical compositions thereof and methods of using that salt for treating various conditions and disorders. The present invention is also directed to processed for preparing sertraline acetate, sertraline L-lactate and sertraline L-aspartate.",PFIZER,ENDE MARY TANYS AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR L;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/175-481-210-402-013,Patent Application,no,0,0,5,54,0,,A61K/;;C07D/,,0,0,,,,PENDING
800,NZ,A,NZ 513456 A,008-937-598-545-279,2003-02-28,2003,NZ 51345698 A,1998-06-15,NZ 50125198 A;;US 5149897 P;;US 5142097 P;;US 5140297 P;;US 5141497 P,1997-07-01,"Sertraline acetate, L-lactate and L-aspartate, processes for their preparation and their uses in psychotic disorders","Sertraline acetate, sertraline L-aspartate and sertraline L-lactate and pharmaceutical compounds containing the compounds are described. The compounds are useful for anorexia, impulse disorders, onychophagia, premenstrual syndrome, psychotic disorders of the schizophrenic type, inflammatory disorders, hyperactive immune system disorders, chemical dependency, mental depression and anxiety related disorders. Sertraline acetate, sertraline L-aspartate and sertraline L-lactate can be prepared by reacting a salt of sertraline with a base in the presence of a suitable organic solvent to form sertraline free base, partitioning the sertraline free base into an organic solvent and reacting the sertraline free base with acetic acid to form sertraline acetate, lactic acid to form sertraline L-lactate or aspartic acid to form sertraline L-aspartate, in the presence of a suitable organic solvent.",PFIZER,AM ENDE MARY TANYA;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR;;HERBIG SCOTT MAX;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE,,https://lens.org/008-937-598-545-279,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,PENDING
801,BG,A,BG 103915 A,045-078-358-433-082,2000-07-31,2000,BG 10391599 A,1999-11-23,IB 9800934 W;;US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,SERTRALINE SALTS AND SERTRALIN-CONTAINING BATCHED FORMS WITH DELAYED RELEASE,"The batched forms release sertraline with a speed between 1 and 40 mgA/hr, in the initial period of delay the sertraline is freed with a speed of 1 mgA/hr. The invention also relates to acetate salt, the salts sertraline L-lactate and sertraline L-aspartate, to their pharmaceutically medicamentous forms, to methods for their application for the treatment of different conditions or diseases and to methods for the production of sertraline acetate, sertraline L-lactate and sertraline L-aspartate. 115 claims",PFIZER,AM ENDE MARY T;;CURATOLO WILLIAM J;;FRIEDMAN HYLAR L;;SHANKER RAVI M;;HERBIG SCOTT M;;FRIESEN DWAYNE T;;WEST JAMES B,,https://lens.org/045-078-358-433-082,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,PENDING
802,HK,A1,HK 1026630 A1,054-505-561-281-838,2000-12-22,2000,HK 00105878 A,2000-09-19,US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P;;IB 9800934 W,1997-07-01,Sertraline salts and sustained-release dosage forms of sertraline,,PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/054-505-561-281-838,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/00;;A61K9/22;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,DISCONTINUED
803,WO,A1,WO 2023/107956 A1,142-600-391-771-759,2023-06-15,2023,US 2022/0081030 W,2022-12-06,US 202163287524 P;;US 202263375826 P,2021-12-08,"PROTEINS BINDING NKG2D, CD16 AND 5T4","Multispecific binding proteins that bind NKG2D receptor, CD16, and 5T4 are described, as well as pharmaceutical compositions, formulations, and therapeutic methods of the multispecific binding proteins useful for the treatment of cancer.",DRAGONFLY THERAPEUTICS INC,BIGELOW MITCHELL;;DEROSE MARK;;DU JINYAN;;FRIEDMAN ROBIN;;HEIN PYAE P;;HICKS STUART WILLIAM;;JUO ZONG SEAN;;LI XINBI;;MORGAN CHRISTOPHER RYAN,,https://lens.org/142-600-391-771-759,Patent Application,yes,84,0,3,3,542,C07K16/2851;;C07K16/30;;C07K2317/31;;C07K2317/92;;C07K2317/73;;C07K2317/94;;C07K2317/71;;C07K2317/64;;A61K39/39591;;A61P35/04;;C07K16/468;;C07K2317/31;;C07K2317/53;;C07K2317/55;;C07K2317/565;;C07K2317/622,C07K16/28;;A61K39/395;;C07K16/30,,38,22,019-745-677-143-457;;061-175-802-642-804;;049-134-753-209-354;;032-720-983-972-675;;095-334-545-560-259;;039-515-794-348-090;;019-982-436-313-59X;;117-139-548-093-070;;120-738-288-740-114;;053-176-154-216-843;;045-003-131-652-516;;043-038-798-231-696;;159-931-401-174-194;;018-454-440-471-739;;022-673-818-418-193;;050-312-406-056-271;;025-354-997-308-889;;040-833-896-641-924;;053-878-668-367-346;;017-752-308-728-583;;045-149-256-448-908;;040-062-044-036-027,pmc7529872;;32468232;;10.1007/s00262-020-02615-7;;408353;;10.1016/s0021-9258(17)39891-5;;10.1016/0022-2836(87)90412-8;;3681981;;10.1006/jmbi.1997.1354;;9367782;;10.1006/jmbi.1996.0548;;8876650;;10.1016/s0145-305x(02)00039-3;;12477501;;11397087;;10.1006/jmbi.2001.4662;;18614234;;10.1016/j.molimm.2008.05.022;;19097774;;10.1016/j.ejca.2008.10.026;;33978465;;10.2214/ajr.21.25814;;10.1006/jmbi.1997.1116;;9231898;;10.1016/j.jmb.2014.02.015;;24576605;;24334029;;10.1016/j.molimm.2013.11.017;;24463572;;10.1038/nbt.2797;;21498564;;10.1093/protein/gzq123;;pmc3527920;;23118228;;10.1074/jbc.m112.397869;;21149738;;10.1073/pnas.1016478108;;pmc3012461;;10917521;;10.1038/35018508;;27757559;;10.1007/s00262-016-1917-3;;10.1016/s0009-8981(01)00423-5;;11412815;;2218494;;10.1126/science.2218494;;10.1073/pnas.082102799;;11959979;;pmc122761,"FENG PO-HAO ET AL: ""NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells"", CANCER IMMUNOLOGY IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 69, no. 10, 28 May 2020 (2020-05-28), pages 2147 - 2155, XP037253281, ISSN: 0340-7004, [retrieved on 20200528], DOI: 10.1007/S00262-020-02615-7;;HARPER J ET AL., MOL CANCER THER, 2017;;KABAT ET AL., J. BIOL. CHEM., vol. 252, 1977, pages 6609 - 6616;;KABAT ET AL., SEQUENCES OF PROTEIN OF IMMUNOLOGICAL INTEREST, 1991;;CHOTHIA CLESK A M, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;AL-LAZIKANI ET AL., J. MOL. BIOL., vol. 273, 1997, pages 927 - 948;;MACCALLUM R M ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745;;LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77;;HONEGGERPLUCKTHUN, J. MOL. BIOL., vol. 309, 2001, pages 657 - 70;;ABHINANDANMARTIN, IMMUNOLOGY, vol. 45, 2008, pages 3832 - 3839;;EISENHAUER ET AL., EUR J CANCER., vol. 45, no. 2, 2009, pages 228 - 47;;PAYDARY ET AL., MOL IMAGING BIOL., vol. 21, no. 1, 2019, pages 1 - 10;;LI ET AL., AJR AM J ROENTGENOL, vol. 217, no. 6, 2021, pages 1433 - 1443;;KERNER ET AL., ETNMMI RES, vol. 6, no. 1, 2016, pages 33;;MARTIN: ""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY;;SCATCHARD ET AL., ANN. N. Y. ACAD. SCI. USA, vol. 51, 1949, pages 660;;ATWELL S, RIDGWAY JB, WELLS JA, CARTER P.: ""Stable heterodimers from remodeling the domain interface of a homodimer using a phage display libraby"", BIOL., vol. 270, no. 1, 1997, pages 26 - 35, XP004453749, DOI: 10.1006/jmbi.1997.1116;;ELLIOTT JMULTSCH MLEE JTONG RTAKEDA KSPIESS C ET AL.: "", Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction"", J. MOL. BIOL., vol. 426, no. 9, 2014, pages 1947 - 57, XP028844614, DOI: 10.1016/j.jmb.2014.02.015;;MIMOTO FKADONO SKATADA HIGAWA TKAMIKAWA THATTORI K: ""Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcyRs"", MOL. IMMUNOL., vol. 58, no. 1, 2014, pages 132 - 8, XP028548629, DOI: 10.1016/j.molimm.2013.11.017;;LEWIS SMWU XPUSTILNIK ASERENO AHUANG FRICK HL ET AL.: ""Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface"", NAT. BIOTECHNOL., vol. 32, no. 2, 2014, pages 191 - 8, XP055240003, DOI: 10.1038/nbt.2797;;MUDA M ET AL., PROTEIN ENG. DES. SEL., vol. 24, no. 5, 2011, pages 447 - 54;;WRANIK, BJ. ET AL., J. BIOL. CHEM., vol. 287, 2012, pages 43331 - 9;;DOPPALAPUDI VR ET AL., PNAS, vol. 107, no. 52, 2010, pages 22611 - 22616;;KABAT ET AL., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, 1991, pages 91 - 3242;;CHOTHIA CLESK A M, J MOL BIOL, vol. 196, 1987, pages 901 - 917;;MACCALLUM R M ET AL., J MOL BIOL, vol. 262, 1996, pages 732 - 745;;SONDERMANN ET AL., NATURE, vol. 406, no. 6793, pages 267 - 273;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NATIONAL INSTITUTES OF HEALTH;;STERN ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 66, 2017, pages 415 - 426;;STEIMER ET AL., CLINICA CHIMICA ACTA, vol. 308, 2001, pages 33 - 41;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", 1999, JOHN WILEY & SONS;;CHAN ET AL., CELL DEATH DIFFER, vol. 21, no. 1, 2014, pages 5 - 14;;GARIEPY ET AL., 106TH ANNU MEET AM ASSOC IMMUNOLOGISTS (AAI) (MAY 9-13, SAN DIEGO, 2019;;ZHOU ET AL., CANCER LETT., vol. 408, 1 November 2017 (2017-11-01), pages 130 - 137;;BOOTH ET AL., CANCER BIOL THER, vol. 19, no. 2, 1 February 2018 (2018-02-01), pages 132 - 137;;STEVEN SHIRE: ""Delivery and Stability of Final Drug Product"", 24 April 2015, WOODHEAD PUBLISHING, article ""Monoclonal Antibodies: Meeting the Challenges in Manufacturing, Formulation"";;LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533;;ROBINSON: ""Protein Deamidation"", PNAS, vol. 99, no. 8, 2002, pages 5283 - 88",PENDING
804,IS,A,IS 5265 A,158-889-956-451-332,1999-11-23,1999,IS 5265 A,1999-11-23,IB 9800934 W;;US 5149897 P;;US 5141497 P;;US 5140297 P;;US 5142097 P,1997-07-01,Sertralín sölt og viðhalds-losandi skammtaform afsertralíni,,PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/158-889-956-451-332,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,PENDING
805,OA,A,OA 11245 A,179-753-355-875-120,2003-07-23,2003,OA 9900305 A,1999-12-23,US 5140297 P;;US 5141497 P;;US 5142097 P;;US 5149897 P,1997-07-01,Sertraline salts and sustained-release dosage forms of sertraline,,PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;FRIEDMAN HYLAR LEWIS;;HERBIG SCOTT MAX;;SHANKER RAVI MYSORE;;WEST JAMES BLAIR,,https://lens.org/179-753-355-875-120,Granted Patent,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
806,UY,A1,UY 27130 A1,012-590-511-716-720,2002-03-22,2002,UY 27130 A,2002-01-21,UY 27130 A,2002-01-21,"SALES DE SERTRALINA Y FORMAS DE DOSIFICACIÓN DE LIBERACIÓN SOSTENIDA TEMPORALMENTE RETARDADA, SENSIBLES AL PH Y A ENZIMAS",Formas de dosificación de liberación sostenida de sertralina que liberan sertralina a una velocidad entre 1 mgA/h y 40 mgA/h.,PFIZER,ENDE MARY TANYA AM;;SHANKER RAVI MYSORE;;FRIEDMAN HYLAR LEWIS;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR;;HERBING SCOTT MAX,,https://lens.org/012-590-511-716-720,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
807,DZ,A1,DZ 2546 A1,068-138-322-121-761,2003-02-08,2003,DZ 980156 A,1998-06-30,US 5149897 P;;US 5141497 P;;US 5140297 P;;US 5142097 P,1997-07-01,Sels de sertraline et formes posologiques de sertraline à libération prolongée et procédé pour leur préparation.,,PFIZER PROD INC,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSHORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES WETS,,https://lens.org/068-138-322-121-761,Granted Patent,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
808,NO,L,NO 996518 L,147-951-033-188-500,2000-02-29,2000,NO 996518 A,1999-12-28,IB 9800934 W;;US 5140297 P;;US 5141497 P;;US 5142097 P;;US 5149897 P,1997-07-01,Sertralinsalter og doseringsformer av sertralin med vedvarende frigjøring,,PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/147-951-033-188-500,Abstract,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/22;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,DISCONTINUED
809,GT,A,GT 199800103 A,124-854-639-847-188,2000-01-04,2000,GT 199800103 A,1998-07-13,GT 199800103 A,1998-07-13,SALES DE SERTRALINA Y FORMAS DE DOSIFICACION DE LIBERACION SOSTENIDA DE SERTRALINA.,"UNA FORMA DE DOSIFICACION DE LIBERACION SOSTENIDA APROPIADA PARA LA ADMINISTRACION ORAL A UN MAMIFERO, QUE CONTIENE SERTRALINA, O UNA SAL FARMACEUTICAMENTE ACEPTABLE, LIBERANDO LA FORMA DE DOSIFICACION LA SERTRALINA EN UN ENTORNO DE USO A UNA VELOCIDAD NO SUPERIOR A 0.8 MGA/H/KG, SIEMPRE QUE DICHA FORMA DE DOSIFICACION (1) NO LIBERE MAS DEL 70% DE LA SERTRALINA CONTENIDA EN LA MISMA EN LA PRIMERA HORA DESPUES DE SU ENTRADA EN DICHO ENTORNO DE USO Y (2) LIBERE SERTRALINA A UNA VELOCIDAD DE AL MENOS 0.02 MGA/H/KG.",,ENDE MARIA TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/124-854-639-847-188,Amended Application,no,0,0,1,1,0,,A61K9/52;;A61K31/4375;;A61P3/10;;C07D471/00,,0,0,,,,PENDING
810,NZ,A,NZ 501251 A,186-274-347-170-193,2001-09-28,2001,NZ 50125198 A,1998-06-15,IB 9800934 W;;US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,Sertraline salts and sustained-release dosage forms of sertraline,"Sustained release dosage forms of sertraline, or pharmaceutically acceptable salts thereof are disclosed. Sertraline is released at a rate of between 0.02 mgA/hr/kg and 0.6 mgA/hr/kg, or between 1 mgA/hr and 40 mgA/hr, where mgA is the amount of active sertraline. The dosage form must not release more than 70% of the sertraline in the first hour following administration. The dosage form is suitable for oral administration to a mammal.",PFIZER,FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR;;HERBIG SCOTT MAX;;AM ENDE MARY TANYA;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE,,https://lens.org/186-274-347-170-193,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,PENDING
811,BR,A,BR 9810403 A,000-325-025-579-174,2000-08-29,2000,BR 9810403 A,1998-06-15,IB 9800934 W;;US 5140297 P;;US 5141497 P;;US 5149897 P;;US 5142097 P,1997-07-01,Sais da sertralina e formas de dosagem de liberação sustentada da sertralina,"Patente de Invenção: <B>""SAIS DA SERTRALINA E FORMAS DE DOSAGEM DE LIBERAçãO SUSTENTADA DA SERTRALINA""<D>. As formas de dosagem de liberação sustentada da sertralina que liberam a sertralina a uma velocidade entre 1 mgA/h e 40 mgA/h. As formas de dosagem podem exibir um período de retardamento inicial durante o qual a sertralina é liberada a uma velocidade menor que 1 mgA/h. A presente invenção refere-se ainda a um sal de acetato, um sal de L-lactato e um sal de L-aspartato, as suas composições farmacêuticas e métodos de utilizar o sal para o tratamento de várias condições e distúrbios. A presente invenção refere-se também a processos para a preparação do acetato de sertralina, o L-lactato da sertralina e o L-aspartato da sertralina.",PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/000-325-025-579-174,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K/;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,DISCONTINUED
812,SK,A3,SK 180499 A3,131-209-321-668-667,2001-08-06,2001,SK 180499 A,1998-06-15,IB 9800934 W;;US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE,,PFIZER,AM ENDE MARY TANYA;;CURATALO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/131-209-321-668-667,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,PENDING
813,PA,A1,PA 8454401 A1,039-203-305-017-627,2000-05-24,2000,PA 8454401 A,1998-06-30,US 5140297 P;;US 5141497 P;;US 5142097 P;;US 5149897 P,1997-07-01,SALES DE SERTRALINA Y FORMAS DE DOSIFICACiON DE LIBERACION SOSTENIDA DE SERTRALINA,"FORMA DE DOSIFICACION DE LIBERACION SOSTENIDA DE SERTRALINA QUE LIBERAN SERTRALINA A UNA VELOCIDAD ENTRE 1 MGA/H. LAS FORMAS DE DOSIFICACION PUEDEN PRESENTAR UN PERIODO DE RETRASO INICIAL DURANTE EL CUAL, LA SERTRALINA SE LIBERA A UNA VELOCIDAD MENOR DE 1 MGA/H.",PFIZER,SHANKER RAVI MYSORE;;WEST JAMES BLAIR;;FRIEDMAN HYLAR LEWIS;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;AM ENDE MARY TANYA,,https://lens.org/039-203-305-017-627,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,PENDING
814,TR,T2,TR 199903280 T2,064-584-664-770-731,2000-11-21,2000,TR 9903280 T,1998-06-15,US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,Sertralin tuzlari ve sertralinin tutmali-bosaltma dozaj biçimleri.,"Sertralin için sertailini 1 mgA/s ile 40mgA/s arasindaki bir hizda bosaltan tutmali bosaltma dozaj biçimleri. Dozaj biçimleri baslangiçta sertralinin 1mgA/s kadar bir hizla bosaltildigi bir gecikme süresini sergileyebilir. Bu bulus ayrica sertralinin bir asetat tuzuna, bir L-laktat tuzuna ve bir L-asparat tuzuna, bunun farmasötik bilesimlerine ve bu tuzu çesitli kosul ve bozukluklarin tedavisinde kullanan yöntemlere de yöneliktir. Bu bulus ayni zamanda sertralin asetat, sertralin L-laktat ve sertralin L-asparat hazirlanmasi için usullere de yöneliktir.",PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/064-584-664-770-731,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,PENDING
815,WO,A1,WO 1999/001121 A1,164-251-923-698-51X,1999-01-14,1999,IB 9800934 W,1998-06-15,US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE,"Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr. The present invention is further directed to an acetate salt, an L-lactate salt and an L-aspartate salt of sertraline, pharmaceutical compositions thereof and methods of using that salt for treating various conditions and disorders. The present invention is also directed to processes for preparing sertraline acetate, sertraline L-lactate and sertraline L-aspartate.",PFIZER;;AM ENDE MARY TANYA;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,AM ENDE MARY TANYA;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/164-251-923-698-51X,Patent Application,yes,5,41,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,PATENTED
816,NO,D0,NO 996518 D0,162-487-311-333-171,1999-12-28,1999,NO 996518 A,1999-12-28,IB 9800934 W;;US 5140297 P;;US 5141497 P;;US 5142097 P;;US 5149897 P,1997-07-01,Sertralinsalter og doseringsformer av sertralin med vedvarende frigjoering,,PFIZER,ENDE MARY TANYA AM;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/162-487-311-333-171,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,DISCONTINUED
817,HU,A2,HU P0002296 A2,035-276-019-252-345,2001-10-28,2001,HU P0002296 A,1998-06-15,IB 9800934 W;;US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE,"A találmány tárgyát sertralint és/vagy gyógyászatilag elfogadhatósóját, továbbá hordozót tartalmazó, elnyújtott felszabadulástbiztosító dózisforma képezi, amelyből a sertralin 1 mgA/óra és 40mgA/óra közötti sebességgel szabadul fel. A fenti dózisforma egykezdeti késleltetési periódussal rendelkezhet, amely alatt a sertralinkevesebb mint 1mgA/óra sebességgel szabadul fel. A találmány mégsertralin-acetát, sertralin-L-laktát és sertralin-L-aszpartát sókra,valamint ezeket tartalmazó gyógyászati készítményekre és ezekkülönböző betegségek és állapotok kezelésében való alkalmazásáravonatkozik. A találmány tárgya még eljárás sertralin-acetát,sertralin-L-laktát és sertralin-L-aszpartát előállítására. Ó",PFIZER,AM ENDE MARY TANYA;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;SHANKER RAVI MYSORE;;WEST JAMES BLAIR,,https://lens.org/035-276-019-252-345,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,DISCONTINUED
818,PE,A1,PE 88699 A1,044-206-827-402-156,1999-09-20,1999,PE 00057298 A,1998-06-26,US 5149897 P;;US 5141497 P;;US 5140297 P;;US 5142097 P,1997-07-01,FORMAS DE DOSIFICACION DE LIBERACION SOSTENIDA DE SERTRALINA,"SE REFIERE A UNA FORMA DE DOSIFICACION QUE LIBERA SERTRALINA A UNA VELOCIDAD NO SUPERIOR A 0,8 mgA/h/Kg, NO LIBERANDO MAS DEL 70% DE SERTRALINA EN LA PRIMERA HORA, Y LUEGO LIBERANDOLA A UNA VELOCIDAD DE 0,02 mgA/h/Kg LA LIBERACION SOSTENIDA SE DESENCADENA POR EL pH. LA SERTRALINA SE ENCUENTRA COMO BASE LIBRE, CLORHIDRATO, ACETATO, ASPARTATO O LACTATO; SIENDO SENSIBLE A LAS ENZIMAS. LAS FORMAS DE DOSIFICACION SE PRESENTAN COMO COMPRIMIDO DE MATRIZ QUE PERMANECE INTACTO DURANTE EL PERIODO DE LIBERACION SOSTENIDA, COMPRIMIDO DE MATRIZ DISGREGABLE, COMPRIMIDO DE MATRIZ PARCIALMENTE RECUBIERTO CON UN POLIMERO QUE IMPIDE LA LIBERACION DE SERTRALINA, COMPRIMIDO OSMOTICO, COMPRIMIDO CON HIDROGEL, SISTEMA MULTIPARTICULAR RECUBIERTO CON UNA MEMBRANA Y BASADO EN LA DIFUSION. LA MEMBRANA TIENE UN LIQUIDO HIDROFOBO DENTRO DE LOS POROS DE LA MISMA. EL LIQUIDO ES IMPERMEABLE AL AGUA Y A LA SERTRALINA, SE MODIFICA POR DEGRADACION ENZIMATICA, SIENDO PERMEABLE AL AGUA Y A LA SERTRALINA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LA COMPOSICION SE PUEDE UTILIZAR PARA EL TRATAMIENTO DE LA ENFERMEDAD PSIQUIATRICA, EYACULACION PRECOZ, DEPENDENCIA QUIMICA",PFIZER,AM ENDE MARY TANYA;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;WEST JAMES BLAIR;;HERBIG SCOTT MAX;;SHANKER RAVI MYSORE;;FRIESEN DWAYNE THOMAS,,https://lens.org/044-206-827-402-156,Patent Application,no,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K9/22;;A61K/;;A61K31/135;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,EXPIRED
819,EP,A1,EP 0999830 A1,166-663-808-091-812,2000-05-17,2000,EP 98923020 A,1998-06-15,IB 9800934 W;;US 5149897 P;;US 5142097 P;;US 5141497 P;;US 5140297 P,1997-07-01,SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE,,PFIZER,AM ENDE MARY TANYA;;CURATOLO WILLIAM JOHN;;FRIEDMAN HYLAR LEWIS;;SHANKER RAVI MYSORE;;HERBIG SCOTT MAX;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR,,https://lens.org/166-663-808-091-812,Patent Application,yes,0,0,47,54,0,A61K9/0004;;A61K9/1652;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2886;;A61K9/5047;;A61K31/135;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/30;;A61P3/04;;A61P37/00;;A61K31/135;;A61K9/2054;;A61K9/5047;;A61K9/2018;;A61K9/0004;;A61K31/135;;A61K9/2013;;A61K9/2886;;A61K9/2009;;A61K9/1652,A61K/;;A61K9/22;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/32;;A61K9/50;;A61K9/52;;A61K9/54;;A61K31/135;;A61P3/04;;A61P25/18;;A61P25/24;;A61P25/30;;C07C209/00;;C07C211/42;;C07D/,,0,0,,,,DISCONTINUED
820,US,A1,US 2004/0138999 A1,027-728-219-435-343,2004-07-15,2004,US 34078403 A,2003-01-13,US 34078403 A,2003-01-13,Systems and methods for managing a credit account having a credit component associated with healthcare expenses,"
   A method for managing a credit account associated with a customer is provided. The credit account has a first credit component associated with purchase transactions and a second credit component associated with healthcare expenses. A payment request from an insurance provider for a customer payment portion associated with a particular healthcare expense is received. A determination is made to see whether the customer payment portion exceeds a limit. The insurance provider is paid the customer payment portion when the limit is not exceeded. The payment of the customer payment portion is requested from a healthcare expense account. 
",CAPITAL ONE FINANCIAL CORP,FRIEDMAN HOWARD S;;BLACKLEY SETH B;;BRAFF ADAM;;CILLUFFO WILLIAM A;;EDMUNDS RICHARD C;;EHRBECK TILMAN D T;;NEWKIRK CHRIS;;SHEKLIN RONALD D,CAPITAL ONE FINANCIAL CORPORATION (2002-10-03),https://lens.org/027-728-219-435-343,Patent Application,yes,11,142,1,1,0,G07F7/1008;;G07F7/1008;;G06Q10/10;;G06Q10/10;;G06Q20/10;;G06Q20/10;;G06Q20/102;;G06Q20/102;;G06Q20/341;;G06Q20/341;;G06Q20/35765;;G06Q20/35765;;G06Q30/04;;G06Q30/04;;G06Q40/08;;G06Q40/08,G06F19/00;;G06Q10/10;;G06Q20/10;;G06Q20/34;;G06Q30/04;;G07F7/10,705/39;;X705 4,0,0,,,,DISCONTINUED
821,WO,A1,WO 1982/001650 A1,034-123-883-185-794,1982-05-27,1982,US 8101466 W,1981-11-02,US 20543680 A,1980-11-10,BIOLOGICALLY ACTIVE HETEROBICYCLIC HYDROXIMIDATES AND THIOLHYDROXIMIDATES AND CARBAMATE ESTER DERIVATIVES THEREOF,"Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described.",DIAMOND SHAMROCK CORP,MAGEE THOMAS A;;CORKINS HARRY G;;LIMPEL LAWRENCE E;;STORACE LOUIS;;BATTERSHELL ROBERT D;;BRAND WILLIAM W;;FRIEDMAN ARTHUR;;OSGOOD EDMOND R;;BUCHMAN RUSSELL,,https://lens.org/034-123-883-185-794,Patent Application,yes,13,1,25,29,0,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07F7/0892;;C07F9/2483;;C07F9/6561;;C07D513/00,A01N47/24;;A01N55/00;;A01N57/08;;A61K31/275;;A61K31/34;;A61K31/35;;A61K31/38;;A61K31/385;;A61K31/39;;A61K31/40;;A61K31/415;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/445;;A61K31/495;;A61K31/505;;A61K31/55;;A61K31/665;;A61K31/67;;A61K31/675;;A61K31/695;;C07D/;;C07D209/02;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07D495/18;;C07F7/08;;C07F9/24;;C07F9/6561,C2C CAA;;C2C CAA;;C2C CAA;;C2C CAA;;C2C CAA;;C2C CAA;;C2C CAA;;C2C CAA;;C2C CAA;;C2C CAA;;C2C CAA;;C2C CAA;;C2C CAA;;C2C CAA;;C2C CKB;;C2C CKN;;C2C CKR;;C2C CKV;;C2C CLS;;C2C CMD;;C2C CMV;;C2C CQZ;;C2C CRC;;C2C CRV;;C2C CSC;;C2C CSU;;C2C CTT;;C2C CZB;;C2C C1200;;C2C C1306;;C2C C134X;;C2C C134X;;C2C C1341;;C2C C1410;;C2C C147X;;C2C C147X;;C2C C147X;;C2C C1470;;C2C C1504;;C2C C1516;;C2C C1516;;C2C C1516;;C2C C1516;;C2C C1516;;C2C C1516;;C2C C1516;;C2C C1516;;C2C C1516;;C2C C1516;;C2C C1516;;C2C C1530;;C2C C1532;;C2C C1544;;C2C C1544;;C2C C1544;;C2C C1562;;C2C C1582;;C2C C1672;;C2C C1678;;C2C C1678;;C2C C171X;;C2C C1718;;C2C C1718;;C2C C1718;;C2C C1718;;C2C C1718;;C2C C1718;;C2C C200;;C2C C200;;C2C C213;;C2C C213;;C2C C213;;C2C C213;;C2C C213;;C2C C213;;C2C C213;;C2C C213;;C2C C213;;C2C C213;;C2C C213;;C2C C213;;C2C C213;;C2C C215;;C2C C215;;C2C C215;;C2C C215;;C2C C22Y;;C2C C22Y;;C2C C22Y;;C2C C22Y,21,12,139-942-540-220-961;;166-838-738-518-48X;;134-903-619-342-343;;039-635-539-011-817;;057-579-658-387-226;;180-930-987-358-56X;;108-220-849-736-676;;183-285-768-523-692;;115-967-944-022-101;;010-558-321-687-188;;030-054-517-259-229;;092-446-997-020-090,10.1021/jo01016a010;;10.1139/v71-624;;10.1016/s0040-4020(01)97437-x;;10.1021/jo01306a034;;10.1021/jo00955a013;;10.1021/jo00890a003;;10.1021/jo00415a006;;10.1016/0048-3575(76)90082-1;;10.1021/jo00884a021;;10.1002/anie.197707353;;412439;;10.1021/jo00414a033;;659709;;10.1021/jf60217a021,"J. Org. Chem., vol. 30, pp. 1390-4, issued (1965) Middleton.;;Can. J. Chem., Vol. 49, pp. 3755-8, issued (1971) Vyas et al:;;Tetrahedron Letters, No. 25, pp. 2139-40, issued (1977) Friedrich et al:;;Tetrahedron, Vol. 30, pp. 2735-40, issued (1974) Boerma et al:;;J. Org. Chem., Vol. 45, pp. 3713-6, issued (1980) Larsen:;;J. Org. Chem., Vol. 34, pp. 860-4, issued (1969) Johnson et al:;;J. Org. Chem., Vol. 38, pp. 2637-40, issued (1973) Reich et al:;;Sythesis, pp. 735-6, issued (1974) Benassi et al:;;J. Org. Chem., Vol. 40, pp. 161-172, issued (1975) Raasch:;;Tetrahedron Letters, pp. 215-8, issued (1976) Allgier et al:;;Dissertation Abstracts, Vol. 40, p. 5672-B, issued (1980) Hong:;;J. Org. Chem., Vol. 43, pp. 4013-20, issued (1978) Ohishi et al:;;""Advanced Organic Chemistry"" 2nd Ed., pp. 386 and 388, issued (1977) March.;;J. Am. Chem. Soc., Vol. 86, pp. 4886-97, issued (1964) Bruice et al:;;Jour. fuer Prak. Chem., Leipzig Vol. 311(1) pp. 61-70, issued (1969) Faust et al:;;Pesticide Biochemistry and Physiology, Vol. 6, pp. 571-83, issued (1976) Huhtanen et al:;;J. Org. Chem., Vol. 41, pp. 3583-6, issued (1976) Moriconi et al:;;J. Chem. Soc., Perkin I, pp. 874-84, issued (1977) Malpass et al:;;Angewandie Chemie, Int. Ed. Vol. 16(11), pp. 735-42, issued (1977) Kuhle et al:;;J. Org. Chem., Vol. 43, pp. 3953-57, issued (1978) Hatch:;;J. Agric. Food Chem., Vol. 26(3), pp. 550-7, issued (1978) Fahmy et al:",PENDING
822,US,A,US 4424213 A,074-426-237-058-829,1984-01-03,1984,US 31751681 A,1981-11-02,US 31751681 A;;US 20543680 A,1980-11-10,Biologically active heterobicyclic hydroximidates and thiolhydroximidates and carbamate ester derivatives thereof,"Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described. ##STR1##",SDS BIOTECH CORP,MAGEE THOMAS A;;BATTERSHELL ROBERT D;;LIMPEL LAWRENCE E;;HO ANDREW W;;FRIEDMAN ARTHUR W;;CORKINS H GLENN;;BRAND WILLIAM W;;BUCHMAN RUSSELL;;STORACE LOUIS;;OSGOOD EDMOND R,DIAMOND SHAMROCK CORPORATION A CORP. OF DE (1981-10-13);;SDS BIOTECH CORPORATION A DE CORP (1983-07-14);;RICERCA INC. A CORP. OF DE (1986-03-01),https://lens.org/074-426-237-058-829,Granted Patent,yes,11,5,1,29,0,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07F7/0892;;C07F9/2483;;C07F9/6561;;C07D221/22;;C07D495/08;;C07F9/6561;;C07F9/2483;;C07F7/0892;;A01N57/08;;C07D335/04;;C07D311/00;;A01N55/00;;C07D313/20;;C07D313/06;;C07D337/06;;A01N47/24;;C07D335/10,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07D495/18;;C07F7/08;;C07F9/24;;C07F9/6561,424/184;;424/200;;548/525;;549/23;;424/202;;549/26;;549/27;;424/246;;549/28;;549/46;;424/248.51;;549/48;;549/53;;424/251;;549/57;;549/4;;424/250;;549/9;;549/5;;424/263;;549/8;;549/6;;424/267;;549/12;;424/274;;424/275;;544/375;;544/376;;544/372;;544/295;;544/337;;544/141;;544/145;;544/243;;544/316;;544/61;;544/58.7;;544/58.2;;544/57;;546/22;;546/274;;546/202;;546/14;;546/24;;548/110;;548/112;;548/406;;548/413,20,0,,,"Middleton J. Orl. Chem., 30, 1390 (1965).;;Vyas and Hay, Can. J. Chem., 49, 3755 (1971).;;Friedrich et al., Tetrahedron Letters, 2139 (1977).;;Boerma et al., Tetrahedron, 30, 2735 (1974).;;Larsen et al., J. Org. Chem., 45, 3713 (1980).;;Johnson et al., J. Org. Chem., 34, 860 (1969).;;Benassi et al., Synthesis, 735 (1974).;;Raasch, J. Org. Chem., 40, 161 (1975).;;Allgier et al., Tetrahedron Letters, 215 (1976).;;Disertation Abstracts, 40, 5672-B (1980).;;Ohishi et al., J. Org. Chem., 43, 4013 (1978).;;March, Advanced Organic Chemistry, 2nd Ed., p. 386, 388 (1977).;;Bruice and Fedor, J. Am. Chem. Soc., 86, 4886 (1964).;;Faust et al., Journal fuer Praktische Chemie, Leipzig, 311(1), 61 (1969).;;Huhtanen and Dorough, Pesticide Biochemistry and Physiology, 6, 571 (1976).;;Moriconi and Hummel, J. Org. Chem. 41, 3583 (1976).;;Malpass and Tweddle, J. Chem. Soc., Perkin I, 874 (1977).;;Ku/ hle and Klauke, Angewandte Chemie, Int. Ed., 16, 735 (1977).;;Hatch, J. Org. Chem., 43, 3953 (1978).;;Fahmy et al., J. Agric. Food Chem., 26, 550 (1978).",EXPIRED
823,BR,A,BR 8108862 A,111-858-103-789-14X,1983-05-31,1983,BR 8108862 A,1981-11-02,US 20543680 A;;US 8101466 W,1980-11-10,HIDROXIMIDATO E TIOL-HIDROXIMIDATOS HETEROBICICLICOS E SEUS DERIVADOS ESTER -CARBAMATO COM ATIVIDADE BIOLOGICA,"Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described. <CHEM> i",DIAMOND SHAMROCK CORP,MAGEE THOMAS ALEXANDER;;BATTERSHELL ROBERT DEAN;;LIMPEL LAWRENCE EUGENE;;WAI WAH HO ANDREW;;FRIEDMAN ARTHUR JAY;;CORKINS HARRY GLENN;;BRAND WILLIAM WAYNE;;BUCHMAN RUSSELL;;STORACE LOUIS;;RANDOLPH EDMOND,,https://lens.org/111-858-103-789-14X,Patent Application,no,0,0,25,29,0,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07F7/0892;;C07F9/2483;;C07F9/6561;;C07D513/00,A01N47/24;;A01N55/00;;A01N57/08;;A61K31/275;;A61K31/34;;A61K31/35;;A61K31/38;;A61K31/385;;A61K31/39;;A61K31/40;;A61K31/415;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/445;;A61K31/495;;A61K31/505;;A61K31/55;;A61K31/665;;A61K31/67;;A61K31/675;;A61K31/695;;C07D/;;C07D209/02;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07D495/18;;C07F7/08;;C07F9/24;;C07F9/6561,,0,0,,,,DISCONTINUED
824,US,A,US 4548929 A,105-888-162-900-936,1985-10-22,1985,US 48621183 A,1983-04-18,US 48621183 A;;US 20543680 A,1980-11-10,"Insecticidal and nematocidal heterobicyclic hydroximinates, thiohydroximidates, and carbamate esters, composition, and method of use thereof","Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described. ##STR1##",SDS BIOTECH CORP,MAGEE THOMAS A;;BATTERSHELL ROBERT D;;LIMPEL LAWRENCE E;;HO ANDREW W;;FRIEDMAN ARTHUR W;;CORKINS H GLENN;;BRAND WILLIAM W;;BUCHMAN RUSSELL;;STORACE LOUIS;;OSGOOD EDMOND R,SDS BIOTECH CORPORATION A DE CORP (1983-07-14);;RICERCA INC. A CORP. OF DE (1986-03-01),https://lens.org/105-888-162-900-936,Granted Patent,yes,1,0,1,29,0,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07F7/0892;;C07F9/2483;;C07F9/6561;;C07D221/22;;C07F9/6561;;A01N55/00;;C07D335/04;;C07D313/06;;C07F7/0892;;C07D495/08;;A01N47/24;;C07F9/2483;;A01N57/08;;C07D337/06;;C07D313/20;;C07D311/00;;C07D335/10,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07D495/18;;C07F7/08;;C07F9/24;;C07F9/6561,514/85;;514/89;;514/90;;514/99;;514/222;;514/227;;514/255;;514/277;;514/320;;514/359;;514/450;;514/456;;514/256;;544/57;;544/58.1;;544/58.2;;544/58.7;;544/60;;544/61;;544/150;;544/151;;544/243;;544/298;;544/316;;544/319;;544/333;;544/335;;548/525;;546/22;;549/214;;549/220;;546/24;;549/354;;549/355;;546/196;;549/386;;549/397;;546/269;;548/406;;548/414,1,1,115-967-944-022-101,10.1021/jo00884a021,"Moriconi et al., J. Org. Chem., vol. 41, No. 22, 1976, pp. 3583 3586.",EXPIRED
825,CA,A,CA 1208638 A,050-496-544-037-086,1986-07-29,1986,CA 389521 A,1981-11-05,US 20543680 A,1980-11-10,BIOLOGICALLY ACTIVE HETEROBICYCLIC HYDROXIMIDATES AND THIOLHYDROXIMIDATES AND CARBAMATE ESTER DERIVATIVES THEREOF,"BIOLOGICALLY ACTIVE HETEROBICYCLIC HYDROXIMIDATES AND THIOLHYDROXIMIDATES AND CARBAMATE ESTER DERIVATIVES THEREOF Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described. < IMG >",SDS BIOTECH CORP,MAGEE THOMAS A;;BATTERSHELL ROBERT D;;LIMPEL LAWRENCE E;;HO ANDREW W;;FRIEDMAN ARTHUR J;;CORKINS HARRY G;;BRAND WILLIAM W;;BUCHMAN RUSSELL;;STORACE LOUIS;;OSGOOD EDMOND R,,https://lens.org/050-496-544-037-086,Granted Patent,no,0,0,25,29,0,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07F7/0892;;C07F9/2483;;C07F9/6561;;C07D513/00,A01N47/24;;A01N55/00;;A01N57/08;;A61K31/275;;A61K31/34;;A61K31/35;;A61K31/38;;A61K31/385;;A61K31/39;;A61K31/40;;A61K31/415;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/445;;A61K31/495;;A61K31/505;;A61K31/55;;A61K31/665;;A61K31/67;;A61K31/675;;A61K31/695;;C07D/;;C07D209/02;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07D495/18;;C07F7/08;;C07F9/24;;C07F9/6561,260-243.91,0,0,,,,EXPIRED
826,IN,B,IN 155748 B,131-596-695-319-886,1985-03-02,1985,IN 1243CA1981 A,1981-11-09,IN 1243CA1981 A,1981-11-09,METHOD FOR THE PREPARATION OF BIOLOGICALLY ACTIVE HETEROBICYCLIC THIOLHYDROXIMIDATES,,SDS BIOTECH CORP,MAGEE THOMAS A;;BATTERSHELL ROBERT D;;LIMPEL LAWRENCE E;;HO ANDREW W;;FRIEDMAN ARTHUR J;;CORKINS H GLENN;;BRAND WILLIAM W;;BUCHMAN RUSSELL;;STORACE LOUIS;;OSGOOD EDMOND R,,https://lens.org/131-596-695-319-886,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
827,HU,A,HU T34316 A,190-808-079-041-325,1985-03-28,1985,HU 382681 A,1981-11-02,US 20543680 A,1980-11-10,PROCESS FOR PRODUCING HETEROCYCLIC HYDROXIMIDATES AND THIOHYDROXIMIDATES AND THEIR CARBAMATE-ESTER DERIVATIVES,"Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described. <CHEM> i",SDS BIOTECH CORP,MAGEE THOMAS A;;RATTERSHELL ROBERT D;;LIMPEL LAWRENCE E;;HO ANDREW W;;FRIEDMAN ARTHUR J;;CORKINS HARRY G;;BRAND WILLIAM W;;BUCHMAN RUSSELL;;STORAGE LOUIS;;OSGOOD EDMOND R,,https://lens.org/190-808-079-041-325,Unknown,no,0,0,25,29,0,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07F7/0892;;C07F9/2483;;C07F9/6561;;C07D513/00,A01N47/24;;A01N55/00;;A01N57/08;;A61K31/275;;A61K31/34;;A61K31/35;;A61K31/38;;A61K31/385;;A61K31/39;;A61K31/40;;A61K31/415;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/445;;A61K31/495;;A61K31/505;;A61K31/55;;A61K31/665;;A61K31/67;;A61K31/675;;A61K31/695;;C07D/;;C07D209/02;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07D495/18;;C07F7/08;;C07F9/24;;C07F9/6561,,0,0,,,,DISCONTINUED
828,FI,A0,FI 822438 A0,082-771-838-439-181,1982-07-08,1982,FI 822438 A,1982-07-08,US 20543680 A;;US 8101466 W,1980-11-10,BIOLOGISKT AKTIVA HETEROCYKLISKA HYDROXIIMIDAT OCH TIOLHYDROXIIMIDAT OCH KARBAMATESTERDERIVAT AV DESAMMA,,DIAMOND SHAMROCK CORP,MAGEE THOMAS ALEXANDER;;BATTERSHELL ROBERT DEAN;;LIMPEL LAWRENCE EUGENE;;HO ANDREW WAI-WAH;;FRIEDMAN ARTHUR JAY;;CORKINS HARRY GLENN;;BRAND WILLIAM WAYNE;;BUCHAM RUSSELL;;STORAGE LOUIS;;OSGOOD EDMOND RANDOLPH,,https://lens.org/082-771-838-439-181,Patent Application,no,0,0,2,29,0,,A61K31/275;;A61K31/34;;A61K31/35;;A61K31/38;;A61K31/385;;A61K31/39;;A61K31/40;;A61K31/415;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/445;;A61K31/495;;A61K31/505;;A61K31/55;;A61K31/665;;A61K31/67;;A61K31/675;;A61K31/695;;C07D/;;C07D209/02,,0,0,,,,DISCONTINUED
829,FI,L,FI 822438 L,003-953-924-595-721,1982-07-08,1982,FI 822438 A,1982-07-08,US 20543680 A;;US 8101466 W,1980-11-10,BIOLOGISKT AKTIVA HETEROCYKLISKA HYDROXIIMIDAT OCH TIOLHYDROXIIMIDAT OCH KARBAMATESTERDERIVAT AV DESAMMA,,DIAMOND SHAMROCK CORP,MAGEE THOMAS ALEXANDER;;BATTERSHELL ROBERT DEAN;;LIMPEL LAWRENCE EUGENE;;HO ANDREW WAI-WAH;;FRIEDMAN ARTHUR JAY;;CORKINS HARRY GLENN;;BRAND WILLIAM WAYNE;;BUCHAM RUSSELL;;STORAGE LOUIS;;OSGOOD EDMOND RANDOLPH,,https://lens.org/003-953-924-595-721,Abstract,no,0,0,2,29,0,,A61K31/275;;A61K31/34;;A61K31/35;;A61K31/38;;A61K31/385;;A61K31/39;;A61K31/40;;A61K31/415;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/445;;A61K31/495;;A61K31/505;;A61K31/55;;A61K31/665;;A61K31/67;;A61K31/675;;A61K31/695;;C07D/;;C07D209/02,,0,0,,,,DISCONTINUED
830,US,B2,US 8636949 B2,195-162-119-284-666,2014-01-28,2014,US 201213619230 A,2012-09-14,US 201213619230 A;;US 84156010 A;;US 77008310 A;;US 17406109 P;;US 22756609 P;;US 28856909 P,2009-04-30,Electron beam sterilization apparatus,Improved electron beam sterilization apparatus and shielding techniques for use in are provided. A controller modulates an electron beam when sterilizing an interior to an object to ensure that adequate dose is received. Sterilization carousels are configured with input/discharge feeds to reduce the possibility of humans being exposed to dangerous levels of radiation. The system reduces the amount of shielding required to thereby lower cost of installation.,BUFANO MICHAEL LAWRENCE;;WALTHER STEVEN RAYMOND;;HAYS PETER F;;THOMSON WILLIAM FREDERICK;;SOMMERSTEIN ARTHUR WAYNE;;FRIEDMAN GERALD MARTIN;;FLETCHER P MICHAEL;;INTO STEPHEN WHITTAKER;;TESTONI ANNE;;PHILLIPS BRIAN S;;HITACHI SHIPBUILDING ENG CO,BUFANO MICHAEL LAWRENCE;;WALTHER STEVEN RAYMOND;;HAYS PETER F;;THOMSON WILLIAM FREDERICK;;SOMMERSTEIN ARTHUR WAYNE;;FRIEDMAN GERALD MARTIN;;FLETCHER P MICHAEL;;INTO STEPHEN WHITTAKER;;TESTONI ANNE;;PHILLIPS BRIAN S,,https://lens.org/195-162-119-284-666,Granted Patent,yes,4,4,4,10,0,A61L2/087;;A61L2202/14;;A61L2202/23;;B65B55/08;;B67C7/00;;G21K5/02;;B29C49/42405;;A61L2/087;;B65B55/08;;A61L2202/23;;G21K5/02;;A61L2202/14;;B67C7/00,B65B55/08;;A61L2/08,422/22;;250/492.3;;250/493.1;;250/92.14;;315/111.81;;53/425,0,0,,,,ACTIVE
831,US,B2,US 8293173 B2,034-453-713-438-025,2012-10-23,2012,US 84156010 A,2010-07-22,US 84156010 A;;US 77008310 A;;US 22756609 P;;US 28856909 P;;US 17406109 P,2009-04-30,Electron beam sterilization apparatus,Improved electron beam sterilization apparatus and shielding techniques for use in are provided. A controller modulates an electron beam when sterilizing an interior to an object to ensure that adequate dose is received. Sterilization carousels are configured with input/discharge feeds to reduce the possibility of humans being exposed to dangerous levels of radiation. The system reduces the amount of shielding required to thereby lower cost of installation.,BUFANO MICHAEL LAWRENCE;;WALTHER STEVEN RAYMOND;;HAYS PETER F;;THOMSON WILLIAM FREDERICK;;SOMMERSTEIN ARTHUR WAYNE;;FRIEDMAN GERALD MARTIN;;FLETCHER P MICHAEL;;INTO STEPHEN WHITTAKER;;TESTONI ANNE;;PHILLIPS BRIAN S;;HITACHI SHIPBUILDING ENG CO,BUFANO MICHAEL LAWRENCE;;WALTHER STEVEN RAYMOND;;HAYS PETER F;;THOMSON WILLIAM FREDERICK;;SOMMERSTEIN ARTHUR WAYNE;;FRIEDMAN GERALD MARTIN;;FLETCHER P MICHAEL;;INTO STEPHEN WHITTAKER;;TESTONI ANNE;;PHILLIPS BRIAN S,HITACHI ZOSEN CORPORATION (2012-04-26),https://lens.org/034-453-713-438-025,Granted Patent,yes,21,9,4,10,0,A61L2/087;;A61L2202/14;;A61L2202/23;;B65B55/08;;B67C7/00;;G21K5/02;;B29C49/42405;;A61L2/087;;B65B55/08;;A61L2202/23;;G21K5/02;;A61L2202/14;;B67C7/00,A61L2/08;;B65B55/08,422/22;;250/492.3;;250/493.1;;250/492.1;;315/111.81;;315/111.91,6,1,067-469-770-445-583,10.1046/j.1365-2672.2002.01777.x;;12452949,"Bufano, et al., Ebeam Sterilization Apparatus, U.S. Appl. No. 12/770,083, filed Apr. 29, 2010, 73 pages.;;Bufano, et al., Ebeam Sterilization Apparatus, U.S. Appl. No. 61/227,566, filed Jul. 22, 2009, 24 pages.;;Thomson, et al., Shielding for Electron Beam Sterilization, U.S. Appl. No. 61/288,569, filed Dec. 21, 2009, 44 pages.;;Walther, et al., Ebeam Sterilization of Deep Hole Targets, U.S. Appl. No. 61/174,061, filed Apr. 30, 2009, 16 pages.;;Carretero Botella, N., et al., PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, International Application No. PCT/US2010/002071, International Filing Date: Jul. 22, 2010, Date of Document Mailing: Nov. 4, 2010, 14 pages, European Patent Office, Rijswijk, Netherlands.;;Cleghorn, D.A., et al., Sterilization of Plastic Containers Using Electron Beam Irradiation Directed Through the Opening, The Society for Applied Microbiology, Journal of Applied Microbiology, vol. 93, Issue 6, pp. 937-943, Aug. 5, 2002.",ACTIVE
832,US,A1,US 2011/0012030 A1,097-816-653-751-583,2011-01-20,2011,US 77008310 A,2010-04-29,US 77008310 A;;US 22756609 P;;US 28856909 P;;US 17406109 P,2009-04-30,EBEAM STERILIZATION APPARATUS,Improved electron beam sterilization apparatus and shielding techniques for use in are provided. A controller modulates an ebeam when sterilizing an interior to an object to ensure that adequate dose is received. Sterilization carousels are configured with input/discharge feeds to reduce the possibility of humans being exposed to dangerous levels of radiation. The system reduces the amount of shielding required to thereby lower cost of installation.,BUFANO MICHAEL LAWRENCE;;WALTHER STEVEN RAYMOND;;HAYS PETER F;;THOMSON WILLIAM FREDERICK;;SOMMERSTEIN ARTHUR WAYNE;;FRIEDMAN GERALD MARTIN;;FLETCHER P MICHAEL;;INTO STEPHEN WHITTACKER;;TESTONI ANNE;;PHILLIPS BRIAN S,BUFANO MICHAEL LAWRENCE;;WALTHER STEVEN RAYMOND;;HAYS PETER F;;THOMSON WILLIAM FREDERICK;;SOMMERSTEIN ARTHUR WAYNE;;FRIEDMAN GERALD MARTIN;;FLETCHER P MICHAEL;;INTO STEPHEN WHITTACKER;;TESTONI ANNE;;PHILLIPS BRIAN S,HITACHI ZOSEN CORPORATION (2012-04-26);;ADVANCED ELECTRON BEAMS (2010-09-20),https://lens.org/097-816-653-751-583,Patent Application,yes,18,32,2,10,0,A61L2/087;;B65B55/08;;B29C49/42405;;A61L2/087;;B65B55/08,A61L2/08;;B65B55/08,250/492.3,0,0,,,,DISCONTINUED
833,US,A1,US 2011/0012032 A1,147-921-323-612-325,2011-01-20,2011,US 84156010 A,2010-07-22,US 84156010 A;;US 77008310 A;;US 22756609 P;;US 28856909 P;;US 17406109 P,2009-04-30,ELECTRON BEAM STERILIZATION APPARATUS,Improved electron beam sterilization apparatus and shielding techniques for use in are provided. A controller modulates an electron beam when sterilizing an interior to an object to ensure that adequate dose is received. Sterilization carousels are configured with input/discharge feeds to reduce the possibility of humans being exposed to dangerous levels of radiation. The system reduces the amount of shielding required to thereby lower cost of installation.,BUFANO MICHAEL LAWRENCE;;WALTHER STEVEN RAYMOND;;HAYS PETER F;;THOMSON WILLIAM FREDERICK;;SOMMERSTEIN ARTHUR WAYNE;;FRIEDMAN GERALD MARTIN;;FLETCHER P MICHAEL;;INTO STEPHEN WHITTAKER;;TESTONI ANNE;;PHILLIPS BRIAN S,BUFANO MICHAEL LAWRENCE;;WALTHER STEVEN RAYMOND;;HAYS PETER F;;THOMSON WILLIAM FREDERICK;;SOMMERSTEIN ARTHUR WAYNE;;FRIEDMAN GERALD MARTIN;;FLETCHER P MICHAEL;;INTO STEPHEN WHITTAKER;;TESTONI ANNE;;PHILLIPS BRIAN S,HITACHI ZOSEN CORPORATION (2012-04-26),https://lens.org/147-921-323-612-325,Patent Application,yes,17,78,4,10,0,A61L2/087;;A61L2202/14;;A61L2202/23;;B65B55/08;;B67C7/00;;G21K5/02;;B29C49/42405;;A61L2/087;;B65B55/08;;A61L2202/23;;G21K5/02;;A61L2202/14;;B67C7/00,B65B55/08,250/492.3,0,0,,,,ACTIVE
834,EP,A1,EP 0051990 A1,195-778-215-370-711,1982-05-19,1982,EP 81305272 A,1981-11-06,US 20543680 A,1980-11-10,Biologically active heterobicyclic hydroximidates and thiolhydroximidates and carbamate ester derivatives thereof.,"Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described.
 ",SDS BIOTECH CORP,MAGEE THOMAS ALEXANDER;;BATTERSHELL ROBERT DEAN;;LIMPEL LAWRENCE EUGENE;;HO ANDREW WAI-WAH;;FRIEDMAN ARTHUR JAY;;CORKINS HARRY GLENN;;BRAND WILLIAM WAYNE;;BUCHMAN RUSSELL;;STORACE LOUIS;;OSGOOD EDMOND RANDOLPH,"SDS BIOTECH CORPORATION (1984-07-18);;RICERCA, INC. (1987-08-31);;CESSIONE;RICERCA INC. (1987-01-09);;RICERCA, INC. TE PAINESVILLE, OHIO, VER. ST. V. AM (1987-04-16)",https://lens.org/195-778-215-370-711,Patent Application,yes,1,0,25,29,0,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07F7/0892;;C07F9/2483;;C07F9/6561;;C07D513/00,A01N47/24;;A01N55/00;;A01N57/08;;A61K31/275;;A61K31/34;;A61K31/35;;A61K31/38;;A61K31/385;;A61K31/39;;A61K31/40;;A61K31/415;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/445;;A61K31/495;;A61K31/505;;A61K31/55;;A61K31/665;;A61K31/67;;A61K31/675;;A61K31/695;;C07D/;;C07D209/02;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07D495/18;;C07F7/08;;C07F9/24;;C07F9/6561,,0,0,,,,EXPIRED
835,US,A1,US 2013/0015365 A1,033-299-538-830-345,2013-01-17,2013,US 201213619230 A,2012-09-14,US 201213619230 A;;US 84156010 A;;US 77008310 A;;US 17406109 P;;US 22756609 P;;US 28856909 P,2009-04-30,ELECTRON BEAM STERILIZATION APPARATUS,Improved electron beam sterilization apparatus and shielding techniques for use in are provided. A controller modulates an electron beam when sterilizing an interior to an object to ensure that adequate dose is received. Sterilization carousels are configured with input/discharge feeds to reduce the possibility of humans being exposed to dangerous levels of radiation. The system reduces the amount of shielding required to thereby lower cost of installation.,HITACHI SHIPBUILDING ENG CO;;BUFANO MICHAEL LAWRENCE;;WALTHER STEVEN RAYMOND;;HAYS PETER F;;THOMSON WILLIAM FREDERICK;;SOMMERSTEIN ARTHUR WAYNE;;FRIEDMAN GERALD MARTIN;;FLETCHER P MICHAEL;;INTO STEPHEN WHITTAKER;;TESTONI ANNE;;PHILLIPS BRIAN S,BUFANO MICHAEL LAWRENCE;;WALTHER STEVEN RAYMOND;;HAYS PETER F;;THOMSON WILLIAM FREDERICK;;SOMMERSTEIN ARTHUR WAYNE;;FRIEDMAN GERALD MARTIN;;FLETCHER P MICHAEL;;INTO STEPHEN WHITTAKER;;TESTONI ANNE;;PHILLIPS BRIAN S,,https://lens.org/033-299-538-830-345,Patent Application,yes,4,12,4,10,0,A61L2/087;;A61L2202/14;;A61L2202/23;;B65B55/08;;B67C7/00;;G21K5/02;;B29C49/42405;;A61L2/087;;B65B55/08;;A61L2202/23;;G21K5/02;;A61L2202/14;;B67C7/00,A61L12/06,250/454.11,0,0,,,,ACTIVE
836,DE,D1,DE 3173404 D1,100-088-164-108-945,1986-02-13,1986,DE 3173404 T,1981-11-06,US 20543680 A,1980-11-10,BIOLOGICALLY ACTIVE HETEROBICYCLIC HYDROXIMIDATES AND THIOLHYDROXIMIDATES AND CARBAMATE ESTER DERIVATIVES THEREOF,"Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described. <CHEM> i",SDS BIOTECH CORP,MAGEE THOMAS ALEXANDER;;BATTERSHELL ROBERT DEAN;;LIMPEL LAWRENCE EUGENE;;HO ANDREW WAI-WAH;;FRIEDMAN ARTHUR JAY;;CORKINS HARRY GLENN;;BRAND WILLIAM WAYNE;;BUCHMAN RUSSELL;;STORACE LOUIS;;OSGOOD EDMOND RANDOLPH,"RICERCA, INC., PAINESVILLE, OHIO, US (1987-03-19)",https://lens.org/100-088-164-108-945,Granted Patent,no,0,0,25,29,0,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07F7/0892;;C07F9/2483;;C07F9/6561;;C07D513/00,A01N47/24;;A01N55/00;;A01N57/08;;A61K31/275;;A61K31/34;;A61K31/35;;A61K31/38;;A61K31/385;;A61K31/39;;A61K31/40;;A61K31/415;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/445;;A61K31/495;;A61K31/505;;A61K31/55;;A61K31/665;;A61K31/67;;A61K31/675;;A61K31/695;;C07D/;;C07D209/02;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07D495/18;;C07F7/08;;C07F9/24;;C07F9/6561,,0,0,,,,EXPIRED
837,AT,T1,AT E17244 T1,169-588-073-294-222,1986-01-15,1986,AT 81305272 T,1981-11-06,EP 81305272 A;;US 20543680 A,1980-11-10,"BIOLOGISCH WIRKSAME, HETEROBICYCLISCHE HYDROXIMIDATE UND THIOLHYDROXIMIDATE UND DEREN CARBAMATESTER-DERIVATE.","Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described. <CHEM> i",SDS BIOTECH CORP,MAGEE THOMAS ALEXANDER;;BATTERSHELL ROBERT DEAN;;LIMPEL LAWRENCE EUGENE;;HO ANDREW WAI-WAH;;FRIEDMAN ARTHUR JAY;;CORKINS HARRY GLENN;;BRAND WILLIAM WAYNE;;BUCHMAN RUSSELL;;STORACE LOUIS;;OSGOOD EDMOND RANDOLPH,,https://lens.org/169-588-073-294-222,Granted Patent,no,0,0,25,29,0,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07F7/0892;;C07F9/2483;;C07F9/6561;;C07D513/00,A01N47/24;;A01N55/00;;A01N57/08;;A61K31/275;;A61K31/34;;A61K31/35;;A61K31/38;;A61K31/385;;A61K31/39;;A61K31/40;;A61K31/415;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/445;;A61K31/495;;A61K31/505;;A61K31/55;;A61K31/665;;A61K31/67;;A61K31/675;;A61K31/695;;C07D/;;C07D209/02;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07D495/18;;C07F7/08;;C07F9/24;;C07F9/6561,,0,0,,,,DISCONTINUED
838,EP,B1,EP 0051990 B1,117-869-781-529-111,1986-01-02,1986,EP 81305272 A,1981-11-06,US 20543680 A,1980-11-10,BIOLOGICALLY ACTIVE HETEROBICYCLIC HYDROXIMIDATES AND THIOLHYDROXIMIDATES AND CARBAMATE ESTER DERIVATIVES THEREOF,"Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described. <CHEM> i",SDS BIOTECH CORPORATION,"MAGEE, THOMAS ALEXANDER;;BATTERSHELL, ROBERT DEAN;;LIMPEL, LAWRENCE EUGENE;;HO, ANDREW WAI-WAH;;FRIEDMAN, ARTHUR JAY;;CORKINS, HARRY GLENN;;BRAND, WILLIAM WAYNE;;BUCHMAN, RUSSELL;;STORACE, LOUIS;;OSGOOD, EDMOND RANDOLPH","SDS BIOTECH CORPORATION (1984-07-18);;RICERCA, INC. (1987-08-31);;CESSIONE;RICERCA INC. (1987-01-09);;RICERCA, INC. TE PAINESVILLE, OHIO, VER. ST. V. AM (1987-04-16)",https://lens.org/117-869-781-529-111,Granted Patent,yes,3,0,25,29,0,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07F7/0892;;C07F9/2483;;C07F9/6561;;C07D513/00,A01N47/24;;A01N55/00;;A01N57/08;;A61K31/275;;A61K31/34;;A61K31/35;;A61K31/38;;A61K31/385;;A61K31/39;;A61K31/40;;A61K31/415;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/445;;A61K31/495;;A61K31/505;;A61K31/55;;A61K31/665;;A61K31/67;;A61K31/675;;A61K31/695;;C07D/;;C07D209/02;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07D495/18;;C07F7/08;;C07F9/24;;C07F9/6561,,1,0,,,"Pesticide Biochemistry and Physiology, vol. 6 (1976), page 571 ff",EXPIRED
839,GR,B,GR 76302 B,186-046-610-465-315,1984-08-04,1984,GR 810166468 A,1981-11-09,US 20543680 A,1980-11-10,GR 76302 B,"Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described. <CHEM> i",RICERCA INC,MAGEE THOMAS ALEXANDER;;LAWRENCE ROBERT DEAN BATTERSHE;;LIMPEL EUGENE;;HO ANDREW WAI-WAH;;FRIEDMAN ARTHU JAY;;CORKINS HARRY GLENN;;BRAND WILLIAM WAYNE;;BUCHMAN RUSSELL;;STORAGE LOUIS;;OSGOOD EDMOND RANDOLPH,,https://lens.org/186-046-610-465-315,Granted Patent,no,0,0,25,29,0,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07F7/0892;;C07F9/2483;;C07F9/6561;;C07D513/00,A01N47/24;;A01N55/00;;A01N57/08;;A61K31/275;;A61K31/34;;A61K31/35;;A61K31/38;;A61K31/385;;A61K31/39;;A61K31/40;;A61K31/415;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/445;;A61K31/495;;A61K31/505;;A61K31/55;;A61K31/665;;A61K31/67;;A61K31/675;;A61K31/695;;C07D/;;C07D209/02;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07D495/18;;C07F7/08;;C07F9/24;;C07F9/6561,,0,0,,,,EXPIRED
840,ZA,B,ZA 817720 B,065-810-296-752-511,1982-10-27,1982,ZA 817720 A,1981-11-09,US 20543680 A,1980-11-10,BIOLOGICALLY ACTIVE HETEROBICYCLIC HYDROXIMIDATES AND THIOLHYDROXIMIDATES AND CARBAMATE ESTER DERIVATIVES THEREOF,"Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described. <CHEM> i",DIAMOND SHAMROCK CORP,MAGEE THOMAS ALEXANDER;;BATTERSHELL ROBERT DEAN;;LIMPEL LAWRENCE EUGENE;;WAI WAH HO ANDREW;;FRIEDMAN ARTHUR JAY;;CORKINS HARRY GLEN;;BRAND WILLIAM WAYNE;;BUCHMAN RUSSELL;;STORACE LOUIS;;OSGOOD EDMOND RANDOLPH,,https://lens.org/065-810-296-752-511,Granted Patent,no,0,0,25,29,0,A01N47/24;;A01N55/00;;A01N57/08;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07F7/0892;;C07F9/2483;;C07F9/6561;;C07D513/00,A01N47/24;;A01N55/00;;A01N57/08;;A61K31/275;;A61K31/34;;A61K31/35;;A61K31/38;;A61K31/385;;A61K31/39;;A61K31/40;;A61K31/415;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/445;;A61K31/495;;A61K31/505;;A61K31/55;;A61K31/665;;A61K31/67;;A61K31/675;;A61K31/695;;C07D/;;C07D209/02;;C07D221/22;;C07D311/00;;C07D313/06;;C07D313/20;;C07D335/04;;C07D335/10;;C07D337/06;;C07D495/08;;C07D495/18;;C07F7/08;;C07F9/24;;C07F9/6561,,0,0,,,,EXPIRED
841,WO,A1,WO 2011/011079 A1,046-662-479-580-125,2011-01-27,2011,US 2010/0002071 W,2010-07-22,US 77008310 A;;US 22756609 P,2009-07-22,IMPROVED ELECTRON BEAM STERILIZATION APPARATUS,Improved electron beam sterilization apparatus and shielding techniques for use in are provided. A controller modulates an electron beam when sterilizing an interior to an object to ensure that adequate dose is received. Sterilization carousels are configured with input/discharge feeds to reduce the possibility of humans being exposed to dangerous levels of radiation. The system reduces the amount of shielding required to thereby lower cost of installation.,ADVANCED ELECTRON BEAMS;;BUFANO MICHAEL LAWRENCE;;WALTHER STEVEN RAYMOND;;HAYS PETER F;;THOMSON WILLIAM FREDERICK;;SOMMERSTEIN ARTHUR WAYNE;;FRIEDMAN GERALD MARTIN;;FLETCHER P MICHAEL;;INTO STEPHEN WHITTACKER;;TESTONI ANNE;;EPSTEIN JOSHUA;;PHILLIPS BRIAN,BUFANO MICHAEL LAWRENCE;;WALTHER STEVEN RAYMOND;;HAYS PETER F;;THOMSON WILLIAM FREDERICK;;SOMMERSTEIN ARTHUR WAYNE;;FRIEDMAN GERALD MARTIN;;FLETCHER P MICHAEL;;INTO STEPHEN WHITTACKER;;TESTONI ANNE;;EPSTEIN JOSHUA;;PHILLIPS BRIAN,,https://lens.org/046-662-479-580-125,Patent Application,yes,17,33,2,10,0,A61L2/087;;B65B55/08;;B29C49/42405;;A61L2/087;;B65B55/08,B65B55/08;;A61L2/08;;B67C7/00,,1,1,067-469-770-445-583,10.1046/j.1365-2672.2002.01777.x;;12452949,"CLEGHORN: ""Sterilization of Plastic Containers Using Electron Beam Irradiation Directed through the Opening"", JOURNAL OF APPLIED MICROBIOLOGY, 2002",PENDING
842,WO,A2,WO 2008/005368 A2,110-054-488-865-94X,2008-01-10,2008,US 2007/0015192 W,2007-06-29,US 81826306 P,2006-06-30,PIPERAZINES AS P2X7 ANTAGONISTS,"Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I), wherein the substituents are as defined herein, which are useful as therapeutic agents.",ABBOTT LAB;;BETSCHMANN PATRICK;;CARROLL WILLIAM A;;ERICSSON ANNA M;;FIX-STENZEL SHANNON R;;FRIEDMAN MICHAEL;;HIRST GAVIN C;;JOSEPHSOHN NATHAN S;;LI BIQIN;;PEREZ-MEDRANO ARTURO;;MORYTKO MICHAEL J;;RAFFERTY PAUL;;CHEN HAIPENG,BETSCHMANN PATRICK;;CARROLL WILLIAM A;;ERICSSON ANNA M;;FIX-STENZEL SHANNON R;;FRIEDMAN MICHAEL;;HIRST GAVIN C;;JOSEPHSOHN NATHAN S;;LI BIQIN;;PEREZ-MEDRANO ARTURO;;MORYTKO MICHAEL J;;RAFFERTY PAUL;;CHEN HAIPENG,,https://lens.org/110-054-488-865-94X,Patent Application,yes,0,62,3,3,0,C07D241/04;;C07D241/36;;C07D295/215;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/06;;C07D405/12;;C07D405/14;;C07D409/06;;C07D409/12;;C07D409/14;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D417/04;;C07D417/06;;C07D417/12;;C07D417/14;;C07D471/04;;C07D487/04;;C07D495/04;;C07D498/04;;C07D513/04;;C07D241/04;;C07D495/04;;C07D403/04;;C07D413/12;;C07D405/14;;C07D413/04;;C07D498/04;;C07D241/36;;C07D295/215;;C07D513/04;;C07D405/12;;C07D403/14;;C07D413/14;;C07D409/06;;C07D487/04;;C07D417/12;;C07D471/04;;C07D409/12;;C07D409/14;;C07D401/06;;C07D405/06;;C07D401/12;;C07D403/12;;C07D417/04;;C07D403/06;;C07D413/06;;C07D401/14;;C07D417/06;;C07D417/14,A61K31/496,,0,0,,,,PENDING
843,WO,A3,WO 2008/005368 A3,199-315-143-114-472,2009-02-26,2009,US 2007/0015192 W,2007-06-29,US 81826306 P,2006-06-30,PIPERAZINES AS P2X7 ANTAGONISTS,"Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I), wherein the substituents are as defined herein, which are useful as therapeutic agents.",ABBOTT LAB;;BETSCHMANN PATRICK;;CARROLL WILLIAM A;;ERICSSON ANNA M;;FIX-STENZEL SHANNON R;;FRIEDMAN MICHAEL;;HIRST GAVIN C;;JOSEPHSOHN NATHAN S;;LI BIQIN;;PEREZ-MEDRANO ARTURO;;MORYTKO MICHAEL J;;RAFFERTY PAUL;;CHEN HAIPENG,BETSCHMANN PATRICK;;CARROLL WILLIAM A;;ERICSSON ANNA M;;FIX-STENZEL SHANNON R;;FRIEDMAN MICHAEL;;HIRST GAVIN C;;JOSEPHSOHN NATHAN S;;LI BIQIN;;PEREZ-MEDRANO ARTURO;;MORYTKO MICHAEL J;;RAFFERTY PAUL;;CHEN HAIPENG,,https://lens.org/199-315-143-114-472,Search Report,yes,1,0,3,3,0,C07D241/04;;C07D241/36;;C07D295/215;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/06;;C07D405/12;;C07D405/14;;C07D409/06;;C07D409/12;;C07D409/14;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D417/04;;C07D417/06;;C07D417/12;;C07D417/14;;C07D471/04;;C07D487/04;;C07D495/04;;C07D498/04;;C07D513/04;;C07D241/04;;C07D495/04;;C07D403/04;;C07D413/12;;C07D405/14;;C07D413/04;;C07D498/04;;C07D241/36;;C07D295/215;;C07D513/04;;C07D405/12;;C07D403/14;;C07D413/14;;C07D409/06;;C07D487/04;;C07D417/12;;C07D471/04;;C07D409/12;;C07D409/14;;C07D401/06;;C07D405/06;;C07D401/12;;C07D403/12;;C07D417/04;;C07D403/06;;C07D413/06;;C07D401/14;;C07D417/06;;C07D417/14,C07D401/12;;A61K31/497;;C07D403/12,,0,0,,,,PENDING
844,US,A1,US 2008/0076924 A1,082-278-088-065-408,2008-03-27,2008,US 82444107 A,2007-06-29,US 82444107 A;;US 81826306 P,2006-06-30,Piperazines as P2X7 antagonists,"Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.",BETSCHMANN PATRICK;;CARROLL WILLIAM A;;ERICSSON ANNA M;;FIX-STENZEL SHANNON R;;FRIEDMAN MICHAEL;;HIRST GAVIN C;;JOSEPHSOHN NATHAN S;;LI BIQIN;;PEREZ-MEDRANO ARTURO;;MORYTKO MICHAEL J;;RAFFERTY PAUL;;CHEN HAIPENG,BETSCHMANN PATRICK;;CARROLL WILLIAM A;;ERICSSON ANNA M;;FIX-STENZEL SHANNON R;;FRIEDMAN MICHAEL;;HIRST GAVIN C;;JOSEPHSOHN NATHAN S;;LI BIQIN;;PEREZ-MEDRANO ARTURO;;MORYTKO MICHAEL J;;RAFFERTY PAUL;;CHEN HAIPENG,ABBOTT LABORATORIES (2007-09-27),https://lens.org/082-278-088-065-408,Patent Application,yes,6,13,3,3,0,C07D241/04;;C07D241/36;;C07D295/215;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/06;;C07D405/12;;C07D405/14;;C07D409/06;;C07D409/12;;C07D409/14;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D417/04;;C07D417/06;;C07D417/12;;C07D417/14;;C07D471/04;;C07D487/04;;C07D495/04;;C07D498/04;;C07D513/04;;C07D241/04;;C07D495/04;;C07D403/04;;C07D413/12;;C07D405/14;;C07D413/04;;C07D498/04;;C07D241/36;;C07D295/215;;C07D513/04;;C07D405/12;;C07D403/14;;C07D413/14;;C07D409/06;;C07D487/04;;C07D417/12;;C07D471/04;;C07D409/12;;C07D409/14;;C07D401/06;;C07D405/06;;C07D401/12;;C07D403/12;;C07D417/04;;C07D403/06;;C07D413/06;;C07D401/14;;C07D417/06;;C07D417/14,C07D471/04;;C07D401/00,544/279;;544/363;;544/382,0,0,,,,DISCONTINUED
845,US,A1,US 2003/0228558 A1,147-569-690-459-406,2003-12-11,2003,US 16682002 A,2002-06-11,US 16682002 A,2002-06-11,Method of training brokers in a multi-level marketing business,"
   A method of training brokers in a multi-level marketing business to make sales of a product and to recruit new brokers includes the steps of presenting materials to train brokers on order form procedures. The order form procedures include collecting identification information and payment information. The method also includes presenting materials to train brokers on recruiting form procedures. The recruiting form procedures include collecting identification information, payment information, and the selection of sales packages. The method also includes presenting materials to train brokers on sales procedures. The sales procedures include the steps of listing prospects, approach prospects, provide a sales presentation, enroll members and brokers, and continually repeat the sales procedure. 
",BLOOM WILLIAM DENNIS;;BLOOM DANIEL FLYNN;;HAMMACK JOHN ASA;;FRIEDMAN BARRY;;AARON DEBRA WIMBERLEY;;BROOKS DALE IRWIN;;DIXON MARK DOUGLAS;;GOODWIN BRENT ALLEN;;GUEITS CARLOS FERNANDO;;HARDIN JAMES EDWARD;;JARVIS MARK LEWIS;;KRANK EUGENE MARVIN;;LANCTO MICHAEL ARTHUR;;MCDONALD JOHN MICHAEL;;MURRAY BRADLEY SCOTT;;ROWDEN LINDA GAYE;;SOUTHERLAND JOHN ALEXANDER;;WRIGHT WILLIAM KIRBY;;WILSON TODD WILLIAM;;WILSON TERRENCE VAN,BLOOM WILLIAM DENNIS;;BLOOM DANIEL FLYNN;;HAMMACK JOHN ASA;;FRIEDMAN BARRY;;AARON DEBRA WIMBERLEY;;BROOKS DALE IRWIN;;DIXON MARK DOUGLAS;;GOODWIN BRENT ALLEN;;GUEITS CARLOS FERNANDO;;HARDIN JAMES EDWARD;;JARVIS MARK LEWIS;;KRANK EUGENE MARVIN;;LANCTO MICHAEL ARTHUR;;MCDONALD JOHN MICHAEL;;MURRAY BRADLEY SCOTT;;ROWDEN LINDA GAYE;;SOUTHERLAND JOHN ALEXANDER;;WRIGHT WILLIAM KIRBY;;WILSON TODD WILLIAM;;WILSON TERRENCE VAN,,https://lens.org/147-569-690-459-406,Patent Application,yes,13,4,1,1,0,G09B19/18;;G09B19/18,G09B19/18,434/107;;434/219;;434/362;;434/365,0,0,,,,DISCONTINUED
846,US,A1,US 2002/0052859 A1,070-588-026-660-795,2002-05-02,2002,US 21894598 A,1998-12-22,US 21894598 A,1998-12-22,"SYSTEM, METHOD AND ARTICLE OF MANUFACTURE FOR A GOAL BASED SYSTEM UTILIZING A TABLE BASED ARCHITECTURE","
   A system is disclosed that provides a goal based learning system utilizing a rule based expert training system to provide a cognitive educational experience. The system provides the user with a simulated environment that presents a business opportunity to understand and solve optimally. Mistakes are noted and remedial educational material presented dynamically to build the necessary skills that a user requires for success in the business endeavor. The system utilizes an artificial intelligence engine driving individualized and dynamic feedback with synchronized video and graphics used to simulate real-world environment and interactions. Multiple correct answers are integrated into the learning system to allow individualized learning experiences in which navigation through the system is at a pace controlled by the learner. A robust business model provides support for realistic activities and allows a user to experience real world consequences for their actions and decisions and entails realtime decision-making and synthesis of the educational material. The system is architected around a table of components to manage and control the system. 
",ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;O'CONNOR MARTHA TORREY;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;ZORBA ALEXANDER;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI DETORO;;BAILEY MATTHEW ALLEN,ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;O'CONNOR MARTHA TORREY;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI DETORO;;BAILEY MATTHEW ALLEN,INDELIQ INC (2001-04-07);;ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE LLP (2001-01-02);;ACCENTURE PROPERTIES (2) B.V (2000-12-04);;ACCENTURE GLOBAL SERVICES GMBH (2003-12-18);;ACCENTURE (2001-01-02),https://lens.org/070-588-026-660-795,Patent Application,yes,0,17,10,10,0,G09B7/04;;G09B7/04,G06F40/00;;G09B7/04,706/47,0,0,,,,EXPIRED
847,US,B2,US 11416136 B2,074-954-460-967-549,2022-08-16,2022,US 202117167896 A,2021-02-04,US 202117167896 A;;US 202063078125 P,2020-09-14,User interfaces for assigning and responding to user inputs,"The present disclosure generally relates to assigning tasks to various user inputs, and detecting and responding to user inputs. In some embodiments, the present disclosure relates to assigning tasks to various user inputs received on a back surface of a device, and detecting and responding to user inputs on the back surface of the device.",APPLE INC,NEFULDA JOHN M;;AVERY KEITH P;;CHINTHAKUNTA MADHU;;FLEIZACH CHRISTOPHER B;;MAUDGALYA VARUN;;PANAGE SOMMER E;;YAN XINYI;;WEINBERG GARRETT L;;WEGRZYNSKI MICHAL K;;CARUSO WILLIAM;;FRIEDMAN KENNETH S;;DHANANI JAMIL;;SHAFIQ MUHAMMAD AMIR;;JEONG MINWOO;;PAEK TIMOTHY S;;LE VIET HUY;;NIETO HERIBERTO;;WESTING BRANDT M;;YADAV RISHABH,APPLE INC (2022-05-16),https://lens.org/074-954-460-967-549,Granted Patent,yes,123,0,2,2,0,H04M2250/22;;H04M1/72403;;G06F1/1626;;G06F2200/1636;;G06F3/0482;;G06F3/04847;;H04M1/72466;;H04M2201/42;;G06F3/0482;;G06F3/016,G06F3/048;;G06F3/01;;G06F3/0482;;G06F3/04847;;H04M1/72466,,53,0,,,"Notice of Allowance received for U.S. Appl. No. 16/245,140, dated Jul. 30, 2021, 8 pages.;;Notice of Allowance received for U.S. Appl. No. 16/245,140, dated May 18, 2021, 14 pages.;;Applicant-initiated Interview Summary received for U.S. Appl. No. 16/245,140, dated Apr. 2, 2021, 4 pages.;;Applicant-Initiated Interview Summary received for U.S. Appl. No. 16/245,140, dated Feb. 1, 2021, 4 pages.;;Anonymous, “Swipe to Edit Using BetterTouchTool: Mac Automation Tips”, Mac Automation Tips, XP55217837, retrieved from the Internet: URL: https://macautomationtips.wordpress.com/2011/03/11/swipe-to-edit-using-bettertouchtool/, Mar. 11, 2011, 1 page.;;Applicant-Initiated Interview Summary received for U.S. Appl. No. 16/245,140, dated Sep. 16, 2020, 6 pages.;;Chavda Prekesh, “Swipe to Edit”, Dribbble, XP55217832, Retrieved from the Internet: URL: https://dribbble.comjshots/1320750-Swipe-to-Edit-animation, Nov. 21, 2013, 7 Pages.;;Decision to Grant received for European Patent Application No. 15716372.6, dated Aug. 16, 2019, 2 pages.;;Decision to Refuse received for European Patent Application No. 11733962.2, dated Sep. 30, 2016, 20 Pages.;;Final Office Action Received for U.S. Appl. No. 14/502,711, dated Sep. 22, 2017, 27 pages.;;Final Office Action received for U.S. Appl. No. 12/832,900, dated Nov. 9, 2012, 13 pages.;;Final Office Action received for U.S. Appl. No. 14/502,711, dated Apr. 12, 2017, 29 pages.;;Final Office Action Received for U.S. Appl. No. 14/503,147, dated Jun. 15, 2017, 18 Pages.;;Final Office Action received for U.S. Appl. No. 16/245,140, dated Feb. 11, 2021, 23 pages.;;Intention to Grant received for European Patent Application No. 15716372.6, dated Apr. 3, 2019, 7 pages.;;International Preliminary Report on Patentability Received for PCT Application No. PCT/US2015/023946, dated Dec. 15, 2016, 17 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2011/043302, dated Jan. 17, 2013, 8 pages.;;International Search Report and Written Opinion Received for PCT Application No. PCT/US2015/023946, dated Oct. 12, 2015, 22 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2011/043302, dated Dec. 15, 2011, 10 pages.;;Minutes of the oral proceedings received for European Patent Application No. 15716372.6, dated Mar. 29, 2019, 9 pages.;;Minutes of the Oral Proceedings received for European Patent Application No. 15716372.6, dated Feb. 21, 2019, 6 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/502,711, dated Apr. 26, 2018, 21 pages.;;Non-Final Office Action Received for U.S. Appl. No. 14/503,147, dated Nov. 2, 2016, 21 pages.;;Non-Final Office Action Received for U.S. Appl. No. 14/502,711, dated Nov. 21, 2016, 23 pages.;;Non-Final Office Action received for U.S. Appl. No. 12/832,900, dated Aug. 29, 2013, 11 pages.;;Non-Final Office Action received for U.S. Appl. No. 12/832,900, dated Jul. 20, 2012, 16 pages.;;Non-Final Office Action received for U.S. Appl. No. 12/832,900, dated Mar. 17, 2014, 12 pages.;;Non-Final Office Action received for U.S. Appl. No. 16/245,140, dated Jun. 2, 2020, 23 pages.;;Non-Final Office Action received for U.S. Appl. No. 16/245,140, dated Oct. 30, 2020, 20 pages.;;Notice of Acceptance received for Australian Patent Application No. 2011274519, dated Jul. 8, 2015, 2 pages.;;Notice of Allowance received for Japanese Patent Application No. 2013-518852, dated Nov. 17, 2014, 3 pages (Official Copy only) (See Communication under 37 CFR § 1.98(a) (3)).;;Notice of Allowance received for Korean Patent Application No. 10-2013-7003037, dated Jul. 14, 2015, 3 pages (1 page of English Translation and 2 pages of Official Copy).;;Notice of Allowance received for U.S. Appl. No. 12/832,900, dated Dec. 4, 2014, 2 pages.;;Notice of Allowance received for U.S. Appl. No. 12/832,900, dated Jan. 17, 2014, 7 pages.;;Notice of Allowance received for U.S. Appl. No. 12/832,900, dated Oct. 24, 2014, 10 pages.;;Notice of Allowance received for U.S. Appl. No. 14/502,711, dated Sep. 28, 2018, 9 pages.;;Notice of Allowance received for U.S. Appl. No. 14/503,147, dated Jan. 28, 2019, 7 pages.;;Notice of Allowance received for U.S. Appl. No. 14/503,147, dated Sep. 12, 2018, 7 pages.;;Notice to Grant received for Chinese Patent Application No. 201180039041.6, dated Dec. 27, 2016, 4 pages (2 pages of English Translation and 2 pages Official Copy).;;Office Action received for Australian Patent Application No. 2011274519, dated Jan. 13, 2015, 3 pages.;;Office Action received for Australian Patent Application No. 2011274519, dated May 12, 2015, 3 pages.;;Office Action received for Australian Patent Application No. 2011274519, dated Oct. 17, 2013, 3 pages.;;Office Action received for Chinese Patent Application No. 201180039041.6, dated Aug. 5, 2016, 4 pages (1 pages of English Translation and 3 pages of Official Copy).;;Office Action received for Chinese Patent Application No. 201180039041.6, dated Jan. 18, 2016, 20 pages (10 pages of English Translation and 10 pages of Official copy).;;Office Action received for Chinese Patent Application No. 201180039041.6, dated Mar. 2, 2015, 18 pages (10 pages of English Translation and 8 pages of Official copy).;;Office Action received for European Patent Application No. 11733962.2 dated Dec. 9, 2015, 7 pages.;;Office Action received for European Patent Application No. 11733962.2, dated Jan. 22, 2014, 4 pages.;;Office Action received for European Patent Application No. 15716372.6, dated Nov. 15, 2017, 8 pages.;;Office Action received for Japanese Patent Application No. 2013-518852, dated Feb. 10, 2014, 3 pages (Official Copy only) (See Communication under 37 CFR § 1.98(a) (3)).;;Office Action received for Korean Patent Application No. 10-2013-7003037, dated Jan. 22, 2014, 4 pages (Official Copy only) (See Communication under 37 CFR § 1.98(a) (3)).;;Office Action received for Korean Patent Application No. 10-2013-7003037, dated Oct. 23, 2014, 7 pages (3 pages of English Translation and 4 pages of Official Copy).;;Summons to Attend Oral Proceeding received for European Patent Application No. 11733962.2, dated Apr. 13, 2016, 8 pages.;;Summons to Attend Oral Proceedings received for European Patent Application No. 15716372.6, dated Jul. 13, 2018, 9 pages.",ACTIVE
848,EP,A1,EP 1141925 A1,073-295-778-423-75X,2001-10-10,2001,EP 99906826 A,1999-02-08,US 9902737 W;;US 21894598 A,1998-12-22,"A SYSTEM, METHOD AND ARTICLE OF MANUFACTURE FOR A GOAL BASED SYSTEM UTILIZING A TABLE BASED ARCHITECTURE",,ACCENTURE PROPERTIES 2 B V,ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;O'CONNOR MARTHA TORREY;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;PUCCIO CARL MICHAEL;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI ADETORO;;BAILEY MATTHEW ALLEN,"ACCENTURE GLOBAL SERVICES LIMITED (2011-04-20);;INDELIQ, INC. (2002-01-16);;ACCENTURE GLOBAL SERVICES GMBH (2010-04-21)",https://lens.org/073-295-778-423-75X,Patent Application,yes,0,0,10,10,0,G09B7/04;;G09B7/04,G06F40/00;;G09B7/04,,0,0,,,,DISCONTINUED
849,AU,A,AU 1999/026648 A,094-462-120-989-500,2000-07-12,2000,AU 1999/026648 A,1999-02-08,US 21894598 A;;US 9902737 W,1998-12-22,"A system, method and article of manufacture for a goal based system utilizing a table based architecture",,ACCENTURE PROPERTIES 2 BV,ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;O'CONNOR MARTHA TORREY;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;PUCCIO CARL MICHAEL;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI ADETORO;;BAILEY MATTHEW ALLEN,,https://lens.org/094-462-120-989-500,Patent Application,no,0,0,10,10,0,G09B7/04;;G09B7/04,G06F40/00;;G09B7/04,,0,0,,,,DISCONTINUED
850,US,B2,US 8429112 B2,140-513-877-571-919,2013-04-23,2013,US 27494308 A,2008-11-20,US 27494308 A;;US 86869501 A;;US 9902737 W;;US 21894598 A,1998-12-22,Goal based system utilizing a table based architecture,A system is disclosed that provides a goal based learning system utilizing a rule based expert training system to provide a cognitive educational experience. The system provides the user with a simulated environment that presents a business opportunity to understand and solve optimally. Mistakes are noted and remedial educational material presented dynamically to build the necessary skills that a user requires for success in the business endeavor. The system utilizes an artificial intelligence engine driving individualized and dynamic feedback with synchronized video and graphics used to simulate real-world environment and interactions. A robust business model provides support for realistic activities and allows a user to experience real world consequences for their actions and decisions and entails realtime decision-making and synthesis of the educational material. The system is architectured around a table of components to manage and control the system.,ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;O'CONNOR MARTHA TORREY;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;PUCCIO CARL MICHAEL;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI DETORO;;BAILEY MATTHEW ALLEN;;ACCENTURE GLOBAL SERVICES LTD,ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;O'CONNOR MARTHA TORREY;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;PUCCIO CARL MICHAEL;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI DETORO;;BAILEY MATTHEW ALLEN,AC PROPERTIES B.V (1998-12-18);;INDELIQ INC (2001-04-07);;ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE LLP (2001-01-02);;ACCENTURE GLOBAL SERVICES GMBH (2003-12-18),https://lens.org/140-513-877-571-919,Granted Patent,yes,103,4,10,10,0,G09B7/04;;G09B7/04,G06F40/00;;G06F17/00;;G06N5/02;;G09B7/00;;G09B7/04,706/46;;706/927;;434/327,99,16,018-421-217-047-918;;094-529-698-788-987;;176-660-309-549-568;;036-063-077-806-024;;000-937-240-855-327;;041-823-310-510-538;;177-674-712-209-639;;070-623-900-555-766;;044-287-884-972-160;;015-458-659-063-333;;063-469-437-501-064;;063-469-437-501-064;;000-937-240-855-327;;015-458-659-063-333;;048-588-948-033-969;;008-360-153-772-58X,10.1109/2.56;;10.1109/2.58216;;10.1109/24.376522;;10.1109/icips.1997.669112;;10.1109/21.293505;;10.1109/tai.1994.346422;;10.1109/wsc.1994.717537;;10.1109/wsc.1995.479050;;10.1145/256562.256784;;10.1049/ic:19980560;;10.1016/s0090-2616(96)90012-1;;10.1016/s0090-2616(96)90012-1;;10.1109/21.293505;;10.1049/ic:19980560;;10.1002/j.1099-1174.1995.tb00090.x;;10.1080/07421222.1997.11518177,"Kingma; PCT/US99/02654, PCT International Search Report; Oct. 18, 1999 int'l search completion, Nov. 3, 1999 Int'l search report mailed.;;Rand Corporation Books and Publications; http://www.rand.org/pubs/drafts/DRU472; 1 page with 13 related pages, Jul. 2005 and Dec. 2005.;;""Automate Your Business Plan"" at http://www.business-plan.com/automate.html, pp. 1-4, Jul. 2001.;;""Brainmaker"" at http://people.becon.org/~echoscan/28-04.htm, 1 page, Jul. 2001.;;Non-Final Office Action Mail Date Apr. 9, 2004; U.S. Appl. No. 09/868,669.;;Final Office Action Mail Date Sep. 30, 2004; U.S. Appl. No. 09/868,669.;;Non-Final Office Action Mail Date Mar. 15, 2005; U.S. Appl. No. 09/868,669.;;Final Office Action Mail Date Feb. 22, 2006; U.S. Appl. No. 09/868,669.;;Advisory Action Mail Date Jul. 18, 2007; U.S. Appl. No. 09/868,664.;;Interview Summary Mail Date Feb. 12, 2007; U.S. Appl. No. 09/868,664.;;Interview Summary Mail Date Oct. 9, 2008; U.S. Appl. No. 09/868,664.;;Interview Summary Mail Date Feb. 23, 2009; U.S. Appl. No. 09/868,664.;;Interview Summary Mail Date Jul. 2, 2009; U.S. Appl. No. 09/868,664.;;Notice of Allowance Date Mailed Oct. 20, 2009; U.S. Appl. No. 09/868,664.;;Non-Final Office Action Mail Date Mar. 9, 2004; U.S. Appl. No. 09/868,664.;;Final Office Action Mail Date Oct. 6, 2004; U.S. Appl. No. 09/868,664.;;Non-Final Office Action Mail Date Mar. 15, 2005; U.S. Appl. No. 09/868,664.;;Non-Final Office Action Mail Date Jan. 10, 2006; U.S. Appl. No. 09/868,664.;;Final Office Action Mail Date May 31, 2006; U.S. Appl. No. 09/868,664.;;Non-Final Office Action Mail Date Oct. 25, 2006; U.S. Appl. No. 09/868,664.;;Final Office Action Mail Date May 11, 2007; U.S. Appl. No. 09/868,664.;;Non-Final Office Action Mail Date Nov. 26, 2007; U.S. Appl. No. 09/868,664.;;Final Office Action Mail Date Apr. 18, 2008; U.S. Appl. No. 09/868,664.;;Non-Final Office Action Mail Date Sep. 12, 2008; U.S. Appl. No. 09/868,664.;;Final Office Action Mail Date Dec. 15, 2008; U.S. Appl. No. 09/868,664.;;Non-Final Office Action Mail Date Mar. 23, 2009; U.S. Appl. No. 09/868,664.;;Automate Your Business Plan-financial statement ratio analysis screen capture [online]. Automate Your Business Plan, 1999 [retrieved on Aug. 9, 1999]. Retrieved from the Internet: , 1 page.;;Useful Software [online]. University of Maryland, Baltimore County, 1999 [retrieved on Aug. 9, 1999]. Retrieved from the Internet: , 1 page.;;Simonini, Dolezel; PCT/US99/02654 International Preliminary Examination Report; Jul. 24, 2000 demand submission date, Mar. 23, 2001 report completion date.;;Brown; Exploring algorithms using Balsa-II; Computer; vol. 21, Is. 5; May 1988; pp. 14-36.;;Stasko; Tango: a framework and system for algorithm animation; Computer; vol. 23, Is. 9; Sep. 1990; pp. 27-39.;;Joshi et al; A Framework for the Optimization of Discrete-Event Simulation Models; 17th American Society for Engineering Management National Conference; Oct. 10-12, 1996; 6 pages.;;Chen et al; A reliability model for real-time rule-based expert systems; IEEE Transactions on Reliability; vol. 44, Is. 1; Mar. 1995; pp. 54-62.;;Ando et al; Rules for describing multi-attribute information and its efficient pattern matching; IEEE International Conference on Intelligent Processing Systems; vol. 2; Oct. 28-31, 1997; pp. 953-957.;;""ACM Transactions on Information Systems,"" 1988 at www.acm.org/pubs/toc/Abstracts/tois/59298.html.;;N.D. Livergood, ""From Computer-Assisted Instruction to Intelligent Tutoring Systems,"" J.O Artificial Intelligence in Education, vol. 2(3), pp. 39-50 Dec. 1997.;;J. Reye, ""A Goal-Centered Architecture for Intelligent Tutoring Systems,"" Proc. Of 7.sup.th World Conf. On Artificial Intelligence in Education, pp. 307-314 Aug. 1995.;;A.J. Gonzalez and L.R. Ingraham, ""Automated Exercise Progression in simulation-Based Training,"" IEEE Trans. On Systems, Man and Cybernetics, vol. 24(6), pp. 863-874 Jun. 1994.;;R.H. Kemp and S.P. Smith, ""Using Planning Techniques to Provide Feedback in Interactive Learning Environments,"" Proc. Sixth Int'l Conf On Tools with Artificial Intelligence, pp. 700-703 Nov. 1994.;;J. Siemer and M.C. Angelides, ""Embedding an Intelligent Tutoring System in a Business Gaming-Simulation Environment,"" Proc. Of the 1994 Winter simulation Conference, pp. 1399-1406 Dec. 1994.;;V.J. Shute ""Smart Evaluation: Cognitive Diagnosis, Mastery Learning & Remediation,"" Proc. Of 7.sup.th World Conf. On Artificial Intelligence in Education, pp. 123-130 Aug. 1995.;;J. Siemer and M.C. Angelides, ""Evaluating Intelligent Tutoring with Gaming-Simulations,"" Proc. Of the 1995 Winter Simulation Conf., pp. 1376-1383 Dec. 1995.;;P. Busilovsky, et al., ""Distributed Intelligent Tutoring on the Web,"" Proc. Of 1997 World Conf. On Artifiical Intelligence in Education, pp. 482-489 Dec. 1997.;;S.J.E. Taylor and J. Siemer, Enhancing Simulation Education with Intelligent Tutoring Systems, Proc. Of the 1996 Winter Simulation Conf., pp. 675-680 Dec. 1996.;;K. Nakabayashi, et al., ""Architecture of an Intelligent Tutoring System on the WWW,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 39-46 Dec. 1997.;;W. Van Joolingen, et al., ""The SimQuest Authoring System for Simulation-Based Discovery Learning,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 79-86 Dec. 1997.;;M. Papagni, et al., ""Teaching through Case-Based Reasoning: An ITS Engine Applied to Business Communication,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 111-118 Dec. 1997.;;R. Azevedo, et al., ""RadTutor: The Theoretical and Empirical Basis for the Design of a mammography Intrepretation Tutor,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 386-393, Dec. 1997.;;R.H. Kemp, ""Using the Wizard of Oz Technique to Prototype a Scenario-Based simulation Tutor,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 458-465 Dec. 1997.;;C.D. Robinson, et al., ""Briding the Virtual and the Physical: The InterSim as a Collaborative Support Interface,"" Proc of 1997 World Conf. On Artificial Intelligence in Education, pp. 556-558 Dec. 1997.;;K. Itoh, et al., ""An Object-Oriented Architecture for Evolutional Development of Interactive Learning Environment with Coached Problem-Solving,"" Proc. Of 1997 World Conf. On artificial Intelligence in Education, pp. 592-594 Dec. 1997.;;B.T. Cheok and A.Y.C. Nee, ""Developing a Design Systen into an Intelligent Tutoring System,"" Intl. J. Engr. Eud., vol. 13(5), pp. 341-346 Dec. 1997.;;J. Breuker, ""What are Intelligent Coaching Systems and Why are They (in)evitable?"" IEE Colloquium on Artificial Intelligence in Educational Software, pp. 2/1-2/5 Jun. 1998.;;J.S. Brown, et al., ""Pedagogical, natural language and knowledge engineering techniques in Sophie I, II and III,"" in Intelligent Tutoring Systems, D. Sleeman and J.S. Brown eds., pp. 227-282 Dec. 1982.;;""Microworlds and Simuworlds: Practice Fields for the Learning Organization,"" Spring 1996, Organizational Dynamics vol. 24, No. 4, pp. 36-49.;;Mark L. Lengnick-Hall, Virtual learning: A Revolutinary Approach to Building a Highly Skilled Workforce, Autumn 1998, Personnel Psychology vol. 51, No. 3, pp. 767-771.;;J. Bernard Keys, Robert M. Fulmer, Stephen A Stumpf, Microworlds and simuworlds: Practice field for the learning organization, Spring 1996, Organizational Dynamics vol. 24, No. 4, pp. 36-49.;;""Automated Exercise Progression in Simulation-Based Training,"" IEEE Trans. On Systems, Man, and Cybernetics, vol. 24(6), pp. 863-874, Jun. 1994.;;""What are Intelligent Coaching Systems and Why are they (in)evitable?"" IEEE Colloquium on Artificial Intelligence in Educational Software, pp. 211-215, Jun. 1998.;;""A Special Section-Goal Based Scenarios: A New Approach to Professional Education: Reengineering Education at Andersen Consulting,"" Educational Technology, Nov.-Dec. 1994.;;""Goal-Based Scenarios and the Problem of Situated Learning: a Commentary on Andersen Consulting's Design of Goal-Based Scenarios,"" Educational Technology, Nov.-Dec. 1994.;;""Development of an Integrated Simulator and Real Time Plant Information System,"" Advances in Operational Safety of Nuclear Power Plants, Proceedings of an International Symposium 1996.;;""The Virtual Learning Environment System,"" 28th Annual Frontiers in Education Conference, Conference Proceedings, vol. 2, No. 4-7, 1988.;;""Developing a Design System into an Intelligent Tutoring System,"" Int'l J. Engr. Eud., vol. 13(5), pp. 341-346, Dec. 1997.;;""Bridging the Virtual and the Physical: The InterSim as A Collaborative Support Interface,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 556-558, Dec. 1997.;;""Task-Oriented Learning on the Web""; Innovations in Education and Training International, vol. 36, No. 1, Feb. 1999.;;""Interactive Multimedia Instructs the Individual,"" Oct. 1994, Occupational Health & Safety vol. 63, No. 10, pp. 144-145.;;""Popular Theory Supporting the Use of Computer Simulation for Experiential Learning,"" http://www.centurionsys.com/rtcl57.html, Aug. 1997.;;""FRA: Teaching Financial Accounting with a Goal-Based Scenario,"" Intelligent Systems, in Accounting, Finance and Management, vol. 4, 1995.;;""Learning with Computers,"" May 1994, Accountancy vol. 113, No. 1209, pp. 60-64.;;""User-Sensitive Multimedia Presentation System,"" Mar. 1, 1996, vol. 39, No. 3, pp. 93-94.;;Template Software Workflow Simulator, Chapter 8, Jun. 1998.;;""Goal-Based Scenarios"", Technical Report #36, Northwestern University, The Institute for the Learning Sciences, Dec. 1992, pp. 1-30.;;""Eight Goal-Based Scenario Tools"", Technical Report #67, Northwestern University, The Institute for the Learning Sciences, Jan. 1996, pp. 1-37.;;""A Role for AI in Education: Using Technology to Reshape Education"", Northwestern University, The Institute for the Learning Science, Journal of Artificial Intelleigence in Education, Winter 1990, Jan. 1990, pp. 1-24 and 2 pgs. of references.;;""The Design of Goal-Based Scenarios"", Technical Report #39, Northwestern University, The Institute for the Learning Sciences, Mar. 1993, pp. 1-58.;;George Cole, Learning with Computers, May 1994, Accountancy vol. 113, No. 1209, pp. 60-64.;;Tony Burns, Multimedia training ""Get lemonade, not a lemon!"", Jun. 1997, Journal for Quality and Participation vol. 20, No. 3, pp. 22-26.;;Lin grensing-Pophal, Flexible learning, Feb. 1998, Credit Union Management vol. 21, No. 2, pp. 32-33+.;;Charles W. Calmbacher, Interactive multimedia instructs the individual, Oct. 1994, Occupational Health & Safety vol. 63, No. 10, pp. 144-145.;;Jean Francios Manzoni, Albert A. Angehrn. Understanding organizational dynamics of IT-enabled change: A multipedia simulation approach, Winter 1997/1998, Journal of Management Information Systems: JMIS, vol. 14, No. 3, pp. 109-140.;;Marianne Kolbasuk Mcgee, train with less pain, Oct. 13, 1997, Informationweek No. 652, pp. 150-154.;;Engines for Education: URL:http:www.ils.nwu.edu/.about.e-for-e/nodes/I-M-INTRO-ZOOMER-pg.html; Viewed Feb. 15, 1999; Roger Schank; Website claims 1994 copyright.;;Socialized Collaborative Learning in Multimedia Virtual Worlds, Learning Environments, National University of Singppore: ULR:http://www.iscs.nus.edu.sg/labs/learning/lels/VRML.html: Viewed Feb. 16, 1999.;;""A Goal-Centered in JackMOO,"" Proceedings of the 1999 IEEE Conference on Virtual Reality, pp. 156-163.;;""A Goal-Centered Arhitecture for Intelligent Tutoring Systems,"" Proc. Of 7th World Conf. On Artificial Intelligence in Education, pp. 307-314, Aug. 1995.;;""Embedding an Intelligent Tutoring System in a Business Gaming-Simulation Environment,"" Proc. Of the 1994 Winter Simulation Conference, pp. 1399-1406, Dec. 1994.;;""Evaluating Intelligent Tutoring with Gaming Simulations,"" Proc. Of the 1995 Winter Simulation Conf., pp. 1376-1383, Dec. 1995.;;""Persistent Issues in the Application of Virtual Environment Systems to Training,"" Aug. 1996, Proceedings. Third Annual Symposium on Human Interaction with Complex Systems, IEEE, pp. 124-132.;;""The Lisp Tutor,"" pp. 159-175, Apr. 1985.;;""Pedagogical, natural language and knowledge engineering techniques in Sophie I, II, and III,"" in Intelligent Tutoring Systems, D. Sleeman & J.S. Brown eds., pp. 227-282, Dec. 1982.;;Interactive Multimedia Distance Learning (IMDL): The Prototype of the Virtual Classroom, 1994.;;""Understanding Organizational Dynamics of IT-Enabled Change: A Multipedia Simulation Approach,"" Winter 1997/1998, Journal of Mangement Information Systems: JMIS, vol. 14, No. 3, pp. 109-140.;;""Intelligent Computer-Aided Instruction: A Survey Organized Around System Components,"" Jan. 1989, IEEE Inc., New York, vol. 49, No. 1, pp. 40-57.;;""Conducting and Supporting a Goal-Based Scenario Learning Environment,"" Educational Technology, Nov.-Dec. 1994.;;""An Object-Oriented Architecture for Evolutional Development of Interactive Learning Environment with Coached Problem-Solving,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 592-594, Dec. 1997.;;""Architecture of an Intelligent Tutoring System on the WWW,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 39-46 Dec. 1997.;;""Socialized Collaborative Learning in Multimedia Virtual Worlds"" URL: http://www.iscs.nus.edu.sg/labs/learning/lels/VRML.html; viewed Feb. 16, 1999.;;Flexible Learning, Feb. 1998, Credit Union Management vol. 21, No. 2, pp. 32-33+.",EXPIRED
851,US,A9,US 2012/0003613 A9,172-708-661-206-964,2012-01-05,2012,US 27494308 A,2008-11-20,US 27494308 A;;US 86869501 A;;US 9902737 W;;US 21894598 A,1998-12-22,Goal Based System Utilizing a Table Based Architecture,A system is disclosed that provides a goal based learning system utilizing a rule based expert training system to provide a cognitive educational experience. The system provides the user with a simulated environment that presents a business opportunity to understand and solve optimally. Mistakes are noted and remedial educational material presented dynamically to build the necessary skills that a user requires for success in the business endeavor. The system utilizes an artificial intelligence engine driving individualized and dynamic feedback with synchronized video and graphics used to simulate real-world environment and interactions. A robust business model provides support for realistic activities and allows a user to experience real world consequences for their actions and decisions and entails realtime decision-making and synthesis of the educational material. The system is architectured around a table of components to manage and control the system.,ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;O'CONNOR MARTHA TORREY;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;PUCCIO CARL MICHAEL;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI DETORO;;BAILEY MATTHEW ALLEN;;ACCENTURE GLOBAL SERVICES GMBH,ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;O'CONNOR MARTHA TORREY;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;PUCCIO CARL MICHAEL;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI DETORO;;BAILEY MATTHEW ALLEN,AC PROPERTIES B.V (1998-12-18);;INDELIQ INC (2001-04-07);;ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE LLP (2001-01-02);;ACCENTURE GLOBAL SERVICES GMBH (2003-12-18),https://lens.org/172-708-661-206-964,Amended Application,yes,0,0,10,10,0,G09B7/04;;G09B7/04,G09B19/00;;G06F17/00;;G06F40/00;;G06N5/02;;G09B7/00;;G09B7/04,434/107;;706/47;;706/11;;434/323,0,0,,,,EXPIRED
852,US,A1,US 2009/0142736 A1,028-127-967-472-943,2009-06-04,2009,US 27494308 A,2008-11-20,US 27494308 A;;US 86869501 A;;US 9902737 W;;US 21894598 A,1998-12-22,Goal Based System Utilizing a Table Based Architecture,A system is disclosed that provides a goal based learning system utilizing a rule based expert training system to provide a cognitive educational experience. The system provides the user with a simulated environment that presents a business opportunity to understand and solve optimally. Mistakes are noted and remedial educational material presented dynamically to build the necessary skills that a user requires for success in the business endeavor. The system utilizes an artificial intelligence engine driving individualized and dynamic feedback with synchronized video and graphics used to simulate real-world environment and interactions. A robust business model provides support for realistic activities and allows a user to experience real world consequences for their actions and decisions and entails realtime decision-making and synthesis of the educational material. The system is architectured around a table of components to manage and control the system.,ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;O'CONNOR MARTHA TORREY;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;PUCCIO CARL MICHAEL;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI DETORO;;BAILEY MATTHEW ALLEN,ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;O'CONNOR MARTHA TORREY;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;PUCCIO CARL MICHAEL;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI DETORO;;BAILEY MATTHEW ALLEN,,https://lens.org/028-127-967-472-943,Patent Application,yes,99,2,10,10,0,G09B7/04;;G09B7/04,G09B19/00;;G06F17/00;;G06F40/00;;G06N5/02;;G09B7/00;;G09B7/04,434/107;;706/47;;706/11;;434/323,0,0,,,,EXPIRED
853,US,B2,US 6542880 B2,156-718-954-819-966,2003-04-01,2003,US 21894598 A,1998-12-22,US 21894598 A,1998-12-22,"System, method and article of manufacture for a goal based system utilizing a table based architecture","
    A system is disclosed that provides a goal based learning system utilizing a rule based expert training system to provide a cognitive educational experience. The system provides the user with a simulated environment that presents a business opportunity to understand and solve optimally. Mistakes are noted and remedial educational material presented dynamically to build the necessary skills that a user requires for success in the business endeavor. The system utilizes an artificial intelligence engine driving individualized and dynamic feedback with synchronized video and graphics used to simulate real-world environment and interactions. Multiple correct answers are integrated into the learning system to allow individualized learning experiences in which navigation through the system is at a pace controlled by the learner. A robust business model provides support for realistic activities and allows a user to experience real world consequences for their actions and decisions and entails realtime decision-making and synthesis of the educational material. The system is architected around a table of components to manage and control the system. 
",INDELIQ INC,ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;O'CONNOR MARTHA TORREY;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;PUCCIO CARL MICHAEL;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI DETORO;;BAILEY MATTHEW ALLEN,INDELIQ INC (2001-04-07);;ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE LLP (2001-01-02);;ACCENTURE PROPERTIES (2) B.V (2000-12-04);;ACCENTURE GLOBAL SERVICES GMBH (2003-12-18);;ACCENTURE (2001-01-02),https://lens.org/156-718-954-819-966,Granted Patent,yes,95,17,10,10,0,G09B7/04;;G09B7/04,G06F40/00;;G09B7/04,706/45;;706/47,99,12,000-937-240-855-327;;041-823-310-510-538;;177-674-712-209-639;;070-623-900-555-766;;044-287-884-972-160;;015-458-659-063-333;;063-469-437-501-064;;000-937-240-855-327;;072-830-336-901-57X;;048-588-948-033-969;;063-469-437-501-064;;015-458-659-063-333,10.1109/21.293505;;10.1109/tai.1994.346422;;10.1109/wsc.1994.717537;;10.1109/wsc.1995.479050;;10.1145/256562.256784;;10.1049/ic:19980560;;10.1016/s0090-2616(96)90012-1;;10.1109/21.293505;;10.1145/249094.249108;;10.1002/j.1099-1174.1995.tb00090.x;;10.1016/s0090-2616(96)90012-1;;10.1049/ic:19980560,"J.R. Anderson and B.J. Reiser, ""The Lisp Tutor,"" Byte, pp. 159-175 Apr. 1985.;;N.D. Livergood, ""From Computer-Assisted Instruction to Intelligent Tutoring Systems,"" J.O Artificial Intelligence in Education, vol. 2(3), pp. 39-50 Dec. 1997.;;W. Regian and G. Pitts, ""A Fuzzy Logic-Based Intelligent Tutoring System,"" Information Processing 92, vol. II, pp. 66-72 Dec. 1992.;;A.J. Gonzalez and L.R. Ingraham, ""Automated Exercise Progression In simulation-Based Training,"" IEEE Trans. On Systems, Man and Cybernetics, vol. 24(6), pp. 863-874 Jun. 1994.;;R.H. Kemp and S.P. Smith, ""Using Planning Techniques to Provide Feedback in Interactive Learning Environments,"" Proc. Sixth Int'l. Conf On Tools with Artificial Intelligence, pp. 700-703 Nov. 1994.;;J. Siemer and M.C. Angelides, ""Embedding an Intelligent Tutoring System in a Business Gaming-Simulation Environment,"" Proc. Of the 1994 Winter simulation Conference, pp. 1399-1406 Dec. 1994.;;V.J. Shute ""Smart Evaluation: Cognitive Diagnosis, Mastery Learning & Remediation,"" Proc. Of 7th World Conf. On Artificial Intelligence in Education, pp. 123-130 Aug. 1995.;;J. Reye, ""A Goal-Centered Architecture for Intelligent Tutoring Systems,"" Proc. Of 7th World Conf. On Artificial Intelligence in Education, pp. 307-314 Aug. 1995.;;J. Siemer and M.C. Angelides, ""Evaluating Intelligent Tutoring with Gaming-Simulations,"" Proc. Of the 1995 Winter Simulation Conf., pp. 1376-1383 Dec. 1995.;;S.J.E. Taylor and J. Siemer, Enhancing Simulation Education with Intelligent Tutoring Systems, Proc. Of the 1996 Winter Simulation Conf., pp. 675-680 Dec. 1996.;;K. Nakabayashi, et al., ""Architecture of an Intelligent Tutoring System on the WWW,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 39-46 Dec. 1997.;;W. van Joolingen, et al., ""The SimQuest Authoring System for Simulation-Based Discovery Learning,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 79-86 Dec. 1997.;;M. Papagni, et al., ""Teaching through Case-Based Reasoning: An ITS Engine Applied to Business Communication,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 111-118 Dec. 1997.;;R. Azevedo, et al., ""RadTutor: The Theoretical and Empirical Basis for the Design of a mammography Intrepretation Tutor,"" Proc. Of 1997 World Conf. On Artificial in Education, pp. 386-393, R.H. Kemp, ""Using the Wizard of Oz Technique to Prot"" Dec. 1997.;;R.H. Kemp, ""Using the Wizard of Oz Technique to Prototype a Scenario-Based simulation Tutor,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 458-465 Dec. 1997.;;P. Busilovsky, et al., ""Distributed Intelligent Tutoring on the Web,"" Proc. Of 1997 World Conf. On Artifiical Intelligence in Education, pp. 482-489 Dec. 1997.;;C.D. Robinson, et al., ""Briding the Virtual and the Physical: The InterSim as a Collaborative Support Interface,"" Proc of 1997 World Conf. On Artificial Intelligence in Education, pp. 556-558 Dec. 1997.;;K. Itoh, et al., ""An Object-Oriented Architecture for Evolutional Development of Interactive Learning Environment with Coached Problem-Solving,"" Proc. Of 1997 World Conf. On artificial Intelligence in Education, pp. 592-594 Dec. 1997.;;B.T. Cheok and A.Y.C. Nee, ""Developing a Design Systen into an Intelligent Tutoring System,"" Int'l. J. Engr. Eud., vol. 13(5), pp. 341-346 Dec. 1997.;;J. Breuker, ""What are Intelligent Coaching Systems and Why are They (in)evitable?"" IEE Colloquium on Artificial Intelligence in Educational Software, pp. 2/1-2/5 Jun. 1998.;;J.S. Brown, et al., ""Pedagogical, natural language and knowledge engineering techniques in SOPHIE I, II and III,"" in Intelligent Tutoring Systems, D. Sleeman and J.S. Brown eds., pp. 227-282 Dec. 1982.;;S.S. Prabhu and A. Srivastava, ""Computer Aided Instruction for Statistics: A Knowledge-Based Systems Approach,"" Int'l J. of Computers in Adult Education and Training, vol. 5(1), pp. 3-14, no date.;;Mark L. Lengnick-Hall, Virtual learning: A Revolutinary Approach to Building a Highly Skilled Workforce, Autumn 1998, Personnel Psychology vol. 51, No. 3, pp. 767-771.;;J. Bernard Keys, Robert M. Fulmer, Stephen A Stumpf, Microworlds and simuworlds: Practice field for the learning organization, Spring 1996, Organizational Dynamics vol. 24, No. 4, pp. 36-49.;;""Evaluating the effectiveness of feedback in SQL-tutor"", IEEE, Proc. Int. Workshop IWALT, pp. 143-144.;;""Automated Exercise Progression in Simulation-Based Training,"" IEEE Trans. On Systems, Man, and Cybernetics, vol. 24(6), pp. 863-874, Jun. 1994.;;""ACM Transactions on Information Systems,"" 1988 at www.acm.org/pubs/toc/Abstracts/tois/59298.html.;;The Virtual Classroom: Great Expectations. Delivering Graduate Education by Computer: A Success StoOry, 1996.;;""A Special Section-Goal Based Scenarios: A New Approach to Professional Education: Reengineering Education at Andersen Consulting,"" Educational Technology, Nov.-Dec. 1994.;;""Goal-Based Scenarios and the Problem of Situated Learning: a Commentary on Andersen Consulting's Design of Goal-Based Scenarios,"" Educational Technology, Nov.-Dec. 1994.;;""DDD-A Free Graphical Front-End for UNIX Debuggers,"" Jan. 1996, ACM Sigplan Notices, vol. 31, No. 1, pp. 22-27.;;""Automated Training of Legal Reasoning"" at http://www.bielta.ac.uk/94papers/muntjew.html, no date.;;""The Virtual Learning Environment System,"" 28th Annual Frontiers in Education Conference, Conference Proceedings, vol. 2, No. 4-7, 1988.;;""Developing a Design System into an Intelligent Tutoring System,"" Int'l J. Engr. Eud., vol. 13(5), pp. 341-346, Dec. 1997.;;""Captor a model for delivering web based intelligent tutoring system technology,"" IEEE Proc. DASC vol. 2, pp. 5.C.4.1-5.;;""Bridging the Virtual and the Physical: The InterSim as A Collaborative Support Interface,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 556-558, Dec. 1997.;;""Task-Oriented Learning on the Web""; Innovations in Education and Training International, vol. 36, No. 1, Feb. 1999.;;""Applications of BrainMaker Neural Network to stocks, business, medical, manufacturing"" at www.calsci.com/Applications.html, no date.;;""KBLPS Overview"" at www.cgi.com/CGIWEB/KBLPS/overindex4.html, no date.;;""Smartlaw: adapting classic expert system techniques for the legal research domain"", ACM pp. 133-141, no date.;;""Interactive Multimedia Instructs the Individual,"" Oct. 1994, Occupational Health & Safety vol. 63, No. 10, pp. 144-145.;;""Practical methods for automatically generating typed links"", ACM Hypertext, pp. 31-41, no date.;;""Popular Theory Supporting the Use of Computer Simulation for Experiential Learning,"" http://www.centurionsys.com/rtcl57.html, Aug. 1997.;;""Technical Report: Computer Aided Education and Training Initiative"" at http://advlearn.lrdc.pitt.edu/advlearn/papers/FINALREP.html, no date.;;""FRA: Teaching Financial Accounting with a Goal-Based Scenario,"" Intelligent Systems, in Accounting, Finance and Management, vol. 4, 1995.;;""Teaching Real-World Analysis Skills for Goal-Based Scenario,"" pp. 68-74, no date.;;""Artificial Intelligence and Mathematics Education"" at http://www.rand.org/hot/mcarthur/Papers/aied.html, no date.;;""The Roles of Artificial Intelligence in Education: Current Progress and Future Prospects"" at http://www.nib.unicamp.br/recursos. . .education/intelligent-tutoring.html, no date.;;""WITS: A Reusable Architecture for a VR-Base ITS"" at http://advlearn.lrdc.pitt.edu/its-arch/papers/tam.html, no date.;;""Brainmaker"" at www.npiec.on.ca/-echoscan/28-04.htm, no date.;;""News for EASP"" at www.hops.wharton.upenn.edu/~esap/news.html, no date.;;""Learning with Computers,"" May 1994, Accountancy vol. 113, No. 1209, pp. 60-64.;;""User-Sensitive Multimedia Presentation System,"" Mar. 1, 1996, vol. 39, No. 3, pp. 93-94.;;""Microworlds and Simuworlds: Practice Fields for the Learning Organization,"" Spring 1996, Organizational Dynamics vol. 24, No. 4, pp. 36-49.;;""What are Intelligent Coaching Systems and Why are they (in)evitable?"" IEEE Colloquium on Artificial Intelligence in Educational Software, pp. 2/1-2/5, Jun. 1998.;;""Development of an Integrated Simulator and Real Time Plant Information System,"" Advances in Operational Safety of Nuclear Power Plants, Proceedings of an International Symposium 1996.;;""A Goal-Centered Arhitecture for Intelligent Tutoring Systems,"" Proc. Of 7th World Conf. On Artificial Intelligence in Education, pp. 307-314, Aug. 1995.;;""Smart Avatars in JackMOO,"" Proceedings of the 1999 IEEE Conference on Virtual Reality, pp. 156-63.;;""Embedding an Intelligent Tutoring System in a Business Gaming-Simulation Environment,"" Proc. Of the 1994 Winter Simulation Conference, pp. 1399-1406, Dec. 1994.;;""Evaluating Intelligent Tutoring with Gaming Simulations,"" Proc. Of the 1995 Winter Simulation Conf., pp. 1376-1383, Dec. 1995.;;""Persistent Issues in the Application of Virtual Environment Systems to Training,"" Aug. 1996, Proceedings. Third Annual Symposium on Human Interaction with Complex Systems, IEEE, pp. 124-132.;;""The Lisp Tutor,"" pp. 159-175, Apr. 1985.;;""Pedagogical, natural language and knowledge engineering techniques in SOPHIE I, II, and III,"" in Intelligent Tutoring Systems, D. Sleeman & J.S. Brown eds., pp. 227-282, Dec. 1982.;;Interactive Multimedia Distance Learning (IMDL): The Prototype of the Virtual Classroom, 1994.;;""Understanding Organizational Dynamics of IT-Enabled Change: A Multipedia Simulation Approach,"" Winter 1997/1998, Journal of Mangement Information Systems: JMIS, vol. 14, No. 3, pp. 109-140.;;""Intelligent Computer-Aided Instruction: A Survey Organized Around System Components,"" Jan. 1989, IEEE Inc., New York, vol. 49, No. 1, pp. 40-57.;;""Conducting and Supporting a Goal-Based Scenario Learning Environment,"" Educational Technology, Nov.-Dec. 1994.;;""Interface design issue for advicing giving expert systems"", Comm. Of theACM, vol. 30, No. 1, pp. 14-31, no date.;;""An Object-Oriented Architecture for Evolutional Development of Interactive Learning Environment with Coached Problem-Solving,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 592-594, Dec. 1997.;;""Architecture of an Intelligent Tutoring System on the WWW,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 39-46 Dec. 1997.;;""Socialized Collaborative Learning in Multimedia Virtual Worlds"" URL: http://www.iscs.nus.edu.sg/labs/learning/lels/VRML.html; viewed Feb. 16, 1999.;;Flexible Learning, Feb. 1998, Credit Union Management vol. 21, No. 2, pp. 32-33+.;;""Teaching Through Case-Based Reasoning: An ITS Engine Applied to Business Communication,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 111-118 Dec. 1997.;;""Train with Less Pain,"" Oct. 13, 1997, Informationweek No. 652, pp. 150-154.;;""Virtual Learning: A Revolutionary Approach to Building a Highly Skilled Workforce,"" Autumn 1998, Personnel Psychology vol. 51, No. 3, pp. 767-771.;;""Intelligent Tutoring Systems: An Overview"" at http://www.intellectbooks.com/authors/lawler/its.htm, no date.;;""No More Boring CPE,"" Jul. 1997, Accounting Technology, pp. 27-35.;;Computer Dictionary, 1997, pp. 264, 276, 383, 446, 462, 507.;;""Rule-Based Programming with OPS5"" at www.mkp.com/books_catalog/O-934613-51-6.asp, no date.;;""From Computer-Assisted Instruction to Intelligent Tutoring Systems,"" J. Artificial Intelligence in Education, V. 2(3), pp. 39-50, Dec. 1997.;;""MUSE U.S. Patents"" at www.muser.com/html/patents.html, no date.;;""Distributed Intelligent Tutoring on the Web,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 482-489, Dec. 1997.;;""RadTutor: The Theoretical and Empirical Basis for the Design of a Mammography Interpretation Tutor,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 386-393 Dec. 1997.;;""Using the Wizard of Oz Technique to Prototype a Scenario-Based Simulation Tutor,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 458-465, Dec. 1997.;;""Using Planning Techniques to Provide Feedback in Interactive Learning Environments,"" Proc. Sixth Int'l Conf. On Tools with Artificial Intelligence, pp. 700-703, Nov. 1994.;;""An Electronic Infrastructure for a Virtual University,"" Communications of the ACM, vol. 40, No. 9, Sep. 1987.;;""Simulation Technology and Parallelism in Learning Environments"" at http://www.to.utwente.nl/prj/min/Book/chapter1.htm, no date.;;""Engines for Education"" URL: http://www.ils.nwu.edu/~e_for _e/nodes/I-M-Intro-Zoomer-pg.html; viewed Feb. 15, 1999.;;""FinPlan System"" at www.rriai.org.ru/FinPlan/, no date.;;""Enhancing Simulation Education with Intelligent Tutoring Systems,"" Proc. of the 1996 Winter Simulation Conf., pp. 675-680, Dec. 1996.;;""Computer Aided Instruction for Statistics: A Knowledge-Based Systems, Approach,"" Int'l J. of Computers in Adult Education and Training, vol. 5(1), pp. 3-14., no date.;;""Teaching with the internet"" 1998, JAI Press Inc., USA. vol. No. 3, pp. 217-222.;;""Development of a Simulation-Base Intelligent Tutoring System for Assisting PID Control Learning,"" Jan. 1994, IEICE Transactions on Information and Systems, E77-D, No. 1, Tokyo Japan, pp. 108-117.;;""Authoring Intelligent Tutoring Systems: An Analysis of the State of the Art"" at http://www.cs.umass/edu/~tmurray/papers/ATSummary/AuthTools.html, no date.;;Multimedia Training ""Get Lemonade, Not a Lemon!"" Jun. 1997, Journal for Quality and Participation vol. 20, No. 3, pp. 22-26.;;""Smart Evaluation: Cognitive Diagnosis, Mastery Learning & Remediation,"" Proc. Of 7th World Conf. On Artificial Intelligence in Education, pp. 123-130, Aug. 1995.;;""Decision Pro3.0"" at www.vanguardsw.com/, no date.;;""A Fuzzy Logic-Based Intelligent Tutoring System,"" Information Processing 92, vol. II, pp. 66-72, Dec. 1992.;;""The SimQuest Authoring System for Simulation-Based Discovery Learning,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 79-86, Dec. 1997.",EXPIRED
854,WO,A1,WO 2000/038149 A1,072-317-108-559-015,2000-06-29,2000,US 9902737 W,1999-02-08,US 21894598 A,1998-12-22,"A SYSTEM, METHOD AND ARTICLE OF MANUFACTURE FOR A GOAL BASED SYSTEM UTILIZING A TABLE BASED ARCHITECTURE",A system is disclosed that provides a goal based learning system utilizing a rule based expert training system to provide a cognitive educational experience. The system provides the user with a simulated environment that presents a business opportunity to understand and solve optimally. Mistakes are noted and remedial educational material presented dynamically to build the necessary skills that a user requires for success in the business endeavor. The system utilizes an artificial intelligence engine driving individualized and dynamic feedback with synchronized video and graphics used to simulate real-world environment and interactions. Multiple 'correct' answers are integrated into the learning system to allow individualized learning experiences in which navigation through the system is at a pace controlled by the learner. A robust business model provides support for realistic activities and allows a user to experience real world consequences for their actions and decisions and entails realtime decision-making and synthesis of the educational material. The system is architected around a table of components to manage and control the system.,AC PROPERTIES BV;;ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;CONNOR MARTHA TORREY O;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;PUCCIO CARL MICHAEL;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI ADETORO;;BAILEY MATTHEW ALLEN,ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;O'CONNOR MARTHA TORREY;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;PUCCIO CARL MICHAEL;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI ADETORO;;BAILEY MATTHEW ALLEN,,https://lens.org/072-317-108-559-015,Patent Application,yes,2,0,10,10,0,G09B7/04;;G09B7/04,G06F40/00;;G09B7/04,,0,0,,,,PENDING
855,US,B1,US 7536363 B1,140-350-224-028-640,2009-05-19,2009,US 86869599 A,1999-02-08,US 9902737 W;;US 21894598 A,1998-12-22,"Goal based system, utilizing a table based architecture",A system is disclosed that provides a goal based learning system utilizing a rule based expert training system to provide a cognitive educational experience. The system provides the user with a simulated environment that presents a business opportunity to understand and solve optimally. Mistakes are noted and remedial educational material presented dynamically to build the necessary skills that a user requires for success in the business endeavor. The system utilizes an artificial intelligence engine driving individualized and dynamic feedback with synchronized video and graphics used to simulate real-world environment and interactions. Multiple “correct” answers are integrated into the learning system to allow individualized learning experiences in which navigation through the system is at a pace controlled by the learner. A robust business model provides support for realistic activities and allows a user to experience real world consequences for their actions and decisions and entails realtime decision-making and synthesis of the educational material. The system is architected around a table of components to manage and control the system.,ACCENTURE GLOBAL SERVICES GMBH,ROSENFELD EREN TOLGA;;BASSEY EKPEDEME MFON;;ZADIK BETH ELYSE;;O'CONNOR MARTHA TORREY;;POON ALEXANDER HAN LEUNG;;LANNERT ERIC JEFFREY;;SOLOMON TRACEY ANDREA;;CONANT JONATHAN CHRISTIAN;;ZORBA ALEXANDER;;PUCCIO CARL MICHAEL;;GOBRAN TIMOTHY JOHN;;GILCHRIST JAMES ANDREW;;NICHOLS MARK STEWART;;FLEISHER BRANDON DENNING;;FRIEDMAN CRAIG WILLIAM;;LIPEDE ADEBISI DETORO;;BAILEY MATTHEW ALLEN,AC PROPERTIES B.V (1998-12-18);;INDELIQ INC (2001-04-07);;ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE LLP (2001-01-02);;ACCENTURE GLOBAL SERVICES GMBH (2003-12-18),https://lens.org/140-350-224-028-640,Granted Patent,yes,108,3,10,10,0,G09B7/04;;G09B7/04,G06F3/00;;G06F17/00;;G06F9/44;;G06F40/00;;G06N5/02;;G09B3/00;;G09B7/00;;G09B7/04,706/11;;706/46;;706/927;;434/323;;434/327;;715/705;;717/124,106,35,073-153-816-170-56X;;158-963-376-806-291;;053-034-665-193-547;;000-782-402-462-937;;057-358-936-530-733;;173-730-748-744-287;;068-510-263-293-675;;073-064-869-192-434;;048-588-948-033-969;;002-369-423-241-467;;016-329-426-238-804;;184-501-813-729-885;;067-432-118-871-267;;142-347-890-824-943;;000-937-240-855-327;;135-235-002-293-276;;072-830-336-901-57X;;177-674-712-209-639;;044-287-884-972-160;;070-623-900-555-766;;019-259-601-053-013;;048-588-948-033-969;;004-054-590-035-595;;104-167-173-292-896;;032-650-848-751-65X;;063-469-437-501-064;;041-435-495-445-909;;016-064-456-677-452;;033-558-461-397-187;;028-348-670-588-485;;146-713-769-205-123;;077-615-646-828-072;;070-704-453-980-158;;041-823-310-510-538;;015-458-659-063-333,10.1109/simsym.1991.151482;;10.1147/sj.331.0131;;10.1145/50087.50089;;10.1145/166025.166083;;10.1007/bf02298246;;10.1145/223355.223735;;10.1145/223355.223730;;10.1007/bf00377985;;10.1002/j.1099-1174.1995.tb00090.x;;10.1145/185087.185110;;10.1145/219717.219761;;10.1145/191081.191113;;10.1109/sma.1997.634884;;10.1145/260750.260769;;10.1109/21.293505;;10.1109/dasc.2000.884883;;10.1145/249094.249108;;10.1109/wsc.1994.717537;;10.1145/256562.256784;;10.1109/wsc.1995.479050;;10.1109/iwalt.2000.890591;;10.1002/j.1099-1174.1995.tb00090.x;;10.1109/21.24530;;10.1111/j.1468-0394.1986.tb00488.x;;10.1145/7885.7886;;10.1016/s0090-2616(96)90012-1;;10.1145/58566.59298;;10.1109/huics.1996.549502;;10.1145/234828.234832;;10.1109/vr.1999.756946;;10.1145/158976.158993;;10.1016/s1096-7516(99)80168-7;;10.1109/fie.1998.738777;;10.1109/tai.1994.346422;;10.1049/ic:19980560,"Kingma; International Search Report; completed Oct. 18, 1999, Mar. 11, 1999 date of mailing.;;Simonini; PCT International Preliminary Examination Report; completed Mar. 26, 2001, Jul. 24, 2000 date of submission of the demand.;;WordNet 2.1 ""presentation"" (definition). Princeton University. Accessed Feb. 10, 2006.;;Draman, M. ""A generic architechture for intelligent simulation training systems"" Proc of the 24th Annual Simulation Symposium. 1991.;;Royce,W.W. ""Managing the development of large software systems"" IEEE WESCON. 1990.;;Capper,N.P. et. al. ""The impact of object-oriented technology on sofware quality: Three case histories"" IBM Systems Journal. 1994.;;Curtis.B. et. al. ""A field study of the software design process for large systems"" ACM. 1988.;;Mehlenbacher,B. ""Software Usability: Choosing Appropriate Methods for Evaluating Online Systems and Documentation"" ACM. 1993.;;Tripp,S.D. et al. ""Rapid Prototyping: An Alternative Instructional Design Strategy"" ETR&D, vol. 38, No. 1, pp. 31-44. 1990.;;Fairley,R. ""Software Engineering Concepts"" McGraw-Hill. pp. 137-139, 184-185, 269-172, and 283-288. 1985.;;Rieman,J. et. a. ""Usability Evaluation with the Cognitive Walkthrough"" CHI'95 Mosaic of Creativity. ACM. May 1995.;;Nielsen,J. ""Usability Inspection Methods"" CHI'95 Mosaic of Creativity. ACM. May 1995.;;Winn,W. ""Some implications of cognitive theory for instructional design"" Instructional Science 19 p. 53-69. 1990.;;Turner,S.G. ""A Case Study Using Scenario-Based Design Tools and Techniques in the Formative Evaluation Stage of Instructional Design: Prototype Evaluation and Redesign of a Web-Enhanced Course Interface"". Dissertation, Virginia Tech. Oct. 1998.;;Foster,D.A. ""FRA: Teaching Financial Accounting with a Goal-Based Scenario"" Intelligent Systems in Accounting. Finance and Management vol. 4: 173-189. 1995.;;Kessler; A client-side stub interpreter; ACM SIGPLAN Notices; Proceedings of the workshop on interface definition languages; vol. 29, Is. 8; Aug. 1994; pp. 94-100.;;Chaib-draa; Industrial applications of distributed AI; Communications of the ACM; vol. 38 Issue 11; Nov. 1995; pp. 49-53.;;Rothering; Development of an OO infrastructure for mainframe database applications; ACM SIGPLAN Notices; Proceedings of the ninth annual conference on Object-oriented programming systems, language, and applications; vol. 29, Is. 10; Oct. 1994; pp. 205-212.;;Bowyer et al; Ten questions that arose in designing the Djinn API for solid modelling; International Conference on Shape Modeling and Applications Proceedings; Mar. 3-6, 1997; pp. 71-76.;;Atkinson et al; Special issue on persistent object systems: Orthogonally persistent object systems; The International Journal on Very Large Data Bases; vol. 4, Is. 3; Jul. 1995; pp. 319-401.;;W. Doube, ""A Browser-Based System to Support & Deliver DE,"" 1998 FIE Conference, Conference Proceedings, vol. 1, pp. 479-484, Nov. 4-7, 1998.;;W. Regian and G. Pitts, ""A Fuzzy Logic-Based Intelligent Tutoring System (ITS),"" Information Processing 92, vol. II, pp. 66-72, Dec. 1992.;;J. Reye, ""A Goal-Centered Architecture for Intelligent Tutoring Systems,"" Proc. of 7th World Conf. on Artificial Intelligence in Education, pp. 307-314, Aug. 1995.;;R. Schank and D. Edelson, ""A Role for AI in Education: Using Technology to Reshape Education"", Northwestern University, The Institute for the Learning Sciences, Journal of Artificial Intelligence in Education, Winter 1990,, pp. 1-24, Jan. 1990.;;A. Nowakowski, ""A Special Section-Goal Based Scenarios: A New Approach to Professional Education: Reengineering Education at Anderson Consulting,"" Educational Technology, pp. 3-8, Nov.-Dec. 1994.;;R. Chellappa, A. Barua and A. Whinston, ""An Electronic Infrastructure for a Virtual University,"" Communications of the ACM, vol. 40, No. 9, pp. 56-58, Sep. 1997.;;K. Itoh M.Itami, K. Ichihara, J. Matsushita, T. Nomizo, T. Shimomura and T. Takahashi, ""An Object-Oriented Architecture for Evolutional Development of Interactive Learning Environment with Coached Problem-Solving,"" Proc. Of 1997 World Conf. On Artificial Intelligence in Education, pp. 592-594, Dec. 1997.;;K. Nakabayashi, M. Maruama, Y. Koike, Y. Kato, H. Touhei and Y. Fukuhara, ""Architecture of an Intelligent Tutoring System on the WWW,"" Artificial Intelligence in Education, pp. 39-46, Dec. 1997.;;D. McArthur, ""Artificial Intelligence and Mathematics Education"" at http://www.rand.org/hot/mcarthur/Papers/aied.html, pp. 1-8, Jan. 2001.;;T. Murray, ""Authoring Intelligent Tutoring Systems: An Analysis of the State of the Art"" at http://www.cs.umass/edu/~tmurray/papers/ATSummary/AuthTools.html, pp. 1-35, Jul. 2001.;;""Automate Your Business Plan Software"" at www.business-plan.com/automate.html, pp. 1-4, Jul. 2001.;;A. Gonalez and L. Ingraham, ""Automated Exercise Progression in Simulation-Based Training,"" IEEE Trans. On Systems, Man, and Cybernetics, vol. 24, No. 6, pp. 863-874, Jun. 1994.;;A. Muntjewerff, ""Automated Training of Legal Reasoning"" at http://www.bileta.ac.uk/94papers/muntjew.html, pp. 1-7, Jul. 2001, 9th BILETA Conference Apr. 1994.;;""Brainmaker"" at htt://people.becon.org/~echoscan/28-04.htm, Jul. 2001, pp. 1.;;Brainmaker Neural Network Application Examples at http://ww.calsci.com/Applications.html, Jan. 2001, 63 pages.;;C. Robinson, E. Arias and H. Eden, ""Bridging the Virtual and the Physical: The InterSim as a Collaborative Support Interface,"" Artificial Intelligence in Education, pp. 556-558, Dec. 1997.;;C. Shreiner, ""CAPTOR a Model for Delivering Web-Based Intelligent Tutoring System Technology"", IEEE Proc. DASC vol. 2, pp. 5.C.4.1.5, 2000.;;S. Prabhu, ""Computer Aided Instruction for Statistics: A Knowledge-Based Systems Approach,"" Int'l J. of Computers in Adult Education and Training, vol. 5(1), pp. 3-14., Nov. 1995.;;J. Montgomery, R. Campbell and C. Moffett, ""Conducting and Supporting a Goal-Based Scenario Learning Environment,"" Educational Technology, pp. 15-20, 1994.;;A. Zeller and D. Lutkehaus, ""DDD-A Free Graphical Front-End for UNIX Debuggers,"" ACM Sigplan Notices, vol. 31, No. 1, pp. 22-27, Jan. 1996.;;Vanguard Software Corporation ""Decision Pro3.0"" at www.vanguard.com/, Jan. 2001, 10 pages.;;B. Cheok and A. Nee, ""Developing a Design System into an Intelligent Tutoring System,"" Int'l J. Engr. Eud., vol. 13(5), pp. 341-346, Dec. 1997.;;T. Nogami, Y. Yokoi, I. Yanagisawa and S. Mitui, ""Development of a Simulation-Based Intelligent Tutoring System for Assisting PID Control Learning,"" IEICE Transactions on Information and Systems, E77-D, No. 1, Tokyo Japan, pp. 108-117, Jan. 1994.;;J. Gonzalez, J. Lopez, F. Bustio, P., Corcuera and E. Mora, ""Development of an Integrated Simulator and Real Time Plant Information System,"" Advances in Operational Safety of Nuclear Power Plants, Proceedings of an International Symposium, pp. 543-549, Sep. 1996.;;P. Brusilovsky, S. Ritter and E. Schwarz, ""Distributed Intelligent Tutoring on the Web,"" Artificial Intelligence in Education, pp. 482-489, Dec. 1997.;;R. Schank and M. Korcuska, ""Eight Goal-Based Scenario Tools,"" Technical Report # 67, Northwestern University, The Institute for the Learning Sciences, pp. 1-37, Jan. 1996.;;J. Siemer and M. Angelides, ""Embedding an Intelligent Tutoring System in a Business Gaming-Simulation Environment,"" Proc. Of the 1994 Winter Simulation Conference, pp. 1399-1406, Dec. 1994.;;Engines for Educationhttp://www.lis.nwu.edu/~e-for-e/nodes/I-M-INTRO-ZOOMER-pg.html; 1994, pp. 1.;;S. Taylor and J. Siemer, ""Enhancing Simulation Education with Intelligent Tutoring Systems,"" Proc. Of the 1996 Winter Simulation Conf., pp. 675-680, Dec. 1996.;;J. Siemer and M. Angelides, ""Evaluating Intelligent Tutoring with Gaming Simulations,"" Proc. Of the 1995 Winter Simulation Conf., pp. 1376-1383, Dec. 1995.;;A. Mitrovic and B. Martin, ""Evaluating the effectiveness of feedback in SQL-tutor"", IEEE, proc. Int. workshop IWALT, pp. 143-144, 2000.;;D. Foster, ""FRA: Teaching Financial Accounting with a Goal-Based Scenario,"" Intelligent Systems in Accounting, Finance and Management, vol. 4, pp. 173-189, Sep. 1995.;;N. Livergood, ""From Computer-Assisted Instruction to Intelligent Tutoring Systems,"" J. Artificial Intelligence in Education, V. 2(3), pp. 39-50, Dec. 1991.;;W. Graham, ""Goal-Based Scenarios and Business Training: A Conversation with Roger C. Schank,"" Educational Technology, pp. 27-29, Nov.-Dec. 1994.;;A. Collins, ""Goal-Based Scenarios and the Problem of Situated Learning: A Commentary on Andersen Consulting's Design of Goal-Based Scenarios,"" Educational Technology, pp. 30-32, Nov.-Dec. 1994.;;R. Shank, ""Goal-Based Scenarios"", Technical Report # 38, Northwestern University, The Institute for the Learning Sciences, pp. 1-30, Dec. 1992.;;J. Rickel, ""Intelligent Computer-Aided Instruction: A Survey Organized Around System Components,"" IEEE Inc., New York, vol. 49, No. 1, pp. 40-57-pp. 1-32, Jan. 1989.;;M. Yazdani, ""Intelligent Tutoring Systems: An Overview"" Experts Systems, vol. 3, No. 3, pp. 154-162, Jul. 1986.;;Calmbacher, ""Interactive Multimedia Instructs the Individual,"" Occupational Health & Safety vol. 63, No. 10, pp. 144-145, Oct. 1994.;;J. Carroll and J. McKendree, ""Interface Design Issue for Advice Giving Expert Systems"", Comm. Of theACM, vol. 30, No. 1, pp. 14-31, Jan. 1987.;;""KBLPS Overview"" at www.cgi.com/CGIWEB/KBLPS/overindex4.html, Aug. 1999, 13 pages.;;""Kiplinger TaxCut Press Releases"" at http://www.taxcut.com/taxcut/98press-releases/pr98-nowshipping.html, pp. 1-2, Dec. 2, 1998.;;G. Cole, ""Learning with Computers,"", Accountancy vol. 113, No. 1209, pp. 60-64, May 1994.;;J. Keys, R. Futmer and S. Stumpf ""Microworlds and Simuworlds: Practice Fields for the Learning Organization,"" Organizational Dynamics vol. 24, No. 4, pp. 36-49, Spring 1996.;;""MUSE Patents"" OCCAM Research Corporation, at www.muser.com/html/patents/html, Jan. 2001, pp. 1-2.;;News for ESAP at www.hops.wharton.upenn.edu/~esap/news.html, Aug. 1999, pp. 1.;;M. Cohn, ""No More Boring CPE,"" Accounting Technology, pp. 27-35, Jul. 1997.;;K. Lai, T. Malon, K. Yu, ""Object Lens: A 'Spreadsheet' for Cooperative Work"", ACM Transactions on Information Systems, vol. 6, No. 4, pp. 332-353, Oct. 1988.;;J. Brown, R. Burton and J. DeKleer, ""Pedagogical, Natural Language and Knowledge Engineering Techniques in SOPHIE I, II, and III,"" Intelligent Tutoring Systems, D. Sleeman & J.S. Brown eds., pp. 227-282, Dec. 1982.;;J. Caird, ""Persistent Issues in the Application of Virtual Environment Systems to Training,"" Proceedings. Third Annual Symposium on Human Interaction with Complex Systems, IEEE, pp. 124-132, Aug. 1996.;;D. Bill, ""Popular Theory Supporting the Use of Computer Simulation for Experiential Learning,"" http://www.centurionsy.com/rtcl57.html, pp. 1-5, Jul. 2001.;;C. Cleary and R. Bareiss, ""Practical Methods for Automatically Generating Typed Links"", The Institute for Learning Sciences, Northwestern University, ACM Hypertext, pp. 31-41, 1996.;;""Projects: FinPlan System"", Russian Research Institute of Artificial Intelligence, at http://www.rrial.org.ru/FinPlan, Jul. 2001, pp. 1-2.;;R. Azevedo, S. Lajole, M. Desaulniers, D. Fleiszer and P. Bret, ""RadTutor: The Theoretical and Empirical Basis for the Design of a Mammography Interpretation Tutor,"" Proc. of 1997 World Conf. On Artificial Intelligence in Education, pp. 386-393 Dec. 1997.;;T. Cooper and N. Wogrin, ""Rule-Based Programming with OPS5"" Morgan Kaufmann Publishers, at www.mkp.com/books-catalog/O-934613-51-6.asp, 1988.;;R. Min, ""Simulation Technology and Parallism in Learning Environments"" at http://www.to.utwente.nl/prj/min/Book/chapter1.htm, pp. 1-26, Jul. 2001.;;J. Shi, T. Smith, J. Granieri and N. Badler, ""Smart Avaters in JackMOO,"" Proceedings of the 1999 IEEE Conference on Virtual Reality, pp. 156-163, 1999.;;V. Shute, ""SMART Evaluation: Cognitive Diagnosis, Mastery Learning & Remediation,"" Proc. of 7th World Conf. On Artificial Intelligence in Education, pp. 123-130, Aug. 1995.;;C. Hafner and V. Wise, ""Smartlaw: Adapting Classic Expert System Techniques for the Legal Research Domain"", ACM pp. 133-141, 1993.;;""Socialized Collaborative Learning in Multimedia Virtual Worlds"" National University of Singapore, School Computing, at http://www.comp.nus.edu.sg/labs/learning/lels/vrml.html, pp. 1-4, Jul. 2001.;;C. Whittington and L. Campbell, ""Task-Oriented Learning on the Web""; Innovations in Education and Training International, vol. 38, No. 1, pp. 26-33, Feb. 1999.;;D. Foster, ""Teaching Real-World Analysis Skills for Goal-Based Scenario,"" The Institute for the Learning Sciences, Northwestern University, pp. 68-74, Jul. 2001.;;M. Papagni, V. Cirillo and A. Micarelli, ""Teaching Through Case-Based Reasoning: An ITS Engine Applied to Business Communication,"" Proc. of 1997 World Conf. on Artificial Intelligence in Education, pp. 111-118, Dec. 1997.;;T. Herron, ""Teaching with the internet"" 1998, The Internet and Higher Education, pp. 217-222, 1998.;;D. Suthers, ""Technical Report: Computer Aided Education and Training Initiative"" at http://advlearn.lrdc.pitt.edu/advlearn/papers/FINALREP.html, pp. 1-51, Jan. 1998.;;Workflow Template-Developing a WFT Workflow System, ""Simulating the Running of the WFT Workflow System"", Template Software Business Simulator, Chapter 8, pp. 1-23, 1998.;;R. Schank, A. Fano, M. Jona and B. Bell, ""The Design of Goal-Based Scenarios"", Technical Report # 39, Northwestern University, The Institute for the Learning Sciences, pp. 1-58, Mar. 1993.;;J. Anderson and B. Reiser, ""The Lisp Tutor,"" Byte, pp. 159-175, Apr. 1985.;;D. McArthur, M. Lewis and M. Bishay, ""The Roles of Artificial Intelligence in Education: Current Progress and Future Prospects"" at http://www.rand.org/education/mcarthur/Papers/role.html, pp. 1-42, 1993.;;W. van Joolingen, S. King and T. de Jong, ""The SimQuest Authoring System for Simulation-Based Discovery Learning,"" Proc. of 1997 World Conf. On Artificial Intelligence in Education, pp. 79-86, Dec. 1997.;;A. Kumar, R. Pakala, R. Ragade and J. Wong, ""The Virtual Learning Environment System"" 28th Annual Frontiers in Education Conference, Conference Proceedings, vol. 2, Nov. 4-7, 1998, pp. 711-716.;;M. McGee, ""Train with Less Pain,"" at www.Informationweek.com, pp. 150 and 154 Oct. 1997.;;""TurboTax Deluxe Product Information"" at http://www.intuit.com/turbotax/prodinfo/ttdix.html, Jan. 2001, pp. 1-2.;;J. Manzoni and A. Angehm, ""Understanding Organizational Dynamics of IT-Enabled Change: A Multipedia Simulation Approach,"" Journal of Mangement Information Systems: JMIS, vol. 14, No. 3, pp. 109-140, Winter 1997/1998.;;""User-Sensitive Multimedia Presentation System,"" IBM Technical Disclosure Bulletin, vol. 39, No. 3, pp. 93-94 Mar. 1996.;;R. Kemp and S. Smith, ""Using Planning Techniques to Provide Feedback in Interactive Learning Environments,"" Proc. Sixth Int'l Conf. On Tools with Artificial Intelligence, pp. 700-703, Nov. 1994.;;R. Kemp, ""Using the Wizard of Oz Technique to Prototype a Scenario-Based Simulation Tutor,"" Proc. of 1997 World Conf. On Artificial Intelligence in Education, pp. 458-465, Dec. 1997.;;R. Schank, ""Virtual Learning: A Revolutionary Approach to Building a Highly Skilled Workforce,"" Personnel Psychology vol. 51, No. 3, pp. 767-771, 1997.;;J. Breuker, ""What are Intelligent Coaching Systems and Why are they (in)evitable?"" IEEE Colloquium on Artificial Intelligence in Educational Software, pp. 2/1-2/5, Jun. 1998.;;""Why Should the Teens Have All the Best Games? Management Skill with Oil, Health, Housing Games,"" Computergram Int'l, Jun. 17, 1996, pp. 1-2.;;E. Tam, P. Allard, M. Faraj, M. Kaddoura, A. Mourad, H. Liu, Malowany, R. Marceau, L. Granger and J. Gagnon, ""WITS: A Reusable Architecture for a VR-Based ITS"" at http://advlearn.lrdc.pitt.edu/its-arch/papers/lam.html, pp. 1-5, Jun. 10, 1996.;;Computer Dictionary, 3rd Edition, pp. 264, 276, 383, 446, 462, 507, 1997.;;L. Grensing-Prphal, ""Flexible Learning"", Credit Union Management vol. 21, No. 2, pp. 32-33 and 38, Feb. 1998.;;J. Wilson and D. Mosher, ""The Prototype of the Virtual Classroom,"" Journal of Instruction Delivery Systems, Summer 1994, at http://www.educause.edu/nlii/articles/moshwils.html, pp. 1-9.;;T. Burns, ""Multimedia Training . . . 'Get Lemonade, Not a Lemon!'"" Journal for Quality and Participation, vol. 20, No. 3, pp. 22-26, Jun. 1997.;;A. Seagren and B. Watwood, ""The Virtual Classroom: Great Expectations. Delivering Graduate Education by Computer: A Success Story,"" 5th Annual International Conf. for Community & Technical College Chairs, Deans and Other Organizational Leaders, pp. 512-517, Feb. 1996.",EXPIRED
856,US,A1,US 2004/0002924 A1,050-887-442-483-761,2004-01-01,2004,US 18742402 A,2002-07-01,US 18742402 A,2002-07-01,Interactive health insurance system,"
   A method for administrating healthcare services allows providers to select cost-sharing levels for each service. Cost-share selections and other provider practice characteristics are stored in a dynamic, cost-sharing database. Individuals seeking a provider can access the database through a network and perform a provider search based on selected criteria. Individuals that receive services from a provider pay the appropriate cost-share at the time of service, and an administrator pays an additional amount based on a fee schedule specifying the amount the administrator will pay for the specified service. 
",UNITEDHEALTH GROUP,BOONE H K;;DEARBORNE CECIL R;;KAPLAN BRIAN S;;MAISER LAURIE H;;MONTGOMERY DAVID D;;POPP GAYLE Y;;STOLAR GLENN A;;WORRELL DEBORAH L;;EMERY JIM D;;FRIEDMAN STUART R;;NUTTALL MELISSA H;;THADANI PRAVEEN G;;HAKIMI NADA M;;HATTING KATHERINE B;;WHITELY WILLIAM P;;REY DAVID A;;FRISCH ROBERT S;;JOHNSON BRIAN A,,https://lens.org/050-887-442-483-761,Patent Application,yes,8,24,2,2,0,G06Q10/087;;G06Q20/102;;G06Q30/0283;;G06Q40/02;;G06Q40/08;;G16H70/20;;G06Q10/10;;G06Q40/02;;G06Q30/0283;;G06Q40/08;;G06Q20/102;;G06Q10/087;;Y10S707/99948;;G16H70/20;;G06Q10/10,G06Q10/08;;G06Q20/10;;G06Q30/02;;G16H10/60;;G16H70/20,7054;;705/2,0,0,,,,EXPIRED
857,US,B2,US 7769606 B2,011-776-566-835-507,2010-08-03,2010,US 18742402 A,2002-07-01,US 18742402 A,2002-07-01,Interactive health insurance system,"A method for administrating healthcare services allows providers to select cost-sharing levels for each service. Cost-share selections and other provider practice characteristics are stored in a dynamic, cost-sharing database. Individuals seeking a provider can access the database through a network and perform a provider search based on selected criteria. Individuals that receive services from a provider pay the appropriate cost-share at the time of service, and an administrator pays an additional amount based on a fee schedule specifying the amount the administrator will pay for the specified service.",BOONE H KEITH;;DEARBORNE CECIL R;;KAPLAN BRIAN S;;MAISER LAURIE H;;MONTGOMERY DAVID D;;POPP GAYLE Y;;STOLAR GLENN A;;WORRELL DEBORAH L;;EMERY JIM D;;FRIEDMAN STUART R;;NUTTALL MELISSA H;;THADANI PRAVEEN G;;HAKIMI NADA M;;HATTING KATHERINE B;;WHITELY WILLIAM P;;REY DAVID A;;FRISCH ROBERT S;;JOHNSON BRIAN A,BOONE H KEITH;;DEARBORNE CECIL R;;KAPLAN BRIAN S;;MAISER LAURIE H;;MONTGOMERY DAVID D;;POPP GAYLE Y;;STOLAR GLENN A;;WORRELL DEBORAH L;;EMERY JIM D;;FRIEDMAN STUART R;;NUTTALL MELISSA H;;THADANI PRAVEEN G;;HAKIMI NADA M;;HATTING KATHERINE B;;WHITELY WILLIAM P;;REY DAVID A;;FRISCH ROBERT S;;JOHNSON BRIAN A,,https://lens.org/011-776-566-835-507,Granted Patent,yes,8,15,2,2,0,G06Q10/087;;G06Q20/102;;G06Q30/0283;;G06Q40/02;;G06Q40/08;;G16H70/20;;G06Q10/10;;G06Q40/02;;G06Q30/0283;;G06Q40/08;;G06Q20/102;;G06Q10/087;;Y10S707/99948;;G16H70/20;;G06Q10/10,G06Q10/08;;G06Q20/10;;G06Q30/02;;G16H10/60;;G16H70/20,705/4;;705/2;;705/3;;705/28;;705/32;;705/40;;709/204;;707/104,4,0,,,Consumers Union; Choosing a health plan-Tip sheet 2001; www.consumersunion.org.;;www.wikipedia.com; description of preferred provider organization.;;Dialog search history.;;Dialog search results.,INACTIVE
858,US,A1,US 2009/0148342 A1,185-879-361-557-576,2009-06-11,2009,US 92728807 A,2007-10-29,US 92728807 A,2007-10-29,Hypochlorite Technology,"This invention generally relates to compositions and method of producing diluted hypohalous acid and hypohalous acid vapor. These compositions can be used to treat allergen containing surfaces, hard surfaces, food contact surfaces, hospital surfaces, food surfaces, kitchen surfaces, bathroom surfaces, human surfaces, animal surfaces, children's items, outdoor surfaces, soft surfaces, and medical instruments. These compositions can be converted to solid particulate or granular compositions. These compositions can be put into a variety of containers which preserve the stability. These compositions can be used to treat allergens and molds and as part of a mold detection system. These compositions can be dispersed into the air to enable microbiological control.",BROMBERG STEVEN E;;BITOWFT BRUCE K;;CRANE ELIZABETH;;EL-SAYED MAHA;;HUITT DANIEL A;;NGUYEN ANDREAS;;GOPEGUI RICARDO RUIZ DE;;SHIEH DORIS S;;SMITH WILLIAM L;;TIMBERMAN JULIE;;GARABEDIAN ARAM;;ARNT LACHELLE;;SHAHEEN ELIAS A;;BROMBERG STEVEN;;FRIEDMAN VICKI;;FUNG JENNIFER;;JULIAN JENNIFER C;;VIEIRA KENNETH;;WIESMAN JULIE;;KENNEDY TIMOTHY;;CHIANG CHIH;;VIEIRA KENNETH L;;OCHOMOGO MARIA G;;CUMBERLAND SCOTT;;HUITT DANIEL AARON;;MELLETT DIANE;;DANI NIKHIL;;EL-SAYED MAHA Y;;FOLAND LAFAYETTE D;;ROBLES JORGE;;SHAHEEN ELIAS A,BROMBERG STEVEN E;;BITOWFT BRUCE K;;CRANE ELIZABETH;;EL-SAYED MAHA;;HUITT DANIEL A;;NGUYEN ANDREAS;;GOPEGUI RICARDO RUIZ DE;;SHIEH DORIS S;;SMITH WILLIAM L;;TIMBERMAN JULIE;;GARABEDIAN ARAM;;ARNT LACHELLE;;SHAHEEN ELIAS A;;BROMBERG STEVEN;;FRIEDMAN VICKI;;FUNG JENNIFER;;JULIAN JENNIFER C;;VIEIRA KENNETH;;WIESMAN JULIE;;KENNEDY TIMOTHY;;CHIANG CHIH;;VIEIRA KENNETH L;;OCHOMOGO MARIA G;;CUMBERLAND SCOTT;;HUITT DANIEL AARON;;MELLETT DIANE;;DANI NIKHIL;;EL-SAYED MAHA Y;;FOLAND LAFAYETTE D;;ROBLES JORGE;;SHAHEEN ELIAS A,,https://lens.org/185-879-361-557-576,Patent Application,yes,99,181,1,1,0,A61L2/18;;A61L2/18;;A01N59/00;;A01N59/00;;A23L3/358;;A23L3/358;;A61L2/20;;A61L2/20;;A61L2/22;;A61L2/22;;A61L2/23;;A61L2/23;;A61L9/01;;A61L9/01;;A61L9/05;;A61L9/05;;A61L9/12;;A61L9/12;;A61L9/14;;A61L9/14;;A61L2202/24;;A61L2202/24;;C11D3/124;;C11D3/124;;C11D3/3953;;C11D3/3953;;C11D3/3956;;C11D3/3956;;C11D3/48;;C11D3/48;;C11D17/041;;C11D17/041,A61L2/20,422/37;;424/661;;422/123,0,0,,,,DISCONTINUED
